<SEC-DOCUMENT>0001000694-22-000016.txt : 20220809
<SEC-HEADER>0001000694-22-000016.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220808193708
ACCESSION NUMBER:		0001000694-22-000016
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		221146002

	BUSINESS ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nvax-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b8f7f396-6255-4acd-a261-8fc9092ca526,g:e7b36f81-b504-4b3e-b499-0ac259afcdda,d:4443801361394f65b2e7b9b03051a84d--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:nvax="http://www.novavax.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF8zLTEtMS0xLTcwMDc3_c1eebc6c-8ab3-4d32-866c-ee790fcf3d8f">false</ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF80LTEtMS0xLTcwMDc3_41646fd1-05a7-46bc-81a1-34cd275196ef">2022</ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF81LTEtMS0xLTcwMDc3_bb955d42-4655-453b-acc8-779f7b4fe7dd">Q2</ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF82LTEtMS0xLTcwMDc3_6fd0f568-f93b-4feb-bf97-dd7efa4da771">0001000694</ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF83LTEtMS0xLTcwMDc3_0262c0a5-ca5f-4a78-9ae8-900e415bf006">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i101c8f6e1aa7408995876bc4fb815e07_D20150601-20150630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQyNQ_9172cf8d-33fb-4432-8f7b-4855b5e3976b">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac274b9c236946588cbd492c3c14688d_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7556a131e55a41578a8e85d487bf5928_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i86be659b16f6450d8c6703acf6588255_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4945289540e9464e912a257f3ab7ee3a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc0120310b244cb8cb07e4863cca3b8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64169e1b64be465ba651f225a820a0a7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740226150bb146dfbab7548d73d95ec3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02740f8f66c940f49f4d45435b5f33fb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4244f94bb3dc4fe284264e5bcde0de65_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i617f9132150b4ac2b7036afe3dadd382_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94de60b1abe4ad58c2380deef7432e1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b847b28162428a9c29f3d458bfa24a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c7c77a593d4ae8b52724afa14921ab_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie0b34d6687584e9692cde7fdd2961e44_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da027fe8b2945be929fc9906ca55864_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96110cf81ced478b94da040072a11097_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983653fedfdd46e4964ac7eaa476f0e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf44cd7a49ed4b979d3cd163e2c5dec2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e37e7f85f974859b9fe1672ca2f4c4b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3693bbbf47294faf81643217cb838507_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99b9d9cf9ba4355b1dc30fa79ba361a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c178e9d82a4bc383bed84c24bc1076_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1af4fb674a440d80223f9f311ac5da_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7901003cbe7c4f97a451e89abdfb7a0f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a6154851b4416b8f89cad0ad7721af_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54872cb8e40f4eb092ba0fc3d8a1095b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa1af89fb9648679fce07310e5756d1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1363bb3470f4a45b7d8cc8d9e9e6aea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab83a560ba0b4becb4f5f507cccb33e3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ae795236fd4899979c4bd46c38a184_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e3eb175a484325be7a301736e4107e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1712c0418943ea9ef19b5b840ad622_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263537bdec814cf6b1cc7b8e9842db81_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac113f7c93d433688947c243e83b2b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i747d203795fc4040966baf276eafa5a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400373f4f92f47119a751c4590a1d32c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df15bfb369349d6aa42604f4e939b05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf962fca8d1f43e9a4a5c58859e8e5b3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0ff7a0136d4a4fb89c7bcb66b8a4d4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f7de39972c467d8d744008d112cbdb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595ec53f965547f3ba917a056296edf8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e1b68160b843778dbca3e791b341ca_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dad49772b0f48038418785e8e761874_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1514b2ba3b4666a00d9813765198b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec245d5ef2c943f88458628a12c5efa7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc8de8da83641cc91ef608da7bf7d7e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36438295aede46c58b4392a1543df581_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3583256bab459492a5d569f0fabc95_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9542317971e482c84dd6b1322d3ee2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47b8f663b084ad7aa112c61216cecf1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77212d37c7d542c58864ca99739f51a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a6ec54d49b44673ad5cceb7f2022d14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c45885967040cb9ddd39bab52e20d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5216318c35f44e2ca8de90f56766c348_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc5b57fa7f04963a7a9f040883b44c2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if166d44b16b444dda0cd485ceb01788d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd833ef8d89041a0a5d6c047bc63754d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7880242152934fbeb18732d8cb58a141_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib399728718c84112836d2a89efc58c0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i523ac32f976545eba62aaa06ede3c7da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95178a09622409fb2fd15e1080134c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ba72b9644274960974bf6ff07008c73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164611e81adc4dada9d43687e47035ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55283e03483840778793f0003169278b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1298fd9885d641b1be701807b92420b3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b6e942b2faa424d97c0830be1ea20ad_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nvax:segment</xbrli:measure></xbrli:unit><xbrli:context id="i4f4b6f5acde242c3ace67f89c0df4c69_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a7f0ae8be1457ba975ad86d4101b1b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d13d4609664545a43b24e97b8b072f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2796d80cfb471e994d0da8cd0437fd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c49f33057824088903829819b53beb0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea0fc725c2844378d5f099dfa98477e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eaafe4f9b3348c5b10a0f78e3633e5c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51025fa58fb149ac918fe80236b6303e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04667b8d3a384b2d9245c1a4fa29d96a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a710118bda240b8b211f8a0825036c5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i551af433d1e246e89e595442fa319aee_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac4f312e40a4461a57f852f3ce23cc4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31f109abc1642b28e93db64fafa6102_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0592102fe89f4264bfef8d819f322688_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8140e44c727f43f39853c42e69847f31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcbc5b4644bd44feaef5b01c2b51ce35_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a08399d05224436b9583db28b4671a7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b84098b8a748f8bfc7222df25285a4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>nvax:dose</xbrli:measure></xbrli:unit><xbrli:context id="id77272a9807949ed93e0c856eca5c6db_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398e1d19b77d4b66b82d84fa9532c022_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d61c79ddcb4213a12c1d9637bd0819_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e25182664da42259f8fddcc4e30be81_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7504caa392fc4b198ba675a27efbc513_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0b072a00284d5e86b6ae1955e77255_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472e0a435709425884b630fb4e4abe4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03121026d664feabb6f6d6ce32a036e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0594bb0e3d49426d8546ac3ef41f5312_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92cf89b34fba4758b7ea6b29bb2b4277_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe5f264f5aae46269f4b5c7f917258db_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce520d7761743ec86392cca9a2d1a9d_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603827ce2ac64ffaac1b057ac83a74b8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d0012acfa204c92bb3e3d28118477f7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8416d2c5f7415e89f5022b56743ac4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i750e9cc522fe4374bb3945dd8f61ee58_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c67801e2acb4e6bb800915f121b2eaf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99533f95b79b45b992b718e063053587_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7188cfe5d6445c9ccfc63027d2b369_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17025047e164926ae984921e6dabb68_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194bb03495444c89b63efab4dad063fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc988bf6562e4a0ab83d5998938f5d7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8814d4d6bb460fb498f2ef6bcb3f07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1427334e93bd4a8f98fd067cf174baff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd64740178f14dfaa8b40016114d8b0b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d2a912e597482e88dad8af2f1eb83a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7365cb3d7724460b7e77eea77c4d02c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961f58e0225b454ea758608f30477153_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c82b31c56a41cabaa12f169afbc6ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id47d8623f27649b88072c3726cf612a4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05545dcab7354afb93e21cdd544ce785_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15eacf51ca7461e831d064a18ed6ec5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c389f5ae034c4a9f241df636dd9408_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9c400472e346bb83cdc03ad62f0f6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieebe69f41a92442fa317d279aecfffa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c56415ec67e4a2f92984c0168e319b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018f2366267542d98a7442366fecb5fb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae5da8be9b04141abe668a81dbf1b8b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33e6ef1fb0544afd9c34afa0943a65e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1c4e3b51c54406bfdcb545ced2f93b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb63dea6d85945d78435e4733601554d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ef495376c841fcad701e4fb99916f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd523551b8c4c88a444bf178a5ead31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:ProprietaryAdjuvantTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:ProprietaryAdjuvantTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3453a5c919a143e6b9635ec05f27f973_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:CollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94545a62f6f04e5d9fe91e26c5041a86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:CollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia288ba6256924eaeb4fd7095a2acd199_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ib60480ff6ace4a9dada2572b7a483040_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298d3ab6290f4c62a68f470f3b16205a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67b8fd3c6684e26893f4f55ee228020_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385f7d6a051e4dafb63d1a63b59be860_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425b5f4d2daa419592347aa121524f6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d5d7e6cc2a6432fad8f4e48c6a737bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6932178ef14e472084b3b902bba8f33c_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8b6ed41b2d43bebac3d158af889817_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b95e06ae99e465cbb5da325d456aede_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i101c8f6e1aa7408995876bc4fb815e07_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec94153dc52b4f0a884461884ed5820d_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c556955c19448f6919e6fc319d19b36_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944814c48d6649559e7aaad2f652d7d9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031d603f91304729bf3df926d55719f3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd34e5e916949209fde4068aa2e6022_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1437c17d92b74d498d6762b05f885fcf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cd14661959040a9a835c1d64370e08c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077e0d963f96436b8a57d5c0ed164f5b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8edaad70b54946b5867782a7dc86da_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9871aabeb83498fbc621e999b2b9f8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib704932e6449470a978301c51c17020a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ca2be2be7e4bc99eb77502e20ad770_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i547e6d19486d49bbba36b7968e867e86_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc85c93fc3d4bb8b1fe33f9fc7a5679_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba39bdd4b0c4361ab34b776c5df1842_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1d79ddc8e64ee499a6e8568258a241_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i420df0b64ff14517bb785ae28358ddd9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b84332994940ec9dd4c1fa8fe32f65_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af1ef6cf5684c3f981161750a479e9e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307541a72a03422fb6a7905e2797b623_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if549400c21a940d9930254a6fde16714_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4319b34bddc14dc7ad516619f65f196d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i962e48035aea4045b0cfe2ace43cde76_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e499e69dfc74d4ab90426c5104422ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad84832faf04aac8ca995f70a7aecd3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadbd33a708c469c910a0ca167cd16cf_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86f32bcfa404cf0815eaf4f567e395f_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4443801361394f65b2e7b9b03051a84d_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA5_960b61ae-16ac-47ab-8848-74294011681b">10-Q</ix:nonNumeric></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA0_03054052-79d7-46d5-b9a8-d52b9e8c3121">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA_9bf230ca-f64c-49b8-9c95-ebae334eea1f">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA1_e8e3b2b3-7826-4b5e-8de0-2b3c9395453b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from          to           .</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA2_506d8bde-d6ba-4f6e-976e-99e7b2cda8de">000-26770</ix:nonNumeric></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA3_f9f4ad81-445f-4732-8b18-6f6e0d15e84c">NOVAVAX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18wLTAtMS0xLTcwMDc3_8e8a6412-232e-4b81-b0b8-1e3f20c5bb4b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18wLTMtMS0xLTcwMDc3_96b1edbb-00c5-4a31-9f12-0b2b5c3ed2d7">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTAtMS0xLTcwMDc3_be2e8fdf-9a45-4f94-81e4-30a2c22217ec">21 Firstfield Road</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTEtMS0xLTcwMDc3_b7b1292f-2070-4461-a397-4742792a223e">Gaithersburg</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityAddressCountry" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTItMS0xLTcwMDc3_eca7fe6a-3117-4464-b541-ed5c152073cc">MD</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTMtMS0xLTcwMDc3_d2dad9ba-7a55-498e-b638-2f7e2ce5888c">20878</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV80NjY_a0851b99-8bf7-4297-937f-914329a217b6">(240)</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTEy_3bd14cb3-7ec7-4565-b625-edb2dca0a2db">268-2000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZmM1ZmY4MWIzYWM2NDBiYzhiZmE2NDYwOTZlZDQ0ZWYvdGFibGVyYW5nZTpmYzVmZjgxYjNhYzY0MGJjOGJmYTY0NjA5NmVkNDRlZl8xLTAtMS0xLTcwMDc3_37778b15-6e19-43a5-9cc9-137fd134605c">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZmM1ZmY4MWIzYWM2NDBiYzhiZmE2NDYwOTZlZDQ0ZWYvdGFibGVyYW5nZTpmYzVmZjgxYjNhYzY0MGJjOGJmYTY0NjA5NmVkNDRlZl8xLTEtMS0xLTcwMDc3_e893880c-7b94-43a6-9b3f-8defc31488da">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZmM1ZmY4MWIzYWM2NDBiYzhiZmE2NDYwOTZlZDQ0ZWYvdGFibGVyYW5nZTpmYzVmZjgxYjNhYzY0MGJjOGJmYTY0NjA5NmVkNDRlZl8xLTItMS0xLTcwMDc3_1767fe33-e981-4dff-ad5f-8aead227677a">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTEw_52540e70-680d-47c8-b039-c0a7e0f26fb2">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTEx_3410d44b-aa86-4426-a5c7-d1735897f9c7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6MWQ4M2RhMmE2MjlhNDI1NjgzYmY0ZjNmNTMxNjFmNDgvdGFibGVyYW5nZToxZDgzZGEyYTYyOWE0MjU2ODNiZjRmM2Y1MzE2MWY0OF8wLTAtMS0xLTcwMDc3_c0dea015-fb2c-47c6-b899-0b0b79650828">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6MWQ4M2RhMmE2MjlhNDI1NjgzYmY0ZjNmNTMxNjFmNDgvdGFibGVyYW5nZToxZDgzZGEyYTYyOWE0MjU2ODNiZjRmM2Y1MzE2MWY0OF8yLTMtMS0xLTcwMDc3_6f00ea92-6ac3-41dd-a54a-f071bb65e709">o</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6MWQ4M2RhMmE2MjlhNDI1NjgzYmY0ZjNmNTMxNjFmNDgvdGFibGVyYW5nZToxZDgzZGEyYTYyOWE0MjU2ODNiZjRmM2Y1MzE2MWY0OF80LTEtMS0xLTcwMDc3_ff821e81-8869-4341-a00a-63b92a6c52ea">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;<ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA4_23dd580e-6967-4d2b-8e43-3c23cbbc49d2">&#9744;</ix:nonNumeric>&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant's Common Stock, $0.01 par value, was <ix:nonFraction unitRef="shares" contextRef="iac274b9c236946588cbd492c3c14688d_I20220731" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMDkx_76ba8793-dd9f-4c60-9c2c-2eba659ff9c6">78,215,105</ix:nonFraction> as of July&#160;31, 2022.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_13">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_16">Unaudited Consolidated Statements of Operations and Unaudited Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_16">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_16"> for the three and six months ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_19">Consolidated Balance Sheets as of June 30, 2022 (unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_22">Unaudited Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the three and six months ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_28">Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_31">Notes to the Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_85">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_85">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_121">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_121">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_124">32</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_127">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_127">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_130">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_130">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_130">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_136">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_133">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_133">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_136">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_136">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_136">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_139">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_139">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_139">35</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_142">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4443801361394f65b2e7b9b03051a84d_142">36</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I. FINANCIAL INFORMATION</span></div><div id="i4443801361394f65b2e7b9b03051a84d_13"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7556a131e55a41578a8e85d487bf5928_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy0xLTEtMS03MDA3Nw_afe642ec-cfca-4c62-aedc-b6617d12cd2e">55,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86be659b16f6450d8c6703acf6588255_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy0zLTEtMS03MDA3Nw_7c96f64c-4693-40ba-80f1-e96f26eda4c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4945289540e9464e912a257f3ab7ee3a_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy01LTEtMS03MzI3Ng_41a0b80b-dfdf-4f7a-9ad4-7d2ea92ccffb">641,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc0120310b244cb8cb07e4863cca3b8_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy03LTEtMS03MzI3Ng_c0fd090c-b348-4a31-865b-5d4120041892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64169e1b64be465ba651f225a820a0a7_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC0xLTEtMS03MDA3Nw_f4658f0c-67ef-468c-9343-2f974a738b8b">107,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740226150bb146dfbab7548d73d95ec3_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC0zLTEtMS03MDA3Nw_29a5f4a4-92f0-42f6-9415-e1703f65b471">272,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02740f8f66c940f49f4d45435b5f33fb_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC01LTEtMS03MDA3Nw_48e4fab0-19f4-4573-9d58-85eb2b0d8901">207,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4244f94bb3dc4fe284264e5bcde0de65_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC03LTEtMS03MDA3Nw_9cf6f22a-3474-4ffc-bcfb-bef1a7893bfd">719,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617f9132150b4ac2b7036afe3dadd382_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS0xLTEtMS03MDA3Nw_81fec82c-2296-466c-aede-6dfcb08b4d16">22,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94de60b1abe4ad58c2380deef7432e1_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS0zLTEtMS03MDA3Nw_76f4bd7e-30a6-44e2-89e5-40c376f74e85">25,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b847b28162428a9c29f3d458bfa24a_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS01LTEtMS03MDA3Nw_52b864b6-5bfa-481f-9f34-570db96acf17">41,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c7c77a593d4ae8b52724afa14921ab_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS03LTEtMS03MDA3Nw_3a571a55-c0e5-4a32-b6d3-18de42d0e740">25,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi0xLTEtMS03MDA3Nw_b1cef4ec-2ed7-4349-a6f6-f9239d3b0277">185,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi0zLTEtMS03MDA3Nw_c880998a-1c7c-4ec4-90b6-6ca0ab2024bc">298,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi01LTEtMS03MDA3Nw_dd87340a-1b7d-4287-9c4a-f617636242d6">889,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi03LTEtMS03MDA3Nw_abaf86db-0c55-4f25-984e-19d89f199b9c">745,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS0xLTEtMS03MDA3Nw_c41cc3f6-f374-4ce0-980b-0f56092eb088">271,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS0zLTEtMS03MDA3Nw_07ce742f-e3cb-43ea-91eb-1683f67581d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS01LTEtMS03MzI4Nw_ac2f840b-7af8-4a7b-9750-0d802417cff5">286,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS03LTEtMS03MzI4Nw_856dc6fe-2336-44fb-8c77-bfb48ca0350b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtMS0xLTEtNzAwNzc_d12a5e62-d254-41e7-9340-130c3afe0605">289,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtMy0xLTEtNzAwNzc_38c7ce33-8df6-4ba0-8ba9-69a81df38188">570,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtNS0xLTEtNzAwNzc_0e5ebe8a-4f1b-4549-83d7-a29b1f2fd583">673,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtNy0xLTEtNzAwNzc_f4c4b08b-d780-4703-b6e8-57808e16651b">1,163,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtMS0xLTEtNzAwNzc_bf0d4e7b-523d-4d1a-a366-097fce47f374">108,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtMy0xLTEtNzAwNzc_4655f40a-4d6d-4154-b446-88606ce7f19d">73,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtNS0xLTEtNzAwNzc_3f4ce3eb-145b-4210-8302-6542325ee8b9">204,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtNy0xLTEtNzAwNzc_959c2b10-0872-4b2c-baf3-f9bba68c8dfc">136,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItMS0xLTEtNzAwNzc_9112a76e-8570-48b0-a2e6-4ecd5c910326">668,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItMy0xLTEtNzAwNzc_44099c0b-a342-4ca2-806c-17c201c2ad48">643,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItNS0xLTEtNzAwNzc_39ec1fdd-12a2-4ee4-9d4a-b6ed05778d57">1,163,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItNy0xLTEtNzAwNzc_03012985-bba0-4ef4-b42e-bd7103f9d90a">1,299,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtMS0xLTEtNzAwNzc_4cc07460-6692-47c3-a4b4-d90d8688ba07">482,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtMy0xLTEtNzAwNzc_d0fd5085-b623-46ac-b707-469b0a7a1f5d">345,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtNS0xLTEtNzAwNzc_eec2f9e0-5c1a-4260-a14b-f12118736539">273,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtNy0xLTEtNzAwNzc_60388d49-fc03-40d2-89fd-e0cd7b4c809f">554,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtMS0xLTEtNzAwNzc_b3e6d438-419c-49bc-92c2-8a825edde6f6">6,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtMy0xLTEtNzAwNzc_3acbb56b-8397-474b-ba5e-427f74fb42cb">5,968</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtNS0xLTEtNzAwNzc_f73fa66b-c752-4e7c-922e-6af24df9a453">11,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtNy0xLTEtNzAwNzc_0a0f1e83-7ef1-4347-a4bc-4e36eeab9432">10,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctMS0xLTEtNzAwNzc_8338aebb-bee4-4ff7-ae73-b4841d1336c9">19,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctMy0xLTEtNzAwNzc_dd2187ae-97b8-46ac-a78d-e976485df9b5">3,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctNS0xLTEtNzAwNzc_d1bf6cd1-b981-41d2-959c-944fe9c1f12c">18,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctNy0xLTEtNzAwNzc_5798b56f-8b49-422c-b1c2-1f8fe13395e4">3,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtMS0xLTEtNzAwNzc_d7995b38-5f5d-471e-a987-9a1e6430a7fe">509,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtMy0xLTEtNzAwNzc_da900809-e4f9-48e3-a84e-2c443f4f2951">348,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtNS0xLTEtNzAwNzc_394e07b7-2344-4dbe-a1e9-a4a37b18f866">302,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtNy0xLTEtNzAwNzc_f67bc456-ed6b-4094-9bf7-1d0bab5fef7b">568,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktMS0xLTEtNzAwNzc_c6e4984c-98e9-42b3-a335-0d63a1166fb1">1,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktMy0xLTEtNzAwNzc_fac6e764-b997-467a-bf11-92536abb7daa">3,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktNS0xLTEtNzAwNzc_52fd194f-0a21-4f14-a6ba-7572f652b329">4,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktNy0xLTEtNzAwNzc_26ea86a4-9dfe-491a-ba9d-907d31f6920f">6,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtMS0xLTEtNzAwNzc_0193cf68-54f9-40f1-8a67-e3a710993f29">510,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtMy0xLTEtNzAwNzc_d12b0340-330b-4d44-b205-5d1a445e562a">352,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtNS0xLTEtNzAwNzc_67a9946a-645a-45c0-8da0-3c9d288b0d95">307,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtNy0xLTEtNzAwNzc_8a98a325-bcce-43b0-96fc-3408adf145d2">575,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtMS0xLTEtNzAwNzc_276eb772-cfca-4fb5-be27-ccad6a76f7ba">6.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtMy0xLTEtNzAwNzc_b55fffe1-fe4c-4548-8300-5136ca8a4aae">4.75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtNS0xLTEtNzAwNzc_92b5a5af-8890-4aaf-b2ba-d55ddfe7026e">3.97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtNy0xLTEtNzAwNzc_3ffe9245-85b3-4cc0-b80a-62bbc6c8c248">7.82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtMS0xLTEtNzAwNzc_da56af27-e89b-4390-8990-4a3c5cd2447b">78,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtMy0xLTEtNzAwNzc_86a91e34-2088-4b74-bbc9-14cca6ad18c9">74,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtNS0xLTEtNzAwNzc_b3058fd8-e21c-4442-8dfe-607895a0f9e2">77,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtNy0xLTEtNzAwNzc_a1b9c7b3-6aac-4082-a652-6f751d2c5165">73,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi0xLTEtMS03MDA3Nw_9ac967a1-e7d6-4fce-9de0-4979e3e83900">510,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi0zLTEtMS03MDA3Nw_a0f014ab-0173-4b63-906b-9c7a41c76fb9">352,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi01LTEtMS03MDA3Nw_c4340e11-f492-4f7b-a7f3-63800a93e74a">307,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi03LTEtMS03MDA3Nw_0f4f8599-f936-41bd-86d9-4dd9fe74561f">575,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on marketable securities available-for-sale, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC0xLTEtMS03MDA3Nw_fe3df98e-43ff-422c-879b-9d36ffc7eb49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC0zLTEtMS03MDA3Nw_a4fcc064-2552-478f-a4b9-8b041cacc6ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC01LTEtMS03MDA3Nw_fd63d77b-c5d8-46b8-acf6-967c743dd122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC03LTEtMS03MDA3Nw_4b8177fa-1b17-4ca3-a134-a4623af892e4">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS0xLTEtMS03MDA3Nw_141d86ef-2ebb-4eaf-b69b-796547b6fe96">9,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS0zLTEtMS03MDA3Nw_41bf2089-0a3a-453e-9c42-e3fbe100384a">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS01LTEtMS03MDA3Nw_cc96118d-1adc-4736-a4bc-fd095f6bbd83">9,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS03LTEtMS03MDA3Nw_207c16d7-6149-47b5-b158-98d4aadc7db2">2,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi0xLTEtMS03MDA3Nw_9f0c5d90-edf6-4199-bace-14d68ee0dbee">9,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi0zLTEtMS03MDA3Nw_f45144d2-f6bf-4ba7-afeb-6c1911957a58">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi01LTEtMS03MDA3Nw_ec8a9a14-998a-4795-8c2c-67bf9dba5fd3">9,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi03LTEtMS03MDA3Nw_402ec931-5233-4edd-8795-24724108ec07">2,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy0xLTEtMS03MDA3Nw_78e46828-a331-4cbf-8f7e-663196f49669">520,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy0zLTEtMS03MDA3Nw_5159d135-1d9c-4b5d-9d6c-e78f0acaf97b">347,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy01LTEtMS03MDA3Nw_a8d28da1-dda5-4255-bdf4-29adcafdbe7c">316,594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy03LTEtMS03MDA3Nw_bc9da64a-83d5-4c58-9b04-6f928fb812ee">577,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span><br/></span></div><div id="i4443801361394f65b2e7b9b03051a84d_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share information)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNC0xLTEtMS03MDA3Nw_94829871-2f04-43fa-ac7f-67c060ce2217">1,375,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNC0zLTEtMS03MDA3Nw_ba87fb7f-dcd4-494c-9c31-6c2d94ca3b1e">1,515,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNi0xLTEtMS03MDA3Nw_2367c1ec-d8b8-49b0-b9b3-c1aa96de1ac9">10,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNi0zLTEtMS03MDA3Nw_dd7c3c63-6acb-4018-ab2a-07eca940f46f">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNy0xLTEtMS03MDA3Nw_a8756f77-f1b8-43c5-8001-7a442fa399d7">194,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNy0zLTEtMS03MDA3Nw_9812aa77-6409-436e-a3d4-3ee3cf3405e7">454,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOC0xLTEtMS03MDA3Nw_305c451a-ecd5-4a14-af63-c716ee109838">256,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOC0zLTEtMS03MDA3Nw_a3835a2e-296f-42ee-a414-cc4f6c7161d5">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOS0xLTEtMS03MDA3Nw_9d5f8203-4298-48ae-bcb4-1279c1c2cfd3">299,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOS0zLTEtMS03MDA3Nw_9d1991b7-80c5-4641-a4bb-fbd9beea2e8c">164,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTAtMS0xLTEtNzAwNzc_2bcd72e2-501d-407b-b1d1-52a20a61f224">2,136,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTAtMy0xLTEtNzAwNzc_9fa209d0-3a79-4644-81ee-41dc8a7c8728">2,155,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTEtMS0xLTEtNzAwNzc_c0349c5f-f8f8-4a8d-878e-e4cb3eae0fc1">254,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTEtMy0xLTEtNzAwNzc_5195ce82-5162-4912-bc8d-0385c38db4d2">228,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use asset, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTItMS0xLTEtNzAwNzc_881fa3ba-f5bd-47c5-93b4-69205ac5404f">85,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTItMy0xLTEtNzAwNzc_d3679db3-01ce-42fd-afdc-5ea8642ae75d">40,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMS0xLTEtNzM1NDM_b312d14d-bccf-4305-8223-d9e110ac0ff7">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMy0xLTEtNzM1NDM_4b11a731-7b1e-4725-98fa-f92fd6b409ce">4,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMS0xLTEtNzI3MTQ_e6b4dc5a-ee30-47d9-bfbf-a75ee03409fa">123,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMy0xLTEtNzI3MTQ_4578d830-3a11-4f76-8d0a-880faba608a2">131,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTUtMS0xLTEtNzAwNzc_c299de3e-d94c-4107-b027-c6ed1c1719b7">19,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTUtMy0xLTEtNzAwNzc_2b13f4b7-167f-443c-a876-d17039fe4d9b">16,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTYtMS0xLTEtNzAwNzc_29994346-c631-4cab-b622-0df8c69d4e3a">2,622,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTYtMy0xLTEtNzAwNzc_a6df94b3-d625-4b88-b291-7ad702fbd778">2,576,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTktMS0xLTEtNzAwNzc_97c1a90b-846a-44cc-80cf-909650829b89">386,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTktMy0xLTEtNzAwNzc_9b7e0d7c-c645-4fa5-bc84-917d5e50c016">127,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjAtMS0xLTEtNzAwNzc_f9417f41-cd0b-4441-87df-0b419657313b">585,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjAtMy0xLTEtNzAwNzc_3151a2a5-c5aa-4065-bf99-724d46906c30">673,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjEtMS0xLTEtNzAwNzc_17874449-a15a-4fb0-b844-2fe4ac857ca4">701,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjEtMy0xLTEtNzAwNzc_89647d2f-448b-4c6a-ac03-af5788e588d8">1,422,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjItMS0xLTEtNzAwNzc_89543840-ca64-4615-b58a-b895a373f7c5">124,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjItMy0xLTEtNzAwNzc_917ff05d-00d4-44ee-a34c-f23181b0f484">130,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjMtMS0xLTEtNzAwNzc_5524f170-3e6d-4b43-910c-59f419590437">324,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjMtMy0xLTEtNzAwNzc_cd3b25b7-eb39-41ed-af8d-b8fdfebf5feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjQtMS0xLTEtNzAwNzc_39f344c3-fdf0-479b-996c-ec734597e21e">34,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjQtMy0xLTEtNzAwNzc_15035823-5d17-4a4f-aa50-9ea46745bd01">36,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjUtMS0xLTEtNzAwNzc_cff91132-5107-4a8b-8f3f-c03f7b1cecef">2,156,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjUtMy0xLTEtNzAwNzc_1328fb64-ea37-4db3-b814-f9c354615b6f">2,390,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjYtMS0xLTEtNzAwNzc_a943e2db-9ee4-47a0-804c-87e88154fcf0">814,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjYtMy0xLTEtNzAwNzc_a7c9692d-e6d4-4a13-b334-e8f26fc34ec5">172,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjctMS0xLTEtNzAwNzc_a025a5fd-5fb1-4f68-9dd7-21d10ec3506b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjctMy0xLTEtNzAwNzc_c8f19f05-01ef-45d4-8277-76fefd2edd40">323,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjktMS0xLTEtNzAwNzc_e5803544-0c08-4100-a0f1-39fab99ddb12">69,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjktMy0xLTEtNzAwNzc_f8885f72-364c-4c92-8b90-b226deee7a87">42,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzAtMS0xLTEtNzAwNzc_4622c8eb-8cba-4ce2-8105-41c4a65220df">3,039,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzAtMy0xLTEtNzAwNzc_bcb898b9-4c43-4338-8d47-c32d785d0c94">2,928,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzItMS0xLTEtNzAwNzc_e578241d-dc17-4132-b771-80e40f34c107"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzItMy0xLTEtNzAwNzc_7be1e852-8087-4766-bbe3-ba01db2da05b"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xOA_3a3ad017-0d88-4a7e-baf0-31712fd7840d"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xOA_faacaa0c-480b-45f1-a9da-32e0f50fee7a">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8zMg_02a5609f-c58d-4162-bb60-092c8840572f"><ix:nonFraction unitRef="shares" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8zMg_aad9caec-fd50-4ecf-8b91-383d7b179198">600,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2022 and December 31, 2021; and <ix:nonFraction unitRef="shares" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV85OA_b754f6c9-dc5e-4cf2-82b1-93865b262990">78,776,234</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xMTk_a127474f-f350-4edd-921b-ddb379b04faa">78,166,935</ix:nonFraction> shares outstanding at June 30,&#160;2022 and <ix:nonFraction unitRef="shares" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xNjM_85b8882a-2cb0-4d9a-aa89-bc2b793b39f7">76,433,151</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xODQ_caa77f7b-6c65-4e2b-9782-f70dee648cf6">75,841,171</ix:nonFraction> shares outstanding at December&#160;31,&#160;2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMS0xLTEtNzAwNzc_2ccbcc3e-3e4d-437d-b31d-d4d136c13c3a">788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMy0xLTEtNzAwNzc_95b846d9-4607-44fe-a365-69376b776d16">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzgtMS0xLTEtNzAwNzc_5b23dff0-69e4-43d8-b09e-13b5b35c41d5">3,604,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzgtMy0xLTEtNzAwNzc_c4c4e1d6-92ca-4a7e-ae27-441424520b96">3,351,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzktMS0xLTEtNzAwNzc_982c065b-fce0-4dd7-8902-9cb753d02384">3,925,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzktMy0xLTEtNzAwNzc_1c5dc0aa-b545-416b-b3e4-9b062b4647ab">3,617,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, cost basis, <ix:nonFraction unitRef="shares" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo3MDIyOGZlNjUyOGU0OGQwYjQwZjkyNzkzNTg4ZGE0MV8zMg_2c8876d5-4d6e-40ff-a268-9a0c1d083c2d">609,299</ix:nonFraction> shares at June 30,&#160;2022 and <ix:nonFraction unitRef="shares" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo3MDIyOGZlNjUyOGU0OGQwYjQwZjkyNzkzNTg4ZGE0MV82NA_e70be996-cd64-4e72-a137-ecdf8f4bf66c">591,980</ix:nonFraction> shares at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMS0xLTEtNzAwNzc_09c15a31-3300-415d-8f41-bdca26ddec97">86,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMy0xLTEtNzAwNzc_2e1aaabd-be1e-4d79-82a5-371266883525">85,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDEtMS0xLTEtNzAwNzc_88c2b89f-daf6-4d0a-b307-c1e41ebcf375">10,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDEtMy0xLTEtNzAwNzc_235cd86c-30fb-4445-830d-e4dd89b3a3b2">1,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDItMS0xLTEtNzAwNzc_7131e1b0-85c8-45b6-8b0d-f5aa6ddf8d8d">416,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDItMy0xLTEtNzAwNzc_b3fe81b2-4b29-4df5-89d1-a05dd61e039b">351,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDMtMS0xLTEtNzAwNzc_98f9fe3c-1715-4a8f-9432-ed1f04a34d32">2,622,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDMtMy0xLTEtNzAwNzc_bb74b947-8b39-465f-82f3-7f66bc034f1c">2,576,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Three and Six Months Ended June&#160;30, 2022 and 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:19.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.676%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96110cf81ced478b94da040072a11097_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0xLTEtMS03NzA2OA_eb57a000-269b-4e93-8877-fd1dcc5d9130">78,722,337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96110cf81ced478b94da040072a11097_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0zLTEtMS03NzA2OA_ec860307-4f42-4e3b-bca1-e6fa11388c86">787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983653fedfdd46e4964ac7eaa476f0e5_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi01LTEtMS03NzA2OA_81d65d33-2aa6-41be-87ad-ac7ac7f52df0">3,566,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf44cd7a49ed4b979d3cd163e2c5dec2_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi03LTEtMS03NzA2OA_96416c52-1ffa-438a-93f6-c13b2f7f81a0">3,414,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e37e7f85f974859b9fe1672ca2f4c4b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi05LTEtMS03NzA2OA_9219926e-575e-4fdd-9521-54926f81c773">85,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3693bbbf47294faf81643217cb838507_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0xMS0xLTEtNzcwNjg_c78bfb3d-d2b8-4b2f-a394-608c1cf9bd4c">1,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia99b9d9cf9ba4355b1dc30fa79ba361a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0xMy0xLTEtNzcwNjg_43179207-d033-4e8d-bb4e-93cf622e5759">65,324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c178e9d82a4bc383bed84c24bc1076_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMy01LTEtMS03NzA2OA_3435db4d-686d-4d69-8b7a-eefd6d01e767">38,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMy0xMy0xLTEtNzcwNjg_b878b650-862e-46bd-b0ef-52e703e5e37d">38,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff1af4fb674a440d80223f9f311ac5da_D20220401-20220630" decimals="INF" name="nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC0xLTEtMS03NzA2OA_ba240175-4812-4bb0-8c2b-8022bd177bbc">53,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1af4fb674a440d80223f9f311ac5da_D20220401-20220630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC0zLTEtMS03NzA2OA_c5d8ddb1-2499-4fea-b83a-c3f28155b809">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c178e9d82a4bc383bed84c24bc1076_D20220401-20220630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC01LTEtMS03NzA2OA_bb1b019a-edf8-4db2-9013-094503369fc5">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7901003cbe7c4f97a451e89abdfb7a0f_D20220401-20220630" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC05LTEtMS03NzA2OA_d73804aa-e6b5-41d6-927f-1c309f322b79">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC0xMy0xLTEtNzcwNjg_dbe0b781-acc8-4e0b-80fb-334c54ddd91d">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4a6154851b4416b8f89cad0ad7721af_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNi0xMS0xLTEtNzcwNjg_775c8a4b-8903-4ade-9562-9f9dbc0759bb">9,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNi0xMy0xLTEtNzcwNjg_808852da-8d03-4589-8020-728edc5f1d8e">9,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54872cb8e40f4eb092ba0fc3d8a1095b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNy03LTEtMS03NzA2OA_162d985d-1a2d-427e-9dc8-bc9b9d4123e5">510,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNy0xMy0xLTEtNzcwNjg_b2a4c1a2-d3d0-4ad8-afd3-40e1faf5bcd9">510,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0xLTEtMS03OTk2OQ_d283d895-2e80-4117-be6b-fb3faf4d0808">78,776,234</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0zLTEtMS03OTk2OQ_7d21b845-ef00-472c-a5b0-54dd3c2a6172">788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1363bb3470f4a45b7d8cc8d9e9e6aea_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC01LTEtMS03OTk2OQ_f5d65690-b75d-441f-8ecc-249b4cf24315">3,604,614</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab83a560ba0b4becb4f5f507cccb33e3_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC03LTEtMS03OTk2OQ_8617db65-8f1d-4cfb-9eef-95d1559e0c23">3,925,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69ae795236fd4899979c4bd46c38a184_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC05LTEtMS03OTk2OQ_51964f10-fbe1-4ad7-91c7-9362b0017a81">86,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2e3eb175a484325be7a301736e4107e_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0xMS0xLTEtNzk5Njk_5dbd0291-fecb-4ef3-a388-ed1f815a6424">10,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0xMy0xLTEtNzk5Njk_bbaac430-00df-4d18-87d7-f66ab32b8bd5">416,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d1712c0418943ea9ef19b5b840ad622_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMS0xLTEtNzcwNjg_d082bcdf-2253-4c06-902b-68df33ddb1a1">74,470,583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1712c0418943ea9ef19b5b840ad622_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMy0xLTEtNzcwNjg_d21f5ec0-6b1d-47cc-978b-7c8ecbb248d9">745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263537bdec814cf6b1cc7b8e9842db81_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtNS0xLTEtNzcwNjg_37e3b838-e71c-4f5f-90b6-dae5a2566d25">3,180,114</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ac113f7c93d433688947c243e83b2b6_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtNy0xLTEtNzcwNjg_d4aa7dac-824c-4f50-879a-c3bd52070563">2,096,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i747d203795fc4040966baf276eafa5a9_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtOS0xLTEtNzcwNjg_98bac3fc-b463-4efc-a6d6-cf68d92b7d1d">44,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i400373f4f92f47119a751c4590a1d32c_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMTEtMS0xLTc3MDY4_65731675-8672-4c33-909e-4766e2aba1a4">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df15bfb369349d6aa42604f4e939b05_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMTMtMS0xLTc3MDY4_57d0edc2-704f-4def-95e7-f414d1de6cda">1,039,127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf962fca8d1f43e9a4a5c58859e8e5b3_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTEtNS0xLTEtNzcwNjg_0bf6673d-5d12-4e93-ac9a-9628fd6cb491">53,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTEtMTMtMS0xLTc3MDY4_c5d83720-4eb7-452e-99cb-b1d40c7c1ec4">53,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f0ff7a0136d4a4fb89c7bcb66b8a4d4_D20210401-20210630" decimals="INF" name="nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItMS0xLTEtNzcwNjg_061b5735-d32e-4d38-b253-aef2bb99a887">201,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0ff7a0136d4a4fb89c7bcb66b8a4d4_D20210401-20210630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItMy0xLTEtNzcwNjg_29e785ef-adcd-403d-8080-980512528110">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf962fca8d1f43e9a4a5c58859e8e5b3_D20210401-20210630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItNS0xLTEtNzcwNjg_f866a21c-9e9c-496d-992b-fa724be2d118">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5f7de39972c467d8d744008d112cbdb_D20210401-20210630" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItOS0xLTEtNzcwNjg_6765118c-750d-4b0d-ba06-6ac0d277802c">2,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItMTMtMS0xLTc3MDY4_05a7b73d-d4a2-4677-85c6-9da1c4f7eb2d">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595ec53f965547f3ba917a056296edf8_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTUtMTEtMS0xLTc3MDY4_b49e87aa-5f38-455c-9ee7-e756e608591b">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTUtMTMtMS0xLTc3MDY4_ab20b6a2-ca01-449b-b76c-50fa22428561">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e1b68160b843778dbca3e791b341ca_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTYtNy0xLTEtNzcwNjg_98c66474-c35a-46fa-94f0-eedc0112974f">352,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTYtMTMtMS0xLTc3MDY4_424b23d5-563f-40b9-8c7b-8881aebdb395">352,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dad49772b0f48038418785e8e761874_I20210630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMS0xLTEtNzk5NzE_a4d77335-dac0-4aff-94d8-7c73065c765d">74,672,351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dad49772b0f48038418785e8e761874_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMy0xLTEtNzk5NzE_49138752-ed90-4289-b389-073fa0218d29">747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1514b2ba3b4666a00d9813765198b7_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctNS0xLTEtNzk5NzE_5e59dd84-b1ac-43e6-8bbd-dc0b0f2f36fc">3,237,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec245d5ef2c943f88458628a12c5efa7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctNy0xLTEtNzk5NzE_be7fca89-e693-4c97-8118-63440de89f90">2,449,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fc8de8da83641cc91ef608da7bf7d7e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctOS0xLTEtNzk5NzE_5eaebe9b-df09-42e0-bc00-0c8f865cc43a">47,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36438295aede46c58b4392a1543df581_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMTEtMS0xLTc5OTcx_7c6b484e-14bf-4883-9ba3-de45237785e0">4,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3583256bab459492a5d569f0fabc95_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMTMtMS0xLTc5OTcx_17c5f039-0184-4c21-a111-e65cfbf14699">745,562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity (Deficit)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9542317971e482c84dd6b1322d3ee2a_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0xLTEtMS03MDA3Nw_120637ea-ca57-4281-8da8-0a97328805fa">76,433,151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9542317971e482c84dd6b1322d3ee2a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0zLTEtMS03MDA3Nw_08db1ad3-83e9-4280-a517-4c8b58bdd45f">764</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47b8f663b084ad7aa112c61216cecf1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy01LTEtMS03MDA3Nw_e762c2a7-d8b5-4eda-98dc-1cc96ff78c41">3,351,967</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77212d37c7d542c58864ca99739f51a6_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy03LTEtMS03MDA3Nw_f1ceeb8b-2cb8-4be0-a940-21b7256cd932">3,617,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a6ec54d49b44673ad5cceb7f2022d14_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy05LTEtMS03MDA3Nw_e598d411-e699-457d-8f41-dcc1cd06f0e4">85,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81c45885967040cb9ddd39bab52e20d4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0xMS0xLTEtNzAwNzc_e7cb9d7f-ea2e-469b-bbcb-15dcb3923aa7">1,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0xMy0xLTEtNzAwNzc_e43926cf-1163-418b-8df8-a2887646e542">351,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNC01LTEtMS03MDA3Nw_1d1ad01d-548d-4449-a3da-f5e1f93ed43a">70,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNC0xMy0xLTEtNzAwNzc_8b28cfaa-1320-466e-8fd2-07678f345001">70,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630" decimals="INF" name="nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS0xLTEtMS03MDA3Nw_764f357d-b3bb-423b-bebf-111f404e2463">145,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS0zLTEtMS03MDA3Nw_cc829f79-d547-46a1-8e97-d4649b4f054e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS01LTEtMS03MDA3Nw_a8d7b2ba-9578-4a42-8ea6-d9b60bdb2702">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5216318c35f44e2ca8de90f56766c348_D20220101-20220630" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS05LTEtMS03MDA3Nw_7ff33c66-41e0-44af-b7b3-58e0719cee42">1,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS0xMy0xLTEtNzAwNzc_044b8a40-0376-4045-beeb-406d97f4ba61">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0wLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjEzYjgxODY2NDhlZjQ3ZTU5OGI5YmZjNDRlMmU4MDViXzU1_ab6cd8ee-65a5-4853-9e4b-5e902b52751d">2,311</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0xLTEtMS03MDA3Nw_a9fa2719-03b4-4ef3-a658-a7a962b52e5d">2,197,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0zLTEtMS03MDA3Nw_baf2935f-03d8-4e4c-b63a-9be943eb1bb6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi01LTEtMS03MDA3Nw_f9b5f5ad-922c-491c-9738-065532802e3a">179,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0xMy0xLTEtNzAwNzc_1fa05ff4-e2fb-4873-b539-6ad81f8b8c6c">179,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cc5b57fa7f04963a7a9f040883b44c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOC0xMS0xLTEtNzAwNzc_85845994-8e20-4f9b-85c1-c0e284394450">9,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOC0xMy0xLTEtNzAwNzc_d200a6db-2462-430e-8a65-4fdfc79ffb8a">9,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if166d44b16b444dda0cd485ceb01788d_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOS03LTEtMS03MDA3Nw_c70e7e09-5b79-4da2-8b68-dcc4e3773531">307,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOS0xMy0xLTEtNzAwNzc_cfc5e28f-f08f-4ad3-b042-78eb18d7e07e">307,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMS0xLTEtNzAwNzc_e2a9930b-a523-4973-a506-2574e7228a28">78,776,234</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMy0xLTEtNzAwNzc_0605bf94-0191-4a5d-8386-1095c65a4157">788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1363bb3470f4a45b7d8cc8d9e9e6aea_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtNS0xLTEtNzAwNzc_02cebf89-1384-46e9-b94a-0d504cddc1a9">3,604,614</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab83a560ba0b4becb4f5f507cccb33e3_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtNy0xLTEtNzAwNzc_8b9485c8-ac9e-40ef-a438-73b48b4ccf90">3,925,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69ae795236fd4899979c4bd46c38a184_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtOS0xLTEtNzAwNzc_b13df168-3df7-49ee-b245-58273ec745d0">86,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2e3eb175a484325be7a301736e4107e_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMTEtMS0xLTcwMDc3_f1234b90-c822-48e2-96f4-e0f5111e9480">10,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMTMtMS0xLTcwMDc3_95a0f8a8-55f0-47dc-94df-6a7004d23908">416,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd833ef8d89041a0a5d6c047bc63754d_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMS0xLTEtNzAwNzc_adaa2ae4-b64d-44ce-888f-c446569f8044">71,350,365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd833ef8d89041a0a5d6c047bc63754d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMy0xLTEtNzAwNzc_f8c7aeb7-1bb0-4b58-949e-a1884bb18942">714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7880242152934fbeb18732d8cb58a141_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItNS0xLTEtNzAwNzc_fca54e23-99b9-492d-80c6-45a4f2aff348">2,535,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib399728718c84112836d2a89efc58c0d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItNy0xLTEtNzAwNzc_18eeb035-084a-426c-b8f9-0e2fbd835179">1,874,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i523ac32f976545eba62aaa06ede3c7da_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItOS0xLTEtNzAwNzc_396f2b6e-759e-4f06-9c0f-e56f8dabb05a">41,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95178a09622409fb2fd15e1080134c5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMTEtMS0xLTcwMDc3_0b7cd7d9-c10e-49e5-9ee7-e2c8e82c2673">7,024</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba72b9644274960974bf6ff07008c73_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMTMtMS0xLTcwMDc3_b654aebb-3feb-43cc-af97-dbd54bddde5d">627,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTQtNS0xLTEtNzAwNzc_5ca49b4c-21ad-4a21-b4ea-11b309880549">106,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTQtMTMtMS0xLTcwMDc3_99635814-0df8-44a0-aef5-7e973855bb58">106,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630" decimals="INF" name="nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtMS0xLTEtNzAwNzc_84b4df42-6ba9-4c8e-a6c8-33d8b7e137f6">743,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtMy0xLTEtNzAwNzc_1f926456-bc53-4199-93c9-89662e0a6e26">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtNS0xLTEtNzAwNzc_0a1ddd2d-5c4d-4b03-a80f-2220ec07edc3">30,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55283e03483840778793f0003169278b_D20210101-20210630" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtOS0xLTEtNzAwNzc_2e693f77-1567-4f19-8ea3-7dce1586ec3b">5,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtMTMtMS0xLTcwMDc3_1fa31234-1f19-40b2-af67-afc573ee83e5">25,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjoxMmYxOWFlNzMzOGQ0YjI3OTZmODEzYThlZDdjOGFkZl81NQ_244bfb1d-5d66-459d-b5c3-37294a63df82">5,145</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMS0xLTEtNzAwNzc_e303be49-25ab-4518-a276-735e06294239">2,578,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMy0xLTEtNzAwNzc_cebfca8e-17ac-4127-9be8-ad56583a2348">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtNS0xLTEtNzAwNzc_f57f4eb4-fe92-4c65-a2b8-e9f667650eb8">564,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMTMtMS0xLTcwMDc3_5356b5ae-5d8b-47dc-8d12-0ddbca131456">564,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1298fd9885d641b1be701807b92420b3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTctMTEtMS0xLTcwMDc3_762ff342-6ce2-4eca-9120-3a64e352697f">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTctMTMtMS0xLTcwMDc3_9cf61b07-c0ae-4ae9-aab4-035ca482a5cc">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1298fd9885d641b1be701807b92420b3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTgtMTEtMS0xLTcwMDc3_b65c548a-e327-47cc-a3d0-559fe77d6be6">2,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTgtMTMtMS0xLTcwMDc3_554bbb47-f638-4c68-9409-fc5383303888">2,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b6e942b2faa424d97c0830be1ea20ad_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTktNy0xLTEtNzAwNzc_b797b75d-ae69-45f5-ba60-295b3616f110">575,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTktMTMtMS0xLTcwMDc3_6a8cb7b5-2140-4556-bbac-fc785d67c2a3">575,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dad49772b0f48038418785e8e761874_I20210630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMS0xLTEtNzAwNzc_c4644608-6cf5-4017-932c-4019e1f5bbf3">74,672,351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dad49772b0f48038418785e8e761874_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMy0xLTEtNzAwNzc_a7d41686-0ff6-4703-9340-6723b26e7b29">747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1514b2ba3b4666a00d9813765198b7_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtNS0xLTEtNzAwNzc_cd2e8f11-2efe-49ba-a2b0-4d348e4c15cb">3,237,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec245d5ef2c943f88458628a12c5efa7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtNy0xLTEtNzAwNzc_99568bc2-0bf0-4895-8192-ac9d48ddb92e">2,449,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fc8de8da83641cc91ef608da7bf7d7e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtOS0xLTEtNzAwNzc_1431682c-a058-4b7e-91de-4837b02d26a0">47,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36438295aede46c58b4392a1543df581_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMTEtMS0xLTcwMDc3_5520fef2-9bef-4398-ba44-4e490e7f698c">4,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3583256bab459492a5d569f0fabc95_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMTMtMS0xLTcwMDc3_16e663af-a8a5-4c44-9263-0ea9deb87d29">745,562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="i4443801361394f65b2e7b9b03051a84d_28"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMy0xLTEtMS03MDA3Nw_be0e94a3-b2ab-43d1-b99c-74e8f0d5cc2f">307,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMy0zLTEtMS03MDA3Nw_fd04c235-d8a2-4aad-aede-e5e59826d806">575,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reconciliation of net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNS0xLTEtMS03MDA3Nw_52ebe00b-c114-4d9b-bf17-2a792a3c1ddb">13,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNS0zLTEtMS03MDA3Nw_5734f9f6-0fa1-4d6b-8baa-9e65372767ce">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNy0xLTEtMS03MDA3Nw_e111240e-f2fa-44a1-a01e-51b3ce928f6b">70,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNy0zLTEtMS03MDA3Nw_c027b1c2-4453-40f0-b63c-258aa1a29e98">106,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for excess and obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0xLTEtMS04NDEzOA_70eae125-4a19-400f-962f-6047a9fa6899">155,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0zLTEtMS04NDIwMA_62a32cf5-8faf-47dc-8f60-44805b32354b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets expensed, net of credits received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0xLTEtMS03MDA3Nw_04f65e7a-f866-4151-8c7a-bab8bf0d8316">3,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0zLTEtMS03MDA3Nw_39f278a0-2c78-42d0-8f80-3dffa7fa928f">12,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOS0xLTEtMS03MDA3Nw_90a8364b-bc39-4fba-ac20-39780da92493">642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOS0zLTEtMS03MDA3Nw_5274bae2-77a7-4464-a505-ea74339f7f95">3,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTEtMS0xLTEtNzAwNzc_d1b828ec-4f7e-4e0f-95b2-0e00ba8f00ec">403,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTEtMy0xLTEtNzAwNzc_f407e322-95b9-468f-9a18-9881e8167226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses, and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTItMS0xLTEtNzAwNzc_2a51bc9c-55ea-46dc-9345-b450a6dfad8a">112,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTItMy0xLTEtNzAwNzc_6864e884-cf53-4626-8141-e88466c45878">193,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTMtMS0xLTEtNzAwNzc_86546006-57a9-4084-aa1b-66372510c831">179,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTMtMy0xLTEtNzAwNzc_b11fbbc5-0dda-454c-9388-5d45b6662bce">115,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTQtMS0xLTEtNzAwNzc_686eb990-0b52-42d3-888b-679189c2cf6a">76,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTQtMy0xLTEtNzAwNzc_7de2a1b1-1b91-4189-a776-a02ef5c9e99d">946,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTUtMS0xLTEtNzAwNzc_b9766fc2-0a77-4ef8-91b9-a659239ce4a0">259,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTUtMy0xLTEtNzAwNzc_496c0c44-2f35-4ed0-a807-a6adc389c5ac">807,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTgtMS0xLTEtNzAwNzc_dbbaa9db-3a8f-4aca-88f7-51cca51c12d4">41,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTgtMy0xLTEtNzAwNzc_e362652c-2ee3-4dca-bd5c-034c6daff0b4">28,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTktMS0xLTEtNzAwNzc_b994aca4-0fc1-408b-9f45-7cd77e7fe2a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTktMy0xLTEtNzAwNzc_f22a9a91-f406-4907-8049-2f3e88657636">2,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjAtMS0xLTEtNzAwNzc_6b3dee7c-e90a-4f27-a17f-7f2fbf6afdbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjAtMy0xLTEtNzAwNzc_d9b87fe6-e251-416f-a00a-71da85ec780e">159,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjEtMS0xLTEtNzAwNzc_4abdd1bb-edc0-4063-82d8-bf103f3c83a1">41,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjEtMy0xLTEtNzAwNzc_ec04fa68-d566-4fce-9c3b-7f702262ed43">128,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from sales of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjQtMS0xLTEtNzAwNzc_a26653c8-a5e3-4ce2-8e8a-0e576d237b50">179,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjQtMy0xLTEtNzAwNzc_90d674a5-48af-4a98-b65d-3637e2f82392">564,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from the exercise of stock-based awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjUtMS0xLTEtNzAwNzc_bb02f1d5-b12a-41fd-b78f-54da6e9e5e5a">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjUtMy0xLTEtNzAwNzc_b1ed3eb3-156b-400e-baa8-1fe446746fef">26,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjYtMS0xLTEtNzAwNzc_678dbdd2-6417-41b7-a96b-81416938585b">15,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjYtMy0xLTEtNzAwNzc_e963d87b-145c-42df-9021-eee461733298">53,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjctMS0xLTEtNzAwNzc_875242e8-b3ff-4e92-bb02-f1d44b668fc2">164,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjctMy0xLTEtNzAwNzc_949835ae-48ef-4aa6-a090-b2e753fd00e7">538,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjgtMS0xLTEtNzAwNzc_7e1e655a-e57c-4104-8a26-35e7a24252d6">4,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjgtMy0xLTEtNzAwNzc_aac27093-89d9-4020-a8a4-1b782a51e105">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjktMS0xLTEtNzAwNzc_20ecc0ec-2ff6-461e-8ca9-df7f8073c0e1">140,744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjktMy0xLTEtNzAwNzc_b15a68fa-541a-4f0f-a9cf-51cb216b1e0a">1,474,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzAtMS0xLTEtNzAwNzc_50dc1c61-9914-4042-9aec-a18389fe8d6d">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba72b9644274960974bf6ff07008c73_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzAtMy0xLTEtNzAwNzc_991105fa-640c-40af-b98f-258b14455432">648,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzEtMS0xLTEtNzAwNzc_5ee608fa-99a5-4852-b134-fda844d27a83">1,387,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3583256bab459492a5d569f0fabc95_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzEtMy0xLTEtNzAwNzc_5f1b9808-6721-48a8-8a05-49387fd14d94">2,122,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets from new lease agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzYtMS0xLTEtNzAwNzc_6b14e19c-1b98-4847-aaf1-fb7eb76bc39a">69,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzYtMy0xLTEtNzAwNzc_30f32306-9ad4-475d-b53d-1450e976f5e8">28,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzctMS0xLTEtNzAwNzc_5ce87283-3199-4a9e-b6c0-e98c9ee9d11d">17,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzctMy0xLTEtNzAwNzc_961d68e9-5dc5-41f9-9297-27a21b7f3402">11,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash interest payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDAtMS0xLTEtNzAwNzc_2546073e-b9b5-444d-97a6-cfd7315a5b72">8,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDAtMy0xLTEtNzAwNzc_1d1a270b-afd8-4d8f-af87-f3bfb2228671">10,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDEtMS0xLTEtNzAwNzc_61f3c126-57f8-44c3-afe3-f7b717faac0b">17,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDEtMy0xLTEtNzAwNzc_41226d33-4bb9-4954-b7d9-b1f2deed5ff0">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i4443801361394f65b2e7b9b03051a84d_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;1&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNC9mcmFnOjYzY2EyYzY0MmYxYTRmZWY4YzUwNjJlYWZmZGE4MDNhL3RleHRyZWdpb246NjNjYTJjNjQyZjFhNGZlZjhjNTA2MmVhZmZkYTgwM2FfMTU5NQ_36643579-64b1-43fb-a4b6-d7fdcc525644" continuedAt="i6521c99d359546499d695b0842b6ffe7" escape="true">Organization and Business</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6521c99d359546499d695b0842b6ffe7"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#8217;s coronavirus vaccine, NVX-CoV2373, and its lead influenza vaccine candidate, a quadrivalent influenza vaccine, previously known as NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. NVX-CoV2373 and the Company&#8217;s influenza vaccine include the use of the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> adjuvant. The Company is developing various variant vaccines, including for Omicron subvariants, and bivalent formulations with prototype vaccine (NVX-CoV2373). The Company has announced preclinical boosting data for NVX-CoV2373, NVX-CoV2515, and bivalent formulations which demonstrated strong antibody levels. The Company is also participating in an ongoing Phase 3 strain change trial to assess safety and antibody responses following primary vaccination with mRNA vaccines.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for NVX-CoV2373, including by the World Health Organization (&#8220;WHO&#8221;), as well as the European Medicines Agency's (&#8220;EMA&#8221;) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), both of which are considered regulatory authorities that apply stringent standards and meet the WHO standards for quality, safety, and efficacy in their regulatory review process. In July 2022, the Company received emergency use authorization for NVX-CoV2373 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company commenced commercial shipments of NVX-CoV2373 doses under the brand name Nuvaxovid&#8482; in 2022.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;2&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMA_32122b51-0b67-4bf2-8ca8-243f67399469" continuedAt="i6666e5cd2cec4f94bc757a6b1e11b147" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6666e5cd2cec4f94bc757a6b1e11b147" continuedAt="i3141ca538a634606b3179cdf7843287f"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxNg_76ec67b5-04b0-4ecf-a142-f7fcc01db9af" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Accumulated other comprehensive income included a foreign currency translation loss of $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfMTQ1MQ_c38dcaf6-311a-4b1b-ace8-c2815ece1d1a">10.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfMTQ1OA_fe6608e4-1f34-4a52-badc-35f2bdc6bd3e">1.4</ix:nonFraction> million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in <ix:nonFraction unitRef="segment" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfMTg2Ng_53f4c064-8699-447d-a540-e3869ff11f0a">one</ix:nonFraction> business segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxNw_3faf240b-b6b6-4ed1-951c-1bc5d890c94d" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="i3141ca538a634606b3179cdf7843287f" continuedAt="i5bd6436a6d114dcba9953cd20ba3526a"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxOA_ac674b7b-a20d-41ff-9050-71ae1b3e5e35" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMQ_da58b4d1-6582-4d3f-9e70-6dce26bcc17e" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition - Product Sales</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Product sales are associated with the Company&#8217;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMg_9e1ad2c6-e27b-410d-9859-3fe2224e8956" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs which were expensed prior to regulatory authorization as described under the caption &#8220;Inventory&#8221; below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxOQ_e5aa6107-7fec-48dc-bce1-0e183efb0dc3" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Inventory</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out (&#8220;FIFO&#8221;) methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, the services and products of third-party suppliers, and the application of manufacturing overhead. The Company utilizes third-party contract manufacturing organizations (&#8220;CMOs&#8221;), contract development and manufacturing organizations (&#8220;CDMOs&#8221;), and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMw_f7926040-c9c8-4d2a-8bac-70c7ab01ab99" continuedAt="icc7a45d4c58140389e0446595fc314e8" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020 and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; (&#8220;CECL&#8221;) model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management is currently evaluating the effect of the guidance and does not expect it to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="i5bd6436a6d114dcba9953cd20ba3526a"><ix:continuation id="icc7a45d4c58140389e0446595fc314e8"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTQ3MQ_dea22a5a-2729-4480-b159-8fb94c4b4c20" continuedAt="ifcb9df698dbb4488b19cfef236a0acc2" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="ifcb9df698dbb4488b19cfef236a0acc2" continuedAt="i4e945e0e3cfb4decbd73ae858c6f677c"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-5" name="us-gaap:BilledContractReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNjY_720575ea-5105-4e94-8c48-a8965c6b74e8">165.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-5" name="us-gaap:BilledContractReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNzM_d0233146-8d5d-48a6-92a0-11b8f3776129">419.7</ix:nonFraction>&#160;million related to amounts that were billed to customers and $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTI5_edc88068-49ff-4201-84de-1b1d698a45eb">29.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTM2_4e43913a-0cbb-46e7-aa5e-b6640d09b857">35.3</ix:nonFraction>&#160;million related to amounts which had not yet been billed to customers as of June&#160;30, 2022 and December&#160;31, 2021, respectively. <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTQ3Mg_73fa8616-16d1-41a6-be70-411292cbb63e" continuedAt="ib1984ba546344f73bcf0d3111a4bb506" escape="true">During the six months ended June&#160;30, 2022, changes in the Company's accounts receivables and deferred revenue balances were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ib1984ba546344f73bcf0d3111a4bb506"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivables:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi0xLTEtMS03MDA3Nw_b442634b-7cdb-4c84-bdb7-ae4b2638d70c">454,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="nvax:ReceivablesNetCurrentAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi0zLTEtMS03MDA3Nw_142e3d40-0d28-4e08-9e6b-352be8dc33a5">808,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="nvax:ReceivablesCurrentNetDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi01LTEtMS03MDA3Nw_82e77136-962e-4eaf-8e3b-f00bec3e140f">1,069,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi03LTEtMS03MDA3Nw_b55c3b48-e962-4f67-b65b-fb0150d08301">194,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="nvax:DeferredRevenueCurrentAndNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC0xLTEtMS03MDA3Nw_5df4dcb0-6749-494b-8460-d8813542d82a">1,595,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="nvax:DeferredRevenueCurrentAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC0zLTEtMS03MDA3Nw_472dfdad-40b5-407a-8970-565a7fe52764">49,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="nvax:DeferredRevenueCurrentDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC01LTEtMS03MDA3Nw_a9f52657-c057-46bb-a199-199806d748fd">128,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="nvax:DeferredRevenueCurrentAndNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC03LTEtMS03MDA3Nw_099fb986-74b2-40f9-a50a-9d37c56f924d">1,516,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount is comprised of $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDAz_f3370d7e-7d6e-4a31-8aa8-fed4e0884ae7">701.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDEw_9dbd40d5-9d29-4eda-b5b5-770e66dccaff">1.4</ix:nonFraction>&#160;billion of current Deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDQ1_b2c22db4-a110-46f2-ba0b-8ce54f1b6653">814.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDUy_50aeb9d4-1f72-49d2-9a5d-b842683874eb">172.5</ix:nonFraction>&#160;million of non-current Deferred revenue as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $<ix:nonFraction unitRef="usd" contextRef="i4f4b6f5acde242c3ace67f89c0df4c69_I20220630" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNzIx_f0c01316-167f-4cb0-8e78-79133af11af2">5</ix:nonFraction>&#160;billion as of June&#160;30, 2022. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 under certain of our APAs. Failure to meet regulatory milestones, product volume, or delivery timing obligations under the Company&#8217;s APA agreements may require the Company to refund portions of upfront payments or result in reduced future payments, which could result in a material and adverse effect on our unsatisfied performance obligations. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than <ix:nonNumeric contextRef="i4f4b6f5acde242c3ace67f89c0df4c69_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTE2Ng_a93b6a94-107e-42d0-84e9-0c79b6273cf8">12</ix:nonNumeric> months.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Grants</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTQ3Mw_0c77827c-d081-4f7a-9556-d4c85a6503d2" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government partnership (&#8220;OWS&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a7f0ae8be1457ba975ad86d4101b1b_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi0xLTEtMS03MDA3Nw_f9ce9d80-d4a1-4c6b-9cc0-d9ee1eb4ad01">107,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d13d4609664545a43b24e97b8b072f_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi0zLTEtMS03MDA3Nw_f08accc6-82c3-4d2e-8d7e-992d86d6c969">239,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2796d80cfb471e994d0da8cd0437fd_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi01LTEtMS03MDg0NA_cf334c6c-7bb0-4c39-af5e-c457bd8de8de">207,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c49f33057824088903829819b53beb0_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi03LTEtMS03MDg0NA_8f18b383-17c0-45f4-afad-88826a1ef096">603,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense (&#8220;DoD&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea0fc725c2844378d5f099dfa98477e_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy0xLTEtMS03MDA3Nw_3390cab5-0858-46ad-8673-1e0d369d8711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eaafe4f9b3348c5b10a0f78e3633e5c_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy0zLTEtMS03MDA3Nw_3d8637c6-69dd-471f-b1b6-10779effad49">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51025fa58fb149ac918fe80236b6303e_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy01LTEtMS03MDg0NA_38b4de13-1efd-4567-9445-bbef97160827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04667b8d3a384b2d9245c1a4fa29d96a_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy03LTEtMS03MDg0NA_06405ff5-df96-4876-a80e-7ea5c2c616d8">20,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a710118bda240b8b211f8a0825036c5_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC0xLTEtMS03MDA3Nw_cfd2bf01-63fd-4e63-ae82-988e943a7e68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551af433d1e246e89e595442fa319aee_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC0zLTEtMS03MDA3Nw_066d9605-3fea-440f-846b-5eae2cfe14ed">31,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac4f312e40a4461a57f852f3ce23cc4_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC01LTEtMS03MDg0NA_c6302cd2-211f-4b72-bc42-33060bdb7aba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31f109abc1642b28e93db64fafa6102_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC03LTEtMS03MDg0NA_145a6fda-3269-44d4-b00b-301ce2f98e69">93,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0592102fe89f4264bfef8d819f322688_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS0xLTEtMS03MDA3Nw_449cb408-955f-444a-b6f0-a3038cc9ac7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8140e44c727f43f39853c42e69847f31_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS0zLTEtMS03MDA3Nw_99cf9bfa-73b7-4bbb-82f0-aea741a31441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcbc5b4644bd44feaef5b01c2b51ce35_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS01LTEtMS03MDg0NA_a8d284df-39e5-41b5-a345-00d8ded9741f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a08399d05224436b9583db28b4671a7_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS03LTEtMS03MDg0NA_0226ca60-4638-464f-820d-61608a18c1d4">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64169e1b64be465ba651f225a820a0a7_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi0xLTEtMS03MDA3Nw_7c8b46c9-b734-4515-95d0-1e8d2710380b">107,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740226150bb146dfbab7548d73d95ec3_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi0zLTEtMS03MDA3Nw_aa8ed260-5441-44f2-b5cd-0fac40914f0b">272,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02740f8f66c940f49f4d45435b5f33fb_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi01LTEtMS03MzI4OQ_e6765784-3d10-4d1e-8f42-4ff2df96e85b">207,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4244f94bb3dc4fe284264e5bcde0de65_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi03LTEtMS03MzI4OQ_54c9c11f-dcc4-46f0-95ce-817ce9a35a11">719,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="i4e945e0e3cfb4decbd73ae858c6f677c" continuedAt="ifd6842d3ea4d4d7c93f3684b54daf270"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Government Partnership</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. government partnership consists of an agreement (&#8220;the &#8220;OWS Agreement&#8221;) with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (&#8220;OWS&#8221;). In July 2021, the U.S. government instructed the Company to prioritize alignment with the FDA on the Company's analytic methods before conducting additional U.S. manufacturing and further indicated that the U.S. government would not fund additional U.S. manufacturing until such alignment was made. In June 2022, the U.S. government agreed to the manufacture and delivery of approximately <ix:nonFraction unitRef="dose" contextRef="i52b84098b8a748f8bfc7222df25285a4_I20220630" decimals="-5" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDcyODY2Nw_bfda9a9e-e648-4941-866d-ee34cf61f12e">3</ix:nonFraction>&#160;million doses of NVX-CoV2373 under the OWS Agreement as the Company had completed alignment with the FDA&#8217;s analytic methods. The Company updated its estimate-at-completion to reflect the impact of this authorization to the recognition of the fixed fee under the contract. In July 2022, the Company formally modified the OWS Agreement to provide for an initial delivery to the U.S. government of approximately <ix:nonFraction unitRef="dose" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDcyODY4MA_c72967a8-eee7-44fe-803d-d85628fc8471">3</ix:nonFraction>&#160;million doses of NVX-CoV2373, and the Company modified its existing agreement with the U.S. Department of Defense (&#8220;DoD&#8221;) to provide for an initial delivery of approximately <ix:nonFraction unitRef="dose" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-5" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1NTA2Nw_c7201d53-6c3d-4092-ad44-da59b20fafc0">0.2</ix:nonFraction>&#160;million doses of NVX-CoV2373 (see Note 15).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i398e1d19b77d4b66b82d84fa9532c022_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTMxNw_78447692-1158-43b2-ab1a-dbd91622f610">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i64d61c79ddcb4213a12c1d9637bd0819_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MDk3Mg_85194190-4062-481c-86f6-42296f879ff8">9.2</ix:nonFraction>&#160;million, respectively, in revenue related to sales-based royalties. During the three months ended June 30, 2022, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTAxMw_0b2587c9-cd8b-4117-919f-37f1567ab1fe"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTAxMw_b7b60680-669b-46bf-ba7b-bda4063be69e">20.0</ix:nonFraction></ix:nonFraction>&#160;million milestone payment upon the first sale of NVX-CoV2373 in Japan. During the three months ended June&#160;30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i3e25182664da42259f8fddcc4e30be81_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTA3OA_890ac430-a11a-4415-9dc9-1447f1f1afd8"><ix:nonFraction unitRef="usd" contextRef="i7504caa392fc4b198ba675a27efbc513_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTA3OA_f9f2c548-ad08-4a66-b2f2-483ee372a04c">23.5</ix:nonFraction></ix:nonFraction>&#160;million in revenue related to sales-based royalties. During the three months ended March 31, 2021, the Company did not recognize any revenue related to sales-based royalties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Advance Purchase Agreements (APAs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Company&#8217;s contracted supply commitment with Gavi, which includes the supply obligation of its licensed partner, Serum Institute of India Private Limited (&#8220;SIIPL&#8221;), <ix:nonFraction unitRef="dose" contextRef="i2e0b072a00284d5e86b6ae1955e77255_I20211231" decimals="-8" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODU3NQ_13fac051-5b9b-4937-9360-10f21311ba64">1.1</ix:nonFraction>&#160;billion doses of NVX-CoV2373 are to be made available to countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. The Novavax portion is a supply agreement that contemplates that the Company will manufacture and distribute <ix:nonFraction unitRef="dose" contextRef="i472e0a435709425884b630fb4e4abe4d_I20211231" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODU0OA_46eb7e4b-d994-407e-ad42-b0ef680c2d03">350</ix:nonFraction>&#160;million doses. Under that agreement with Gavi, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic03121026d664feabb6f6d6ce32a036e_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODU2MQ_0b9e21f2-a1a3-44c8-a0d3-90f137e6dd14">350</ix:nonFraction>&#160;million from Gavi in 2021 and an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i0594bb0e3d49426d8546ac3ef41f5312_D20220101-20220331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODUzNA_c4f2819b-e5c0-4459-96d8-6e3118932e19">350</ix:nonFraction>&#160;million in the first quarter of 2022 related to the Company&#8217;s achieving WHO Emergency Use Listing. Although Novavax is prepared to deliver the quantities of NVX-CoV2373 doses to Gavi under the terms of the supply agreement, the Company was notified by Gavi of its intent to seek to revise the number and timing of doses of NVX-CoV2373 supplied by Novavax under such agreement. Furthermore, Gavi may seek partial or full recovery of the prior nonrefundable payments it has made to Novavax. The Company&#8217;s position is that Gavi has no contractual right to recover prior nonrefundable payments. To date, Novavax has not received an order from Gavi and the timing and quantities of future orders to deliver NVX-CoV2373 to the COVAX facility are unclear.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Company&#8217;s SARS-CoV-2 Vaccine Supply Agreement, originally entered into in October 2020 (the &#8220;Original UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), the Authority agreed to purchase <ix:nonFraction unitRef="dose" contextRef="i92cf89b34fba4758b7ea6b29bb2b4277_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1NTA5MQ_d512411b-f87d-4a1b-b862-95edb57d456d">60</ix:nonFraction>&#160;million doses of NVX-CoV2373. In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with the Authority, under which the Authority agreed to purchase a minimum of <ix:nonFraction unitRef="dose" contextRef="ibe5f264f5aae46269f4b5c7f917258db_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTEyNjQyNg_8e93467f-e4aa-4936-8655-2001ad59ecbc">1</ix:nonFraction>&#160;million doses and up to an additional <ix:nonFraction unitRef="dose" contextRef="i7ce520d7761743ec86392cca9a2d1a9d_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTEyNjQ2MA_b4aebde9-11ff-4ec1-91e4-f65cfe44dae3">15</ix:nonFraction>&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) (see Note 15).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of <ix:nonFraction unitRef="dose" contextRef="i603827ce2ac64ffaac1b057ac83a74b8_I20220630" decimals="INF" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ0Mw_c2f12b87-4480-4320-b4f3-49135da7c8dd">20</ix:nonFraction>&#160;million and up to <ix:nonFraction unitRef="dose" contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630" decimals="INF" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQzMA_b6c8b378-eb58-4f13-9f5b-c15088e4c3dd">100</ix:nonFraction>&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional <ix:nonFraction unitRef="dose" contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630" decimals="INF" name="nvax:PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ1NQ_d5b9fb07-7436-4ea8-925e-228c612380d4">100</ix:nonFraction>&#160;million doses up to a maximum aggregate of <ix:nonFraction unitRef="dose" contextRef="ife8416d2c5f7415e89f5022b56743ac4_I20220630" decimals="INF" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ2OA_d5d05c8d-b02a-4d0b-900e-0967bf17e266">200</ix:nonFraction>&#160;million doses in one or more tranches, through 2023. The Company is in the process of finalizing a revised delivery schedule for the remaining <ix:nonFraction unitRef="dose" contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1ODQxOQ_ba004901-166d-4bde-9196-c301b6a1bb38">42</ix:nonFraction>&#160;million doses of the <ix:nonFraction unitRef="dose" contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1ODQwNw_0c5fb594-aeed-48a1-af74-0fd3dff3432c">70</ix:nonFraction>&#160;million previously committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. In July and August 2022, the Company was notified by the EC that it was cancelling <ix:nonFraction unitRef="dose" contextRef="i750e9cc522fe4374bb3945dd8f61ee58_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesCancelled" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ5Mw_216f6767-c485-4dc5-afc9-f2b6c88cd903">5</ix:nonFraction>&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to <ix:nonFraction unitRef="dose" contextRef="i750e9cc522fe4374bb3945dd8f61ee58_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1ODQzMQ_941fc2db-ad87-4d83-b04b-6de2cb343e14">65</ix:nonFraction>&#160;million doses (see Note 15).</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8211; <ix:continuation id="ifd6842d3ea4d4d7c93f3684b54daf270" continuedAt="ia87621c5f6de4d1abfbfaeb5c242ff81">Collaboration, License, and Supply Agreements</ix:continuation></span></div><ix:continuation id="ia87621c5f6de4d1abfbfaeb5c242ff81"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Serum Institute</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company&#8217;s Matrix-MTM adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. The Company has expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s) so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, and supply such variant vaccine to the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases the Company&#8217;s Matrix-M&#8482; adjuvant to manufacture NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373 in the low to middle double-digit range. During the three months ended June 30, 2022, the Company recognized a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i3c67801e2acb4e6bb800915f121b2eaf_I20220630" decimals="-5" name="nvax:PotentialFutureMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80Ni9mcmFnOjNmN2I4NmNkZDM4ZjRkZjZhYjkxZDdkZTY0NjI5YjFhL3RleHRyZWdpb246M2Y3Yjg2Y2RkMzhmNGRmNmFiOTFkN2RlNjQ2MjliMWFfMTU2Mw_5cd50fdc-ef3f-48c1-8e9e-74c90bed97f9">20.0</ix:nonFraction>&#160;million upon the first sale in Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">SK bioscience, Co., Ltd.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of Korea, Thailand, and Vietnam. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants (see Note 15). The companies also signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Supply Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and in doing so, recognizes that significant costs may be incurred.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RleHRyZWdpb246MGRkNzRkNjgxOTdkNDY0MThkZTI1MWJhNWY3ZWIxMDlfMzkz_8a00b301-09bf-4d7e-83fa-aa4a25b0e263" continuedAt="i33a10fe22b3548ab8331ef5b615ee9f9" escape="true">Cash, Cash Equivalents, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i33a10fe22b3548ab8331ef5b615ee9f9"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RleHRyZWdpb246MGRkNzRkNjgxOTdkNDY0MThkZTI1MWJhNWY3ZWIxMDlfMzky_240cfa87-af5a-45f2-8f25-49ad1f17ccae" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMS0xLTEtMS03MDA3Nw_81b3218a-ded3-46b3-9489-8fc5e5fc3274">1,375,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMS0zLTEtMS03MDA3Nw_9055ac00-7881-44dd-86dd-93e39fa0ebdc">1,515,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMi0xLTEtMS03MDA3Nw_dfd96597-b0df-49ea-8277-e42ad8ec20a6">10,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMi0zLTEtMS03MDA3Nw_2882a503-ce6f-47a8-a50f-76307209937d">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMy0xLTEtMS03MDA3Nw_1ce2ea2f-108e-4b95-923b-091484901cf6">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMy0zLTEtMS03MDA3Nw_3ad5dba3-ca4e-4a98-ad0a-29f23fb1c0fc">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfNC0xLTEtMS03MDA3Nw_ff47fbf3-98db-459f-af15-d97f30d19668">1,387,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfNC0zLTEtMS03MDA3Nw_350cee61-7c92-491d-b5b1-f30c341cf4c4">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as Other non-current assets as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;6&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RleHRyZWdpb246MWI0YWFlY2I2YjgyNDM5Zjk2OGJhMjQ0OGYzMjI3ZmJfNjg1_cd919a75-7178-45db-8dba-59fbaec84fef" continuedAt="i9348b70230b94ee5b9e66c98cfd9b2d2" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i9348b70230b94ee5b9e66c98cfd9b2d2"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RleHRyZWdpb246MWI0YWFlY2I2YjgyNDM5Zjk2OGJhMjQ0OGYzMjI3ZmJfNjg0_ce46b99e-f41c-4b5a-acf2-10bce174a3dc" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99533f95b79b45b992b718e063053587_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi0xLTEtMS03MDA3Nw_5bf8ff54-1f9a-4dfb-bdbb-b389b46d9b09">500,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7188cfe5d6445c9ccfc63027d2b369_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi0zLTEtMS03MDA3Nw_192a197f-b4f6-4dfa-b1c3-701cbab46658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17025047e164926ae984921e6dabb68_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi01LTEtMS03MDA3Nw_da85ecaa-2209-40e9-a4bd-f1c381ad9d47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194bb03495444c89b63efab4dad063fe_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi03LTEtMS03MDA3Nw_f5ed1936-e7d7-4736-90f3-31272799d399">361,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc988bf6562e4a0ab83d5998938f5d7f_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi05LTEtMS03MDA3Nw_3090976b-0851-47d9-9da6-12e2d780dfb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8814d4d6bb460fb498f2ef6bcb3f07_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi0xMS0xLTEtNzAwNzc_e8850438-83bb-4b72-b875-c7be476d3a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1427334e93bd4a8f98fd067cf174baff_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy0xLTEtMS03MDA3Nw_0907b471-b1f2-4e50-866f-534fd7c486b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd64740178f14dfaa8b40016114d8b0b_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy0zLTEtMS03MDA3Nw_ba684bcc-a9ed-4c20-b117-da6fdc1260bc">179,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d2a912e597482e88dad8af2f1eb83a_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy01LTEtMS03MDA3Nw_8befbac1-0bc6-41d0-ad0f-300da02c6df5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7365cb3d7724460b7e77eea77c4d02c_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy03LTEtMS03MDA3Nw_3bdcd33d-277e-4bdb-986a-b92248974439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961f58e0225b454ea758608f30477153_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy05LTEtMS03MDA3Nw_68d8a6bb-693e-4492-9048-8c9ea73d7374">266,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c82b31c56a41cabaa12f169afbc6ea_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy0xMS0xLTEtNzAwNzc_156dc1cb-bdf2-4fa9-be23-fffec7e35aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47d8623f27649b88072c3726cf612a4_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS0xLTEtMS03MDA3Nw_4b7ad496-8063-4c10-b6ae-38765ed82d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05545dcab7354afb93e21cdd544ce785_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS0zLTEtMS03MDA3Nw_e5148687-dc95-49e2-ae75-8504d0d7e618">594,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15eacf51ca7461e831d064a18ed6ec5_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS01LTEtMS03MDA3Nw_ce1d6d86-e09c-4f92-8a99-1c631ce0a24d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c389f5ae034c4a9f241df636dd9408_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS03LTEtMS03MDA3Nw_e40a3082-68dd-43da-a991-636c7494e841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9c400472e346bb83cdc03ad62f0f6a_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS05LTEtMS03MDA3Nw_1c6683ea-ebcc-4650-91d8-a7265ffc5857">790,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebe69f41a92442fa317d279aecfffa9_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS0xMS0xLTEtNzAwNzc_6dfbe7f9-d15e-47dd-a9d8-bc16c415c22f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c56415ec67e4a2f92984c0168e319b7_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy0xLTEtMS03MDA3Nw_7fa6f3b1-ca68-4864-8e9d-b698cbc5fb16">500,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f2366267542d98a7442366fecb5fb_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy0zLTEtMS03MDA3Nw_73124e02-a912-4c9f-a980-cdc40668b1b1">774,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae5da8be9b04141abe668a81dbf1b8b_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy01LTEtMS03MDA3Nw_96278320-0398-4a0c-ad66-8f33e9c78ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e6ef1fb0544afd9c34afa0943a65e3_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy03LTEtMS03MDA3Nw_dd06ae4e-9f29-48ba-839c-2e6b68f553db">361,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1c4e3b51c54406bfdcb545ced2f93b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy05LTEtMS03MDA3Nw_3020fca7-5c02-496e-93f6-deb93aabc922">1,056,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb63dea6d85945d78435e4733601554d_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy0xMS0xLTEtNzAwNzc_c9f45cae-5071-4682-984b-dbfd5f2ae735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c56415ec67e4a2f92984c0168e319b7_I20220630" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS0xLTEtMS03MDA3Nw_4123c843-a6fd-45cc-a92e-a305937ac3d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f2366267542d98a7442366fecb5fb_I20220630" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS0zLTEtMS03MDA3Nw_852a7717-5547-4f32-84f2-f08bb6ed75ec">323,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae5da8be9b04141abe668a81dbf1b8b_I20220630" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS01LTEtMS03MDA3Nw_7213b96b-daac-4273-8eb0-9ad1ffc16307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e6ef1fb0544afd9c34afa0943a65e3_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS03LTEtMS03MDA3Nw_b718e574-e588-46a8-b289-d2234c0b9bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1c4e3b51c54406bfdcb545ced2f93b_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS05LTEtMS03MDA3Nw_5cedec60-72db-40c3-abf8-463714470777">447,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb63dea6d85945d78435e4733601554d_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS0xMS0xLTEtNzAwNzc_4c2dc6f6-e189-4527-8283-e3b971cc619d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as cash and cash equivalents as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature. Pricing of the Company's Notes&#160;(see Note&#160;10) has been estimated using other observable inputs, including the price of the Company's common stock, implied volatility, interest rates, and credit spreads among others.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six&#160;months ended June&#160;30, 2022 and 2021, the Company did not have any transfers between levels</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNzc_f5b03686-a1c4-4bf5-89e8-1ee18d3615e1" continuedAt="ib692714d10f047b29f066e61f35e4f3e" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ib692714d10f047b29f066e61f35e4f3e"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNzg_97fed881-6748-46af-a1ea-848d0d1b965d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMS0xLTEtMS03MDA3Nw_aa235dfc-1e2d-4910-b10e-223bc99d938b">55,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMS0zLTEtMS03MDA3Nw_0a69e924-a4af-44a4-800e-2ad4de9056f1">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMi0xLTEtMS03MDA3Nw_92ddccd2-bbf0-4355-8fd5-46bcd405debf">71,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMi0zLTEtMS03MDA3Nw_6d6f6f78-9116-44e4-a030-779d1b3616be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMy0xLTEtMS03MDA3Nw_692524f2-5951-4c43-8790-0d2f0a75a9b8">129,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMy0zLTEtMS03MDA3Nw_aefe983d-05cb-4ce8-948e-2a43912f87eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfNC0xLTEtMS03MDA3Nw_d34209dd-2637-40f5-a05e-b12571b23a19">256,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfNC0zLTEtMS03MDA3Nw_a64f1cbb-2c1f-4361-96da-23c6ae3c8557">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the three months ended June&#160;30, 2022, inventory write-downs were $<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfOTM0NTg0ODgzNzMzNg_48466421-ac17-4552-8baf-bdb511bfd3b8">155.7</ix:nonFraction>&#160;million. There were <ix:nonFraction unitRef="usd" contextRef="i29ef495376c841fcad701e4fb99916f6_D20220101-20220331" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4NQ_f6561524-c4a0-4083-b47a-06767297902f">no</ix:nonFraction> inventory write-downs for the three months ended March 31, 2022. For the three months ended June&#160;30, 2022, losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfOTg5NTYwNDY1MTQ5Mg_baa1a62f-deea-40b7-8b05-875f0d04beb6">99.6</ix:nonFraction>&#160;million. There were <ix:nonFraction unitRef="usd" contextRef="i29ef495376c841fcad701e4fb99916f6_D20220101-20220331" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4Nw_284df8d8-bf39-4a6c-a93f-211bc41ea593">no</ix:nonFraction> losses on firm purchase commitments during the three months ended March 31, 2022. There were <ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4Ng_91a6fd3f-adcc-4a58-b1b1-7de3b0e3c2c0"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4Ng_ab3be8fc-b535-4fcd-b6c1-c2073e1e20e4">no</ix:nonFraction></ix:nonFraction> inventory write-downs or losses on firm purchase commitments during 2021.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;8&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfNTI1_4502db5a-1ce6-4fb1-95f1-f68483f6725d" continuedAt="iebf34c5ce3e443fc9734162bdcb72bf2" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="iebf34c5ce3e443fc9734162bdcb72bf2" continuedAt="i024f6b82addf47b88bff5b966b3292ba"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identifiable Intangible Assets</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfNTI4_b64f8f43-7f29-4dee-870d-4247aebae5f5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets consisted of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated&#160;<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible<br/>Assets,&#160;Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated&#160;<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible<br/>Assets,&#160;Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary adjuvant technology</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecd523551b8c4c88a444bf178a5ead31_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy0xLTEtMS03MDA3Nw_b2c87e58-f8b7-4a98-bcd2-5d851fa50a79">7,278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iecd523551b8c4c88a444bf178a5ead31_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy0zLTEtMS03MDA3Nw_4422f718-091a-4df7-87e3-3152e48c1d44">3,245</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecd523551b8c4c88a444bf178a5ead31_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy01LTEtMS03MDA3Nw_16ad4d17-d060-4c04-b9e3-8f49e62a771e">4,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy03LTEtMS03MDA3Nw_a8473f74-c000-47f6-a2cf-65e92769daf2">8,239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy05LTEtMS03MDA3Nw_1716f03a-6d43-4ff1-8ec1-c08e3d9d1596">3,469</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy0xMS0xLTEtNzAwNzc_a5bf89f5-cbab-455c-9efb-3a32a8cedbb6">4,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3453a5c919a143e6b9635ec05f27f973_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC0xLTEtMS03MDA3Nw_a6e35ff2-048f-439e-a6ff-6245a853dcba">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3453a5c919a143e6b9635ec05f27f973_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC0zLTEtMS03MDA3Nw_534ba86b-206f-404c-9e16-f21e52252431">3,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3453a5c919a143e6b9635ec05f27f973_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC01LTEtMS03MDA3Nw_2b9d1ae2-227f-4869-a367-cc8b3ef83e83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94545a62f6f04e5d9fe91e26c5041a86_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC03LTEtMS03MDA3Nw_c23cac90-f0d8-4ea5-9adc-0c40a5bfcc3a">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i94545a62f6f04e5d9fe91e26c5041a86_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC05LTEtMS03MDA3Nw_aa11df11-4a1f-4c13-aeb9-a5f7c5ed5b2a">3,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94545a62f6f04e5d9fe91e26c5041a86_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC0xMS0xLTEtNzAwNzc_2855308f-e6f4-4265-96d2-2b670042a5ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total identifiable intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS0xLTEtMS03MDA3Nw_2971a99e-9b54-43aa-aae5-25162d63ee54">10,564</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS0zLTEtMS03MDA3Nw_4db40f12-aa93-46e6-bf23-89f34391d745">6,531</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS01LTEtMS03MDA3Nw_dbbcb876-91eb-4f19-ad97-1bbd61a48879">4,033</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS03LTEtMS03MDA3Nw_cb87db85-5f4b-49ae-b4c3-78b86fe073af">11,961</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS05LTEtMS03MDA3Nw_568848d8-b72e-4d40-805f-e01bd9bcc9ed">7,191</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS0xMS0xLTEtNzAwNzc_77718245-99d9-479f-9412-f29d116bf573">4,770</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="i024f6b82addf47b88bff5b966b3292ba"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the six months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfMzAx_09898a23-4662-4b3c-8b59-454c049f6909"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfMzAx_225e5208-2bac-42ec-be8a-892297593456">0.2</ix:nonFraction></ix:nonFraction> million. <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfNTI5_65db4ef8-8734-4110-9125-99e9aea6ccb7" continuedAt="i329845c7aa134c469da9505f1a9d15e4" escape="true">Estimated amortization expense for existing intangible assets for the remainder of 2022 and for each of the five succeeding&#160;years ending December&#160;31 will be as follows (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="i329845c7aa134c469da9505f1a9d15e4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfMS0yLTEtMS03MDA3Nw_eaebd5ee-ab04-4b5d-b8b5-766a6df41d88">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfMi0yLTEtMS03MDA3Nw_a0f172d7-688f-4a4a-ace5-b302da9db9ed">364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfMy0yLTEtMS03MDA3Nw_a2475dfb-77a2-434e-971d-505ce3cb4b40">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfNC0yLTEtMS03MDA3Nw_797c5767-5989-45a5-b461-19f20f0969b4">364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfNS0yLTEtMS03MDA3Nw_3125f1b9-4b51-401a-804e-e0c77ca7e710">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfNi0yLTEtMS03MDA3Nw_d5f17be6-5a2a-4b9c-8483-d803b2d2be8e">364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfMzg0ODI5MDY5Nzk5NA_d29df0e7-ca3a-4fd1-830f-f9e6679b0ac4" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmNhNDA3MGE1MTc3ZDRmZDA5YWI4MDJlMDllZmI0OWI3L3RhYmxlcmFuZ2U6Y2E0MDcwYTUxNzdkNGZkMDlhYjgwMmUwOWVmYjQ5YjdfMS0xLTEtMS03MzU3NQ_4d3152e4-bfc4-4cca-843a-0c552e721fab">131,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmNhNDA3MGE1MTc3ZDRmZDA5YWI4MDJlMDllZmI0OWI3L3RhYmxlcmFuZ2U6Y2E0MDcwYTUxNzdkNGZkMDlhYjgwMmUwOWVmYjQ5YjdfMi0xLTEtMS03MzU3NQ_b238c14e-dd25-4ea6-a64c-07028f6d2e82">8,012</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmNhNDA3MGE1MTc3ZDRmZDA5YWI4MDJlMDllZmI0OWI3L3RhYmxlcmFuZ2U6Y2E0MDcwYTUxNzdkNGZkMDlhYjgwMmUwOWVmYjQ5YjdfMy0xLTEtMS03MzU5MA_43430323-cfef-469f-bb94-71d8c470fd87">123,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 - <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjYzNg_0350681c-f5d1-44c1-ae37-879ced2de090" continuedAt="iac4aea22294f439d89fdcaf3cab226c8" escape="true"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjYzNg_f531d1cb-0a01-4d61-88f3-c4afcb7fa302" continuedAt="ie1d7b717d2fb4b00af29c641fc43481c" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="iac4aea22294f439d89fdcaf3cab226c8"><ix:continuation id="ie1d7b717d2fb4b00af29c641fc43481c"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2022, the Company concluded that changes in facts and circumstances on its CMO and CDMO agreements that had previously been determined to represent embedded lease arrangements resulted in the modification of existing leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration in the contracts and reassessed the lease classification as of the effective date of the modification. As a result, during the six months ended June&#160;30, 2022, the Company recognized a Right-Of-Use (&#8220;ROU&#8221;) asset and a corresponding long-term operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfNjU2_74d75fb7-7f7d-4972-a163-5f86d826e024">19.8</ix:nonFraction>&#160;million&#160;on the remeasurement of one of its long-term supply agreements using an average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="3" name="nvax:LongTermSupplyAgreementIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfNzYx_842b25eb-9c3e-4127-97cf-f009e6aaba18">3.0</ix:nonFraction>%. The Company expensed the ROU asset since it relates to research and development activities for the development of NVX-CoV2373 for which the Company does not have an alternative future use.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June&#160;30, 2022, the Company recognized a short-term lease expense of $<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTM3Nw_52114bee-1fe3-44fc-b075-85606e9464ec">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTE4Mg_0ef3a907-3adb-4868-b57b-7a7631e946e9">83.9</ix:nonFraction>&#160;million, respectively, related to its embedded leases and expensed $<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTIwOTQ2Mjc5MTE4OTA_7294d27a-67c4-4177-b2f1-19869bbf524a">9.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjc0ODc3OTA3OTEzMw_74d75fb7-7f7d-4972-a163-5f86d826e024">19.8</ix:nonFraction>&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2021, the Company recognized a short-term lease expense of $<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU2OA_de33132a-e5de-4796-869d-3e78c97b1f05">86.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU3Mg_1e9c1a4f-1a74-44bf-ab4b-86b8ed91977e">214.2</ix:nonFraction>&#160;million, respectively, related to its embedded leases and expensed $<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU3Ng_7020c1c4-2a7d-42ee-a8f5-018241bf430b">11.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU4MA_5a813bfc-fe7e-4f7c-be9e-4345b6d6f8f0">12.4</ix:nonFraction>&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTcxNg_c0e0eeb1-299c-4fd3-b948-b62e6b7d7ffe">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTk3OA_893dde33-e585-4586-9499-6e126d425caf">3.4</ix:nonFraction>&#160;million of interest expense, respectively, on its finance lease liabilities. During the three and six months ended June&#160;30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMjEzMw_cf8e1c67-5e56-46cd-abd8-5323771a450d">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMjEzNw_72c006a5-eaa0-493d-80dd-b7f46fbbfd2f">4.0</ix:nonFraction>&#160;million of interest expense, respectively, on its finance lease liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland. The lease is for approximately <ix:nonFraction unitRef="sqft" contextRef="ia288ba6256924eaeb4fd7095a2acd199_D20200101-20201231" decimals="INF" name="nvax:FacilityNumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTk2OQ_390bb36a-5e88-43fc-b0b4-718cbfc82717">170,000</ix:nonFraction> square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is <ix:nonNumeric contextRef="ib60480ff6ace4a9dada2572b7a483040_I20201231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjEwOA_fb764335-5475-487a-b285-b8830e0fc452">15</ix:nonNumeric> years with options to extend the lease. The lease provides for an annual base rent of $<ix:nonFraction unitRef="usd" contextRef="i298d3ab6290f4c62a68f470f3b16205a_D20200101-20200630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjE5MQ_e5eaed76-0366-4728-934d-f3bb953a4822">5.8</ix:nonFraction>&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the three months ended March 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the third floor of the premises and recognized a ROU asset of $<ix:nonFraction unitRef="usd" contextRef="ic67b8fd3c6684e26893f4f55ee228020_I20220630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjQ5Mw_7c4af3a3-f82d-411b-83df-749fc00345c1">47.8</ix:nonFraction>&#160;million and related lease obligation for the combined third floor and land lease as the lease commencement date for accounting purposes had occurred.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTMx_7942ef48-58e2-4ab6-8918-21ce2e92b678" continuedAt="i218abae4541f4082948040f10163d2b8" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i218abae4541f4082948040f10163d2b8"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfNzM_d0ada1d3-63ff-497d-bead-d139c08f8a80">10.0</ix:nonFraction> million of debt issuance costs during the first quarter of 2016 relating to the issuance of $<ix:nonFraction unitRef="usd" contextRef="i385f7d6a051e4dafb63d1a63b59be860_I20160331" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfMTYw_58112353-5fee-4305-9dc3-6ef29215a517">325</ix:nonFraction> million&#160;aggregate principal amount of convertible senior unsecured notes that will mature on&#160;February&#160;1, 2023&#160;(the &#8220;Notes&#8221;), which were recorded as a reduction to the Notes&#160;on the consolidated balance sheet. The $<ix:nonFraction unitRef="usd" contextRef="i385f7d6a051e4dafb63d1a63b59be860_I20160331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfMzY3_310c4a53-74af-4f51-bd7b-8c85318309f2">10.0</ix:nonFraction> million of debt issuance costs is being amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTMy_7cdef1b1-72fb-4bcd-9200-3a0ff1e3fbe8">seven-year</ix:nonNumeric> contractual term of the Notes&#160;on a straight-line basis, which approximates the effective interest rate method.</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTI5_dd1a3443-8ae8-4814-bbfc-52673d158c00" continuedAt="iec4052cc2fc6411cbfed0b8cd34661f6" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable consisted of the following at (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount of Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMS0xLTEtMS03MDA3Nw_949007cf-faf6-42c5-bfc9-8f0be318e49d">325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMS0zLTEtMS03MDA3Nw_999c32bd-bb96-41a9-b8da-efcd2df42f35">325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMi0xLTEtMS03MDA3Nw_a0f7163d-3e67-4f5d-887a-3ea0f126374b">831</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMi0zLTEtMS03MDA3Nw_c0aa00de-1b81-4a61-9fa9-b3f85a5f7272">1,542</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMy0xLTEtMS03MDA3Nw_26444d15-8818-451b-a534-d70eba27ed74">324,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMy0zLTEtMS03MDA3Nw_3cb560c3-5a69-4ba2-8602-d571cb1f96b3">323,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="iec4052cc2fc6411cbfed0b8cd34661f6" continuedAt="ifd065364c0074ce381008f67a1a6a718">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd065364c0074ce381008f67a1a6a718">Convertible notes are classified as current liabilities and as non-current liabilities in the consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</ix:continuation> </span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTMw_ae31818f-b862-45e3-bdbe-86f031ff3452" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense incurred in connection with the Notes&#160;consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon interest at <ix:nonFraction unitRef="number" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0wLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmRlYjY4ZmE3ODdkNjQ5MTI5YzQ2YTA5MmExNzMxMmE5XzIz_9a2fe667-c344-46d2-bde3-9011a85dab0b">3.75</ix:nonFraction>%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0xLTEtMS03MDA3Nw_52d24ec4-7f95-47ed-889d-6442739e2e18"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0xLTEtMS03MDA3Nw_ce738a56-2ab3-4023-828a-6e3ef15983b5">3,047</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0zLTEtMS03MDA3Nw_315f6f38-9598-491d-b308-d65e62c38b7a"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0zLTEtMS03MDA3Nw_36906248-268b-4ab2-acad-888f7e04ba50">3,047</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi01LTEtMS03MDA3Nw_8d8bc590-42b7-48b9-bc32-9b3b61e8e58e"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi01LTEtMS03MDA3Nw_e4d0aa63-e1df-4416-b684-f518072ac272">6,094</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi03LTEtMS03MDA3Nw_0e8d24a6-5852-4411-a92d-2b8b7facd30a"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi03LTEtMS03MDA3Nw_6f7eb5e3-35f2-425e-9b47-e9d2fdfc4477">6,094</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0xLTEtMS03MDA3Nw_6a15b836-40e1-4fac-854f-92d1582701f3"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0xLTEtMS03MDA3Nw_9ae67e96-6594-4893-8553-d856c56188f3">356</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0zLTEtMS03MDA3Nw_6b03c95f-4bae-4c25-9f4b-206f2729cb42"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0zLTEtMS03MDA3Nw_719c9878-189b-4a14-8ca0-638b67f13fd0">356</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy01LTEtMS03MDA3Nw_3c789a3a-acd8-4822-b353-ddc74e1deb3f"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy01LTEtMS03MDA3Nw_b1d9a95c-155f-4f3b-a9a6-a484ae89373e">712</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy03LTEtMS03MDA3Nw_22bf4a5a-de6f-46df-9a9e-ab7bf8cc039f"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy03LTEtMS03MDA3Nw_536b8fa5-8a16-4628-b03b-21e7a6a99f4e">712</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on Notes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC0xLTEtMS03MDA3Nw_6f75f40d-b914-475d-b8d4-53726bd676b5">3,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC0zLTEtMS03MDA3Nw_1b6c7a36-45df-455b-85cd-4bd268642cc5">3,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC01LTEtMS03MDA3Nw_e0a21ba1-edab-465c-b7d6-e2ba3c65fa2a">6,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC03LTEtMS03MDA3Nw_d17ed56f-1be8-4f65-b43e-0ee4c666fbb6">6,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;11&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNjU0_e7b4e050-dce2-4e11-b10d-5d58c05b2734" continuedAt="i0517311371bf4ad1ba8bd8bff48a27f4" escape="true">Stockholders' Equity (Deficit)</ix:nonNumeric></span></div><ix:continuation id="i0517311371bf4ad1ba8bd8bff48a27f4"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="i425b5f4d2daa419592347aa121524f6f_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfOTc_effed2e9-6df5-4fc7-9e44-9caf3990c55a">2.2</ix:nonFraction>&#160;million of shares of its common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i2d5d7e6cc2a6432fad8f4e48c6a737bb_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfMTcz_9957efbb-d6df-4d75-aabb-f5d6695df5cc">179</ix:nonFraction>&#160;million, under its most recent At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;), which allows it to issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="i6932178ef14e472084b3b902bba8f33c_D20210601-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfMzMw_b1f46253-47c5-4b7e-9713-f99a954f6e35">500</ix:nonFraction>&#160;million in gross proceeds of shares of its common stock. As of June&#160;30, 2022, the remaining balance under the June 2021 Sales Agreement was approximately $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-6" name="nvax:ShelfRegistrationStatementRemainingUnissuedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNDY4_a81e1ebf-440d-4fb9-ad28-49abd1ab2467">318</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNTIz_9327c6f9-283b-49d5-98f9-f5125303c418">2.6</ix:nonFraction>&#160;million shares of its common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNTk2_87f788ee-b388-4c7a-8782-7b87c96f8445">565</ix:nonFraction>&#160;million, under its various At Market Issuance Sales agreements.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;12&#160;&#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQyNw_18ba9a8b-22eb-4092-8e35-49a109e0e328" continuedAt="i02f2039bac5f451fb7f6d8527a80ffac" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i02f2039bac5f451fb7f6d8527a80ffac" continuedAt="iaa26575e292549c28415cdf5d07612d2"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company's annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDAy_84036ca9-8f5f-4cf4-ae41-401bb05f0b40">14.8</ix:nonFraction>&#160;million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of <ix:nonFraction unitRef="shares" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjc0ODc3OTA3NDQyMw_e482b19e-7160-4bfe-90cd-f02ecf84b946">2.4</ix:nonFraction>&#160;million shares approved for issuance under the 2015 Plan at the Company's 2022 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;4, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="iaa26575e292549c28415cdf5d07612d2" continuedAt="iada80c8f94e24448aabad30fa2deb4ed"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock units (&#8220;RSUs&#8221;). In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of <ix:nonNumeric contextRef="i3f8b6ed41b2d43bebac3d158af889817_D20150601-20150630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTE4OA_c9a1de2f-21c9-4813-bd16-a74d0dc9020f">ten years</ix:nonNumeric> and may be or were granted with an exercise price that is no less than <ix:nonFraction unitRef="number" contextRef="i4b95e06ae99e465cbb5da325d456aede_I20150630" decimals="2" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTI2Mg_c5c45cbd-185d-4105-8440-9d891dd1e41e">100</ix:nonFraction>% of the fair market value of the Company's common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQyNQ_9172cf8d-33fb-4432-8f7b-4855b5e3976b">one</span> to <ix:nonNumeric contextRef="iec94153dc52b4f0a884461884ed5820d_D20150601-20150630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQzMQ_c5fb4bac-e3ee-48ad-87e1-ede6666608f2">four years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQyOA_527c3ea4-048d-4272-8925-ea03f6ec8efe" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded all stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c556955c19448f6919e6fc319d19b36_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi0xLTEtMS03MDA3Nw_9a61af78-e42d-4487-a556-c0d618bf3417">19,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i944814c48d6649559e7aaad2f652d7d9_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi0zLTEtMS03MDA3Nw_f5d37f1d-5f9f-4eb7-966c-b00ed5593eff">24,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i031d603f91304729bf3df926d55719f3_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi01LTEtMS03MTAzOQ_47c404c6-264e-4a09-9fcc-45ec3afb0c74">36,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9cd34e5e916949209fde4068aa2e6022_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi03LTEtMS03MTAzOQ_9250a055-8e79-48aa-a240-278b7251bfb2">48,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1437c17d92b74d498d6762b05f885fcf_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy0xLTEtMS03MDA3Nw_2a1960ce-7817-4253-bbe5-8f333d590cea">18,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6cd14661959040a9a835c1d64370e08c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy0zLTEtMS03MDA3Nw_0c92f801-da05-4e16-8000-1cc0b7b77815">28,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077e0d963f96436b8a57d5c0ed164f5b_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy01LTEtMS03MTAzOQ_735ab940-eefe-4d2e-be5c-c3640ca830b8">34,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8edaad70b54946b5867782a7dc86da_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy03LTEtMS03MTAzOQ_1a482da1-1909-48fd-978a-6bb89cf5cab0">57,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC0xLTEtMS03MDA3Nw_c7ea5f1c-db50-4f48-a62b-2c382caede9b">38,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC0zLTEtMS03MDA3Nw_b3a2d2be-56c2-4a39-895e-4270c01063b3">53,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC01LTEtMS03MzMwOQ_a634afd6-138a-4e5d-9da6-c377ffa90fa7">70,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC03LTEtMS03MzMwOQ_7f5fb1a2-e2f8-4126-9391-6b5fc6dc15e0">106,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTYwMw_ada22db7-a128-4c4d-9185-94ccbf7f4c68">212</ix:nonFraction>&#160;million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the Company&#8217;s Employee Stock Purchase Plan, as amended (&#8220;ESPP&#8221;). This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTgzNQ_99d74da2-dbd3-41c2-90c3-50493f58aa13">one year</ix:nonNumeric>. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option&#160;and SAR holders exercised their stock options and SARs on June&#160;30, 2022. This amount is subject to change based on changes to the closing price of the Company's common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the six&#160;months ended June&#160;30, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjU3OQ_898d7dcd-21a2-4d7e-8a52-1857e74e118f">8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjU4Ng_0ad4647f-8859-4dab-8ea2-80dba52f8e86">115</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQzMg_79acf495-176e-479b-a268-fa9cbada3d29" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2015 Plan and 2005 Plan for the six&#160;months ended June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2005&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia9871aabeb83498fbc621e999b2b9f8e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi0xLTEtMS03MDA3Nw_3cd18bb7-3b49-449b-9f2b-3e003a400699">3,635,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9871aabeb83498fbc621e999b2b9f8e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi0zLTEtMS03MDA3Nw_e121e101-1f12-45e7-a6d7-42044eefe2f0">42.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib704932e6449470a978301c51c17020a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi01LTEtMS03MDA3Nw_b4f45904-518d-470f-8ef2-4bbaefc2721b">68,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib704932e6449470a978301c51c17020a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi03LTEtMS03MDA3Nw_d1b16a80-591b-4a03-8038-1aa03c15691c">109.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy0xLTEtMS03MDA3Nw_619fccc4-3410-4a4c-823a-037022edf572">506,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy0zLTEtMS03MDA3Nw_03455b6a-ea93-43be-94a9-ac3a042c0a35">73.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy01LTEtMS03MDA3Nw_5ced7789-c82f-4aa4-b963-618038881924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy03LTEtMS03MDA3Nw_e4bfc8a0-5607-41d8-baf0-54d8ef8844f4"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC0xLTEtMS03MDA3Nw_d52fc2b0-81c9-4170-842c-da9711cc4e40">59,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC0zLTEtMS03MDA3Nw_c2825818-0eea-48cd-84b3-82d40f15b48b">15.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC01LTEtMS03MDA3Nw_72ee88c7-39e6-470a-8a20-1c731465c84f">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC03LTEtMS03MDA3Nw_97c59bd7-5f9b-486c-aaad-29a7d20e3550">31.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS0xLTEtMS03MDA3Nw_a9f59888-2358-48cd-bc4c-6c1b5585a1fd">35,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS0zLTEtMS03MDA3Nw_aecbab3e-ebab-45a4-ae50-1bde74e57c09">78.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS01LTEtMS03MDA3Nw_88feeb06-1a50-4718-bcd9-00883346e22c">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS03LTEtMS03MDA3Nw_6289cd6c-79fa-4ebb-b240-01eab7965714">121.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi0xLTEtMS03MDA3Nw_1495e523-9394-4968-b5bc-66c2a6bfff3d">4,047,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi0zLTEtMS03MDA3Nw_784882a2-ee23-4eb4-9af9-5cd323a072eb">46.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi01LTEtMS03MDA3Nw_b3221a82-0b2a-492c-b479-2f1fa0970c03">63,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi03LTEtMS03MDA3Nw_8f1b77a1-0509-4fce-8766-bec66d9b7df3">112.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy0xLTEtMS03MDA3Nw_b9605c61-4225-4e4b-a078-a4a0eebe78a4">1,463,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy0zLTEtMS03MDA3Nw_f8f464d0-04bc-4c4c-87b3-a772c8a54882">55.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy01LTEtMS03MDA3Nw_2a5cfb2b-ec63-488a-a302-6b900af8adf2">63,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy03LTEtMS03MDA3Nw_5a16253d-abfb-4b6c-9c9d-51e49946d8fd">112.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for grant at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfOC0xLTEtMS03MDA3Nw_14220fe7-c9c7-4112-bae1-6a70f029b2b6">4,834,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="iada80c8f94e24448aabad30fa2deb4ed"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQyOQ_69524aef-f777-48d6-b171-43cad976b057" continuedAt="i603d6c54de234adfa08934af492fcf97" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmZiMzZjNWUwODk4MjRlODY5NmU0ZDcxNGU1MTIwYTJiXzQ_a3b976f0-f13b-4cda-b5e5-ec03150c4784">43.21</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi0zLTEtMS03MDA3Nw_9cd480b6-ad55-427c-996e-c49abf3a81ab">166.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi00LTEtMS03MDA3Ny90ZXh0cmVnaW9uOjdkYzJkN2YzZDg0MTRiMThhNzlkOGIxMjRlMmFjNGFjXzEwOTk1MTE2Mjc3OTA_9b0a40ab-cb3e-49ee-89de-2c91018a7ab2">62.52</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi02LTEtMS03MDA3Nw_a58b02d7-6c91-4486-b807-bb1f3a7135f7">131.66</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjllYTE1ZGNlMjAwODRlMTZhOGM5MjQ3NDY4MzcyNWQ3XzQ_006140b0-9c48-4763-a315-9bb88b36ebe2">2.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjllYTE1ZGNlMjAwODRlMTZhOGM5MjQ3NDY4MzcyNWQ3Xzc_dfcab499-0462-42f2-8b93-4a5c48cb2a64">3.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjhkMzA5ZjM5MGQwNjQxNjBhMzRhODM0Y2M5NjNjNGNkXzQ_90ce6687-58c4-4d1b-991e-321ef334567d">0.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjhkMzA5ZjM5MGQwNjQxNjBhMzRhODM0Y2M5NjNjNGNkXzc_f809c817-7ffb-454b-ace1-bf7d9c404f96">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOmIyNDI4YmI5NTg1NzQxZWNhMTY1NjY5ZWNkODU3NDIyXzEwOTk1MTE2Mjc3OTA_9a07068d-b367-4d72-bf6f-c1b3b1fda397">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOmIyNDI4YmI5NTg1NzQxZWNhMTY1NjY5ZWNkODU3NDIyXzEwOTk1MTE2Mjc3OTc_34161e85-3d43-4224-b2d1-8f8deda1ecfa">3.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy03LTEtMS03MTUxMC90ZXh0cmVnaW9uOjA2NzQwNjljYWQ4MTRiM2Y5NjY3NjQ5YjlhOGNkZTViXzEwOTk1MTE2Mjc3OTM_8624253f-3e99-4045-838f-8d3322e15e31">0.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy03LTEtMS03MTUxMC90ZXh0cmVnaW9uOjA2NzQwNjljYWQ4MTRiM2Y5NjY3NjQ5YjlhOGNkZTViXzEwOTk1MTE2Mjc4MDA_087b45b0-7087-4a22-b165-b5d079a47cdc">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC0xLTEtMS03MDA3Nw_1a430459-307a-44ab-a75e-1740ae88e908">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC0zLTEtMS03MDA3Nw_112cb0ac-c29d-4f9d-a826-bb1700dab51c">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC00LTEtMS03MDA3Nw_0598508c-ff16-44dc-bc56-46b7df542519">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC02LTEtMS03MDA3Nw_9c9587ba-e38d-433e-8d94-407aca685231">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjAxZjIxZjljMTY5ZTQ4MTZiYzBiMGI2NTNkMzg0MjQ0XzQ_3a14cbd9-2603-4d88-bda0-8731e2ff7328">120.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjAxZjIxZjljMTY5ZTQ4MTZiYzBiMGI2NTNkMzg0MjQ0Xzc_c7326007-d3d1-4e96-9e1a-9ab4d516bfea">136.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmUyNjc0YTZjOWM0YzRiNDNiNzBmOWY3YzMzZjE5YTE1XzQ_d4a86471-1f0e-4b49-a931-e48a6624726d">126.2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmUyNjc0YTZjOWM0YzRiNDNiNzBmOWY3YzMzZjE5YTE1Xzc_99d8a98c-af14-40bc-9907-38939b32d57f">142.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjM1YTNkZDljZjU3NTRjOTY4MWI3M2NlNmI2ZDExNDgyXzI3NDg3NzkwNjk0NTA_8c74817a-1341-4d58-bf59-8a4efa587208">120.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjM1YTNkZDljZjU3NTRjOTY4MWI3M2NlNmI2ZDExNDgyXzI3NDg3NzkwNjk0Njc_6b456945-6b45-4a99-88e4-05bca8c842ea">136.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS03LTEtMS03MTUyNi90ZXh0cmVnaW9uOjdjZWEzMzc4NzY1MDQzOTA4NTI2OTcwNmE5YTY2MzdlXzEwOTk1MTE2Mjc3OTk_ea31291e-f0fa-4f16-9b4b-7209fb085e1e">124.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS03LTEtMS03MTUyNi90ZXh0cmVnaW9uOjdjZWEzMzc4NzY1MDQzOTA4NTI2OTcwNmE5YTY2MzdlXzEwOTk1MTE2Mjc4MDg_59f4e35d-90c8-433a-9e25-c0caf808e82a">142.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib8ca2be2be7e4bc99eb77502e20ad770_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmYyNWFiYjM5NzVkZjRiN2VhNTdmYWVhMmJiMTc1YWZmXzQ_84816be7-87b8-4f61-8215-164baa6d196b">4.0</ix:nonNumeric>-<ix:nonNumeric contextRef="i547e6d19486d49bbba36b7968e867e86_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmYyNWFiYjM5NzVkZjRiN2VhNTdmYWVhMmJiMTc1YWZmXzc_bcb55e98-2dfe-444d-8f44-5cd0ce3855f4">6.2</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc85c93fc3d4bb8b1fe33f9fc7a5679_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjNhMTY0ZGZhOTc3YzQ1OWE4NjIxN2Q5ZjE4NzlhYTNkXzQ_e209ce16-4130-410d-8bad-f271241ffcd2">4.1</ix:nonNumeric>-<ix:nonNumeric contextRef="i3ba39bdd4b0c4361ab34b776c5df1842_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjNhMTY0ZGZhOTc3YzQ1OWE4NjIxN2Q5ZjE4NzlhYTNkXzc_19ce18be-2586-4120-b002-f98c828c50dc">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d1d79ddc8e64ee499a6e8568258a241_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjAyMzRjMWNmMjhkMjQ3YjFhN2ExNTY1Y2U0NjNmZjQwXzI3NDg3NzkwNjk0NTA_2e6b84ac-0766-4233-ae8b-b6dadb675a05">4.0</ix:nonNumeric>-<ix:nonNumeric contextRef="i420df0b64ff14517bb785ae28358ddd9_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjAyMzRjMWNmMjhkMjQ3YjFhN2ExNTY1Y2U0NjNmZjQwXzI3NDg3NzkwNjk0NTQ_b8cadc83-c21a-4dd4-92ea-0ff44e4a035e">6.2</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20b84332994940ec9dd4c1fa8fe32f65_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi03LTEtMS03MTUzOC90ZXh0cmVnaW9uOjBmOWRiMTQxNmU4MTRmMTk4NTFjMGQ1OThiM2ZjZDE1XzEwOTk1MTE2Mjc3OTA_3b36341c-ff3a-4074-aef2-b4196f1d6939">4.1</ix:nonNumeric>-<ix:nonNumeric contextRef="i0af1ef6cf5684c3f981161750a479e9e_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi03LTEtMS03MTUzOC90ZXh0cmVnaW9uOjBmOWRiMTQxNmU4MTRmMTk4NTFjMGQ1OThiM2ZjZDE1XzEwOTk1MTE2Mjc3OTY_c19b42ac-19c7-4d31-a105-c8235937c189">6.1</ix:nonNumeric></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2015 Plan and 2005 Plan as of June&#160;30, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzEzNA_7e1d7bbf-aacd-4533-b210-774fbffffa11">91</ix:nonFraction> million and <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzE0MQ_4c30d204-fa3c-4a78-96df-f7f52e552fa2">7.5</ix:nonNumeric> years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2015 Plan and 2005 Plan as of June&#160;30, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzM0Mg_97ec5b2c-df55-47ba-bfef-ba825f9f88d4">30</ix:nonFraction> million and <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzM0OQ_4f37f2ee-a1f3-460c-b00c-7ffb9107b983">6.5</ix:nonNumeric> years, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQzMA_1cd1b29a-c97f-46f8-a46e-f2ca1bfa362f" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMS0xLTEtMS03MDA3Nw_6d61bd77-13a1-475e-acf5-772b15267bc1">819,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMS0zLTEtMS03MDA3Nw_e267a336-90ee-4e28-9937-9f6edb9990bc">116.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMi0xLTEtMS03MDA3Nw_7c52155c-ab35-49de-aec8-bce265e26fc1">882,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMi0zLTEtMS03MDA3Nw_f7c7faae-ce7f-4565-89d8-281e20e4f316">74.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMy0xLTEtMS03MDA3Nw_af0fd1a5-1990-4b53-9184-c5cfb55b9137">55,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMy0zLTEtMS03MDA3Nw_7039b83b-d40c-46b0-a76c-cb136957cbf4">157.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNC0xLTEtMS03MDA3Nw_c17dc3ed-4c4b-4e78-b2dd-a7bae74fad4d">71,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNC0zLTEtMS03MDA3Nw_01feec56-1a88-4efb-92ec-e76caa831d48">110.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i307541a72a03422fb6a7905e2797b623_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNS0xLTEtMS03MDA3Nw_8413ac7e-25ef-4874-8873-9038ec395c82">1,575,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i307541a72a03422fb6a7905e2797b623_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNS0zLTEtMS03MDA3Nw_e81f14d3-6fae-45bd-89e5-4c8795b99476">91.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company's annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of <ix:nonFraction unitRef="shares" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjc0ODc3OTA3NjMyMw_2333de62-2a9e-4522-a1fc-7035a7188317">1.1</ix:nonFraction> million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase <ix:nonFraction unitRef="number" contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630" decimals="INF" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzg0ODI5MDcwNDc2OQ_5852f707-d0a0-4d7d-ae84-cfd13946fd28">5</ix:nonFraction>% on each anniversary of its adoption up to a maximum of <ix:nonFraction unitRef="shares" contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjc0ODc3OTA3NjMzNg_25b6ebf8-69eb-4587-90c3-51cdcdce8f13">1.65</ix:nonFraction> million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of <ix:nonFraction unitRef="number" contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzg2NQ_1a31d31b-2247-4dcc-9654-5eebab486345">15</ix:nonFraction>% of their compensation, at <ix:nonFraction unitRef="number" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzg5NA_f64fcb0d-9c5d-4854-b504-a19768d62652">85</ix:nonFraction>% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). No ESPP option periods commenced during the three months ended June 30, 2022 and 2021. As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDE1NQ_a897b57e-75aa-46d8-a5be-d65288068acb">0.7</ix:nonFraction>&#160;million shares available for issuance under the ESPP.</span></div><ix:continuation id="i603d6c54de234adfa08934af492fcf97"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Range of Black-Scholes fair values of ESPP shares granted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4319b34bddc14dc7ad516619f65f196d_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjQ1YWY0ZmViOWU4NzRkNTM4YTI4ZWE5MWVlNmFkOTgxXzI3NDg3NzkwNjk0NTQ_4483ed59-8582-48ec-bb02-e33350210982">44.67</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i962e48035aea4045b0cfe2ace43cde76_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjQ1YWY0ZmViOWU4NzRkNTM4YTI4ZWE5MWVlNmFkOTgxXzI3NDg3NzkwNjk0NTg_a759601e-a5a6-439d-8776-4e830c897c26">79.74</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6e499e69dfc74d4ab90426c5104422ea_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi03LTEtMS03MTM4NS90ZXh0cmVnaW9uOmI0NWNiZWZiMzIwODRjYjhiMzNiMjkyNGQ5OTQ0YzVjXzEwOTk1MTE2Mjc4MDQ_aeb9d6f6-1a80-418c-b010-f43fb9dfa1e8">128.70</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i7ad84832faf04aac8ca995f70a7aecd3_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi03LTEtMS03MTM4NS90ZXh0cmVnaW9uOmI0NWNiZWZiMzIwODRjYjhiMzNiMjkyNGQ5OTQ0YzVjXzEwOTk1MTE2Mjc4MTQ_025a7764-e649-4437-a2d4-6067668f6214">238.85</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMy01LTEtMS03MDA3Ny90ZXh0cmVnaW9uOmJhNTUwMDIyNmViYjRjNjRiY2U0YmRhOGU2NzYzMGVhXzI3NDg3NzkwNjk0NTQ_e2a4ffba-a479-4e5c-bc60-ec3f1e4d2699">0.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMy01LTEtMS03MDA3Ny90ZXh0cmVnaW9uOmJhNTUwMDIyNmViYjRjNjRiY2U0YmRhOGU2NzYzMGVhXzI3NDg3NzkwNjk0NTg_b2843694-5a46-45be-9110-f50ecd022be3">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMy03LTEtMS03MzMxMg_f4e0bd4b-c8f0-4de6-824f-e6bd77530b38">0.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNC01LTEtMS03MDA3Nw_ca358cd5-9c52-4691-a597-53b146f1c467">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNC03LTEtMS03MDA3Nw_aec23234-451f-4136-99dd-21501414ea05">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjhmNjg0MDUyYTdiMDQ5ODdiOTc2MDg5NWRmNGFjZDI4XzI3NDg3NzkwNjk0NTQ_a0bfccb7-cfb5-4b9c-89f3-bc5ac5eb89d4">116.2</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjhmNjg0MDUyYTdiMDQ5ODdiOTc2MDg5NWRmNGFjZDI4XzI3NDg3NzkwNjk0NTg_81b8cee7-641a-4cff-aadf-5a9a8fa73eb0">142.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS03LTEtMS03MTQwOS90ZXh0cmVnaW9uOjcxNTIwNmU0YzE3ZDQ4NmZiZTQ3ZGRmZTJhZTgxYTFmXzEwOTk1MTE2Mjc4MDQ_47678425-5c48-4d38-9ac4-d8fa2b6e013c">120.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS03LTEtMS03MTQwOS90ZXh0cmVnaW9uOjcxNTIwNmU0YzE3ZDQ4NmZiZTQ3ZGRmZTJhZTgxYTFmXzEwOTk1MTE2Mjc4MDg_d9978562-6ead-4428-8a73-2f1cb6c2901a">159.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4319b34bddc14dc7ad516619f65f196d_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjAxNThmODZhYTUyNjQzOTBhZGM3NDA2ZWQyMTU2MjRlXzI3NDg3NzkwNjk0NTQ_596f4ea0-7c70-45c4-abf5-28fec18dc42d">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="i962e48035aea4045b0cfe2ace43cde76_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjAxNThmODZhYTUyNjQzOTBhZGM3NDA2ZWQyMTU2MjRlXzI3NDg3NzkwNjk0NTg_56e73cbf-b14d-44e8-86ce-941bf152a373">2</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e499e69dfc74d4ab90426c5104422ea_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi03LTEtMS03MTQyNS90ZXh0cmVnaW9uOjAzNmFlOGU2ZTcyZDQ1ZTJiNTY2ZDI1OGQ0MGNhY2Y0XzEwOTk1MTE2Mjc3OTQ_690b4f97-968e-461f-9b57-ca7f3c292f85">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="i7ad84832faf04aac8ca995f70a7aecd3_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi03LTEtMS03MTQyNS90ZXh0cmVnaW9uOjAzNmFlOGU2ZTcyZDQ1ZTJiNTY2ZDI1OGQ0MGNhY2Y0XzEwOTk1MTE2Mjc3OTg_f8c434b6-75a1-4e1f-a4b0-b4322db17e0c">2.0</ix:nonNumeric></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 &#8211; <ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTM0OQ_e6c3585c-0e81-40c0-b1d6-44d51436a019" continuedAt="i05b657daf16740dbab6e8a000b527787" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="i05b657daf16740dbab6e8a000b527787"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective evidence evaluated was the cumulative loss incurred over the three-year period ended June&#160;30, 2022 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June&#160;30, 2022, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent Net Operating Losses (&#8220;NOLs&#8221;) have been used to reduce taxable income. The Company&#8217;s remaining U.S. Federal NOLs are subject to limitation in accordance with the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), which limits allowable NOL deductions to 80% of federal taxable income. Effective January 1, 2022, a provision of the TCJA has taken effect creating a significant change to the treatment of research and experimental expenditures under Section 174 of the IRC (&#8220;Sec. 174 expenses&#8221;). Historically, businesses have had the option of deducting Sec. 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and will require Sec. 174 expenses associated with research conducted in the U.S. to be capitalized and amortized over a five-year period. For expenses associated with research outside of the U.S., Sec. 174 expenses will be capitalized and amortized over a 15-year period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized federal and state income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630" decimals="-5" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA0NA_10747308-ea86-4e7c-a6b9-4735129f973a">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyODI2NDg_10805370-ecc3-4304-bf62-65fa3060e991">1.9</ix:nonFraction>&#160;million, in total, for the three and six months ended June&#160;30, 2022, respectively, and did <ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="INF" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTM1MA_3b37c1bc-8f4e-4a42-9272-2448385bb3c5"><ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="INF" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTM1MA_a587d0d7-fb03-464d-806b-9a90e33a091e">no</ix:nonFraction></ix:nonFraction>t recognize federal or state income tax expense for the three and six months ended June&#160;30, 2021. The Company recognized income tax expense related to foreign withholding tax on royalties of $<ix:nonFraction unitRef="usd" contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyODI2NjM_a93e10f8-4c3f-465a-b531-28d3289e6d23">2.2</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyOTI2Mw_2557dd1d-2636-42ee-85c4-0ca07b63df18">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyODI3Mjg_1ed8b242-b16c-40ec-b1fe-bc8a2de8f286">6.6</ix:nonFraction> million for the three and six months ended June&#160;30, 2021, respectively. The Company did not recognize income tax expense related to foreign withholding tax on royalties for the three months ended June&#160;30, 2022.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83OS9mcmFnOmYxMDQzNTIzNjU3ODQyNjI5YjczY2ZiZTY0MDQ2OGQyL3RleHRyZWdpb246ZjEwNDM1MjM2NTc4NDI2MjliNzNjZmJlNjQwNDY4ZDJfNDA3NQ_fa44f2fa-6195-4e49-be1b-cd94d5ccfbd5" continuedAt="i3154cb8f00fd491d942f03148590189c" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i3154cb8f00fd491d942f03148590189c" continuedAt="i7208403e9d62455bae21bff12c5f4988"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On June 9, 2022, the co-lead plaintiffs filed an opposition to the motion to dismiss and on July 11, 2022, the Company filed a reply brief. The matter is now fully briefed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Court has not indicated whether it intends to schedule any hearing on the motion before issuing a ruling.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After the Sinnathurai Action was filed, five derivative lawsuits were filed: Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), William Kirst, et al. v. Stanley C. Erck, et al., No. 8:22-cv-00024-TDC (the &#8220;Kirst Action&#8221;), Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), and Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the U.S. District Court for the District of Maryland. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the U.S. District Court for the District of Maryland by the defendants. The derivative lawsuits name members of the board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><ix:continuation id="i7208403e9d62455bae21bff12c5f4988"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the Court issued a memorandum opinion and order remanding the Kirst Action to state court. On February 4, 2022, the Court entered an order consolidating the Meyer and Yung Actions (the &#8220;Consolidated Derivative Action&#8221;). The plaintiffs in the Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Court entered an order in the Consolidated Derivative Action granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. If a related derivative action is filed and is not stayed, the Meyer and Yung plaintiffs may seek to terminate the stay. On June 10, 2022, the Snyder and Blackburn Actions were filed. The Snyder and Blackburn plaintiffs have expressed their intent to move the court to consolidate all of the derivative actions pending in Maryland federal court and to appoint lead counsel. On July 21, 2022, the Court ordered the parties in the Consolidated Derivative Action, the Snyder Action, and the Blackburn Action to meet and confer concerning consolidation, the appointment of lead counsel, and the ongoing stay of proceedings in the Consolidated Derivative Action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Should the parties fail to reach agreement on those issues, the Snyder and Blackburn plaintiffs were granted leave to file a motion for consolidation and appointment of lead counsel by August 18, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 29, 2022, Par Sterile Products, LLC (&#8220;Par&#8221;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (&#8220;MSA&#8221;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. While the Company maintains that no breach of the MSA has occurred and intends to vigorously defend the matter, if the final resolution of the matter is adverse to the Company, it could have a material impact on the Company&#8217;s financial position, results of operations, or cash flows.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows.</span></div></ix:continuation><div id="i4443801361394f65b2e7b9b03051a84d_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMTc2MQ_c58738b7-5e8d-46d7-855f-a4d5e12629a9" continuedAt="i409ce50892f041839c8f1d2c94c7212a" escape="true">Subsequent Events</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="i409ce50892f041839c8f1d2c94c7212a"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, the Company received emergency use authorization for NVX-CoV2373 from the FDA to provide a two-dose primary series in individuals 18 years of age and over.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, the Company entered into a modification to the OWS Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately <ix:nonFraction unitRef="dose" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNjA0NzMxMzk5MDYwOQ_c72967a8-eee7-44fe-803d-d85628fc8471">3</ix:nonFraction>&#160;million doses of NVX-CoV2373, contingent on the timing of EUA approval by the FDA, as well as the timing of label language and artwork approvals by the FDA and the recommendation of the Advisory Committee on Immunization Practices within the United States Centers for Disease Control and Prevention, and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of <ix:nonFraction unitRef="dose" contextRef="idadbd33a708c469c910a0ca167cd16cf_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMzg0ODI5MDcyMTA5Mg_89da6869-1bf3-4bca-9e37-cd4afe8aab11">100</ix:nonFraction>&#160;million doses of NVX-CoV2373 contemplated by the original OWS Agreement (inclusive of the initial batch of approximately <ix:nonFraction unitRef="dose" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2MjY4Mg_220dd5d1-e241-4896-a621-f019e78148bb">3</ix:nonFraction>&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The <ix:nonFraction unitRef="dose" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNjA0NzMxMzk5MDYzNQ_c72967a8-eee7-44fe-803d-d85628fc8471">3</ix:nonFraction>&#160;million initial doses were delivered in July 2022. Additionally, in July 2022, the Company modified its existing agreement with the DoD to provide for the initial delivery of <ix:nonFraction unitRef="dose" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-5" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMzg5ODA_f1168f25-ec99-40ba-a8e5-eb01009f927d">0.2</ix:nonFraction>&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining <ix:nonFraction unitRef="segment" contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731" decimals="-5" name="nvax:PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMzg5ODQ_caa57b9b-9f11-4e7e-b460-64e192822be7">9.8</ix:nonFraction>&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, the Company entered into the Amended and Restated UK Supply Agreement with the Authority, which amended and restated in its entirety the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of <ix:nonFraction unitRef="dose" contextRef="ibe5f264f5aae46269f4b5c7f917258db_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2Mjc0NQ_8e93467f-e4aa-4936-8655-2001ad59ecbc">1</ix:nonFraction>&#160;million doses and up to an additional <ix:nonFraction unitRef="dose" contextRef="i7ce520d7761743ec86392cca9a2d1a9d_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2MjcyMQ_b4aebde9-11ff-4ec1-91e4-f65cfe44dae3">15</ix:nonFraction>&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#8217;s timely achievement of supportive recommendations from the JCVI. In the event that the Company is unable to achieve the JCVI supportive recommendations, it may have to repay up to $<ix:nonFraction unitRef="usd" contextRef="ib86f32bcfa404cf0815eaf4f567e395f_I20220731" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMjc0ODc3OTEwODMwNQ_a5f35ea2-cf75-4268-9c30-59c2e9ad691a">225.0</ix:nonFraction>&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional <ix:nonFraction unitRef="dose" contextRef="ib86f32bcfa404cf0815eaf4f567e395f_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2MjczMw_3d64ccfc-cdb6-4d0f-96e8-acd416c28799">44</ix:nonFraction>&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022 and August 2022, the Company was notified by the EC that it was cancelling its prior commitment for <ix:nonFraction unitRef="dose" contextRef="i750e9cc522fe4374bb3945dd8f61ee58_I20220731" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesCancelled" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNjA0NzMxMzk5MDczNw_216f6767-c485-4dc5-afc9-f2b6c88cd903">5</ix:nonFraction>&#160;million doses originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company signed an agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. In addition, the companies signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any statements in the discussion below and elsewhere in this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) about expectations, beliefs, plans, objectives, assumptions, or future events or performance of Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation, statements about our capabilities, goals, expectations regarding future revenue and expense levels, and capital raising activities; our operating plans and prospects; potential market sizes and demand for our product candidates; the efficacy, safety, and intended utilization of our product candidates; the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies; the development of our preclinical product candidates; our expectations related to enrollment in our clinical trials; the conduct, timing, and potential results from clinical trials and other preclinical studies; plans for and potential timing of regulatory filings; our expectation of manufacturing capacity, timing, production, distribution, and delivery for our coronavirus vaccine candidate (&#8220;NVX-CoV2373&#8221;) by us and our partners; our estimate of the number of individuals who may potentially be reached by NVX-CoV2373; our expectations with respect to the anticipated ongoing development and commercialization or licensure of NVX-CoV2373 and our seasonal quadrivalent influenza vaccine, previously known as NanoFlu; the expected timing, content, and outcomes of regulatory actions; funding from the U.S. government partnership formerly known as Operation Warp Speed (&#8220;OWS&#8221;), the U.S. Department of Defense (&#8220;DoD&#8221;), and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;), and payments from the Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;); funding under our advance purchase agreements and supply agreements and amendments to, or termination of, any such agreement; our available cash resources and usage and the availability of financing generally; plans regarding partnering activities and business development initiatives; and other matters referenced herein. Generally, forward-looking statements can be identified through the use of words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; or &#8220;assume,&#8221; the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities, such as the U.S. Food and Drug Administration (&#8220;FDA&#8221;), World Health Organization (&#8220;WHO&#8221;), United Kingdom (&#8220;UK&#8221;) Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), the Republic of Korea&#8217;s Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), or Japan&#8217;s Ministry of Health, Labour and Welfare (&#8220;MHLW&#8221;); unanticipated challenges or delays in conducting clinical trials; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, constraints on the ability of Novavax to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and other risks and uncertainties identified in Part I, Item 1A &#8220;Risk Factors&#8221; of the Company's Annual Report on Form&#160;10-K for the&#160;fiscal year ended December&#160;31, 2021, which may be detailed and modified or updated in other documents filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) from time to time, and are available at www.sec.gov and at www.novavax.com. You are encouraged to read these filings as they are made.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information in this Quarterly Report includes a financial measure that was not prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), which we refer to as adjusted cost of sales. We are presenting this non-GAAP financial measure to assist an understanding of our business and its performance. Adjusted cost of sales includes an estimate of standard manufacturing costs that were previously expensed to research and development prior to regulatory approvals for NVX-CoV2373 that would otherwise have been capitalized to inventory. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by GAAP, have no standardized meaning prescribed by GAAP, and may not be comparable to the calculation of similar measures of other companies.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot guarantee future results, events, level of activity, performance, or achievement. Any or all of our forward-looking statements in this Quarterly Report may turn out to be inaccurate or materially different from actual results. Further, any forward-looking statement speaks only as of the date when it is made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Overview</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novavax, Inc., together with our wholly-owned subsidiaries, is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Our proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our vaccine candidates are genetically engineered nanostructures of conformationally correct recombinant proteins that mimic those found on natural pathogens. This technology enables the immune system to recognize the right target proteins from different angles and develop protective antibodies. We believe that our vaccine technology may lead to the induction of a differentiated immune response that may be more efficacious than naturally occurring immunity or other vaccine approaches. Our vaccine candidates also incorporate our proprietary saponin-based Matrix-M&#8482; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have developed a COVID-19 vaccine (&#8220;NVX-CoV2373,&#8221; &#8220;Nuvaxovid&#8482;,&#8221; &#8220;Covavax&#8482;&#8221;), and are developing an influenza vaccine, a COVID-19-Influenza Combination vaccine (&#8220;CIC&#8221;), and additional vaccine candidates. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (&#8220;CMA&#8221;), and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally. In addition to COVID-19 and seasonal influenza, our other areas of focus include respiratory syncytial virus (&#8220;RSV&#8221;) and malaria.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div id="i4443801361394f65b2e7b9b03051a84d_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Technology Overview</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe our recombinant nanoparticle vaccine technology together with our proprietary Matrix-M&#8482; adjuvant is well-suited for the development of vaccine candidates targeting a broad scope of respiratory and other emerging infectious diseases at scale.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recombinant Nanoparticle Vaccine Technology</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:33pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Once a pathogenic threat has been identified, the genetic sequence encoding the antigen is selected for subsequent use in developing the vaccine construct. The genetic sequence may be optimized to enhance protein stability or confer resistance to degradation. This genetic construct is inserted into the baculovirus Spodoptera frugiperda (&#8220;Sf9/BV&#8221;) insect cell-expression system, which enables efficient, large-scale expression of the optimized protein. The Sf9/BV system produces proteins that are properly folded and modified &#8211; which can be critical for functional, protective immunity &#8211; as the vaccine antigen. Protein antigens are purified and organized around a polysorbate-based nanoparticle core, in a configuration that resembles their native presentation. This results in a highly immunogenic nanoparticle that is ready to be formulated with Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> adjuvant. </span></div><div style="text-align:justify;text-indent:33pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Matrix-M&#8482; Adjuvant</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our proprietary Matrix-M&#8482; adjuvant has been a key differentiator within our platform. This adjuvant has demonstrated potent, well-tolerated, and durable efficacy by stimulating the entry of antigen presenting cells (&#8220;APCs&#8221;) into the injection site and enhancing antigen presentation in local lymph nodes. This in turn activates APCs, T-cell and B-cell populations, plasma cells, and high affinity antibodies, thereby boosting immune response. This potent mechanism of action enables a lower dose of antigen required to achieve the desired immune response and we believe thereby contributes to increased vaccine supply and manufacturing capacity. These immune-boosting and dose-sparing capabilities contribute to the adjuvant&#8217;s highly unique profile. </span></div><div id="i4443801361394f65b2e7b9b03051a84d_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NVX-CoV2373 Regulatory and Licensure</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to make progress in advancing NVX-CoV2373 toward regulatory approvals. We have received numerous authorizations globally for primary series, and both homologous and heterologous booster indications, which collectively have the potential to reach over six billion individuals. To date, we have received approval, interim authorization, provisional approval, CMA, and EUA for both adult and adolescent populations, and we expect to initiate additional rolling submissions worldwide. We continue to work closely with governments, regulatory authorities, and non-governmental organizations in our commitment to facilitate equitable global access to our COVID-19 vaccine. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the territories in which our vaccine has gained authorization, NVX-CoV2373 is marketed under the brand names (i) Nuvaxovid&#8482; COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]), (ii) Covovax&#8482; (manufacturing and commercialization by the Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;)), or (iii) Novavax&#8217; COVID-19 Vaccine, Adjuvanted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through the date of filing this Quarterly Report, the below is a summary of regulatory authorizations for NVX-CoV2373:</span></div><div style="text-align:justify"><img src="nvax-20220630_g1.jpg" alt="nvax-20220630_g1.jpg" style="height:742px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Regulatory approval received in partnership with SIIPL.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;Regulatory manufacturing and marketing approval received by partner Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022, we completed additional regulatory submissions in major markets for both adult and adolescent populations for primary and booster indications. We are in active discussions with regulatory authorities and remain focused on seeking additional authorizations for NVX-CoV2373.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below is a summary and status of our regulatory submissions completed through the date of filing this Quarterly Report.</span></div><div style="text-align:justify"><img src="nvax-20220630_g2.jpg" alt="nvax-20220630_g2.jpg" style="height:529px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Regulatory filing submitted in partnership with SIIPL.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;Regulatory filing submitted by our partner, SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;).</span></div><div id="i4443801361394f65b2e7b9b03051a84d_97"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Clinical Pipeline</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical pipeline encompasses vaccine candidates spanning multiple therapeutic areas including coronavirus, seasonal influenza, RSV, and Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> adjuvant collaborations for the prevention of malaria. Our COVID-19 vaccine candidate, NVX-CoV2373, is our leading product, having received approval, interim authorization, provisional approval, CMA, and EUA from multiple regulatory authorities globally. We advanced NVX-CoV2373 through two pivotal Phase 3 clinical trials that demonstrated high efficacy against both the original COVID-19 strain and commonly circulating COVID-19 variants of concern (&#8220;VoC&#8221;), while maintaining a favorable safety profile. We also advanced our influenza vaccine through a Phase 3 clinical trial, which demonstrated positive top-line results and achieved statistical significance in key secondary endpoints. We initiated a trial of a CIC consisting of our influenza vaccine and NVX-CoV2373. In April 2022, we announced initial results from Phase 1/2 clinical trial of CIC demonstrating that formulating the combination vaccine is well-tolerated and immunogenic. Modeling results showed that combined formulation has the potential to reduce total antigen amount by up to 50% overall, optimizing production and delivery. Additionally, we remain interested in further development of our RSV Program for respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (&#8220;RSV F Vaccine&#8221;). Ongoing Phase 3 trials are being conducted by our partner, Jenner Institute, University of Oxford, for R21, a malaria candidate currently under development by the University of Oxford in partnership with SIIPL, which is formulated using our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> adjuvant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We remain focused on bringing our NVX-CoV2373 vaccine candidate to market following global regulatory authorizations. Through ongoing booster studies in our clinical trials, as well as the development of COVID-19 variant strain vaccine candidates, we continue to collect data to characterize and improve vaccine performance. In April 2022, we announced the initiation of a Phase 3 COVID-19 vaccine booster study in adolescents ages 12-17 years as part of our PREVENT-19 trial, and in May 2022, we announced our participation in University of Oxford&#8217;s Com-COV3 booster trial of COVID-19 vaccines in adolescents ages 12-15 years. Additionally, in May 2022, we announced the initiation of a Phase 3 clinical trial for use of our Omicron variant strain vaccine as a booster. We remain in close collaboration with regulatory authorities for providing additional variant data. We expect to leverage these clinical insights to advance the use and additional regulatory approvals of our COVID-19 vaccine for primary, booster, and pediatric indications globally, amidst the ongoing and evolving COVID-19 pandemic.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pipeline chart below summarizes the core clinical and preclinical development programs that we are focusing on in the near-term.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-align:justify"><img src="nvax-20220630_g3.jpg" alt="nvax-20220630_g3.jpg" style="height:307px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Supported by OWS, DoD, CEPI, and BMGF.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;Authorized for provisional approval, CMA, or EUA in select geographies under trade names Nuvaxovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and Covovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Received EUA from the U.S. FDA. PREVENT-19, a Phase 3 clinical trial in the U.S. and Mexico; Ongoing PREVENT-19 pediatric expansion in the U.S.; Phase 3 clinical trial in the UK; Ongoing Phase 2b clinical trial in South Africa. We, along with our partners, will have commercial rights in authorized geographies to sell and distribute NVX-CoV2373.</span></div><div style="padding-left:36pt"><span><br/></span></div><div id="i4443801361394f65b2e7b9b03051a84d_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Second Quarter 2022 and Recent Highlights</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Progressed COVID-19 Global Regulatory Strategy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%"> </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Received EUA from U.S. FDA with label expansion underway, marking first protein-based COVID-19 vaccine available for use domestically</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Authorized for primary series in adults 18 and older with unanimous recommendation received from U.S Centers for Disease Control and Prevention (&#8220;CDC&#8221;)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Planned submission for boosting data from PREVENT-19 Phase 3 trial in August of 2022</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Nuvaxovid or Covovax authorized in 43 countries for primary series in adults 18 and older, with additional label expansions received and underway in several geographies</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Authorized for boosting in adults 18 and older in Japan, Australia and New Zealand </span></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Nuvaxovid filings completed in the European Union (&#8220;EU&#8221;), Great Britain and Switzerland</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Authorized for primary series in adolescents aged 12 through 17 in the EU, India, Australia, Japan and Thailand</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Nuvaxovid filings completed to the WHO, Great Britain, Canada, Switzerland, New Zealand and Taiwan</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Expect to file for authorization of Omicron-containing vaccine with U.S. FDA in the fourth quarter of 2022</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">COVID-19 Vaccine Manufacturing and Distribution</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Delivered over 73 million doses of Nuvaxovid and Covovax globally to date, including 23 million doses since the start of the third quarter 2022, reflecting strong momentum for the remainder of 2022 </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Secured order from U.S government for 3.2 million initial doses under existing agreements, with distribution underway</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Received approval from EMA for SK bioscience to manufacture and supply the active substance in the Nuvaxovid COVID-19 vaccine to the EU</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Expanded partnership with SK bioscience to support manufacturing of Omicron-containing vaccine and to manufacture vaccine in prefilled syringes for commercial supply in 2023</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">COVID-19 Clinical Development Program</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Ongoing development of Omicron BA.1 specific vaccine (&#8220;NVX-CoV2515&#8221;), Omicron BA.5 specific vaccine and bivalent format with prototype vaccine (&#8220;NVX-CoV2373&#8221;)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Announced positive preclinical boosting data for NVX-CoV2373, NVX-CoV2515, or bivalent formulation, demonstrating strong antibody levels</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Ongoing Phase 3 strain change trial to assess safety and antibody responses following primary vaccination with mRNA vaccines; initial results expected near the end of the third quarter of 2022</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Initiated Phase 2b/3 Hummingbird global clinical trial in younger children aged six months through 11 years with initial results expected in the first quarter of 2023</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Expected to enroll total 3,600 participants across nine countries, evaluating safety, effectiveness (immunogenicity) and efficacy of two doses of NVX-CoV2373, followed by a booster at least six months after primary vaccination in three age cohorts</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Advanced multiple studies evaluating homologous and heterologous boosting in adolescents for NVX-CoV2373</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Completed administration of homologous third-dose booster for select participants in PREVENT-19 Phase 3 booster study in adolescents aged 12 through 17</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Ongoing participation in University of Oxford&#8217;s Com-COV3 Booster trial in adolescents aged 12 through 15 to evaluate heterologous boosting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">COVID-19-Influenza Combination (CIC) Vaccine Candidate Clinical Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Announced initial results of CIC Phase 1/2 trial demonstrating robust immune response with both stand-alone influenza and CIC vaccine candidates</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Phase 3 trial to evaluate efficacy on-track to be initiated in 2023</span></div><div id="i4443801361394f65b2e7b9b03051a84d_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022, we sold 2.2&#160;million of shares of our common stock resulting in net proceeds of approximately $179&#160;million, under our most recent At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;), which allows us to issue and sell up to $500&#160;million in gross proceeds of shares of our common stock. As of June&#160;30, 2022, the remaining balance under our June 2021 Sales Agreement was approximately $318&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2021, we sold 2.6&#160;million shares of our common stock resulting in net proceeds of approximately $565&#160;million, under our various At Market Issuance Sales agreements then in effect. </span></div><div id="i4443801361394f65b2e7b9b03051a84d_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements (unaudited) and the accompanying notes, which have been prepared in accordance with generally accepted accounting principles in the United States.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and equity and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Our critical accounting policies and estimates are included under Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC, and are updated for inventory valuation below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory Valuation </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We periodically analyze our inventories for excess amounts or obsolescence and write down obsolete or otherwise unmarketable inventory to its estimated net realizable value based on assumptions about expected future demand and market conditions. Our assumptions about expected future demand are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory write down that we report in a particular period. Expense incurred related to excess inventory and obsolete inventory is recorded as a component of cost of sales in the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 2&#8213;Summary of Significant Accounting Policies&#8221; included in our Notes to Consolidated Financial Statements (under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div id="i4443801361394f65b2e7b9b03051a84d_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion of the historical financial condition and results of our operations that should be read in conjunction with the unaudited consolidated financial statements and notes set forth in this Quarterly Report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June&#160;30, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,092)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Revenue for the three months ended June&#160;30, 2022 was $185.9 million as compared to $298.0 million for the same period in 2021, a decrease of $112.1 million. Revenue for the three months ended June&#160;30, 2022 was primarily comprised of revenue for services performed under the agreement with the U.S. government partnership formerly known as OWS (&#8220;OWS Agreement&#8221;) and revenue from product sales of NVX-CoV2373. Revenue for the three months ended June&#160;30, 2021 was primarily comprised of revenue for services performed under the OWS Agreement and our funding agreements with CEPI. The decrease in revenue was due to decreased development activities under the OWS Agreement as we began commercial sales of NVX-CoV2373, partially offset by an increase in revenue due to the commencement of product sales of NVX-CoV2373.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expect revenue in 2022 to significantly increase as compared to 2021 due to product sales of NVX-CoV2373 under various supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), as a result of multiple global regulatory approvals. Certain revenue from product sales of NVX-CoV2373 that was originally planned for the three months ended June 30, 2022 is now planned for the second half of 2022 based on requested and revised customer delivery plans. Revenue in 2022 is also expected to increase due to royalties from the sale of NVX-CoV2373 under our supply and license agreements with strategic partners to supply NVX-CoV2373 in their specified territories where we are entitled to receive royalties from such sales, and our NVX-CoV2373 program, which we anticipate will continue to be funded by OWS and other revenue sources.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,846&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cost of sales was $271.1&#160;million, or 489% of product sales, for the three months ended June&#160;30, 2022, including expense of $255.3&#160;million related to excess, obsolete, or expired inventory and losses on firm purchase commitments. Prior to receiving regulatory approval, we expensed manufacturing costs as research and development expenses. After receiving regulatory approval, we capitalize the costs of production for a particular supply chain when we determine that we have a present right to the economic benefit associated with the product. While we tracked the quantities of our manufactured vaccine product and components, we did not track pre-approval manufacturing costs and therefore the manufacturing cost of our pre-launch inventory produced prior to approval is not reasonably determinable. However, based on our expectations for future manufacturing costs to produce our vaccine product and components inventory, we estimate at June&#160;30, 2022 we had approximately $0.3&#160;billion of commercial inventory that was expensed prior to approval. We expect to utilize all of our reduced-cost inventory during 2022. If inventory sold for the three months ended June&#160;30, 2022 was valued at expected standard cost, including expenses related to excess and obsolete inventory, adjusted cost of sales for the period would have been approximately $279.5&#160;million, or 504% of product sales, an adjustment of $8.4&#160;million as compared to cost of sales recognized. The cost of sales to high income countries is expected to be between 15% and 30% of product sales based on our standard cost. The cost of sales as a percentage of product sales may fluctuate in the future as a result of changes to our customer mix or standard costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased to $289.6&#160;million for the three months ended June&#160;30, 2022 as compared to $570.7 million for the three months ended June&#160;30, 2021, a decrease of $281.0 million primarily due to research and development of NVX-CoV2373, as summarized in the table below (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NVX-CoV2373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Influenza vaccine</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other vaccine development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct external research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for NVX-CoV2373 for the three months ended June&#160;30, 2022 and 2021, included a benefit of $87.2&#160;million related to previously accelerated manufacturing costs and an expense of $20.0&#160;million related to the acceleration of manufacturing costs, respectively, for leases that we determined were embedded in multiple manufacturing supply agreements with Contract Manufacturing Organizations (&#8220;CMOs&#8221;) and contract manufacturing and development organizations (&#8220;CDMOs&#8221;). For 2022, we expect total research and development expenses to decrease as compared to 2021. The decline in 2022 is anticipated to result from expected capitalization of manufacturing costs during 2022 that were previously recognized as research and development expenses in prior periods, partially offset by research and development expenses related to increased clinical activities as we continue to develop our NVX-CoV2373 and other programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased to $108.2&#160;million for the three months ended June&#160;30, 2022 from $73.2&#160;million for the same period in 2021, an increase of $35.0&#160;million. The increase in selling, general, and administrative expenses is primarily due to an increase in professional fees in support of our NVX-CoV2373 program. For 2022, we expect selling, general, and administrative expenses to increase significantly as compared to 2021 due to increased activities related to supporting our NVX-CoV2373 program and increases in employee-related costs and professional fees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense) (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,968)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,940)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,167)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total other expense, net, of $26.1&#160;million for the three months ended June&#160;30, 2022 as compared to $2.9&#160;million for the same period in 2021. During the three months ended June&#160;30, 2022 and 2021, other income (expense) included a loss of $20.1 million and $2.7 million, respectively, incurred by our foreign subsidiaries, primarily related to the impact of foreign exchange rate differences on an intercompany loan with Novavax CZ.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended June&#160;30, 2022 and 2021, we recognized $1.4&#160;million and $3.5&#160;million, respectively, of income tax expense related to federal and state income taxes and foreign withholding tax on royalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss (in thousands, except per share information):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(510,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss for the three months ended June&#160;30, 2022 was $510.5&#160;million, or $6.53 per share, basic, as compared to a net loss of $352.3 million, or $4.75 per share, basic, for the same period in 2021. The change in net loss during the three months ended June 30, 2022, was primarily due to decreased&#160;revenue under the OWS Agreement and the write-down of excess, obsolete, or expired inventory and losses on firm purchase commitments, partially offset by revenue from commercial sales of NVX-CoV2373 and a decrease in research and development expense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in weighted average shares outstanding for the three months ended June&#160;30, 2022 is primarily a result of sales of our common stock and exercises of stock-based awards in 2022 and 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2022 and 2021</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,896&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the six months ended June&#160;30, 2022 was $889.9&#160;million as compared to $745.2&#160;million for the same period in 2021, an increase of $144.7&#160;million. Revenue for the six months ended June&#160;30, 2022 was primarily comprised of revenue from product sales of NVX-CoV2373 and, to a lesser extent, revenue for services performed under the OWS Agreement. Revenue for the six months ended June&#160;30, 2021 was primarily comprised of revenue for services performed under the OWS Agreement and our funding agreements with CEPI. The increase in revenue was due to the commencement of product sales of NVX-CoV2373 and, to a lesser extent, royalties under our licensing arrangements, partially offset by decreased development activities under the OWS Agreement and our funding agreements with CEPI as we began commercial sales of NVX-CoV2373.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,143)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cost of sales was $286.3&#160;million, or 45% of product sales, for the six months ended June&#160;30, 2022, including expense of $255.3&#160;million related to excess, obsolete, or expired inventory and losses on firm purchase commitments. Prior to receiving approval, we expensed manufacturing costs as research and development expenses. After receiving approval, we capitalize the costs of production for a particular supply chain when we determine that we have a present right to the economic benefit associated with the product. While we tracked the quantities of our manufactured vaccine product and components, we did not track pre-approval manufacturing costs and therefore the manufacturing cost of our pre-launch inventory produced prior to approval is not reasonably determinable. However, based on our expectations for future manufacturing costs to produce our vaccine product and components inventory, we estimate at June&#160;30, 2022 we had approximately $0.3&#160;billion of commercial inventory that was expensed prior to approval. We expect to utilize all of our reduced-cost inventory during 2022. If inventory sold for the six months ended June&#160;30, 2022 was valued at expected standard cost, adjusted cost of sales for the period would have been approximately $439.5&#160;million, or 69% of product sales, an adjustment of $153.2&#160;million as compared to cost of sales recognized. The cost of sales to high income countries is expected to be between 15% and 30% of product sales based on our standard cost. The cost of sales as a percentage of product sales may fluctuate in the future as a result of changes to our customer mix or standard costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased to $673.1&#160;million for the six months ended June 30, 2022 from $1.2 billion for the same period in 2021, a decrease of $490.2 million, primarily due to decreased development activities relating to NVX-CoV2373, as summarized in the table below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NVX-CoV2373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Influenza vaccine</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other vaccine development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct external research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for NVX-CoV2373 for the six months ended June&#160;30, 2022 and 2021, included a benefit of $67.4&#160;million related to previously accelerated manufacturing costs and an expense of $43.0&#160;million related to the acceleration of manufacturing costs, respectively, for leases that we determined were embedded in multiple manufacturing supply agreements with CMOs and CDMOs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased to $204.2&#160;million for the six months ended June 30, 2022 from $136.4&#160;million for the same period in 2021, an increase of $67.8&#160;million. The increase in selling, general, and administrative expenses is primarily due to an increase in professional fees in support of our NVX-CoV2373 program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Expense</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Expense (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,110)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,807)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,329)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,010)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,319)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total other expense, net of $29.3 million for the six months ended June 30, 2022 as compared to $14.0 million for the same period in 2021. In the six months ended June 30, 2022 and 2021, we also recorded interest expense of $3.4&#160;million and $4.0&#160;million, respectively, for finance leases. During the six months ended June 30, 2022 and 2021, other income (expense) included a loss of $21.5 million and $3.9 million, respectively, incurred by our foreign subsidiaries, primarily related to the impact of foreign exchange rate differences on an intercompany loan with Novavax CZ.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022 and 2021, we recognized $4.1&#160;million and $6.6&#160;million, respectively, of income tax expense related to federal and state income taxes and foreign withholding tax on royalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss (in thousands, except per share information):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the six months ended June 30, 2022 was $307.1&#160;million, or $3.97 per share, as compared to $575.0 million, or $7.82 per share, for the same period in 2021. The change in net loss during the six months ended June 30, 2022 was primarily due to the commencement of commercial sales of NVX-CoV2373, partially offset by decreased&#160;revenue under the OWS Agreement, and a decrease in research and development expense, partially offset by the write-down of excess, obsolete, or expired inventory and losses on firm purchase commitments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in weighted average shares outstanding for the six months ended June 30, 2022 is primarily a result of sales of our common stock in 2022 and 2021.</span></div><div id="i4443801361394f65b2e7b9b03051a84d_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity Matters and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future capital requirements depend on numerous factors including, but not limited to, revenue from our product sales and royalties under licensing arrangements with our strategic partners; funding under our grant agreements; our projected activities related to the development and commercial support of NVX-CoV2373 and variant candidates, including significant commitments under various CRO, CMO, and CDMO agreements; the progress of preclinical studies and clinical trials; the time and costs involved in obtaining regulatory approvals; the costs of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights; and other manufacturing, sales, and distribution costs. We plan to continue developing other vaccines and product candidates, such as our influenza vaccine candidate and potential combination vaccines candidates, which are in various stages of development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into supply agreements, sometimes referred to as APAs, with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;); the European Commission (&#8220;EC&#8221;); and various countries globally. We also have grant and license agreements. As of June&#160;30, 2022, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties under the license agreements, was approximately $5&#160;billion. The timing to fulfill performance obligations related to grant agreements will depend on the results of our research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to supply agreements will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 under certain of our APAs. The supply agreements typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings upon delivery of NVX-CoV2373. Such upfront payments under our supply agreements generally become non-refundable upon our achievement of certain development, regulatory, and commercial milestones. Failure to meet regulatory milestones, product volume, or delivery timing obligations under our supply agreements may require us to refund portions of upfront payments or result in reduced future payments, which could result in a material and adverse effect on our financial condition. In addition, we continue to assess our manufacturing needs and intend to modify our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and in doing so recognize that significant costs may be incurred.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of our contracted supply commitment with Gavi, which includes the supply obligation of our licensed partner, SIIPL, 1.1 billion doses of NVX-CoV2373 are to be made available to countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. The Novavax portion is a supply agreement that contemplates that we will manufacture and distribute 350 million doses. Under that agreement with Gavi, we received an upfront payment of $350 million from Gavi in 2021 and an additional payment of $350 million in the first quarter of 2022 related to our achieving WHO Emergency Use Listing. Although Novavax is prepared to deliver the quantities of NVX-CoV2373 doses to Gavi under the terms of our supply agreement, we were notified by Gavi of its intent to seek to revise the number and timing of doses of NVX-CoV2373 supplied by Novavax under such agreement. Furthermore, Gavi may seek partial or full recovery of the prior nonrefundable payments it has made to Novavax. Our position is that Gavi has no contractual right to recover prior nonrefundable payments. To date, Novavax has not received an order from Gavi and the timing and quantities of future orders to deliver NVX-CoV2373 to the COVAX facility are unclear.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement originally entered into in October 2020 (the &#8220;Original UK Supply Agreement&#8221;). Pursuant to the Original UK Supply Agreement, the Authority agreed to purchase 60 million doses of NVX-CoV2373. Under the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1 million doses and up to an additional 15 million doses of NVX-CoV2373, with the number of additional doses contingent on our timely achievement of supportive recommendations from the United Kingdom&#8217;s Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;). In the event that we are unable to achieve the JCVI supportive recommendations, we may have to repay up to $225.0 million related to the upfront payment we received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44 million doses, in one or more tranches, through 2024.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have an APA with the EC acting on behalf of various EU member states to supply a minimum of 20 million and up to 100 million initial doses of NVX-CoV2373, with the option for the Commission to purchase an additional 100 million doses up to a maximum aggregate of 200 million doses in one or more tranches, through 2023. We are in the process of finalizing a revised delivery schedule for the remaining 42 million doses of the 70 million previously committed doses under our APA with the EC that were originally scheduled for delivery during the first and second quarters of 2022. In July and August 2022, we were notified by the EC that it was cancelling 5 million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to 65 million doses.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we entered into a modification to the OWS Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3 million doses of NVX-CoV2373, contingent on the timing of EUA approval by the FDA, as well as the timing of label language and artwork approvals by the FDA and the recommendation of the Advisory Committee on Immunization Practices within the CDC, and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100 million doses of NVX-CoV2373 contemplated by the original OWS Agreement (inclusive of the initial batch of approximately 3 million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. Additionally, in July 2022, we entered into a modification to our existing agreement with the DoD that amended the terms of such agreement to provide for the initial delivery of 0.2 million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8 million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the six months ended June&#160;30, 2022, we primarily funded our operations with cash and cash equivalents, upfront payments under APAs, revenue from product sales, royalties under licensing arrangements with our strategic partners, and proceeds from the sale of common stock together with revenue under the OWS Agreement that supports our NVX-CoV2373 vaccine development activities. We anticipate our future operations to be funded by revenue from product sales, royalties under licensing arrangements with our strategic partners, revenue under our OWS Agreement, our cash and cash equivalents, and other potential funding sources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $1.4&#160;billion in cash and cash equivalents and restricted cash as compared to $1.5&#160;billion as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash flows for the six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,066,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect on exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,744)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,745)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122,739&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735,224)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $259.4 million for the six months ended June&#160;30, 2022, as compared to net cash provided by operating activities of $807.5 million for the same period in 2021. The decrease in cash provided is primarily due to the application of upfront payments under APAs resulting from sales of NVX-CoV2373 during the six months ended June&#160;30, 2022 as compared to an increase in cash due to the receipt of upfront payments under APAs during the six months ended June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, our investing activities consisted primarily of capital expenditures and maturities and sale of marketable securities, net of purchases. Capital expenditures for the six months ended June&#160;30, 2022 and 2021 were $41.4 million and $28.9 million, respectively. For 2022, we expect our capital expenditures to continue to increase due to further development activities for our NVX-CoV2373 program, including the additional build-out of research and development and manufacturing facilities and related equipment, and the build-out of our new corporate office facility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities consisted primarily of sales of our common stock under our At Market Issuance Sales Agreements, payments of finance lease liabilities, and exercise of stock-based awards. In the six months ended June&#160;30, 2022 and 2021, we received net proceeds of approximately $179&#160;million and $565&#160;million, respectively, from selling shares of common stock through our At Market Issuance Sales Agreements. </span></div><div id="i4443801361394f65b2e7b9b03051a84d_121"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flows, and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rate movements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are headquartered in the U.S., our results of operations, including our foreign subsidiaries&#8217; operations, are subject to foreign currency exchange rate fluctuations, primarily the U.S. dollar against the Euro, Pound Sterling, Swedish Krona, and Czech Koruna. This exchange exposure may have a material effect on our cash flow and results of operations, particularly in cases of revenue generated under APAs that include provisions that impact our and our counterparty&#8217;s currency exchange exposure. To date, we have not entered into any foreign currency hedging contracts, although we may do so in the future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face foreign currency exchange exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. While the financial results of our global activities are reported in U.S. dollars, the functional currency of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. A 10% decline in the foreign exchange rates (primarily against the U.S. dollar) relating to our foreign consolidated subsidiaries would result in a decline of stockholders&#8217; equity of approximately $24 million as of June&#160;30, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is preservation of capital, with the secondary objective of maximizing income.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is primarily confined to our investment portfolio, which historically has been classified as available-for-sale. We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our investment portfolio. Changes in interest rates may affect the investment income we earn on our marketable securities when they mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income is recorded when earned and included in investment income. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in investment income. The specific identification method is used in computing realized gains and losses on the sale of our securities.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Notes have a fixed interest rate, and we have no additional material debt. As such, we do not believe that we are exposed to any material interest rate risk as a result of our borrowing activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the assistance of our chief executive officer and chief financial officer, has reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of June&#160;30, 2022. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving such control objectives. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management, including our chief executive officer and chief financial officer, have evaluated changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2022, and have concluded that </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i4443801361394f65b2e7b9b03051a84d_127"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i4443801361394f65b2e7b9b03051a84d_130"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland against Novavax and certain members of senior management, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Sothinathan Sinnathurai v. Novavax, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased Novavax securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On June 9, 2022, the co-lead plaintiffs filed an opposition to the motion to dismiss and on July 11, 2022, the Company filed a reply brief. The matter is now fully briefed. The Court has not indicated whether it intends to schedule any hearing on the motion before issuing a ruling.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After the Sinnathurai Action was filed, five derivative lawsuits were filed: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Robert E. Meyer v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Shui Shing Yung v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">William Kirst, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 8:22-cv-00024-TDC (the &#8220;Kirst Action&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Amy Snyder v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Charles R. Blackburn, et al. v. Stanley C. Erck, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the U.S. District Court for the District of Maryland. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the U.S. District Court for the District of Maryland by the defendants. The derivative lawsuits name members of the board of directors and certain members of senior management as defendants. Novavax is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the Court issued a memorandum opinion and order remanding the Kirst Action to state court. On February 4, 2022, the Court entered an order consolidating the Meyer and Yung Actions (the &#8220;Consolidated Derivative Action&#8221;). The plaintiffs in the Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Court entered an order in the Consolidated Derivative Action granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. If a related derivative action is filed and is not stayed, the Meyer and Yung plaintiffs may seek to terminate the stay. On June 10, 2022, the Snyder and Blackburn Actions were filed. The Snyder and Blackburn plaintiffs have expressed their intent to move the court to consolidate all of the derivative actions pending in Maryland federal court and to appoint lead counsel. On July 21, 2022, the Court ordered the parties in the Consolidated Derivative Action, the Snyder Action, and the Blackburn Action to meet and confer concerning consolidation, the appointment of lead counsel, and the ongoing stay of proceedings in the Consolidated Derivative Action. Should the parties fail to reach agreement on those issues, the Snyder and Blackburn plaintiffs were granted leave to file a motion for consolidation and appointment of lead counsel by August 18, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Par Sterile Products, LLC Arbitration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 29, 2022, Par Sterile Products, LLC (&#8220;Par&#8221;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (&#8220;MSA&#8221;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. While the Company maintains that no breach of the MSA has occurred and intends to vigorously defend the matter, if the final resolution of the matter is adverse to the Company, it could have a material impact on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company's financial position, results of operations, or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, we do not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flows.</span></div><div id="i4443801361394f65b2e7b9b03051a84d_133"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information regarding risk and uncertainties related to our business appears in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on March 1, 2022. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K other than set forth below.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The emergence and transmissibility of variants of the SARS-CoV-2 virus may affect market acceptance or sales of NVX-CoV2373, and our strategy to develop versions of our COVID-19 vaccine to protect against certain variants may not be successful.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our prototype COVID-19 vaccine, NVX-CoV2373, was developed based upon the genetic sequence of the SARS-CoV-2 virus that was first discovered in December 2019. As the SARS-CoV-2 virus continues to evolve, new strains of the virus, or those that are already in circulation, may prove more transmissible or cause more severe forms of COVID-19 disease than the predominant strains to date. For example, the Omicron and Delta variants have been observed to be more transmissible, or contagious, than previous variants. NVX-CoV2373 may not be as effective in protecting against these or other future variant strains, and NVX-CoV2373 may fail to achieve market acceptance or significant sales, despite gaining regulatory approval, provisional registration, conditional marketing authorization or emergency use authorization in a number of jurisdictions, including emergency use authorization the United States, as demand for variant-specific vaccines increases. We have several variant-specific vaccine candidates in development, including for Omicron subvariants, and bivalent formulations with NVX-CoV2373, and may develop others in the future. However, if these efforts are unsuccessful, we are slower to develop variant-specific vaccines than competitors, or these vaccine candidates prove less effective than competitors&#8217; vaccines, these shortcomings may lead to reputational harm, loss of market share, and adverse financial results. Additionally, counterparties to certain of our existing APAs may request variant-specific vaccines in place of NVX-CoV2373 and, depending on when we are able to offer variant-specific vaccines, if at all, such counterparties may seek to delay, reduce or otherwise renegotiate their purchase commitments, which may adversely impact our ability to realize the full financial benefit of such APAs. In addition, we may expend significant resources adapting NVX-CoV2373 or conducting clinical trials to protect against variants of the SARS-CoV-2 virus, but a market for this adapted vaccine may not develop and demand may not align with our projections or cost expenditures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 1, 2022, Novavax, Inc. (the &#8220;Company&#8221;) entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60 million doses of the Company&#8217;s vaccine candidate for the SARS-CoV-2 virus (the &#8220;Vaccine&#8221;) and made an upfront payment to the Company.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1 million doses and up to an additional 15 million doses of Vaccine, with the number of additional doses contingent on, and subject to reduction based on, the Company&#8217;s timely achievement of a supportive recommendation from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of Vaccine for (i) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom (&#8220;UK&#8221;) or (ii) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the UK or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the UK. If the Authority does not purchase the additional 15 million doses of Vaccine or the number of such additional doses of Vaccine is reduced, the Company would have to repay a portion of the upfront payment previously received from the Authority. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44 million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the material terms of the Amended and Restated UK Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the Amended and Restated UK Supply Agreement, which the Company intends to file with the Securities and Exchange Commission as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed on May&#160;9, 2019 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465921085180/tm2120584d1_ex3-1.htm">Amended and Restated By-Laws of the Registrant (Incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465921085180/tm2120584d1_ex3-1.htm">filed on June 24, 2021 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Appendix C of the Registrant&#8217;s Definitive Proxy Statement filed on May 2, 2022 in connection with the Annual Meeting held on June 16, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Amended and Restated Novavax, Inc. 2013 Employee Stock Purchase Plan (Incorporated by reference to Appendix D of the Registrant&#8217;s Definitive Proxy Statement filed on May 2, 2022 in connection with the Annual Meeting held on June 16, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*&#177;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex103.htm">Contract Development Manufacture Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex103.htm">, dated October 21, 2021,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex103.htm"> between Novavax, Inc. and Serum Life Sciences Limited</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*&#177;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm">Amendment No. 1 to the Contract Development Manufacture Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm">between Novavax, Inc. and Serum Life Sciences Limited</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm">, executed as of April 29, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm">2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex104.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*&#177;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex105.htm">Statement of Work No. 1 to the Contract Development Manufacture Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex105.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex105.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex105.htm">effective as of April 29, 2022, between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex105.htm">Novavax </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex105.htm">Inc. and Serum Life Sciences Limited</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20220630xex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Operations for the three- and six-month periods ended June 30, 2022 and 2021, (ii) the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021, (iii) the Consolidated Statements of Comprehensive Income (Loss) for the three- and six-month periods ended June 30, 2022 and 2021, (iv) the Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the three- and six-month periods ended June 30, 2022 and 2021, (v) the Consolidated Statements of Cash Flows for the three- and six-month periods ended June 30, 2022 and 2021, and (vi) the Notes to Consolidated Financial Statements.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________________</span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed or furnished herewith.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#177;&#160;&#160;&#160;&#160;Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i4443801361394f65b2e7b9b03051a84d_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4443801361394f65b2e7b9b03051a84d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOVAVAX, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Stanley C. Erck</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stanley C. Erck<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James P. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James P. Kelly<br/>Executive Vice President, Chief Financial Officer and Treasurer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>nvax-20220630xex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0d4647554dad4628bbc52dc4091b917d_1"></div><div style="min-height:119.52pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.3</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div></div><div style="margin-bottom:12pt;margin-top:216pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTRACT DEVELOPMENT MANUFACTURE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Serum Life Sciences Limited</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">October 21, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="i0d4647554dad4628bbc52dc4091b917d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTRACT DEVELOPMENT MANUFACTURE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This CONTRACT DEVELOPMENT MANUFACTURE AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of October 21, 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware USA corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Serum Life Sciences Limited, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a company duly incorporated having its registered office situated in England and Wales, formerly known as Covicure Holdings Limited having its principal office at 12 New Fetter Lane, London, United Kingdom, EC4A 1JP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Novavax and SLS may, from time to time, be individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, Novavax is developing vaccine product candidates comprised of (i) its proprietary antigens, including, but not limited to, its BV2373 and BV2438 antigens targeting SARS-CoV-2 (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Antigen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (ii) its Matrix-M&#8482; adjuvant (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adjuvant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and is seeking to engage a manufacturer to supply commercial quantities of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Drug Product(s) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as defined below)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, SLS is engaged in the business of supply, distribution and marketing of vaccine products, life-saving drugs and other pharmaceutical products at commercial scale&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, Novavax wishes to engage SLS to Develop (as defined below) or have Developed, Manufacture (as defined below) or have Manufactured and supply of Drug Product, either itself or through one or more Affiliates or Subcontractors, in a manner as provided in this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whereas, the Parties are entering into this Agreement to govern SLS&#8217; Development, Manufacture and supply (itself or through one or more Affiliates or Subcontractors) of Novavax&#8217; requirements for Drug Products for further commercial use and sale by Novavax in the Territory (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.07pt"><br><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Quantity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3.1 (Acceptance of Purchase Order).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adjuvant Components</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; the components of the Adjuvant, Matrix-A and Matrix-C.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means,</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">with respect to Novavax, any Person that controls, is controlled by, or is under common control with another Person, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">with respect to SLS, mean any &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the preceding definition, &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with) shall mean the possession, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directly or indirectly, of more than 50% of the outstanding voting securities of or comparable equity interest in any other type of a Person, or otherwise having the legal power to direct the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Antigen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as may be applicable to each Party respectively for their performance of this Agreement or any SOW, any federal, state, local, municipal, foreign or other law, statute, legislation, constitution, principle of common law, resolution, ordinance, code, edict, decree, proclamation, treaty, convention, rule or regulation issued, enacted, adopted, passed, approved, promulgated, made, implemented or otherwise put into effect by or under the authority of any Governmental Authority, including the applicable regulations and guidance of the FDA, EMA (and national implementations thereof), or MHRA, and any other applicable Regulatory Authority that constitute good clinical practices or good laboratory practices or GMP or good clinical practices (and, if and as appropriate under the circumstances, International Conference on Harmonization (ICH) guidance or other comparable regulation and guidance of any applicable Governmental Authority).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Background Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Intellectual Property of a Party, which, (1) already existed as of the Effective Date of this Agreement or (ii) as demonstrated by corroborating evidence, was developed or obtained by or on behalf of such Party independent of this Agreement, and without reliance upon the Confidential Information of the other Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Batch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a quantity of Drug Product that is intended to have uniform character and quality and that has been or is being supplied in accordance with the applicable Specifications during the same cycle of Manufacturing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.2 (Termination for Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day other than a Sunday, or bank or other public holiday in either Washington D.C., U.S.A, or London, England.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the respective periods of three consecutive calendar months ending on March 31st, June 30th, September 30th, or December 31st in any Calendar Year.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any calendar year beginning on January 1st and ending on December 31st.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Certificate of Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CoA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Batch, a certificate in the applicable format for the applicable Drug Product manufactured under GMP, from time to time during the Term, issued by SLS, either itself, or through an Affiliate or Subcontractor, and executed by SLS&#8217; responsible person certifying that a Batch meets the Drug Product Requirements and such other criteria as identified in the Certificate of Analysis.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Certificate of Conformance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CoC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Batch, a certificate in the applicable format for the applicable Drug Product from time to time during the Term, issued by SLS&#8217;, either itself or through an Affiliate&#8217;s or Subcontractor&#8217;s, quality </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">department and executed by SLS&#8217; responsible person (a) listing the date of manufacture, unique Batch number, and quantity of Drug Product in such Batch, (b) certifying that such Batch was Manufactured in compliance with the applicable Drug Product Requirements, and (c) certifying that all investigative and corrective action reports are completed and approved.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.3 (Change Order).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1 (Indemnification by SLS)</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means chemistry, manufacturing, and controls.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to market, promote, otherwise offer for sale, distribute, and sell the Drug Products. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">to Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to engage in Commercialization and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has a corresponding meaning.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to an objective, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1 (Definition).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.2 (Termination for Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.4 (Delivery). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Deliver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; will be construed accordingly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3 (Purchase Orders).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Destination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.4 (Delivery).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to discover, research, or otherwise develop any compound or product, including conducting non-clinical research or clinical trials prior to or after receiving Regulatory Approval and any formulation, Technology Transfer or Process Development with respect to any compound or product. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to engage in Development.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Batch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Drug Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Batch or Drug Product produced during Development including Process Development and before receiving Regulatory Approval through the applicable standard review procedure for the Commercialization of the Drug Product. For greater clarity, Emergency Use Drug Product shall be deemed as Development Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1 (Definition-Confidential Information).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. dollar, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; will be interpreted accordingly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Drug Product(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#47; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means vaccine resulting from the filled and finished form of the Antigen and the Adjuvant that SLS shall have Manufactured through an Affiliate or Subcontractor, under and in conformance with the Drug Product Requirements, including Development Drug Product, all as applicable pursuant to the relevant Statement of Work(s).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Drug Product Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the applicable Specifications and the requirements and&#47;or criteria of or set forth in the Certificate of Analysis, and Certificate of Conformance, GMP, the Master Batch Record, this Agreement, the Quality Agreement, any applicable Regulatory Approval, the requirements of all applicable Regulatory Authorities, and Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Emergency Use Drug Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Drug Product(s) through conditional Regulatory Approval of unapproved medical, pharmaceutical or vaccine products or unapproved uses of approved medical products to be used in public health emergency based on a minimum set of available quality, safety and performance data including without limitation Emergency Use Listing Procedure by WHO (&#8220;EUL&#8221;), or any other conditional Regulatory Approval granted by an applicable Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, if and where applicable, any equipment (a) provided by Novavax or (b) procured by or on behalf of SLS and charged to Novavax under a Statement of Work.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to Develop or have Developed, Commercialize, Manufacture or have Manufactured, and otherwise exploit. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exploiting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to engage in Exploitation and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exploited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has a corresponding meaning.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any facility set forth on Exhibit A (Facilities) in which Drug Product is Manufactured, either by SLS itself or through an Affiliate or Subcontractor, or the activities related to Process Development are carried out by SLS, either itself or through an Affiliate or Subcontractor. For the purpose of clarity, consent of Novavax is hereby deemed granted for the Facilities listed in the Exhibit A as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 13.13 (Force Majeure).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Manufacturing Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applicable current good manufacturing practices, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 11, 210, 211, 601, 610 and 820, (b) European Directive 2003&#47;94&#47;EC and Eudralex 4, (c) the principles detailed in the International Conference on Harmonization&#8217;s Q7 guidelines, and&#47;or (d) the equivalent Applicable Law in any relevant country or region, each as may be amended and applicable from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any court, judicial, legislative, administrative or Regulatory Authority, commission, department, board, bureau or body, or other government authority or instrumentality or any person or entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, whether foreign or domestic, whether federal, state, provincial, municipal, or other.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all discoveries, inventions, developments, modifications, innovations, updates, enhancements, improvements, writings or rights, and other Intellectual Property in such Improvements, that are made, discovered, conceived, created, invented, developed, or reduced to practice in the performance of this Agreement, and includes Novavax Improvements and SLS Improvements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.3 (Indemnification Procedure).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.2 (Forecast).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.44.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indirect Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means goods and services tax (&#8220;GST&#8221;), value added tax (&#8220;VAT&#8221;), sales tax, service tax, customs duties, excise taxes or any other similar taxes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.45.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all copyrights, trademarks, patents, trade secrets, designs, information, documentation, drawings, methods, techniques, data, regulatory submissions, specifications, and other intellectual property of any kind (whether or not protected under patent, trademark, copyright or similar laws), and includes all Intellectual Property in Know-How.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.46.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any records, chemical or biological materials, know-how, processes, techniques, show-how, design information, information, formulations, technology, practices, trade secrets, inventions, methods, data (including animal data, raw data, clinical data, and quality control data) and results in any form whatsoever, whether patentable or not.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.47.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Laboratory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.5.1 (Non-Conformance Disputes).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.48.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">&#8220;Latent Defect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a defect which is not a Manufacturing Defect, and which relates to a defect in the Adjuvant and&#47;or Antigen that Novavax supplies to SLS under this Agreement, which causes the Drug Product to be defective and&#47;or non-conforming with the Drug Product Requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.49.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1 (Indemnification by SLS).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.50.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, Deliver, or otherwise ship or temporarily store the Drug Product or any component thereof. When used as a noun, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all activities involved in Manufacturing any product or any component thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.51.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing Defect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a defect resulting from performance of the Manufacturing Process that causes a Batch of Drug Product to fail to conform to the Drug Product Requirement, which condition is not capable of being discovered upon inspection and testing in accordance with Section 4.5 (Non-Conforming Batches).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.52.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the process, or applicable portion(s) thereof for the Manufacture, analysis, documentation, quality evaluation, storage, and shipping of components, intermediates, and Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.53.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Master Batch Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the production record and data for a Batch, which will be prepared and maintained in SLS&#8217; standard format in accordance with the Quality Agreement. Master Batch Records and other Batch documents shall be written in English.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.54.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MHRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Medicines &#38; Healthcare products Regulatory Agency in the United Kingdom.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.55.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.2 (Termination for Cause).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.56.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Improvements related to the Antigen, Adjuvant and Adjuvant Components whether made, discovered, conceived, created, invented, developed, or reduced to practice by either Party or jointly by both Parties.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.57.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax Supplied Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the items specifically set forth in this Agreement or SOWs as being provided by Novavax to SLS, together with any other tangible items, information, or documentation supplied by Novavax in connection with the performance of this Agreement or SOW, including but not limited to the Manufacturing Process, Antigen the Adjuvant Components, any active pharmaceutical ingredient, critical reagents, master cell bank, working cell bank, master virus seed, plasma, component, or Raw Materials.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.58.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.59.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.60.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Process Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the conduct by SLS, either itself or through an Affiliate or Subcontractor, of activities to develop, confirm and&#47;or refine processes for producing the Drug Product and&#47;or activities to develop, scale-up, optimize, qualify and&#47;or validate the Manufacturing Process (including process performance qualification) suitable for GMP Manufacture of the Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.61.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble in Section 2.2</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.62.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purchase Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3 (Purchase Orders).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.63.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the agreement between the Parties, attached to this Agreement and incorporated herein, establishing the quality assurance standards and responsibilities between SLS and Novavax for the Manufacture of Drug Products to be performed by SLS, either itself or through an Affiliate or Subcontractor, for Novavax.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.64.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Raw Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.5 (Raw Materials).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.65.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any recall or market withdrawal of any Drug Product that was Manufactured, either by SLS itself or through an Affiliate or Subcontractor, under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.66.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1 (Definition-Confidentiality).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.67.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all technical, medical, and scientific licenses, registrations, authorizations, and approvals of any Regulatory Authority necessary for the Development, Manufacture or Commercialization of a pharmaceutical or biologic product in a given country in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.68.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any governmental agency or authority responsible for granting Regulatory Approvals for a Drug Product in the Territory, including, without limitation, the FDA in the United States and the EMA in the European Union.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.69.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2 (Obligations).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.70.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Process Development or Manufacturing activities to be performed by SLS, either itself or through an Affiliate or Subcontractor, as set forth in this Agreement including the applicable Statement of Work(s).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.71.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SLS Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall means any and all Improvements, either by SLS itself or through an Affiliate or Subcontractor, other than Novavax Improvements, in and to, the Manufacturing Process, and including Process Developments, made, discovered, conceived, created, invented, developed, or reduced to practice solely by SLS, its Affiliate or a Subcontractor during the Manufacture of the Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.72.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the specifications for the Drug Product that are set forth in the applicable SOW (as such schedule may be updated from time to time pursuant to Section 3.2 (Specifications and Manufacturing Process).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.73.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Statement of Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a mutually agreed upon document setting forth the scope of the project, general statement of stages and activities, pricing, the schedule of milestones, INCOTERMS for Novavax Supplied Items, deliverables and payments and other pertinent information, in order to prepare for, initiate and conduct the Services, including, as applicable, the project plan, Technology Transfer and Process Development for and Manufacture of the applicable Drug Product. Once finalized and signed by all Parties, the SOW is incorporated into and deemed a part of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.74.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Third Party(ies) engaged by a Party to perform certain obligations or exercise certain rights on behalf of such Party under this Agreement (including any other contract manufacturers).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.75.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supply Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.4.4 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Failure to Satisfy Delivery Date)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.76.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the transfer from Novavax to SLS of Novavax Supplied Items and any other Intellectual Property associated therewith as set forth in the SOW(s), in Novavax possession and control that is necessary for SLS to perform Process Development and scale- up related to the planned Manufacture of the Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.77.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.1 (Term).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.78.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the entire world, except for India, unless specified otherwise in a SOW.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.79.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person other than a Party or an Affiliate of a Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.80.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States of America, including all territories and possessions, as constituted as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.81.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Updated Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.2 (Forecast).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.41pt"><br><br>STATEMENTS OF WORK&#59; TECHNOLOGY TRANSFER&#59; PROCESS DEVELOPMENT</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.82.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Statement(s) of Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax and SLS shall coordinate to perform all activities related to Technology Transfer (as may be necessary), Process Development and any Manufacture of Drug Products, subject to the terms and conditions set forth in this Agreement and the SOW(s). Prior to commencing Services, the Parties shall agree upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and execute a SOW, which shall, without limitation, identify the Antigen involved and detail the stages, activities and responsible Party, approvals, timelines, deliverables, financials related to each transaction and&#47;or other information pertinent to the Services.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.83.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The day-to-day interactions and management with respect to a SOW will be performed by two project managers, one appointed by each Party and each one having the authority to manage activities under the SOW on behalf of their respective Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Project Managers shall be the principal point of contact between the Parties with respect to the performance of the applicable SOW. As part of their duties, the Project Managers shall establish operating guidelines, define communication formats, form and approve project teams and monitor general progress and budget against the applicable SOW. The Project Managers will meet at regular intervals and will coordinate calls&#47;meetings between project teams and management as they deem necessary to implement the applicable SOW.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.84.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Change Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Parties desire to change the Services or other obligations under a particular SOW, SLS, either itself or through an Affiliate or Subcontractor, shall prepare a change order or amendment to the SOW detailing the nature of such proposed changes and impact of such changes on the SOW&#8217;s budget and project timelines (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for Novavax review and approval. Once signed by an authorized signatory of each Party, the Change Order shall become effective and the Parties shall implement the changes set forth therein promptly after its execution. SLS will not be obligated to initiate the changes described in a Change Order and Novavax will not be obligated to pay for such changes until the Change Order is duly executed by each Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.85.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Provision of Novavax Supplied Items. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax shall provide Novavax Supplied Items and any additional technical information pertaining thereto as may be required for SLS&#8217; performance of the Services as expressly and specifically set forth in the SOW. For such Novavax Supplied Items, Novavax shall provide SLS with material information in its possession or control concerning health hazards or potential health hazards associated with exposure to or the handling, storage, use or disposal of the Drug Product and Novavax Supplied Items, including, without limitation, the applicable material safety data sheets, and the importer of record shall be mutually agreed and detailed in the SOW. Title to Novavax Supplied Items shall transfer &#91;***&#93; and &#91;***&#93; shall have all risk of loss or damage to all Novavax Supplied Items &#91;***&#93;. Except for the Novavax Supplied Items, SLS, either itself or through an Affiliate or Subcontractor, shall provide, at its own expense unless otherwise provided for in the applicable SOW, all other items needed for SLS&#8217; performance of the Services and its other obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.86.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Raw Materials Procurement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless specifically stated otherwise in the applicable SOW, SLS will (either itself or through an Affiliate or Subcontractor), &#91;***&#93;, procure all required raw materials as well as consumables other than Novavax Supplied Items (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Raw Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall at all times retain &#91;***&#93;. SLS shall, either itself or through an Affiliate or Subcontractor, order such Raw Materials and will ensure such Raw Materials are delivered in time to perform the applicable Services. SLS will, and will cause its Affiliates and Subcontractors to, treat Novavax&#8217; bill of materials, including the Raw Materials included therein, as Confidential Information of Novavax.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.87.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:10pt;padding-left:73pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6.1. The Parties agree that SLS can subcontract or have the SLS&#8217; obligations subcontracted to any of the Affiliates or Subcontractors. The Subcontractors will be approved in accordance with the Quality Agreement. For the Affiliates or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subcontractors listed hereunder Exhibit B, consent of Novavax is hereby deemed granted in accordance with the Quality Agreement.</font></div><div style="margin-bottom:10pt;padding-left:73pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6.2. The Parties agree that for any additional Subcontractor(s) or Affiliate(s) not included in the said Exhibit B and which are required by SLS in relation to the provision of Services and Drug Products, SLS will provide a &#91;***&#93; prior written notice to Novavax for the engagement of such additional Subcontractor(s) or Affiliate(s). The Parties agree and acknowledge that any such additional Subcontractor(s) or Affiliate(s) may perform SLS&#8217; obligations under this Agreement and the Quality Agreement after the responsible Party completes any GMP-required supplier qualification and Novavax confirms that there are no adverse tax implications which the applicable Party shall use &#91;***&#93; to complete within the said &#91;***&#93; notice period without any unreasonable delay. The Parties agree that any non-Manufacturing services can be assigned by SLS to any Subcontractors without consent of Novavax in accordance with the Quality Agreement.</font></div><div style="margin-bottom:10pt;padding-left:73pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6.3. SLS shall remain responsible for its performance, and for the performance of its Subcontractors and Affiliates hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.75pt"><br><br>COMMERCIAL MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.88.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to the terms of this Agreement including the relevant SOW(s), SLS will, itself or through one or more Affiliates or Subcontractors in accordance with Section 2.6 (Subcontracting), Manufacture or have Manufactured and supply&#47;sell Novavax requirements of Drug Product for Development and&#47;or Commercial use and&#47;or sale, as applicable, in the Territory by Novavax and&#47;or its Affiliates or designated Third Parties.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.89.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Specifications and Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Specifications for a Drug Product shall be specified in an applicable SOW or in the applicable Quality Agreement. SLS may not make any changes to the Specifications or Manufacturing Process for a Drug Product without the &#91;***&#93; consent or agreement of Novavax.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.90.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Drug Product Packing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Drug Product supplied by SLS, either itself or through an Affiliate or Subcontractor, will include all packaging and labeling in accordance with the requirements set forth in the Specifications, SOW and&#47;or Quality Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.91.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">CDMO Oversight. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax has the right to have its personnel at the Facility (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Persons in Plant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with the Quality Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.92.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As between the Parties, all matters pertaining to release of a Batch, Quality Control and Quality Assurance, Stability Testing and Waste under this Agreement shall be governed by the Quality Agreement. The terms and conditions of this Agreement which relate to any of the aforementioned matters shall be read and interpreted harmoniously with the terms and conditions of the Quality Agreement, however, in the event of any conflict between any of the terms of this Agreement, and those of the Quality Agreement, the Quality Agreement shall supersede as it relates to quality responsibilities.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.41pt"><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>FORECASTS, PURCHASE ORDERS, DELIVERY, NON-CONFORMING PRODUCT AND RECALLS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.93.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless otherwise specified in this Agreement or an applicable SOW, this Article 4 governs the procedures and the Parties&#8217; rights and obligations with respect to Forecasts, purchase orders, delivery and rejection and non-conformance of Drug Products provided under this Agreement for Development and&#47;or Commercial purposes including Emergency Use Drug Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.94.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless otherwise specified in the applicable SOW, within &#91;***&#93; after the execution of such SOW, Novavax will provide SLS an initial, non-binding &#91;***&#93; forecast of Novavax anticipated &#91;***&#93; demand for such Drug Product for commercial sale, as may be applicable under Emergency Use Authorization approvals, in the Territory by Novavax, which initial forecast will be non-binding and for planning purposes only (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). SLS may request revision of the forecasted quantities of the Drug Product within &#91;***&#93; of receiving the Initial Forecast, and Novavax will be bound to consider SLS&#8217; reasonable revisions in good faith and review the Initial Forecast accordingly. Novavax will update the Forecast no less than &#91;***&#93; before the beginning of each &#91;***&#93; on a &#91;***&#93; basis to enable SLS to engage in capacity planning (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Updated Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). SLS will have the right to review and comment on each update to the Forecast and Novavax will consider SLS&#8217; reasonable comments in good faith.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.95.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax will issue firm written purchase orders (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for SLS to Manufacture or have Manufactured and Deliver specified quantities of Drug Products at least &#91;***&#93; prior to the applicable Delivery Date for such Drug Products. Each Purchase Order will specify the quantity of Drug Product being ordered (which will be in whole Batches), the requested delivery date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Novavax purchase order number, and any other information necessary to ensure the timely Manufacture and Delivery of such Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Acceptance of Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will review each Purchase Order, and if the quantity of Drug Product requested by Novavax is within the quantity forecasted in the Initial Forecast or an Updated Forecast, as applicable, in such Purchase Order, such Purchase Order shall be accepted by SLS. If the quantity of Drug Product requested by Novavax is in excess of the quantity forecasted in the Initial Forecast or an Updated Forecast (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Quantity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the amount which is within the quantity forecasted in the Initial Forecast or an Updated Forecast shall be deemed automatically accepted by SLS and, SLS will, no later than &#91;***&#93; after SLS&#8217; receipt of each such Purchase Order, notify Novavax &#91;***&#93; of SLS&#8217; acceptance or rejection of such Additional Quantity. SLS shall notify Novavax in writing of the actual delivery date for Delivery of Drug Product ordered (including whether SLS agrees to supply any Additional Quantity) under such Purchase Order within &#91;***&#93; of receipt of the Purchase Order (or &#91;***&#93; if such Purchase Order requested Additional Quality). If SLS fails to provide such notice to Novavax within such applicable period, then such Purchase Order will automatically be accepted for delivery upon the Delivery Date specified in such Purchase Order.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Modification of Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax may adjust the quantity of Drug Product to be delivered under a particular Purchase Order by &#91;***&#93; notice to SLS&#59; provided, however, that Novavax will reimburse SLS for all incurred, non-cancelable and reasonable expenses related to any cancelled Drug Products&#59; provided further, however, that SLS will use &#91;***&#93; to mitigate any such expenses.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">No Other Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No terms, provisions, or conditions of any Purchase Order or other business form or written authorization used by Novavax or SLS will have any effect on the rights, duties, or obligations of the Parties under or otherwise modify this Agreement or any Purchase Order, regardless of any failure of Novavax or SLS to object to such terms, provisions, or conditions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.96.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will deliver &#91;***&#93;. Title and risk of loss or damage to Drug Products will &#91;***&#93;. SLS will Manufacture or have Manufactured, either itself or through an Affiliate or Subcontractor, and Deliver the Drug Product specified in an accepted Purchase Order for Delivery on the applicable Delivery Date, or such other extended delivery date mutually agreed to between the Parties in accordance with Section 4.4.3.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Delivery Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will &#91;***&#93; notify Novavax when an order of Drug Product is ready to be shipped. SLS, either itself or through an Affiliate or Subcontractor, will be responsible for appropriate packaging (including satisfying all requirements in each country in the Territory for Drug Products supplied in such country and in accordance with the Quality Agreement), labelling, and issuance of carrier&#8217;s declaration for all Drug Products shipped under this Agreement. SLS and Novavax will ensure that each of their respective employees involved in activities related to shipments (and in the case of Novavax, receipt of shipments) of Drug Product have received adequate training to properly handle such Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Without derogating from Section 4.4, SLS is aware that Novavax may reasonably request SLS to deliver the Drug Product to a designee of Novavax in certain specified countries. The quantities and delivery obligations for such supply of Drug Product shall be mutually agreed between the Parties under the relevant SOW.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Storage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax shall &#91;***&#93; take delivery of Batches of the Drug Product at &#91;***&#93; and shall be solely responsible for activities in relation thereto. If Novavax fails to make arrangements to take delivery of any Drug Products on the applicable Delivery Date, then, at SLS&#8217; sole discretion, and subject to SLS&#8217; storage capacity, SLS may temporarily store such Drug Products in accordance with the Quality Agreement and invoice Novavax on a &#91;***&#93; basis for all actual reasonable costs and expenses incurred in storing such Drug Products as specified in the applicable SOW until &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Failure to Satisfy Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SLS &#91;***&#93; will notify Novavax if SLS believes it will not deliver all or any portion of the Drug Products on the delivery date specified in the applicable Purchase Order. In the event of a delay or failure to supply as per the delivery schedule (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supply Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), both the Parties shall mutually agree on the path forward. SLS shall not be liable for any delay or failure in the supply of all or any portion of the Drug Products, on the delivery date specified in the applicable Purchase Order, which is due to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.97.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Non-Conforming Batches</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax will have the right to inspect and determine whether each Batch conforms to the applicable Drug Product Requirements. During the &#91;***&#93; period after Delivery of each Batch or after release of Batch, whichever occurs later, Novavax may reject any Batch that does not conform to the applicable Drug Product Requirements by providing written notice thereof to SLS&#59; provided, however, that with respect to any Batch that includes a Manufacturing Defect, such &#91;***&#93; period shall not commence until Novavax has actual knowledge of such Manufacturing Defect. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any claim by Novavax that Drug Product does not meet the Drug Product Requirements must be made &#91;***&#93; to SLS within such applicable &#91;***&#93; period. Upon Novavax &#91;***&#93; notification to SLS of Novavax rejection of a Batch, and upon review and agreement by SLS&#8217; quality assurance department, Novavax will be entitled to the remedies under Section 4.6 (Remedies for Non-Conforming Batches) with respect to such Batch.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Non-Conformance Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of a disagreement between the Parties concerning whether or not a Batch meets the applicable Drug Product Requirements under Section 4.5, Novavax and SLS will appoint an &#91;***&#93; to undertake analysis of the Batch to determine whether or not it meets the applicable Drug Product Requirements. Each Party will &#91;***&#93; cooperate with and provide all information, documentation, and materials in its power or possession relevant to the disagreement to &#91;***&#93;. The findings of &#91;***&#93; will be binding on the Parties, except in the case of a manifest error on the part of &#91;***&#93;. All costs and expenses incurred by &#91;***&#93; under this Section 4.5.1 (Non-Conformance Disputes) shall be borne by &#91;***&#93;, provided however such costs and expenses shall be borne by &#91;***&#93; if &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.98.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Remedies for Non-Conforming Batches or Short Orders. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Section 4.5 (NonConforming Batches), if any Delivery to Novavax of (a) a Batch is timely rejected by Novavax or discovered to contain a Manufacturing Defect, in each case, in accordance with Section 4.5 (Non-Conforming Batches) or (b) any quantity of Drug Product is short against the quantity specified in a Purchase Order, then in each case ((a) or (b)), SLS will, &#91;***&#93;, replace, &#91;***&#93;, the short or nonconforming Drug Product with Drug Product that conforms to the Drug Product Requirements by a date mutually agreed by the Parties or refund to Novavax the amounts paid by Novavax for any non-conforming Drug Product. SLS will instruct Novavax to destroy or return any nonconforming Batch to SLS, in each case, &#91;***&#93;. SLS will instruct Novavax to destroy or return any non-conforming Drug Product at SLS&#8217; election and provide Novavax with a destruction certificate.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.99.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Latent Defects, Pharmacovigilance, Adverse Events and Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Both Parties confirm that since</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">SLS, either itself or through an Affiliate or Subcontractor is performing this Agreement solely in the capacity of a contract manufacturer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Novavax owns, controls and shall provide SLS with the Novavax Supplied Items (including Antigen and Adjuvant Components)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Novavax shall have the right to inspect and determine whether each Batch conforms to the applicable Drug Product Requirements in accordance with Section 4.5.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Novavax will have sole right, duty obligation and discretion, over handling any and all claims related to (a) any Latent Defects in the Drug Products, (b) all pharmacovigilance activities, (b) any adverse events notifications and complaints, and (c) whether and under what circumstances to require a Recall of the Drug Product in a country in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; will be responsible for all costs and expenses associated with any Recall, except to the extent Recall results from SLS&#8217; failure to Manufacture or have Manufactured the Drug Product in accordance with the GMP, in which case then &#91;***&#93; will be responsible for costs and expenses associated with such Recall.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6pt">Conditions for Manufacture, Supply and Delivery of Drug Product by SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">SLS shall commence Manufacturing operations, either itself or through an Affiliate or Subcontractor, and shall supply and Deliver the Drug Product only after it receives all necessary approvals, authorizations, permissions, licenses or any other requirements, conditions or approvals of the Regulatory Authority &#47; Government Authority in India.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Novavax confirms that the Manufacture, supply and Delivery obligations of SLS in relation to the Drug Product under each and every SOW are entirely subject to receipt by SLS of all necessary and applicable authorisations from the Regulatory Authority &#47; Government Authority, including any export permissions and &#47; or any other requirements, conditions or approvals in India.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Novavax confirms that unless conditions stipulated under Section 4.8.1 and Section 4.8.2 are satisfied for a SOW, any delay or non-performance by SLS of any of the terms and conditions of such SOW shall not be construed as breach by SLS and Novavax hereby waives, and holds SLS harmless for any claims in relation thereto as long as SLS is using &#91;***&#93; to meet such conditions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.07pt"><br><br>REGULATORY MATTERS GOVERNING PERFORMANCE OF PARTIES SPECIFIC AND<br>RESTRICTED TO THIS AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Specific and restricted to the context of this Agreement, SLS, either itself or through an Affiliate or Subcontractor, will be &#91;***&#93; responsible for obtaining and maintaining any permits or other Regulatory Approvals required under Applicable Law to Manufacture or have Manufactured the Drug Product. SLS will (i) provide necessary documentation for Novavax with respect to SLS&#8217; drug master files as set forth in Section 5.2 (Right of Reference) and&#47;or (ii) develop investigational medicinal product dossiers (IMPDs) and chemistry, manufacturing and controls (CMC) sections, as required to support program needs, in each case, without incremental charge to Novavax. All such documents shall be available in English, and, if translated from another language, certified to be accurate and complete by a Third Party provider of translation services qualified by SLS and approved by Novavax (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Certified Translation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If Novavax requires such documentation to be translated into a nonEnglish language, then SLS will provide a Certified Translation in the language requested by Novavax as a Service at &#91;***&#93; cost pursuant to a mutually agreed SOW.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Documentation for Drug Product Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At &#91;***&#93; expense, SLS, either itself or through an Affiliate or Subcontractor, will maintain and keep updated drug master files for the Drug Product. SLS shall provide all necessary documentation to Novavax with respect to the Drug Product master files for use in regulatory filings related to the Drug Product. At Novavax written request, SLS will take other reasonable as may be requested by any Regulatory Authorities to give Novavax the benefit of such master files.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Records and Accounting by SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will keep and shall ensure that each Affiliate and Subcontractor keeps records of the Manufacture (including production data), testing, and shipping of each Batch and retain samples of all Batches in accordance with the Quality Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Audits and Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Audits and Regulatory Inspections of the Facilities and Affiliate&#47;Subcontractor facilities will be conducted as specified in the Quality Agreement. Novavax will execute any &#91;***&#93; confidentiality agreement required by any Affiliate or Subcontractor in connection with such visit, audit or inspection of the Facility of such Affiliate or Subcontractor, and will comply with such Affiliate&#8217;s or Subcontractor&#8217;s reasonable rules and regulations. In the event Novavax foresees the existence of an operational issue in the Manufacture of any component of the Drug Product that Novavax &#91;***&#93; believes &#91;***&#93; may result in a GMP or other regulatory deficiency or failure of SLS to meet its obligations under this Agreement or the Quality Agreement (such as failure of a Drug Product to meet the Drug Product Requirements), then Parties shall agree mutually to conduct joint inspections.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Notification of Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any Governmental Authority provides SLS notice of its intent to conduct an inspection or investigation, or to take any other type of regulatory action with respect to any Facility under the Agreement, then SLS will give Novavax notice &#91;***&#93;. SLS will provide to Novavax all information and findings pertaining thereto no later than &#91;***&#93; after receipt. If the inspection or investigation relates to Drug Product, then Novavax shall be entitled to be present during any such inspection or investigation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will supply &#91;***&#93; such necessary and applicable data reasonably in its control relating to the Drug Products, including release test results, complaint test results, and all investigations (in Manufacturing, testing, and storage), that Novavax requires or otherwise requests in order to complete any filing with any Regulatory Authority. Further, SLS will provide Novavax with written reports in the format reasonably required by Novavax and hold meetings with Novavax Representatives &#91;***&#93; on the progress of any Services at Novavax request and as provided for in the relevant SOW.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Complaints</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In connection with any Drug Product complaints or customer communications reasonably relating to the Services that are received by SLS, SLS will &#91;***&#93; report such to Novavax. In addition to what is agreed between the Parties under the Quality Agreement, for the sake of clarity, it is reiterated that Novavax shall be solely responsible obligated and responsible to conduct investigation of any such complaints and otherwise handle all claims or complaints towards any Latent Defects in the Drug Products, or any adverse events notifications, or and Drug Product recalls.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.41pt"><br><br>PAYMENTS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Invoice and Payment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SLS will issue to Novavax a written invoice (i) in accordance with each SOW or (ii) upon Delivery of the Drug Product set forth in a Purchase Order, and Novavax will pay SLS all undisputed amounts within &#91;***&#93; of receipt of each such invoice. All invoices issued and payments to be made between the Parties under this Agreement shall be made in Dollars and shall be paid by wire transfer in immediately available funds to a bank account designated by the receiving Party. If, due to restrictions or prohibitions imposed by national or international authority, a given payment cannot be made as provided in this Section 6.1 (Payments), then the Parties will consult with a view to finding a prompt and acceptable solution. Upon agreement of the Parties in a SOW, Novavax may deliver such payment in the relevant country and in the local currency of the relevant country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as expressly set forth in Section 6.2.2 (Withholding Taxes) and stated below, each Party will pay any and all taxes levied by Applicable Law on account of all payments received by such Party from the other Party or any third party as a result of this Agreement, including all taxes based on any net income of such Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will provide such information and documentation to Novavax as are &#91;***&#93; requested by Novavax to determine if any withholding taxes apply to any payments to be made by Novavax to SLS under this Agreement. If any taxes are required to be withheld with respect to any such payments to be made by Novavax to SLS under this Agreement, Novavax will&#58; (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, (c) send evidence of the obligation together with proof of tax payment to SLS on a &#91;***&#93; basis following such tax payment, and (d) if applicable, &#91;***&#93; assist SLS in its efforts to obtain a reduced withholding tax rate or a refund or credit for such tax payment. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty that is in effect. The Parties will discuss applicable mechanisms for minimizing such taxes to the extent possible in compliance with Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Each Party shall be responsible with respect to any and all of its respective Indirect Tax liabilities arising out of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Cooperation. The Parties will cooperate in accordance with Applicable Law to minimize indirect taxes (such as value added tax, sales tax, consumption tax, and other similar taxes) in connection with payments to be made under this Agreement. Further, both Parties acknowledge and agree that in the event of any enquiry, scrutiny, audit, assessment or any other tax proceedings are initiated, it shall &#91;***&#93; co-operate with the other by furnishing the relevant information related to the sale of goods as a result of this Agreement on &#91;***&#93; basis as may be required from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Financial Reports</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SLS shall furnish a certificate from its Certified Auditors for the calculation of amounts as payable under Section 6.1.1 for every &#91;***&#93; (the &#8220;&#91;***&#93; Certificates&#8221;) within &#91;***&#93; of end of each such &#91;***&#93;. As used herein, &#8220;Certified Auditors&#8221; means an auditor firm duly licensed to practice as an auditor and whose lead individual responsible for &#91;***&#93; audits will have a minimum of ten years of experience similarly auditing for biotechnology, biopharma or pharmaceutical companies and who is responsible and liable under Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.75pt"><br><br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Background Intellectual Property. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement does not affect the ownership of a Party&#8217;s Background Intellectual Property which remains the property of such Party (or its licensors). SLS does not acquire a license or any other right to Novavax Background Intellectual Property except for the limited purpose of carrying out its duties and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations under this Agreement or SOW as set forth in Section 7.4.1 (Novavax as Licensor).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Ownership of Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93; shall own all right in and title to &#91;***&#93;. Any &#91;***&#93; necessary for &#91;***&#93; to perform this Agreement shall be promptly disclosed to &#91;***&#93;. In the event &#91;***&#93;, either itself or through an Affiliate or Subcontractor, conceives, develops or reduces to practice during the Term any &#91;***&#93;, then &#91;***&#93; shall promptly disclose in writing to Novavax any such &#91;***&#93;. &#91;***&#93; assigns (and if required shall enter into contracts with its Subcontractors &#47; Affiliates pursuant to which the Subcontractors &#47; Affiliates shall assign to &#91;***&#93; to effect the intent of this provision) right, title and interest in and to any &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93; shall own all right in and title to &#91;***&#93;, either alone, or jointly with its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Rights in Intellectual Property. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Party who owns a particular &#91;***&#93;, shall have the worldwide right to control the drafting, filing, prosecution, defense, maintenance and enforcement of patents or other Intellectual Property rights covering or claiming such &#91;***&#93;, including decisions about the countries in which to file patent applications. Patent costs associated with the patent activities described in this Section shall be borne by the applicable owner in the case of an &#91;***&#93; owned solely by such Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">License Grant&#59; Covenant Not to Sue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Novavax as Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term of this Agreement, Novavax hereby grants to SLS a non-exclusive, transferable (only in conjunction with a permitted assignment under Section 13.3), paid-up, royalty free, license to SLS, its Affiliates (sublicensable to their respective Subcontractors) to use Novavax Background Intellectual Property, Novavax Supplied Items, Know How, and Novavax Improvements only to the extent necessary to carry out its duties and obligations of Product Development and Manufacture of the Drug Product by SLS, either itself or through an Affiliate or Subcontractor, under this Agreement or the applicable SOW.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Covenant Not to Sue. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SLS on behalf of itself, and its Affiliates, hereby covenants not to assert or cause to be asserted, and will cause its Affiliates and Subcontractors not to assert or cause to be asserted, against any Covenant Beneficiary, &#91;***&#93;. Each Covenant Beneficiary that is not a party to this Agreement is a third party beneficiary solely of this Section 7.4.2 (Covenant Not to Sue). If SLS or any of its Affiliates sells, assigns, exclusively licenses, transfers or otherwise grants any right under any SLS Improvement to a Third Party, then SLS or such Affiliate, as applicable, will require such purchaser, assignee, licensee, or transferee to agree in writing to be bound by the same covenant to the same extent as made by SLS and its Affiliates in this Section 7.4.2.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:11.09pt"><br><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the terms and provisions of this Agreement and other Know-How, trade secrets, inventions, materials, and other proprietary information and data of a financial, commercial, or technical nature (in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whatever form) that a Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any of its Affiliates has supplied or otherwise made available to the other Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or its Affiliates, which are disclosed in writing or orally and whether or not specifically marked or designated by the Disclosing Party as confidential. For clarity, Novavax Confidential Information includes Novavax Supplied Items and all other data, information and Know-How associated therewith. For clarity, SLS&#8217; Confidential Information includes (i) all data, information and Know-How owned or controlled by SLS (including all data, information and Know-How owned or controlled by an Affiliate &#47; Subcontractor) in relation to any Development or Manufacturing activities at its Facilities or the Facilities of a Subcontractor or Affiliate, (ii) all records, reports books of accounts maintained by SLS in the performance of this Agreement and any SOW, and (iii) any non-public information or data that may be disclosed to or shared with, or to which Novavax or any of its Affiliates or any other Third Party acting on its behalf (including any auditors appointed by Novavax) may be exposed to during any site visits or inspection visits or regulatory visits at any of SLS&#8217; and &#47; or a Subcontractor&#8217;s Facilities (as the case may be).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Receiving Party will (a) protect all Confidential Information of the Disclosing Party against unauthorized disclosure to Third Parties and (b) not use or disclose the Confidential Information of the Disclosing Party, except as permitted by or in furtherance of exercising rights or carrying out obligations hereunder. The Receiving Party will treat all Confidential Information provided by the Disclosing Party with the same degree of care as the Receiving Party uses for its own similar information, but in no event less than a reasonable degree of care. The Receiving Party may disclose the terms and conditions of this Agreement and the Confidential Information to its Affiliates, and their respective directors, officers, employees, Subcontractors, sublicensees, consultants, attorneys, accountants, banks, financial advisors, funders and investors (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) who have an absolute need- to-know such information to carry out the activities and transactions or to exercise its rights contemplated by this Agreement , </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the such Representatives are bound by written obligations of confidentiality at least as restrictive as those set forth in this Agreement. Each Party will promptly notify the other Party of any misuse or unauthorized disclosure of the other Party&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Exceptions to Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The obligations under this Article 8 (Confidentiality) will not apply to any information to the extent the Receiving Party can demonstrate by competent evidence that such information&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement by the Receiving Party or any Representatives to whom it disclosed such information&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">was known to, or was otherwise in the possession of, the Receiving Party prior to the time of disclosure by the Disclosing Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">is disclosed to the Receiving Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">is independently developed by or on behalf of the Receiving Party or any of its Affiliates, as evidenced by its written records, without use or access to the Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Receiving Party may disclose Confidential Information of the Disclosing Party that the Receiving Party is required to disclose under Applicable Laws or a court order or other governmental order, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Receiving Party&#58; (a) provides the Disclosing Party with &#91;***&#93; notice of such disclosure requirement&#59; (b) affords the Disclosing Party an opportunity to oppose or limit, or secure confidential treatment for such required disclosure&#59; and (c) if the Disclosing Party is unsuccessful in its efforts pursuant to point (b) hereinabove, discloses only that portion of the Confidential Information that the Receiving Party is legally required to disclose as advised by the Receiving Party&#8217;s legal counsel.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">SEC Filings and Other Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax may disclose such &#91;***&#93; redacted terms of this Agreement (after SLS having reviewed and commented on the same) only to the extent in the &#91;***&#93; opinion of Novavax or its outside legal counsel required to comply with the rules and regulations promulgated by the United States Securities and Exchange Commission or similar security regulatory authorities in other countries. If Novavax must disclose this Agreement or any of the terms hereof in accordance with the preceding sentence, then Novavax agrees, &#91;***&#93;, to seek confidential treatment of portions of this Agreement or such terms as may be &#91;***&#93; requested by SLS, and to cause all Persons to whom any terms of this Agreement are disclosed to be bound by written obligations of confidentiality and non-use no less stringent than the confidentiality terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Other Permitted Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the restrictions set forth in this Article 8 (Confidentiality), Novavax may disclose the terms and provisions of this Agreement to any Third Party in connection with any actual or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> prospective acquisition, merger, financing, transfer or sale of all or substantially all of the assets of the business of Novavax to which this Agreement relates as permitted under Section 13.3 (Assignment)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> such Third Party is bound by written obligations of confidentiality at least as restrictive as those set forth in this Agreement. Novavax agrees that in the event it is requested to disclose any portion of SLS&#8217; Confidential Information to such Third Party for the context laid out above, then, it must secure &#91;***&#93; consent from SLS &#91;***&#93;, failure of which shall be a considered a breach of the terms of confidentiality of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Continuing Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If and whenever any Confidential Information is disclosed in accordance with this Section 8.4 (Permitted Disclosures), such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Ongoing Obligation for Confidentiality. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon expiration or termination of this Agreement, the Receiving Party will, and will cause its Representatives to, destroy, delete, or return (as requested by the Disclosing Party and any such destruction or deletion shall be certified by the Receiving Party in writing) any Confidential Information of the Disclosing Party, except for one copy, which may be retained in its confidential files for archive purposes. Notwithstanding the foregoing, the obligations set forth under this Section shall survive the termination or expiration for &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.41pt"><br><br>REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Representations, Warranties and Covenants of Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party represents, warrants and covenants that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">it has full corporate power and authority to execute, deliver, and perform under this Agreement, and has taken all corporate action required by Applicable Laws and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">all consents, approvals, and authorizations from all Governmental Authorities or other Third Parties required to be obtained in connection with this Agreement have been obtained&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and will not&#58; (a) conflict with or result in a breach of any provision of its organizational documents&#59; (b) result in a breach of any agreement to which it is a party that would impair the performance of its obligations hereunder&#59; or (c) violate any Applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Representations, Warranties and Covenants of SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS represents, warrants and covenants that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">neither it nor any Person acting for or on behalf of SLS will, in connection with the performance of this Agreement, (i) use any funds for contributions, gifts, entertainment, or other payments related to political activity or (ii) make any payment to any government official, in each case in violation of any Applicable Law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">(i) neither it nor any Affiliate &#47; Subcontractor has been debarred under the provisions of the Applicable Law, or by any Regulatory Authority, (ii) neither it nor any Affiliate &#47; Subcontractor will use in any capacity, in connection with the performance of this Agreement, any Person who has been debarred pursuant to the foregoing, and (iii) if at any time during the term of this Agreement, it or any Person engaged by SLS to perform this Agreement (a) becomes debarred, or (b) receives notice of action or threat of action with respect to its debarment, SLS shall notify Novavax immediately, and Novavax shall have the right to terminate this Agreement immediately.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Batch Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS warrants that all Batches Manufactured, either by itself or through Subcontractor, under this Agreement will&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">for Batches delivered for Commercial use, be Delivered with full title and with the applicable Certificate of Analysis, Certificate of Conformance, Master Batch Record, applicable master safety data sheet, and additional Batch-related documentation identified in the Quality Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">be Manufactured in accordance with GMP or otherwise in accordance with all Applicable Law and the terms of the applicable Quality Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">at the time of the Delivery, conform to the applicable Specifications in all respects.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Representations, Warranties and Covenants of Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax represents, warrants and covenants that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">All Novavax Background Intellectual Property, Novavax Supplied Items (including the Antigen), other Raw Materials and any Know-How provided to SLS under this Agreement or under any SOW have been Manufactured by Novavax (or procured from a Third Party manufacturing them, as the case may be), strictly in accordance with all Applicable Laws and GMP&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Novavax controls or has all such right title and interest in the Novavax Background Intellectual Property, Novavax Supplied Items (including the Antigen), other Raw Materials and any Know-How, as may necessary for Supply to and use by SLS, either itself or through an Affiliate or Subcontractor, thereof, for the performance of SLS&#8217; obligations under this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Supply to and use by SLS, either itself or through an Affiliate or Subcontractor, of any Novavax Background Intellectual Property, Novavax Supplied Items (including the Antigen), other Raw Materials and any Know-How for the Development or Manufacture of the Drug Products under this Agreement or any SOW - (i) free of any Third Party lien, (ii) does not infringe any valid Third Party Intellectual Property Rights, (iii) is not in violation of any agreement or other contractual arrangement by which Novavax may be bound and (iv) is compliant with all Applicable Laws which may apply the Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">DISCLAIMER OF WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">NO CONSEQUENTIAL DAMAGES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EXCEPT FOR DAMAGES RESULTING FROM (A) BREACHES OF ARTICLE 8 (CONFIDENTIALITY) OR (B) INDEMNIFIABLE CLAIMS UNDER ARTICLE 10 (INDEMNIFICATION&#59; INSURANCE), IN NO EVENT WILL EITHER PARTY HAVE ANY CLAIMS AGAINST OR LIABILITY TO THE OTHER PARTY WITH RESPECT TO ANY &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.07pt"><br><br>INDEMNIFICATION&#59; INSURANCE</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Indemnification by SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. SLS will indemnify, defend, and hold harmless Novavax and its Affiliates and their respective officers, directors, employees, successors, and permitted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assigns, (each a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Novavax Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all losses, liabilities, damages, costs, fees, and expenses (including reasonable attorneys&#8217; fees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) suffered by any Novavax Indemnified Party in connection with any suits or claims brought by any Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) arising out of or resulting from (in each case, except to the extent arising out of or resulting from any Novavax Indemnified Party&#8217;s negligence or willful misconduct, or any Latent Defects in any of the Antigen or Adjuvant as provided by Novavax)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Indemnification by Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Novavax will indemnify, defend, and hold harmless SLS and its Affiliates and their respective officers, Subcontractors, directors, employees, successors, and permitted assigns (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SLS Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against Losses suffered by any SLS Indemnified Party in connection with any Claims arising out of or resulting from (in each case, except to the extent arising out of or resulting from any SLS Indemnified Party&#8217;s negligence or willful misconduct)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Indemnification Procedure. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with any Claim for which an Indemnified Party seeks indemnification from the other Party pursuant to this Agreement, the Indemnified Party will&#58; (a) give the other Party &#91;***&#93; written notice of the Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that failure to provide such notice will not relieve the other Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure&#59; (b) cooperate with the other Party, at &#91;***&#93; expense, in connection with the defense and settlement of the Claim&#59; and (c) permit the other Party to control the defense and settlement of the Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the other Party may not settle the Claim without the Indemnified Party&#8217;s &#91;***&#93; consent &#91;***&#93;, if such settlement &#91;***&#93;. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by counsel of its selection and at &#91;***&#93; expense.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Insurance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SLS and Novavax, each at their own expense, shall obtain and thereafter maintain during the Term and thereafter all necessary insurance covering each Party&#8217;s performance under this Agreement, as may be applicable to each Party under the respective Applicable Law. Each Party shall provide the other a certificate of insurance upon the written request of the other Party.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.41pt"><br><br>TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement will commence upon the Effective Date and, if not otherwise terminated earlier pursuant to this Article 11 (Term and Termination), will continue in full force and effect until three (3) years or until two (2) years following the date of expiration or termination of the last SOW, whichever is later (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Either Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will have the right, without prejudice to any other remedies available to it at law or in equity, to terminate this Agreement in the event the other Party breaches (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) any of its material obligations hereunder and fails to cure such breach within &#91;***&#93; after receiving notice thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (a) if the breach by its nature is not curable, then the NonBreaching Party will be entitled to seek such relief within &#91;***&#93; of providing written notice to the Breaching Party, and (b) if such breach by its nature is curable, then such period will be extended as and for so long as the Breaching Party is making &#91;***&#93; to cure such breach, but in no event will such additional period exceed &#91;***&#93; (that is, for a total cure period of up to &#91;***&#93;) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in each case (a) and (b), at the end of which such termination shall become effective, unless, such allegedly breaching Party disputes such breach in accordance with Section 11.2.2 below. Any termination by a Party under this Section 11.2 (Termination for Cause) will be without prejudice to any damages or other legal or equitable remedies to which it may be entitled from the other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">If the Parties &#91;***&#93; disagree as to whether there has been a material breach, including whether such breach was material or curable, the Party that disputes whether there has been a material &#47; curable breach may contest the allegation in accordance with Section 13.2 (Dispute Resolution). Notwithstanding anything to the contrary in Section 11.2.1, if a Party contests the allegation in accordance with Section 13.2, the Cure Period for any dispute will extend from the date that written notice was first provided to the Breaching Party by the Non-Breaching Party until the end of the escalation period stipulated under Section 13.2.2, and it is understood and acknowledged that, during such period, all of the terms and conditions of this Agreement will remain in effect, and the Parties will continue to perform all of their respective obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Termination and Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be terminated by a Party &#91;***&#93; to the other Party if the other Party files a petition in bankruptcy or of insolvency, or is adjudicated insolvent, or takes advantage of the insolvency law in any state or country, or makes an assignment for the benefit of creditors, or a receiver, trustee or other court officer is applied for or appointed for its property.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Termination for Change of Control of Novavax. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SLS shall have the right, in its sole discretion to terminate this Agreement by a &#91;***&#93; to Novavax, in the event Novavax </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">undergoes a change of control event as stipulated under Section 13.3 (b) and the party acquiring or merging with or in any other manner controlling Novavax &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Termination by Mutual Consent. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event, the applicable Regulatory Authority in the Territory does not approve any of the Drug Products (or any other product containing or comprised of any of the Drug Products) for marketing or distribution or withdraws marketing or distribution approval, or SLS fails to maintain the consents, approvals, and authorizations from all Governmental Authorities or other Third Parties required to Manufacture the Drug Products then both Parties may mutually agree in good faith to decide the path forward.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Termination of SOWs for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any right for a Party to terminate a SOW for convenience shall be set forth in the applicable SOW</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.75pt"><br><br>EFFECTS OF TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Accrued Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration or termination of this Agreement will not relieve the Parties of any liability that accrued hereunder prior to the effective date of such expiration or termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, and any such expiration or termination will be without prejudice to the rights of either Party against the other, provided that SLS, unless otherwise requested by Novavax, will use its &#91;***&#93; to cancel, any third party obligations for, or repurpose for other uses by SLS, either itself or through an Affiliate or Subcontractor, any Raw Materials or capacity, for which Novavax may owe an obligation of reimbursement to SLS.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon the expiration or termination of this Agreement, the Receiving Party will return to the Disclosing Party (or, as directed by the Disclosing Party, destroy, at the &#91;***&#93; sole cost, in which case, the Receiving Party shall certify any such destruction in writing) all Confidential Information of the Disclosing Party that is in the Receiving Party&#8217;s possession or under its control (other than any Confidential Information required to continue to exercise a Party&#8217;s rights that survive termination of this Agreement). Notwithstanding the foregoing, the Receiving Party shall not be required to return or destroy Confidential Information contained in any computer system back-up records made in the ordinary course of business and shall be entitled to retain in its possession one copy of such Confidential Information, solely to the extent necessary to comply with Applicable Law and to monitor its continuing obligations under the Agreement, and provided further that in each instance, all terms of confidentiality, non-use and non-disclosure shall continue to govern the Confidential Information so retained by the Receiving Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following provisions, as well as any other provisions which by their nature are intended to survive termination or expiration, will survive termination or expiration of this Agreement&#58; Article 1 (Definitions)&#59; Section 4.7 (Latent Defects, Pharmacovigilance, Adverse Events and Recalls) Article 6 (Payments)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">Art</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">7Art</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Intellectual Property)&#59; Article 8 (Confidentiality)&#59; Article 9 (Representations, Warranties, and Covenants), Article 10 (Indemnification and Insurance)&#59; Article 12 (Effect of Termination)&#59; Article 13 (Miscellaneous).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article XIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:11.09pt"><br><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">No Third Party Obligation on SLS</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">1Novavax expressly agrees that SLS is performing its obligations under this Agreement, either itself or through an Affiliate or Subcontractor, solely in the capacity of a contract manufacturer to supply the Drug Product quantities mutually agreed between the Parties under a SOW. SLS shall not be bound by or obligated to any Third Party to fulfill any Drug Product supply commitments or assurances or covenants as a result of this Agreement, whether as of Effective Date, or at any time during the Term, which are given by Novavax to any Third Party, including without limitation to any Government Authority &#47; Regulatory Authority in any country within the Territory, or any international for-profit organization or any international non-profit organization or any statutory or governmental entity or any other private or public corporation, and Novavax shall be solely obligated to fulfill any and all of its covenants to any such Third Party without any recourse to SLS.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">For the sake of clarity, by executing this Agreement, SLS shall not, either directly, or by any implication, be responsible for or become to a party to, any obligations, commitments, promises or other assurances by Novavax to any Third Party in relation to the supply of the Drug Product, and Novavax indemnifies and holds SLS harmless against any claims from any such Third Party in relation thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Disputes Generally. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties recognize that a dispute may arise relating to this Agreement. In the event of a dispute, the Project Managers will negotiate &#91;***&#93; to settle any such dispute. If the Project Managers are unable to resolve a dispute within &#91;***&#93;, then either Party may escalate the dispute pursuant to Section 13.2.2.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Escalation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93; after the written request of either Party, each of the Parties will appoint a designated representative with appropriate seniority, experience, and authority to meet in person or by telephone to attempt &#91;***&#93; to resolve any dispute that arises under this Agreement. If the designated representatives do not resolve the dispute within &#91;***&#93; of such request, then either Party may commence legal proceedings in accordance with Section 13.5 below.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">a. Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No Party hereto may assign any right or obligation hereunder to a Third Party without the &#91;***&#93; consent of the other Party hereto. Notwithstanding the foregoing, either Party may assign this Agreement, or all of its rights or obligations hereunder to any Affiliate of such Party and shall notify the other Party in writing of such assignment thereafter, in which event, the assigning Party hereby guarantees the performance by such Affiliates of such Party&#8217;s obligations under this Agreement and will cause such assignee Affiliate to comply with the provisions of this Agreement in connection with such performance.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b. Change of Control. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to &#91;***&#93; notice to SLS, Novavax may assign this Agreement, or all of its rights or obligations hereunder and thereunder to any Affiliate of Novavax, or to any Person that acquires all or substantially all of the stock or assets of the business to which this Agreement relates (by merger, stock or asset purchase, operation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of law, or otherwise), provided that such Third Party acquiring Novavax shall be bound by the terms and conditions of this Agreement and accordingly be obligated to perform all the obligations and responsibilities of Novavax under this Agreement, and provided further that, in the event of any failure of any such party acquiring or merging with Novavax to comply with the provisions of this Section 13.3b., &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c. Successors and Assigns. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement will be binding on and insure to the benefit of the Parties, their executors, administrators, successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Should one or more of the provisions of this Agreement become void or unenforceable as a matter of law, then such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement, and the Parties agree to substitute a valid and enforceable provision therefor which, as nearly as possible, achieves the desired economic effect and mutual understanding of the Parties under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Governing Law&#59; Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the &#91;***&#93; without regard to conflict of law principles thereof. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to any Purchase Order made pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver will be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Nothing contained in this Agreement will be deemed to constitute a partnership, joint venture, or legal entity of any type between SLS and Novavax, or to constitute one Party as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give any Party the power or authority to act for, bind, or commit the other Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement will be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been duly given when&#58; (a) delivered by hand (with written confirmation of receipt)&#59; (b) sent by fax (with written confirmation of receipt), provided that a copy is sent by an internationally recognized overnight delivery service (receipt requested)&#59; or (c) sent by email to the addressee, and marked as &#8220;Notice&#8221; under this Section 13.9, provided sender receives electronic confirmation of receipt by such recipient, or (d) when received by the addressee, if sent by an internationally recognized overnight delivery service, receipt requested, in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as a Party may designate by written notice)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">If to SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;<br>Serum Life Sciences Ltd.<br>12 New Fetter Lane, London, United Kingdom, EC4A 1JP</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">If to Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;<br>Novavax, Inc.<br>21 Firstfield Road<br>Gaithersburg, MD 20878<br>Attn&#58; &#91;***&#93;<br>E&#58; &#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Further Assurances. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax and SLS hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge, and deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">No Third Party Beneficiary Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as expressly provided in this Agreement, this Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Entire Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, together with its Exhibits, SOWs, and the Quality Agreement, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a material provision of this Agreement, any Exhibit hereto and&#47;or SOW, the order of precedence shall be as follows&#58; Agreement, the Exhibit and the SOW, unless any such conflict is specifically and expressly identified in the applicable a SOW, in which case, such conflicting provision shall control. Notwithstanding the foregoing, the Quality Agreement shall control with respect to all quality matters.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither Party will be liable or deemed in default for failure to perform any duty or obligation that such Party may have under this Agreement where such failure has been occasioned by any act of God, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, civil unrest, other factors that affect the supply or procurement of Raw Materials, or intervention of any Governmental Authority (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and which is beyond its reasonable control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Party affected will &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Cumulative Remedies. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as otherwise set forth in this Agreement, no remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Waiver of Rule of Construction. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Construction&#59; Rules of Construction. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interpretation of this Agreement will be governed by the following rules of construction&#58; (a) words in the singular will be held to include the plural and vice versa, and words of one gender will be held to include the other gender as the context requires&#59; (b) references to the terms &#8220;Section,&#8221; or &#8220;clause&#8221; are to a Section of this Agreement unless otherwise specified&#59; (c) the terms &#8220;hereof,&#8221; &#8220;hereby,&#8221; &#8220;hereto,&#8221; and derivative or clause or similar words refer to this entire Agreement&#59; (d) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">word &#8220;including&#8221; and words of similar import when used in this Agreement will mean &#8220;including without limitation,&#8221; unless otherwise specified&#59; (e) the word &#8220;or&#8221; will not be exclusive&#59; (f) references to &#8220;written&#8221; or &#8220;in writing&#8221; include in electronic form&#59; (g) the titles and headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement&#59; (h) the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59; (i) references to &#8220;days&#8221; will mean calendar days, unless otherwise specified&#59; and (j) a reference to any Person includes such Person&#8217;s successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email or other electronically transmitted signatures and such signatures will be deemed to bind each Party as if they were original signatures.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Signature page follows on the next page&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In Witness Whereof, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERUM LIFESCIENCES LIMITED</font></div><div style="padding-left:270pt"><font><br></font></div><div style="padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Signature)</font></div><div style="padding-left:270pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOVAVAX, INC.</font></div><div style="padding-left:270pt"><font><br></font></div><div style="padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John A. Herrmann III&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Signature)</font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">John A. Herrmann III&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:270pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EVP, CLO&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FACILITIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Appendix setting forth facilities rights has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted appendixes to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBCONTRACTORS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Appendix setting forth the list of subcontractors has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted appendixes to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>nvax-20220630xex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie346e4669c074b9a9490c0d971d3df2e_1"></div><div style="min-height:133.92pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.4</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:180pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 TO THE CONTRACT DEVELOPMENT MANUFACTURE AGREEMENT</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BETWEEN</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOVAVAX, INC</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERUM LIFE SCIENCES LIMITED</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#NUM_PAGES#</font></div></div></div><div id="ie346e4669c074b9a9490c0d971d3df2e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment No. 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;Amendment No. 1&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Contract Development Manufacture Agreement, dated 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, October 2021 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;CDMA&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is entered into and made effective as of 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;Effective Date of Amendment No. 1&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax, Inc., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware USA corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Serum Life Sciences Limited, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a company duly incorporated having its registered office situated in England and Wales, formerly known as Covicure Holdings Limited having its principal office at 15 Grosvenor Street, London, W1K 4QZ, United Kingdom </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;SLS&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax and SLS may each be referred to herein individually as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Party&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and collectively as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Parties.&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalized terms not otherwise defined in this Amendment No. 1 shall have the meanings respectively ascribed to them in the CDMA.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties have entered into a Contract Development Manufacture Agreement, dated 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, October 2021 (hereinafter &#8220;CDMA&#8221;) to govern SLS&#8217; Development, Manufacture and supply (itself or through one or more Affiliates or Subcontractors) of Novavax&#8217; requirements for Drug Product(s) for further commercial use and sale by Novavax in the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties wish to amend the CDMA to clarify certain terms, including without limitation, terms relating to title and risk of loss of Novavax Supplied Items&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in accordance with Clause 13.6 of the CDMA, the Parties hereto desire to amend and modify the CDMA in accordance with the terms and subject to the conditions set forth in this Amendment No. 1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Clause 2.4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In Clause 2.4, the sentence, &#8220;Title to Novavax Supplied Items shall transfer to &#91;***&#93; and &#91;***&#93; shall have all risk of loss or damage to all Novavax Supplied Items &#91;***&#93;.&#8221;, shall be deleted and replaced by the following sentence&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Unless set forth otherwise in the applicable SOW, title and risk of loss of Novavax Supplied Items shall &#91;***&#93; unless any loss or damage is due to the gross negligence or willful misconduct of &#91;***&#93;, in which case &#91;***&#93; shall bear the cost (including any indirect taxes thereon, including but not limited to, which may be applicable in the hands of &#91;***&#93;) incurred by &#91;***&#93; for such Novavax Supplied Items.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Clause 7.4.2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following sentence shall be added to the end of Clause 7.4.2&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;For the purposes of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Covenant Beneficiary&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Novavax or any of Novavax&#8217; Affiliates, or any of its or their direct or indirect licensees, sublicensees, importers, exporters, suppliers, manufacturers, distributors, contractors, agents, or customers.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Parties agree and accept that throughout the CDMA, wherever the SLS&#8217; office address has been referenced as &#8220;12 New Fetter Lane, London, United Kingdom, EC4A 1JP&#8217;&#8217; and including, namely in the following sections or clauses -</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">On the Second Page of the CDMA (name clause), and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Clause 13.9 of the CDMA on page 27.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#NUM_PAGES#</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, each such reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;12 New Fetter Lane, London, United Kingdom, EC4A 1JP&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the SLS&#8217;s office address shall be amended and replaced with the following-</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;15 Grosvenor Street, London, W1K 4QZ, United Kingdom&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Except as expressly set forth hereinabove, all of the terms and conditions of the CDMA remain unchanged and are in full force and effect and shall supersede any conflicting terms of this Amendment No. 1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This Amendment No. 1 may only be modified by a written document, signed by the duly authorized representatives of each Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This Amendment No&#59; 1 may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Amendment No. 1 may be executed by facsimile, PDF format via email or other electronically transmitted signatures and such signatures will be deemed to bind each Party as if they were original signatures.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature page to follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#NUM_PAGES#</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties have caused this Amendment No. 1 to be executed by their respective duly authorized officers as of the Effective Date of Amendment No. 1.</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOVAVAX, INC.</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John A. Herrmann III&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Signature)</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">John A. Herrmann III&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EVP, CLO&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29 April, 2022</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERUM LIFE SCIENCES LIMITED</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; 29&#47;04&#47;2022&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Signature)</font></div><div style="padding-left:234pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#NUM_PAGES#</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>nvax-20220630xex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i53db6b59659041419cfb24e41206d359_1"></div><div style="min-height:131.76pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.5</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STATEMENT OF WORK #1<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTRACT DEVELOPMENT MANUFACTURE AGREEMENT<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">between<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERUM LIFE SCIENCES LIMITED<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>NOVAVAX, INC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIS STATEMENT OF WORK No. 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOW No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made, effective as of 29, April 2022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date of SOW No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between Serum Life Sciences Limited (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a company duly incorporated having its registered office situated in England and Wales, formerly known as Covicure Holdings Limited having its principal office at 15 Grosvenor Street, London, W1 K 4QZ, United Kingdom, and Novavax, Inc., a Delaware USA corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and is incorporated as an integral part of the Contract Development Manufacture Agreement dated October 21, 2021, as amended from time to time, (hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and entered into between the Parties.  SLS and Novavax may each be referred to, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have entered into the Agreement to govern SLS&#8217; Development, Manufacture and supply (itself and&#47;or through one or more Affiliates or Subcontractors) of Novavax&#8217; requirements of Drug Products for further commercial use and sale by Novavax in the Territory&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the Agreement, the Parties have agreed to execute, as required, mutually agreed upon Statements of Work (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOWs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to set forth the scope of the project, general statement of stages and activities, pricing, the schedule of milestones, deliverables and payments and other pertinent information, in order to prepare for, initiate and conduct the Services, including, as applicable, the project plan, Technology Transfer and Process Development for and Manufacture of the applicable Drug Product&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, accordingly, the Parties now intend to execute this SOW No. 1, which is made an integral part of the Agreement from the Effective Date of SOW No. 1&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, capitalized terms used in this SOW No. 1 will have the same meaning as set forth in the Agreement unless otherwise defined herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the mutually agreed terms and conditions and covenants herein and in the Agreement, the sufficient of which the Parties acknowledge, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Scope of Work</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">SLS shall (either itself or through its Affiliates or Subcontractors)&#58;  (i) receive from Novavax and properly store Antigen and Adjuvant, including other Novavax Supplied Items, for use in the Manufacture by SLS of Drug Product NVX-CoV2373&#59; (ii) SLS to perform aseptic Manufacturing of Drug Product in &#91;***&#93; vials, including process performance qualification (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PPQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and commercial scale Manufacturing based on Novavax defined Specifications&#59; (iii) undertake </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:131.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">secondary commercial packaging in respect of the Manufactured Drug Product based on Novavax defined Specifications, (iv) procure all Raw Materials required for such activities&#59; (v) perform testing required for release of the Manufactured and packaged Drug Product&#59; and (vi) store and Deliver the packaged Drug Product outside India at a location as preferred and instructed by Novavax.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Responsibilities and Activities of Parties</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Novavax&#8217; Responsibilities and Activities include&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Provide the Novavax Supplied Items for Manufacture.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Transfer, including Technology Transfer, of methods and process knowledge essential to Manufacture of Drug Product based on the Specifications provided.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Provide formulation strategy and Specifications.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Transfer of test methods required for release of Manufactured Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Provide secondary packaging artwork and label text, specific to all applicable end markets, for commercial packaging of Drug Product to be done by SLS.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">SLS&#8217; Responsibilities and Activities include&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Pursuant to Section 5 below, secure an ongoing supply of the Raw Materials necessary for Manufacture and secondary packaging of Drug Product, pursuant to Novavax&#8217; Initial Forecast and &#91;***&#93; Updated Forecast and associated Purchase Orders.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">&#91;***&#93; upon its receipt of any Novavax Supplied Items, SLS shall label and inventory the Novavax Supplied Items as distinct and separate from any other inventory maintained by SLS (whether for purposes of this SOW No. 1 or any other SOW or other agreement with Novavax or any other entity).  Such inventory shall be available for review and audit by Novavax on a &#91;***&#93;.  Additionally, SLS shall provide &#91;***&#93; assistance, including records and reporting, as required, in order to allow Novavax to satisfy its requirements under US GAAP.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Manufacture of Drug Product will be performed on a commercial scale upon the successful completion of start-up activities (engineering run(s), small scale GMP runs, and PPQ batches), based on parameters agreed by the Parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:131.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:172.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Associated start-up activities SLS to be responsible for, as deliverables to Novavax, include&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:144pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24pt">Technical risk assessment.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:144pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24pt">Provision of Master Batch Record.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:144pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24pt">Provision of PPQ protocol.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Drug Product will be formulated based on a mutually defined and agreed to strategy, including the Specifications provided by Novavax.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Carry out manufacture at Batch size and scale defined and approved by Novavax.  Current validated range of up to &#91;***&#93; per Batch.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Manage time out of refrigeration (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for formulated Drug Product at a level below the Novavax recommended TOR threshold of &#91;***&#93;, unless otherwise agreed in writing between the Parties.  TOR to be documented in the Master Batch Record.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Specifications&#58; See Annex 1.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Novavax Supplied Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Novavax shall supply Antigen and Adjuvant Components for use in Manufacture of Drug Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Raw Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SLS shall provide the Raw Materials set forth in the regulatory filings supporting the applicable Regulatory Approval(s).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Milestones and Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">SLS to commence commercial Manufacturing based on the Initial Forecast and periodic Updated Forecast, and associated Purchase Orders, provided by Novavax&#8217; Supply Chain Planning, carried out upon associated regulatory approvals.  SLS will provide an ongoing schedule to Novavax confirming anticipated release of Product consistent with the Delivery Date specified in a Purchase Order, to support Novavax arrangement of shipments of Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">SLS, either itself or through its Affiliates or Subcontractors, will &#91;***&#93; notify Novavax if SLS is aware that it will be unable to meet any deadline for Release of a Batch or any other milestone or deliverable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Initial Forecast&#59; Purchase Orders</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Initial Forecast is set forth in Annex 2.  Initial Forecast is conditional to the final formulation strategy determined by SLS and Novavax (impacts to dosage outputs), the projected output of Novavax&#8217; drug substance supply, and the securing of all needed import licenses by SLS to enable shipment of Novavax Supplied Items.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax will issue Batch specific Purchase Orders (PO), and SLS&#8217; invoices shall be submitted per Batch with reference to the appropriate PO.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:131.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Delivery Terms</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incoterms based on activity related to this SOW No. 1&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Novavax Supplied Items&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Novavax shall deliver Novavax Supplied Items &#91;***&#93;, provided that title and risk of loss to Novavax Supplied Items &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">&#91;***&#93; are responsible for obtaining import licenses as needed to support the program, as well as act as the Importer of Record (IOR).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Finished Drug Product for Novavax customers&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">SLS shall (either itself or through its Affiliates or Subcontractors) ship Drug Product &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">&#91;***&#93; shall &#91;***&#93; be responsible for the exportation clearance and process and act as Exporter of Record.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Pricing&#59; Storage Fee</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Service Fee and Incentive Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The price per dose of Drug Product Delivered under this SOW No.1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Drug Product Dose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Service Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) plus &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Incentive Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Service Fee shall be due and payable upon Delivery of the Drug Product Dose in accordance with the terms and conditions of the Agreement, including, but not limited to, Section 6.1.1 of the Agreement.  The Incentive Fee shall be paid in accordance with Section 9.1.2 below.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Incentive Fee Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any Incentive Fee Amount(s) payable under this SOW No.1 shall be calculated &#91;***&#93; as of &#91;***&#93; (each a &#8220;Incentive Fee Payment&#8221;).  Novavax shall submit the Incentive Fee Payment together with the delivery of a written sales report to SLS within &#91;***&#93; that show Net Sales of Drug Product Doses recognized during such &#91;***&#93;, stating gross sales (including number of doses, price per dose, Net Sales Price(s), and reasonable details relating to the deductions made in determining Incentive Fee Amount(s)).  All such Incentive Fee Payments shall be made in &#91;***&#93;.  For the purpose of computing the Net Sales sold in a currency other than &#91;***&#93;, such currency shall be converted from local currency to &#91;***&#93; by Novavax in accordance with the rates of exchange for the relevant month for converting such other currency into &#91;***&#93; used by Novavax&#8217; internal accounting systems. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">If storage is needed as provided for in Section 4.4.3 of the Agreement, then SLS shall invoice Novavax on &#91;***&#93; basis for all actual reasonable costs and expenses incurred in storing such Drug Products.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:131.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Quantity of Drug Product Doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Under this SOW No.1, Novavax hereby commits to purchase and SLS hereby, subject to the terms of the Agreement, agrees to Manufacture or have Manufactured, and supply the quantity of Drug Product Doses as specified in each Purchase Order issued hereunder&#59; provided, however, that the aggregate quantity under this SOW No. 1 shall not exceed eighty million (80,000,000) Drug Product Doses.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The delay or failure by Novavax in obtaining any import or other authorizations, which Novavax is required hereunder to obtain for the Delivery of Drug Product pursuant to this SOW No. 1, may affect the timing of Delivery by SLS.  Accordingly, to the extent such delay or failure by Novavax is the direct cause of a delay in Delivery by SLS despite its use of &#91;***&#93;, such delay in Delivery by SLS shall not be construed as a breach of this SOW No. 1 by SLS or its Affiliates or Subcontractors.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The Term of this SOW No. 1 shall commence from the Effective Date of SOW No. 1 and shall thereafter continue for a period of one (1) year unless terminated or extended as per the mutual agreement between the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">All terms and conditions of this SOW No. 1 shall be read conjunctively and harmoniously with the Agreement and Quality Agreement, and, except as expressly stated to the contrary herein, all terms and conditions of the Agreement shall continue to apply to this SOW No. 1.  Further, any conflict between the terms of the Agreement and this SOW No.1, then the terms of the Agreement shall take precedence.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">This SOW No. 1 may only be modified by a written document, signed by the duly authorized representatives of both Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Subject to clause 5.4 of the Agreement, Novavax will have restricted access to the Drug Product manufacturing facilities and storage locations used by SLS for the purposes of this SOW No. 1.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows this Page&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><div id="i53db6b59659041419cfb24e41206d359_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have caused this SOW No. 1 to be executed by their respective duly authorized officers as of the Effective Date of SOW No. 1.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOVAVAX, INC.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SERUM LIFE SCIENCES LIMITED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John A. Herrmann III&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">***&#93;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">John A. Herrmann III&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EVP, CLO, BD&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29 April 2022&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29&#47;04&#47;2022&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNEX 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Drug Product Specifications</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Appendix setting forth drug product specifications has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted appendixes to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNEX 2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Forecast</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Appendix setting forth the initial forecast has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted appendixes to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>nvax-20220630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1e901502e52b466e9da4317410159814_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, Stanley C. Erck, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">I have reviewed this Quarterly Report on Form 10-Q of Novavax, Inc.&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.02pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Stanley C. Erck</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stanley C. Erck</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:261pt;text-indent:-261pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>nvax-20220630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic51a574ef4b34a96a7933ddf5f9514b5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, James P. Kelly, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">I have reviewed this Quarterly Report on Form 10-Q of Novavax, Inc.&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President, Chief </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Officer and Treasurer</font></div></td></tr></table></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>nvax-20220630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1fed1a46cce7408dbb1a0a54361d4b52_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO 18 UNITED STATES CODE &#167;1350<br>(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the Quarterly Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the fiscal period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Stanley C. Erck, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Stanley C. Erck</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stanley C. Erck</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:261pt;text-indent:-261pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>nvax-20220630xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic89fedf9ed354dc9a7020ba6899d793f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 UNITED STATES CODE &#167;1350<br>(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the Quarterly Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the fiscal period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James P. Kelly, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report. </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President, Chief </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Officer and Treasurer</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>nvax-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b8f7f396-6255-4acd-a261-8fc9092ca526,g:e7b36f81-b504-4b3e-b499-0ac259afcdda-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novavax.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.novavax.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1001002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.novavax.com/role/OrganizationandBusiness">
        <link:definition>2101101 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesBasisofPresentationDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.novavax.com/role/Revenue">
        <link:definition>2105103 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.novavax.com/role/RevenueTables">
        <link:definition>2306301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails">
        <link:definition>2407402 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails_1" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1">
        <link:definition>2407402 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" roleURI="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails">
        <link:definition>2408403 - Disclosure - Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueDetails">
        <link:definition>2409404 - Disclosure - Revenue - Schedule of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandSupplyAgreements" roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements">
        <link:definition>2110104 - Disclosure - Collaboration, License, and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandSupplyAgreementsDetails" roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails">
        <link:definition>2411405 - Disclosure - Collaboration, License, and Supply Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>2112105 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>2313302 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2414406 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.novavax.com/role/FairValueMeasurements">
        <link:definition>2115106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.novavax.com/role/FairValueMeasurementsTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails">
        <link:definition>2417407 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.novavax.com/role/Inventory">
        <link:definition>2118107 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.novavax.com/role/InventoryTables">
        <link:definition>2319304 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.novavax.com/role/InventoryDetails">
        <link:definition>2420408 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2121108 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2322305 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails">
        <link:definition>2423409 - Disclosure - Intangible Assets and Goodwill - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails" roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails">
        <link:definition>2424410 - Disclosure - Intangible Assets and Goodwill - Identifiable Intangible Assets, estimated amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillDetails" roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails">
        <link:definition>2425411 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.novavax.com/role/Leases">
        <link:definition>2126109 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.novavax.com/role/LeasesDetails">
        <link:definition>2427412 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.novavax.com/role/Debt">
        <link:definition>2128110 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.novavax.com/role/DebtTables">
        <link:definition>2329306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.novavax.com/role/DebtNarrativeDetails">
        <link:definition>2430413 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNotesPayableDetails" roleURI="http://www.novavax.com/role/DebtNotesPayableDetails">
        <link:definition>2431414 - Disclosure - Debt - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.novavax.com/role/DebtInterestExpenseDetails">
        <link:definition>2432415 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.novavax.com/role/StockholdersEquityDeficit">
        <link:definition>2133111 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitDetails" roleURI="http://www.novavax.com/role/StockholdersEquityDeficitDetails">
        <link:definition>2434416 - Disclosure - Stockholders' Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.novavax.com/role/StockBasedCompensation">
        <link:definition>2135112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.novavax.com/role/StockBasedCompensationTables">
        <link:definition>2336307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails">
        <link:definition>2437417 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationCompensationExpenseDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails">
        <link:definition>2438418 - Disclosure - Stock-Based Compensation - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsandAppreciationRightsDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails">
        <link:definition>2439419 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails">
        <link:definition>2440420 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>2441421 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2442422 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.novavax.com/role/IncomeTaxes">
        <link:definition>2143113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.novavax.com/role/IncomeTaxesDetails">
        <link:definition>2444423 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.novavax.com/role/CommitmentsandContingencies">
        <link:definition>2145114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.novavax.com/role/SubsequentEvents">
        <link:definition>2146115 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.novavax.com/role/SubsequentEventsDetails">
        <link:definition>2447424 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nvax_TwoThousandFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RoyaltiesAndOtherMember" abstract="true" name="RoyaltiesAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_DeferredRevenueCurrentAndNonCurrent" abstract="false" name="DeferredRevenueCurrentAndNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AmendedAndRestatedUKSupplyAgreementMember" abstract="true" name="AmendedAndRestatedUKSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" abstract="false" name="NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_TwoThousandFiveStockIncentivePlanMember" abstract="true" name="TwoThousandFiveStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CollaborationAgreementsMember" abstract="true" name="CollaborationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SalesBasedRoyaltiesMember" abstract="true" name="SalesBasedRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfDosesCancelled" abstract="false" name="PurchaseAgreementNumberOfDosesCancelled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_TakedaArrangementMember" abstract="true" name="TakedaArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_DeferredRevenueCurrentAdditions" abstract="false" name="DeferredRevenueCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" abstract="true" name="JointCommitteeOnVaccinationAndImmunizationJCVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GrantsUSGovernmentContractAndJointVentureAbstract" abstract="true" name="GrantsUSGovernmentContractAndJointVentureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" abstract="true" name="CollaborationUsGovernmentAgreementAndJointVentureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ProprietaryAdjuvantTechnologyMember" abstract="true" name="ProprietaryAdjuvantTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" abstract="false" name="PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_OperatingAndFinanceLeaseWriteOff" abstract="false" name="OperatingAndFinanceLeaseWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_A700Q0AgreementMember" abstract="true" name="A700Q0AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" abstract="false" name="SharebasedCompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_ShelfRegistrationStatementRemainingUnissuedCapital" abstract="false" name="ShelfRegistrationStatementRemainingUnissuedCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DeferredRevenueCurrentDeductions" abstract="false" name="DeferredRevenueCurrentDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ReceivablesNetCurrentAdditions" abstract="false" name="ReceivablesNetCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FacilityNumberOfSquareFeet" abstract="false" name="FacilityNumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="nvax_CollaborationAgreementUpfrontPaymentAmount" abstract="false" name="CollaborationAgreementUpfrontPaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfDosesRemaining" abstract="false" name="PurchaseAgreementNumberOfDosesRemaining" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_LongTermSupplyAgreementIncrementalBorrowingRate" abstract="false" name="LongTermSupplyAgreementIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_GovernmentBackedSecuritiesMember" abstract="true" name="GovernmentBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CollaborativeArrangementAbstract" abstract="true" name="CollaborativeArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" abstract="false" name="InterestExpenseRelatedToConvertibleNotesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" abstract="false" name="ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_ReceivablesCurrentNetDeductions" abstract="false" name="ReceivablesCurrentNetDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_USGovernmentPartnershipMember" abstract="true" name="USGovernmentPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_USDepartmentOfDefenseDoDContractMember" abstract="true" name="USDepartmentOfDefenseDoDContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfDosesToBeDistributed" abstract="false" name="PurchaseAgreementNumberOfDosesToBeDistributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_CompensationStockIssuedUnderIncentiveProgram" abstract="false" name="CompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DeferredRevenueIncreaseDecreaseAbstract" abstract="true" name="DeferredRevenueIncreaseDecreaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_PotentialFutureMilestonePayments" abstract="false" name="PotentialFutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_EuropeanCommissionsECMember" abstract="true" name="EuropeanCommissionsECMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfVaccineDoses" abstract="false" name="PurchaseAgreementNumberOfVaccineDoses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" abstract="true" name="AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" abstract="true" name="GaviAdvancePurchaseAgreementCOVAXFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_BillMelindaGatesFoundationMember" abstract="true" name="BillMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementSIIPLMember" abstract="true" name="GaviAdvancePurchaseAgreementSIIPLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>nvax-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b8f7f396-6255-4acd-a261-8fc9092ca526,g:e7b36f81-b504-4b3e-b499-0ac259afcdda-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_65b5adbb-36ad-4cba-8b6e-6a2dfdde20ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1fadeb13-0881-4881-b16f-1f66c6c609b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_65b5adbb-36ad-4cba-8b6e-6a2dfdde20ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_1fadeb13-0881-4881-b16f-1f66c6c609b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3c8802e2-0bed-482b-bd68-a90c6c8c7e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_65b5adbb-36ad-4cba-8b6e-6a2dfdde20ac" xlink:to="loc_us-gaap_InterestExpense_3c8802e2-0bed-482b-bd68-a90c6c8c7e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_02d1f6c0-8afb-4021-8563-f3e56d74e82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_65b5adbb-36ad-4cba-8b6e-6a2dfdde20ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_02d1f6c0-8afb-4021-8563-f3e56d74e82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_01eacdad-6b8c-4338-a3d5-036bdabcfdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a3ee1bfd-2049-4126-a3e8-580658fca372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_01eacdad-6b8c-4338-a3d5-036bdabcfdc4" xlink:to="loc_us-gaap_Revenues_a3ee1bfd-2049-4126-a3e8-580658fca372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0c23c75d-2d81-4c42-9bcf-a9c0c83824ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_01eacdad-6b8c-4338-a3d5-036bdabcfdc4" xlink:to="loc_us-gaap_CostsAndExpenses_0c23c75d-2d81-4c42-9bcf-a9c0c83824ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ac3ecf69-175d-4f36-a3e6-c456fab0ca69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dd6eee97-8408-4b27-953e-efb757cbcbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac3ecf69-175d-4f36-a3e6-c456fab0ca69" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dd6eee97-8408-4b27-953e-efb757cbcbad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_68bee2e7-73e3-4e62-af91-90fb7cbc6943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac3ecf69-175d-4f36-a3e6-c456fab0ca69" xlink:to="loc_us-gaap_CostOfRevenue_68bee2e7-73e3-4e62-af91-90fb7cbc6943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1476b302-6132-4f98-8aa4-fa50460f8bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac3ecf69-175d-4f36-a3e6-c456fab0ca69" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1476b302-6132-4f98-8aa4-fa50460f8bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_495f8129-85a2-4777-beed-c7892f169a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70e827a1-ccf2-4737-bf73-2d36171d5649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_495f8129-85a2-4777-beed-c7892f169a59" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70e827a1-ccf2-4737-bf73-2d36171d5649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ded2fd2-0ba1-4803-b508-64efa947779b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_495f8129-85a2-4777-beed-c7892f169a59" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ded2fd2-0ba1-4803-b508-64efa947779b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5d2c4446-c28e-42b1-802c-e7182463092d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1394a9ea-dac1-4c3d-bf9f-20afa23c6150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5d2c4446-c28e-42b1-802c-e7182463092d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1394a9ea-dac1-4c3d-bf9f-20afa23c6150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_00978953-e618-4a26-a535-6d9c9d58f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5d2c4446-c28e-42b1-802c-e7182463092d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_00978953-e618-4a26-a535-6d9c9d58f1f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a90a886d-11c1-4025-acf2-7fc1d8ac2516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47bfda5a-030b-44e8-bf3a-cda233781843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a90a886d-11c1-4025-acf2-7fc1d8ac2516" xlink:to="loc_us-gaap_NetIncomeLoss_47bfda5a-030b-44e8-bf3a-cda233781843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9380564a-c7b5-4f05-a6a9-b4f80d4eb6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a90a886d-11c1-4025-acf2-7fc1d8ac2516" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9380564a-c7b5-4f05-a6a9-b4f80d4eb6e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cba032d5-1685-4643-862e-e765ea59ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7df2aa0e-7e8a-42a6-854c-b2d1a03dae98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cba032d5-1685-4643-862e-e765ea59ecab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7df2aa0e-7e8a-42a6-854c-b2d1a03dae98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5ced39f8-09e9-448d-8396-5599421a6bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cba032d5-1685-4643-862e-e765ea59ecab" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5ced39f8-09e9-448d-8396-5599421a6bad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6ae00f5a-08d0-4e2a-a4e2-099662a28080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cba032d5-1685-4643-862e-e765ea59ecab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6ae00f5a-08d0-4e2a-a4e2-099662a28080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d868ec23-c303-45ec-9151-ecdf5cf714d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cba032d5-1685-4643-862e-e765ea59ecab" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d868ec23-c303-45ec-9151-ecdf5cf714d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cedae7c8-6ec8-4de1-a477-ac6566eb6c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cba032d5-1685-4643-862e-e765ea59ecab" xlink:to="loc_us-gaap_InventoryNet_cedae7c8-6ec8-4de1-a477-ac6566eb6c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31329bde-bb32-4765-b24c-0ba75db28cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0fcace7b-f696-459c-8bb0-0e2ad1717649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31329bde-bb32-4765-b24c-0ba75db28cfa" xlink:to="loc_us-gaap_Liabilities_0fcace7b-f696-459c-8bb0-0e2ad1717649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_569f0349-894e-4f09-875d-bc4fda3e56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31329bde-bb32-4765-b24c-0ba75db28cfa" xlink:to="loc_us-gaap_StockholdersEquity_569f0349-894e-4f09-875d-bc4fda3e56cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8bf38bcf-00a1-4051-b4d0-78775bbf6cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31329bde-bb32-4765-b24c-0ba75db28cfa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8bf38bcf-00a1-4051-b4d0-78775bbf6cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b42ac4b9-c522-42a1-8255-001abb0fb019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b42ac4b9-c522-42a1-8255-001abb0fb019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dcf4409c-7e63-409a-af5a-fc9fab94286c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:to="loc_us-gaap_AssetsCurrent_dcf4409c-7e63-409a-af5a-fc9fab94286c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f84f0f7a-49e7-49b7-b850-2a0e8044f1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f84f0f7a-49e7-49b7-b850-2a0e8044f1d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b550f33e-8995-462e-9bcb-4f92b55abd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b550f33e-8995-462e-9bcb-4f92b55abd94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0efc769b-1ea3-47f6-8dde-b3ce53538de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0efc769b-1ea3-47f6-8dde-b3ce53538de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ed4c70b-e40d-4756-b93b-1b88d44ab49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9a5ad1c9-2700-4c54-8347-7aa71e82ab74" xlink:to="loc_us-gaap_Goodwill_0ed4c70b-e40d-4756-b93b-1b88d44ab49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_977aba16-5140-4eff-9c98-62d1dc722a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ad861d5d-a94a-4d6a-bea8-a3bed871633e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_977aba16-5140-4eff-9c98-62d1dc722a1f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ad861d5d-a94a-4d6a-bea8-a3bed871633e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70c6c552-2e6f-48d9-826b-048c36deedcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_977aba16-5140-4eff-9c98-62d1dc722a1f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70c6c552-2e6f-48d9-826b-048c36deedcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cff70f54-c50d-4175-a987-08226b3df4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_977aba16-5140-4eff-9c98-62d1dc722a1f" xlink:to="loc_us-gaap_CommonStockValue_cff70f54-c50d-4175-a987-08226b3df4f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7b74a5b1-5c2c-42cd-81ff-b4753b72425e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_977aba16-5140-4eff-9c98-62d1dc722a1f" xlink:to="loc_us-gaap_TreasuryStockValue_7b74a5b1-5c2c-42cd-81ff-b4753b72425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baf0c8ef-bcb6-4618-b637-c2923a78f480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_977aba16-5140-4eff-9c98-62d1dc722a1f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baf0c8ef-bcb6-4618-b637-c2923a78f480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8f655a82-77c8-4bed-aa06-2d6da16f9230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_337ce881-02ce-458a-bbe0-310a8e898a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8f655a82-77c8-4bed-aa06-2d6da16f9230" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_337ce881-02ce-458a-bbe0-310a8e898a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_66a39ae0-b65b-4351-9cca-c47ae728c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8f655a82-77c8-4bed-aa06-2d6da16f9230" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_66a39ae0-b65b-4351-9cca-c47ae728c23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8635efd1-64e6-487e-b4e0-3111ea697a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8f655a82-77c8-4bed-aa06-2d6da16f9230" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8635efd1-64e6-487e-b4e0-3111ea697a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5807ee35-eae5-4ba5-ad9d-8ed49eb75633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8f655a82-77c8-4bed-aa06-2d6da16f9230" xlink:to="loc_us-gaap_LiabilitiesCurrent_5807ee35-eae5-4ba5-ad9d-8ed49eb75633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7c3588c9-324d-4464-a50f-3b29f5d74547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7c3588c9-324d-4464-a50f-3b29f5d74547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cde5ab6e-5fe2-42ff-afbf-d98a1417cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cde5ab6e-5fe2-42ff-afbf-d98a1417cec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_a7116cbe-971a-4c75-9e0b-49844a03c90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_a7116cbe-971a-4c75-9e0b-49844a03c90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_233729fd-7b99-466e-af18-63bbd595372a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_233729fd-7b99-466e-af18-63bbd595372a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_30f6739f-486e-4fea-86a5-356cbda0ced4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_30f6739f-486e-4fea-86a5-356cbda0ced4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_30f735f4-dc36-4a36-9ae6-946988586384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4d0fb3-e995-4d63-9feb-fa9931c31c68" xlink:to="loc_us-gaap_AccountsPayableCurrent_30f735f4-dc36-4a36-9ae6-946988586384" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ed4f262-fc9c-43c2-9438-77723128e02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6ab1fbe7-3d5f-43cc-94dd-79b6ff009db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ed4f262-fc9c-43c2-9438-77723128e02b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6ab1fbe7-3d5f-43cc-94dd-79b6ff009db6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a0a36df9-d07d-4271-b97d-383a60f43058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ed4f262-fc9c-43c2-9438-77723128e02b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a0a36df9-d07d-4271-b97d-383a60f43058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2fb1c43f-b3bb-4d8a-944f-a6ec8641d446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ed4f262-fc9c-43c2-9438-77723128e02b" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2fb1c43f-b3bb-4d8a-944f-a6ec8641d446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92ece29c-4fd7-4f69-9356-2ae63aee4460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_790276cf-5659-4a99-a4f4-6406e38f95f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92ece29c-4fd7-4f69-9356-2ae63aee4460" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_790276cf-5659-4a99-a4f4-6406e38f95f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3f064c75-e0a6-43b4-b405-472c8f5837a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92ece29c-4fd7-4f69-9356-2ae63aee4460" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3f064c75-e0a6-43b4-b405-472c8f5837a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_197e44a2-42ea-48ad-a119-5ac9c8263c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92ece29c-4fd7-4f69-9356-2ae63aee4460" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_197e44a2-42ea-48ad-a119-5ac9c8263c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ed395bb-7932-4c24-998a-8296994443fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae337ee7-863c-4005-bd24-05b4ab1c9381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ed395bb-7932-4c24-998a-8296994443fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae337ee7-863c-4005-bd24-05b4ab1c9381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42786e08-c743-40e6-9615-d8ffbb1998ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ed395bb-7932-4c24-998a-8296994443fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_42786e08-c743-40e6-9615-d8ffbb1998ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4956bdd-51c9-41d8-9830-09e8dd99e968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ed395bb-7932-4c24-998a-8296994443fa" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4956bdd-51c9-41d8-9830-09e8dd99e968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef3a12e4-7dc1-423e-9d14-509d74aec30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ed395bb-7932-4c24-998a-8296994443fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef3a12e4-7dc1-423e-9d14-509d74aec30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_72be9d79-04ec-4b5d-be49-118739125ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_DepreciationAndAmortization_72be9d79-04ec-4b5d-be49-118739125ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a54949a-b7c1-4e4a-b1b5-0ef5ee1c28b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a54949a-b7c1-4e4a-b1b5-0ef5ee1c28b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_06edd3f4-38a1-4d2d-aba4-3bf86fb0d27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_06edd3f4-38a1-4d2d-aba4-3bf86fb0d27e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1a4f5549-69c0-4d3e-8c07-0f956c5d5ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_ShareBasedCompensation_1a4f5549-69c0-4d3e-8c07-0f956c5d5ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_158d4ee3-afa8-447f-9887-fb90ebca4840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_158d4ee3-afa8-447f-9887-fb90ebca4840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff_3eb56f8e-1aca-4ffe-96a2-752641d76229" xlink:href="nvax-20220630.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_nvax_OperatingAndFinanceLeaseWriteOff_3eb56f8e-1aca-4ffe-96a2-752641d76229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5b8ecbb0-61e2-4a88-b0eb-45b55e888cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5b8ecbb0-61e2-4a88-b0eb-45b55e888cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34a9e1c3-025f-4375-a749-a26e2de056cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_NetIncomeLoss_34a9e1c3-025f-4375-a749-a26e2de056cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6549a625-46f9-4b37-ad68-ad98e19755ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6549a625-46f9-4b37-ad68-ad98e19755ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_7e71631c-260a-482e-8914-510fde2b17bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a19e0ca8-41cf-4bd5-bc87-77d7ef4cfe28" xlink:to="loc_us-gaap_InventoryWriteDown_7e71631c-260a-482e-8914-510fde2b17bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#CashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48eb15b4-c392-4615-88c1-f3525a6dbbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_47d3b9c5-5e45-49e5-bfc2-6929255ea3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48eb15b4-c392-4615-88c1-f3525a6dbbe5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_47d3b9c5-5e45-49e5-bfc2-6929255ea3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d0d54ff8-a605-43c4-a9a4-ddd1d30fdc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48eb15b4-c392-4615-88c1-f3525a6dbbe5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d0d54ff8-a605-43c4-a9a4-ddd1d30fdc8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b6fa0ac-ca3f-41af-9db1-8fbb203e2e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48eb15b4-c392-4615-88c1-f3525a6dbbe5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b6fa0ac-ca3f-41af-9db1-8fbb203e2e9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4916c1d6-2b36-4e6c-900a-5325dd765e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_cfb165c2-3299-408c-b72a-88e249507e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4916c1d6-2b36-4e6c-900a-5325dd765e40" xlink:to="loc_us-gaap_InventoryRawMaterials_cfb165c2-3299-408c-b72a-88e249507e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_329e4b4c-7c8f-40f6-a116-f18974743031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4916c1d6-2b36-4e6c-900a-5325dd765e40" xlink:to="loc_us-gaap_InventoryWorkInProcess_329e4b4c-7c8f-40f6-a116-f18974743031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_52fa5100-7550-43b3-9ee3-a993287f8b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4916c1d6-2b36-4e6c-900a-5325dd765e40" xlink:to="loc_us-gaap_InventoryFinishedGoods_52fa5100-7550-43b3-9ee3-a993287f8b24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44e3e09d-4325-4c61-baae-ec754fdbcead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_35663bc4-7235-48b7-a3b7-c332056db956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44e3e09d-4325-4c61-baae-ec754fdbcead" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_35663bc4-7235-48b7-a3b7-c332056db956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1da8cfca-2831-421d-a601-3e3531df34fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_44e3e09d-4325-4c61-baae-ec754fdbcead" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1da8cfca-2831-421d-a601-3e3531df34fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/DebtNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#DebtNotesPayableDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/DebtNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_a2f8d137-75c3-4528-a5fc-34170eb82070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7933ba1a-2bbf-4abc-b11b-5f49f59dd525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayable_a2f8d137-75c3-4528-a5fc-34170eb82070" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7933ba1a-2bbf-4abc-b11b-5f49f59dd525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_efb9817e-0fe5-4759-a37e-b87252d1b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayable_a2f8d137-75c3-4528-a5fc-34170eb82070" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_efb9817e-0fe5-4759-a37e-b87252d1b18b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#DebtInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_059fe748-c41e-49c7-87fe-ce232458641f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d8cea08b-f54f-4fde-8e23-e6523c9f13fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_059fe748-c41e-49c7-87fe-ce232458641f" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d8cea08b-f54f-4fde-8e23-e6523c9f13fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_006dbeb8-2778-4ab2-8a7e-81ee0b81cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_059fe748-c41e-49c7-87fe-ce232458641f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_006dbeb8-2778-4ab2-8a7e-81ee0b81cfda" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>nvax-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b8f7f396-6255-4acd-a261-8fc9092ca526,g:e7b36f81-b504-4b3e-b499-0ac259afcdda-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="id7246585c773457493873b7885e9c56b_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0dc1cebd-8e66-4bf5-9926-3c618fd43c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_RevenuesAbstract_0dc1cebd-8e66-4bf5-9926-3c618fd43c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3766c2d1-87a9-4b8f-b4b0-c03316d132d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0dc1cebd-8e66-4bf5-9926-3c618fd43c53" xlink:to="loc_us-gaap_Revenues_3766c2d1-87a9-4b8f-b4b0-c03316d132d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_efab74c7-34e7-4d96-ac5f-cba6c00c0a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_CostOfRevenue_efab74c7-34e7-4d96-ac5f-cba6c00c0a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6b15d1ed-faaa-4e58-aac1-9ad661f837a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6b15d1ed-faaa-4e58-aac1-9ad661f837a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ddcc3d0d-6823-4d9d-bd6c-fc0d7f0a37de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ddcc3d0d-6823-4d9d-bd6c-fc0d7f0a37de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cf1f7e47-7870-42be-be6a-9c89ca9e41e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_CostsAndExpenses_cf1f7e47-7870-42be-be6a-9c89ca9e41e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_248291a7-bce0-4712-a549-8e32263722a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_OperatingIncomeLoss_248291a7-bce0-4712-a549-8e32263722a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9756621-6964-4587-80f9-abffc040bee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:to="loc_us-gaap_InterestExpense_b9756621-6964-4587-80f9-abffc040bee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5db2c905-3d9b-4e1e-9863-c8e92eb3bea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5db2c905-3d9b-4e1e-9863-c8e92eb3bea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d8a938a-0af8-4fd8-b98e-12a3c6d4efff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d8a938a-0af8-4fd8-b98e-12a3c6d4efff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50ee0860-39bd-46a3-89bb-e66b9eb88ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50ee0860-39bd-46a3-89bb-e66b9eb88ee7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e736582b-79e0-4773-9ded-9913fb2b75e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_NetIncomeLoss_e736582b-79e0-4773-9ded-9913fb2b75e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b663023d-d9dd-4c85-ae24-3d96c675e8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b663023d-d9dd-4c85-ae24-3d96c675e8aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e64fd268-961b-4f67-ba4b-0f5a1229cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b663023d-d9dd-4c85-ae24-3d96c675e8aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_e64fd268-961b-4f67-ba4b-0f5a1229cf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8b07d523-159d-4811-a32d-423a23ea1667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8b07d523-159d-4811-a32d-423a23ea1667" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e90fe42e-d518-4e11-8112-bf13ae018027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8b07d523-159d-4811-a32d-423a23ea1667" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e90fe42e-d518-4e11-8112-bf13ae018027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:to="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_999e34d0-d993-45b1-99e5-6cc81fe3d7da_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:to="loc_srt_ProductsAndServicesDomain_999e34d0-d993-45b1-99e5-6cc81fe3d7da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:to="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4d3b3137-9880-4594-accc-24911c9fe49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:to="loc_us-gaap_ProductMember_4d3b3137-9880-4594-accc-24911c9fe49f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6a4106f2-be91-4d82-b39b-acaa2d2a9b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:to="loc_us-gaap_GrantMember_6a4106f2-be91-4d82-b39b-acaa2d2a9b33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember_75926167-1036-49dd-9381-6c192daecd94" xlink:href="nvax-20220630.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:to="loc_nvax_RoyaltiesAndOtherMember_75926167-1036-49dd-9381-6c192daecd94" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i4e481698a12e4336987b2ad1b697aee3_CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_350a2457-b0c9-4b63-b91c-77fe9bdd2616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_350a2457-b0c9-4b63-b91c-77fe9bdd2616" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_169bcba0-fff4-45a7-a591-e5e388b7bcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_SharesIssued_169bcba0-fff4-45a7-a591-e5e388b7bcd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70947aa4-a598-4700-8c4f-b8fbe896a56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockholdersEquity_70947aa4-a598-4700-8c4f-b8fbe896a56d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67f7cd8b-ee3c-4565-a277-57f065e678c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67f7cd8b-ee3c-4565-a277-57f065e678c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_100de8cf-08bf-47aa-872a-fa3e37dc1744" xlink:href="nvax-20220630.xsd#nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_100de8cf-08bf-47aa-872a-fa3e37dc1744" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_5393987e-c40f-4b53-a47d-352b6a4f6a2c" xlink:href="nvax-20220630.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_5393987e-c40f-4b53-a47d-352b6a4f6a2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9862023a-a724-4f28-b7e3-1db1516a7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9862023a-a724-4f28-b7e3-1db1516a7bf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6616e866-c47f-4e07-b4d7-da65bb2aa10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6616e866-c47f-4e07-b4d7-da65bb2aa10c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1f369125-b9b9-44f8-b54a-16db174b73ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1f369125-b9b9-44f8-b54a-16db174b73ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4b9d6207-a7a0-46aa-b057-827f1ac1626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4b9d6207-a7a0-46aa-b057-827f1ac1626b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_733200de-bc05-4799-b359-91730e654904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_NetIncomeLoss_733200de-bc05-4799-b359-91730e654904" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b479c8c3-9b0b-497d-9e88-1f08ff52d531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c1f0572-4960-42ed-acac-ab157e56fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_350a2457-b0c9-4b63-b91c-77fe9bdd2616" xlink:to="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6d0cac0-1b43-4066-9550-68c49291b34a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:to="loc_us-gaap_EquityComponentDomain_e6d0cac0-1b43-4066-9550-68c49291b34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:to="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2d4666c1-0691-4fd2-ade2-e338f38d4e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_CommonStockMember_2d4666c1-0691-4fd2-ade2-e338f38d4e55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_84d6bb50-01e3-4b59-9238-5f2d401de382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_84d6bb50-01e3-4b59-9238-5f2d401de382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d2f70ce1-b701-4b51-8793-47bcff98b6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_RetainedEarningsMember_d2f70ce1-b701-4b51-8793-47bcff98b6f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2557e1d5-637d-4a09-9c20-45afd1b51361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_TreasuryStockMember_2557e1d5-637d-4a09-9c20-45afd1b51361" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c94fdaa8-54a6-4ac2-95d2-e525e58c826a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c94fdaa8-54a6-4ac2-95d2-e525e58c826a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended" id="ida8e4444441c47d4921be33b1866bc4f_RevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_a89fbf31-ef58-4b83-acd4-fc5a2f71925a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_BilledContractReceivables_a89fbf31-ef58-4b83-acd4-fc5a2f71925a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_12df06b5-426a-418f-b653-550d3056b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_UnbilledContractsReceivable_12df06b5-426a-418f-b653-550d3056b60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3dee1e32-a33f-465e-848e-629059e6eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3dee1e32-a33f-465e-848e-629059e6eb6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_42f7d2c9-a9aa-42e7-8282-021e53d53392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_42f7d2c9-a9aa-42e7-8282-021e53d53392" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_c6e42071-81ba-48c3-8ab6-f682db953f9e" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_c6e42071-81ba-48c3-8ab6-f682db953f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_d1df7ed0-b8c3-4f7f-b40a-00e84340566c" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_d1df7ed0-b8c3-4f7f-b40a-00e84340566c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_762ec15f-1f23-4e8f-a111-0b736cdd6060" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_762ec15f-1f23-4e8f-a111-0b736cdd6060" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9f25fe13-e44a-4072-816f-b018c7e67807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_Revenues_9f25fe13-e44a-4072-816f-b018c7e67807" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0c3f4a3d-553c-4d5f-b09c-4a54fbd2bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0c3f4a3d-553c-4d5f-b09c-4a54fbd2bb36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesRemaining_cffcc27a-15d9-419b-b6a7-0f9109eccda6" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesRemaining_cffcc27a-15d9-419b-b6a7-0f9109eccda6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_3ba8b2cf-f2c5-4047-b6ff-55174ba8bd6d" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_3ba8b2cf-f2c5-4047-b6ff-55174ba8bd6d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_9956a5d8-c1e5-4416-b4ec-3d56b94cf074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_9956a5d8-c1e5-4416-b4ec-3d56b94cf074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd30011f-feb9-4101-ba9f-7fcd939d44cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:to="loc_srt_ProductsAndServicesDomain_fd30011f-feb9-4101-ba9f-7fcd939d44cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:to="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_3cc86f89-fa92-4f46-b3a2-8f04b3b17f4d" xlink:href="nvax-20220630.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_3cc86f89-fa92-4f46-b3a2-8f04b3b17f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8bba8bb1-b140-440c-b29c-10d6dece6f4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8bba8bb1-b140-440c-b29c-10d6dece6f4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_ed7890b7-e6d9-4fc1-8746-48d116981c5f" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_USGovernmentPartnershipMember_ed7890b7-e6d9-4fc1-8746-48d116981c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_01bbf3dc-78d4-4198-ab21-67c87e3c7bd8" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_01bbf3dc-78d4-4198-ab21-67c87e3c7bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ba174110-de92-4158-82a1-7140ae8e1d58" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ba174110-de92-4158-82a1-7140ae8e1d58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_d88f9fb6-aef1-469c-9efb-fbf6b91d85cc" xlink:href="nvax-20220630.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_EuropeanCommissionsECMember_d88f9fb6-aef1-469c-9efb-fbf6b91d85cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_e93c8da6-321f-47ff-baa6-174c6fad2215_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_e93c8da6-321f-47ff-baa6-174c6fad2215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_30daff77-b677-4a1b-a656-109c71de1336" xlink:href="nvax-20220630.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_30daff77-b677-4a1b-a656-109c71de1336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4436aa4c-818a-49cd-a3fe-6e80099a9d18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4436aa4c-818a-49cd-a3fe-6e80099a9d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_20b66ffc-4ef1-4192-9d0b-58371cd1e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:to="loc_us-gaap_SubsequentEventMember_20b66ffc-4ef1-4192-9d0b-58371cd1e6b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad095ceb-d008-4d1f-aa11-15788bd09a7c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:to="loc_srt_RangeMember_ad095ceb-d008-4d1f-aa11-15788bd09a7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:to="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3ce2874-5dbc-49a1-a86a-1eaddbf282ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:to="loc_srt_MinimumMember_d3ce2874-5dbc-49a1-a86a-1eaddbf282ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f98386ef-e9e0-43f0-b4dd-a534355a7e51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:to="loc_srt_MaximumMember_f98386ef-e9e0-43f0-b4dd-a534355a7e51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended" id="i57e3471312fd4858910d50c5ffdfb3e2_RevenueAdditionalInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_a89fbf31-ef58-4b83-acd4-fc5a2f71925a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_BilledContractReceivables_a89fbf31-ef58-4b83-acd4-fc5a2f71925a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_12df06b5-426a-418f-b653-550d3056b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_UnbilledContractsReceivable_12df06b5-426a-418f-b653-550d3056b60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3dee1e32-a33f-465e-848e-629059e6eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3dee1e32-a33f-465e-848e-629059e6eb6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_42f7d2c9-a9aa-42e7-8282-021e53d53392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_42f7d2c9-a9aa-42e7-8282-021e53d53392" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_c6e42071-81ba-48c3-8ab6-f682db953f9e" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_c6e42071-81ba-48c3-8ab6-f682db953f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_d1df7ed0-b8c3-4f7f-b40a-00e84340566c" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_d1df7ed0-b8c3-4f7f-b40a-00e84340566c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_762ec15f-1f23-4e8f-a111-0b736cdd6060" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_762ec15f-1f23-4e8f-a111-0b736cdd6060" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9f25fe13-e44a-4072-816f-b018c7e67807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_Revenues_9f25fe13-e44a-4072-816f-b018c7e67807" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0c3f4a3d-553c-4d5f-b09c-4a54fbd2bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0c3f4a3d-553c-4d5f-b09c-4a54fbd2bb36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesRemaining_cffcc27a-15d9-419b-b6a7-0f9109eccda6" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesRemaining_cffcc27a-15d9-419b-b6a7-0f9109eccda6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_3ba8b2cf-f2c5-4047-b6ff-55174ba8bd6d" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_3ba8b2cf-f2c5-4047-b6ff-55174ba8bd6d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd30011f-feb9-4101-ba9f-7fcd939d44cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:to="loc_srt_ProductsAndServicesDomain_fd30011f-feb9-4101-ba9f-7fcd939d44cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:to="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_3cc86f89-fa92-4f46-b3a2-8f04b3b17f4d" xlink:href="nvax-20220630.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_3cc86f89-fa92-4f46-b3a2-8f04b3b17f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8bba8bb1-b140-440c-b29c-10d6dece6f4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8bba8bb1-b140-440c-b29c-10d6dece6f4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_ed7890b7-e6d9-4fc1-8746-48d116981c5f" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_USGovernmentPartnershipMember_ed7890b7-e6d9-4fc1-8746-48d116981c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_01bbf3dc-78d4-4198-ab21-67c87e3c7bd8" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_01bbf3dc-78d4-4198-ab21-67c87e3c7bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ba174110-de92-4158-82a1-7140ae8e1d58" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ba174110-de92-4158-82a1-7140ae8e1d58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_d88f9fb6-aef1-469c-9efb-fbf6b91d85cc" xlink:href="nvax-20220630.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_EuropeanCommissionsECMember_d88f9fb6-aef1-469c-9efb-fbf6b91d85cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_e93c8da6-321f-47ff-baa6-174c6fad2215_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_e93c8da6-321f-47ff-baa6-174c6fad2215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_30daff77-b677-4a1b-a656-109c71de1336" xlink:href="nvax-20220630.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_30daff77-b677-4a1b-a656-109c71de1336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4436aa4c-818a-49cd-a3fe-6e80099a9d18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4436aa4c-818a-49cd-a3fe-6e80099a9d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_20b66ffc-4ef1-4192-9d0b-58371cd1e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:to="loc_us-gaap_SubsequentEventMember_20b66ffc-4ef1-4192-9d0b-58371cd1e6b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad095ceb-d008-4d1f-aa11-15788bd09a7c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:to="loc_srt_RangeMember_ad095ceb-d008-4d1f-aa11-15788bd09a7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:to="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3ce2874-5dbc-49a1-a86a-1eaddbf282ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:to="loc_srt_MinimumMember_d3ce2874-5dbc-49a1-a86a-1eaddbf282ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f98386ef-e9e0-43f0-b4dd-a534355a7e51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:to="loc_srt_MaximumMember_f98386ef-e9e0-43f0-b4dd-a534355a7e51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueScheduleofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofRevenueDetails" xlink:type="extended" id="i3719a74580024f17b54feff24c99915a_RevenueScheduleofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6e1a84a5-8ddc-4f7a-ad9d-680e60c6ec9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_60536a7f-e2b6-4487-a4a9-888e97dd0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6e1a84a5-8ddc-4f7a-ad9d-680e60c6ec9f" xlink:to="loc_us-gaap_Revenues_60536a7f-e2b6-4487-a4a9-888e97dd0782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6e1a84a5-8ddc-4f7a-ad9d-680e60c6ec9f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:to="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:to="loc_srt_ProductsAndServicesDomain_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2f3f4c8-11ee-475b-9283-cc9a5d4e2e5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:to="loc_srt_ProductsAndServicesDomain_a2f3f4c8-11ee-475b-9283-cc9a5d4e2e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0a959ee1-1036-440a-938c-fcfbdcb5b460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a2f3f4c8-11ee-475b-9283-cc9a5d4e2e5a" xlink:to="loc_us-gaap_GrantMember_0a959ee1-1036-440a-938c-fcfbdcb5b460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41ffc2e2-27b8-4dcc-857b-ff214c2be877_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41ffc2e2-27b8-4dcc-857b-ff214c2be877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_9f32cc08-d5ce-4870-a4e7-3553bc41111a" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_USGovernmentPartnershipMember_9f32cc08-d5ce-4870-a4e7-3553bc41111a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember_e08b702c-ad2b-4a1b-a3ee-1550458ec8b4" xlink:href="nvax-20220630.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_USDepartmentOfDefenseDoDContractMember_e08b702c-ad2b-4a1b-a3ee-1550458ec8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_50e3d503-9e7a-4534-8f6b-5985f37e2315" xlink:href="nvax-20220630.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_50e3d503-9e7a-4534-8f6b-5985f37e2315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BillMelindaGatesFoundationMember_d80ad9cd-1157-475a-a6bf-b7b3539db107" xlink:href="nvax-20220630.xsd#nvax_BillMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_BillMelindaGatesFoundationMember_d80ad9cd-1157-475a-a6bf-b7b3539db107" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#CollaborationLicenseandSupplyAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="extended" id="i2023715432ed463593d5838230d4656b_CollaborationLicenseandSupplyAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdafea30-7002-4296-86ed-3de319df5f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PotentialFutureMilestonePayments_700e4566-30bf-4032-9621-952496424968" xlink:href="nvax-20220630.xsd#nvax_PotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdafea30-7002-4296-86ed-3de319df5f5c" xlink:to="loc_nvax_PotentialFutureMilestonePayments_700e4566-30bf-4032-9621-952496424968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdafea30-7002-4296-86ed-3de319df5f5c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b8b1176-dbfe-4660-9d8f-b872deb1558a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b8b1176-dbfe-4660-9d8f-b872deb1558a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_306542bb-e9e7-4850-a813-d8ae5e01cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_306542bb-e9e7-4850-a813-d8ae5e01cc77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_66e086b1-6aa8-4641-aa01-aeb076ee5082" xlink:href="nvax-20220630.xsd#nvax_TakedaArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_306542bb-e9e7-4850-a813-d8ae5e01cc77" xlink:to="loc_nvax_TakedaArrangementMember_66e086b1-6aa8-4641-aa01-aeb076ee5082" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="idc3034e987a145f2b7ddf16c3b625ed6_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b5c1c0aa-8bb0-4204-94f4-75bd50318d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b5c1c0aa-8bb0-4204-94f4-75bd50318d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_ef3d11af-6c9a-45e3-a5ec-5e165774d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b5c1c0aa-8bb0-4204-94f4-75bd50318d5c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_ef3d11af-6c9a-45e3-a5ec-5e165774d51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1420dcc1-5b2d-4885-a735-e31fc761b79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1420dcc1-5b2d-4885-a735-e31fc761b79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_c06bd265-602b-468b-973a-2541b6bb4c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1420dcc1-5b2d-4885-a735-e31fc761b79f" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_c06bd265-602b-468b-973a-2541b6bb4c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc74b28a-c0a5-420f-8833-92603101f6d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc74b28a-c0a5-420f-8833-92603101f6d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2f823466-89c4-4977-aee8-abb8cfb5f275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2f823466-89c4-4977-aee8-abb8cfb5f275" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56778f21-3486-45aa-8128-a3d1f25fce01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56778f21-3486-45aa-8128-a3d1f25fce01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9802701a-1ec8-40d5-879d-b7bb1648e318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9802701a-1ec8-40d5-879d-b7bb1648e318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_50df47a1-0257-4f10-820f-e5b546291758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_50df47a1-0257-4f10-820f-e5b546291758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a791b4f0-50c3-4c10-a6aa-7b8c9721f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a791b4f0-50c3-4c10-a6aa-7b8c9721f87d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentBackedSecuritiesMember_820b03d9-4aba-44b6-b944-a9e2946b6c91" xlink:href="nvax-20220630.xsd#nvax_GovernmentBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:to="loc_nvax_GovernmentBackedSecuritiesMember_820b03d9-4aba-44b6-b944-a9e2946b6c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ae083ce-2cd8-492b-97cf-ca13fadacc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ae083ce-2cd8-492b-97cf-ca13fadacc53" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="ice6463768a3d443c87189eeb9fa9a34a_IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1fc7424a-9679-4974-85ba-9ad35d14b9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1fc7424a-9679-4974-85ba-9ad35d14b9da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_237e7ae9-706e-4eda-884f-e3b162596156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_237e7ae9-706e-4eda-884f-e3b162596156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fdbbaead-ac79-498c-9e3f-d7ec65db9831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fdbbaead-ac79-498c-9e3f-d7ec65db9831" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_869600de-513c-4da9-b590-b34529f421d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_869600de-513c-4da9-b590-b34529f421d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80713a3e-cefd-49ff-8e33-c48c0932ac59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80713a3e-cefd-49ff-8e33-c48c0932ac59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProprietaryAdjuvantTechnologyMember_dd6aa588-e038-4326-9967-1e3a7eaa2fb1" xlink:href="nvax-20220630.xsd#nvax_ProprietaryAdjuvantTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:to="loc_nvax_ProprietaryAdjuvantTechnologyMember_dd6aa588-e038-4326-9967-1e3a7eaa2fb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementsMember_c6056f2a-0add-44e0-8eae-fe669f8babeb" xlink:href="nvax-20220630.xsd#nvax_CollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:to="loc_nvax_CollaborationAgreementsMember_c6056f2a-0add-44e0-8eae-fe669f8babeb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LeasesDetails" xlink:type="extended" id="id45a21b96ce64c7ba8841010b9dadb01_LeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c8aa1222-7ae3-46ac-8ede-d49a5ad3f937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c8aa1222-7ae3-46ac-8ede-d49a5ad3f937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_ba11669a-99e7-4837-9c8d-62f978f3722a" xlink:href="nvax-20220630.xsd#nvax_LongTermSupplyAgreementIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_ba11669a-99e7-4837-9c8d-62f978f3722a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_59b60fc1-d00a-464d-be1e-fbfcf9338dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_ShortTermLeaseCost_59b60fc1-d00a-464d-be1e-fbfcf9338dc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a700adf0-7d4d-42f8-9375-9abd71cbfb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_OperatingLeaseExpense_a700adf0-7d4d-42f8-9375-9abd71cbfb68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_713f633b-bfba-46c8-a559-90f6b99989b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_713f633b-bfba-46c8-a559-90f6b99989b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet_5208933b-66c9-4864-8bb3-eac5b820eebf" xlink:href="nvax-20220630.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_nvax_FacilityNumberOfSquareFeet_5208933b-66c9-4864-8bb3-eac5b820eebf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b84a9b74-7440-42b6-8268-610fcc3f0f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b84a9b74-7440-42b6-8268-610fcc3f0f04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_35c3e0e3-5a5e-47d7-911d-ceb6b8eb7253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_35c3e0e3-5a5e-47d7-911d-ceb6b8eb7253" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:to="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0fb5953-54bf-4f65-ab8f-e2f41e027447_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0fb5953-54bf-4f65-ab8f-e2f41e027447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27b6f8d3-f59e-4391-a2d6-11d1ff3f1bdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27b6f8d3-f59e-4391-a2d6-11d1ff3f1bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700Q0AgreementMember_f03fbff5-c338-4287-8e77-c5d42b9f2ceb" xlink:href="nvax-20220630.xsd#nvax_A700Q0AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27b6f8d3-f59e-4391-a2d6-11d1ff3f1bdf" xlink:to="loc_nvax_A700Q0AgreementMember_f03fbff5-c338-4287-8e77-c5d42b9f2ceb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockholdersEquityDeficitDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockholdersEquityDeficitDetails" xlink:type="extended" id="i7d953bd95bf74637aa626435cd6a0f78_StockholdersEquityDeficitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce900f65-78e4-4627-a11e-f79180f309e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce900f65-78e4-4627-a11e-f79180f309e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13e98542-74ab-45f1-9ff3-a5b176c425b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13e98542-74ab-45f1-9ff3-a5b176c425b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_ca0ff74e-4611-4ede-bd71-7900ac5e3428" xlink:href="nvax-20220630.xsd#nvax_ShelfRegistrationStatementRemainingUnissuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_ca0ff74e-4611-4ede-bd71-7900ac5e3428" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbddab75-97f1-4c88-a1f6-1139b2734745_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:to="loc_us-gaap_EquityComponentDomain_bbddab75-97f1-4c88-a1f6-1139b2734745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:to="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1dd5576f-469d-41a0-a938-764d4e8b1c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:to="loc_us-gaap_CommonStockMember_1dd5576f-469d-41a0-a938-764d4e8b1c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f93473a4-0b40-465f-a222-60da430d424c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f93473a4-0b40-465f-a222-60da430d424c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended" id="ia361587d2c724307a1a7130039aafe70_StockBasedCompensationStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0634b530-2b16-4f98-9004-2286d531de76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0634b530-2b16-4f98-9004-2286d531de76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ffe42f1d-3ca0-4435-abb9-bc0d9c10d7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ffe42f1d-3ca0-4435-abb9-bc0d9c10d7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8b89a685-5140-4e65-81b5-9bf9f90ea6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8b89a685-5140-4e65-81b5-9bf9f90ea6da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8ca57641-8bb0-4360-968d-f7b620bd30f3" xlink:href="nvax-20220630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8ca57641-8bb0-4360-968d-f7b620bd30f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5dd8a4b8-e20d-4672-814b-f706242f0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5dd8a4b8-e20d-4672-814b-f706242f0a03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8269ee5f-6611-4cf5-8b5d-6540c1f1acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8269ee5f-6611-4cf5-8b5d-6540c1f1acb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d0d6ae6-a14e-43e1-94de-56ad263e4f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d0d6ae6-a14e-43e1-94de-56ad263e4f3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_43101f02-0151-46bc-9736-303b426910f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_43101f02-0151-46bc-9736-303b426910f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60369e0d-c956-4ec5-a2d2-2aacf47fccd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60369e0d-c956-4ec5-a2d2-2aacf47fccd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7167468f-0070-43e3-98e4-f8881155128a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7167468f-0070-43e3-98e4-f8881155128a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_efe30073-efae-4405-8bae-5cbe6b684ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_efe30073-efae-4405-8bae-5cbe6b684ce0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8e8433ee-97a8-43c1-9005-15dbba14e728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8e8433ee-97a8-43c1-9005-15dbba14e728" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_bbe37efd-6da2-4165-b89f-542c2fbade9f" xlink:href="nvax-20220630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_bbe37efd-6da2-4165-b89f-542c2fbade9f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_226d6211-c257-497d-bf81-1b13eb42ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_075940b2-bb52-4ed3-a843-72f8e4fd665b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_075940b2-bb52-4ed3-a843-72f8e4fd665b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3d111e53-4883-4082-8bfa-2b7f60c5c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3d111e53-4883-4082-8bfa-2b7f60c5c2ad" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9f5ecc33-214b-4b05-a074-02f3109cb74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9f5ecc33-214b-4b05-a074-02f3109cb74e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47c96961-7913-4433-ae4d-fd1e45f29e57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:to="loc_us-gaap_PlanNameDomain_47c96961-7913-4433-ae4d-fd1e45f29e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_acde5732-7342-4c2a-8566-f7a6189a14b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:to="loc_us-gaap_PlanNameDomain_acde5732-7342-4c2a-8566-f7a6189a14b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_a629c5f5-6510-4c6e-9116-68fca87f0a8c" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_acde5732-7342-4c2a-8566-f7a6189a14b3" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_a629c5f5-6510-4c6e-9116-68fca87f0a8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbdbc74f-6c56-484c-9189-427d38b4f415_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:to="loc_srt_RangeMember_cbdbc74f-6c56-484c-9189-427d38b4f415_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:to="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c219e714-09c0-43e7-8a55-0c7ff249bb0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:to="loc_srt_MinimumMember_c219e714-09c0-43e7-8a55-0c7ff249bb0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60b200b7-f1e1-497e-a590-a0ef807df1c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:to="loc_srt_MaximumMember_60b200b7-f1e1-497e-a590-a0ef807df1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a94688e-1d46-4c77-a55b-52b8bae07f21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a94688e-1d46-4c77-a55b-52b8bae07f21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd044e2c-6764-487f-bca7-53c3e03c4e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd044e2c-6764-487f-bca7-53c3e03c4e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_58334340-da10-4f03-9955-c182990b49cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd044e2c-6764-487f-bca7-53c3e03c4e69" xlink:to="loc_us-gaap_EmployeeStockMember_58334340-da10-4f03-9955-c182990b49cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails" xlink:type="extended" id="i6a2e2056ba5a4e999aa491513b75c714_StockBasedCompensationCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_03e729f0-c44d-4366-be29-5915ff1970d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8f036d-f867-4f74-a925-ebaeb91aaf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_03e729f0-c44d-4366-be29-5915ff1970d7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8f036d-f867-4f74-a925-ebaeb91aaf15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_03e729f0-c44d-4366-be29-5915ff1970d7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d53eb1fa-97da-448d-b56c-c40b3628650c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d53eb1fa-97da-448d-b56c-c40b3628650c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4781480-44cb-46ed-909c-ae0fab5c9103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4781480-44cb-46ed-909c-ae0fab5c9103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9a617b7a-f9c4-4730-905a-5502bbfad3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9a617b7a-f9c4-4730-905a-5502bbfad3a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationStockOptionsandAppreciationRightsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails" xlink:type="extended" id="i4fe4233fc26645658fc7b0c9618ee14e_StockBasedCompensationStockOptionsandAppreciationRightsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9936ace7-3e99-430e-b1b6-6f9759af8b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9936ace7-3e99-430e-b1b6-6f9759af8b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2556517b-6e2c-46e0-b5a7-0feda86c01a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2556517b-6e2c-46e0-b5a7-0feda86c01a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e402c73-7714-4cec-a935-8d7f2683ae12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e402c73-7714-4cec-a935-8d7f2683ae12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a90dc5a8-2217-422e-b2c8-77c7fba364c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a90dc5a8-2217-422e-b2c8-77c7fba364c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd73f07-4397-45c6-817f-7f0716b2e718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1d1f43c-9c81-4c3e-ac2a-db1226d8f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1d1f43c-9c81-4c3e-ac2a-db1226d8f1e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16915a7e-54df-471b-ae65-8f8170ab2085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16915a7e-54df-471b-ae65-8f8170ab2085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17c06188-c304-4c9f-b0a9-501f1f55d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17c06188-c304-4c9f-b0a9-501f1f55d4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc6d0e72-d06b-4cc6-9e62-21078fc875a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc6d0e72-d06b-4cc6-9e62-21078fc875a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9cb14f8c-a46a-429a-81b8-3644dcba930a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9cb14f8c-a46a-429a-81b8-3644dcba930a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d1faf9b-fab5-4bae-91ad-83d7c59abcee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d1faf9b-fab5-4bae-91ad-83d7c59abcee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1e7b7a91-87af-458e-acf1-cb31a41601b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8131b168-26e9-43fc-a587-953ff04705ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8131b168-26e9-43fc-a587-953ff04705ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:to="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86642a7e-2f4e-4cfd-a88d-959b2732cec6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:to="loc_us-gaap_PlanNameDomain_86642a7e-2f4e-4cfd-a88d-959b2732cec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:to="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_be751e08-efa5-403b-b6bd-170c6b55b59a" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_be751e08-efa5-403b-b6bd-170c6b55b59a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_f871e166-52c0-4f5f-8ac2-b6c83e318658" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_f871e166-52c0-4f5f-8ac2-b6c83e318658" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="extended" id="id3c14276fa3c47ab9b6b5811ffd5facc_StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1770d4d7-5fa6-46a2-8bdf-4e93e27b3e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1770d4d7-5fa6-46a2-8bdf-4e93e27b3e2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18d5bbd-d38d-458d-ade6-ae5a3c423482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18d5bbd-d38d-458d-ade6-ae5a3c423482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0c4f3ca4-f63f-4c54-bfbc-0e3054d4ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0c4f3ca4-f63f-4c54-bfbc-0e3054d4ca95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_976705b7-f483-464f-8477-88f54501061d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_976705b7-f483-464f-8477-88f54501061d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_299ddb72-00de-4a2f-8489-bf2a536f5211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_299ddb72-00de-4a2f-8489-bf2a536f5211" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_82089dad-d415-4aa1-9113-44672c518530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_82089dad-d415-4aa1-9113-44672c518530" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d99ecfb0-a4c7-48fd-802a-2fd3ab3073a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d99ecfb0-a4c7-48fd-802a-2fd3ab3073a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a4789e6c-9713-42e0-9167-14d88b2022d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a4789e6c-9713-42e0-9167-14d88b2022d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1770d4d7-5fa6-46a2-8bdf-4e93e27b3e2e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:to="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9163c5cd-696d-481e-9f8f-7f8e54824507_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9163c5cd-696d-481e-9f8f-7f8e54824507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5881a7f7-a90f-4164-8f75-1a32b7a4773f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5881a7f7-a90f-4164-8f75-1a32b7a4773f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b9794a90-0a2e-4bff-b553-cd8a8ac54e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5881a7f7-a90f-4164-8f75-1a32b7a4773f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b9794a90-0a2e-4bff-b553-cd8a8ac54e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:to="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9b96d75-4bdc-42bd-a398-625013924e6e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:to="loc_srt_RangeMember_a9b96d75-4bdc-42bd-a398-625013924e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:to="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2100d2c6-e6bd-4107-813c-e535be7dc748" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:to="loc_srt_MinimumMember_2100d2c6-e6bd-4107-813c-e535be7dc748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9bb128f2-000f-47de-9f11-186631b4cb47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:to="loc_srt_MaximumMember_9bb128f2-000f-47de-9f11-186631b4cb47" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i7765c1f0cb0243fab984e1b4096091ee_StockBasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_add5b693-bddf-4dfa-9f81-ea68aac85684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_add5b693-bddf-4dfa-9f81-ea68aac85684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_632e6d1b-15d4-4efe-8199-3fa009258c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_632e6d1b-15d4-4efe-8199-3fa009258c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d1728c7c-5a7b-43bf-8637-ef47f2577fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d1728c7c-5a7b-43bf-8637-ef47f2577fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d8eef005-6014-4cca-99be-99f2b066955d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d8eef005-6014-4cca-99be-99f2b066955d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5913957-768a-4f8d-835d-b5b9af0196a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a975c593-4815-451b-ac20-8f417877036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a975c593-4815-451b-ac20-8f417877036e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31987949-6e5b-4cef-b4a9-30c8c3931066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31987949-6e5b-4cef-b4a9-30c8c3931066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae2e83f3-51d0-4e51-8bdd-87378ff84fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae2e83f3-51d0-4e51-8bdd-87378ff84fb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5bb2dbca-56e7-4afc-adab-6d97bdfc0e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5bb2dbca-56e7-4afc-adab-6d97bdfc0e38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_efc4a512-744b-404a-985b-311982d3d854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:to="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3da5024-edc7-4127-9c11-2fbd692aacb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3da5024-edc7-4127-9c11-2fbd692aacb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_603ebafb-117b-4e81-9fa2-742e4bbc254e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_603ebafb-117b-4e81-9fa2-742e4bbc254e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6ea4373-496a-4089-8ff1-4e8c27d51912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_603ebafb-117b-4e81-9fa2-742e4bbc254e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6ea4373-496a-4089-8ff1-4e8c27d51912" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i4ddbae0d0bfb42f3b8dfac7df66587ad_StockBasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b01afb4-fab5-40ea-9eed-70cfc067ee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b01afb4-fab5-40ea-9eed-70cfc067ee0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_803038e7-7670-403f-b28b-6c44f046bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_803038e7-7670-403f-b28b-6c44f046bc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_61e71bb2-2323-4a01-81fa-ae9ea584e673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_61e71bb2-2323-4a01-81fa-ae9ea584e673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ac4afe87-3022-4fdd-b2f2-55929cf58fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ac4afe87-3022-4fdd-b2f2-55929cf58fe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bbac0270-2469-47bb-a732-0eea02153446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bbac0270-2469-47bb-a732-0eea02153446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_51b518b4-cc3e-415d-aabd-cc57c1e7edb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_51b518b4-cc3e-415d-aabd-cc57c1e7edb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_30842713-d3b5-4910-b880-ff44dca61ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_30842713-d3b5-4910-b880-ff44dca61ac9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2429eab-87bc-452d-a3c5-5414b4b45821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2429eab-87bc-452d-a3c5-5414b4b45821" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b01afb4-fab5-40ea-9eed-70cfc067ee0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:to="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ed20080-b505-4abb-a644-a246f1062fee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ed20080-b505-4abb-a644-a246f1062fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67cec4e6-db80-4011-8d28-506c40d7231c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67cec4e6-db80-4011-8d28-506c40d7231c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c8cc91c5-92eb-49df-91f9-418ffe31bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67cec4e6-db80-4011-8d28-506c40d7231c" xlink:to="loc_us-gaap_EmployeeStockMember_c8cc91c5-92eb-49df-91f9-418ffe31bc67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:to="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_818ecff6-48c7-42d0-a178-1b2943fe1ff0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:to="loc_srt_RangeMember_818ecff6-48c7-42d0-a178-1b2943fe1ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:to="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e800e39d-da3b-4721-9796-363bc171954c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:to="loc_srt_MinimumMember_e800e39d-da3b-4721-9796-363bc171954c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a91e422-faad-4bd3-a357-e54e7df5db66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:to="loc_srt_MaximumMember_5a91e422-faad-4bd3-a357-e54e7df5db66" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="extended" id="i237eac5fee5947ceaf54ec662b88a505_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_6a98a875-ba4c-4496-b53d-84a6be2db3f7" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_6a98a875-ba4c-4496-b53d-84a6be2db3f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_79e7c303-9c1a-4989-9943-cd8e66b60873" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_79e7c303-9c1a-4989-9943-cd8e66b60873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_6ce968c8-e8db-4cd7-a9ac-cf0c715b2184" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_6ce968c8-e8db-4cd7-a9ac-cf0c715b2184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_5af85c7e-aa5c-408d-bcf4-38b40d054e04" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_5af85c7e-aa5c-408d-bcf4-38b40d054e04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_2c88c16c-200f-4785-829a-6048e13828cc" xlink:href="nvax-20220630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_2c88c16c-200f-4785-829a-6048e13828cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c76b191a-6e5e-408d-9f61-ac96a803f50f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c76b191a-6e5e-408d-9f61-ac96a803f50f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_96e4e433-8cb3-405b-b536-a21a4086a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_96e4e433-8cb3-405b-b536-a21a4086a5e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9cc288d8-696a-4e1e-86a3-33d5b064d1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_96e4e433-8cb3-405b-b536-a21a4086a5e6" xlink:to="loc_us-gaap_SubsequentEventMember_9cc288d8-696a-4e1e-86a3-33d5b064d1fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:to="loc_srt_RangeMember_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:to="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b273db60-4c36-47dd-8a6f-2e8b7b512c17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:to="loc_srt_MinimumMember_b273db60-4c36-47dd-8a6f-2e8b7b512c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e9858a5c-8130-40a6-8d06-29ff57fb24f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:to="loc_srt_MaximumMember_e9858a5c-8130-40a6-8d06-29ff57fb24f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c96e841-68dc-46c1-bf2f-11fc86c96158_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c96e841-68dc-46c1-bf2f-11fc86c96158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_21a64e26-155f-48cc-a01b-195760fdd189" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:to="loc_nvax_USGovernmentPartnershipMember_21a64e26-155f-48cc-a01b-195760fdd189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_65581678-957e-40e3-a047-259a14000ed7" xlink:href="nvax-20220630.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_65581678-957e-40e3-a047-259a14000ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_0cea937c-d0ca-4ded-a662-19e7dc0ab1bb" xlink:href="nvax-20220630.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:to="loc_nvax_EuropeanCommissionsECMember_0cea937c-d0ca-4ded-a662-19e7dc0ab1bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_d36a574f-4b88-47a5-8c18-2624876b9b2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_d36a574f-4b88-47a5-8c18-2624876b9b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_68139a5a-23cb-4d36-b2a7-66a3faabe40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_68139a5a-23cb-4d36-b2a7-66a3faabe40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e6b25ca6-fa1c-40bf-b29d-487b08efe310" xlink:href="nvax-20220630.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_68139a5a-23cb-4d36-b2a7-66a3faabe40c" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e6b25ca6-fa1c-40bf-b29d-487b08efe310" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>nvax-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b8f7f396-6255-4acd-a261-8fc9092ca526,g:e7b36f81-b504-4b3e-b499-0ac259afcdda-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_23b2c37b-c653-4df3-b79e-859126db42b1_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a26dfa61-2228-41e2-a15a-c3032e2908ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_549fbed7-40c5-4674-977b-60bc42e7e9ae_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_3865cfe5-36f3-4bf3-bc84-b2127d623703_terseLabel_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC")</link:label>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_label_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC") [Member]</link:label>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_documentation_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember" xlink:href="nvax-20220630.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EuropeanCommissionsECMember" xlink:to="lab_nvax_EuropeanCommissionsECMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_468841f2-81b8-4b4a-85c8-9c90033b5bdc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_504c9af0-5947-4170-b00f-9405b01cdcb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_0afa1756-9da3-4d25-b2a8-418d67187bbe_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_fd396441-625b-4eef-8adc-4c3a3f59b9c4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_85073c5d-f231-49b1-987d-e3bd67a58fda_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1e5feed6-652b-4bc2-b67d-63744d20ec09_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_c421d848-9bba-4132-8d8f-110fe72fbf6e_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest at 3.75%</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08400ed6-695f-428d-9784-e56797804fce_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e249b722-8801-4ced-8efb-0ced2dbd2322_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_32b951c6-3a15-479f-8155-acafa02ead6e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_efd7c08f-f6db-4494-bf38-50e2156442c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c70727c1-a813-4d62-855d-38f45d89365c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7505c431-2f10-4b96-8812-3479a2d7c5e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_36fe4653-377e-4a82-afdf-7889c041a126_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9f8592b6-7bde-4c30-8495-71ad43420531_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_233d6b53-0530-4913-8ec9-d7e2fd03df97_terseLabel_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets expensed, net of credits received</link:label>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_label_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Write-off</link:label>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_documentation_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Write-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff" xlink:href="nvax-20220630.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OperatingAndFinanceLeaseWriteOff" xlink:to="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_20b66a25-8c9e-46f9-9b44-8ef10f089a5c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5b722ea2-ab39-4358-90c2-c673fde2aa73_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_068b5e7a-88dd-4df4-b5e8-b7494e8879c3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e726171e-7f39-4019-bdb1-139ed30c1c2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8f4e4835-a9ee-4242-b304-1a6ff746a45b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_3919ff2b-07b5-41c7-8a5f-01c2a6f2ef5f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5533e008-c338-4fc4-885f-21418e27ed2e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f5f79a7f-c9eb-46fa-8c99-03d93c67ea58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a05160e5-25b3-4322-b39e-21be2dbab754_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ce1c0629-945f-4352-b282-3dbd96a477ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5cb28103-a4e2-4094-a649-1c262a0e6af3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_148fdc77-43ce-4ab4-a033-eaa52f8b7a39_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_cff754cd-5402-46e6-adcc-0e75b9324508_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProprietaryAdjuvantTechnologyMember_79d1eedd-3a61-44cb-b92f-97330897e80d_terseLabel_en-US" xlink:label="lab_nvax_ProprietaryAdjuvantTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary adjuvant technology</link:label>
    <link:label id="lab_nvax_ProprietaryAdjuvantTechnologyMember_label_en-US" xlink:label="lab_nvax_ProprietaryAdjuvantTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Adjuvant Technology [Member]</link:label>
    <link:label id="lab_nvax_ProprietaryAdjuvantTechnologyMember_documentation_en-US" xlink:label="lab_nvax_ProprietaryAdjuvantTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Adjuvant Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProprietaryAdjuvantTechnologyMember" xlink:href="nvax-20220630.xsd#nvax_ProprietaryAdjuvantTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProprietaryAdjuvantTechnologyMember" xlink:to="lab_nvax_ProprietaryAdjuvantTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_38e1e809-3396-4cd3-889c-621742e913bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_10528799-3e48-4b4f-ad93-b057141aa0a7_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase of shares each anniversary</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:href="nvax-20220630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_3cd8e342-8b78-4666-b80e-db203ec61ac0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3d062b8a-0097-4ba0-8c55-53172b5dd8e1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4cb0e82c-14fb-4566-824a-0b0b4c7a20b7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_78225559-889a-4c17-8af1-c5d59f4ec659_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_51d902ff-d5c6-48be-935a-9716f95a5e3d_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2005&#160;Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Five Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_123446d3-57b8-48ca-9feb-cb73a6706101_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#8203;Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_482cd511-d935-4985-ae4d-914893745094_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d9e2e50b-be17-45f6-a544-d17721fa64f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3ed7c328-d8ff-4e53-8483-27b3bbfff47e_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ca781584-5a1e-4e18-8fd8-401cffaf2e55_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_label_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture [Abstract]</link:label>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_documentation_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:href="nvax-20220630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:to="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_866fb8c0-4e85-4130-abb8-a6dc28e995ef_terseLabel_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation stock issued under incentive program</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued issued under incentive programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20220630.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0fb60fd5-e252-43e3-8d77-a9e6aee76d1a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277222a9-d244-491f-9936-af4a1c711ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c74defe9-0ae1-43b8-902c-f0eef1b3d5e4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e8612aaf-8a84-4a8d-bea0-5109c7e05722_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5c083dc9-c4f4-4102-b62e-f18b68ca4304_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares sold, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_32f4da03-175e-4559-acd6-ddadd4097fd1_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional purchase option, number of doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Doses Of Vaccine Candidate, Additional Purchase Option</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Doses Of Vaccine Candidate, Additional Purchase Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:to="lab_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_16a03669-a865-4f97-8f6b-2d23bb2e473f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a25fd2c0-2eba-4325-a349-7d254e496a84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f9a2fde8-34b8-4474-88d3-78d8dd5626fd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bebf1f7e-e750-47f4-b28e-8023b285c987_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_469187e3-d622-473c-9718-118edb4b5347_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_70710d5f-01df-4fa2-a861-0d76aecdc650_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cd130c5b-4116-4ebf-b4f5-e77c3236b9a2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74be2849-7fea-46d9-9023-89f8571156dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Unvested, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5c090abd-88af-41a6-8e79-0a511b445f61_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Unvested, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_712adfa1-2a9a-432d-bc39-0ed69fa88ecf_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b38da9de-1518-4246-8f59-02a43214df1c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_68cdff9c-4f11-42ff-a8a1-a92b6ce5e072_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_62856123-aa6e-433b-8613-03db9b80d2ea_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_047e27ad-4086-4022-96c1-230e70babf87_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_31a2ab1f-c12a-40a4-91f1-ef12e05de781_terseLabel_en-US" xlink:label="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unissued capital</link:label>
    <link:label id="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_label_en-US" xlink:label="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement Remaining Unissued Capital</link:label>
    <link:label id="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_documentation_en-US" xlink:label="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement Remaining Unissued Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:href="nvax-20220630.xsd#nvax_ShelfRegistrationStatementRemainingUnissuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:to="lab_nvax_ShelfRegistrationStatementRemainingUnissuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2c88bcd6-e6cc-4065-8f9d-ddd2ac0da4ef_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6aa4c3bd-8d46-4cfe-98ad-2bf5f4e41a0a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_98e85eb6-9354-4ff4-8b6e-7199ff1c305f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_462a7e79-1927-45f4-95ae-8236a3291724_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_77fd6171-cbc5-4f0a-a605-d4a12b3dbd3b_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:href="nvax-20220630.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:to="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3fad0538-af39-4059-abb1-ef030061f8c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fe6908c4-0199-45a2-8749-4efdf72b4036_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b3410636-2d7d-4784-93bf-f4ee791e70a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4a280c38-4e9d-44b0-a75f-bab4ed67e94a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueCurrentDeductions_e1d5f988-98b2-4a25-bab2-b8ac14338c21_negatedTerseLabel_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentDeductions_label_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current, Deductions</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentDeductions_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentDeductions" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueCurrentDeductions" xlink:to="lab_nvax_DeferredRevenueCurrentDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_92203a90-0d06-4533-bece-3d61f66e123f_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government partnership (&#8220;OWS&#8221;)</link:label>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_label_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Partnership [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentPartnershipMember" xlink:to="lab_nvax_USGovernmentPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_afab732d-5df5-4629-be05-a4db93bad54b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_ebfd9223-b167-434a-831a-e3be33cef945_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e9213a33-b175-4ddc-9940-3d6bd6eadf11_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_52c85ef9-3725-465a-b980-d2c6bbc62855_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b7bf5e0-0054-4b61-be91-5432e0dac139_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_cec2e266-0add-442c-a02c-f27c08f6a402_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4e616331-bce3-41cb-83af-c1c7b9c7d19b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f67ba1b8-9514-4979-b217-7051765b26e4_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense on Notes</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_aae58b0e-aba2-435e-9b70-54e464c65eaf_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6b845f05-019f-4f9c-a64b-a9cb2209d0a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_350d9bf9-03fb-4ea7-8443-99a32c4936c8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_907377b1-4884-4509-83da-ed1738d82b7d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_73f39f57-2c17-45db-8567-2157bd72fae6_terseLabel_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets from new lease agreements</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:href="nvax-20220630.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:to="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fe01de07-db28-4d9d-b665-c96377c10f91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Estimation of Fair Value of Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bce450-f76e-402d-854f-56c1860faefd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d3e9f52-0c69-4db7-9506-87eef8223d4b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_da7b6e57-cceb-4d2f-a617-7ffa39ff15cc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5f5c4608-ddd8-4345-8e79-c9b7b8106448_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_d1b5e14f-1ab3-4993-a99d-7633e351b532_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesRemaining_8e1a9259-b960-4967-ac54-e34ff686f092_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses, remaining</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesRemaining_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Remaining</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesRemaining_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesRemaining" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfDosesRemaining" xlink:to="lab_nvax_PurchaseAgreementNumberOfDosesRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_33491da0-7c9e-4b87-9a11-4f3d9483a045_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_adeba2d1-208f-40c3-89a7-092cd34a0dd5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be86e845-81c4-4f5d-a568-c019fa33d249_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e786ba3d-fae9-44f8-bc8d-64c49eb0274c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_A700Q0AgreementMember_9d33c2c8-44a4-4995-a7ea-a8700c80ad37_terseLabel_en-US" xlink:label="lab_nvax_A700Q0AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700Q0 Agreement</link:label>
    <link:label id="lab_nvax_A700Q0AgreementMember_label_en-US" xlink:label="lab_nvax_A700Q0AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700Q0 Agreement [Member]</link:label>
    <link:label id="lab_nvax_A700Q0AgreementMember_documentation_en-US" xlink:label="lab_nvax_A700Q0AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700Q0 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700Q0AgreementMember" xlink:href="nvax-20220630.xsd#nvax_A700Q0AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_A700Q0AgreementMember" xlink:to="lab_nvax_A700Q0AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_64def278-ca00-4552-b8dd-eff80e53c16a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4f4d1ed5-9a88-422c-91f1-6b57fdf872b8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4b5aea40-2b1c-4d80-8e55-7acd13f5d4c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3db8647e-aa3c-42fb-985f-9d2998ce129f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_4b620f72-d68c-4dda-9ffd-c8796b4f6f2b_terseLabel_en-US" xlink:label="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government Agreements, Grants and Licenses</link:label>
    <link:label id="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_label_en-US" xlink:label="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government Agreements, Grants and Licenses</link:label>
    <link:label id="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_documentation_en-US" xlink:label="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" xlink:href="nvax-20220630.xsd#nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" xlink:to="lab_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ReceivablesNetCurrentAdditions_efacd624-074b-475f-bbb5-1d7d26f39aeb_terseLabel_en-US" xlink:label="lab_nvax_ReceivablesNetCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_ReceivablesNetCurrentAdditions_label_en-US" xlink:label="lab_nvax_ReceivablesNetCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current, Additions</link:label>
    <link:label id="lab_nvax_ReceivablesNetCurrentAdditions_documentation_en-US" xlink:label="lab_nvax_ReceivablesNetCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ReceivablesNetCurrentAdditions" xlink:href="nvax-20220630.xsd#nvax_ReceivablesNetCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ReceivablesNetCurrentAdditions" xlink:to="lab_nvax_ReceivablesNetCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aefe451e-e9a5-457e-ac9f-a08ccf579001_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1969e3ed-be9e-4fca-a499-dc55765f522d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a8bfd22d-715b-4a15-a884-3a3836fa4947_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0d27d659-443b-4f3e-bc71-82e258f33433_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cf971abe-4480-4e4c-8218-73a3975ee47c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_label_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Abstract]</link:label>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_documentation_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract" xlink:href="nvax-20220630.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborativeArrangementAbstract" xlink:to="lab_nvax_CollaborativeArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e67b6f55-1eea-476b-9541-6701607f8d54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_ce0449f4-4c18-412c-8ab1-00ac27801e09_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_3e35c64d-45fa-4e4b-bcd3-507e1bbe30b0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for excess and obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_8eded0bb-f7f9-421a-be30-e682f9cda8cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f4e2976a-1b9e-4685-a38c-d566eedde4f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_09f2d4b9-65eb-4c86-9738-83d4b51150f1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1be29108-c0a3-4ddf-9122-55f564c588e9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2eb195d5-5764-42e4-812e-787d47211e4a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6cfb5395-33b1-4021-9f92-535c29545201_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c5e3148-5b57-4b5b-835a-860309a6d3a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5282185e-b6c0-4e73-94c2-94d3c1ea52d5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_f5ac32a7-9c5d-424f-a694-b13a0f08bfce_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_45f72798-d345-4869-b904-976e34b25528_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_32d75ce2-ab7f-45e3-afdf-90e840cee0c4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7be59df6-cb3f-49bc-bec7-2eec8d0a01bc_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_68fd0654-dd45-4bd7-b573-d47b3189ceb3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_616fb16f-6294-47e6-b26e-1017d6eec930_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_cb209697-81c0-4c5c-9620-224420c69272_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_452e570b-a24d-4363-864d-bcdf7b83ec7e_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bf71f587-3f35-418e-83af-ca80d1785226_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4cffa176-1e2a-462a-9a0e-cbbc65b4313a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a5ee4efe-992c-488e-ba1d-de41cbc1df86_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_da26f013-a2b0-4358-8a1c-f8e44a0139f1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_49d60336-5978-441a-a1ff-366c8d805e45_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_31c1538e-5797-495b-9954-31aeea00d419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a00908a9-902e-4835-9261-9c3faa74085e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest payments</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7ce46762-1753-4841-985a-2f998c44d562_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PotentialFutureMilestonePayments_fa9db2f6-15cc-4236-958b-1572bdaae6d1_terseLabel_en-US" xlink:label="lab_nvax_PotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_nvax_PotentialFutureMilestonePayments_label_en-US" xlink:label="lab_nvax_PotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments</link:label>
    <link:label id="lab_nvax_PotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_nvax_PotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PotentialFutureMilestonePayments" xlink:href="nvax-20220630.xsd#nvax_PotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PotentialFutureMilestonePayments" xlink:to="lab_nvax_PotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5a4478bd-dfeb-47c1-83a9-06ecd1dff3f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_1ccad03f-be26-416d-b66c-24458732ca28_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_bb550810-872c-442c-abb2-9616f303ca1a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_7e9d1cab-c508-4259-9f35-568739acd4f2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_874780bd-de33-4e28-a756-026058439eea_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f395d491-2c17-4967-8b49-c01b7842c97f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1077f24d-616c-4604-af39-b5c5fa08dcd4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c57818f1-0c1a-4e99-b396-8d5f07d664ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c6f13ee0-0dc6-4d97-a5d5-ba4bbdd185bc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_19ecf16c-3f96-481f-9533-8eeba81741cd_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated&#160; Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ab67714-0e96-48bb-8826-63b897b11b36_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_14eb09c7-015a-4727-94a0-93ce4f3a2b46_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4405534b-86bc-43f3-9d02-e31396fbe59c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2dab3ba6-275d-43e9-966b-f5c23e1ad447_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_37581dbd-2ca7-4462-8bed-28df80d60fd7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_38c02bcb-32e4-41a3-ba45-ad35d5a181d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription rate cap</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2942f2a3-9ed1-4ee5-8c42-0a722a114272_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9a95bbdc-44b5-48d0-a183-122497a803c9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6a88342b-857c-4ff9-888a-b3792d9b7ed0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_36a45ce8-da92-4b1e-bd68-f34579974cbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_e4e91e29-9ae8-4a07-8d50-10d79a6b1389_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition - Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_23f9b324-c77a-4453-869f-a4d55272868f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f20e30ee-6d37-4ec8-87bb-d22382ae9d32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_5a3ecb96-9e11-48e1-a9af-ad831d33372f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_7054246b-e386-4a69-8239-1dff08a6fd0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, beginning balance</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_53e38ec0-99c5-404f-aae9-0c319084f6eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, ending balance</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fb4c274c-00e6-497c-a56a-71e2ee229965_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ef8fc387-75e8-4f8b-880c-cc8e2fe72c6a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentBackedSecuritiesMember_a1ce8586-ef5b-4727-9ddf-cd828ec217ca_terseLabel_en-US" xlink:label="lab_nvax_GovernmentBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-backed securities</link:label>
    <link:label id="lab_nvax_GovernmentBackedSecuritiesMember_label_en-US" xlink:label="lab_nvax_GovernmentBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Backed Securities [Member]</link:label>
    <link:label id="lab_nvax_GovernmentBackedSecuritiesMember_documentation_en-US" xlink:label="lab_nvax_GovernmentBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to government backed securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentBackedSecuritiesMember" xlink:href="nvax-20220630.xsd#nvax_GovernmentBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentBackedSecuritiesMember" xlink:to="lab_nvax_GovernmentBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bdea8619-a238-4da4-a95f-582109b172e5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3183347d-a9bd-49c5-82c2-b18c4d69bfed_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4c3a195-c726-4923-a7db-6610d8cd06b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_cb34faaa-2654-4d32-a9e7-a16140789cb0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_f9173d6d-caf3-4d76-a0ef-2c2c8e5f0af0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9bd9193f-5409-4742-ae4d-f191799333a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fc2f1239-af73-4ae4-bae4-256ad1a2e7d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_21d26cdd-c8be-4084-8247-b5d778f8f243_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fe522004-39fc-4470-a844-9a406adf5c21_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5010eea6-d4ff-40b0-85a9-a2e90687e9df_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f0c1d729-2b60-48b7-bb69-55f7db830b58_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_72e0a369-fb7d-414b-8d7c-12d777aace58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_885e050a-f685-49f1-b306-8180b305a415_terseLabel_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties</link:label>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_label_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties [Member]</link:label>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_documentation_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember" xlink:href="nvax-20220630.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SalesBasedRoyaltiesMember" xlink:to="lab_nvax_SalesBasedRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a9a60e5-e3dd-4e7c-acf1-46a36ae8436a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bca5fc26-dd32-4494-b71a-2313c13ef3ea_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fb80745f-d2f9-44d0-9238-172cee020389_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d8effc58-b8aa-4a72-9aba-f6f2bcae1f15_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3147805b-0484-492c-94ad-3c5796832608_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0bc02bf8-f915-44af-895f-65c33ca0388f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_b6ceb727-f9d3-4830-8080-c4c719858028_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b1b1028-84d8-46b8-85a0-b75e7edd381c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_0fa4f976-7734-4918-a22c-bdd3e8c192e4_terseLabel_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, number of square feet</link:label>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_label_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Number of Square Feet</link:label>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_documentation_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet" xlink:href="nvax-20220630.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FacilityNumberOfSquareFeet" xlink:to="lab_nvax_FacilityNumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_BillMelindaGatesFoundationMember_534e25e3-6f04-437f-a9b0-ee0a507e89e5_terseLabel_en-US" xlink:label="lab_nvax_BillMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;)</link:label>
    <link:label id="lab_nvax_BillMelindaGatesFoundationMember_label_en-US" xlink:label="lab_nvax_BillMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_nvax_BillMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_nvax_BillMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to grant agreement with Bill &amp; Melinda Gates Foundation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BillMelindaGatesFoundationMember" xlink:href="nvax-20220630.xsd#nvax_BillMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_BillMelindaGatesFoundationMember" xlink:to="lab_nvax_BillMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_243cf595-cf89-408a-8f1f-94425bbc084e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_a0e6fea3-1a43-41b2-9cb9-61e5cd859fab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f147c847-4e8f-4d31-a5ae-d9ff9693d73d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bb3593ff-c694-4e43-9fb1-6e9f9955f070_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7a826fa2-b677-4a09-a72d-2def28adfa01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option and Appreciation Rights Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0d7c49d6-70ef-47d5-9c4d-0feae3c5b4e1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3da32f8e-5714-431a-8e81-c6320a07d791_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_09eb22fd-ffb4-4ea8-a070-5ff2cbaf3c24_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_89157bfa-d834-45f2-a8c3-68e56ab7d698_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_6035b66a-5a25-41e4-b66b-13261ca3e152_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses of vaccine to be distributed</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_cbf76105-7394-4e8f-b1ac-4a2668644d0d_verboseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses to be distributed</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, To Be Distributed</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, To Be Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesToBeDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:to="lab_nvax_PurchaseAgreementNumberOfDosesToBeDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a6224192-21f6-4938-a709-5bbf524f0fb8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, prepaid expenses, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_14c9f4cd-af2d-4ad3-964a-0e0a6b13c8ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_85534f92-a5d1-4474-b8a4-449796fa5ab0_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3d962980-14f5-4038-8693-319412654347_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_bf7a4b11-9b1b-4bb6-bd05-8e2996d4bdbf_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_ecccec64-8672-4aa3-a91f-2692bf0408ec_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93bb4814-569c-49a5-a79b-fea174026e54_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5065fc36-0874-409a-9a3d-a5c40929239f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e8c0f5ea-ca0b-4f1c-9bca-e45da49193cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_b134e6ce-a9be-464f-ab08-cfeadf789b5b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal, state and local, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_27889960-cfc4-4866-85a4-34e80cfd5df5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcb634c3-4043-40ee-87f8-e0d447fc23bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueCurrentAdditions_a423bf8f-e9b6-45e8-9fa0-8e80e18b32e2_terseLabel_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentAdditions_label_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current, Additions</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentAdditions_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentAdditions" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueCurrentAdditions" xlink:to="lab_nvax_DeferredRevenueCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0fb4714a-16f9-429e-be26-2d39d46b57fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9da833c4-458e-43ae-96fd-cfcd42bcae75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_180784da-2912-4879-b64f-ff5d436d4157_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase agreement, number of vaccine doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Vaccine Doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Vaccine Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:to="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ad07bbe8-6c3c-4385-9910-60dcbc8a14e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c308a94f-9194-4465-adbc-b373463469b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_313a510e-e314-48a8-a708-78849c00bc68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, stock options and vesting RSA's</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TakedaArrangementMember_15acb77e-82ec-40c7-8218-143159a89bdc_terseLabel_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_label_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement [Member]</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_documentation_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember" xlink:href="nvax-20220630.xsd#nvax_TakedaArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TakedaArrangementMember" xlink:to="lab_nvax_TakedaArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ee364904-5b6f-421e-9fec-ab644e5286eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0dd0f83e-89f0-4279-ba20-0d061a33cd38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_0265f85f-de17-4746-8b09-9f578700693b_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed contracts receivable</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_455a558b-efc1-462d-b543-09fb9716fe8f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c13875a0-dbbb-4562-8d17-0bd1f5da5dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueCurrentAndNonCurrent_1e76a291-5b53-43a8-936b-8e11eb83a339_periodStartLabel_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentAndNonCurrent_9af03626-521f-45d9-b8ff-5d1e92656e09_periodEndLabel_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, ending balance</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentAndNonCurrent_label_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Current and Non Current</link:label>
    <link:label id="lab_nvax_DeferredRevenueCurrentAndNonCurrent_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Current and Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentAndNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:to="lab_nvax_DeferredRevenueCurrentAndNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5263e8dc-5e83-4fe5-8be3-7d8bb7dd7a14_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 600,000,000 shares authorized at June 30, 2022 and December 31, 2021; and 78,776,234 shares issued and 78,166,935 shares outstanding at June 30,&#160;2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December&#160;31,&#160;2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_d13242ed-a07d-4736-85ea-465227ec6bb4_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses, cancelled</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Cancelled</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:to="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_c73c62ac-a76f-4e5a-9602-0ebc10a0bbb9_terseLabel_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement</link:label>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_label_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement [Member]</link:label>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_documentation_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:href="nvax-20220630.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:to="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48c5c1a1-0eb5-46ab-9a24-fc6373805a40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_503bf0c9-8ff9-49f6-9364-12f1f60047ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_89621bd4-03af-4dc8-bfd8-9a8a8843dbba_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8cba05c-7ef8-462e-95cd-9fec95efca71_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b52a907-1efb-4584-8b2c-30edad2018ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b3d9d36-4826-4c7f-8e74-0d09462c908f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_a057bcf1-ed03-4148-9572-e0e33c286874_verboseLabel_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest expense</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_label_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Related to Convertible Notes [Table Text Block]</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_documentation_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of interest expense related to convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:href="nvax-20220630.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:to="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_597d9181-777b-40ff-8cbc-607b8072ee49_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b18fa0b0-4dc4-4a6f-aaba-885a1bcaedbe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9e293121-a580-41f5-9c5f-8796a78eee1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the exercise of stock-based awards</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1bc80851-7086-47ea-a639-5728d5ca80e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3aeea294-52e0-41e1-8e2c-f8b18da7ffd1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_28e94473-4f15-479d-bb1d-953b18bd3eb9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_47c92579-a8da-4394-837a-df463082218c_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_453eb15b-4ff1-4e3d-bc89-549d91c62c05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_0957141a-6d89-4b9b-bc10-397c14b32afb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_393508d3-f9d4-4096-b51c-53deea5f1704_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ed3e366-9ea4-40ca-b062-3330a1774ba8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value:</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0966074e-6ce1-4265-a4d7-602cf2ef7a2f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_b80a70c0-68da-4b34-9a77-67873516ec44_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb61fd24-68a1-4fec-8931-a13ab9204e5c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_da340fd3-afdd-41ec-8096-41327039150c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_516cbc4a-6b58-48f2-97bd-0243f0c8deb0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3656ccbc-5d7a-4946-886f-277f222103c8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5ce3395e-dab5-4598-b9fc-cbb5b2fa362e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_89cc3afd-4422-45e7-8e89-e50fd3b233ba_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_abb10c2c-7120-4e00-acc9-714e7ab09613_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7cdccb7f-be57-482d-aa8f-690f5683b3d0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b9a1db26-7b03-4749-97d6-8e04b5318566_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_99cda2f1-c41c-4d4f-9a4b-818dfb65c60f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_fb840c5d-7e86-4b55-9575-bbbb89d0fc43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4db86d0a-1ca8-4949-9a2e-73fde0787489_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_68a03340-708a-4ec6-b864-397667681b20_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015&#160;Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a0070949-c7f5-4f68-9289-a89a58e1f4cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_87a8f846-a648-4f5a-90b3-469e488801d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_01e21819-1662-4d24-9f79-9f05dd9e12ac_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_01f5467c-7a35-499e-b6af-12481ca41791_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c16dd31-03ac-41bf-90e9-a729e57eae2c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee6eb158-789f-4b0c-a4eb-094f790c50f6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_49be1e7e-8933-420e-a042-032899645d26_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_691d0a32-431e-432c-ac03-0bd7b1e085cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c66d313c-09b4-490b-84be-4da7c4319aec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_0cd1ab14-3702-44ff-b4d1-1750e06c2248_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, cost basis, 609,299 shares at June 30,&#160;2022 and 591,980 shares at December 31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_93036aa2-128e-47bc-88f8-7bae0ee0363b_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;)</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations Award [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:href="nvax-20220630.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_691da0df-1561-4b9a-9ba2-5ae61f36a1d2_negatedNetLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_11f45277-c570-4706-bf3b-c0b4813cf758_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_884a07dd-83a2-4f21-ae51-6e7fe1361148_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fce6e0e5-5344-44a5-9799-1fb0a8fe5944_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_90ffad11-3835-416a-abd1-805b5ff98b64_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_36cfaddc-a3dc-4654-a3fc-59b5db5a6507_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Unbilled Services and Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_label_en-US" xlink:label="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Unbilled Services and Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Unbilled Services and Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" xlink:href="nvax-20220630.xsd#nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" xlink:to="lab_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c112ee3-d981-46fc-960c-46530f58233b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_4f975575-7ac6-4375-8fe6-6a73966b32ab_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64388cec-4a7a-4e2c-b9db-737eb7b17b1d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c71c579d-d9f9-4fc9-9a3c-527f83c9ac83_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_90dd044c-7ae2-486b-b481-9046be2ea5e7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_06b345e4-8465-4c4f-a3cb-df4c8884fad1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Semi-finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_389c9529-d476-414f-96b3-dafcfe05d7c9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_83e546c9-2ef9-4a18-9ade-abb5efd858e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7859befd-a295-411f-8874-9a1a4cf2d71c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4c20946a-3ec9-466d-b864-a9ad373121cb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0fe0b9b7-f6c9-406c-ad21-72a67c737221_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fca26261-5c88-44c5-8543-8b40f09908f4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f8cefb0a-dfa1-42f5-9bcb-adaf8c93a08a_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets,&#160;Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f1aac04b-c6e1-4d17-94a6-164d0bdfb70b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_83782542-edc6-40df-80c0-d54c08c7e0c5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_1ccbb09e-3fb9-4f9f-9ff0-66d904716638_terseLabel_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:to="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9e792a24-9696-476c-9290-f4704d37500e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_e8e4261e-6764-488b-96a6-ed497696d556_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm purchase commitment loss</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7bd4dee1-539c-4a7d-ba28-119f6d710cce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bcd9c158-b5dc-4151-af6b-3a4b2b00888c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d085b84f-2912-4a80-871c-b2349b6dbdc9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_804ceb0d-7b11-4dcf-b3bb-0682f85b532c_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement upfront payment amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_label_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:href="nvax-20220630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:to="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_dbf7e311-6c3e-40c9-94cc-d8a6ea634694_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7a647950-0769-42b8-8ba8-88f15f613500_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_792bb6b2-ebd9-41bb-a168-168b7807f850_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5cb025d1-ef4c-46da-bde0-7b01f8bc931c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22b7e23b-43bc-4ea4-afd2-2f057dcf566e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2631944d-2cc3-4a4d-81a2-4472cbeceece_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bea16a12-c5cf-4817-9f48-59105671d2b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f93ffe86-fcae-4ee6-b194-66ebe9e357e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_121cb479-16d0-4c0f-8c6f-6f2b865dc576_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6ab4aa26-9291-4640-a97c-1845aeddaa1b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_120ee3dc-b0f6-4abf-9bff-5e1d08c3c196_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8764e595-9ebd-45ee-a7cc-00f8fabe7f7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3e9c10aa-dcf6-48c4-bee0-a8dc435ce7c8_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e07cc468-a013-4710-8b2e-9f847a3a46a8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b885d969-b411-4697-bd73-d26bb75366ea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sales of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e21b0bc-ed2b-45e2-8de7-41c409a6c231_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementsMember_f57296ba-fc5d-4678-8b3a-8a1328bf87d7_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_nvax_CollaborationAgreementsMember_label_en-US" xlink:label="lab_nvax_CollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements [Member]</link:label>
    <link:label id="lab_nvax_CollaborationAgreementsMember_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementsMember" xlink:href="nvax-20220630.xsd#nvax_CollaborationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementsMember" xlink:to="lab_nvax_CollaborationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f0196fd-f4aa-4779-99a9-84fdafbd8ccb_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a89a9565-2ead-41f6-97e9-a83ab49ade90_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_24e4485b-e82e-4d96-becb-fbc787c46980_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e578cf57-bcb6-4942-b33d-e19f9c77d688_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_55cedc79-2e6c-4aeb-81ff-c4e15c126b3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3aff785-1b5d-4e29-a543-743e6a989310_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8b234bbb-0d57-4e14-b8f9-61b6007cc8ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_15972530-d802-4ac9-a139-d2a07526cc20_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_85817bd8-6262-4ece-b8ab-07dc56d81f3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_cba617f7-790f-4121-8fcf-3d8b966a8431_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_28cc679b-fb2f-4687-a889-a02d31f3afcf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_f85b7a60-c65b-4164-8549-cd02de9083b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_88ac2ca9-4a80-4a75-9aaa-922649cace2a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_722f23eb-5e42-4f6d-b797-0ed66529d724_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_26a26052-e444-4b08-8aed-b73e67634bd7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_a02d66ad-8caa-4026-9128-dc7db00202aa_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_81e611ec-5f62-421d-b9dc-5f5ab167929a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9593b4c7-dd8c-485e-bad5-d03f1fe9c279_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_477d1516-ec9e-40f8-a0f7-7814ef690991_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense:</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f129fcd1-ab6d-458e-9dd5-a83240e44073_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_02bbf8dd-c8cb-4fc2-af3f-85e4b62e2ec1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_782dd146-026b-4932-a697-3ec01fdda220_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54a248f0-b6ab-4e00-a952-f0758dac7e85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_604f5a73-6288-4cd1-a6e6-a77001b2a694_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_51e22956-ae0a-434b-83a1-8726c7ab3fe6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8677d31a-de76-4403-a0bc-bb8dde27b3b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ReceivablesCurrentNetDeductions_bfa3dee6-7227-4eb7-a564-b368c26879af_negatedTerseLabel_en-US" xlink:label="lab_nvax_ReceivablesCurrentNetDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_ReceivablesCurrentNetDeductions_label_en-US" xlink:label="lab_nvax_ReceivablesCurrentNetDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Current, Net, Deductions</link:label>
    <link:label id="lab_nvax_ReceivablesCurrentNetDeductions_documentation_en-US" xlink:label="lab_nvax_ReceivablesCurrentNetDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Current, Net, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ReceivablesCurrentNetDeductions" xlink:href="nvax-20220630.xsd#nvax_ReceivablesCurrentNetDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ReceivablesCurrentNetDeductions" xlink:to="lab_nvax_ReceivablesCurrentNetDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3ea09055-6e30-4428-b304-5466a114c57e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price not yet satisfied</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_66818036-2fd5-4954-98d4-f2b07d968e48_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_82f7d2bd-33ce-4d61-b393-5d1c5417424b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_fae92612-2334-43b2-b173-aebde16500b9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e08cf592-46ad-4d5e-87a5-6c1e7c997633_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_091df579-d4db-458e-bd54-d6177c2a8e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2a38d33a-9ddb-4517-822b-7ebf5cd1ec95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_bad4dfcd-53f7-4b66-8e38-3dba999fefc6_terseLabel_en-US" xlink:label="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term supply agreement, incremental borrowing rate</link:label>
    <link:label id="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_label_en-US" xlink:label="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Supply Agreement, Incremental Borrowing Rate</link:label>
    <link:label id="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Supply Agreement, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LongTermSupplyAgreementIncrementalBorrowingRate" xlink:href="nvax-20220630.xsd#nvax_LongTermSupplyAgreementIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LongTermSupplyAgreementIncrementalBorrowingRate" xlink:to="lab_nvax_LongTermSupplyAgreementIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_2749f7fd-39be-47df-b95f-33c61442d255_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_80053268-4615-48a4-a925-051235aba45e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_f2810eed-22e8-47f0-b5e5-f36e2281b089_terseLabel_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other</link:label>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_label_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and Other [Member]</link:label>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_documentation_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember" xlink:href="nvax-20220630.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RoyaltiesAndOtherMember" xlink:to="lab_nvax_RoyaltiesAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_4a0308a2-7e4d-4a8d-8f81-f3437be2e8be_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6d28c274-c62e-44d1-9090-f19ba5be6963_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_e0672ed2-da4d-4710-ad3d-fce9b7fd1566_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_94c85030-3a07-45a3-bcb9-de9cdb1e5242_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_46aa7024-5657-4108-a46d-207d3673c087_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on marketable securities available-for-sale, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fb13a0e8-f02f-42e4-b772-7a98e9860efd_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_207a6012-f9c9-4db3-8b9c-761a7974fe3d_terseLabel_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_label_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI) [Member]</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_documentation_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:href="nvax-20220630.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:to="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ede1ca49-0920-4149-a69c-71901888531d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_e586188e-1826-459a-af1c-4d58e095d46d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_588dea53-3429-4611-8789-8f0ca054aa34_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f7ec3cde-9a41-426f-8b4c-da5d205441be_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c9359e2-6e33-4275-a64a-af2831920377_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_6e88427d-2c78-4583-b15d-3754d4595622_negatedLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3c0d1491-3da6-4fbf-a413-a09b66b7955b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4a41a4c4-b3b5-4f30-b698-eb35f70d1e09_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_69fd40ca-4785-49a6-a0b8-6c4e49cc9bbe_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remainder)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_1cfe27f7-c9ac-46fa-9274-402ba47652d0_terseLabel_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Department of Defense (&#8220;DoD&#8221;)</link:label>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_label_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Defense ("DoD Contract") [Member]</link:label>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_documentation_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Defense ("DoD Contract")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember" xlink:href="nvax-20220630.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USDepartmentOfDefenseDoDContractMember" xlink:to="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a529374f-546b-4328-8ca3-9203caecb1e4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_20e1d3d5-2480-4d93-bd91-82ebbb9f4b14_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum grant price, percent of common stock fair value</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:href="nvax-20220630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_fa038dfb-09cf-479b-93dd-ab2f59e88046_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e181dee2-b25d-4b3d-b10e-6ec3c391e995_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_888f495c-da45-46db-bf7d-6b60b2469814_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_816f1a7d-ed2c-4e86-9f36-90acf252b260_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense, fiscal year maturity</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cf94cfde-7abe-485e-ab9f-cb333dac2fbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per&#160;Share Weighted- Average Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f9a0172-aef5-49be-819f-02f3ccee68a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817eb1be-c2f5-4810-b050-76444e598833_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_759515b3-d70d-4c95-af9d-e82651938605_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_de7b95c5-a038-4fec-b5be-b571a134a0cc_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, License, and Supply Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b0888816-890d-489a-9229-447f6cff3400_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_27071a1c-2b47-4cf4-8a77-c258c0247295_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f9c4196f-6642-4e6a-8beb-dcff6909a3c3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_97ffc9f4-9494-4d69-8e93-dccc1d152e18_terseLabel_en-US" xlink:label="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under incentive programs (in shares)</link:label>
    <link:label id="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation stock issued under incentive program</link:label>
    <link:label id="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in incentive program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20220630.xsd#nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1fbcaa23-b5d1-4c19-aee8-2db9ff1d73ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_415c6602-f077-4247-8e35-5d4bd59c265b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_f4d44523-04f4-4b07-a1b2-65badbe8f58e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b27b0a41-eb96-4679-8b3f-9820970b4c70_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_aa372868-5a75-4dc4-811a-b67727a5244c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6f54ce59-4a0a-4d37-8d49-68404531af8c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Black-Scholes fair value of stop options and SARs granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e2658756-60ae-40a0-9adc-74bb8aff9890_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Black-Scholes fair values of ESPP shares granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_95858db4-8483-4665-b1f8-b1d2b47a184e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1ca4234c-6e56-4f23-bc2c-da4652cffb71_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d6f3d04d-9340-4926-976f-0985a782d849_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a05ca654-62b8-49cc-a06b-5899a817a51a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2c3f34b7-468d-40b8-97fa-8ee039104e4f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets and lease liabilities obtained, operating lease</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_00ff7117-27fc-4e21-a040-fdd25638225b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_77edb3bf-f902-48dd-8505-9c60a2070d89_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:href="nvax-20220630.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:to="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>nvax-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b8f7f396-6255-4acd-a261-8fc9092ca526,g:e7b36f81-b504-4b3e-b499-0ac259afcdda-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CoverPage" xlink:type="simple" xlink:href="nvax-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_32bad268-1252-4fbc-a006-da2b8c195a11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_DocumentType_32bad268-1252-4fbc-a006-da2b8c195a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7909c2cc-283d-4601-8fb6-5d1b087a2996" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_DocumentQuarterlyReport_7909c2cc-283d-4601-8fb6-5d1b087a2996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_72c692b0-d344-466b-a1e2-59c66a1db536" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_DocumentPeriodEndDate_72c692b0-d344-466b-a1e2-59c66a1db536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c33e1ad8-fd98-427b-8f2f-cef1f75df316" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_DocumentTransitionReport_c33e1ad8-fd98-427b-8f2f-cef1f75df316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_74f2148c-3bd6-4754-b4dc-742a5e6d3cb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityFileNumber_74f2148c-3bd6-4754-b4dc-742a5e6d3cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6188e3c1-bf00-44ad-a5b6-6836646fb981" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityRegistrantName_6188e3c1-bf00-44ad-a5b6-6836646fb981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c0bf67fc-38e3-44ad-b73e-dcb3bc80b1e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c0bf67fc-38e3-44ad-b73e-dcb3bc80b1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3a08d87f-99b4-4a26-8942-e6618150b09b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityTaxIdentificationNumber_3a08d87f-99b4-4a26-8942-e6618150b09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_20654898-146b-41e0-b7a4-7f3aa20a1479" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityAddressAddressLine1_20654898-146b-41e0-b7a4-7f3aa20a1479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_35897eb4-18d1-4a3a-bcc4-294fa875ac11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityAddressCityOrTown_35897eb4-18d1-4a3a-bcc4-294fa875ac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_767df0f6-9db9-4348-ac34-b0b1b90c507d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityAddressCountry_767df0f6-9db9-4348-ac34-b0b1b90c507d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_30a481e5-6250-4db0-8c3c-a18922230c6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityAddressPostalZipCode_30a481e5-6250-4db0-8c3c-a18922230c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7226b1ba-3392-4090-9ee6-9feb1f5d836c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_CityAreaCode_7226b1ba-3392-4090-9ee6-9feb1f5d836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_72b7d45c-054e-4a1f-8772-18d64dd1fc4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_LocalPhoneNumber_72b7d45c-054e-4a1f-8772-18d64dd1fc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4d0aa407-cf6e-46fa-99bf-c823e9837834" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_Security12bTitle_4d0aa407-cf6e-46fa-99bf-c823e9837834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_67eabbda-656b-40e1-8313-ce77ecec98a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_TradingSymbol_67eabbda-656b-40e1-8313-ce77ecec98a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1ab9cca6-95f1-4c16-ace8-a3c8be400ef3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_SecurityExchangeName_1ab9cca6-95f1-4c16-ace8-a3c8be400ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_19f05274-17c0-48f7-87b0-8f1822da9e91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityCurrentReportingStatus_19f05274-17c0-48f7-87b0-8f1822da9e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8511b4d8-756a-4d8f-8764-0ee5d28a0915" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityInteractiveDataCurrent_8511b4d8-756a-4d8f-8764-0ee5d28a0915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_391258b8-e912-4317-9e42-b383e0e2032c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityFilerCategory_391258b8-e912-4317-9e42-b383e0e2032c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8a688e7c-fc72-4227-bea7-cb7e040a0e0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntitySmallBusiness_8a688e7c-fc72-4227-bea7-cb7e040a0e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_09d77171-94eb-41ee-b73b-2e0949958a0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityEmergingGrowthCompany_09d77171-94eb-41ee-b73b-2e0949958a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2781f0b9-70ea-42b9-b986-9217597d6026" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityShellCompany_2781f0b9-70ea-42b9-b986-9217597d6026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ac6ff673-f1d9-41e1-8a38-c88a0a00d595" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ac6ff673-f1d9-41e1-8a38-c88a0a00d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b92db895-c1e9-48e4-ab16-214200c34624" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_AmendmentFlag_b92db895-c1e9-48e4-ab16-214200c34624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_19ae3018-a1f9-4df1-b971-d0bbd481feb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_DocumentFiscalYearFocus_19ae3018-a1f9-4df1-b971-d0bbd481feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_beea1db4-f251-4922-90c8-db9f9229d55c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_beea1db4-f251-4922-90c8-db9f9229d55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4d8d1c6e-7b6f-4a98-8a2e-f3d0c3102460" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_EntityCentralIndexKey_4d8d1c6e-7b6f-4a98-8a2e-f3d0c3102460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28cb179a-60b3-4372-9b0a-839847aed2c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b20e2fb-9cd0-49d2-9f3d-8ef6d9bb9b0d" xlink:to="loc_dei_CurrentFiscalYearEndDate_28cb179a-60b3-4372-9b0a-839847aed2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_63108c5c-390f-47f1-ac1b-7b2b4107a297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63108c5c-390f-47f1-ac1b-7b2b4107a297" xlink:to="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:to="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_999e34d0-d993-45b1-99e5-6cc81fe3d7da" xlink:to="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4d3b3137-9880-4594-accc-24911c9fe49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:to="loc_us-gaap_ProductMember_4d3b3137-9880-4594-accc-24911c9fe49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6a4106f2-be91-4d82-b39b-acaa2d2a9b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:to="loc_us-gaap_GrantMember_6a4106f2-be91-4d82-b39b-acaa2d2a9b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember_75926167-1036-49dd-9381-6c192daecd94" xlink:href="nvax-20220630.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d92d0f87-000e-4fcd-9ba3-1d0144ac53a5" xlink:to="loc_nvax_RoyaltiesAndOtherMember_75926167-1036-49dd-9381-6c192daecd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_15037a92-3984-440a-b829-accb9e8ca87c" xlink:to="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0dc1cebd-8e66-4bf5-9926-3c618fd43c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_RevenuesAbstract_0dc1cebd-8e66-4bf5-9926-3c618fd43c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3766c2d1-87a9-4b8f-b4b0-c03316d132d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0dc1cebd-8e66-4bf5-9926-3c618fd43c53" xlink:to="loc_us-gaap_Revenues_3766c2d1-87a9-4b8f-b4b0-c03316d132d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_efab74c7-34e7-4d96-ac5f-cba6c00c0a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_CostOfRevenue_efab74c7-34e7-4d96-ac5f-cba6c00c0a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6b15d1ed-faaa-4e58-aac1-9ad661f837a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6b15d1ed-faaa-4e58-aac1-9ad661f837a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ddcc3d0d-6823-4d9d-bd6c-fc0d7f0a37de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ddcc3d0d-6823-4d9d-bd6c-fc0d7f0a37de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cf1f7e47-7870-42be-be6a-9c89ca9e41e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4465c437-dd1a-4c75-b86d-2f08715bb3ae" xlink:to="loc_us-gaap_CostsAndExpenses_cf1f7e47-7870-42be-be6a-9c89ca9e41e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_248291a7-bce0-4712-a549-8e32263722a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_OperatingIncomeLoss_248291a7-bce0-4712-a549-8e32263722a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9756621-6964-4587-80f9-abffc040bee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:to="loc_us-gaap_InterestExpense_b9756621-6964-4587-80f9-abffc040bee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5db2c905-3d9b-4e1e-9863-c8e92eb3bea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b4937931-ae27-44ca-a23f-c72f59827a25" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5db2c905-3d9b-4e1e-9863-c8e92eb3bea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d8a938a-0af8-4fd8-b98e-12a3c6d4efff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d8a938a-0af8-4fd8-b98e-12a3c6d4efff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50ee0860-39bd-46a3-89bb-e66b9eb88ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50ee0860-39bd-46a3-89bb-e66b9eb88ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e736582b-79e0-4773-9ded-9913fb2b75e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_NetIncomeLoss_e736582b-79e0-4773-9ded-9913fb2b75e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b663023d-d9dd-4c85-ae24-3d96c675e8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b663023d-d9dd-4c85-ae24-3d96c675e8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e64fd268-961b-4f67-ba4b-0f5a1229cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b663023d-d9dd-4c85-ae24-3d96c675e8aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_e64fd268-961b-4f67-ba4b-0f5a1229cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8b07d523-159d-4811-a32d-423a23ea1667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d595ee7c-49cc-4902-81d9-9316300e6d3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8b07d523-159d-4811-a32d-423a23ea1667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e90fe42e-d518-4e11-8112-bf13ae018027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8b07d523-159d-4811-a32d-423a23ea1667" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e90fe42e-d518-4e11-8112-bf13ae018027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37ede1c4-e916-4ea0-b963-0d30cf82cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b899d0bc-fdfc-452e-870b-d737d55bcd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37ede1c4-e916-4ea0-b963-0d30cf82cbbb" xlink:to="loc_us-gaap_NetIncomeLoss_b899d0bc-fdfc-452e-870b-d737d55bcd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b2ab6fe-81e6-499d-a1d8-522b4faa3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37ede1c4-e916-4ea0-b963-0d30cf82cbbb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b2ab6fe-81e6-499d-a1d8-522b4faa3f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f595f510-bbc1-4afb-98bd-48fb9100ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b2ab6fe-81e6-499d-a1d8-522b4faa3f9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f595f510-bbc1-4afb-98bd-48fb9100ba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ac22c966-9252-42f7-aaec-80e2b6b97284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b2ab6fe-81e6-499d-a1d8-522b4faa3f9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ac22c966-9252-42f7-aaec-80e2b6b97284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5606bffc-116a-4e9c-a65a-10c7e65a0567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b2ab6fe-81e6-499d-a1d8-522b4faa3f9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5606bffc-116a-4e9c-a65a-10c7e65a0567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7da652e5-a18c-4f8e-94ce-706fd3380b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37ede1c4-e916-4ea0-b963-0d30cf82cbbb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7da652e5-a18c-4f8e-94ce-706fd3380b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_548c58df-ab05-4227-921f-12080554bfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548c58df-ab05-4227-921f-12080554bfe7" xlink:to="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8637b22-c12d-4d53-a309-79cc177696b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8637b22-c12d-4d53-a309-79cc177696b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1d4f7af9-b736-4921-b85a-4e68c1a53dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1d4f7af9-b736-4921-b85a-4e68c1a53dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_684ba9b2-4f51-4ad7-9bd0-7a8d4c24c204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:to="loc_us-gaap_ReceivablesNetCurrent_684ba9b2-4f51-4ad7-9bd0-7a8d4c24c204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f37c4379-c068-47a0-a8be-a2dbddb3d569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:to="loc_us-gaap_InventoryNet_f37c4379-c068-47a0-a8be-a2dbddb3d569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7e919040-ee64-4aa2-a15b-31181f6ba0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7e919040-ee64-4aa2-a15b-31181f6ba0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e83e7ef-521c-4f0a-9c56-18215088cb78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_21f7e994-ad17-4901-a215-bd146e0458d6" xlink:to="loc_us-gaap_AssetsCurrent_0e83e7ef-521c-4f0a-9c56-18215088cb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bed7fc86-96bd-4f61-b18d-2f79ac928bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bed7fc86-96bd-4f61-b18d-2f79ac928bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_345189e6-0c22-4d1d-9ad7-b0dea12b20e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_345189e6-0c22-4d1d-9ad7-b0dea12b20e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88492627-ac39-40b9-bef9-7ac18e569571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88492627-ac39-40b9-bef9-7ac18e569571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_13691299-5303-4879-91fd-05988a807623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_Goodwill_13691299-5303-4879-91fd-05988a807623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ce600d46-799f-4136-8f4a-82841ebc677f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ce600d46-799f-4136-8f4a-82841ebc677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_92ecb0d6-9900-4c00-8016-f134632f3e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27c7c86e-504b-461c-a97c-3cf7fdf2f747" xlink:to="loc_us-gaap_Assets_92ecb0d6-9900-4c00-8016-f134632f3e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_548c58df-ab05-4227-921f-12080554bfe7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_880db1c6-63f1-4a1a-84ff-61e9191a8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_AccountsPayableCurrent_880db1c6-63f1-4a1a-84ff-61e9191a8cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_701c319b-fbdb-400c-8c12-669412ac562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_701c319b-fbdb-400c-8c12-669412ac562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_18057b23-3c06-4fa7-9025-b69f16389957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_18057b23-3c06-4fa7-9025-b69f16389957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d22eb810-e76e-4f5e-9df1-fac1751f1dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d22eb810-e76e-4f5e-9df1-fac1751f1dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_c251f7a7-4e6a-4e88-8ed7-c60e15293b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_c251f7a7-4e6a-4e88-8ed7-c60e15293b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_95b75040-e259-4cb7-b2e9-ffeddf71246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_95b75040-e259-4cb7-b2e9-ffeddf71246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_05342581-461b-4e21-ac68-77557b9ad96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_09a5833e-3a09-4b69-89c8-e5c00ddcadda" xlink:to="loc_us-gaap_LiabilitiesCurrent_05342581-461b-4e21-ac68-77557b9ad96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1cd791cf-bb38-4995-a1dc-4a391af88887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1cd791cf-bb38-4995-a1dc-4a391af88887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_209ac8a4-c142-4552-9e15-c3113b912a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_209ac8a4-c142-4552-9e15-c3113b912a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7dd164eb-ccb1-432a-a14e-7482104d1009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7dd164eb-ccb1-432a-a14e-7482104d1009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_76485a3b-180e-4d07-a5ba-ae378d5403cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_Liabilities_76485a3b-180e-4d07-a5ba-ae378d5403cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c2b902aa-14f9-4881-b107-bba2f441c9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c2b902aa-14f9-4881-b107-bba2f441c9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a70375f1-9f05-4372-b727-739915704f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:to="loc_us-gaap_CommonStockValue_a70375f1-9f05-4372-b727-739915704f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_24c5e9c4-8cae-4837-be85-053eded51f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_24c5e9c4-8cae-4837-be85-053eded51f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1bdca8e3-3514-4d46-bd9a-8e55d6b9aecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1bdca8e3-3514-4d46-bd9a-8e55d6b9aecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d318d4eb-631e-4000-ab77-5d50673afdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:to="loc_us-gaap_TreasuryStockValue_d318d4eb-631e-4000-ab77-5d50673afdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_06bd27cb-7a8c-4370-8271-06da3524ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_06bd27cb-7a8c-4370-8271-06da3524ffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ecb7fedc-bd18-47b8-a37d-67405aaff2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e445e9f9-1aa2-406e-90b5-a18c7782a9eb" xlink:to="loc_us-gaap_StockholdersEquity_ecb7fedc-bd18-47b8-a37d-67405aaff2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd91db8-4683-4ca2-ac44-5d0b074b2625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e83f1dd8-cfeb-41b0-a3d1-6357b64cec14" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bd91db8-4683-4ca2-ac44-5d0b074b2625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_86fefe66-84e2-4648-b976-4ece5dae6bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3caff151-f3b7-4f8d-8801-21b8913a9c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86fefe66-84e2-4648-b976-4ece5dae6bae" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3caff151-f3b7-4f8d-8801-21b8913a9c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b2918cfb-cf7b-4adf-a0c8-e061d1cca91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86fefe66-84e2-4648-b976-4ece5dae6bae" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b2918cfb-cf7b-4adf-a0c8-e061d1cca91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3a30bc43-adb5-4773-ad34-794a85920642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86fefe66-84e2-4648-b976-4ece5dae6bae" xlink:to="loc_us-gaap_CommonStockSharesIssued_3a30bc43-adb5-4773-ad34-794a85920642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c4ecb3c7-df9a-40d4-95cc-fa62316e060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86fefe66-84e2-4648-b976-4ece5dae6bae" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c4ecb3c7-df9a-40d4-95cc-fa62316e060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_f3a690bb-4af2-4bd5-954e-61a7ee434925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86fefe66-84e2-4648-b976-4ece5dae6bae" xlink:to="loc_us-gaap_TreasuryStockShares_f3a690bb-4af2-4bd5-954e-61a7ee434925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f3090afd-9ea0-46e9-a59a-68cf2dbdb5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f3090afd-9ea0-46e9-a59a-68cf2dbdb5e6" xlink:to="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6d0cac0-1b43-4066-9550-68c49291b34a" xlink:to="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2d4666c1-0691-4fd2-ade2-e338f38d4e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_CommonStockMember_2d4666c1-0691-4fd2-ade2-e338f38d4e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_84d6bb50-01e3-4b59-9238-5f2d401de382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_84d6bb50-01e3-4b59-9238-5f2d401de382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d2f70ce1-b701-4b51-8793-47bcff98b6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_RetainedEarningsMember_d2f70ce1-b701-4b51-8793-47bcff98b6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2557e1d5-637d-4a09-9c20-45afd1b51361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_TreasuryStockMember_2557e1d5-637d-4a09-9c20-45afd1b51361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c94fdaa8-54a6-4ac2-95d2-e525e58c826a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_11d53172-b91a-484d-a054-48aa253cd759" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c94fdaa8-54a6-4ac2-95d2-e525e58c826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_350a2457-b0c9-4b63-b91c-77fe9bdd2616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be688205-f8f6-43cc-b38c-78f4202d85c7" xlink:to="loc_us-gaap_StatementLineItems_350a2457-b0c9-4b63-b91c-77fe9bdd2616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_350a2457-b0c9-4b63-b91c-77fe9bdd2616" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_169bcba0-fff4-45a7-a591-e5e388b7bcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_SharesIssued_169bcba0-fff4-45a7-a591-e5e388b7bcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70947aa4-a598-4700-8c4f-b8fbe896a56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockholdersEquity_70947aa4-a598-4700-8c4f-b8fbe896a56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67f7cd8b-ee3c-4565-a277-57f065e678c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67f7cd8b-ee3c-4565-a277-57f065e678c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_100de8cf-08bf-47aa-872a-fa3e37dc1744" xlink:href="nvax-20220630.xsd#nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram_100de8cf-08bf-47aa-872a-fa3e37dc1744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_5393987e-c40f-4b53-a47d-352b6a4f6a2c" xlink:href="nvax-20220630.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_5393987e-c40f-4b53-a47d-352b6a4f6a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9862023a-a724-4f28-b7e3-1db1516a7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9862023a-a724-4f28-b7e3-1db1516a7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6616e866-c47f-4e07-b4d7-da65bb2aa10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6616e866-c47f-4e07-b4d7-da65bb2aa10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1f369125-b9b9-44f8-b54a-16db174b73ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1f369125-b9b9-44f8-b54a-16db174b73ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4b9d6207-a7a0-46aa-b057-827f1ac1626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4b9d6207-a7a0-46aa-b057-827f1ac1626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_733200de-bc05-4799-b359-91730e654904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_NetIncomeLoss_733200de-bc05-4799-b359-91730e654904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b479c8c3-9b0b-497d-9e88-1f08ff52d531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_SharesIssued_b479c8c3-9b0b-497d-9e88-1f08ff52d531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c1f0572-4960-42ed-acac-ab157e56fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04b3cf2e-41e5-43cd-a34a-19187e744517" xlink:to="loc_us-gaap_StockholdersEquity_6c1f0572-4960-42ed-acac-ab157e56fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_13d7725e-5ae4-445a-b0bc-5b172120596f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8c822c46-a87e-4027-aff4-6113800447b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_13d7725e-5ae4-445a-b0bc-5b172120596f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8c822c46-a87e-4027-aff4-6113800447b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d5b45a5-585c-4284-ae4d-b92aea5b9411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d5b45a5-585c-4284-ae4d-b92aea5b9411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fedf5e0e-41db-4868-9bbe-cd326f161fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d5b45a5-585c-4284-ae4d-b92aea5b9411" xlink:to="loc_us-gaap_NetIncomeLoss_fedf5e0e-41db-4868-9bbe-cd326f161fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d5b45a5-585c-4284-ae4d-b92aea5b9411" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_82a26269-d01d-4fd8-b3b0-c3ed5ff7ba72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:to="loc_us-gaap_DepreciationAndAmortization_82a26269-d01d-4fd8-b3b0-c3ed5ff7ba72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9151732f-129a-4a7d-93b3-3c3d4a5e6667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:to="loc_us-gaap_ShareBasedCompensation_9151732f-129a-4a7d-93b3-3c3d4a5e6667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f535a267-0ecd-45cb-8a8a-cc52582527de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:to="loc_us-gaap_InventoryWriteDown_f535a267-0ecd-45cb-8a8a-cc52582527de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff_49b4e3f5-5b7b-48d7-9e06-ad49e354ec12" xlink:href="nvax-20220630.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:to="loc_nvax_OperatingAndFinanceLeaseWriteOff_49b4e3f5-5b7b-48d7-9e06-ad49e354ec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_bda78006-05e5-4210-963d-dbc1bb1fc039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_bda78006-05e5-4210-963d-dbc1bb1fc039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5dfab5b-b110-49db-88be-4b9768a306ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2f9cd9b-5636-4ff0-b784-539208d1e0ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5dfab5b-b110-49db-88be-4b9768a306ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_37eb6793-bc78-4e06-8581-bc18baca0f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5dfab5b-b110-49db-88be-4b9768a306ed" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_37eb6793-bc78-4e06-8581-bc18baca0f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6532a829-f60b-4ef3-bc4a-138c05802ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5dfab5b-b110-49db-88be-4b9768a306ed" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6532a829-f60b-4ef3-bc4a-138c05802ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_576aaee2-3934-49a5-a04f-7a72d0ab6eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5dfab5b-b110-49db-88be-4b9768a306ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_576aaee2-3934-49a5-a04f-7a72d0ab6eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_cdcd19e3-d481-44b2-8219-253ba169b7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5dfab5b-b110-49db-88be-4b9768a306ed" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_cdcd19e3-d481-44b2-8219-253ba169b7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43d09324-fa11-4d28-a52f-eb0561c70acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d5b45a5-585c-4284-ae4d-b92aea5b9411" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43d09324-fa11-4d28-a52f-eb0561c70acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17f67a18-2d6e-4664-aa13-cc7e16d64ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17f67a18-2d6e-4664-aa13-cc7e16d64ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_e7cfc643-7624-443d-b1a1-c7da17da8de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17f67a18-2d6e-4664-aa13-cc7e16d64ab8" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_e7cfc643-7624-443d-b1a1-c7da17da8de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e3403f45-57d3-417a-a24a-a9bb45e1e972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17f67a18-2d6e-4664-aa13-cc7e16d64ab8" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e3403f45-57d3-417a-a24a-a9bb45e1e972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1930cfc7-3ca9-44fc-a703-d49ff62ebd91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17f67a18-2d6e-4664-aa13-cc7e16d64ab8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1930cfc7-3ca9-44fc-a703-d49ff62ebd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd26b73e-4ba5-486e-bc35-6f73bbb02bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17f67a18-2d6e-4664-aa13-cc7e16d64ab8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd26b73e-4ba5-486e-bc35-6f73bbb02bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c991c313-627e-4f6f-a094-3bac969aaed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c991c313-627e-4f6f-a094-3bac969aaed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_eb4fcdbc-19d5-4e08-aefc-5da37b3bfa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c991c313-627e-4f6f-a094-3bac969aaed7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_eb4fcdbc-19d5-4e08-aefc-5da37b3bfa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_596251d9-b786-4487-bcc8-f59b4df0722c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c991c313-627e-4f6f-a094-3bac969aaed7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_596251d9-b786-4487-bcc8-f59b4df0722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_af0c502c-ee69-44a0-8249-757a3830e33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c991c313-627e-4f6f-a094-3bac969aaed7" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_af0c502c-ee69-44a0-8249-757a3830e33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2593ae96-082a-4312-9b11-30091a64c436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c991c313-627e-4f6f-a094-3bac969aaed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2593ae96-082a-4312-9b11-30091a64c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0425517f-5685-49c3-9b44-045d54866146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0425517f-5685-49c3-9b44-045d54866146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_26877252-82f2-45aa-b0dc-2609b197a43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_26877252-82f2-45aa-b0dc-2609b197a43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6ecb993-b67a-4ba8-a76b-acf2f1c1d645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6ecb993-b67a-4ba8-a76b-acf2f1c1d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bad76d40-ca1e-4fc3-9aa9-fad0a002592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bad76d40-ca1e-4fc3-9aa9-fad0a002592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e4de918c-c8f9-4627-aa16-190b4366be79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e4de918c-c8f9-4627-aa16-190b4366be79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_ff107c48-c68d-442e-ae28-e1310a96874a" xlink:href="nvax-20220630.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e4de918c-c8f9-4627-aa16-190b4366be79" xlink:to="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_ff107c48-c68d-442e-ae28-e1310a96874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dd8e57eb-ebf7-43b1-bb2b-6721b4526778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e4de918c-c8f9-4627-aa16-190b4366be79" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dd8e57eb-ebf7-43b1-bb2b-6721b4526778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ef519f-7130-4143-8b7e-641c8e624df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b0164e-1393-4cbe-a121-7c6c091c5711" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ef519f-7130-4143-8b7e-641c8e624df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3b86a491-cd40-4be3-9600-a8d53f244b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ef519f-7130-4143-8b7e-641c8e624df9" xlink:to="loc_us-gaap_InterestPaidNet_3b86a491-cd40-4be3-9600-a8d53f244b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_0373148c-78c5-48ca-8820-c00557fbe1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_02ef519f-7130-4143-8b7e-641c8e624df9" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_0373148c-78c5-48ca-8820-c00557fbe1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="nvax-20220630.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1740268a-60c8-4051-bfa8-36f1a806c97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_ac4f61b6-960d-444e-8613-c0df940fc64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1740268a-60c8-4051-bfa8-36f1a806c97c" xlink:to="loc_us-gaap_NatureOfOperations_ac4f61b6-960d-444e-8613-c0df940fc64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nvax-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6769e0bc-c607-440a-a81b-225b3a3c6629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d40334c5-e3d1-4d9c-8718-dcb672443c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6769e0bc-c607-440a-a81b-225b3a3c6629" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d40334c5-e3d1-4d9c-8718-dcb672443c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nvax-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_75f9d5d8-75b8-44d9-8d78-a93001fbd93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_75f9d5d8-75b8-44d9-8d78-a93001fbd93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_13dae815-7037-4d96-97a3-feb8395a42e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_13dae815-7037-4d96-97a3-feb8395a42e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_526d4181-1392-455d-a9a5-b7f944c4ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_UseOfEstimates_526d4181-1392-455d-a9a5-b7f944c4ef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ac962016-241e-47d5-9699-4007a2908d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ac962016-241e-47d5-9699-4007a2908d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_6782e6ed-f91e-4965-98c4-418b49531ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_6782e6ed-f91e-4965-98c4-418b49531ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_328926af-c2ee-4ad0-874c-50743aca4701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_328926af-c2ee-4ad0-874c-50743aca4701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6b8c083e-3e7f-4ba2-a834-77a48170900d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb548769-1363-46c6-b788-343156c728f5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6b8c083e-3e7f-4ba2-a834-77a48170900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#SummaryofSignificantAccountingPoliciesBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5499cace-8a55-4f7c-803b-45ba7b21d289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4233c189-41aa-4786-aa94-d83412502447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5499cace-8a55-4f7c-803b-45ba7b21d289" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4233c189-41aa-4786-aa94-d83412502447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_39e99b09-5c20-4302-b0aa-eb15f2b4308e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5499cace-8a55-4f7c-803b-45ba7b21d289" xlink:to="loc_us-gaap_NumberOfOperatingSegments_39e99b09-5c20-4302-b0aa-eb15f2b4308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Revenue" xlink:type="simple" xlink:href="nvax-20220630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_ea395316-d041-48b6-a207-411bd8580583" xlink:href="nvax-20220630.xsd#nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ee361fba-ae83-4e8c-8fee-7733e12ae1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_ea395316-d041-48b6-a207-411bd8580583" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ee361fba-ae83-4e8c-8fee-7733e12ae1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_e1155714-06d5-458c-ae26-5a2e5a5cd489" xlink:href="nvax-20220630.xsd#nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_e6068938-8663-41a5-9d5b-a29b49dc0a06" xlink:href="nvax-20220630.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_e1155714-06d5-458c-ae26-5a2e5a5cd489" xlink:to="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_e6068938-8663-41a5-9d5b-a29b49dc0a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_abcb7e39-919c-4b7e-9362-3f1c94e61c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract_e1155714-06d5-458c-ae26-5a2e5a5cd489" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_abcb7e39-919c-4b7e-9362-3f1c94e61c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_48069072-e3e1-4181-8d6e-8b1c97bcf346" xlink:href="nvax-20220630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_48069072-e3e1-4181-8d6e-8b1c97bcf346" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_9956a5d8-c1e5-4416-b4ec-3d56b94cf074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_9956a5d8-c1e5-4416-b4ec-3d56b94cf074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fd30011f-feb9-4101-ba9f-7fcd939d44cc" xlink:to="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_3cc86f89-fa92-4f46-b3a2-8f04b3b17f4d" xlink:href="nvax-20220630.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b77383d-7f96-4221-9798-f5d8b85038a6" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_3cc86f89-fa92-4f46-b3a2-8f04b3b17f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8bba8bb1-b140-440c-b29c-10d6dece6f4b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_ed7890b7-e6d9-4fc1-8746-48d116981c5f" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_USGovernmentPartnershipMember_ed7890b7-e6d9-4fc1-8746-48d116981c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_01bbf3dc-78d4-4198-ab21-67c87e3c7bd8" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_01bbf3dc-78d4-4198-ab21-67c87e3c7bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ba174110-de92-4158-82a1-7140ae8e1d58" xlink:href="nvax-20220630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ba174110-de92-4158-82a1-7140ae8e1d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_d88f9fb6-aef1-469c-9efb-fbf6b91d85cc" xlink:href="nvax-20220630.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c89a1a59-d25c-49ae-bf25-807ceb53666e" xlink:to="loc_nvax_EuropeanCommissionsECMember_d88f9fb6-aef1-469c-9efb-fbf6b91d85cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_e93c8da6-321f-47ff-baa6-174c6fad2215" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_30daff77-b677-4a1b-a656-109c71de1336" xlink:href="nvax-20220630.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_d4dd1951-f588-4c2d-b28b-b1b7c1ba3223" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_30daff77-b677-4a1b-a656-109c71de1336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4436aa4c-818a-49cd-a3fe-6e80099a9d18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_20b66ffc-4ef1-4192-9d0b-58371cd1e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f38ee73f-0801-4060-b8d8-09eaea04bdb6" xlink:to="loc_us-gaap_SubsequentEventMember_20b66ffc-4ef1-4192-9d0b-58371cd1e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ad095ceb-d008-4d1f-aa11-15788bd09a7c" xlink:to="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3ce2874-5dbc-49a1-a86a-1eaddbf282ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:to="loc_srt_MinimumMember_d3ce2874-5dbc-49a1-a86a-1eaddbf282ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f98386ef-e9e0-43f0-b4dd-a534355a7e51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fd38d6a5-a3de-45cd-80aa-21ad6dfa62e9" xlink:to="loc_srt_MaximumMember_f98386ef-e9e0-43f0-b4dd-a534355a7e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4348da49-840c-4dfa-8d0b-8ede419133bd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_a89fbf31-ef58-4b83-acd4-fc5a2f71925a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_BilledContractReceivables_a89fbf31-ef58-4b83-acd4-fc5a2f71925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_12df06b5-426a-418f-b653-550d3056b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_UnbilledContractsReceivable_12df06b5-426a-418f-b653-550d3056b60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3dee1e32-a33f-465e-848e-629059e6eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3dee1e32-a33f-465e-848e-629059e6eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_42f7d2c9-a9aa-42e7-8282-021e53d53392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_42f7d2c9-a9aa-42e7-8282-021e53d53392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_c6e42071-81ba-48c3-8ab6-f682db953f9e" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_c6e42071-81ba-48c3-8ab6-f682db953f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_d1df7ed0-b8c3-4f7f-b40a-00e84340566c" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesToBeDistributed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_d1df7ed0-b8c3-4f7f-b40a-00e84340566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_762ec15f-1f23-4e8f-a111-0b736cdd6060" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_762ec15f-1f23-4e8f-a111-0b736cdd6060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9f25fe13-e44a-4072-816f-b018c7e67807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_Revenues_9f25fe13-e44a-4072-816f-b018c7e67807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0c3f4a3d-553c-4d5f-b09c-4a54fbd2bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0c3f4a3d-553c-4d5f-b09c-4a54fbd2bb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesRemaining_cffcc27a-15d9-419b-b6a7-0f9109eccda6" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesRemaining"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesRemaining_cffcc27a-15d9-419b-b6a7-0f9109eccda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_3ba8b2cf-f2c5-4047-b6ff-55174ba8bd6d" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_44afd386-e814-4961-9863-047c9165153e" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_3ba8b2cf-f2c5-4047-b6ff-55174ba8bd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_899a578d-99d8-4ac0-8107-1837a3ab5a09" xlink:href="nvax-20220630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_5507dfa0-78bc-4f4b-9b81-2f7283d3f2a6" xlink:href="nvax-20220630.xsd#nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_899a578d-99d8-4ac0-8107-1837a3ab5a09" xlink:to="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_5507dfa0-78bc-4f4b-9b81-2f7283d3f2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5b7b2c1b-322b-4cb2-ba43-5ad1bf7dcee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_5507dfa0-78bc-4f4b-9b81-2f7283d3f2a6" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5b7b2c1b-322b-4cb2-ba43-5ad1bf7dcee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ReceivablesNetCurrentAdditions_a6ac37ef-7c35-4465-8a26-436fb054159a" xlink:href="nvax-20220630.xsd#nvax_ReceivablesNetCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_5507dfa0-78bc-4f4b-9b81-2f7283d3f2a6" xlink:to="loc_nvax_ReceivablesNetCurrentAdditions_a6ac37ef-7c35-4465-8a26-436fb054159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ReceivablesCurrentNetDeductions_54e5e22c-d6ad-4c4b-ac2c-be3004093d25" xlink:href="nvax-20220630.xsd#nvax_ReceivablesCurrentNetDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_5507dfa0-78bc-4f4b-9b81-2f7283d3f2a6" xlink:to="loc_nvax_ReceivablesCurrentNetDeductions_54e5e22c-d6ad-4c4b-ac2c-be3004093d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_30260d05-b3b7-40cb-bcec-3050dc6b30aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward_5507dfa0-78bc-4f4b-9b81-2f7283d3f2a6" xlink:to="loc_us-gaap_ReceivablesNetCurrent_30260d05-b3b7-40cb-bcec-3050dc6b30aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_d054679c-2400-4bcc-b970-96f2a40410f8" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_899a578d-99d8-4ac0-8107-1837a3ab5a09" xlink:to="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_d054679c-2400-4bcc-b970-96f2a40410f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentAndNonCurrent_4f77bc06-85b1-4ed3-8f44-a6d6221f5ae6" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentAndNonCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_d054679c-2400-4bcc-b970-96f2a40410f8" xlink:to="loc_nvax_DeferredRevenueCurrentAndNonCurrent_4f77bc06-85b1-4ed3-8f44-a6d6221f5ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentAdditions_449cdafc-0a70-4217-a37c-a17a0869c8f9" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_d054679c-2400-4bcc-b970-96f2a40410f8" xlink:to="loc_nvax_DeferredRevenueCurrentAdditions_449cdafc-0a70-4217-a37c-a17a0869c8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentDeductions_507bd53e-d4a6-4bab-85ee-f5f22b96e451" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_d054679c-2400-4bcc-b970-96f2a40410f8" xlink:to="loc_nvax_DeferredRevenueCurrentDeductions_507bd53e-d4a6-4bab-85ee-f5f22b96e451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueCurrentAndNonCurrent_25228331-450d-4d75-ab25-40e3a232fcfe" xlink:href="nvax-20220630.xsd#nvax_DeferredRevenueCurrentAndNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_d054679c-2400-4bcc-b970-96f2a40410f8" xlink:to="loc_nvax_DeferredRevenueCurrentAndNonCurrent_25228331-450d-4d75-ab25-40e3a232fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73ac5f18-f691-4599-891a-81854415e6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_899a578d-99d8-4ac0-8107-1837a3ab5a09" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73ac5f18-f691-4599-891a-81854415e6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_05839800-b97f-437c-93e9-dbf18fec7749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_899a578d-99d8-4ac0-8107-1837a3ab5a09" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_05839800-b97f-437c-93e9-dbf18fec7749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#RevenueScheduleofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_10d341eb-719a-46d1-a3ba-ae015a0d7407" xlink:href="nvax-20220630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_10d341eb-719a-46d1-a3ba-ae015a0d7407" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:to="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2f3f4c8-11ee-475b-9283-cc9a5d4e2e5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_746ddf4f-cbd5-455a-be42-3ac6c7e08ea7" xlink:to="loc_srt_ProductsAndServicesDomain_a2f3f4c8-11ee-475b-9283-cc9a5d4e2e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0a959ee1-1036-440a-938c-fcfbdcb5b460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a2f3f4c8-11ee-475b-9283-cc9a5d4e2e5a" xlink:to="loc_us-gaap_GrantMember_0a959ee1-1036-440a-938c-fcfbdcb5b460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41ffc2e2-27b8-4dcc-857b-ff214c2be877" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_9f32cc08-d5ce-4870-a4e7-3553bc41111a" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_USGovernmentPartnershipMember_9f32cc08-d5ce-4870-a4e7-3553bc41111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember_e08b702c-ad2b-4a1b-a3ee-1550458ec8b4" xlink:href="nvax-20220630.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_USDepartmentOfDefenseDoDContractMember_e08b702c-ad2b-4a1b-a3ee-1550458ec8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_50e3d503-9e7a-4534-8f6b-5985f37e2315" xlink:href="nvax-20220630.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_50e3d503-9e7a-4534-8f6b-5985f37e2315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BillMelindaGatesFoundationMember_d80ad9cd-1157-475a-a6bf-b7b3539db107" xlink:href="nvax-20220630.xsd#nvax_BillMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e4b3c8b-4028-4d6d-8d96-64de1980f719" xlink:to="loc_nvax_BillMelindaGatesFoundationMember_d80ad9cd-1157-475a-a6bf-b7b3539db107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6e1a84a5-8ddc-4f7a-ad9d-680e60c6ec9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8fda0724-7425-4584-865f-8e5426836a8f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6e1a84a5-8ddc-4f7a-ad9d-680e60c6ec9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_60536a7f-e2b6-4487-a4a9-888e97dd0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6e1a84a5-8ddc-4f7a-ad9d-680e60c6ec9f" xlink:to="loc_us-gaap_Revenues_60536a7f-e2b6-4487-a4a9-888e97dd0782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements" xlink:type="simple" xlink:href="nvax-20220630.xsd#CollaborationLicenseandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_1873b963-2b0e-4633-9897-72b39360f15f" xlink:href="nvax-20220630.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_94ece6ca-65c3-4558-ac5b-9308c2470fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_1873b963-2b0e-4633-9897-72b39360f15f" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_94ece6ca-65c3-4558-ac5b-9308c2470fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#CollaborationLicenseandSupplyAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_bcaad6bc-150a-4981-a091-3f7246554978" xlink:href="nvax-20220630.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_bcaad6bc-150a-4981-a091-3f7246554978" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_306542bb-e9e7-4850-a813-d8ae5e01cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6b8b1176-dbfe-4660-9d8f-b872deb1558a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_306542bb-e9e7-4850-a813-d8ae5e01cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_66e086b1-6aa8-4641-aa01-aeb076ee5082" xlink:href="nvax-20220630.xsd#nvax_TakedaArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_306542bb-e9e7-4850-a813-d8ae5e01cc77" xlink:to="loc_nvax_TakedaArrangementMember_66e086b1-6aa8-4641-aa01-aeb076ee5082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdafea30-7002-4296-86ed-3de319df5f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_231a8473-2dc8-4e5d-a17f-0c256e17d7b9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdafea30-7002-4296-86ed-3de319df5f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PotentialFutureMilestonePayments_700e4566-30bf-4032-9621-952496424968" xlink:href="nvax-20220630.xsd#nvax_PotentialFutureMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdafea30-7002-4296-86ed-3de319df5f5c" xlink:to="loc_nvax_PotentialFutureMilestonePayments_700e4566-30bf-4032-9621-952496424968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nvax-20220630.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_c8daea99-3f70-47f1-b527-0524618732d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_16dead5d-b81c-4ca0-baf7-fb59179c8ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8daea99-3f70-47f1-b527-0524618732d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_16dead5d-b81c-4ca0-baf7-fb59179c8ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f22bef99-e3e0-4ecf-bdd5-3d9add9c43f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_86709ee2-a5a4-416e-9e51-9a8f9c4c617c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f22bef99-e3e0-4ecf-bdd5-3d9add9c43f4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_86709ee2-a5a4-416e-9e51-9a8f9c4c617c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#CashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_74e44d57-a412-4a17-b553-2bfcd487d870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8a3fc5c-c98c-4a72-a04a-de64193e3897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74e44d57-a412-4a17-b553-2bfcd487d870" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8a3fc5c-c98c-4a72-a04a-de64193e3897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2a8ada13-98df-450f-abba-3f66ebe13f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74e44d57-a412-4a17-b553-2bfcd487d870" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2a8ada13-98df-450f-abba-3f66ebe13f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c356eff9-ce9d-4695-bf7c-cbf01ff85bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74e44d57-a412-4a17-b553-2bfcd487d870" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c356eff9-ce9d-4695-bf7c-cbf01ff85bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89efb498-706c-4149-84de-3d75b35b3cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74e44d57-a412-4a17-b553-2bfcd487d870" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89efb498-706c-4149-84de-3d75b35b3cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nvax-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_614e74c1-54d3-498a-8765-b4051c2455e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_90c3eb9a-9271-4aa1-af44-c5218111e2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_614e74c1-54d3-498a-8765-b4051c2455e4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_90c3eb9a-9271-4aa1-af44-c5218111e2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d60f1072-960b-472f-a356-7a01540a8261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_0bec070c-a1fa-4016-9228-8cc7c5e6363f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d60f1072-960b-472f-a356-7a01540a8261" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_0bec070c-a1fa-4016-9228-8cc7c5e6363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6e180c36-cf87-46b8-8803-edb6acbf549b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e180c36-cf87-46b8-8803-edb6acbf549b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc74b28a-c0a5-420f-8833-92603101f6d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2f823466-89c4-4977-aee8-abb8cfb5f275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2f823466-89c4-4977-aee8-abb8cfb5f275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56778f21-3486-45aa-8128-a3d1f25fce01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56778f21-3486-45aa-8128-a3d1f25fce01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9802701a-1ec8-40d5-879d-b7bb1648e318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d7835b9-85af-4f4a-a075-5245fe14f9d2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9802701a-1ec8-40d5-879d-b7bb1648e318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_50df47a1-0257-4f10-820f-e5b546291758" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a791b4f0-50c3-4c10-a6aa-7b8c9721f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a791b4f0-50c3-4c10-a6aa-7b8c9721f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentBackedSecuritiesMember_820b03d9-4aba-44b6-b944-a9e2946b6c91" xlink:href="nvax-20220630.xsd#nvax_GovernmentBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:to="loc_nvax_GovernmentBackedSecuritiesMember_820b03d9-4aba-44b6-b944-a9e2946b6c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ae083ce-2cd8-492b-97cf-ca13fadacc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4483fb43-d8c2-402b-96b3-3e7668b15ec8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ae083ce-2cd8-492b-97cf-ca13fadacc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e305a53-ea4f-4ed4-b894-0e2f73e6760e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b5c1c0aa-8bb0-4204-94f4-75bd50318d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b5c1c0aa-8bb0-4204-94f4-75bd50318d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_ef3d11af-6c9a-45e3-a5ec-5e165774d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b5c1c0aa-8bb0-4204-94f4-75bd50318d5c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_ef3d11af-6c9a-45e3-a5ec-5e165774d51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1420dcc1-5b2d-4885-a735-e31fc761b79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c91704-7bb0-424f-a2a7-c4a030eb39dd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1420dcc1-5b2d-4885-a735-e31fc761b79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_c06bd265-602b-468b-973a-2541b6bb4c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1420dcc1-5b2d-4885-a735-e31fc761b79f" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_c06bd265-602b-468b-973a-2541b6bb4c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Inventory" xlink:type="simple" xlink:href="nvax-20220630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fb18cb3d-eb50-4c27-851c-a4958b965453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_04588b0e-737e-495e-8118-f0c7e108e518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fb18cb3d-eb50-4c27-851c-a4958b965453" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_04588b0e-737e-495e-8118-f0c7e108e518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ae15fc9b-3f28-47a1-a429-4fd3e7c4ac0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8d6ecd5d-c180-4048-b2d6-c32a82247978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae15fc9b-3f28-47a1-a429-4fd3e7c4ac0f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8d6ecd5d-c180-4048-b2d6-c32a82247978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_9fbe299e-3c6e-450e-a265-b33c3b8cbcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:to="loc_us-gaap_InventoryRawMaterials_9fbe299e-3c6e-450e-a265-b33c3b8cbcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_76021110-d7cf-4abe-971a-6a1cb2761c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:to="loc_us-gaap_InventoryWorkInProcess_76021110-d7cf-4abe-971a-6a1cb2761c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f66f0ec4-a5be-406c-905e-8df9bce6076a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:to="loc_us-gaap_InventoryFinishedGoods_f66f0ec4-a5be-406c-905e-8df9bce6076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7cdfb701-8f79-4280-b299-0723b93a15cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:to="loc_us-gaap_InventoryNet_7cdfb701-8f79-4280-b299-0723b93a15cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_6eb3d051-2d1c-4444-be5c-e074d056ee35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:to="loc_us-gaap_InventoryWriteDown_6eb3d051-2d1c-4444-be5c-e074d056ee35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_79de9cde-2552-45db-945e-d7b4a32cffea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8425288-687e-47e0-8bbb-4000fa8c11be" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_79de9cde-2552-45db-945e-d7b4a32cffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f5488b5e-f37a-439f-8e52-f509e8611625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fa7a9760-4d4a-4c76-b35c-e607c9fea7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f5488b5e-f37a-439f-8e52-f509e8611625" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fa7a9760-4d4a-4c76-b35c-e607c9fea7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160f6be8-72e5-4eb4-a2ec-19aa15c04f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_94f65d1e-64d4-4140-b85e-11610580e03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160f6be8-72e5-4eb4-a2ec-19aa15c04f02" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_94f65d1e-64d4-4140-b85e-11610580e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_47840079-7310-4058-bdaf-bfd2002e5c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160f6be8-72e5-4eb4-a2ec-19aa15c04f02" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_47840079-7310-4058-bdaf-bfd2002e5c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_71a62ad1-f5c0-4eea-963f-0d6edf50040e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_160f6be8-72e5-4eb4-a2ec-19aa15c04f02" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_71a62ad1-f5c0-4eea-963f-0d6edf50040e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5dc9ab3a-1c4a-4709-a06c-cfeb27408295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5dc9ab3a-1c4a-4709-a06c-cfeb27408295" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_80713a3e-cefd-49ff-8e33-c48c0932ac59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProprietaryAdjuvantTechnologyMember_dd6aa588-e038-4326-9967-1e3a7eaa2fb1" xlink:href="nvax-20220630.xsd#nvax_ProprietaryAdjuvantTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:to="loc_nvax_ProprietaryAdjuvantTechnologyMember_dd6aa588-e038-4326-9967-1e3a7eaa2fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementsMember_c6056f2a-0add-44e0-8eae-fe669f8babeb" xlink:href="nvax-20220630.xsd#nvax_CollaborationAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43b3c8d6-a9d6-4363-a050-2332fb416bde" xlink:to="loc_nvax_CollaborationAgreementsMember_c6056f2a-0add-44e0-8eae-fe669f8babeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d865c74-da5f-45d6-bf6c-0eec64e85e18" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1fc7424a-9679-4974-85ba-9ad35d14b9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1fc7424a-9679-4974-85ba-9ad35d14b9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8a3fd23-6866-4bfa-b8cf-897c74da7d65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_237e7ae9-706e-4eda-884f-e3b162596156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_237e7ae9-706e-4eda-884f-e3b162596156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fdbbaead-ac79-498c-9e3f-d7ec65db9831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fdbbaead-ac79-498c-9e3f-d7ec65db9831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_869600de-513c-4da9-b590-b34529f421d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_70503852-34a8-4867-9f01-461b4ae47804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_869600de-513c-4da9-b590-b34529f421d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ddcc60ab-ad75-4573-8f40-c7a94dfdc65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ddcc60ab-ad75-4573-8f40-c7a94dfdc65c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e810e390-f9cc-41b1-a722-611d06f43ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e810e390-f9cc-41b1-a722-611d06f43ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_da661a9f-e329-4a3b-aa26-02a1731068ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_da661a9f-e329-4a3b-aa26-02a1731068ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5a8b639a-6905-47b6-8586-f433c449f67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5a8b639a-6905-47b6-8586-f433c449f67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2f005ae-c917-4061-933d-d691d8a132bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2f005ae-c917-4061-933d-d691d8a132bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6055f190-14ce-4937-8899-9bd541a06251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6055f190-14ce-4937-8899-9bd541a06251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e1d2373b-b716-434e-94e3-0793220948e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7548fb5a-6113-4dcc-89f4-607683dbe20c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e1d2373b-b716-434e-94e3-0793220948e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b1446ad7-53b9-4b5d-a14a-b0c0c046abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_1e76a279-42b4-41e8-9648-c58b763f495b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b1446ad7-53b9-4b5d-a14a-b0c0c046abb5" xlink:to="loc_us-gaap_GoodwillRollForward_1e76a279-42b4-41e8-9648-c58b763f495b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ae019bec-0983-47db-8167-12babd7c2605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1e76a279-42b4-41e8-9648-c58b763f495b" xlink:to="loc_us-gaap_Goodwill_ae019bec-0983-47db-8167-12babd7c2605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b5274d1a-769f-447d-8732-55917a1e1a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1e76a279-42b4-41e8-9648-c58b763f495b" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b5274d1a-769f-447d-8732-55917a1e1a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_84258e75-6a43-4b07-9437-7eab764570a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1e76a279-42b4-41e8-9648-c58b763f495b" xlink:to="loc_us-gaap_Goodwill_84258e75-6a43-4b07-9437-7eab764570a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Leases" xlink:type="simple" xlink:href="nvax-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9a452487-4633-476e-9efa-36370df44c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_09cfa9ca-4a53-46f6-8aaa-5134f37b5868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a452487-4633-476e-9efa-36370df44c95" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_09cfa9ca-4a53-46f6-8aaa-5134f37b5868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a3f8cb4f-378c-4bd0-9310-c83440755632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a452487-4633-476e-9efa-36370df44c95" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a3f8cb4f-378c-4bd0-9310-c83440755632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d94661fb-8429-4342-8494-4394eeb06647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d94661fb-8429-4342-8494-4394eeb06647" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:to="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27b6f8d3-f59e-4391-a2d6-11d1ff3f1bdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c0fb5953-54bf-4f65-ab8f-e2f41e027447" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27b6f8d3-f59e-4391-a2d6-11d1ff3f1bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700Q0AgreementMember_f03fbff5-c338-4287-8e77-c5d42b9f2ceb" xlink:href="nvax-20220630.xsd#nvax_A700Q0AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27b6f8d3-f59e-4391-a2d6-11d1ff3f1bdf" xlink:to="loc_nvax_A700Q0AgreementMember_f03fbff5-c338-4287-8e77-c5d42b9f2ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ac4fb634-15df-4cd3-a401-492b2059ac29" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c8aa1222-7ae3-46ac-8ede-d49a5ad3f937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c8aa1222-7ae3-46ac-8ede-d49a5ad3f937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_ba11669a-99e7-4837-9c8d-62f978f3722a" xlink:href="nvax-20220630.xsd#nvax_LongTermSupplyAgreementIncrementalBorrowingRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_nvax_LongTermSupplyAgreementIncrementalBorrowingRate_ba11669a-99e7-4837-9c8d-62f978f3722a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_59b60fc1-d00a-464d-be1e-fbfcf9338dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_ShortTermLeaseCost_59b60fc1-d00a-464d-be1e-fbfcf9338dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a700adf0-7d4d-42f8-9375-9abd71cbfb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_OperatingLeaseExpense_a700adf0-7d4d-42f8-9375-9abd71cbfb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_713f633b-bfba-46c8-a559-90f6b99989b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_713f633b-bfba-46c8-a559-90f6b99989b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet_5208933b-66c9-4864-8bb3-eac5b820eebf" xlink:href="nvax-20220630.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_nvax_FacilityNumberOfSquareFeet_5208933b-66c9-4864-8bb3-eac5b820eebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b84a9b74-7440-42b6-8268-610fcc3f0f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b84a9b74-7440-42b6-8268-610fcc3f0f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_35c3e0e3-5a5e-47d7-911d-ceb6b8eb7253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_af4f5ce4-aa75-43de-a53f-3cdcaf402a02" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_35c3e0e3-5a5e-47d7-911d-ceb6b8eb7253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Debt" xlink:type="simple" xlink:href="nvax-20220630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5048465c-893d-4eb1-ae75-a826ae8b6163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_b1fbcc0c-cb3e-4046-8844-6befc4bb29a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5048465c-893d-4eb1-ae75-a826ae8b6163" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_b1fbcc0c-cb3e-4046-8844-6befc4bb29a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/DebtTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ad7491fc-9154-4638-adf2-311fcbef770f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_c4a03e95-0b9a-44cc-9833-f260a11fdc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ad7491fc-9154-4638-adf2-311fcbef770f" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_c4a03e95-0b9a-44cc-9833-f260a11fdc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_9d90175f-56d5-4153-8fcb-d9cb032e925c" xlink:href="nvax-20220630.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ad7491fc-9154-4638-adf2-311fcbef770f" xlink:to="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_9d90175f-56d5-4153-8fcb-d9cb032e925c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7987c906-3da5-4dbc-ba4b-1e965d182457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_8ebe5dd0-5527-4583-b3db-29c8cff5986d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7987c906-3da5-4dbc-ba4b-1e965d182457" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_8ebe5dd0-5527-4583-b3db-29c8cff5986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d85e1bcf-db38-404d-872b-5b7a2c5ca1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7987c906-3da5-4dbc-ba4b-1e965d182457" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d85e1bcf-db38-404d-872b-5b7a2c5ca1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6c138f95-a1f0-44c1-a13d-2ab710176ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7987c906-3da5-4dbc-ba4b-1e965d182457" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6c138f95-a1f0-44c1-a13d-2ab710176ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_591daef1-9e43-4bfc-bc50-123724a407c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7987c906-3da5-4dbc-ba4b-1e965d182457" xlink:to="loc_us-gaap_DebtInstrumentTerm_591daef1-9e43-4bfc-bc50-123724a407c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/DebtNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#DebtNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/DebtNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_39093fa7-659f-4f77-a811-1d963e763518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_483711e6-4567-4c46-9dce-c84610f44015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39093fa7-659f-4f77-a811-1d963e763518" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_483711e6-4567-4c46-9dce-c84610f44015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_eff2bb65-a729-4fe9-8e21-1db04281deb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39093fa7-659f-4f77-a811-1d963e763518" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_eff2bb65-a729-4fe9-8e21-1db04281deb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_138abdaf-a62f-44e9-9469-83c71e010d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_39093fa7-659f-4f77-a811-1d963e763518" xlink:to="loc_us-gaap_ConvertibleNotesPayable_138abdaf-a62f-44e9-9469-83c71e010d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_57fde905-600a-4bea-b5e9-a5a24e423038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7bf3643c-0cf4-4b01-96f7-1efcea7abba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_57fde905-600a-4bea-b5e9-a5a24e423038" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7bf3643c-0cf4-4b01-96f7-1efcea7abba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_87b71163-5178-4c8f-b4df-0efabf38bc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_57fde905-600a-4bea-b5e9-a5a24e423038" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_87b71163-5178-4c8f-b4df-0efabf38bc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7935a61c-f8b4-4e5a-bd35-e2e07f8ce14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_57fde905-600a-4bea-b5e9-a5a24e423038" xlink:to="loc_us-gaap_InterestExpenseDebt_7935a61c-f8b4-4e5a-bd35-e2e07f8ce14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b1dfcada-1b76-43d1-9ccd-9293915771b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_57fde905-600a-4bea-b5e9-a5a24e423038" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b1dfcada-1b76-43d1-9ccd-9293915771b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d54c3eb6-03c5-4a22-aeb5-e63501e0beca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0d06d317-d79c-4f15-8961-9cdd765149e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d54c3eb6-03c5-4a22-aeb5-e63501e0beca" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0d06d317-d79c-4f15-8961-9cdd765149e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockholdersEquityDeficitDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersEquityDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fe7dfe37-bd47-40d6-b27b-63478ae9dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fe7dfe37-bd47-40d6-b27b-63478ae9dd66" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbddab75-97f1-4c88-a1f6-1139b2734745" xlink:to="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1dd5576f-469d-41a0-a938-764d4e8b1c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:to="loc_us-gaap_CommonStockMember_1dd5576f-469d-41a0-a938-764d4e8b1c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f93473a4-0b40-465f-a222-60da430d424c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8e6017f-9475-438b-a5a0-a5d64368064b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f93473a4-0b40-465f-a222-60da430d424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a2d71b73-2be7-4f5d-abdf-22578c55fedf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce900f65-78e4-4627-a11e-f79180f309e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce900f65-78e4-4627-a11e-f79180f309e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13e98542-74ab-45f1-9ff3-a5b176c425b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13e98542-74ab-45f1-9ff3-a5b176c425b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_ca0ff74e-4611-4ede-bd71-7900ac5e3428" xlink:href="nvax-20220630.xsd#nvax_ShelfRegistrationStatementRemainingUnissuedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f95837c8-cb48-4f2f-b0eb-0fb7434040a4" xlink:to="loc_nvax_ShelfRegistrationStatementRemainingUnissuedCapital_ca0ff74e-4611-4ede-bd71-7900ac5e3428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_665d44e5-aac5-4def-9c4c-3af446f077ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77d13590-40c4-4e56-8adf-d3cbb60024c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_665d44e5-aac5-4def-9c4c-3af446f077ed" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77d13590-40c4-4e56-8adf-d3cbb60024c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8ec7031-c02a-47ab-91cd-6ab786c12719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_13c9b29a-ecef-49d6-b1cd-0342cdf2f660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8ec7031-c02a-47ab-91cd-6ab786c12719" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_13c9b29a-ecef-49d6-b1cd-0342cdf2f660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d40abd99-c47e-4bb9-89d6-5be52d066ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8ec7031-c02a-47ab-91cd-6ab786c12719" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d40abd99-c47e-4bb9-89d6-5be52d066ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5cdc1246-98d9-4c49-98e4-4607d0aae1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8ec7031-c02a-47ab-91cd-6ab786c12719" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5cdc1246-98d9-4c49-98e4-4607d0aae1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_44213f11-2656-4e5c-8b28-16d6c15febed" xlink:href="nvax-20220630.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8ec7031-c02a-47ab-91cd-6ab786c12719" xlink:to="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_44213f11-2656-4e5c-8b28-16d6c15febed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64a62c4f-b07f-419a-9cec-065f36be50b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64a62c4f-b07f-419a-9cec-065f36be50b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_acde5732-7342-4c2a-8566-f7a6189a14b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_47c96961-7913-4433-ae4d-fd1e45f29e57" xlink:to="loc_us-gaap_PlanNameDomain_acde5732-7342-4c2a-8566-f7a6189a14b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_a629c5f5-6510-4c6e-9116-68fca87f0a8c" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_acde5732-7342-4c2a-8566-f7a6189a14b3" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_a629c5f5-6510-4c6e-9116-68fca87f0a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cbdbc74f-6c56-484c-9189-427d38b4f415" xlink:to="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c219e714-09c0-43e7-8a55-0c7ff249bb0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:to="loc_srt_MinimumMember_c219e714-09c0-43e7-8a55-0c7ff249bb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60b200b7-f1e1-497e-a590-a0ef807df1c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0addcd5d-87cd-4c09-a0b0-aee08afffcb1" xlink:to="loc_srt_MaximumMember_60b200b7-f1e1-497e-a590-a0ef807df1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd044e2c-6764-487f-bca7-53c3e03c4e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3a94688e-1d46-4c77-a55b-52b8bae07f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd044e2c-6764-487f-bca7-53c3e03c4e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_58334340-da10-4f03-9955-c182990b49cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd044e2c-6764-487f-bca7-53c3e03c4e69" xlink:to="loc_us-gaap_EmployeeStockMember_58334340-da10-4f03-9955-c182990b49cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb5429b3-32b3-41c5-a374-1a8ed241a05a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0634b530-2b16-4f98-9004-2286d531de76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0634b530-2b16-4f98-9004-2286d531de76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ffe42f1d-3ca0-4435-abb9-bc0d9c10d7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ffe42f1d-3ca0-4435-abb9-bc0d9c10d7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8b89a685-5140-4e65-81b5-9bf9f90ea6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8b89a685-5140-4e65-81b5-9bf9f90ea6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8ca57641-8bb0-4360-968d-f7b620bd30f3" xlink:href="nvax-20220630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8ca57641-8bb0-4360-968d-f7b620bd30f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5dd8a4b8-e20d-4672-814b-f706242f0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5dd8a4b8-e20d-4672-814b-f706242f0a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8269ee5f-6611-4cf5-8b5d-6540c1f1acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8269ee5f-6611-4cf5-8b5d-6540c1f1acb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d0d6ae6-a14e-43e1-94de-56ad263e4f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d0d6ae6-a14e-43e1-94de-56ad263e4f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_43101f02-0151-46bc-9736-303b426910f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_43101f02-0151-46bc-9736-303b426910f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60369e0d-c956-4ec5-a2d2-2aacf47fccd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60369e0d-c956-4ec5-a2d2-2aacf47fccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7167468f-0070-43e3-98e4-f8881155128a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7167468f-0070-43e3-98e4-f8881155128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_efe30073-efae-4405-8bae-5cbe6b684ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_efe30073-efae-4405-8bae-5cbe6b684ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8e8433ee-97a8-43c1-9005-15dbba14e728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8e8433ee-97a8-43c1-9005-15dbba14e728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_bbe37efd-6da2-4165-b89f-542c2fbade9f" xlink:href="nvax-20220630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_bbe37efd-6da2-4165-b89f-542c2fbade9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_226d6211-c257-497d-bf81-1b13eb42ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_075940b2-bb52-4ed3-a843-72f8e4fd665b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_075940b2-bb52-4ed3-a843-72f8e4fd665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3d111e53-4883-4082-8bfa-2b7f60c5c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3d111e53-4883-4082-8bfa-2b7f60c5c2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9f5ecc33-214b-4b05-a074-02f3109cb74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf3cc5ba-5f34-4b8c-b079-0f4dd028317c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9f5ecc33-214b-4b05-a074-02f3109cb74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16465a78-ea21-4611-a75d-1d6170731b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16465a78-ea21-4611-a75d-1d6170731b89" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d53eb1fa-97da-448d-b56c-c40b3628650c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4781480-44cb-46ed-909c-ae0fab5c9103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4781480-44cb-46ed-909c-ae0fab5c9103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9a617b7a-f9c4-4730-905a-5502bbfad3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e552d3e5-748c-4800-8131-952613200767" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9a617b7a-f9c4-4730-905a-5502bbfad3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_03e729f0-c44d-4366-be29-5915ff1970d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b53acce2-6afe-4a6e-b102-58136f6be262" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_03e729f0-c44d-4366-be29-5915ff1970d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8f036d-f867-4f74-a925-ebaeb91aaf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_03e729f0-c44d-4366-be29-5915ff1970d7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc8f036d-f867-4f74-a925-ebaeb91aaf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationStockOptionsandAppreciationRightsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f46d0d0-bc72-4954-b7a9-93e8976655e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f46d0d0-bc72-4954-b7a9-93e8976655e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:to="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_86642a7e-2f4e-4cfd-a88d-959b2732cec6" xlink:to="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_be751e08-efa5-403b-b6bd-170c6b55b59a" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_be751e08-efa5-403b-b6bd-170c6b55b59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_f871e166-52c0-4f5f-8ac2-b6c83e318658" xlink:href="nvax-20220630.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f034ed09-9836-4201-8182-4026df62bfd8" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_f871e166-52c0-4f5f-8ac2-b6c83e318658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_508728f3-6759-4a07-9a79-9a20b6e3e7cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9936ace7-3e99-430e-b1b6-6f9759af8b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9936ace7-3e99-430e-b1b6-6f9759af8b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2556517b-6e2c-46e0-b5a7-0feda86c01a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2556517b-6e2c-46e0-b5a7-0feda86c01a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e402c73-7714-4cec-a935-8d7f2683ae12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e402c73-7714-4cec-a935-8d7f2683ae12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a90dc5a8-2217-422e-b2c8-77c7fba364c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a90dc5a8-2217-422e-b2c8-77c7fba364c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd73f07-4397-45c6-817f-7f0716b2e718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ea2a87c-e6d1-4c50-aa7c-5b2c8fe4637f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd73f07-4397-45c6-817f-7f0716b2e718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1d1f43c-9c81-4c3e-ac2a-db1226d8f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c1d1f43c-9c81-4c3e-ac2a-db1226d8f1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16915a7e-54df-471b-ae65-8f8170ab2085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16915a7e-54df-471b-ae65-8f8170ab2085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e02fea24-00e1-4db4-afb6-de80f64f9324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17c06188-c304-4c9f-b0a9-501f1f55d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17c06188-c304-4c9f-b0a9-501f1f55d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc6d0e72-d06b-4cc6-9e62-21078fc875a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc6d0e72-d06b-4cc6-9e62-21078fc875a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9cb14f8c-a46a-429a-81b8-3644dcba930a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9cb14f8c-a46a-429a-81b8-3644dcba930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d1faf9b-fab5-4bae-91ad-83d7c59abcee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d1faf9b-fab5-4bae-91ad-83d7c59abcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1e7b7a91-87af-458e-acf1-cb31a41601b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1e7b7a91-87af-458e-acf1-cb31a41601b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8131b168-26e9-43fc-a587-953ff04705ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1912e7c-7cc8-40af-bdd3-2c5de53b3ca1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8131b168-26e9-43fc-a587-953ff04705ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a580299-b801-4a21-8269-315e395911af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a580299-b801-4a21-8269-315e395911af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:to="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5881a7f7-a90f-4164-8f75-1a32b7a4773f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9163c5cd-696d-481e-9f8f-7f8e54824507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5881a7f7-a90f-4164-8f75-1a32b7a4773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b9794a90-0a2e-4bff-b553-cd8a8ac54e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5881a7f7-a90f-4164-8f75-1a32b7a4773f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b9794a90-0a2e-4bff-b553-cd8a8ac54e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:to="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a9b96d75-4bdc-42bd-a398-625013924e6e" xlink:to="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2100d2c6-e6bd-4107-813c-e535be7dc748" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:to="loc_srt_MinimumMember_2100d2c6-e6bd-4107-813c-e535be7dc748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9bb128f2-000f-47de-9f11-186631b4cb47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6b9f1a8-e28d-49d5-a6ca-b10286832e89" xlink:to="loc_srt_MaximumMember_9bb128f2-000f-47de-9f11-186631b4cb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1770d4d7-5fa6-46a2-8bdf-4e93e27b3e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b1738d-c808-4bf0-802c-d06225f7cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1770d4d7-5fa6-46a2-8bdf-4e93e27b3e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1770d4d7-5fa6-46a2-8bdf-4e93e27b3e2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18d5bbd-d38d-458d-ade6-ae5a3c423482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18d5bbd-d38d-458d-ade6-ae5a3c423482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0c4f3ca4-f63f-4c54-bfbc-0e3054d4ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0c4f3ca4-f63f-4c54-bfbc-0e3054d4ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_976705b7-f483-464f-8477-88f54501061d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_976705b7-f483-464f-8477-88f54501061d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_299ddb72-00de-4a2f-8489-bf2a536f5211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_299ddb72-00de-4a2f-8489-bf2a536f5211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_82089dad-d415-4aa1-9113-44672c518530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_82089dad-d415-4aa1-9113-44672c518530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d99ecfb0-a4c7-48fd-802a-2fd3ab3073a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d99ecfb0-a4c7-48fd-802a-2fd3ab3073a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a4789e6c-9713-42e0-9167-14d88b2022d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_290ffcf0-2978-446e-9ad4-69a581a6d09d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a4789e6c-9713-42e0-9167-14d88b2022d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5962b7e-1fcb-4040-a712-01a66cd3f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5962b7e-1fcb-4040-a712-01a66cd3f9b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:to="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_603ebafb-117b-4e81-9fa2-742e4bbc254e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f3da5024-edc7-4127-9c11-2fbd692aacb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_603ebafb-117b-4e81-9fa2-742e4bbc254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6ea4373-496a-4089-8ff1-4e8c27d51912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_603ebafb-117b-4e81-9fa2-742e4bbc254e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6ea4373-496a-4089-8ff1-4e8c27d51912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_67a535ce-0afb-4285-8a8c-83cac02eaa9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_add5b693-bddf-4dfa-9f81-ea68aac85684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_add5b693-bddf-4dfa-9f81-ea68aac85684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_632e6d1b-15d4-4efe-8199-3fa009258c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_632e6d1b-15d4-4efe-8199-3fa009258c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d1728c7c-5a7b-43bf-8637-ef47f2577fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d1728c7c-5a7b-43bf-8637-ef47f2577fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d8eef005-6014-4cca-99be-99f2b066955d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d8eef005-6014-4cca-99be-99f2b066955d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5913957-768a-4f8d-835d-b5b9af0196a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_71b5376d-8d66-489e-a9e0-130e0c2a5571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5913957-768a-4f8d-835d-b5b9af0196a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b947ae3-e2ee-4b57-88c1-3dd8385a9998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a975c593-4815-451b-ac20-8f417877036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a975c593-4815-451b-ac20-8f417877036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31987949-6e5b-4cef-b4a9-30c8c3931066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31987949-6e5b-4cef-b4a9-30c8c3931066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae2e83f3-51d0-4e51-8bdd-87378ff84fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae2e83f3-51d0-4e51-8bdd-87378ff84fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5bb2dbca-56e7-4afc-adab-6d97bdfc0e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5bb2dbca-56e7-4afc-adab-6d97bdfc0e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_efc4a512-744b-404a-985b-311982d3d854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_591667aa-2f88-4802-b573-9ae158b8aee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_efc4a512-744b-404a-985b-311982d3d854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da3de214-df73-40d1-8c7e-c732c526fada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da3de214-df73-40d1-8c7e-c732c526fada" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:to="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67cec4e6-db80-4011-8d28-506c40d7231c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2ed20080-b505-4abb-a644-a246f1062fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67cec4e6-db80-4011-8d28-506c40d7231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c8cc91c5-92eb-49df-91f9-418ffe31bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67cec4e6-db80-4011-8d28-506c40d7231c" xlink:to="loc_us-gaap_EmployeeStockMember_c8cc91c5-92eb-49df-91f9-418ffe31bc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:to="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_818ecff6-48c7-42d0-a178-1b2943fe1ff0" xlink:to="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e800e39d-da3b-4721-9796-363bc171954c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:to="loc_srt_MinimumMember_e800e39d-da3b-4721-9796-363bc171954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a91e422-faad-4bd3-a357-e54e7df5db66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26754934-e551-4a8d-9ff8-d22a5e73c147" xlink:to="loc_srt_MaximumMember_5a91e422-faad-4bd3-a357-e54e7df5db66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b01afb4-fab5-40ea-9eed-70cfc067ee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e83f41aa-d414-4531-a8ad-9ddf79fe8661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b01afb4-fab5-40ea-9eed-70cfc067ee0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b01afb4-fab5-40ea-9eed-70cfc067ee0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_803038e7-7670-403f-b28b-6c44f046bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_803038e7-7670-403f-b28b-6c44f046bc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_61e71bb2-2323-4a01-81fa-ae9ea584e673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_61e71bb2-2323-4a01-81fa-ae9ea584e673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ac4afe87-3022-4fdd-b2f2-55929cf58fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ac4afe87-3022-4fdd-b2f2-55929cf58fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bbac0270-2469-47bb-a732-0eea02153446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bbac0270-2469-47bb-a732-0eea02153446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_51b518b4-cc3e-415d-aabd-cc57c1e7edb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_51b518b4-cc3e-415d-aabd-cc57c1e7edb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_30842713-d3b5-4910-b880-ff44dca61ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_30842713-d3b5-4910-b880-ff44dca61ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2429eab-87bc-452d-a3c5-5414b4b45821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_dcdd760f-5535-4d3a-8559-f52e047d2171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2429eab-87bc-452d-a3c5-5414b4b45821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nvax-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b3d2ae53-fa92-4887-8475-b2a4476cd36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_33e75abb-fcaf-419e-a54e-40b1d0cc27ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3d2ae53-fa92-4887-8475-b2a4476cd36c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_33e75abb-fcaf-419e-a54e-40b1d0cc27ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dfb34e50-4a00-4090-afff-c96e458c8a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_bf02ff1b-a37d-4089-b075-b1e32309d5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dfb34e50-4a00-4090-afff-c96e458c8a58" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_bf02ff1b-a37d-4089-b075-b1e32309d5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_417715f6-d2e6-4938-9644-266d97148572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dfb34e50-4a00-4090-afff-c96e458c8a58" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_417715f6-d2e6-4938-9644-266d97148572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nvax-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_512243ba-1ec8-4ac2-9a33-52f96d16eb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fa18cd91-3588-47c7-9ef8-5232ed76c28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_512243ba-1ec8-4ac2-9a33-52f96d16eb7e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fa18cd91-3588-47c7-9ef8-5232ed76c28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nvax-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6aca4036-c14e-4682-87bd-08e04d980f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_098dd572-6264-49c5-acf5-047b969060a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6aca4036-c14e-4682-87bd-08e04d980f8a" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_098dd572-6264-49c5-acf5-047b969060a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nvax-20220630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e7946f5d-314e-4a98-8b92-64ca708b172b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e7946f5d-314e-4a98-8b92-64ca708b172b" xlink:to="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_96e4e433-8cb3-405b-b536-a21a4086a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c76b191a-6e5e-408d-9f61-ac96a803f50f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_96e4e433-8cb3-405b-b536-a21a4086a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9cc288d8-696a-4e1e-86a3-33d5b064d1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_96e4e433-8cb3-405b-b536-a21a4086a5e6" xlink:to="loc_us-gaap_SubsequentEventMember_9cc288d8-696a-4e1e-86a3-33d5b064d1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dab7d75b-2f6f-4bae-b12f-a43fa7781f7d" xlink:to="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b273db60-4c36-47dd-8a6f-2e8b7b512c17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:to="loc_srt_MinimumMember_b273db60-4c36-47dd-8a6f-2e8b7b512c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e9858a5c-8130-40a6-8d06-29ff57fb24f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5cfed9fd-2bf9-457d-a1ed-fe9ca30d0e8a" xlink:to="loc_srt_MaximumMember_e9858a5c-8130-40a6-8d06-29ff57fb24f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9c96e841-68dc-46c1-bf2f-11fc86c96158" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_21a64e26-155f-48cc-a01b-195760fdd189" xlink:href="nvax-20220630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:to="loc_nvax_USGovernmentPartnershipMember_21a64e26-155f-48cc-a01b-195760fdd189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_65581678-957e-40e3-a047-259a14000ed7" xlink:href="nvax-20220630.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_65581678-957e-40e3-a047-259a14000ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_0cea937c-d0ca-4ded-a662-19e7dc0ab1bb" xlink:href="nvax-20220630.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02dd029e-5027-4515-8f58-9c571c569462" xlink:to="loc_nvax_EuropeanCommissionsECMember_0cea937c-d0ca-4ded-a662-19e7dc0ab1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_68139a5a-23cb-4d36-b2a7-66a3faabe40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_d36a574f-4b88-47a5-8c18-2624876b9b2a" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_68139a5a-23cb-4d36-b2a7-66a3faabe40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e6b25ca6-fa1c-40bf-b29d-487b08efe310" xlink:href="nvax-20220630.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_68139a5a-23cb-4d36-b2a7-66a3faabe40c" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e6b25ca6-fa1c-40bf-b29d-487b08efe310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2bc9523-495a-4924-ab03-d1907a0c18a5" xlink:to="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_6a98a875-ba4c-4496-b53d-84a6be2db3f7" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_6a98a875-ba4c-4496-b53d-84a6be2db3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_79e7c303-9c1a-4989-9943-cd8e66b60873" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesToBeDistributed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesToBeDistributed_79e7c303-9c1a-4989-9943-cd8e66b60873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_6ce968c8-e8db-4cd7-a9ac-cf0c715b2184" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_6ce968c8-e8db-4cd7-a9ac-cf0c715b2184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_5af85c7e-aa5c-408d-bcf4-38b40d054e04" xlink:href="nvax-20220630.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_5af85c7e-aa5c-408d-bcf4-38b40d054e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_2c88c16c-200f-4785-829a-6048e13828cc" xlink:href="nvax-20220630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_229588fe-7a18-4191-9745-a3b25d5ef248" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_2c88c16c-200f-4785-829a-6048e13828cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nvax-20220630_g1.jpg
<TEXT>
begin 644 nvax-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 27!#H# 2(  A$! Q$!_\0
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M )*9XL_["MU_Z-:N7K]NHY?@W3BW1CLOLH_/)XJNIOWW][,C_A'/^H[XF_\
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M[XF_\*&]_P#CM:]%']GX/_GS'_P%?Y!]:K_\_'][,C_A'/\ J.^)O_"AO?\
MX[1_PCG_ %'?$W_A0WO_ ,=K7HH_L_!_\^8_^ K_ "#ZU7_Y^/[V9'_".?\
M4=\3?^%#>_\ QVC_ (1S_J.^)O\ PH;W_P".UKT4?V?@_P#GS'_P%?Y!]:K_
M //Q_>S(_P"$<_ZCOB;_ ,*&]_\ CM'_  CG_4=\3?\ A0WO_P =K7HH_L_!
M_P#/F/\ X"O\@^M5_P#GX_O9D?\ ".?]1WQ-_P"%#>__ !VC_A'/^H[XF_\
M"AO?_CM:]%']GX/_ )\Q_P# 5_D'UJO_ ,_'][,C_A'/^H[XF_\ "AO?_CM'
M_".?]1WQ-_X4-[_\=K7HH_L_!_\ /F/_ ("O\@^M5_\ GX_O9D?\(Y_U'?$W
M_A0WO_QVC_A'/^H[XF_\*&]_^.UKT4?V?@_^?,?_  %?Y!]:K_\ /Q_>S(_X
M1S_J.^)O_"AO?_CM'_".?]1WQ-_X4-[_ /':UZ*/[/P?_/F/_@*_R#ZU7_Y^
M/[V9'_".?]1WQ-_X4-[_ /':/^$<_P"H[XF_\*&]_P#CM:]%']GX/_GS'_P%
M?Y!]:K_\_'][,C_A'/\ J.^)O_"AO?\ X[1_PCG_ %'?$W_A0WO_ ,=K7HH_
ML_!_\^8_^ K_ "#ZU7_Y^/[V9'_".?\ 4=\3?^%#>_\ QVC_ (1S_J.^)O\
MPH;W_P".UKT4?V?@_P#GS'_P%?Y!]:K_ //Q_>S(_P"$<_ZCOB;_ ,*&]_\
MCM'_  CG_4=\3?\ A0WO_P =K7HH_L_!_P#/F/\ X"O\@^M5_P#GX_O9D?\
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M_P"$<_ZCOB;_ ,*&]_\ CM'_  CG_4=\3?\ A0WO_P =K7HH_L_!_P#/F/\
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MNB3?XW2,7QQ^S3XPT+QEK>EZ'HM]J^EV#KLOI&B4M&5+!V^8 #Y6YXZ5Q?\
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M$XR->I*%-N%FHZ:72NO/5W7;:SU-(T<.Z<5*2YM&_1_AIH_O/%_ _P *=?\
M&UYISVVFW#Z5<:HFERWD13]W(>64 GJ%!;ICBO2]<_93U*S7QM;Z8FJ:CJNC
MWUM!IMHJ1DWL$H_UK$?=QANX''-7-4\9>!/ 7AG1?#7AGQ9+XB$_BJ+7;O45
MMGMTM85;&PYY)QZ=>?I2^-?C)I-QX?\ C)'I'B.47NNZO;R::T+2H\]LH ?:
MV!M7KQD5E4Q&.JU%*DK1>UXO^:*N^NU^VFI<:6'A%J;N_5=GM^!XW-\,/%MO
MXP7PJ_A^^'B)AN73]@+E<9W @[=N/XLX]ZM7WP>\:Z;XIL_#=UX;O8-;O$:2
MVM&"YF502Q1L[3@ ]#7NH^.7A6;Q=IGVKQ!<PQ:CX*AT.[UZS1S/IUV&+,QR
M,GGJ5SVI^@_%SP5X0\2?#715\7W'B73_  _/>7=WXEOH) J^;"ZI"BD%]H)'
MKT'/I;Q^-2_A:V;VEO9]?5)<N[N3]6P]_CZ]UW7Z:WV."\)?LUZCJ\=A9ZO9
MZWIFMS:U#87%ND,)A@MWB\TR%BV?,"9;:1T'2N2^*WP9U_X7:MJ'VK3KH:#'
M?M9V>HS%#Y_&Y,A"<,R\X(%>@_#?XKZ-I?@^RBU;7VCU7_A.H-7G,AD9S:!<
M/*6 .1VQG/M76_"_QEHWBSQK\6?[;636O T%Y_PDT5VS-MBDAES%C=R-Z@ +
MWVXK*6*QM"I.I45X1Z6M?5+W7\]%J6J.'J0C&+LWY^74^9_$WA75O!NI_P!G
M:U8R:=?>4DQMY2I8(XRI."<9'.#S656QXQ\57GCCQ5JNOWYS=ZC<-.X[*"?E
M4>P&!^%8]?2T^?D7M/BZV[GDRY>9\NP4445H0%%%% !1110 4444 %%%% !1
M110 4444 %=3\+_ LWQ*\?:/X<BD:!;R7]].H!,,*@M(^#Z*#^.*Y:O8O@'X
M^\+?"S2?%7B'6(AJVMSP+IMCHR.T3R12']\_FA2$&,#(YX/K7'C*E2G0DZ*O
M+9>KT_#?4WH1C*HE-V74POBW\(Y/A]\0+30-)N)-;LM3BAGTJ[^7-TLG P1A
M<[LCTZ5SZ_#7Q1)?:Y8IHTS7FB8_M"$.F;?)VC/S<Y) XS7KGB_XO>"O%W@G
MPG=Z;I0\+ZOX.U2+[%HK7#W)N+,LK.%E*]B. QXP<5K>/OB!\/;#1_B7K?A[
MQ/<:SK?C>*../2_L;1-8Y(9R[G@XYZ=#QSUKRJ>+Q<80A.F^;;5=>9:NVB]U
MWWM?2YW2H4)2E*,M-]_)]]=]"K?_ +(TVG^(+O3GGU3 \-MJUJ5CB9Y[Q-H>
MV '8%U&>O/4UXSXD^&'BWP?J6GZ?K7AZ]L+[4,?98&0.9R2!M3:3DY(XZC-?
M0+?'#PY#XRU;4X/$S*#X%33;6?$N1?@#*+E>'R/O=..M8/@OXZ:+X;\-_"*;
M5KZ;6=0T&^OCJ,#;Y)[>*561) S##$;L@ D\5S4,1F%-7G'FTVLT[\K?YI)^
M;Z&M2EA9.T7;Y^:7_!/)?$OP?\:^#I-.36O#=YIYU"58+4R!2LDC'"IN!(#'
M/0D5T$/P)UG2-%\1S^*=+U?1[^PLA=V<,444B2?.4)E._*KNP 1UY->B:M\1
M/!WA3PS+HMCX[U#QY+K'B"SU-[F^AD5-,BCF5W;YN2Y P=O7T'?/UCXJ:'K/
MB+XX2R^(%DAU^U2VT66;S"LBA^ O&44#GD"MUB\942]RR[\LE?6*T3VW=[]K
MF?L,/%_%^*[/MOLOO/-/%'P-\>>"=%EU;7?#=QING1E5>>6:(C<QPH #DDDG
MH!4[? #XC1Z:M^_A#48[-H&N/-<(H6-5W$L"V5XYP<$^E>L^/_%O@>Q\#^";
M;1/B FOKX6N(;V;1I+:=I-4N?,4R.TLF  !NVJ1P*Z*W^)GP_A\7>*_%O_"T
M-3N_^$@TZXBC\/W5M,([9W3Y8W/*\'A0!QZFL_[0QGLU+V>NOV)]&K*W2ZUO
MMTW*^JX?FMS=OM1^?^5M^IP4?[+LEK8^$KS4?[;6#6-,FN[K['!#*UO<*N](
MP"P^4H"Q)ST[5YAX=^$/C7Q;X?DUS1_#5_J&DQ[LW42##;>NT$Y;'^R#7M?@
MWXP>&;&3X;"^\0[$TOPO?6-^)!*PBN77$:D8.21P",X]:E\&_%3P7?:7\/=8
MU'QOJGA.[\'VBVT_ARU@=H[\I_$A7Y?G'#;OIQUJ(XK'TE+FCS?]NOO/HM=;
M)7V5TV4Z.&FU9V^:[1[_ #/$?"OP=\:^.--34-!\-WFJ633-;^?#L"B11EE;
M+#;CU.!2:/\ !_QKKVL:GI5CX;O9M1TQ@EY P6,PL?NJ2Q R>P!.>V:]$\1?
M&6SOOA'<VND:G)HNL7WC"?5Y-.M6>-X[9CN3+*,8!QP#U'2O0F^,WA*^^+OB
MV]N?%&DW'@S58[%;JQU"QG<7GEP@-)"RKE)488 ( .<Y& :Z*F,QL>9^S[VT
M;V:[;W3=MMM[&4</AY67/VZKJG^5M?4^3)X9+6>2&9&CEC8HZ,,%6!P0??-,
MJ]KLEA)KFHOI221Z6US(UHDQRZPECL#>^W%4:^@B[I,\MZ.P44450@HHHH *
M*** "BBNY;X5W<OPY\.^)K&:74+S6M2ETV'2H+<M)N09!4@_,3Z8K*I5A3MS
MNUW;]?T+C"4[\JV.O\)_M"+X9^!>J>"S93R:XXGMM/U)=NVVMIBIE3).X9PW
M '<>E97@/XD>$X_AU-X(\<Z'J&IZ/'?'4K*XTF=8YXI2NUE;<0"I'?W/%</K
M'@;Q)X=T];[5?#^IZ;9-(81<W=J\<9<$@KN(QG@_E75_##X'Z_\ $3Q!H]K/
M9:AHVC:EYGE:U+8N\'RHS#!X!SMQUKRZE'!TZ<ZCE9-\S:?5=K?/1>9V1J8B
M4XP2NTK6MT\SO=2_:.\-S>-+6>W\-7A\)3>&U\.7^ES3 3"$,2#$X/...3@G
MGI7*6WQ)\$_#[QMX9U[X>^&]3MWTN61[J36KL.]TCJ5,85<A<*6PWN.*Y?Q)
M\/UT/POX:U2VOKC4+K69;B'[&-/EC"-&^P!)#Q*3Z+TK'\0^#/$'A'R/[<T/
M4='\\9B^W6SQ>9],CFBEA<);E@W9W5KO6UT[KKUU_P" .=:O>\EM9WLM.N_0
M[SQ1XK^%BS6M[X5\+:Y9:H=2AOI9[^\5D@19 [QQJ"=P/(&[&..:T_B5\;M(
M\:>&_'FG6EC?02^(=;@U.!I@@5(TC52KX8_-E<\9'3FO/9?ACXQAM!=2>%-9
M2V:!KD3-8R!3$H!+YQ]T CGWKT2\_9JN]*CT>74M1O;.'4-"DU<N-(EE\J9!
MG[,P4G!P<ECC [5G*.#I.#G-MK;5R>EGY]D5%XB:DHQLNNEO+]3H--_:@TW3
M?&GVY=.U1='N_#UIHMXUM,L%Y%)#NQ+"P;'5CU(S7G_QH^*%K\1+S38=,N/$
M,VEV,9P?$.H?:99)&ZN%'"<<<'G':N/T_P %>(M6T.;6;+0=2N](ASYE]!:N
M\*8ZY<#'%3:+\/\ Q1XDM8+G2?#FJ:G;3LR136EH\B.5^\ 0,$CO6U/!X.A4
M]M%V:TW\NOG8SE7KU(\CV?D8%%27%O-9W$L%Q%)!/$Q22*52K(P.""#T-1UZ
MQPA1113 **** "BBB@!&.!FOHGQA^S/X>TO1=<&C^(]5GU_1](CUJXM[ZR"V
MKPLNXJLP &[&>,GZ5\[-RM>X_M"?';4?%UU_8'A[Q-)<^#GTZUCDMH$\M&E5
M/WBL2H<C<!P3CBO)Q:Q,JU*-!V6K?;1KR?GIIZZ';0=*-.;J*[TM^/G_ )GG
M]E\'_&VI>%3XEMO#&H3:'L,OVQ4&"@ZN%SN*^X&*G\-?!+QWXQTJTU/1/#-Y
MJ.GW8=H;F)DV,%.&Y+#'/'.,]J]\TOXT>!Y-:T#Q[/XUU;3[G2M*6R?P/% Y
MCED6/9M5A\FQB<\^@Y'2JMM_8>J? /X='6O'5]\/8I+^^NHI+**22.4B8DH=
MA!#*&^4G(Z\5YTLQQ4;<T+7=OAD^DFU;>5K+5::G6L+1>TKZ7W7E]V^SU/G3
M_A O$7V?7IFT>YBCT':-4\T!&M-QP-ZD@\GT!KL/A[\$[SQ+?RQZZMUH]K+H
M%SKEA-'L;[2D8&.YPIS[&O2;KXR>"_'OC+XEZ=J>I7&@:#XGT^UL[;69;8RM
MYEN/]9(B\_/C_'%3_P#"V?!&G^*K?3K'6VGT71_!-UH4&J3P.@N[E\$;5 R
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M UP!^\,2O@A.F!@=#Q7G]>S0G*I2C.:LVM5M^!P5(J$W&+ND%%%%=!D%%%%
M#X?]:G^\*_67P/\ \B5X?_[!]O\ ^BUK\FH?]:G^\*_67P/_ ,B5X?\ ^P?;
M_P#HM:^"XL_AT?5_H?2Y)\=3Y?J?E_\ %+_DIGBS_L*W7_HUJY>K?Q3\=^&A
M\3/%@/B'2@1JUT#_ *;'_P ]F]ZY?_A//#/_ $,6E?\ @;'_ /%5]C1K4_9Q
M]Y;+J>#4ISYWH]S=HK"_X3SPS_T,6E?^!L?_ ,51_P )YX9_Z&+2O_ V/_XJ
MMO;4OYE]Y'LY]F;M%87_  GGAG_H8M*_\#8__BJ/^$\\,_\ 0Q:5_P"!L?\
M\51[:E_,OO#V<^S-VBL+_A//#/\ T,6E?^!L?_Q5'_">>&?^ABTK_P #8_\
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M4?\ ">>&?^ABTK_P-C_^*J_;4OYE]XO9S[,W:*PO^$\\,_\ 0Q:5_P"!L?\
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MKFHV.FWNG6U_<V^GWNW[5:Q2E8Y]IRN]1PV#TS7*_P#">>&?^ABTK_P-C_\
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MBTK_ ,#8_P#XJC_A//#/_0Q:5_X&Q_\ Q5'MJ7\R^\/9S[,W:*PO^$\\,_\
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MBTK_ ,#8_P#XJCVU+^9?>'LY]F;M%87_  GGAG_H8M*_\#8__BJ/^$\\,_\
M0Q:5_P"!L?\ \51[:E_,OO#V<^S-VBL+_A//#/\ T,6E?^!L?_Q5'_">>&?^
MABTK_P #8_\ XJCVU+^9?>'LY]F;M7;G6]1O-,L]-N+^XGT^S+-;6DDI:*$M
M]XHO1<]\5RO_  GGAG_H8M*_\#8__BJ/^$\\,_\ 0Q:5_P"!L?\ \52=6D]Y
M+[T')/LS=HK"_P"$\\,_]#%I7_@;'_\ %4?\)YX9_P"ABTK_ ,#8_P#XJG[:
ME_,OO#V<^S-VBL+_ (3SPS_T,6E?^!L?_P 51_PGGAG_ *&+2O\ P-C_ /BJ
M/;4OYE]X>SGV9NT5A?\ ">>&?^ABTK_P-C_^*H_X3SPS_P!#%I7_ (&Q_P#Q
M5'MJ7\R^\/9S[,W:*PO^$\\,_P#0Q:5_X&Q__%4?\)YX9_Z&+2O_  -C_P#B
MJ/;4OYE]X>SGV9NT5A?\)YX9_P"ABTK_ ,#8_P#XJC_A//#/_0Q:5_X&Q_\
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MB=>$_P#P1VW_ ,11_P **^&G_1.O"?\ X([;_P"(KN**+(+LX?\ X45\-/\
MHG7A/_P1VW_Q%'_"BOAI_P!$Z\)_^".V_P#B*[BBBR"[.'_X45\-/^B=>$__
M  1VW_Q%'_"BOAI_T3KPG_X([;_XBNXHHL@NSA_^%%?#3_HG7A/_ ,$=M_\
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M ,**^&G_ $3KPG_X([;_ .(H_P"%%?#3_HG7A/\ \$=M_P#$5W%%%D%V</\
M\**^&G_1.O"?_@CMO_B*/^%%?#3_ *)UX3_\$=M_\17<446079P__"BOAI_T
M3KPG_P"".V_^(H_X45\-/^B=>$__  1VW_Q%=Q119!=G%0_ GX:&9!_PKKPG
M]X?\P.V]?]RO2+&RM["QM[:UMXK:VAC6.*&% B1H  %51P    !6?!_KH_\
M>'\ZUH_]6OTK*9K S+O_ (^&_#^50U-=_P#'PWX?RJ&M5L9/<****8@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /)/CUXVG\)ZQ\.[,^+O^$)TC6-7GM=1U3-LI$:6DLJ*
M'N$=%RZ+SC)Z5SVA_'[_ (12ZN['4YM4\>Z?>ZVND>&=6TVRC,VJ2&T\]XR4
MV1N$963SE"IZXVDUZ3XV\$W?B;QG\/\ 5X);=+;P]J5Q>74<V=TB26DL*A,
MC(9P><< U/XM\(W>O>,O 6KV\T,5MX?O[BZN(Y"0SI):R0@)@8SN<$YQQFHU
M*T."T/X^P0WFFZ*NF^(O%/B#6[K5I+*SBM;:(P):70AEA>02"-4C+ +(S?.
M,G<<5J0_M!V%YI.KWUGX5\0WG_"/R20^(;>..!9=(DC4.Z.&E F8(0^(2^5*
MD=0*A^'?P?U7PCXTL-9N[NRFM[>/7$9(2Y<F]U!+F+&5'W44AO?ID<UH:/\
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M^YF:]8C=<1OE@4*A0V%)P2WJ7POTOQ%HOP]T&Q\6Z@-4\1V]L$O;O?YA=LG
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M* "BBB@ HHHH ?!_KH_]X?SK6C_U:_2LF#_71_[P_G6M'_JU^E8U#:!F7?\
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MZ]?:M3PQ\3->\0?%CQ5X2N)]&T"YTYYDT_2[^UG-Y<PA$,5^C[U2>%F8AD0
MIC!8&IH_@+IL<::6->U<^#4OAJ*>%<Q?9!*)?.">9L\TPB7Y_*W[<\=.*VE^
M&8N/B)8^+-3\0:GJ\FF27,NEZ=<K"L%BTZ;)-K(@D<;,J [$#<?;"U#0\*^
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M 0&R!@9MZ;^SSHUBVNS3ZWK6IWVN:MI^M7]Y>31M))<V;(8]H"!40^6H*
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M:IXN2:<ZAJ.G6VF2PL1Y2QPR2NK*,9W$RMG)Q@"N@JD(****8@HHHH ****
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M%FC:3J-KI-S%J]P+6-O#\MW<2V4C E3.)($4Q\;3(IPI()&#D7-1^-'BZX\
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MA=Q>$O$SB\&B0X0:9?%M\ES:2YS'ND"2[,;5D4L/O$5Z?12L.YQ&B^"?%/\
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MXR_>5&Z.1SPI)X/H:AU#XX> -*U633+OQ?I,%_'<FSF@:Z7=#,"!LD_YYG)
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MR^.,4 >C_%'XA:[X5\1^#- \.Z9IU_J7B.ZN(%DU2ZD@A@6&W:8GY(W+$[<
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MKJZZG9MI3+N%\MPA@(SC/F9VXSQUZUHT %%%% !1110 4444 %%%% !1110
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M?^'[GX8Z0!]NM] ^U3W.H*FU ?(>)% ))!8SYQZ(U 'J=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MM>"K'X?Z?\0O&W_"50:K:^))O%]S-:@+J21R(3'Y+CR_W14D=>AQSWHUPW6A
M^!?C%\/+C2]2D\3^)]3U271H+>REDBO(KT?NI%F"^6JKN._<P*[&)[9^I:*
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M7_GHWYT>S8>T1KU2NM%T^^F,MS86UQ*0@+RPJS'8V].2/X6^8>AY%5?M,O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %2W7^N/T'\JBJ6Z_UQ^@_E2ZCZ$5
M%%%,1Y!^T%\8]9^&$>B6_AG2$U[59&DU74[5LYAT:VPUY,N/^6F&54!ZL<5V
MOB/XF:%X=TO1KT27&JMKA7^R;/2H?M%Q?Y3S 8D! P$^8LQ"J.I%<79_ ]?%
M?Q"\7>+O&WVB2ZO9%TS2+;3=7NK=;;2HE^5',#Q[FED:21E;.,J,\5@>&/@[
MXO\ A[)H$^D)9:M%X.N=0T[1K&\O"K7FB7(C=(C*5/E3PLBHI;(9$Y(W9$:E
M:'0:9\=K.;XA^*+/5)7\/:#X?\.6^JZA!K%MY%S92M/,K&0@D,IC1"NPL"<X
M)/%=+H?Q@T?5-;TK3+W3-<\/2:NQ73)=;L#;17S!2Y2-LG:^P%@D@1B <#@X
M\WUSX0^-_B9XG\::MKJZ5X9@U71-/L=)A@F^V26UQ:WCW*FY(51(K,5R%X"D
MCD\UU^K:'XS^).J>&H-?T?3_  SI>C:O;ZQ=7%OJ O)+V6 EHXX%"+Y:%\%F
M?YMHV@<DA78]"/P;\9/,\!Z7J.N1SZEKVI:EJ-G9Z9HUION+D6]U+&-D>0 %
MC12SLRJ.Y!(%:=Q\<O#FGZ+JEYJ-OJVEWVFRV\$^BWED4OS)</Y=NJ1ABKB5
M_E5E8KD$$C!QYK<?L\:DNF^$=2O="T3Q7J&AW.L1W&@ZE,!!<6MY>-.KQ2E2
MJ3)B/[PP074D<&MO3_@_Y'AGQ89_AAX16#64M[5/"]G(L,CVZ-N<SWH7#/N.
M]%4!4*C#9)(>H:'?ZA\5-,TO2=)N;G3M8CU/56D2S\/_ &$G4I63_6#R@< +
MU+E@@!'S<C,=O\7M#72]8O-6M]4\--I*))>6NL6+Q2JKG$939N67<WR@1LQW
M8&,\5Y_X2^%_COP@/"_B9IX->\0:7:ZAIDVCZEJ+2N=.GN%F@A6]9?FFA$:*
M9'7$@SD\ UL?$#P-XL^-7@35=)UW2]%T$)<VE]I6GW%RU\LD\$HEVWA4!/*<
MJ%VH"0"6SD 478M#JM#^*EAJFN6FD7VC:[X:O[Y6:Q37+(0+>;5+,L;*S+O"
M@ML8JV 3C@XYWPO^TKX2\8:9I6KV-IKT?AS4KE;*'7[K36BLA<&0Q")G+;AF
M0;-^TIN(&[-9O@CX4M!XTTG6&^&GA'P/;::LDCR6YCOKR>=D*(8)%51"B[F)
M8_,P., 9JK'\&_$4?[+NA>  +,>(+/[#YNVX_<?NKZ.=\/CGY%...3Q1J/0L
M6_[0#Z-X^^*5EXDTO4K'P]X7:P2TN/L:$R/,@41@K(6=I9&7RP0.#R17K'AW
M6_\ A(=)BOO[/O\ 2F<LK6>IP>3/&5."&7)'T()!'(-><ZU\.-0N->^+=]=>
M'M-\5:5XH33H[?1[R[$2W4<4'ES+(Q4B,]2I[D#D=:W?@KX9\0>$/ J:;XBN
M9)KA;NXDM+>:]:]DLK-GS!;/<, 9BB\;S[#)QDBN([NBBBK))KK_ %B_[H_E
M4-377^L7_='\JAI+8;W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** 'P?ZZ/_>'\ZUH_]6OTK)@_UT?^\/YUK1_ZM?I6-0V@
M9EW_ ,?#?A_*H:FN_P#CX;\/Y5#6JV,GN%%%%,04444 %%%% !1110 4444
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M3G8IX^5<#@<<5=T_P?H6D2:?)8Z19VDFG"<6;0Q!3;^<VZ;9Z;V +>IK8HH
MY/3_ (2^"])\1'7;+POIEMJYE:<74< !65OO2*OW5<Y.6 !.3SS70:;H]CHJ
M7*6%G#9K<W$EW,L*[1)-(=TDC>K,>2:N44 <SXJ^&7A/QQ=176O>'[+4KN)/
M+2ZD0K,$Z[/,4ABN?X2<5HVGA/0['P\V@6^CV$.AO&T3Z:MNGV=T;[P9,8;=
MDYSUSS6K118#FO"OPT\*>!S<MH/A^QTM[A/*EDA0EWC[)N8DA?\ 9!Q[5;_X
M0GP__P ([9:!_8UG_8=B86M=/\H>3"8F#Q%5[;&52/0@5M44 <IX@^%'@WQ5
MK@UG6/#.FZCJF%5[J>$%I0OW1(.D@';>#BM^WT>PM=6N=4@LX8=1N8HX)KJ-
M ))(XRQC0GT4NV!VW&KE%%@.'F^!OP\NKRYNIO!>C337+^9+YEL"I<L&+A/N
MJQ8 [E .:ZVQT>QTNXOI[.TAMIKZ?[3=21+AIY=JIO?U;:BC/HHJW10!RTGP
ML\'2^)/[??PSIK:QYGG&Z, R9,Y\PK]TOGG?C=GG.:W(M$T^#6KK6([*%-5N
MH8[>>\5/WLL498QHS=PI=R!_M&KM% &)JW@?P]KTFHR:EHME?/J5O%:7K3Q!
MC<0QL7CC?U569B!V)-7KS1=/U#4].U&ZLH;C4-.:1K.YD3,EN778Y0]MR\'V
MJ[10!Q5Q\$_A_>:A=7L_@[1YKFZ8O*SVP*LQ.2^S[H8D9+  GUK2U;X;^%=<
MTNXTZ_\ #]A=65Q=MJ$D4D(YN6.6F!'*R$]6!!YKHZ*+ 8'A;X?^&? \MQ+X
M?T&PT::XC2*>6SA"/,J%BN]NK$%V.3D_,:W^G2BB@ HHHIB"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .*N?@KX%N]?GUN7PQ9G5KBY^V
M372&1&DFX_>,%8 MP.<<XK1U3X:^%-;\30^(;_P]I]WK<)0K?2P@OE/N%NS%
M?X2P)';%=)12LAW*%AH.FZ7J&IW]G8P6U[J<JS7UQ&@$ERZH$5G/<A0%'H!1
M:Z!IMCK-_J]O8P0:IJ"11W=W&F)+A8P1&'/?:&8#TS5^B@ HHHIB"BBB@ HH
MHH **** "BBB@ HHHH **** *5]HFGZG?:=>7=E#<W>G2M-9S2)EK>1D*,R'
ML2K,OT)I;S1['4+[3[RZM(;B[T^1I;.:1<M;NR%&9#V)5BOT)JY12&8^F^#]
M"T>^CO+'2+.TNXQ.$FAB"NHGD$LP!_VY &;U(S4L/A?1[>WU:WBTRUC@U>22
M;4(UC 6[>1 CM)_>+* I]A6G10!RVN?"OP?XEL=,L]3\.:?=VVF1""Q5H]IM
MH@ !&C*00F !MSC@<5/HOPZ\*^&YK>;2?#FF:9);RRSPM9VRQ>7)*BI*R@<
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MW]M:+  D-R)#()E])-Y+;NN2?6M^BBPPZ\T444Q!1110 4444 %%%% #X/\
M71_[P_G6M'_JU^E9,'^NC_WA_.M:/_5K]*QJ&T#,N_\ CX;\/Y5#4UW_ ,?#
M?A_*H:U6QD]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC^50U-=?ZQ?]T?RJ&DMAO<****8@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ?!_KH_]X?SK6C_U:_2LF#_71_[P_G6M'_JU^E8U
M#:!F7?\ Q\-^'\JAJY<6LLDQ95R/K47V&;^[^HJTU8S:=R"BI_L,W]W]11]A
MF_N_J*?,NX6?8@HJ?[#-_=_44?89O[OZBCF7<+/L045/]AF_N_J*/L,W]W]1
M1S+N%GV(**G^PS?W?U%'V&;^[^HHYEW"S[$%%3_89O[OZBC[#-_=_44<R[A9
M]B"BI_L,W]W]11]AF_N_J*.9=PL^Q!14_P!AF_N_J*/L,W]W]11S+N%GV(**
MG^PS?W?U%'V&;^[^HHYEW"S[$%%3_89O[OZBC[#-_=_44<R[A9]B"BI_L,W]
MW]11]AF_N_J*.9=PL^Q!14_V&;^[^HH^PS?W?U%',NX6?8@HJ?[#-_=_44?8
M9O[OZBCF7<+/L045/]AF_N_J*/L,W]W]11S+N%GV(**G^PS?W?U%'V&;^[^H
MHYEW"S[$%%3_ &&;^[^HH^PS?W?U%',NX6?8@HJ?[#-_=_44?89O[OZBCF7<
M+/L045/]AF_N_J*/L,W]W]11S+N%GV(**G^PS?W?U%'V&;^[^HHYEW"S[$%%
M3_89O[OZBC[#-_=_44<R[A9]B"BI_L,W]W]11]AF_N_J*.9=PL^Q!14_V&;^
M[^HH^PS?W?U%',NX6?8@HJ?[#-_=_44?89O[OZBCF7<+/L045/\ 89O[OZBC
M[#-_=_44<R[A9]B"BI_L,W]W]11]AF_N_J*.9=PL^Q!14_V&;^[^HH^PS?W?
MU%',NX6?8@HJ?[#-_=_44?89O[OZBCF7<+/L045/]AF_N_J*/L,W]W]11S+N
M%GV(**G^PS?W?U%'V&;^[^HHYEW"S[$%%3_89O[OZBC[#-_=_44<R[A9]B"B
MI_L,W]W]11]AF_N_J*.9=PL^Q!14_P!AF_N_J*/L,W]W]11S+N%GV(**G^PS
M?W?U%'V&;^[^HHYEW"S[$%%3_89O[OZBC[#-_=_44<R[A9]B"BI_L,W]W]11
M]AF_N_J*.9=PL^Q!14_V&;^[^HH^PS?W?U%',NX6?8@HJ?[#-_=_44?89O[O
MZBCF7<+/L045/]AF_N_J*/L,W]W]11S+N%GV(**G^PS?W?U%'V&;^[^HHYEW
M"S[$%%3_ &&;^[^HH^PS?W?U%',NX6?8@HJ?[#-_=_44?89O[OZBCF7<+/L0
M45/]AF_N_J*/L,W]W]11S+N%GV(**G^PS?W?U%'V&;^[^HHYEW"S[$%%3_89
MO[OZBC[#-_=_44<R[A9]B"BI_L,W]W]11]AF_N_J*.9=PL^Q!14_V&;^[^HH
M^PS?W?U%',NX6?8@J6Z_UQ^@_E3OL,W]W]14TUG))(6&,8'?VHYE<.5E*BK/
M]GR_[/YT?V?+_L_G1S(.5]C&\1::^M>'=6TZ,XDO+.:V0YQ\SQLH_4UX+X7\
M"W'QL^"_P:TBZ:-?!EA:PS>(;=9Y(I[FXLX_*AM@%PP5;A"['<"#"H[U])_V
M?+_L_G2+IKJ,*$4=<+Q2NNX[/L?/GCC]GFST^^UN[T"2\LO#WB#0+O2/$Z&\
MN;VZ*JA>UN8%D:1I)(V,B>6",K)QTQ7)>,OB-KWQ,\*>%O"FGS>%[_49=9T@
MR2:1J+7<UU'#<Q2R/]E\L/: +&68S'Y,%>217UC]@E]5_.HH]%6&:2:.""*:
M3_62(@5G^I R?QI:=&/7L?.\WP"G\/ZQXGCLO '@KQC!J^I7.IV.M:Z%2XLG
MN',CQW"&)FG5)&8J58$KA3C&:T?%GP<UR:?P3;^'M*T73-2T&.UCC\8:;<'3
MGM464/=P"RC0K)!*JD"(MM!?)P5R??/[/E_V?SH_L^7_ &?SHT[BU[$#$%F(
M& <X%>'6/P2UV']GOP?X0DFT]O$'AVZMM1%O,[/87DD%PTH@E(7)C8$<[>&"
MG!Q7O']GR_[/YT?V?+_L_G3N@LSR_P />%_$.N?%*+QSXBTVR\/2VFCR:1!I
M]G>_:Y;@23)*TDTH1!M38 B8."[G(SBMK4OA;X?U;QYIWBVYL89-1LK*XLEB
M:WB,4JS/&S.^5R7!B7!SW;UKMO[/E_V?SH_L^7_9_.B\0M(\G^%\":A\4?BQ
MKT*C[))J-EI$3+T9K2U428^CRE>/[I]*]/JPNFR+P B]^.*7^SY?]G\Z$UW"
MS[%:BK/]GR_[/YT?V?+_ +/YT^9=Q<K[#+K_ %B_[H_E4-7)[25W! R, =:B
M^PS?W?U%"DK T[D%%3_89O[OZBC[#-_=_44<R[A9]B"BI_L,W]W]11]AF_N_
MJ*.9=PL^Q!14_P!AF_N_J*/L,W]W]11S+N%GV(**G^PS?W?U%'V&;^[^HHYE
MW"S[$%%3_89O[OZBC[#-_=_44<R[A9]B"BI_L,W]W]11]AF_N_J*.9=PL^Q!
M14_V&;^[^HH^PS?W?U%',NX6?8@HJ?[#-_=_44?89O[OZBCF7<+/L045/]AF
M_N_J*/L,W]W]11S+N%GV(**G^PS?W?U%'V&;^[^HHYEW"S[$%%3_ &&;^[^H
MH^PS?W?U%',NX6?8C@_UT?\ O#^=:T?^K7Z50BLY5D0E> 03S5]1A0/:LILT
M@F.HHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ%XQ^"W@?5+NVUUO&-S>7=CI^E#4[:WBGLY;B=83)-(ABB= 7!&53D8+$'(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2T<Q2.-CL(!Y['@\UU!\>: ? \GC"/4X9_#<=DVHG4(CN0P*A=G'T /'7C%
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MG+QE^T+XAN/!?Q)\1^#;O0VM?"=_!;PB_L)YOM*O;V[ND@$T;1R)),X.1_"
M5!YJ'X@?M*:[\$_BI9Z/XS.CW/@FWT1+O5]?M+66WE@NYI+@6P$9ED C;[/Y
M>"2?,D3G!Q0!])T5Y-^S7\3/%/Q2\#ZGJ/C+2['1M=L]7N+&2RT\/LB10C(K
M;V)\P*X#=L@X KUF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /+_C;X?U35=0\!:EI_AV;Q/;Z-KC7E[86[VXD,1L[B(,
MHG=$;#R)QNSSGM6/XDT/6M6U/P1XQT?P3>:?/X9U&Z>?P[<2VD-Q<P3VS0M)
M$T<K1;E+*0KNNX*PR.,^T44 ?.>I?"OQ1XP\77'BR[T%; :AXIT.\_LF[N(9
M);>SL5<&:0JQ3>6D)"(S8"KSG('96NE>)/AM\0/&>JV?AN?Q9IGB:X@O8Y=/
MG@CNK65($A,,HFD0-%B,,K*21O8;>Y]:HH ^39O"_B3X>_%;X57,NF66J:W?
MZAXHUNXT>VG"K;+<)$QAMI' 4NH89+;5<M)RN[-='\0_@_XH^.$GB_5[O2D\
M*M<Z/:Z5INEZA=*TEX8;Q;LFZ:W9A'&S((@$=F"O(W!(%?0TVFVES>VUY+:P
MRW=L'$%P\8,D08 .%8C*Y &<=<"K- 'S[X8^%S:KXN\.7;_#F\\/0:;.;V[O
M/$'B.6_:.<1LJ?8XTN9%9MS?ZR4+A<C:2W&5?>$_B'X>_9YUKX4:9X%@US44
MTFZTBQUB2^MX]-NXG1U2656?S5E(8%DV$%\_/@Y'TO10!Y#\'?AWK/A+QYXH
MU74[&.WM[[1=#L8)Q(CL[VT$RS(<$D!6<=>#DXIWPO\ A7=I^S]/X%\5VYM9
M+Z/4[6ZBCE60K#<7$Y4AE)&?+D4^W2O7** /)O#/B+XA^$?#EKH6J^!Y?$>K
M6,0MH=7TF^MHK*\5!M2602R+)"6 !9520*2=I88JHV@^.=%\::#X\U#2++Q#
MJ;:%)H^K:3HDPC-LQG$RR6K7#*'7C8X9D+;48=-M>R44 ?//B+X4^)_&UUXD
M\07>BP6,NM:SX?DCT.2>-I([6QNED>:=PQ0RL&;Y5+86- "QZ=_J'@K4+K]H
M;1/%GV.-])L_#5YIQNRZ[HYY;FW<(%SNP5B)) Q\HKT>B@#Y]TSX1^)%\60W
MEWIL;VD?Q(NO$2LT\;;;-M/>&.4#/7S"!M^\,YQ7=^'?!6H6'QZ\:^*KBSC3
M3M2T;2[&UN]ZEW:%[II$QG< /-0\C!W<=Z]'HH ^3]!^!.OV>DO!XG\(7.O6
M#:;<6SV>FZE##=)*VMSW44L,AE3;)'&\<JD.N",9R,5H:IX!^)-UX6\*7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,J1@_>9L=J[;Q'\5M"\/:1HEZC7&LR:[M_LFQTJ+S[B_RGF9C7(&T)\Q=B%
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M3=.O[SBVM;N[CBEFYQ\B,06YXX%%]XQT#2]%36+W7--M-(<@+J$]W&EN23@
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M&]B1B"RK(@;:<=QG!]Q0!N4444 )2TE+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17%?%CQC?\
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MIX#8X)XKG/B-\?\ 7O!/A7X@ZE!IAU"?0_$]GHUFEG9//B&5;-G:50XY_?R
M$$#)08]0#W^BO$[+]H86_P 1O&VA7^F:A=Q:3!IMU:Z?I>F2SWT<,\#22/.B
MYP PVC@'(( )%>@>&_BEX:\7:Q;:;I.HK>3W6EQZS:NJ,([BT=RGF(Q&#M;
M9>J[ER!D4 =916%X+\::3\0-!36M#G:[TR2::&*X*%5E\N1HV9,]5+(V&Z$<
MC@US^I>.-1L_CAH/A%$@.E7V@WNI2LR'S1+%/;H@!S@+B9LC'7'- '>T5Q?B
MSXL:+X3UQ-%,&I:SK1A%U)I^BV,EW-#"25$L@0?(I((&3DX. <&N U/]J3PY
M>7'A'4- U!;SP]?>(;S0+^5[*;SS<0VDL@AACP',GFHBXVG^(<=0 >YT5P^@
M?&/PWK:ZNMQ+<^'[O2+;[=?6>NV[64T%M\W[\A\9C^5OG!(!!!P:JZ#\=/#&
MO:KIEEMU/35U9MFE7FJ:=-:V^HML+@0NZ@$E06"G!8#@&@#T*BN,_P"%O>&O
M^%?:OXU^U3?\(_I37:W4_P!G?>IMI7BFPF-QP\; 8'.,BF:%\8?#?B;QUJGA
M'2YKJ]UK2FV:BD=K)Y=F3&DB>;)C:N]9!M&<MAL=#0!VU%<;XN^*NC>$=9BT
M9H-2UC6I(?M1TW1K*2[GC@W%?-<(,(A8$ L1D@XS@XY?_AJ;X<MH46L)J]S+
M93:ZWAJ/R]/G,CZBL9D-N(]F_=P5Z?>&.M 'K5%<'I?QL\+7VCZ]J%[<7'A\
M:"BRZG;:U;/:SVJ,"8W9&&2KX.TKG<00.1BN8U+X_17/B[P+HNGV-]I<^NZL
MUM);Z]ILMK+/:K:SRF2#=C.'CCSGD!N5&<T >QT5POCOQIJ7A/QQX!M$2W.A
M:Y?7&FWLDB$R1S&W>6W*G. "T3J<@YW+TQSX_I/[5&L:OX!^*^N)IEI%/H]V
MR^%?O%=1M993:VLSKG)#7,<H."/EV].M 'TU17#:]\5=/\*WT>D36NJ>(-<A
MMXYKRW\/Z=)=& ," \@7(0,5;:I.X@' .,UDW_Q@BO?$G@%= DCU'1->;41<
ML(7^T V\#/Y:J<%'#J596&<C& : /3Z*\%^$7[0TGB#P!?\ C#Q>+K3+>ZU>
M;3],TO\ LB2*9V6>6*."(!G:YD81@G:JX(;C )'0W'[3_@73;C5;35I]2T+4
M-*TJ36[ZQU33IH)K>S21(S,P*X*EG&,$]&_NF@#UFBO.V^.GAQ],T^[M+;6-
M2EU(22V5A9Z9,]U<0(P4W"Q8!$)W*1(V =RXSD56UGXM6NL^&[&?P_<W%I>3
MZY9Z/<Q75J8KFQ>25-Z20RKE6V'C(Y#!@3P: /3:*\1\5:IXY\+P^*;^V\3R
M:L+'2;R]N%;3X8[.RN$VO;PP-MW$E P<.S\$-E,@'VFUG%U;0S ;1(@< ]LC
M- $M%%% !1110 4444 %%%% !115/6-7L_#^DWNJ:C<):6%E ]S<3R'"QQHI
M9F/L ": +E%>.? /XZ7WQ.T#7Y_$NC?\(WK&F2"]%@"69M,G0S64Y'7<T60P
M[/&XQQ5K0?VGO WB32],UFREU3_A&=1\M8/$4VF31Z=OD(54:9E 4[B%R?E#
M<9S0!ZS17F=]^T'X6M_$VN^'[*#6M;UG0IUAU2TTG2IKEK3=&LBLY5<;2KC&
M"2<' X-22?M">"&U7P[IMEJ<NK7WB&V%YI<&G6LD[7,/F"-W&U?E"$Y?=C8
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M3ZAH/B?P'\4O$/BG0]"7Q7IOB2VM([FUBNXK>ZM)K=712IE(1XF5^1N#*P)
M.[C@O"?P@\=2:UIVJZ_I6DVES_PL>Z\3S0V-R)(XK)].>",@E07D#E0W ).6
M'&*^E:* /"?B9\&O$?C3QYXKU.Q:T@@GTO1&TV2[?=%+>6-]-=>5,@Y$;;D4
ML,_>) .,5+KVF_$#XB?$/X;:C<^#K7PYHWAW59;[4)+S48;BX<M:3PKY'EY&
MP-(,EBK'(^48->XT4 >6?M,?#[Q!\2/A#JFF^$+B&R\86\L-[HUW.0$ANHY
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M[N[MF8M(DKAIQM8E<N-P)QGYB:]' "@ # %+10 4444 %%%% !1110 4444
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M8I&SRK'(Q:1E<*JH<[&)( Y\U\-_'#6=*\<>+8];TF]1Y_%^D>'(],GN@8[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?HKB/ WCJ]\0^,O'GA[4(((9_#]_#' ]N& EM9K>.6-FR3\^3(IQQ\HXKMZ
M"BBB@!*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BF[A[_D:-X]_P C0 ZBF[Q[_D:-X]_R- #J*;O'O^1H
MWCW_ "- #J*;O'O^1HWCW_(T .HIN\>_Y&C>/?\ (T .HIN\>_Y&C>/?\C0
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M[1?B+1?"'QP\.ZWXB\$OXXT:Q\)7SW,"V]K.+)#>VRFY9;A@ BY^9ER57)/
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MSBC0-2GI/PKTNUU9M5U:^U+Q;J?V62QCN=>DCF\BWDQYL<<:1I&H? #-MW,
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MMQ%;27,#1*MO)$Q9T&9,E@S9!!&""*ZK5/A#HEWX+\.^';![C0T\-F%]%OK
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MUK8RW,.E7$D,D5XEQ$G(M)-Q;<F3&TK-C KZ5_L__:/Y?_7I1IY4Y#D'Z?\
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MI.CR:?X3LM(DD5Y8-/2S:10=I98@A8>V1FNA_L__ &C^7_UZ/[/_ -H_E_\
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M$]7\.ZCXD@\/:?X+U'2]8OI]1M[SQ#IYDO-,EG8O* %0BX02,SJ&:,C=M)(
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M9!RLIT5<_L__ &C^7_UZ/[/_ -H_E_\ 7HYD'*RG15S^S_\ :/Y?_7H_L_\
MVC^7_P!>CF0<K*=%7/[/_P!H_E_]>C^S_P#:/Y?_ %Z.9!RLIT5<_L__ &C^
M7_UZ/[/_ -H_E_\ 7HYD'*RG15S^S_\ :/Y?_7H_L_\ VC^7_P!>CF0<K*=%
M7/[/_P!H_E_]>C^S_P#:/Y?_ %Z.9!RLIT5<_L__ &C^7_UZ/[/_ -H_E_\
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MH ZD\9^SGXFU3QEJWPDUG6=9_P"$AU.Z\(ZRTVJA0HNL:A;*) !P%( P/3%
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M"!\9ZAX@T*'PI%J$>FZE*LT]I,UVZEGDP&;<H&W><@ ]L5HZI)J7Q$^-&O\
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MO-'\:/$7C[5/L<MQ+IUOHND"!3YL%FK&6;S&(&6>9N@R L:<Y)KT&@ HHHH
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MHOYG_"CE8<\2Y15/^T!Z+^9_PH_M >B_F?\ "CE8<\2Y15/^T!Z+^9_PH_M
M>B_F?\*.5ASQ+E%4_P"T!Z+^9_PH_M >B_F?\*.5ASQ+E%4_[0'HOYG_  H_
MM >B_F?\*.5ASQ+E%4_[0'HOYG_"C^T!Z+^9_P *.5ASQ+E%4_[0'HOYG_"C
M^T!Z+^9_PHY6'/$N453_ +0'HOYG_"C^T!Z+^9_PHY6'/$N453_M >B_F?\
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M#_POAN;GQ!!K<-A:Q+-/J%IHMU=6L:DX&98T9<YP,9SR/6NUAS<1I(B/AE#
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M@CPWX<5!I/A[2=*$:NJ?8;&*':'QO VJ,!MJY'? STHLQW/E+PE;ZEI/PA^
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MM'_JU^E9,'^NC_WA_.M:/_5K]*QJ&T#,N_\ CX;\/Y5#6G)9QR,6.[/UIO\
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M&H0,Q\J1X\F%26&YD/TSS0!Z316=;^(])NM6FTN'5+.;4X1NELH[A&FC'JR
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MHK?+&H. 0:Y*W\%ZYJ6H^-?$^G^!-4T6P@\>Z1XD@TMX ES?VL%M"D\T41(
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M .!C/6@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA/CU;RW7P/\
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M:K=:A(]P]W*FG3+&URW0H-J*$("< ;>>?H:B@#Y0^&OPUL/$'Q4\*S:WX?\
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ML;1;]B@J6)$:KM QTR" ?5]%?(]Q-XG\;:Q\0M8UK6M'TYM U>[M@EYXDO\
M3)=&M8S_ *._E0@1G?&%F$C!@^_'0;1HZQK&NZ!=?#SQIXIUYO%>BC3=-M;L
M:/?SZ;/:W<]P%COQ9DIY\<P=$>.0;EV$JO+  'T]J5^FEZ?<7DL<\L<$9D:.
MVA>:5@!G"H@+,?8 DUSEC\5/"U_\.X?'*:M'%X6E@^TK?W$;Q#83M&48!@V[
MY=N,D\8S75MT-?(NGW"-^P_X&L7$<$.I75E9'5I7*QZ06OLI?,01_JG5&7)
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MM,O_ #T:C[3+_P ]&H]FP]HC7HK(^TR_\]&H^TR_\]&H]FP]HC7HK(^TR_\
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M>:_S*%*1M8R0KL'\7SLHP.W->@TU?J)^044450@HHHH **** "BBB@ HHHH
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MJ;%7/G7XE>"]7M_''C#Q),MK;Z:=;\-:C81ZC=1P0:M);(Z26V]CA'+,FTN
M"ZIVY"?$/4-0^*'QF^'&ECP[J'AJ06.NAKW5#$M_;++9>3YB1QNY$0=T^<L
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M1W-PT<[0M&L=M ;F5)"P=E9WPH4\9)X]RHHY0N>/? '0=>\,7.M:6--UO1/
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MUKPC\2OAUX?T$1M976L6J^(IF0.8K2X+P6Z#(X,D^#G@A8F]: /;**\/T?\
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M_:%?PC<W=CJD^I^/=.O=;72/#.K:;91F;4Y#:&=XSLV1L$973SE"I_>(VLU
M'T/17A^B_M!PVMYINC#3?$?BKQ!KEWJSV5G#9VL30):70AEA>02"-4C+!5D9
MOG &3N.*THOVCK"\TC5[^S\*>(;S^P)9(?$-O'% )=(DC4.Z.&E E8(0^(3)
ME64CJ!0!Z]17GNH_&2RDU:'2_#6C:EXRU!K*'49DTKR4CMK>4$PO))-(B!G
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M@EAAR3@]V.,T >JZ7JEGK6FVNH:?=0WMC=1K-!<V[AXY4895E8<$$'K7DGQ
M^.&J>&=)^+FH:=I5K/:^"-/B>&:ZD8+=7C0F9T;'1$1X<D<Y9O2MS]G/PSJO
M@[X,^'-&UNT>PU.U6=9+9V5B@-Q(R#*DC&TKT->4Z[X=U3Q)\/?VF/"EA9OJ
M6O76ISR6]BK+OF2>PMC$HW$##;6 R0.#0!UNB_'36HY/'6G7PT'7K[P[X?\
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MXSO*'S06<Y>)<Y/-=U\&X_MGCWXNZQ&Q:UNO$4=K&<Y!:WLK>*0CZ.&7ZJ:
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MU[XB6OC)9O"NERZ;H5_INFZ1Y\]PD=W.\!6XEF\I"Z 1'Y BXP!D[B5]THH
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M%_.LBBCV:#VC-?[1%_ST7\Z/M$7_ #T7\ZR**/9H/:,U_M$7_/1?SH^T1?\
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M-:?^T1XR\3>'_P#A*]"\.WUSITP:>PT >%-1FDO+<$[#]O3]VLDBC<,1LBY
M+=2/0+/QOXL\>^*M;T[PLFF^'['01;1WDVNVDEQ/-=S0)/\ 9Q&DB>6J)(@9
MR6.XD!?ER1?@'ID6GW6AV_B+7[/P;=3/-)X7M[B-+8!W+O$DH3SXX68DF-9
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ML=BQ<!0HZDUYKH?Q"\3^$OB!XO74;2Q.HZAXYT/0KCRV=X&@EL8P9H03E"0
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M0V,<]Q=W5W;^;A5D!1(E ]"2Q(!7;R >ZTQIHTD2-G59'SM4D MCK@=Z\Q^
MOB[Q/XHL_&MOXKN[&^U#1?$UWI4,VGP^5&T$:1-&2N20Q#DD$G!)'0"O /C!
M\0KS7OBQJOCW1K?Q)?1?#&Y2STF'2M+NI[+4&W?\3@22QHT>1%^Y7)^5X6-
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M9X)'&,#UFN=\%_#W0/A[:W5OH5@;07<HFN)I9Y+B:=PH4%Y9&9VPJA1EC@
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M/.""0016+:?LU^"K?5K[5IX]2U'6;^.TCO-2OM1FFGN!;7"W$&XEL?+(HX
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M5L\AD-OYF3NB#$;4;(7 VXQ4N@?L_P#@OPS;F+3[&XC#:W'XBD>2\ED>6_1
MGG.S,2Q(7+ G!.37H]% &(G@_3(_&DOBH1/_ &S+IZ:8TOF-M\A9&D5=O3.Y
MVYZUQ^H?L[^"=2L]4MI[&Y:+4DOTN0+N0%A>7"7-Q@YXS)&A&.@&!P:]+HH
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M')#?ZX8&OAYK&*1XD\M'"9PK;-JDCJ$7/2MZB@ HHHH **** "BBB@ HHHH
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MQ\$KKQM:Z#HT_B>;_A&--:RE>UNK1;F^DFMI!(DJWCMO1V*J&;:Q(S@KN)H
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M'.S2^W)ZK^O^%'VY/5?U_P *Q5U*T;47T\74)OTA6X:U$@\U8BQ4.5Z[258
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M "BE56;[JEOH*&4J<$8/O0 E%*01U&*2@ HHHH **** "BBB@ HHHH ****
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MPD\>^)_$GBC7-)\&Z-I=S;>'Y8[2_O\ 6[J6%9[IHED,$*QHQ^573=(W&6P
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MBBB@ HHHH ?!_KH_]X?SK6C_ -6OTK)@_P!='_O#^=:T?^K7Z5C4-H&9=_\
M'PWX?RJ&IKO_ (^&_#^50UJMC)[A1113$%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 /@_UT?^\/YUK1_ZM?I63!_KH_\ >'\ZUH_]6OTK&H;0,R[_ ./AOP_E
M4-37?_'PWX?RJ&M5L9/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M85Y;\,K5)OB]\6M2MABR6YTS2DVGY/,M[,&0#Z><H/TKU*J0F%%%%,04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^
M#_71_P"\/YUK1_ZM?I63!_KH_P#>'\ZUH_\ 5K]*QJ&T#.NHV:9B!D<?RJ'R
MW_NFMC ]*-H]*.<.0Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK
M8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8V
MCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCT
MHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHV
MCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCT
MH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]
MH'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'
ML_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_
M,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q
M_+?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+
M?^Z:/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^
MZ:/+?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:
M/+?^Z:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^Z:/+
M?^Z:V-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^
MZ:V-H]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:
MV-H]*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-
MH]*-H]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]
M*-H]*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-
MH]*/:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]
M*/:![/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/
M:![/S,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:!
M[/S,?RW_ +IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/
MS,?RW_NFCRW_ +IK8VCTHVCTH]H'L_,Q_+?^Z:/+?^Z:V-H]*-H]*/:![/S,
M@1N.0"#532]%M-$LUL].L8;"T5F=8+:,1H&9BS$*.,EB2?4DFNBVCTHVCTH]
MIY![/S,?RF_NY_"N<T7X8^%/#>L2:MI/A;2=-U.3=NO+6RCCEYZ_,!QGVKN]
MH]*-H]*.?R#V?F8_EO\ W31Y;_W36QM'I1M'I1[0/9^9C^6_]TT>6_\ =-;&
MT>E&T>E'M ]GYF/Y;_W31Y;_ -TUL;1Z4;1Z4>T#V?F<]8Z/;:6LZV=G#:+/
M,]Q*(8PGF2L<M(V.K$]2>35GRW_NFMC:/2C:/2CVGD'L_,Q_+?\ NFCRW_NF
MMC:/2C:/2CV@>S\S'\M_[IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?\ NFMC
M:/2C:/2CV@>S\S'\M_[IH\M_[IK8VCTHVCTH]H'L_,Q_+?\ NFCRW_NFMC:/
M2C:/2CV@>S\S'\M_[IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?\ NFMC:/2C
M:/2CV@>S\S'\M_[IH\M_[IK8VCTHVCTH]H'L_,Q_+?\ NFCRW_NFMC:/2C:/
M2CV@>S\S'\M_[IH\M_[IK8VCTHVCTH]H'L_,Q_+?^Z:/+?\ NFMC:/2C:/2C
MV@>S\S'\M_[IH\M_[IK8VCTHVCTH]H'L_,Q_+?\ NFCRW_NFMC:/2C:/2CV@
M>S\S*AC831G:?O#^=:D?^K7Z4N!Z4M1*7,5&/*%%%%26%%%% !1110 4444
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M!KF]._:(\(66CZ:OB#Q'I*Z]-IUOJ,]GHQGNU\J52R31J(_,:(A2=Y08[XH
M]4HKSW4OC'H6EZHEU/KVB#PPVCIJ8NH[AY+F3S)A'$T:*A5XWY4;6+%L *<U
MB^+/VBM"T+Q)\-[&SD^W6/B^[F@%TMK<$QHD,C @+&<-YB!"K8*Y). #0!ZY
M17"V?QR\!:AINIZA;>*=/FL--5#=W2N?+B+L55"V,>86! C'S<CCD9BTWX\>
M!-8NI[.S\01R:C#:37TFG-!,EVL$6W?(8&028^=<?+\V>,T =_17B_P=_:$@
M^*F@>&]9>72=+M;S1[G4]1@N)9X9K<Q/&NY!)&JM"H<[I"PP2N,C)';>%_C%
MX-\::JFFZ/KL%U?21M+!"R/$;F,8R\)=0)5 ()9-PP0<\T =E17GFG_M"?#O
M5M1M[*S\5V5S+/<FS5XPYA6X#E/)>7;L23<I 1F#$XP#D5Z'0 45XCKOQUUM
M?"5[J^E:;IMNLOB]?#.FSZG,XA>+SQ ]S)MY \P2X4'D*O/-6/$OQ(\<:##X
M,TR ^%=1U[Q'K4NG"ZA:<V4$26LL^< EF<F+;C('S T >S45YMI7Q"\0Z#XR
MTCPSXVTS3[>361(NF:QI$SM;3S1H7>W>-P&C?8&93E@P5N01@T?$WQ^L?#GQ
MRT#X?-I\D]O?0 7FL(P\FPNI0QL[:0=FF6&<C_=7^\* /5Z*XQ?'D\?Q@;P9
M/:1I;3:&-7M+M6.YV2?RIHV&,?+OA((/.X^E=G0 4444 %%%% !1110 4444
M %%%% '*_%;Q1=^"/ACXM\0V"PO>Z3I-U?0+< F/?'$SKN ()7(&<$<=Q7G_
M (1^,-E8Z+JGB'7OBGX4\2:7IVEMJ-[:Z':*LUK&H#/*VRYE8JHR"-O<<UW?
MQ@\/W_BSX3^,M$TN);C4M1T>[M+:)G"!Y7A954L>!DD#)XKS[Q5I7B3Q]\'O
M%/A)/A]>:#J%WH,EG#-?7=B8IY2@7R\PS.1GGE@!@4 ='8_M%>"[Z:!//U*V
M^V1&;3&N]+N(1JJC'%IN0>>V"IVKS@@XQS6MIOQD\+7WA_5]7FO)]*ATB58=
M0M]3M9;>YM9&"E%:%EWY<.A4 '=N&W)XK+\:^ ]0UKXA_"G5+:SADT_P[=7D
MUVS.H,&^QDAC*J>IW/CCH":\]^)OP%U_QUXE^(%^EO;RV]S?:#JFEVMQ>-%%
M?M9*_FP2-'\\0;=@/CAMK8(7% 'IUC\;O#=P;Q+V/5M"N+:TFOQ;ZUID]I)/
M!$NZ5X@ZCS-HQE5RPR.*JV7[0G@O5/#=GKFGW=YJ-CJ$_P!GTP6MA-)+J;!-
M[&VC"[I549RZC:-IR>*\T_X4O=:U_:-QI_PWM_"[0Z+?P6\FL:N;V]>\GMVA
M00;)GBB3:[AG<[B& "@9-:6L65Q\,=>^%.I@6,^JV'AZ70I/#\MU';-*NRW9
MVM97Q$9$:$#8S+N0D@_+R =]HOQ^\%:U-X@@_M*;3;KP]:17FKV^J6DMK)8Q
MR%PGF"11@G8V ,DY&.HJ[X=^+VA^(=:M]*-OJVCWUT&-G'K6ESV0O-HW-Y1D
M4!B%^8K]['., X^?M5\)ZS^T%XR^+*1:?IVGJ=-T&*WB:[\V.2XM;F:Z^RW<
ML!(RP*!A&S;%D4Y)XKN_!?PI\_QOX?U)OAG!X7M=+=[J>ZUC6&U"?[1Y;(GV
M14F=1@LV9) #MR F6R #J/#_ .TUX#\41V5UIU[?S:3=W?V!=8;3+A+%+KS#
M'Y#SL@57WC9R<;B!G)Q6]XB^,&@^']:N-(2'5-:U&U"M>6^B:;->FT##*^:8
MU(0D<A2<XYQ@BO+H?@[XHA_9%M_ B6$">)D:-C;+<($R-1$['?\ =SLRWU]Z
MZC0-)\6?";7/%T5AX8D\7Z3KFL3:U;7-C>P03P23*F^*=9W0%59?E="QV;05
M&WD [3PQ\4_#/C+58=.TC4?M5S/IZZI"#"\8EMS(T192RC)5UVLO525R!D5S
M'C[XT06GP+\2^/O"$D.I)I\4_P!EEN8G\B9XI3$Q RI9-RMA@<'&02*X/]HF
MQ\3ZEX9\!W5C-9>&OBCJ.I-HEJEG(]S&MO=JPNU#[5+>7"GG[RN \"\<UZ1X
MV^#]KJWP'U#X;Z"\>EVW]D#3+%Y!N6+8@$9?')&5&3U.2>M #_'/Q)N/!_C[
MP+I<AM(='UB+49M0N;@$-"EO;B4,K9P!USD'@=JLZ3\:O"^J>$[KQ*9K[3]'
M@,>V;4-/GMS.LF/*:%60-*)-PV[ 220,9KD_^$?\5?$#QCX=UW7_  @FB0^&
M]/OD^PW%_#<#4KFXB6(HA0D"$*K?-(%8[U^08-><K\ ?%>M>";_2DTB;2_#V
MDZQIVK^'O!VN:P)MODHXN;87,+,8H6WCR06;RVC!PJX4 'O?A7XK:+XJU?\
MLE8-4TC56B:>*QUK3IK*6>-2 SQB11O +#.W)&1G&1795X?\-_A>+;X@6&O#
MX>6_A*STZVF$<VJZFU_J!GD 4^2$FDCCCV;@S$EFR!A0,GW"@ HHHH ****
M"BBB@ HHHH **\Z^*WCCQ%X:USP5H?AFUTR74/$5_-:&?53+Y4"1VLLY;;'R
M2?+V]0!G-8^B_'[3]#N-?TOX@W>E^']4T6]2R:ZMIF:UO&>V%RHB##<'\LD&
M,Y.0,9W"@#UVBO+[/X^>%]/L(IO$/B#2;:>^NKQ=-@L&FFDN889_*($9C#F5
M25#HJG:V<9 S6A-\?/A_;Z99:B_B:U^Q76=LRI(RQ -M)FPO[@!@03+MP00>
MAH ] HKE/%GQ2\+>!YK2#6-7C@N;M#+!;0QR7$SQCK((XU9M@R/GQMYZUC_\
M-"?#C^SDOT\8Z7-9R7$MI%-#+Y@EGB"&2)-H.]P)$^5<DEL $T >AT5RZ_$[
MPL_@T>*QK5L/#QD\K[<<A?,\WR=F"-P;S/DVXSNXQ744 %%%% !1110 4444
M %%%% !1110 5XS\5OV@)/AU\3O#'AZ#3$O]&8QS>)M2+X_LBWN)/L]G(>QW
MW!P0>B*S=J]EKYYT7]F=O'VD^,=4^(=_K5EKOC&YF-_IVE:S+%;V]F,Q6MOB
M-MCE(0I+8Y=FH ]<\9?$S1? ]Y96-X;R]U:^5Y+;2]+M)+NZE1,;Y!'&"0B[
MAEC@9(&<FN)\)_M#:1K7B3Q)!=W,<>E0:[8:#IC);2B<W-Q;)(8IU/*.)&9>
M0N !GUK \&^&?B/X.UC1_%FK:$GB?6#H:>'-6M;6\@CN&^S7$K07L+2,L969
M7+/&S*5)7&<$5BK\)/'VN7GC#Q+?Z)INFZM+XNTOQ/I>DPWBE;F*UMXHS#+*
M!A96"N-V"N[;R5YH ]7^*GQ7MO!.B^*;:PDCD\4:9X<NO$$%K/$YB:./*@LP
MP,;P!M!!Q7-R_'XZ7\8G\+ZK936>@V_A4:[=:LUC*((7#$NQFSL$00'G'W@1
MGM6-XP^'_BWXF3>/-?ET!M N;WP=<>&M,TN\O(9)YY9&>1I)&C9HXUW;%7YB
M3\Q..!707GP]U=OB5=:U/HMOJ^CMX&_L5[.6= +JX\YG: @]%93C<1CF@#O_
M  3XXT_Q]I3:AIUOJ%M"K!=FI6,MI(05#*P6102I!!!'%=#7DW[/GA+Q'X-T
MS7+'4[:^TKPV+F,:!HNJWZ7UUI]N(E#QF9&8&/>#L4NQ51C/0#UF@ HHHH *
M*** "BBB@ KQOXS?'Z3X-_$/P=I][H\E[X5U2TOKG5]4MP6DTF.%K=5N'0?>
MA!F(<@948;H#7LE><>*/!.HZS\;?!^OBUBGT*PT;5+&]:1U^_.UJ478?O B*
M3/;CGK0 ^3XER+\8K7PZLMB?#DOA>77C?;N=RW$<882;MOE['+9QZ'.*31?C
MYX0UR^TR&&XOK>TU:58=,U2\T^:"RU"1@2JPSNH1RP!V\_-_#GBO)D_9/U;3
M?&/BW3=,UM;?X>:IX1O-#T>U<%I]$EGF1V@3GY[8;2R*3\@W)]W;77^)M!\<
M?$KP?IW@K4/"UOX<1;BR;4-;2]BEME2WFCE)LT4^9N8Q +YBILW9YVX(!Z1I
MWQ*\.:EH.O:S'J*Q6&@SW-OJ<EPC1FT>WR90ZL 1A0&![JRD9!%8=U\=/#$,
M>EBV35M4O-0L8M333].TN>XNH;60?)+-$J[H@>@#X)(( X..&^)?P%USQ/\
M%2"XTB\M[;P'XF>"3QK8/D27#6?S6_E8_P">WR0S>L<2UT4VB^)_A[\3O%7B
M#1_#G_"6:5XF2UD>.UNX;>YLIX(?)VGSF57A90K JVY6+_*=V: -;PK\?_ W
MC1M+_L?6?M46IZC=:1:3FWECCDN[=-\L.YE&'"AL XSL8#)4U>\1_&7PEX4U
M;5-,U+4S%>:;!;3W,<<$DA4W#LEO$NU3NED9&VQKEB!G&.:\K\.?!#Q1X@^%
M/C?3O$=O8^'?%M_XJN_$VCSZ;,)H[.X$B2VLH; ).Y 'R 6!?C#4[2?@OXQT
M_P &>&O$E\+#5OB7;Z__ ,)5K5D9BMK=SO!) UK%(0=@AAD"1,> 8@3C<30!
MW$/[1O@Y]8ET:<ZO8:_%IUQJS:/>:1<QW9M8=N^18RF6'S  +DDY Y&*L:M\
M8M-UW1-7M_ M_:ZYXD7PXVO:>HBDEM2CHWV8RL@X$C#A,AV"L0.*X?Q!;_$S
M7OBQHWC2T^']M:66AZ!J=M:V5]J=O]MN;R8VYC1VC9DCA/E'D,QX)(' -G]G
MOX,:_P# ?7-5TUOLFL:+XDWZYJ&I6ZI UIJS,/.A2, $VS YB YCV,#]X&@#
MO=:^(TO@?X0P>+/$=DS:C'86[SZ?9KAI;R4(BP1ACP6E<(-QXR,UDRQ_%X:.
M=6CN?"YU+RO-'ADVTWEENOE?;O,SNQQO\G&>V*Z3XJ> U^)7@34] ^U_V?<3
M^7-:WFP/]GN(I%EADVG[P61$)'< BN:;QA\46T<V*_#^S7Q)Y7EC4FU:(Z/Y
MN,>9U^T[,\[/*SVW?Q4 )>^//%?BKQA)X5\,6EAH]WIUE;W6N:GJ>;I+&692
MT=K%$C+YLF 69BRJJE>I8 0_\)IXR\->*(?"&O-I-U?ZU9W+>'O$%M;R16\M
MW%&7:"YMR[%2%^<%7(94<?*1RDGA?Q;X#\<7_BO2+&W\41:]:6J:YI<$RVLR
MW<">6MS;&5MA5DPK1NRXV(0Q.0;%AX=\1^/OB%H7B?Q'I2^&M*\.K.^FZ4UT
MEQ=3W,L9B::<QDQHJQLZJBL^3(22, 4 8\G[0$J_L\CQO_9\?_"4LO\ 9:Z&
M"3G6O-^S?9<9W8^T<>NSFL/QK\;O&/A32?B5 5T=M7\+V^A+!<"VD:%Y[QE2
M=F3S 2H))5<@XQDFKG_"@=4;]HQ?$9O(/^%=+(?$:Z/M&_\ X2 Q?9C-_N>3
M\_\ UT)-9OQ6^$?BS7C\8Y]+TR.];7QH3:9$+J-&N#:R!IE)8@(0!QN(!H [
M#Q-XJ\;_  EMK76O$=]I'B?PN+B*#4I[*PDL;FQ2218UG53+*LB*S#>/E(7)
M&<8/K39*D*<''!QFO&_'5AXP^-&B_P#")7'A";PEX?OIHO[6U#5+ZVEF:V21
M7>*"."23+OM";G90H8D!C@5Z#H?@6WT'7KS58]6UN[DNMVZVOM3FGMX]S;OD
MB9BJ8Z# X'% 'G7AGXQ:_9_"[XD:_K5K;ZYJ7A'5-2LHX],MW@%VEN 4)0M(
M5)SS@G@9 [4[PU\4-=LO'G@[1-8UWPYXHM_%EK<W%O)H$3Q&T:*-92PS))YL
M)#;?,.P[BG'S8'1?!OP?JO@Z/QN-4@2$ZGXIO]4M=D@??;RE"C''0G!X/(KG
M_@C\%T\+^*/$OQ US0]+TCQAK[FW6STV*,1Z=8(Y,4 =  [N?WLDG\3MC[J+
M0![+1110 4444 %%%% !1110 4444 %%%% 'F7QJ\/ZK=7G@CQ)I6GRZPWAC
M6?[0N=.MBHGG@>VF@?RMQ 9U\X-M)&X*0.<5C>&)-9TKQ!X^^([^$]8D36!I
MUG8Z$JQ+J$D< 9&E9&D"H-T[G:6SMCSC) KV:B@#Y]\5:+XB\3?%SP]J-KX,
MO-!\5Z1K'EOXHM)D^PWFA;B7BF;(:0LI $+*2DHW*0,D^U^&==N/$%K=S7.C
M7VB-!=S6RQ:@(]TRHQ43+L=AL<?,N2#@\@=*UZ* /(=%^%.GZM\:?B#KWB+P
MKI^H07(TT:9?:A9PSD^7 PD\LL"R[6QZ<UF^%_[:^%$GB[1[SP5J/B:36-9O
M-2M=0TM(GBOTG.Y4N6=E\ID!$)+C;M12#C@>X44 ?-_@'X>>)/@C?>%=8U+1
M)/%$%KX8&BSQZ*HFGTN47+S[(48J7A*R)%E>1]FC)&.D.K?#7Q3KFL:MXZ@\
M."&%_$^FZY%X3GDC2>\AMK9X7ED^;RUN&,BR*K'_ )=H@Q#=/I:B@#PB)M<\
M??M#>"/%$7@74=%T'2=)U2TGU;5DCAN3+*;<I%Y08MY?R,=QX+=!WK8UZUU;
MP#\9M3\9'P]?^)]'U?2+;3EDTI%FNM.DADE<IY18$Q2^:&)7.&C&X8((]?HH
M ^2M.^&?BCQ!K]YJ=_X!.B6UY\4['Q$+%GAD_P!$CL57[7)M8KO\Q0S 9(;U
MQFNP^-GPI\2>/?'7BK^RK%&L[WPE9VT<ERX2WN[B#4FN#:R$<@/&"A)& )3U
MY%?0M% 'SWXXO/$'Q0\5?"[[%\.-6TV#0?$D-_J-]JRPQ?84%O-&1#M<F4$N
M 67Y<8ZY%=E^TEH^IZU\,1'I.F76KW5OK&E7K6EBJM,\4-]!+(54D D(C'&>
M<5ZE10!XIXTOM<^-UG8>&+#PGK6@Z-+J%K<ZKJVN1):^7!!,D_EPIO+O([1J
MF<!5!))R #S%I\*=<T[X.Z&]IX>\K6](\;3>*;G2HO+CFOE&H3NQ#9VF1HI%
M8;CSM521V^DJ* /F7XE>%=8^*S>._$YMI?!.EGPF-$MY?$S):^>_VGSY3(-Q
M\N$JHC+-U\QCC Y7XN>,;CQE_P *MTT>!K[29X?&6DR;M2\E5@V,S,;4H[>=
MA%?+)\H3))Z _2MQ;Q7=O)!/$DT,JE'CD4,KJ1@@@]01VKE?#/PE\&^#=4;4
MM$\-Z?IU^P($\,(#(#U"?W ?1<4 <E^T!X/UWXI0^'/ UBMU9>'=4O/M/B#6
M+<QY@M(,2+ N\,"\LOE+RK#8LF>V>(\8_ _Q5IWB3Q/::-KNK:Y8_$'0;C2M
M4U+4!;J=/O8H2+2X;R8XOW;HSQ,0I;B/G X^DJ* /FGXB2>)O'O@?PCX5L?A
M9J%C?:3K6C7%Y]H\E+/3HK:YB9WM9 _[W"J0NT#Y"2<=#T%I\.=4M_AK\=[-
M=%9-3\27^L36L8";[Y9+18H6SGOMVC<1T[5[M10!X;XE\ ZPO@7X+Z;I>DR*
M^A7]F;V"(J/LL*Z;<0OGGH&=5.,_>JA^S7\-]9\(>(KS4-;T-M/G;PAX=TM+
MF8(7\R"*?SX002?D9USVR1C-?0-% 'Q[X?\ @_JUKHJQ^*/"OB!["'3)HX_[
M">-;ZUN!KL]Q;2P$.,/&C1RC&>.,'E:]#T/0_B!KLGP9U+Q+9W%Q?Z7K&HS7
M]S*D44R6K6MU%;27"1ML65E>(.J9 9CT'3W^B@#YG\,?"C7?"_PE^&5S!X9$
MU]X8URXUG4O#JF-);OS&N5,J\[&F3SEE7<>2N,@XK>L%UWQQ^TCX:\6)X$O]
M#T&P\.:A8/K6J+'%=23236[+"8@Q98QL9@6ZDM@#J?>J* /CVS^!OC35_AUX
M2T9]&^SWEIX,DL[BWOY%$,LZZC:S_8I2"<"6.)U)Y&"<^E>K^(O[9^+&O>";
M>T\(:GX;70-:AU2\U+6(XXOLZ1HX:&W*.QD,FXQDK\NPL2>0#[710!\S)\+-
M?M/V-]=\+6WA]X?$UU/?7*Z?&(Q))(^I23*^<XW%2KY)ST[U],+G:,]:6B@#
MY:\*>#[KQI\ _"&@R:6FM2:9XY9=7LYU211'#JTS3&16X("X8CGJ.M=M\5_"
M,?@_6/AEJ'A?P?+)I&C^()KV^LO#=C&&C5[&XB$GE*5!R[HI(R>1Z5[!I6@Z
M=H;7K:?9061OKEKRY\A OG3, &D;'5B%&3WQ5^@#Q?59-<^*WC#PKJ)\+ZMH
M/ACPO=2:S(^I(D5W?W2P211010AR0H\UF+/@$A0,Y)'$:;^S7XD\=?#?7M4\
M0>)]8\/^-?%%W_PD$VFP?9'MK"]1E:QCW&%I,0+%;J=LG)1\$;J^GZ* /"?"
M.J:MXP^-W@K4=8TR;1-:LO!%Q+JNGR%3]GGN+J!0AP3P6MIBISR%KW:J5OHM
MA::K>:G#9PQ:A>)''<72H!)*L>[RU9NI"[VP.VX^M7: "BBB@ HHHH ****
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M549Z 5?H **** "BBB@ HHHH **** $KF/!7Q#TOQQX+3Q3:B6TT:0SM'/>
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M?&%[+4OML:6KOK5S>D2;);9P-YA(V%&0^6L> <884 ?4_@OQXOC+[3(-'O\
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MXI<Q5CZ=\;^-++P/X8US6+C%T^DZ=-J;V$4JB>2*-225!/0D8W'C-8UI\8=
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M8W"O*RQLIW@)M'/Z@8^@M0\,:-JVJ6>I7VCZ?>ZE9?\ 'K>7-I')-!SG]V[
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M&2$*&M)P^%WAX"GS;1EE?CBO4;>PM;2:YF@MH8)KIQ)/)'&JM,X4*&<@98X
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MRO(V#R]F,;-O3;CC'3%2U<I,\F\"^(H]"^,GQ M==U9+*T.EZ-?6,-_=!(A
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MW^S?^FGZ4?V;_P!-/THYD'*RE15W^S?^FGZ4?V;_ --/THYD'*RE15W^S?\
MII^E']F_]-/THYD'*RE15W^S?^FGZ4?V;_TT_2CF0<K*5%7?[-_Z:?I1_9O_
M $T_2CF0<K*5%7?[-_Z:?I1_9O\ TT_2CF0<K*5%7?[-_P"FGZ4?V;_TT_2C
MF0<K*5%7?[-_Z:?I1_9O_33]*.9!RLI45=_LW_II^E']F_\ 33]*.9!RLI45
M=_LW_II^E']F_P#33]*.9!RLI45=_LW_ *:?I1_9O_33]*.9!RLI45=_LW_I
MI^E']F_]-/THYD'*RE15W^S?^FGZ4?V;_P!-/THYD'*RE15W^S?^FGZ4?V;_
M --/THYD'*RE15W^S?\ II^E']F_]-/THYD'*RE15W^S?^FGZ4?V;_TT_2CF
M0<K*5%7?[-_Z:?I1_9O_ $T_2CF0<K,^:&.XADAF020R*8W0]&4C!'Y&N+^'
M'POM/!'AGPM8WQMM9U7PY:2Z?8:LUOLEBMG;A%Y.T[%C5B.NSMTKT3^S?^FG
MZ4?V;_TT_2CFB'+(YO7_  O8^('M;F:-8M5L1,=.U-8T:>QDDC,;21%@1G:>
M000>XKR'3_V:1-JEFVKGPTNGVU[!?2/HVCO;7-[)"XD0/ND:.%6=5=Q"J[L8
MX!(KZ"_LW_II^E']F_\ 33]*7-$?+(XCQ#\*?!OBS7/[8UGPSINI:GA5>YGA
MRTH7[HD'20#L'!Q4^K_#?PKK_B*PUW4O#]A?:Q8A!;7<T66BV$E,#I\I)*Y'
MRDY&*[#^S?\ II^E']F_]-/THYHBY9%*L:+P7H$/A7_A&4T6Q'AWR3;_ -E&
M!3;^63DKL/&,DGZUTW]F_P#33]*/[-_Z:?I3YHARR.3\)^ ?#G@.&XC\/Z-:
MZ4+@J9FA4EY-N=H9V)8@9. 3@9.*Z#)Z9XJY_9O_ $T_2C^S?^FGZ4<T0Y9'
M%^#O!;>&-6\6:G<7:WM]X@U,WSR+'L$42Q)%##U.=B)U[ECP*Z>KO]F_]-/T
MH_LW_II^E'-$.612HJ[_ &;_ --/TH_LW_II^E',@Y64J*N_V;_TT_2C^S?^
MFGZ4<R#E92HJ[_9O_33]*/[-_P"FGZ4<R#E92HJ[_9O_ $T_2C^S?^FGZ4<R
M#E92HJ[_ &;_ --/TH_LW_II^E',@Y64J*N_V;_TT_2C^S?^FGZ4<R#E92HJ
M[_9O_33]*/[-_P"FGZ4<R#E92HJ[_9O_ $T_2C^S?^FGZ4<R#E92HJ[_ &;_
M --/TH_LW_II^E',@Y64J*N_V;_TT_2C^S?^FGZ4<R#E92HJ[_9O_33]*/[-
M_P"FGZ4<R#E92HJ[_9O_ $T_2C^S?^FGZ4<R#E92HJ[_ &;_ --/TH_LW_II
M^E',@Y658/\ 71_[P_G6M'_JU^E58]/V2*WF9P<]*MJ-J@>E9R:>QI%-;BT4
M45F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !17+_%+Q5<^!OAIXK\1V4<,UWI.E75]#
M'<9\MGCB9U#X(.W(&<$<=ZXCPI\7([71]1UWQ)\1/!FK:38::VH7D6@VK++:
MHH#/(Y%U,2BC(.$'4<]J /7Z*\WL/VAO NH/&L>JW$0N(3<637&GW,*ZB@(&
M;0O&!<GD<1;C@@XQ6MIWQ>\*:AX>U;6FU,V%GI$GE:BNI6\MI/:.0I59(I55
MU+!E*C;\VX8SF@#LJ*X6P^-7A6\:\CFN+[2I[6SEU!K?5],N;*62WC&9)8TF
MC4R*HZ[ <9'K5:T^/O@?4O#UOK=CJ\E_IUY<?9+%[2RGE>_EV[BMLBH6GP,Y
M,88#:V2,' !Z'17!:+\=/!&O2Z]%#K:VMQH-LEWJT&H6\MI)81N7VF9954H3
ML;@\XP<8(S:\._%WPWXFUBWTJ"6_L;^Z1I+2'5=,N;$W:J,L83-&HDP.3MR0
M.>E '9T5YEH/[27P^\3?8Y-,UJ:ZL;JZ^P1ZF-/N5LA=;RGD/<&,1I)N&W:S
M Y('4BMOQ%\7/#GAO6)M)FEOK_4K=%EN;;2=-N+][5&&5:80H_E@CD;L9'-
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MH+1=>\1>(H+B]MHM)M]:L=$TR>.*7S9KFXMDD\J52,HX=F7!"XQSS0!ZU17
M_%#XJ6G@?0_$\=G+#/XGTOP]<Z_#83H^QXH@0&9A@8W@ @'-<XWQ\BL/C$WA
M+4[62RTF'PNNO7&J/8W AB?<2Y:<CRQ$$!^8G[P*YSQ0![#17/\ @SQQI7CW
M37OM)-YY"L%(O;&:T?E0RL$E16*E6!# 8(-=!0 4444 %%%% !1110 4444
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MC-\0KKX=^$K>XTNWAO-?U/4;72-+M;C=Y<MS/*$&[:0=JKO<X/1#7=#/?K0
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M";P?>>"8%L%N1XBUF/2I&:0I]G#6\TN\<'<<PXQQUZ\4FK?&CP/H?B!M$O\
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M R2!S7F_B?P_?^-O@[XK\+:?\-+[P_JUYH$MG')>KI\45Q(4"^5NAG<\G^\
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M0^,?$.LPVLR1R+:":VMU@G^4E0\A$A^7.&+#/&: /I)/B-X8D\(CQ2NN6?\
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M6-WXV_:,T&WELY/^$?\ !VF2:H;B2,B.74;DM#"JDC#&.%9V.,X,JUZW110
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M=!'O'DQQO(LCLJXX=BB G/10*WZ "BBB@ HHHH **** "BBB@ HHHH ****
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MNRQU-E\U_LO]EX_>;/)\G9Y'0YS\VZOJ58TCR515)ZX&,T&-68,5!8=#CD4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nvax-20220630_g2.jpg
<TEXT>
begin 644 nvax-20220630_g2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -$!#@# 2(  A$! Q$!_\0
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MT"Q:^U";G:" J*.K,QX51ZFIEE^ IQ<I4HI+R0XXK$R=HS;?J>1?\*/\.?\
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M.17%*CE4*CI2A'F6ZY?^!YG1&IC914U)V?F?-'_"C_#G_/?5_P#P9R_XT?\
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M\*/\.?\ /?5__!G+_C7?-*BMAG53Z$TK,%7)( ]371_9F"_Y\Q^Y&7US$?\
M/Q_><!_PH_PY_P ]]7_\&<O^-'_"C_#G_/?5_P#P9R_XUWAN(]N=ZGC/!'->
MKS?L]ZM:Z]X3TNYU[1;1O$=B;^WN;B9HXHD"YVN2/O=N,UA5P>74;>TI15[]
M.VK-88C%U/AFW\^Y\V?\*/\ #G_/?5__  9R_P"-'_"C_#G_ #WU?_P9R_XU
MZ5K5C_8FJ7MC+<03FUF>$SP.&B<J2-RMW!Q5/S%V[MPV^N>*V66X%JZHQ^Y&
M?UO$)V]H_O.!_P"%'^'/^>^K_P#@SE_QH_X4?X<_Y[ZO_P"#.7_&N]$T9( =
M23TYZT^G_9F"_P"?,?N0OKF(_P"?C^\\_P#^%'^'/^>^K_\ @SE_QH_X4?X<
M_P">^K_^#.7_ !KT"BC^S,%_SYC]R']<Q'_/Q_>>?_\ "C_#G_/?5_\ P9R_
MXT?\*/\ #G_/?5__  9R_P"->@44?V9@O^?,?N0?7,1_S\?WGG__  H_PY_S
MWU?_ ,&<O^-'_"C_  Y_SWU?_P &<O\ C7H%%']F8+_GS'[D'US$?\_']YY_
M_P */\.?\]]7_P#!G+_C1_PH_P .?\]]7_\ !G+_ (UZ!11_9F"_Y\Q^Y!]<
MQ'_/Q_>>?_\ "C_#G_/?5_\ P9R_XT?\*/\ #G_/?5__  9R_P"->@44?V9@
MO^?,?N0?7,1_S\?WGG__  H_PY_SWU?_ ,&<O^-'_"C_  Y_SWU?_P &<O\
MC7H%%']F8+_GS'[D'US$?\_']YY__P */\.?\]]7_P#!G+_C1_PH_P .?\]]
M7_\ !G+_ (UWY.!FO?[/]C+Q9J&BV%];:_H$EQ?6BW=MI[3.DTBLH8 97&>>
MO2N3$8?*\+9UJ<8W\O\ @&U*KC*U_9R;MYGR#_PH_P .?\]]7_\ !G+_ (T?
M\*/\.?\ /?5__!G+_C7H^I64^CWUS9WL9MKJVD:&:.3@HZG!!_&JRR*R[@P*
M^H/%=:RW M75&/W(Q^MXC;G?WG _\*/\.?\ /?5__!G+_C1_PH_PY_SWU?\
M\&<O^-=[YT?'[Q>>G(YIS.JD L 3T!/6C^S,%_SYC]R%]<Q'_/Q_><!_PH_P
MY_SWU?\ \&<O^-'_  H_PY_SWU?_ ,&<O^->BV,'V[4+:S1U66>5(EW'H68
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M #WU?_P9R_XT?\*/\.?\]]7_ /!G+_C7H%%']F8+_GS'[D'US$?\_']YY_\
M\*/\.?\ /?5__!G+_C1_PH_PY_SWU?\ \&<O^->@44?V9@O^?,?N0?7,1_S\
M?WGG_P#PH_PY_P ]]7_\&<O^-'_"C_#G_/?5_P#P9R_XUZ!11_9F"_Y\Q^Y!
M]<Q'_/Q_>>?_ /"C_#G_ #WU?_P9R_XT?\*/\.?\]]7_ /!G+_C7H%%']F8+
M_GS'[D'US$?\_']YO?LD_!CP[9?M%^"+I)-4>2VNWGC674)'7<D3LN03@C('
M%%=W^RI_R7[PE_UUF_\ 1$E%?G?$E"EA\5"-&*BN7IIU9]3E-2=6C)S=W?\
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M6CMP,1E0I63GYP0HSTK#-,%5QD8*D[6OY=&K:='L_(TP>(AAW)S5[V_,]X^
M$6D>)H?B-\4?$=E;G6UU%E5+FPDO(['< 6)A3YC][!(QC:?>L_XV-\/?B%IO
MA.:"2&#Q%>:G!:M>Z?HUQI\$]JS[7_UHP2N1WS7B_AWX[>,/"?C+5/$VD7MO
M8W^J.9+RWBMQ]EF8]S%G&>2>#U-1?$+XT>*/BS?6$GBO46GL[5P5MK&,0JG]
MYE7GY\=S7$LMK_6U7YK1TM9[*UN6W+JK^:]+G0\72]A[.UWZ;Z[WO^A]1:YX
MLA\*_&31OAE9?"S3[GPTDD"1W4EH6E<8#><KXVX4]<YSM/-9UCH-G??%CX[Z
M?;Z;;S3+I0-K;K;J=I\O'R#'!R1TK3\)_M ^#M&T#3S>?%K4M1MK6,,=/N=*
M5;V0#D1O(J8)[=>?6OFS6_CIK4?QDUGQYX:F;29[R8[(I '#0X "R+T.0 2/
M6O*PN#Q%9SA&'+:-KOFM*2DG?WEUMK:YVUJ]*FHR<KZ[*VBLUT[7ZG;Z!H?]
MG_LAWMW>Z<+:[F\0PK!-/ %E9=Z @$C.,JWY&O9=<\(Z3X@_:.U[5=2TL:[/
MH/A>WOK/2V&1<3#?@8[G@ >[#@U\L?$?X\>,_BM'91>(-0BDMK.0316MK"(H
MO,'1F&3D_C3=0^.OC+4/'UOXR_M&.TUZ"!;99;2$1QM&N?E9,D,#GG->I/+L
M55YIMJ,I<^S>G-RV5_2.K\SCCBJ,+12;2Y>G:^OXGT5X+\>/\6/ 7Q(O-7^'
MFFZ!=6.ERQQ:A;V90'Y6_=G>/OCKD5/XJ\2IX_\ A#\'-#U*PT^SL?%5U%:W
M4D2%3;)&RG]T2?E+;<'ZFO$=<_:T^)'B*QO[*]U"Q>SO;9K6:!;)0NUL@D<Y
M#8/7-<-K7Q,U[7O"?A[PY=30KIN@$FP\F+9*A/<OGDUE#*:KFIM*-I75FW;W
M6NOG9ERQT.5Q3;TMLE?6_P"5T?75KJEEK'Q<N_A'<?"NS@\(QQ- MZML1*J!
M,B?S,8VD].<Y/4]*XK0M7T_X0?L\ZYJEEI&FZY?6/BB[TVRN;^!9-H+%1)G'
M)"KTSC)KRZY_:P^)MWX;;17UV,0M%Y+72VX%T5Z?ZS/7'?&:XAOB)K3?#W_A
M"C) =!^V_P!H;3%^]\[UWYZ>V*=+*J]E&I91O&Z4F[VO=Z]7?84\;3NW&][.
MSLM+VLOD?2.C_#NP_:-\,_#GQ2D5K:OI<S6/B41*D0:*,;]Y  R3@?@Y]*\!
M^-GC6V\>?$C5M1T^"&UTF-_LUC%!$L:B%.%.!W/)_&NR\$?$K2_AS^S_ .)=
M/TW6FD\7>([@0O8QJP^R0 %2^2,9*ENA[BO$]HV[<<=*]# 8:<*U24OABVH^
MC=W^.B?9'+B:T94XI;NSE^2_S?J?97P$^&_B'1_V>[F_\.WMCI'B?Q)=1SQ7
M6H2F,):QL,!2 3D@'C'\=<W^UGX%&E_$CPAXQ\N V^KR00W[6YWPBXC9<X/<
M%?7KMKP/QU\2M;^(T>CQ:R]M]GTFW^RV<%K (HXT_P!W)YX'/M2?\+)UO_A7
M8\$.]O+H"W/VN-)(<RQ29SE'S\H]O<UST\NQ,<1]:E-7DW=6Z/3?K:RLK&TL
M51E2]BHNR2L_->7G=GT_KW@QF_;:TE8M$4Z2UJDY"VH^SE!"06/&W[WZU8\.
M_$5]!^#7Q@DM=)TR>'1]6N(X4DA^6999"?G Z[=W&.F!7A]K^UC\3+/PTNB1
MZW%Y"P^0MTUL#=!>F?,SU [XS7$Z3\2M=T7P9KOA:WF@.DZVXDO?-BW2LPP<
MA\\=*YUE6(J1C&M;W>1+5ZJ+NWMNUT-?KM*+;IWUYGMW6B^\^J_&'Q7L_AIX
M=^$D1\,:=KEWJ&GPQ2W&H)N,,'R K'Z,2<Y/'%0+\)_"MG^TEXYGCT"/4(M%
MT>+5[/0HP-D]RX8G"].JC Z9;I7R]XH^*&O^,(O#L>I26S+H,2PV/E0!,*I!
M&[GYN@K1U#XY>,=0^(B^-_[1CM/$*QK"9K2()&T:C&UDR001US3CE->$&J<K
M-J2>KU;DFOPNM-KB>.IRE[RNDU;1=K/\3VOQ)J%O\</@1XT\0Z]X)M?"6J^'
M6#V%]:PF%9>>8CNP21T/;)'2NH^(GB:QTGXB?"_P;9^'M)CAU8:=>7]X;9?-
MDPV%CZ8V_+D^N:^=/B1^T#XW^*VF1Z;K^I1'3U;>;6SA$*2,.A;D[L51UGXR
M>)M>\7:!XENY;1M5T..**R9+8+&%C)*;ES\W4U4,KK-+FLDN9J-VTKI):O?5
M7\B98RGK:[>FMEK9N_X:'US;^.W\(>'_ (X)9:-I9BT#4/,@B>#"2^8%.V11
MP0O8"N,TGX<Z9^T%IOPW\;K!:6=K8![;Q-'$JQ)MA&_<0!R6(&?9O:O +KXX
M>*[RU\702S69C\52++J>+8 LR@ ;.?EZ>]=;X7^)6E_#_P#9TUK1=*UEI_%7
MB2[VW-G&& L[<#:3DC&648."?O5SO+:V'CS4M*DFE=7>CBE*_H[O[C7ZW3JN
MT_A2>_K=6_!'#?&#QI#X^^(FL:O9P0VNG-+Y-G##$L:K G"< =3U/N:XV@<<
M"BOKJ=.-*"IQV6AX<Y.<G)[L****U("BBB@ HHHH **** /H_P#9'U"RTGPS
M\5KS4=.35["#28Y)["0@+<(!*2A)!X(XZ5H_!_5/"OCS5OB=?Z-X-L?#6G0^
M%'\K3E5)524"3,H.T8)R.@[5X-X1^(^M^!])U_3M*DMTM=<MOLMZ)H=[&/##
MY3GY3\QYH\#_ !'UOX>1ZS'HTEO&NKV;6-WY\/F9B.<A>1@\GFOGJ^7SJ3KU
M(O6?+;5[*U[K;H>I3Q481IQ>RO?1=;GUWX0L;;4O$GP!M[RVANX&\-W9,4\8
M=3B*+!P1BN2\.^)M,^'/[.>I^(W\-:7KFHP^)KF&T2^@4HCF0X+$<X S@ ^E
M>):;^T%XRTF]\,7=O/8B;PY:26.GEK0$+$ZJK!^?F.%'/%8E]\4M?U#P/-X1
MFDMCHLM\VHLJP 2><Q))W9Z9)XQ7''*JS:4VN6ZOJ]N:;?X21N\;32;CO9]/
M**_1GTEXQ\'>%_B?XX^"VL7&CVVDKXGB=]0M[4!(YO+0.J$#U.5SUP:Z?P3X
M]_X2CX[3^"KWX6Z;8:3I;S+;7?V+$L 0%5D8D;2KCIC^\.M?*T?Q3U#Q#)X-
MTWQ#?SV.C>'6VVMUH\*K=VZG'S@L<.1M!YQT-?5]O^TSX.\.6*7]W\2[OQ6U
MM#^ZTN'3!;RS/C \Q@@!]^0,\\UY^-P=>C3C3Y7/225N;W;R=G=*VUEK;;>Q
MUX>O3J2<[\NJ;VUT5_Q['QSXLM;F7XF:S;Z;$_VLZM*MM';KAM_FG8$ [YQB
MOHR^\.ZO\:M-\0:9KNF:AX/^)^F:8C7EX@9;35[9 "J38XSP,?X9%?+FL:Q-
MJVOWNK?\>]Q<W3W0\LD>6S,6&#[&O3-4_:J^).L>%Y-!N=:B-K+#Y$EPEN%N
M'0C!!DSW'!.*^AQ>&Q%14O8VO'JV[K;U36FJ?DSRJ%:E!S]I>SZ=_P#)^9TG
MC+06U+]E'X>7FG:9Y]PM_)%<36UN&DR68 ,0,GFO8H=-@TC]I[X96D=I%93Q
M^&F\^*.((=^SG=@<G(-?,7PU^/\ XU^$VFS:=X?U"%=/E?S/LMY )D1NY09&
MW/>JUK\;O%]K\1O^$Y;4([KQ%M:,37,(>-4(QM"9   /'I7%5R[$U.>%UR^_
M;5W?/W5M+?,Z(8JC'EEK?W;_ /;O^9],>#/$T'Q6^('B'X=:W\+[+2?#\:W'
M^F+;,LULRDE9)'(P68G((QR>]<WX3\1:3\+OV7X]=;P]IGB+4;77[BVLVU"$
M,NX2, [$#)PH/&>]>6:U^U9\2]>\.SZ+=:U"EM.I22>"V$<[*<Y7>#P,'' Z
M5Q4WQ(UN?X=P^"'DM_[ ANC>(@A_>^8<\[\].3QBHAE59I1FDH\T6TI-[7N[
MOJ[K3R*EC::UC=NSULNMK+Y'U/\ $;XG>&O -OX&\8V'@'1YM8\56\9NVFB^
M6*$;=P0#C<2W7'0#.:O7O@G0='^,7Q;AM-)LX[9O"(OD@\E2D<S+)N=01\I)
M /&*^3/$_P 2]<\7Z3X=TW4I+=K708_*L1%"$8+Q]XY^;[HKH[K]HKQK>>(-
M:UF6>P-]K&G#2KMEM %-N-V HSPWS'FH_LFM&"5-ZV:>K_F3C]R17UZG*5Y+
M32VB[-/[V?4C?&6\L?#/P6<:#H\I\12K#*)(21:@8&8>?E-%O::-XZ^/'C[5
M]=TJQD;P;:1P6:+:-/O+%W,\D2\R,N,8'8^M?(LGQC\32V/A&T:6T\GPK)YF
MF?Z,,JW^V<_/T]JDL_C=XPT[XA7GC6SU%+37;P_Z088@(9AQ\K1YP1P*S_L6
MI%2=.T6U)7N^LKK_ ,ET*_M"#MSZI-?E;\]3W/XZ:Y\/_&_PQDO&>U/B2&Y6
M*POM,T"ZL(F^<!XF,@(/RECR>PQ6[XX\06WP8U;POX$T#X967B#1+RWA>6]F
MMVDEO7<C<8W X88!R<]1TKYW^)7QZ\:?%FR@LO$.I1O8PMO%I:0B&)F&<,PR
M<D9..:U?#?[4GQ'\*^&8M"L=:C:SA3RX9+BW66:)>RJY[#MD'%;+*Z\:,(_%
M9OW7)VUM9II+;M;JR'C*3G*6UTM4ETWT;>_J=!^VE_R6^;Y=O_$NMOE].#Q7
MA%=+\0?B'K7Q/\1-KFO202Z@T20EK>+RUVKG'&3SS7-5[^"HRP^&IT9[Q21Y
M>(J*K6E..S84445W'.%%%% !7T)^SJH^)'PU\>?#&0J;NY@_M/2]Y&!,N,@>
MA)"\^A-?/=;_ (%\=:O\./$UMKVA31P:C;JRHTJ;T*L,$%>XKAQM"6(HN,-)
M*S7JM4=.'J*E43EML_1GM?[1[6VA-\//A3;3K#9Z1! VH-'C'VB4@,Q/J 6;
M_@=>E>,/$UO\,_B+H/PUTCX66.K>''%NOVF2U9YKG=@M(C@8RIZDYY!Z5\@^
M+/%.I>-O$5_KFKS"XU&^D\R9U7:N<8  [    >U>CZ-^U=\3-"\/V^CVVMQ/
M;P*J1SW%LLDX48PN\GD<8Y&<5XM3+:WLJ45:32=TVTN:6O-==G<]"&,I\\Y.
MZO:VB>BZ:GN5QX#T#4OVBOB1J=UH,6M/X=TJ"\L-#A152>4H?X ,$C:.W5@:
M\>^)7QBN_B/X%NXM4^&.GZ5+#<JD.M6=M)"+3/5#QRQQW..O%<9-\;O%\GQ$
M?QQ%J*6GB&151Y;:()$Z@ ;63)!! &0:T?B%^T=X\^)VB_V3K>IPKIK'=);V
M5N(5EQR-_)) /:G1R^O3J4Y5$I645?FDN6RULEH[[_F*IBJ<H246U=OHM;[7
M[6/=/&GB2#]G9?#'ASPO\.;'Q!8W]G%<7&J7ELTSWTC<,J,H/S?7(^8<8KE/
MA\FGZYH7QWO3X4M_#ICTO?#I<D6YK-MDF<%QE3GGC ]*X+P;^U'\1? OA^'1
M=.U:WFL8!MA%[;"9XE[*K$C@=@<XKG[7XT>+;?\ X2HR7\=Y+XGA\C4YKJ(.
M[I@@!#QMP&(&/:HAEV(C"46ES.WO<TKRM)/5;+3^K%2Q5)R33=M=++32VY](
M^(_B1I7PH\(_"<P^#]'U6_U2RB2XNKN!=R0_(&"X'WB3U/I5_3_A#X/_ .&H
M_%C2:5!_9^EZ1#JL6G" R1&=R=SB(<MC;G:.YKY2\3_$[7O%]GX=MM2DMFBT
M")8;'RH A51C&[GYN@K4U#XZ^,K_ .(4?C8:E':>($B6#S;2$)&T:_P,F2"#
MWJ/[)KQ@_9RM*2DF[OK)-?A=>5ROKM-R7.KI-6T7:S_$][^,WB3X?>-/A;K,
MMV;.36[1L:;>:7X=N[!8Y>OE.\@(.<<Y(%>=?L8_\EBD_P"P7<_^@BN3^(W[
M1'CGXIZ2FF:[J4/]G!@[6UG (4D(.07Y)./KBN;^'_Q"UGX9:\=9T)X([XPM
M 3<0^:NQNO&1S752R^K# 5,/?WI7LKW2^=E^1C/%0EB85>B\K?JSZ#^&_B+3
M/ O[.'B7Q)<^'=.UZ^M?$$JVT=]"K*)"XVECC.!SQFM#QUX8\-_%B\^">O7.
MCVNBR^*+AH-1CLAY:2(BD[./4J0#UPU?.(^)FNCP'>^#_,M_[$O+PWTJ^0/-
M,I.<A\\#/;%.UCXH>(=;\->&]"GN8HK'P\Q?3FMX_+EC8]RX/)J/[-J^U=:,
MK2<I:W?PN-EIZZC^N0Y%!JZ273JG_D?7/AOXARG]H"#P+%\+[*QTC2[AH[2^
MAM62>!44A9]^-NPC_P!"')K@=6TBROOA7\9Y9H(!<?\ "6I"MVT2F2)6FA!P
MQ&0,$]ZX*']L3XHPVUI"-8M'%N0?,>R4O+@8Q(<\_ABN*NOC!XDO/#OB31)9
M;0Z?XAO?M]^HMP&:7*G*'/RC*CBN:CE>(A-2LH_#M)N]I7;U77L;5,92E%J[
M>_1+=62T/H_Q_P"+8?@)XBTKP1X:^%]CKFBR6\;O>7%LTLNHLP^8HX!&>W.>
M3TKE/@;I>D-_PLWQXO@B.XU70V!T[PN59UMBV=WRL"21CTX .,5P?AK]JSXD
M^%?#\&C6>L6\UK GEQ27EL)9D7&  Y/8=,YKE/#'Q@\7^$?&%UXGT_69?[9O
M"3=2S@2+<Y.<2+T(_+':M89;B%1G3:7,[:\TO>UN[]KK33\B)8NDZD9:V72R
MTTZ=['T6WC?_ (3O]G7QUXIOO FF>']3M9(=EQ!:;(KK8ZD8W#<,8VG!YS7H
M>M>,!XF^(7P?TB]T72WM=4LGU*7, 8QL(''EJ#D;/FSCU KY4\8?M.>/_'7A
M_5M$UB_LY]-U)%CFA2T5-@'/R'.5R1SUK/7X_>,%U[PUK FL?MWAVU-G8'[(
M-JQE=IWC/S''?BN9Y/6DF^5+XK*[=KQ26MNYLL=3BTKM[7T6MG=_@>V^&[;3
M_AG\._&/Q TWPG;>*?$#^([NQ\N>+S(K&%96 .Q>0O3IC[P[59\2>']*UWQ%
M\%_&\GAJ'PSK.O:D(;_2O+ CE4 D/L([X'4=&&?6O!/!/QX\9_#W6=5U+1-1
MCA?5)FN+JWEA#P/(Q)+!,\'D]#46O?&[QAXF\<:9XLU/44NM5TV19+-&B'D0
MD'.!'TQGKZUT_P!FXGVKG===;N]G&RC;:R>MS#ZW1Y%&W;2R[WO?<^L--\7>
M'?%WQR\5?"^;P1HT>BF&8R72P 3R3*H+L3T ],<C KX;U"%;74+N%,[(IY(U
MR<G 8@?H*[/2OC3XHT;XC7OCBVEM!X@O-_FN]L&B.\ -A,\<#UKB)YFN+B69
M\%Y7:1L# R22?U->AE^"E@Y/LXQZM^\KW>O?0YL5B(UTNZ;Z=.@RBBBO://"
MBBB@ HHHH **** "BBB@ HHHH 1ONFOMWX@?$#P%\-!\,M>\0:'J6K>*K/P_
M')I<EK)MA1=B@A_F'.3UVFOB,\C%=1XX^)&N?$1=&76I+>0:1:"QM?(A\O$0
MQ@-R<G@<UY.-P7URI3N[17->SL]5;_ASNP^(]A"=MW:WR9[S\+=0MQX"\>_&
M"3PQ;^*O%DFJNJ6,D?F1VB/M9I-O7'SG)ZX7MS5WQQINF^-O"_PS^(-WX8M_
M"OB"^UV&RN+**+9'=Q;CB38>WRC&1G#=^*\!^&_Q:\4?"?4)[OPWJ M3<+MF
M@F020RXZ%D/<9X/6MK4OC5XA^(GQ"\-ZOXOU59+73[R*0)%'Y<,"!@68(,\X
M')Y/%>=4R^O&NZD;6Z.[O;EMR6VM?K^IU1Q5-TE![^BM>]^:^Y],>,/'QT+X
M[)X&M_A7IMYHVIRQQW-T;(F6X5P%:52!M"J.N?[IY%<EH/P_TK1-2^/WAW1[
M&.\6SME>RA\H2/$"A8JA(R,$D<>E8'Q4_:[\46?C;7+?P7X@MKKPW/M^S7#V
MFYX\H VPL 1SGJ#S7BO@SXJ>*/ /BJ;Q%I&J2)JMQN^TR3CS%N,G)$@/WN>?
MK7'A<MQ+H7246XQTN]6FG=WVVM\SHK8NBJEM]7T6B::T[]SV'2=%73/V4_#]
MQ>:>MM?7'BNW,4LT 65X_,7N1G'RM^5>M:]X8TO4/VAOB'XBO=&7Q'?^'M$M
M+JPTEAN\Z4QGG;@Y(V@#C^*OE?XA?';QE\4+K39M?U"*5-/E6:WM[>$1PK(#
MD.5SR>W)Z4ZX^/'C2;XB'QO'J4=IK[1+"[VT(6*2-1@*T>2", 5T2RW%5.:;
M:4I<W5_:<7:^]K*S?F8QQ=&-E9M*W3LGK][/H+0/'+?%'X._$O5]4\ :;H%]
M96)2*^MK,HLN 2$^89W+W(/<5U.I>.F\26OP+LKO1=+^SZ]<)-.@AR(?+0D+
M&#P%/<&OG#Q)^U7\1?%FDZGIFI:A8R6&HV_V::!+)5 4YR5.<@G/7GH*Y^/X
MW>*HF\(%9K//A0DZ7_HP^7(Q\_/S\?2L/[(JRU<4M6TN9NUX66K7>S-?KT(Z
M)MZ*^B5_>O\ D?0UCH^E>!_^%N^/K+PM;^)]=T[Q!-8VNGM$&BM(<C,FP#A?
MF.<#.%XQS63XXTW3?&WA3X:_$*[\,6_A7Q!>Z[#97%G%%LCNXMQP^P]OE&,C
M.#WXKQ/PY\>O&GA/QAK'B72]2CM]0U>5IKV$PAK>5R2<F,GC&3C!R*A\9?&[
MQAX^\1Z9K6M:BEQ<Z;(LMI"D02")@0<A.^2!G)YKHCEN)552;7K=WMRVY;;6
MOK?]3*6+HN#C;Y67>][[WL?6]QXW\/W'[1EU\,SX(T5M)OH"+N[:V7SI)?*W
M>F-NT8]>]?$GC#3H-'\7:Y86RE;:UOIX(E)R0BR, ,_05T8^-7B@?$S_ (3W
MS;/_ (2/&/,^S#R?N;/N9]#ZUQ^JZE/K6J7FH714W-W,]Q*47:N]F+' [#)K
MMR_ SP<K]'&*>K?O*]WJ<V*Q,<0O.[^[H5:***]T\X**** "BBB@ HHHH **
M** /6?V5/^2_>$O^NLW_ *(DHH_94_Y+]X2_ZZS?^B)**_+^*?\ >X?X?U9]
MCDW\"7K^B///C+)X\_X6]XW^R?"'QIJ-K_;E]Y5Y:V0:*=/M#[9$.>588(/H
M:X[S?B)_T17QW_X #_&OV*GE<2-AV')[^YJ/SI/[[?G7-#/L?&*BI*R\D7++
ML-)MN/XL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?
MWV_.K_U@S#^9?<B?[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G
M_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F
M7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^=
M'G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\
M=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17Q
MW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_
M "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]
M]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G
M_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F
M7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^=
M'G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\
M=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17Q
MW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_
M "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]
M]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G
M_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F
M7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^=
M'G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\
M=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17Q
MW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_
M "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]
M]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G
M_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F
M7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^=
M'G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\
M=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17Q
MW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_
M "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]
M]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G
M_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F
M7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^=
M'G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\
M=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17Q
MW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_
M "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]
M]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G
M_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F
M7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^=
M'G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\
M=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17Q
MW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_
M "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]
M]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _
MQK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_
M !H\WXB?]$5\=_\ @ /\:_8;SI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL
M_'GS?B)_T17QW_X #_&CS?B)_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#
M,/YE]R#^S<+_ "_BS\>?-^(G_1%?'?\ X #_ !H\WXB?]$5\=_\ @ /\:_8;
MSI/[[?G1YTG]]OSH_P!8,P_F7W(/[-PO\OXL_'GS?B)_T17QW_X #_&CS?B)
M_P!$5\=_^  _QK]AO.D_OM^='G2?WV_.C_6#,/YE]R#^S<+_ "_BS\S_ -EG
M4/&UC\?_  ;)J7PE\9:38M=M%+?7EF%A@#Q.F]SGA06&:*_3BRD9IL%F(]S1
M7AX[&5L=452N[M*W8]/"T*>'@XTUH07'^M;ZG^9J.I+C_6M]3_,U'6"V&]PH
MHHIB"BBB@ HHHH **** "BO*U^/T5]K.O6&B^ ?&GB--%U"72[J]TRSM3;FX
MCQO5#)<HQ R.=HKTW3[I[[3[:Z>UN+)IHU<V]TJB6(D9V.%) 8=#@D>]*]QD
M]%+M)QP:-IXX//2F(2BE967J"/J*41LW12?PI -HHIQ1E&2I ]<4P&T4JJ6X
M )/M058=01^% "44[RVY.TX'7BFT %%>?:U\;-'LM>O]$T72M:\:ZOIS"._M
M?#=JDXLW(!V2RR/'&KX.2F\L.X'%7/!7Q>\/^.-:O-"A^V:/XFLXEGNM UFW
M-M>Q1DX$@7)61,\;XV90>"<TKH9VM%+L8KD*2/7% !/09IB$HI2C*0"I!^E#
M*5X((/N*0"44[RVP3M.![4FUMN<''KB@!**Q]-\31:IXFUG0TT_4H9M+6!GN
M[BU9+6X\U=P$$G20KT;'W3Q6SM;=MVG/IB@!**QKKQ1%:>+K#P\VGZD\]Y:3
M7:WT=JS6<0C95,<DW19&W953R0#Z5M;&VYVG'KB@8E%*%+=!FAE*\$$'WIB$
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **H:]KV
MF^%M%O=7UB_M]+TJRB,US>74@CBB0=69CTKS[_A?UG):C48?!/C:Y\/E/-_M
MN/1QY'E]?,\HR"X*XYXBSCM2NAGJ%%>>>(/C]X&\._#O3/'4NMQWGA74;RVL
M8-1LQO3S)Y1$I;)&P*Q^;."N#D9&*]#8A02S*% R6)XQZYH **Y/X7_%#0/C
M%X0B\3^&;B2ZT>:XN+:.:1-A=H96B<@9.5+(2#W!!I(?BIX9N/BE<_#N/4D;
MQ;;Z8NKR6/=;=GV!L^N<''H0>] '6T444Q!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%*JEV"CJ3B@!**\8TG]JKPSJ=F-5E\/\ BG3?"_\
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M67R$&Z2^'L;+#;O[[U[#I?P)\*>'[KP.VC6TVD6?@]KI].L+9\Q.\Z;)'F+
ML[8W'=NR2Q)S4UO\$_"]K\:+OXI1VT@\4W6EKI4C;AY.Q6SY@7'$A7Y"V>5
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MDUVU16MNMI:P0(24AC6-2W7"@ 9_*I:LD****8@HHHH **** "BBB@ HHHH
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M?YFHZDN/]:WU/\S4=;+8Q>X4444Q!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU.:2E8+GB_QO\+>'_AY^S;\0UTK1--TV6;P[/9.^G645NUQ(\1B0':!G+N,
M^M>H>#=+?0O!V@Z;)G?9Z?;V[9ZY2-5/\J@\;>!]+^(&D0:9K*S26,5Y;WQA
MAE*"22"198U?^\F]5)7O@5T!.233 2BBBF(**** "BBB@ HHHH **** +-C_
M *ZBBQ_UU%83W-X;%QK9&.3_ "'^%)]E3_*K_A4]%1=EV1!]E3_*K_A1]E3_
M "J_X5/11=ARH@^RI_E5_P */LJ?Y5?\*GHHNPY40?94_P JO^%'V5/\JO\
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M?94_RJ_X4?94_P JO^%3T478<J(/LJ?Y5?\ "C[*G^57_"IZ*+L.5$'V5/\
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MX.#@G%8%Q^TE\-[75)K*3Q+&%@F^SS7ZVD[:?%*&VE'O!'Y"D-\I!D&#QUH
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M^[G'-83?LQ:M:Q^-?#6B7%EH/A=M8M?%7A":#D:5J2G=-";<  0%UW84])7
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MG06ESJ,A)-Q(B!6?+<G)'?GUKJ: "BBB@ HHHH **** "BBB@ HHHH ****
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MY%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _SF_V?^^11YS?[/_?(IE%
M#_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _SF_V?^^11YS?[
M/_?(IE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _SF_V?
M^^11YS?[/_?(IE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*91
M0 _SF_V?^^11YS?[/_?(IE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W
M^S_WR*910 _SF_V?^^11YS?[/_?(IE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]
MG_OD4><W^S_WR*910 _SF_V?^^11YS?[/_?(IE% #_.;_9_[Y%'G-_L_]\BF
M44 /\YO]G_OD4><W^S_WR*910 _SF_V?^^11YS?[/_?(IE% #_.;_9_[Y%'G
M-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _SF_V?^^11YS?[/_?(IE% #_.;
M_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _SF_V?^^11YS?[/_?(
MIE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _SF_V?^^11
MYS?[/_?(IE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_WR*910 _S
MF_V?^^11YS?[/_?(IE% #_.;_9_[Y%'G-_L_]\BF44 /\YO]G_OD4><W^S_W
MR*YSQ=X^\/\ @/\ L?\ M_5(=,.L:A%I5@)C_K[J3.R,>YP:Z C!(-&@#_.;
M_9_[Y%'G-_L_]\BL/QEXOTOP#X7U+Q%K<[6VDZ?'YMS-'&TC*NX+D*O)Y(Z5
MKQN)(T=>590P^A&11H!+YS?[/_?(H\YO]G_OD5!<W$=G;37$IVQ0HTCD#.%
MR3CZ"L[PGXHTWQMX9TOQ!H\S7&E:G;I=6LKQF-GC<94E3R..QH V/.;_ &?^
M^11YS?[/_?(IE% #_.;_ &?^^11YS?[/_?(IE% #_.;_ &?^^11YS?[/_?(I
ME% #_.;_ &?^^11YS?[/_?(K'\6>*-.\$>%]5\0ZQ,UOI6EVTEY=3)&9&2)%
M+,0HY/ Z"KNGWT.J:?:WMLQ>VN8EFB8@@E& (.#TX(HT M^<W^S_ -\BCSF_
MV?\ OD4RB@!_G-_L_P#?(H\YO]G_ +Y%,HH ?YS?[/\ WR*/.;_9_P"^13**
M '^<W^S_ -\BCSF_V?\ OD4RB@!_G-_L_P#?(H\YO]G_ +Y%,HH MV<C--@X
M_("BFV/^NHK&>YO#8BN/]:WU/\S4=27'^M;ZG^9J.MEL8O<****8@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBE7[P^M #A$Y&0C$?2F5\>^$Y_A;K7C#XN-\0O&?V#Q
M!:>++Z"TAE\67-I<PVZHAC$-LLZ@@')4!#D]C75^ _VBO$/AK0OA[X1USPQK
MGBKQ]X@TFXO[%6"P2W$4=T8XFNB5Q 3 8Y'=@ "<;=QQ4<W<JQ],%2O48[TE
M?-^D_M!:7\/]%TO[)X9\3:Y?>*_%VKZ7!8?V@MY,E[$\FY49L!8"T9VC@1KS
M[5UR_'[4=(\46_A+Q-X%O='\8:G ]QH>FV=_'>PZFJ8$H$ZJJQ&/(+[QPIR-
MW2GS!8]BHKSGPI\7WO-?UGP_XNT)O!>N:7IZZO)'+?)=VTMD2RF9)U"_=9&#
M*5!''7-85K\>M=U303XLTWX::Q?^!?*-S'J:WD27T]N.?/BL2-S(1\P!<,5Y
M"]J+A8]CHKYZTW]L2PU[2?AY-H_@S6-5U3QWIEUJ&CZ9;RINW0RK&8Y7QMC7
M#;S(W"A2,$\5Z1X%^+EGXIL?%S:O8MX8U#PG=R6NL6=U.LH@58Q*LPD  :-X
MV# X'IU%%T*QWM%<I\*_'H^*'@#1_%<>EW&CVVK1M<6UK=L#*8"Q$<C8 QO4
M!P.H#"NKI@%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%1W"2
M26\J0S&WF9&5)@H8QL1@-@\'!YP?2@#XS^-]]X?^/GQ:\6Z+K$/B&Y\/^#]-
MDTO1[O1= O=0A37I=KR7/F6\3@/;[85 )!!+5W]G^T9K6O?LV>&-=TU(K'QU
MJNJ6OA.Z%_"P73=2:3RII)8G ;Y0I<(P&=Z U[!\(?AC8?!WP'9>&M.N9K[R
MY);FZU"X 6:]N97,DL\FWC<S,>G08':N=U/]G?P_K6J^/I+VZNI-(\8M:W-U
MI<06,6M]",+>02CYDE.V,^F8P?6HLR[H\O\ VH/AGKG@O]GWQAJ%CX\U_7)O
MLT::E;^(KL3VUU&9HPYC3 $#@G*[..@((KN+F\UWXI_%?6/!]MXAO_"_A;PO
MIED][_8[^1?:A=7,9=,3X)CB1 /N<LQ()P*J^._V:=9^*GA.?PQXQ^*.LZOH
M?[MH(8-/M[60R1L&C>X=.9]I4'!"@GDYZ5VGBGX2#4O$D7BGPYKMQX2\6+9)
MITVHV]O'<17ENIRB7$#X60H2Q5L@KN(SCBE8+G'0:IKOP[^)%YX!U'7KOQ3X
M?UKPY>:II5QJA$E]8R082:*64 >;&PD5E9OF!##D8KS'P_\ $;Q'8_"[X#^
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M%SF/ACHNM_'KP/I?CS7O&GB+1$UI6N]/T?PS?_8H+&W+D1HY4$S284%F?N2
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M%SYY\<:AJOC+]F/X\^&]<\0:I=W7@J?4-.BU>WG^S7-]"EL)(A<%!A^)-K\
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M^!'@VU\"7/@^;3I+_1)]1FU;9=3LTL5U+,TQECD7#(RNQ*E2".F:+!<S[?\
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M%^$OA>UN=9TC5+2^UW6&U/Q#+83ZY-&R*T;W(CE;!+^8\:!01@# &*]&TO\
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M60,'+HRJ,'KBKGP9^&OAK6_V@/CYXBU/2+75-2_M^VLH_MT:S1PQBPMV;8C
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MW>U=5X5\2V'C#P]8:OIMY:7UK=1+();*X6>(,0"RAU)!P<C\*^)_#.C^%/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!. 55V!(SQQ7@/Q"\*>$/#?[8?P;ET.WL]-\336VKM<Z=9*L2/&+=?+EDC7
M5LY4-C)'':N;^ 7@?Q3X_P# NJZ[=ZOX N]<N]1O!XBC\1>%YKZ]M+E975H)
MI#>+M5%50@"HNS:0.<T78['UEJFL6&AZ?+J&IW]KIUA$ TEW>3K%"@/0EV(
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M7]:+H=F> _#;X#SZ;X\T7Q1J7A_1?"-KH4%RFGZ-I-Y)J$KSSA5DGGNY%5G
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M/[/D]5_6CF0<K"Q_UU%36MJT,FXD45C-W9M#1%RBBBH+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#P3X2?5M':QUN>'6;#2;B%;D$0M/<Q1,&VYVNJR[MI]O6O1: "BBB@ HHHH
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M(/<,JD>X%&L>&-(\076EW.IZ;:W]QI=S]LL9;B(.UM-M9/,C)^ZVUV&1V)H
M^9?#?@BZ^#OQSAT705CN=7N_AE+'#/)C-WJ%O=;C(_N[W#,?=C6!\"?!&JZ]
M\!+?6)/'O@DZ?<02R^(CKW@\3SQW>2;I+V1[T$R*^X-O X X Q7UQ<^%](O/
M$-EKT^G6\NLV4,EO;7S1@S11R$%T5NH#;5R/85RNM? /X=>(_$C>(-3\&Z/>
MZP[B22ZEME+2,.C..CGW8&@#YQTW3]-@\*_ '3->\33>*?A=>:E>R-J%_9/9
M6T\NTMID$L<CL1"#Y@C$C$,4BSVKK?VF]/\ !^C_ !3^!:VZV]AXLG\7VHAM
MK,"-Y[58YB_FJO6-6(P6X#$XYS7T=K/A[2_$6C3Z3JFGVVH:7.GER6=Q$KQ,
MO8%2,<?IBN2\/? 3X=^%&A?2?!VDV<D-S'>1R+;@NDR9V.&.2"NYL8/&30!X
MW8Z>_P "_C#:?;+/1?%_A+QOXLG?3M57:=6T?4ID8O&V<^;#F-U#*0T8^5@0
M*U_V7])\.Z]\/_$E[XHMK&_\;2ZG?)XO.J(CS13"5P(I ^=L(B";!]W9@CJ:
M]7TKX+^!=#\97'BVP\*Z7:^)+AY))-2CMP)B[_?8'LS=R.34?B[X(^ O'FM1
MZOX@\)Z7JNIH OVJX@!=@.@8C[P'H<T ?%FGV7A4?L>_M)Q^$C'>>&(O%%]_
M9\A_>(%#0#]VQSE <A3Z=.*]H_:"TO4=0^-'PFT3^U='\->%IH+N6S;5M*^V
M6$^K )Y4;Q"6)?,\LR-'DGY@V!FO>?\ A57@[^P-8T,>&=+71M8E,VH6"VJ"
M&Z<A06= ,$_*OY"M/Q/X1T7QIH<VCZ]I5IJ^ES8WVEY$)(SCH<'H1V(Y% 'S
MXO@>[T?]H3P+_:OQ"T+_ (2M8[F8:;X>\*&SN+VR$9\Q+F074@6'<5*EU^^!
MMYS7TU7+>!_A;X2^&L,\?A?P_8Z(+@@RM:Q /)CH&;J0/3.*ZF@ HHHH ***
M* "BBB@ HHHH *\T_:8_Y-V^)G_8MZA_Z3O7I=4M:T:Q\1:1>Z5J=I%?Z=>P
MO;W-K.H:.6-@59&!Z@@D$4 >,?#WX$P:]X)\&2^*/&'B3Q=IUO;6-_#H^J26
MJ6@F2-6C++!!&T@5L$*[,,J"02*\X\$^#GT3P-^T1XT\*V$EU\0)O$&OPV5U
MS+-$$D;;';CG9SEL*/F8@G/%?6MG9P:=9P6EK$D%M!&L4448PJ(HPJ@=@  *
MJ:+X=TSPZMXNF6$%@MY=27MP($"^;/(<R2-CJS'DGO0!XKX/\&_!^X_9BM=]
MOI,_@:721/>ZA=E2[,4#2RS2GYA/OR6).X/Z$5Y^VC^,+C]F_P"%_P 5(K:^
MN_'O@J'[?Y-PI6\U/268K-;R@X)DDM1')AN?,0<9->_W/P'^'EYXE_X2";P=
MI$FK[MYN&MEY;KN*_=)SSDC.>:[ME#*5(R#P0: /CZ/5K3]HKPK\4_C0L;3>
M%[/PSJ>A^#3,A7?!]G?[9>;2.#)(/+4]=L)_O55U#3G^$&FZ;\4FL]%\8^$K
M_1] M?$&BWX0W^FR1Q1QPSVC-D'[Z,8#M)/S*<G%?6MOX1T2U\+GPW!I5G#H
M#6[6ATV.%5@\E@0T>P#&T@G(]S7-W'P*^'UUXEL/$$W@_29-9L5A2VO&ME+Q
M")=L6.WR* %/; Q0!\P-'8WGBB+3/$XV_#^]^*VM?VMYAVVTMTL:M8Q7)Z>4
MTN>&^5G6,'/ /JW[1NE:-X?UWX:ZCX<M(+/XA_\ "0VMMI2:>@2>>S=\7J2*
MG+6XAWLV?E!5#P<5[0O@?P\FFZKIXT6Q-CJMQ)=WULT"F.YF<@O(ZD89B0"2
M?05E>"_@_P""OAU=37/AOPSI^D7,W#SV\(\P@]0&.2![#B@#QS]GOX>^'K[X
MS?'WQ'>:5;WNKS>*A9>?=1K)Y<*V5LVQ P^4$MEL?>PN>@KR^22"Q^']WX=U
M!VLOAG8_%R\TK5X48K!;Z7YC-% YS\EN;AHE8<*%;!P*^T='\,Z3X?NM4N=-
MTZWL;C5+G[9?201A6N)MJIYCD=6VHHR>RBJ]GX)T#3[+5K.WT:QCM-6N);K4
M(! I2ZEE_P!8\BXPQ;OGK0!\T_MT^'_AS8?";PY->6^GZ=K2Z[I:>'S8HD<T
MK&[AW1H%QNB\O)8?=X4]0M>F?#?_ ).5^,G_ %ZZ'_Z(FK=TW]G#X7Z3%<1V
MO@71(TN&1I%:U5^4=77&[.W#*K<8Y4>E=O9^'=,T_6=1U:VL((-3U%8EN[N-
M ))Q&"(PY[[02!Z9H \!_:TO-8^(5]X7^#?AB"SO-3\1R'5-734)9([9-*M7
M5I$E>-691-)Y<0P#G+5EZ1)XS^$/[1FFZ]XLTW0-+\.^/XH= G7P_>SSQ1ZE
M C&SED$L4>W?$&@&W.2L>>U?1L'A/1K;Q-=>(HM,MDUVZMDLY]1$8\^2%&+)
M&6Z[06)QZFCQ+X4T?QEIZ6&N:;;:K9QSQ720W48=5EC</'(,]&5@"#V(H ^:
M?V._#_@C4-8^+\[6UC>^*SXSU6.^2[422QV_G QA5;I$<Y^7@L6SS7DGQ>CT
M1?A#\8M.T^>5?A1;>-M%2QDLG;RH&:X@.HI:LG(19#D;. Q?;S7TGX'_ &8-
M"_L77[/Q[HVC^))KSQ)J6LVLFQF,<-Q,71"Q"G(!Y'(SZUO?&3X-MXR^&.F^
M$O"T6FZ+!8ZKIM[' R&*!(;>[CF=%5%/)5& XP2>?6@#B_VCM!^'VC_LWWEW
MI$&F6#V=LC^%+K1PBS#4!C[(+5DY9FDVC"DY!;/&:R?A3X(74_CI\7?%VI:=
M'>>.;&UTF&W%P=T5M<-I4+2&-/NJS/A2XYV@#.,Y]GTKX&^ -#\5'Q)8>$-)
MM=<WF07L=LN]&/5E[*?=0*ZBP\.Z9I>J:GJ5I806U_J;QR7MS&@#W#(@1"Y[
MD* HSV% 'A'[,'ASP7KGP'^VZM9V6HZOJ'VB3Q?-K**]R;XLPN4NO,&5V\J%
M; "!<<8KB?"/@'5?B3^S/??\(O-/]M\+^(KS4?AWJ%TS&1K>VE)MDWMRT,@\
MV$$G!B9>HQ7T+XD^!_@'QAKJ:SK/A+2]0U13DW,UN-S'U;'WO^!9KM;>WBM8
M(X((TAAC4(D<:A550,  #H .U 'R]\)O&T'[7OQ-TOQ?_9T]KX/\"1*L5I>1
MLC-X@DCQ.&4CG[*AV9_OR$CI6U^R_I7A_7O!/BJ]\46UE?>.9=6OH_%G]J(C
MS0R+*X6)PV=L(A";!]W9R.IKWS1]!T[P_#/#IEC;V$4\\EU*EM&$#S2,6>0@
M=69B23WKE_%_P1\!>/M8CU;Q#X3TO5=2C4*+JX@!D*CH&(^\!Z'- 'QKX'A\
M,6_P9^)D?@V43^&%^+5BMBZ,7CV"^L@1&Q)S&#D*?0#'&*_0&N6A^%G@^WT^
M[L(?#6EPV-W>QZC/;1VJ+')<H49)2H&-RF-"#VVBNIH **** "BBB@ HHHH
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M\X_$9=3\*_'[QM#X'M(K/6K_ .&-Q>0PVD07S[Z&XD2W<@8!<;MH)YQ@5O>
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MYV:WVB/^\O\ WT/\:/M$?]Y?^^A_C6311R(.=FM]HC_O+_WT/\:/M$?]Y?\
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M4-%>'^)/%WQ&^$MUX7UKQ9K>B:[HNL:M:Z/?Z58Z:;9M/DN6VQR03EV,JJ^
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M5MN5)4D#((..:ZNF(****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1*NU&>V5?+ED50!N\U0Q&2!TKUZBIL.YXQ=?L^OX7T'X?-X&U&*W\0>"#/\
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M@51\ _"7PS\/_ 6B>%+72K.ZL-,LDLO,N;=)))@%P[.Q&26.22?6NRZ<44[
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MW?TV[<<=<YKO**+"N<!\"_AU>_"GP3)HFH7=O>W#:MJ&H"6U#!-EQ=23*OS
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MI@XR*U-)T/3- MW@TO3;/3(7;<T=E;I"K'U(4#)I6"YY7HOP[\>_"G5-<M_
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M5_9UU7QCXP\&>)_%_P 0K_7-1\*:DNH6-M::=%961^1U8-"K-EVW#]X6. N
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M7O?P@^%]K\(?"LVE6]_-JM]>WUQJFI:K<(L<M[=3R%WE=5X'90!T55%8VL?
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M@5[9\(]:TSQ!\/=(O]&\4S^--,E1O)UFZ(\^8!B-LN%7YU^Z<@-D<C-9-O\
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M'+(H45?_ +/_ -I?R/\ C1_9_P#M+^1_QHYD'*RA15_^S_\ :7\C_C1_9_\
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M^S_]I?R/^-',@Y64**O_ -G_ .TOY'_&C^S_ /:7\C_C1S(.5E"BK_\ 9_\
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MDNHR6/.];=G9%DZ8P65AU[57\(^/_#_CY=3?P]JD.K1:;>/87,UN&,:3I]]
M^-K8)P2I(!R,Y% '04444 %%%% !117/:?\ $#P]JWC35_"5IJL,_B/2;>&Z
MOM/7/F012Y\MFXQAMIQ@]J .AHHK&\6>,=%\"Z4NIZ_J4.E6#7$-J+BX.%\V
M618XU^K.RC\: -FBBN,;XR^"E\-_\)!_PD5FVB_VG_8WVU2QC^V>?Y'D\#[W
MF_)Z9[T =G116+J_C/1=!U_1-$U#4(K75=;:5-.M7SNN6B3?(%P,?*O/- &U
M12,P523P!R:R?"7B[1_'7AVRUW0+^/4](O5+V]W#G;(H)4D9 /4$?A0!KT44
M4 %%%% !17*:U\4_"_A_QGIOA.]U0)XBU%!);V,4$LK;"Q4.Y12(U+ @,Y4$
M@XJ7X@?$CPY\+M&@U7Q/J/\ 9ME/<I9PL())FDF<$K&J1JS,QVG@#M0!TU%<
MIX$^*'AWXE)=OH%S=7"VI42_:M.N;3&[.,>=&F[H>F:ZN@ HHHH ***R?"OB
MO2?&^@VFMZ%?1ZEI5T"T%U%G:X#%3C(!Z@C\* -:BBB@ HHHH **R=.\6:1J
MVO:OHEG?1SZKI'E?;K5<[H/-3?'NXQ\R\\5K4 %%%% !1110 4444 %%%<'X
M[^.7@KX:Z]::+X@U>2VU>ZMC=PV5M8W%W*T(;:9-L,;D+NXR<<T =Y17/>"?
MB!X>^(NE/J/AW4XM2MHY##+M#))#(.J21N \;=#M8 X(/>NAH ***QF\8:,G
MBZ/PNU_&-?DLCJ*V'.\VX?RS)TQC=QUH V:**RE\4Z1)XGD\.KJ-NVNQVBW[
MZ>''FK;ER@D*_P!TL",^HH U:*** "BBB@ HHHH **** "BBLGPQXJTGQGI(
MU/1+Z/4; RRP">+.WS(Y&CD7D=0ZL/PH UJ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **RM>\4Z1X7_L_^UM1M]/_ +0NX["T\]PO
MGW#YV1+ZL<' ]JU: "BLKQ1XITKP5X?O=<UR]CT[2;)/,N+J7.V-<@9. 3U(
MK3CD66-70[E89!]0: '45'<7$=K;RSS,$BC4N['H% R35'PWXBTWQ=H.GZWH
M]VE_I6H0+<VMU'G;+&PRK#/."* -*BBB@ HHHH **** "BLWQ)XBTWPAX?U'
M6]8NTL-*T^![JZNI,[8HD!9F..<  U;L;V#4K.WN[:036UQ&LL4B]&5AD$?4
M$4 3T444 %%%% !1110 4444 %%%% !1110 4444 %?-?Q,L=0^ ?B[Q?XUN
M-$3QE\+/%1BE\4V(B$MYI3)&(FN50@B>VV ;X_O)@LN1D5]*5XOXI^"/BS4+
MKQ98:)X^;3O"WBR1GU&ROK$W=U9^8@2864QD"Q!U'1TD"DDKB@"/7?&FN^/O
MB=9>!/!&LP^'M"M-%AUG4]=MH$GN&BF8K;0VBN#&NX([&1E<   +SD)!XF\6
M_"_XG:3X1UW7F\6:'XCL;N32=4O+>**_M;NWC\QXIO*5(Y(VCW,K!%*E-ISD
M&MC6/@<--UC0M?\  VJKX9U_1]*31$-S ;JTO+%,>7#<1[E9MA7*LCJPR1G!
M(JQX9^$^HS>.;?QKXWUJW\0^(K.TDL=/@L;,VMA81R$><T<3/(QD<*H+N[8
MP, G(!B_!'XA:_XO_98T;Q?JU]]J\0W&BSW<EYY2)NE7S-K;% 7^$<8QQ7C'
MCQ_$7Q1^%G[,GB.^\9:MIVJ:IK>E-=/I\-HJM<26L[FX"O"V''( ^YACE3P1
MZQ:? 7QCX;\+WW@?PUX[M=+\!7/G1PQSZ29M4L()68O!!<>:(]HW,%,D3LH/
M4X!KJ?%'P0LM4T7X;Z1I-V-(TSP7JUGJ%O"8O-\V*WADB6+.X8)#@[N>G3F@
M#RO0?#WB?6_VK?BQIFE^))M T]-%T(WFKVT,,E_+((YPJH)$:) 1N9F*'T '
M4>D_!'QAKM]X@\>^#/$6I#7=0\(ZA!;1ZP8%ADNX)[=)XS*B ()%W%24 4[0
M<#.*WO#/PS;P]\6O&OC0ZB)U\1VNGVXLO)V_9_LRR+G?N^;=YGH,8[T>"?AF
MWA'XA_$#Q.=1%T/%5S9W M?)V?9O(MEAQNW'=NV[N@QG'/6@#Y6_::\27FE?
MM?Z=I%SJUWX6\$Z[X6M+#Q'XDLD/F6=N;RX\N+S1_J%F?$9F_@![9R/HGXD:
M]%\"_A7HFD> M)T^WN[R\M- \/V<@*V<,LS85Y-O)15#R'!RQ7&<MFM/5/@Q
M8Z]\5-;\4ZM)!J6E:OX;C\.7.BW%L&22,322,S,3R&$FW;M[9S7+:+^S3]E^
M'6I^ =5\3W>J>&+>\BN_#$VPKJ.A^6PDA47!9O-\IP-A90=ORMN% %3XB0_$
M3X+^#+OQS%X[N/&*Z0@O-8T75K"V@MI[5<&?[*T,:R0NJ[F7>\H.W:>N:S_#
MOCCQQXO^,GQ F?Q+'I7PU\*/8W\<-O:QM>7:R:?%.UNQ9#LB^8N3RY+!05 K
MI_$'P?\ &7Q'TO\ X1SQUXRT_4/"+21M=6NCZ2UG=:E&C!O*N)3,ZA&(&X1(
MF>1D D5UG@[X9IX5\7^.]9:[2ZM_$UQ:S"S\G:MND-K';[,Y.X$1YZ#&<4 ?
M.7AOXU>,_B9H,'BI[OXE>'3J*FYT[3?#O@V.ZT^*W))A\R26)WN"R[2S(\8.
M< #&:[6#XV_$#7_"O@+P^VBMX2\>^*=2N[![S5+%HX[>UM5+RWJ6[-NW.FS9
M&YX9SDD+ST?A_P""OCGX=:7<>&O!'CNQT[P<TDALK?5=(:[O=*C=BQBMYA,B
ME%).P2HY48&2 !6IJW[/=C<>!O#.D:=K^JVFO^&;DW^E>)KJ475XMRV[S7EW
M\2+('<.AP"#@8P, ' ?&*3XH_!MO!-YI'Q!N/$>C:EXET_3=636["T%U'%++
MM)@>&*-=IX5E92PSE6'2O8O^%=PZ+XZ\4^.-+B@E\0:KI5O8K$T8C#M!YK(7
MD'+;C(J\] @Q7FWCC]G_ ,=?%B]\*7'B[X@6*1>'-9M-7@T_0M'>VMKIX6R3
M.))Y'9L$A<,%4\[2:]YO(Y9K2>.";[/.R,L<VT-L8CAL'@X/.* / OV6_B'J
MWCK[<OB7QG?7/C"VAQKG@O5=-AM)M(N?,/,(5%=H"!M5F,@8 '<"<5'^VIX9
MA^(G@WP1X#N)'CMO%/BNSL+@QMM81+'-,Q!'0CR@1]*ZOP7\(/$D/Q-M?'/C
M7Q+IVNZSI^D2:-9?V3I)L%:*21))))RTLA=R8TP 51?FPN6KH?'?PS;QMXX\
M Z\VH+;6_A>]N+XVA@WFY=X&B3#;ALV[V/0Y]J /)[/XT:W_ ,,]R:;)+GXF
M0:D? SJ@(;^T]WE+<#/8PE;G/3!KSSX437GP.\!ZQX)T&[V0:/\ %>VT;,T2
MREK2[E@E=3OW<L)F.[J">#7O'_#.>F?\-%'XI_VE<%38A/[#Q_H_VX*8Q>CG
M'F>03%TZ8.>*I:Y^SF^K>+/$.KQZ\MO!JWB71_$?V;['DQ/9(BO'NWC=Y@C7
MYL?+SP: .3^%<GQ/^,=_\1YKWXB7/AK2-'\5:CI.C+H^GVC3M'$X ,[31.&5
M2=H50K$#)<YXS?#WQW\<>+H?A_\ 8DL+G7[B#Q/9W5H( L%]?:>!' P9LM$K
MN-Q"M_&1D@"O;_A/\,V^&-GXG@;41J/]M>(+[7 PA\ORA<.'\K[QSMQC=QGT
M%<!X3_9GOO!\V@7-EXJ5;W1[GQ!=PS?8 ?GU)]Z':7(_=''7._\ V: ,_P#9
M^\6:C\4O!.LPW/Q,UJ7Q-]DC35-*O-+M+/4O#UZ03(JQF''EYR%\Q) 0,ASF
MO'?A#JWQ#\$?L^_ G3O!GBDW=_XIU>6QD&O00-;VEOY-TS;!'$K,%9!( 3EF
M&-P4XKZ2\ _"#7=,^(VI>._%_B#3]9\17&D1Z)%_8^EFQ@6W63S"[AI9&DD+
M]RP"CA0,FLOPC^SB_A;PK\)M'.OK<GP+?RWK3?9-OVW?%/'MQO.S'GYSEON^
M] $?A_QEKWPI^*5[X5\<^)YM>T&^T3^U])US4+>"!Q);+B^A?RD1>%*3#(R
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MBGXC?$[4O!/AW7&\)Z%X;TZTEU75;6WBFO[BYN$+Q0P^:K1QHL8#,[(Y)8*
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MW.M16T&L36<4EY'9R^;"LQ0%Q&_\2[LX/<8K7H **** "BBB@ HHHH ****
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MD?&C5/@SXLT5$FDO--UBV:TL4\012ZM=::-CW-B]W$JB.;:6"2'#%2N3GYJ
M/J^N%^,/Q;L?@MX3?Q)JNCZOJFDPNJW4NDQ12&U4D 22*\B';D@?+N//2LK]
MGGQ%X;\0>!9QX:GUP06=]-:W6F>))I9+_3+@8+VTAE+/\NX$99N&!#$$5SW[
M;'_)K_CO_KVB_P#1\= 'JWC#QEI'@'PW>:]KMXMCIEHH:24J6))(5555!+,S
M$*% ))( &37'^&?CKINM>)M/T#5O#WB#P=J6J([Z8GB&UCB6_P!@W.L;1R2
M.%^;8^UL=N#CL/$WA#1_&5K8P:U9+?065Y#J$".[*$GB;=&_!&=K<X.1D#BO
M#9]>F_:+^,&AW7AZ)I/AUX OY;Z?78^FKZHD;Q+;6O\ ?BB#OODSM+X49P30
M!]&5P?A'XO6'BWXA^)O!G]C:OI&L:##!<S'48HEBN(9FD6.2%DD?*DQ/]X*1
MQQ3_  7\4)?&6L2V#^"_%7A\1QF3[7K5C'# V"!M#+(QR<^G:N$\&_\ )XWQ
M,_[%?1?_ $;>4 =OXM^)^I>%]:EL+;X=^+?$,**K"_TE+(V[9&< RW4;9'0Y
M7\ZY_P ._M->&O$'@#0_&)TK7--T;5];70H&O+:/<LS2M$)6V2,ODF12HD4G
M)QV.:J?M*>*M3N-,T;X;^%[K[/XN\;S-8I.A^>PT]0#>WGMLC.U?]N1*QOVI
MO"VF>#/V2]7TC1[)+6PT.+3Q86\(QY7DW<'EXQW^4<]Z /H&BHK60RVT3L,,
MR G\14M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7E6N_ 4WWQ&UGQIHWCGQ+X4U36+6VM+V+2Q920R+ &$9VSV
MTI!^=LX/->JT4 >?^"/@SI/@_P 1S^);K4M5\4^*9K?[(=:UVX$LT<.<F.)$
M58X5) )$:+D@9S4WA_X,^&M#^$Z?#F6"75O#/V62SDAU!PSRQNS,0S*%YRQP
M1@C QR*[JB@#RC2?V?+.WU#1)=:\7>)O%NG:'.MUI>EZU<PO;V\J B.1C'$C
MS,@/RF9GP1NZ\UQ?Q1TN_P!#^)6IZ[%HGC+P_+=PQ0Q^(_A^L>H-J**O^KO+
M.2)U5T)(638WRG <=*^BZ* / /V>?A7>:/\ $CQQ\0;RPU33%U^WL[*WCUR<
M2:A=K"'+W5PHXB9BX58Q@*J?=7(%=WXW^"UCXM\4)XFT_7M:\(>(S9_V=/J6
MA31*]S;;BPBD66.1#M8DJVT,NXX89KT2B@#S6Y_9\\'2_#_2/"5O:W6GVFCS
MB\T[4+2Y9+ZUNLL3<K/][S&+.6)R&W,""#BL#4OV7=*\3>(/#6N>*?%WBCQ5
MJ_AS4(M1TRXU"Y@C2W=,Y7RH88XR&S\S%=Y  # 5[310!ROA_P"'.F>'/'7B
MSQ7;2W+ZCXE6T2\CE=3$HMT=(]@ !&0YSDG/'2N(B_9KT_2X+[3- \8>*O#/
MA:]EDEF\.:7=PK:+YA)D6%GB::!6))VQ2(!DX S7L-% 'G^O? WPKK'PYTKP
M-;VLFB^'=+N+.XM+;36">6;:9)HURP;(+(-V>3D\Y.:X_P#:@^'MS\9K7P9X
M!?0CJ/A_4M:BOM:U"1 8[.UM?WI4-VDE;9&,?PM)7N%% $?V>+R1#Y:F(  )
MM&,#IQ4E%% #(XTAC"1HJ(.BJ, 4^BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *&O:#IWBC1;[2-7LH=1TN^A:WN;2X
M0/'+&PPRL#U!!KS6S^ ,NCVL>F:1\1_&ND^'HT$4>D17L$RQQ@8V)<30/<*,
M<#$N5 &"*]9HH \R7]G7P9:>&?#&@:;:7&DZ;X?UJ'7[=;68L\]W&S-OG>3<
MTA8L2Q)W'UKHO&OPWTSQWJWA34=0ENHY_#>IC5K-;=U57E$4D6),@Y7;(W P
M<@<UU=% 'EVI? 6T7Q#JNK^&O%7B'P1)K$IN-3M=#F@^SW<Q #2F.:*01R,
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M*'PZTSXM> ]6\)ZQ+<P:;J2+'-)9N$E 5U<;200.5'8UU-% ''_%CX<)\6/
M>I>%)M?UGPW::BGE7%YH,Z0W1B_BC#NC[0PX.!G&1GDUSO@+X)7_ ,/4T>SL
M?B+XDFT+2T6*'19+32X[4Q*,",^59HP7_=8'WKU*B@ KE--^&^F:5\2M<\;P
MRW3:MK%A:Z=<1.ZF%8X&D9"JXR&)E;))/0<"NKHH Y.S^&NDVOQ+U'QT[W%W
MKEW81:9&;AU:.TMT8N4A& 5WN=S9)R0.PQ7)_M&>'-5\<>%M"\*Z;87%U;ZO
MKMBNI7$(^6ULXI1/)(YST)B51ZEZ]8HH **** "BBB@ HHHH **** "BBB@
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MHHY$'.S5^U)Z_P#CP_QH^U)Z_P#CP_QK*HHY$'.S5^U)Z_\ CP_QH^U)Z_\
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M2>O_ (\/\:RJ*.1!SLU?M2>O_CP_QH^U)Z_^/#_&LJBCD0<[-7[4GK_X\/\
M&C[4GK_X\/\ &LJBCD0<[-7[4GK_ ./#_&C[4GK_ ./#_&LJBCD0<[-7[4GK
M_P"/#_&C[4GK_P"/#_&LJBCD0<[-7[4GK_X\/\:/M2>O_CP_QK*HHY$'.S5^
MU)Z_^/#_ !H^U)Z_^/#_ !K*HHY$'.S5^U)Z_P#CP_QH^U)Z_P#CP_QK*HHY
M$'.S5^U)Z_\ CP_QH^U)Z_\ CP_QK*HHY$'.S5^U)Z_^/#_&C[4GK_X\/\:R
MJ*.1!SLU?M2>O_CP_P :/M2>O_CP_P :RJ*.1!SLU?M2>O\ X\/\:/M2>O\
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M?B738IXK'5[2.\MX[A0)51UR P!(!QZ$T ;E%.:-D^\I7ZBC8P4,5(7UQQ0
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M:+'&H"JBC 4#@ #T I:**HD**** "BBB@ HHHH **** "BBB@ HHHH ****
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M&?EKTWPW#J]OH-C%K]S:7NLI&%NKFQB:*"5Q_$J,25!&.,G'/-.XC2)V@D]
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M:XGQM\:?!?P[U$6'B#6UL[H1+/+'';37'V:)CA99S$C"",D'#R%5X//!K$^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS''(GE=1MSYF=W/3I7.-\(/$'A;Q1KNJ^ /%]OX<L=>N3?7^C:KI7]H6JW1
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MC-\/[CQ3J>I:NFM^(?$VHC4=2N[>S%G;[UC6)$BA#,5 1!DLS,QR2:[VBBF
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MUX!OFNAH-QIZ:8[0RA9_)4*!A\$;L*.<55A7/-I)YOC;\9-=\)ZU>7NG>%M
MT73[_P#LC3[I[5M3ENU9C++(A#F*/9L558?-N)[5TJ_L_P"EZ?8ZWINC>(/$
M&D:+K&FRV,FD_P!IS30Q2L,+<PR2,98I%/=7P>.*V?%7P@T3Q3>:9J27.HZ%
MX@TVU%E::[HUP(+Q(./W;$JR2)D9VNC ') !IW@_X3:?X5\02:_=:SKGB?Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44N#C..*2@ HI<'&<<4E !
M12X."<<4$$8R,9H 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S8_P"N
MHHL?]=16$]S>&Q%<?ZUOJ?YFHZDN/]:WU/\ ,U'6RV,7N%%%%,04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !113HUWR*IZ$XH ;17S!IW[17Q!M?A?<?%#5[7PK+X3MM:F
MTZ71[6WN8;\PK>FU5HYGF9'DSAMGEC=R 17T3XF\6Z'X+TEM3\0:O9Z)IRD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-_*90 T99&96 Y5@:^B/%G@+PSX^M(+7Q-X=TKQ#;0-OAAU2SCN$C;&,J'!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2DT'0]-TR, )96T5LN!@81 O]*LW%K!=J@G@BG$;B1!*@<*PZ,,C@CL>M2T
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MR$#^#I-&1%N!J *BU6TV<G<< A>"A;/&:3P;;6NM?M/^(CXY@B?Q-:Z'I_\
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M#J,+W0 &2?*#;N!STKX8\56/@J/PS^V9;>!W@.AM8622K8L/LT=P;=A,L)'
M 8GA> V<5[I^T)X%T#X>_LJP/H&DVNFS>'I=*N=-N(8PLMO,+RW4R!QAM[!W
MW-G+;VSG)H ]]\5>./#G@2RCO/$NOZ7X>M)&V)/JEY';(S>@9V )]JY?P_\
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M[[]K31?!=GXT^"<K0V=IXM'C33ULEME5)I(,2>8' ZQCCKP#C'- 'U%1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445P/CCX\>!?
MASX@CT/Q!KGV/5Y+9;P6<5I/<2>2690Y$2-@%E8<^AH [ZBN,TGXQ^#]:TW1
MK^VUE5MM8O\ ^R[!KF"6!KBYVLWE*LBJV=J,>F.#6YJ?BW1]&U[1]%O=0AMM
M5U@S"PM7)WW'E*&DV_[JD$_6@#7HK+\0>)])\*6L%SK&H6^FV\]Q':127+A%
M>:1ML<8)ZLQ( %:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45Y;JW[3WPRT37-3TB[\3JM_IEPUK>K'97$J6TJX+(\B1E%(!
M&<GCO7I.G:E::Q8V]]8W,-[97""6&XMY \<B$9#*PX(([B@"S16/X9\8:-XR
MAOYM%U&'4HK&]FTZY:$Y$5S$VV6(_P"TIX-;% !1110 4444 %%%% !1110
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M*G[1&GZ7\ _&WC'PRVJ+J&E6=Q'#'/H5WY]M="%GC,UN\0=4^Z2SJ$P<DXH
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M/Q2\,_!Z^N?$;Z9JNL6,TVIZ;>^'YH#J\B6Z,Y@=U58T1G#;ERK@X!H ]?\
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MOK&L>(I]8M-6UB9;>#4[*15$ CG<A6:)5\HQYRNW.,-FOHKRT#!@J[@, XY
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MTTHK,K%067H<<BG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?VB+_GHOYT?:(O\ GHOYT687)**C^T1?\]%_.C[1%_ST7\Z+,+DE%1_:(O\
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MH,G"GJ.3UJU5DA1110 4444 %%%% !1110!9L?\ 7446/^NHK">YO#8BN/\
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M8%M=.L+>.UMH4& D:*%5?R JY5$A1113$%%%% !1110 4444 %%%% !1110
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M6L32>9*T8QG>Y"!B2>$ &.:ZJB@ HHHIB"BBB@ HHHH **** "BBB@ HHHH
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M/NKB(+SU+ 4#/4HY#-#%(WWG16/U(!IU*V-QP,+VI*9(4444P"BBB@ HHHH
M**** +-C_KJ*+'_745A/<WAL17'^M;ZG^9J.I;C_ %C?4_S-15LMC%[A1113
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"_MI_\CT?\+0^*G_17O&'_ ']M/_D>BBB["R#_ (6A\5/^BO>,/^_MI_\
M(]'_  M#XJ?]%>\8?]_;3_Y'HHHNPL@_X6A\5/\ HKWC#_O[:?\ R/1_PM#X
MJ?\ 17O&'_?VT_\ D>BBB["R#_A:'Q4_Z*]XP_[^VG_R/1_PM#XJ?]%>\8?]
M_;3_ .1Z**+L+(/^%H?%3_HKWC#_ +^VG_R/1_PM#XJ?]%>\8?\ ?VT_^1Z*
M*+L+(/\ A:'Q4_Z*]XP_[^VG_P CT?\ "T/BI_T5[QA_W]M/_D>BBB["R#_A
M:'Q4_P"BO>,/^_MI_P#(]'_"T/BI_P!%>\8?]_;3_P"1Z**+L+(/^%H?%3_H
MKWC#_O[:?_(]'_"T/BI_T5[QA_W]M/\ Y'HHHNPL@_X6A\5/^BO>,/\ O[:?
M_(]'_"T/BI_T5[QA_P!_;3_Y'HHHNPL@_P"%H?%3_HKWC#_O[:?_ "/1_P +
M0^*G_17O&'_?VT_^1Z**+L+(/^%H?%3_ **]XP_[^VG_ ,CT?\+0^*G_ $5[
MQA_W]M/_ )'HHHNPL@_X6A\5/^BO>,/^_MI_\CT?\+0^*G_17O&'_?VT_P#D
M>BBB["R#_A:'Q4_Z*]XP_P"_MI_\CT?\+0^*G_17O&'_ ']M/_D>BBB["R#_
M (6A\5/^BO>,/^_MI_\ (]'_  M#XJ?]%>\8?]_;3_Y'HHHNPL@_X6A\5/\
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M_P"_MI_\CT?\+0^*G_17O&'_ ']M/_D>BBB["R#_ (6A\5/^BO>,/^_MI_\
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6Z)/8W<EL8IEYRK;80<?0BBBBD,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nvax-20220630_g3.jpg
<TEXT>
begin 644 nvax-20220630_g3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'G!#P# 2(  A$! Q$!_\0
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MJ_!KPYKOA1OAE?O/#'K5]'-_:EK9S.S20^6!L=OF8;B?XCR.,=5^T%^QP_Q
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M&35/BBGC&'=<OM^PCJ&^3B3_ &>GO7UG]JUS_H'V?_@4W_Q%'VK7/^@?9_\
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M ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P!
M^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U
M:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H
M^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB
M@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\
MP*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[
M/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5K
MG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[
M5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B*
M-BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P#
MIO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L_
M_ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?
M] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6
MN?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V
M**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F
M_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\
M"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T
M#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y
M_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8H
MK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_
M .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*
M;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/
ML_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_
M $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL
M?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\
MXBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO
M_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S
M_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\
M0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^(H V**Q_
MM6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_ ,"F_P#B
M*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P! ^S_\"F_^
M(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U:Y_T#[/_
M ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H^U:Y_P!
M^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB@#8HK'^U
M:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\ P*;_ .(H
M^U:Y_P! ^S_\"F_^(H V**Q_M6N?] ^S_P# IO\ XBC[5KG_ $#[/_P*;_XB
M@#8HK'^U:Y_T#[/_ ,"F_P#B*/M6N?\ 0/L__ IO_B* -BBL?[5KG_0/L_\
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M^$(\=>(-,N@6^SQKI*LHG,TN/W6>F5&XG_<-?&GBZY\)V_[9WQI/BCXN:_\
M"I/^):()= OC;->G[*FY9"$;(3C'3[QKNOCMKWB+XI?'3X>>$_ 6AQ_$W3_
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MY[WXB6^L:=:W/A\6TJW%LT$S>:T@*@*H !SGH?8X]CF\8:?^S+^UU\0?$/Q
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M (?S(C4E;WF>P:'^VU%J7PP^(OC:]\ :MI-EX+N8[*ZMY[J)GGN#*L<D2D<
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M$LT;_H*6O_?T5I?9XO\ GDG_ 'R*/L\7_/)/^^12 S?^$LT;_H*6O_?T4?\
M"6:-_P!!2U_[^BM+[/%_SR3_ +Y%'V>+_GDG_?(H S?^$LT;_H*6O_?T4?\
M"6:-_P!!2U_[^BM+[/%_SR3_ +Y%'V>+_GDG_?(H S?^$LT;_H*6O_?T4?\
M"6:-_P!!2U_[^BM+[/%_SR3_ +Y%'V>+_GDG_?(H S?^$LT;_H*6O_?T4?\
M"6:-_P!!2U_[^BM+[/%_SR3_ +Y%'V>+_GDG_?(H S?^$LT;_H*6O_?T4?\
M"6:-_P!!2U_[^BM+[/%_SR3_ +Y%'V>+_GDG_?(H S?^$LT;_H*6O_?T4?\
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M_GDG_?(H^SQ?\\D_[Y%(#-_X2S1O^@I:_P#?T4?\)9HW_04M?^_HK2^SQ?\
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M_?J'_P"(KQ+S*3S*/J]#^1?<@]C2_D7W(]M_X;'^,7_0\7O_ 'ZA_P#B*/\
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MU??]^H?_ (BO#/.I/.I>PH_R+[D+V5+^1?<CW/\ X;.^,O\ T/5[_P!^H?\
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MBD_X;2^,_P#T/=]_WZA_^(KPC[12>>:/8T?Y%]R%[&E_*ON1[O\ \-I?&?\
MZ'N^_P"_4/\ \12?\-I?&?\ Z'R^_P"_4/\ \17A'GTGG&CV-'^1?<@]C2_E
M7W(]X_X;3^,__0]WW_?F'_XBD_X;4^-'_0^7W_?F'_XBO!_.]Z;YWO2]C1_D
M7W(/94OY5]R/>?\ AM3XT?\ 0^7W_?F'_P"(H_X;4^,__0^7W_?J'_XBO!O.
M]Z;YWO2]C1_D7W(7LJ7\J^Y'O7_#:WQH_P"A\OO^_,/_ ,12?\-K?&C_ *'V
M^_[\P_\ Q%>"^=2>=1[&C_(ON0>RI?RK[CWK_AM;XT?]#Y??]^8?_B*3_AM?
MXT?]#[??]^H?_B*\%\ZD\[WH]C1_D7W(/94OY5]R/>O^&V/C3_T/E]_WYA_^
M(K]#OV%_B/XC^*7P/;6_%&JRZQJ?]J3P?:)E53L58R%^4 =S^=?CMYWO7ZP?
M\$T6W?LVD_\ 4:NO_0(J\K,J=.-"\8I.ZZ'G8Z$(T;QBEKV/J^BBBOE3YT**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\
M+_<U/_L(3_\ H5;58OA?[FI_]A"?_P!"H \_L_VC-$D^/&H_"Z]MFT_4H8D>
MTO))08[MVC60Q@8^5L,<9)SM/MG)\4?M.1^&X?B#.OA>YOH/!=_:VEZT5RH:
M2.;.95&W^$X^7OG.1BO)_$GPG3XM?'[XU6EK*+'Q'IUOI-]HVI+P]M=)$2N&
M[*V #^!Z@5:_9=M[WXMR?'*R\8Z=_9^HZM-;V>I6FTKY<GDRQN0.QW*6'IVK
MW/J]",/:-7LHW7K;7YIOT9ZWL:,8\]ME&Z];?FKGN_Q2^--C\.?#_A[4+6Q?
M7[KQ!>P66FV=O*(S.THR&W$'"@8YQW%4]0^/VE^&?B-K?A3Q39MX=2RTXZK:
M:G<3!H+ZW49D*<##+@C;R3M/MGYW_9HLO$'Q$^*FA:1XGMW6V^$]G/898DK+
M=M*T<;'Z1H,?]<P>]=!^T]HM[^TEXW_X0;PA9V=U<>$()-1U#4[E<J+AEQ'9
M*P[N1\W;(_V#4_5:4:GL9]FV^W;\+?>+ZO3C4]E+M=OMV_KS/H7X/_$:?XK>
M#(?$KZ)-H5E=R.;*.XE#R30 X64@ ;=W.!SP <D$57^*WQDT?X46^G175M>:
MQK6J2F'3M%TN+S;JZ<==J]E&1ECZ]ZY;P/\ $C7OBM\%[*_^'T6BZ-XGM'6Q
MO--UA)/L]C)'\LD16/YAV*^Q&:X;XB_\)-\-?BE\/?B=XPL$UBSL]+FTK6IM
M ADEBL979RLZ(WS[2'P3['U //&A&59J2MO[M]=-E\S&-%.JU)6WTOKZ'>>&
M?C]K%QXJTS0O%?PV\0>$Y=4?R[.\^6\MV;&=LCQCY#]0> 2<"O6FU2S2^6R:
M[@6\8;A;F1?,(]=N<XKR72OVI/!OC;Q%8^'_  ;+?^)=1O0P-S96$OV>R^5B
MKSLX7:N0!QGK7RD__"%1_#77;3Q1;:RW[0DE[,8\K<F^:\\S]RT++\GE8 Z=
MMV.U:QPGM7K%PVTWWOK9NZ2ZFD<-[1ZQ<=M-]^NNR[GVG-\6([/XT0?#Z]TN
M6VDO-,;4;'4O-!CN=K8>+;C(888]3P/>L/5/VBM(T?QIXUTBXL9?[)\(:<E[
MJ>K)*&"R/@I;K'CER#QSU!%>>?M :?XB\,?#/X;_ !+O(!<^,/!<EK<:HL?'
MG1R(J729'8MCGL":N_ &XT[X=? O6_B5XWD6"7Q-<RZ]J#S(7.QWQ!&J]\@@
MJ/62I5"G[-5+7^S9?S7_ ,OQ9*HT_9JI:_2WG?\ R_,Z?X=_M)CQAXNTG0=:
M\(:IX1FUVT:^T6:_='6^B5=QX7[C;<-M.?Y9H6G[5MI+XJTVUN_"&LZ=X6U/
M5/[&L?$ET D<]T?NCRCA@C$'#>W3@X\P^#'QB\/_ !H^-'_"9:QJMO%KD$,^
MG^$_""(X>)-K%Y))=FP2.%/? 'T%87CKXGZ;\2OB!X+\2:%_;*_$VPU2.TD\
M!:E US:VH5BKRX*!4;!#>8#D<' VY'5]4C[1Q=.VGGH]?ZOM>YT?5H\[BX6T
M\]'K_5]MSVSXI_M'>*/A7_:U[??"Z^F\/6,_DKJ_]JPHDP+A494VEOF)&!UY
MJ_XP_:(U#PS_ &59VGP_UG6=<FTH:QJ-C;NJIIT.,D/,1M9P<C:/3W%9/CJV
MF^,W[0FB^$6AD_X17P:L>MZJ74A+F\8?Z-%S]X*,L>Q^8=JROVEOB1X:NI]8
M^'WCF[USP3I<EJE[8:_IK.Z:B=I#0%50Y )(*$_-M'(XSA"G3DX1]GK:[M?;
MII?YZ&,*<).$>37=VOMTZ_/0ZC0_C1=_$SXF>!+#PM<_8_#E]H-SXBU#[1 I
MFF02K;QP<YV8D+%B.3L !Q67;_$KQ]K/P]^,/^G:3:>)O"%[/%8W=C9L()5B
M@CN KI([_>#%"01UR,5D?L]^"/%>HV/PQ\<SVMEHT]GI%UH>H:=)";<S:>90
M]M+&B@A9 R*Q!P&#D\&O1?%7P@N+?P7\1K+PA=K!KGC*62::?5)"88'EB2%V
M4(F<"-<A><MW Z1/V-.IR*VGZ2Z_(X:L5"<HKHSCO"/QB\;?$Z^\7ZCX0M;&
MX@TW2]+CT[1[QA%')>7<*7$LTTN-VV*.50$7[VT]R#6.WQX\:1>"[CQ#/<:7
M=VOAWQA;Z-?WVE6Y6SUFSD>.&1H0[,R-')-C*L03$W)S@=-IO[-TVDW7BK1;
M/7+G3?!_B'2=/M)Y--F\C48;BUB6W.QBC+Y<L*(&/WL@XZYI-2_9MNK3P/H7
M@G2/$M]?>&H=7LKN\76Y8VDAM+9Q(L%NL4*+\SHF2W;)R35<V&OTMITZ6U^>
M_P#5C(]VHHHKR "BBB@ HHHH *^0_C%^TIX\\(_$3XA>&="2UF-U';Z/X,=X
M P_MD0Q2W*2''S*(KA9.<_ZIA7UY63_PBFB-=17;:/8-=1W+7J3FU0NMPR;&
ME#8R'*?*6ZD<9Q6U*<8.\HW(DF]F?/<?[9D2S>'+2U\.C65O+?15N[\ZI!:D
M7&H>6(A% WSRH-Y+,HP"".<$CF_ ?[5GC/7/"UM#K>@M8W]MJFG6]WK-K=V\
MBRK=ZH]M%&(=G&41PQ'("Y')%?2\GPO\&S7FG7;^$M#>ZTU%CLIVTV$O:J'#
MJL3;<H P# +C!&:LQ> O#,,+11^'=*CB9XI&1;*, M&YDC8C;U1V9E/8DD<F
MM_:4;64".6?<\K\(_M26GB:X\;QGPMJ;_P#"(W*V-_%HY_M.XFN#*R8@AA4O
M)%M"L9,#!+KC*-7E?Q5_:B\>:!XS^(>@>'XK=I;T0:7X*::W!(U..&*6]248
MYVQSB3#=/+85]7Z3X0T+0)HYM,T73].EC@-LDEI:I$RQ%RYC!4#Y=Q+8Z9)/
M4TO_  B.A"[CNO[%T_[3'<27B3?98]ZSNNV24-C(=E^4MU(X-3&I2C)ODT_K
M^O0;C)K<_.W_ (* >)D\9>!?"OB&*19$U70]+O0R=#YDCM_6OD#37_T5/I7V
MG_P4RTVTT:QL;*PM8;*RM[&SCAM[>,1QQJ+B7"JH& /85\2:;)BU3Z5]]2:]
ME0M_(OS8<&[8_P#Z_P O_2*9I;J-U5_,I/,-;W/T:Y8W>]&[WJOYE)YE*XKE
MGS/>D\RJWF>])YGO3N%RSO%'F56\SWI/,I7"Y9\RD\RJ_F4GF47%<L^92>9[
MU6\RCS*5PN6/,H\RJWF4GF>]',%RUYE)YAJKYOO1YE+F%<L[S2>958R4GFBC
MF#F+7F4GF>]5?.]Z3SJ.8.8M>9[T>953SJ3SJ7,+F+?F4GF54\ZCSJ.8.8M^
M92>953SO>D\ZES!<N>92>95/SO>D\[WHN*Y<\SWI/-JGYWO2>=[TN8+ESS/>
MD\RJ?G4GG4<PKESS1ZT><*I>?3?.I<P7+WG4GG51^T4>?2Y@N7?.I/.JEYYI
MOG47%<O^=3?.JCYU)YWO1S!<O><:3SO>J/G>])YWO2YA7+_G>]-\X>M4?.]Z
M3SJ.8+E[SO>CSA5#SJ3SA2Y@YB]YU)YXJAY]'G^]',*Y>\^D^T51\ZD,U+F#
MF+WG&D\^J'G4>=1S!<O>=2>=5'SO>D\ZES"N7O.]Z3SO>J/G>])YU%PN7O.]
MZ3SJH^=2>=2YA7+WG4GG51\VD\ZBX7+OG4>=[U1\[WI/.]Z7,%R]YWO2>=5'
MSJ3S:+BN7?.H\ZJ7FTGG?YS2Y@N7/.I/.]ZI^=2>=1<+ESSJ3SO>J?G>]'G>
M]%Q7+?G4GG54\[W-)YW^<TKA<N>=2>;5/SJ3SJ+A<N>=2>=[U3\VD\[WHN%R
MYYWO7ZU?\$R&W?LTD_\ 4:NO_0(J_(GS?>OUQ_X)@MN_9E8_]1NZ_P#0(J\G
M,G^X^:/-QS_<_,^N****^5/G0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "L7PO]S4_^PA/_P"A5M5B^%_N:G_V$)__ $*@
M#66WBCE>58T61\;G"@%L=,GO1'!'&[ND:H\AR[*H!;Z^M244 1QP10L[)&J-
M(<NRJ 6/J?6DBMXH&=HXDC:0[G*J 6/J?6I:* (X;>*W9S%$D9D.YRB@;CZG
MU-/(# @C(I:* (;>S@LPP@@CA#<GRT"Y_*E-K"UP)S#&9P,"3:-P'IFI:* &
M21I-&R2(LB,,%6&0?PILEM#+#Y+Q(\. /+905P.G%2T4 58=*LK>0216=O'(
MO1DB4$?CBI5M85G:<0QB9A@R!1N(^M2T4[L8F!G..>F:CGM8;H*)H8Y@IROF
M*&P?49J6BD(**** "BBB@ HHHH **** "BBB@ KQKQ+\5/%/PQ\278\0:.FL
M>&)IW:VOM-XFMXRWRK(O0D#CMTZFO9:S-8T&VUF$I/&&R,5UX>M"C)^TIJ:?
M1_HUL_ZL>;CL+5Q45["LZ<HZIJS7I)/1K[GV:,_P;\0_#WCZS%SH>IPWF!EX
M<[98_P#>0\C^5='7@7C#]GN);X:IH,\VCZE&=R7%FQ0@_0?TQ7.6_P =?B/\
M/X=1L/$/APZTMJ?*M=6?$2S<##';G*]>H4Y'4]:]&.!HXQ_[%/5_9DTG\GL_
MP?D>++-<7EL6\THWBO\ EY33E'YQUG'_ ,FC_>/INXN8K.!YIY4@AC&YY)&"
MJH]23TKP[XC?M9>&_"RSV^A*->O8P=TX;9:Q^Y?^+\./>OESXN_$SXI>.P/*
MT34/$3R?-%86LB6UG%Z;@S G\B?>O ];_9M_:.^*#'[5X1O5L"<K9V]S!%"/
MJ/,^;\<UZ]++\NP3OBZJJ3_EB[17K+_(\ZGBL\X@TR^"PM%_\O*GQM?W:?3U
ME\BQ^U7^T=!\88Y[2XOTU356>)0UE&!;6\:.6V!N_)/KUZUXKI\A6W4'TKU^
MS_8)^-=NH/\ P@-QG_K]M?\ X[6BO[#_ ,<%&!X#N /^OZU_^.UWRQM*I)2;
MC%)6235DC]+X?RO#9#AI4(5G4<I.4I2DFW)I)O\ !:'B_FTGF>]>T_\ #$/Q
MP_Z$.X_\#K3_ ..TG_##_P <?^A#N/\ P.M?_CM'UJC_ #K[T?3_ %BE_.OO
M1XMYHI/-]Z]J_P"&(/CC_P!"%<?^!UI_\=I/^&'_ (X_]"%<?^!UI_\ ':7U
MJC_.OO0?6*7\Z^]'BOG4&:O:?^&'_CE_T(5Q_P"!UI_\=I/^&'_CE_T(5Q_X
M'VG_ ,=H^M4?YU]Z%]8I?SK[T>*^=2>=7M?_  P_\<_^A"N/_ ZT_P#CM)_P
MP]\<_P#H0KC_ ,#[3_X[2^M4?YU]Z#ZQ2_G7WGBOG4AF]Z]J_P"&'?CG_P!"
M%<?^!UI_\=I/^&'/CG_T(5Q_X'VG_P =H^M4?YU]Z#V]+^=?>>*^=2>=[U[5
M_P ,-_'3_H0KC_P/M/\ X[2?\,-_'3_H0;C_ ,#[3_X[2^M4?YU]Z%]8I?S+
M[T>*^=[TGG>]>U_\,-_'3_H0KC_P/M/_ ([2']AKXZ?]"#<?^!]I_P#'J/K5
M'^=?>@^L4OYU]Z/%/.]Z3SA7M?\ PPS\=/\ H0;C_P #[3_X]1_PPS\=/^A!
MN/\ P/M/_CU'UJC_ #K[T'UBE_,OO/$_.I//KVS_ (89^.G_ $(-Q_X'VG_Q
MZD_X88^.O_0@W'_@?:?_ !ZE]:H_SK[T+ZQ2_F7WGB?GBD^T5[9_PPS\=?\
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M@GX^?]$^N?\ P86?_P >I?6*7\Z^]![:G_,OO/"?.]Z3SOK7N_\ PP1\>_\
MHGUS_P"#"S_^/4?\,$?'O_HGUS_X,+/_ ./4?6*7\Z^]"]M3_F7WG@_G?YS2
M>;7O'_#!/Q[_ .B>W/\ X,+/_P"/4G_#!/Q[_P"B>7/_ (,+/_X]1]8I?SK[
MT'MJ?\R^\\'\VCSJ]X_X8(^/?_1/+G_P86?_ ,>H_P"&"/CY_P!$\N/_  86
M?_QZCZQ2_G7WH/;4_P"9?>>#>=[TGG>]>]?\,$?'W_HGEQ_X,+/_ ./4G_#!
M/Q]_Z)Y<?^#"S_\ CU+ZQ2_G7WH/;4_YE]YX+YIH\RO>?^&!_C[_ -$]N?\
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M.0@%SD.DK';SDJ"=N <5].5SU:,J-N;JKF-2DZ5K]=0HHHK Q"BBB@ HHHH
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MN<8$J1-]TCL,X'85Z7116<JDIVYG>Q$IRE;F>P4445! 4444 %%%% !1110
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M/^ O[+E_/^!^X]%?AJWQ?\;_ /0XZ]_X,IO_ (JHV^,'C?\ Z''7O_!E-_\
M%4O['E_/^ O[+E_/^!^YU%?A:WQA\;_]#EKW_@SF_P#BJ_3W_@GSKVI>)/V>
M8+W5=0NM3NSJ=RIGO)FE? V8&YB3BN/%9>\-3YW*YS8C!/#PYW*Y]*T445Y)
MYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !17YY?\ !0CQKXA\-_&?2K?2==U+3+=M#A=H;2[DB0MY
MTXW84@9P!S["OF#_ (6KXT_Z&[7/_!C-_P#%5]!0RB5>E&HIVOY'M4<LE6IJ
MIS6OY'[645^*7_"U?&G_ $-VN?\ @QF_^*H_X6MXT_Z&[7/_  8S?_%5O_8<
MO^?GX&W]DR_G_ _:VBOQ1/Q6\:?]#=KG_@QF_P#BJ:?BOXT_Z&[7/_!C-_\
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M;XO^-_\ H<=>_P#!E-_\54;?&+QO_P!#EKW_ (,YO_BJ7]CR_G_ 7]F2_G_
M_=*BOD?_ ()J^)M6\4_!WQ'<ZQJEYJMQ'KSQI+>SO,RK]G@.T%B<#))Q[FOK
MBO$K4_8U'3O>QY-6G[*;AV"BBBL3(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUJ=%*3B]?E;=H]MHHHKRCS@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA>[_ /9*\K,OX'S/.QW\'YGUG1117RQ\\%%%% !1110 4444 %%%% !1110
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M +[%']HXC^;\$'UVOW_ _-(_\$EO%7_0_:1_X!R_XTW_ (=)^*O^A^TC_P
MY?\ &OTO^W6W_/Q%_P!]BC[=;?\ /Q%_WV*7]H8CO^"%]=K]_P #\S_^'27B
MK_H?M'_\ Y?\:0_\$D?%1_YG_1__  #E_P :_3'[=;?\_$7_ 'V*/MUM_P _
M$7_?8H_M#$=_P0?7:W?\#\S/^'1_BK_H?]'_ / .7_&C_AT?XJ_Z'_1__ .7
M_&OTS^W6W_/Q%_WV*/MUM_S\1?\ ?8H_M#$=_P $'UVMW_ _,O\ X=&^*O\
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M14'VZV_Y^(O^^Q1]NMO^?B+_ +[% $]%0?;K;_GXB_[[%'VZV_Y^(O\ OL4
M3T5!]NMO^?B+_OL4?;K;_GXB_P"^Q0!\J_M6_L7ZQ^T1\1++Q'8>)+'2(+?3
M8[$P7$#NQ99)7+9!QC]X/RKQ8_\ !+/Q-_T/&E?^ LM?HG]NMO\ GXB_[[%'
MVZV_Y^(O^^Q7HT\PQ%.*A%Z+R1W0QE:G%1B]$?G2W_!+'Q.?^9YTG_P$E_QI
MC?\ !*WQ.?\ F>M)_P# 27_&OT9^W6W_ #\1?]]BC[=;?\_$7_?8J_[2Q/\
M-^"*^OXCO^"/SD/_  2J\3_]#WI/_@)+_C3#_P $I_%!_P"9[TG_ ,!)?\:_
M1[[=;?\ /Q%_WV*/MUM_S\1?]]BE_:6)_F_!"^O5^_X(_-YO^"4?B@_\SYI/
M_@)+_C3#_P $H?%!_P"9\TG_ ,!)?\:_23[=;?\ /Q%_WV*/MUM_S\1?]]BC
M^T<3_-^"#Z]7[_@?FS_PZ>\4?]#[I'_@)+_C33_P2<\4G_F?=(_\!)?\:_2C
M[=;?\_$7_?8H^W6W_/Q%_P!]BE_:.(_F_!!]>K]_P/S5/_!)GQ3_ -#[H_\
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M%:-%=9F9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P!
MVT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] V
MT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".
MZ5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PC
MNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!
MG?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+
M_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_
M (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P!
MVT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] V
MT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".
MZ5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PC
MNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!
MG?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+
M_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_
M (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P!
MVT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] V
MT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".
MZ5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PC
MNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!
MG?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+
M_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_
M (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P!
MVT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] V
MT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".
MZ5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PC
MNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!
MG?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+
M_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P! VT_[\+_A1_PCNE?] VT_[\+_
M (5HT4 9W_".Z5_T#;3_ +\+_A1_PCNE?] VT_[\+_A6C10!G?\ ".Z5_P!
MVT_[\+_A1_PCNE?] VT_[\+_ (5HT4 9W_".Z5_T#;3_ +\+_A5JVL;>SC\N
MW@C@3.=L:!1GUXJ>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K%\+_ '-3_P"PA/\ ^A5M5B^%_N:G_P!A"?\
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M>DO_ $#(_P#OX:/^%Z2_] R/_OX:\D\SWH\SWH_UTS?_ )__ (1_R#^P,O\
M^??XO_,];_X7I+_T#(_^_AH_X7I+_P! R/\ [^&O)/,]Z/,]Z/\ 73-_^?\
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M_OX:/^%Z2_\ 0,C_ ._AKR3S/>CS/>C_ %TS?_G_ /A'_(/[ R__ )]_B_\
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MI+_T#(_^_AH_X7I+_P! R/\ [^&O)/,]Z/,]Z/\ 73-_^?\ ^$?\@_L#+_\
MGW^+_P SUO\ X7I+_P! R/\ [^&C_A>DO_0,C_[^&O)/,]Z/,]Z/]=,W_P"?
M_P"$?\@_L#+_ /GW^+_S/6_^%Z2_] R/_OX:/^%Z2_\ 0,C_ ._AKR3S/>CS
M/>C_ %TS?_G_ /A'_(/[ R__ )]_B_\ ,];_ .%Z2_\ 0,C_ ._AH_X7I+_T
M#(_^_AKR3S/>CS/>C_73-_\ G_\ A'_(/[ R_P#Y]_B_\SUO_A>DO_0,C_[^
M&C_A>DO_ $#(_P#OX:\D\SWH\SWH_P!=,W_Y_P#X1_R#^P,O_P"??XO_ #/6
M_P#A>DO_ $#(_P#OX:[7P'XS?QE;7,K6RV_DE1A6SG.?\*^;_,]Z]H^!+;M,
MU/\ WT_]FKZOA?B;,<RS6GAL15YHOFTLND6^B/#SK*<)A<%*K2A:2MU?<]1H
MHHK]S/S@**** "BBB@ HHHH **** "LJ/Q1I4VI&P2^B-V&*^7G^(=0#T)]J
MU:\ZACC\+:Q;OBVU31KN\_<S?*TEM,>.O?I^G8]?F,ZS+$9;*A*FE[.4K3;N
M^5:*]DT[7=G+51=KJS;7H87#PKJ:E>Z6B[_UVZGHM%>57?BO7-2U#56MQJ,2
MVLK10I9VPDC4J3]\DCKWK9GU[5]4FT+3FD.C3WD;23R-'AB5)&U0>F<9_P"!
M#\?'I<98.LYJG1F[-*.B2FW-05FW9>\U\36FO<ZI975A;FDO/RTO^78[RBN"
ML;K7(=;UK38]2&HSP6A:WW*JX<[< CID9[_C5+3_ !=?:7H&K/<27DVK6JQA
MK>\1<(S$*77 !(Y!P?;US6G^MV%IV>(I3@OWEV[63I7YE=-IR]UM)-NVNU[3
M_9E27P23^'O]K9[;:]3TJBN#DOM5\.W&B3R:L-6BU"5(I(-@_B_C0CL,_P J
MS&U'7)[7Q%?IK$D<6GWKQQP^6#G##@GTP1@?6E6XMI4$U/#3YXW;C[ETE#GO
M?GY;<O1.]]+;#CELIZJ:MWUWO:VU]ST^JNI:E;:/9O=7DH@MTQN<@G&3@=/<
MUQ\FL:EX@URQTV&^&EHUBEV[(N7E9AT'L,_H:Y[7+Z_F\-^+K6]U#^T?LLD"
M)*  /O'/ Z'@9]Q6&/XNA1HU9X>C)V511D^7E<H4Y3::YN>VEME?OLRZ.6.<
MXQJ26O+=:WLY)=K'J5YJ-OI]FUW<2B.W4 E\$]2 .GN14\<BRQJZ'<K $'U!
MKF/''_(B77_7.+_T-:R99]5U#Q=:Z5::G)8VW]F1SOM0-WQQGH>G/IFO2QF?
M3P6-^K.DYIQIV4;7<IRJ+>32M[B_$YZ.#5:E[12M9RO?:R2[*_4['5M;L=#A
M66^N%MXV;:I8$Y/7H*?8ZK::DTZVTPE,+;), C:?3FO+;BXOO$-KX;-S?.)U
MOVM_,51R05P^/7G]*MG4+C2+;Q%-;SM$ZZJ$:0>F"#^M?,QXUJ2K2K>R_P!G
M23_O_P )U']JUUHMK;ZOIWO*HJ"CS>_^'Q6['J5%<9JOB"[L?&-XD4C36EOI
M#77V=>5,@8X_3%<Q8^*O$<EO;7\4>I74TDF6B^QC[.ZY^ZI!SG'MFO<QG&&#
MP=9T72G)IR3Y4G91:3>^NKT2N]'IWY:>5U:L5-2232W\SUJBO/[RXUC4_$FO
MP6VJR65M9PI*L80'DQ@@>PSG-,O-8U"\\'Z?J*ZC-#?S P1P0J,SR[B >WIS
M3GQ92C[:V'G[G.UK#WE3GR2M[W1M63LWLKLG^S9>[[ZUMWTYE=7T['H=%<%)
M-K"ZQIOA]]5>"0VWVF>[906D<D_(OL,?D*L^#;[4&\4:[I][J7]I):K$$<
M#(/8=_7W!KJH<1PK8FGAG0G'FER7?+934'-Q:4N;1*U[6OL[:D3P#C3E/G3L
MK]=KVOM8[2BBBOL#RPHHHH *Q?"_W-3_ .PA/_Z%6U6+X7^YJ?\ V$)__0J
M//-:@O)O$WB?R@[Z:LUNU]'"<2M'L['TZY_#MFM?5;+2M?\ $GA6&!5DTMHI
M=J1DJ.%)P>^<CGOUKT0(JL2% +=3CK2+#&F-L:KCI@#BOSA<'QYJGM*JG&I-
M3:E&^BK.KRK72+3::U3E[W='O/-':-HV<596?]WEN_/JO+0\K^SW-KHWB2SL
M/.%I#J6)(XV)80Y;<%_(?D<U=TS^RKGQ1I8\,K*8/+9;[A_*\O' ;=WZ]/:O
M2%15R0H!/)P.M"1I'G:JKGKM&*5+@]4JE*2JJT6OL>]%1J2FE3ES>XFGRR5G
M=+H*69\RE[NKOUT=TEJK:[76VIY!=6&K"XNM*MSB'0'DO82<DOE@R#ZXW'\Q
M5G4+62\\#WVK72>7<ZI>+(<?PQ@D*N>XQG\#7J^T;B<#)ZG'6D\M"H4JNT=%
MQQ7-_J-#EJQ^L-J<912:NHW7+!I7^Q3;ATON:?VP_=?(M&GZ]7]\M?(X33]*
MM_#_ ,2+>UL5:&"33LNF\L&.X\G/?BI_B$,7VC/?"1M"61C="//#8&PMCG'7
M]:[38N[=M&[INQS2LH92",@]0:]^7#D%@*^ I248U)\Z7+[JUB^5QNDXMQ]Y
M:739QK'/VT*TE=I6WU>^M^CUT/*M(_L:;QIJ TJ22VL'TN7=, PVL6 9ESS@
M?SS6C\-&2UU2ZLHH[2[C6$,-2M%*[AD85_\ :Y/OQWKT)8T4@A%! P"!V]*5
M(UCSM4+GD[1BO-P/";P>)HXE5(IPE.5HPY5:?V4N9J*TWLWV:-ZV9*K3E3Y7
MJDM7?;J]%?\ (X+Q+HL'B#X@)97 ^632VVMC)1MYPP]Q6%I[:W)JVN6\J,-5
MM]-^SJR9W2!77Y@?4J>*]:V+NW;1NQC=CFC:N[=M&[IG'-/%\(0Q.)EB8UG"
M4IRD[+>+CRI;[Q;;C+I=JVH4\T=."IN%TDDK]T[_ '/JCQK4Y/#K:+IRV"3#
M5%=1-D/P?X]^>.OI6]<:'9ZQXP\6/=Q>9]GMT:/YB,,8NO'?C]:]&\E.?D7Y
MN3QUI?+7<3M&6ZG'6N.CP534E[>5-QO%N,:?+%\L*D%=<TKM\ZDWW6W;26;.
MWN)WL]7*[U<7V7:WS/*EE\S1?"SZH9GT-?,6?R\E0X9@F_'.!@8QZ&IX#"UG
MXK?21(-!-D^W?N"&;')7=S_>S^'M7IWEILV;5V?W<<4>6H38%&SIMQQ6E/@^
M4'%NNG:*7-R>_=4O96YN;^&_BY+?%U)>:)W]SKM?3XN;:V_2_;H>:)H:V/PU
MDO!>WDYN+*/]S--NB3+*?E7'%6(]6M_#7B*&\ORT-K/I4:QR["P+ *2..^%_
ME7H?EKMV[1MZ;<<4-&CJ R*P'0$5U?ZJ>Q=*IA*JA*G&"5XMKF@YW;7,G:7.
M]$U;OT,_[2Y^958W4F^MM';RZ6/.]-M7L_A'<K=)Y3.DCJLGN_R?TQ^%=KX=
MW_\ "/Z;YGW_ +-'G/KM%0^(O#Z^)+>&VFG:.U60/+$JC][@@@$]A_GM6LJA
M5"J, #  KTLIRFIE^)2_Y=TZ5.E%Z7ERW;=ELM4E?K?IJ\,3B8UZ;?VI2<GY
M7Z"T445]>>8%%%% "&O#_#?[8'@;Q1;^"Y+-=0W^*]=NO#]G"\2[HI[<L':7
M#<(=J8(SGS4XYKVJ^A>YLIX8Y6MY)(V19E&2A(P& ]NM?/VD_L6^&]#U2/4+
M'6]0M[J"TTF"V*JFR":RDB=[A5_OSB"-9/9>*Z*7LK/VA$N;[)V_CG]ICX<^
M!=%\07T_BK2M1N-#XOM-L+^&2ZB(=$8%-XP09%SG&,U=A^/O@:\U&.*S\1Z7
M>Z?]FFN9M4M]0MVM[<1/$K*YW[@<S)R 0,\D9&?,(?V*=,A>^A;Q9?3:6UC=
M:=86<EA;9LX9[J&Y8&0('F8/#@-(2<,>_)WV_97L;>RB@L/$-QI[KINKZ8\L
M=G"Q>/4+M+B9B",;E">6I(/!R>@K7EP]M),B]3L>QZ/XBTOQ#:SW6EZC;:A;
M0326\LUM*LB)(APZ$@XRI!!'8BO(/"W[7W@;Q=#X#>Q74!)XQU:\T>RADB0-
M#-;;O,:7#?*IVK@C.?,3UK1\*_LS^&_"WA/1=%666]F\.1W5OX=U*X7_ $C3
M(9E*A<J0LI4'[SC)P,\\GF-'_8Q\.:!K*:I8:UJ$%U!'I"VN%39;R6+QL\JK
M_>N!#&)/7'%3%4->9OR_K[G^ WSZ6/G7QY?2VOQLU]$8JK:I=9'_ &V:O2+6
M8M A/7%>6?$N3'QPUP],ZI=G_P C-7HUK-_HZ?2OY<\6JDJ?%%>W:G_Z;@??
M>&>O#=#UJ?\ IV9I>;1YM4O.H\ZOQ?ZQ,_5.5%WS:/-JEYU'G4?6)ARHN^;1
MYM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEY
MU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZC
MZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)AR
MHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:
M/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O
M.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4
M?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.
M5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;
M1YM4O.H\ZCZQ,.5%WS:/-JEYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:/-JE
MYU'G4?6)ARHN^;1YM4O.H\ZCZQ,.5%WS:]M^ +;M+U3_ *Z1_P#LU>"^=7NG
M[/+;M*U;_KI'_)J_1?#ZM*7$5!/M/_TAGS'$B7]FS]5^:/7****_KL_&0HHH
MH **** "BBB@ HHHH *P;?P/HEIJ0OXK%5N VX?,=JGCD+G Z#Z5O45Q8C!8
M7%RA+$4HS<'>-TG9]U?9FL*U2DFH2:OO9[F#J7@?1=6O&NKFR#3-R[([+O\
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M70S&$*<<9.,O=5W:TG+K>S<4O2^NSL>17=!MNDFM>]U;[KDE%%%>V<@4444
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MZ!ES_P!^S1_PC>L_] RY_P"_9H^IUOY']S#V\/YD1?:/>C[1[U+_ ,(WK/\
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M +]FCZG6_D?W,/;P_F1%]H]Z/M'O4O\ PC>L_P#0,N?^_9H_X1O6?^@9<_\
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M+G_OV:/J=;^1_<P]O#^9$7VCWH^T>]2_\(WK/_0,N?\ OV:/^$;UG_H&7/\
MW[-'U.M_(_N8>WA_,B+[1[U[_P#LWMOT?5C_ --(_P#V>O!?^$;UG_H&7/\
MW[->]_LY6-W8:3JR75O);L9(R!(I&?OU^A< X>I3X@H2E%I6GT_N,^<XAJQE
MEU1)]OS1[#1117]9GY %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+X7^YJ?_80G_\
M0JVJQ?"_W-3_ .PA/_Z%0!FZQXXGTW5KRT@TI[V*RC66XF28+Y:D9SM(Y_/M
M5Z;Q9 LFB+!&9EU7F-BVTJN <XQZ']*\XUZ;2[C7_%'VR^N(+N1ECMH8 2)2
MH(PW&,9 ZD=36O?:Q!IFM>$I]8(LA;6;.ZB,X5F4J!M XZ?A7XI2XHQGML1[
M3$)052*3]RT(^WY&GHN7]WK[]V_B35CZV674N6'+!WY7WU?)?3O[W:W8]&U"
M^ATRQGNIVVPPH78_3M]:QO#_ (L/B30KB_M;7]_"S)]F,G5@ 0-V.,Y]*P?%
M&I3>,;BRTS1U2[MMBWEP9"51ER"J'OSG..O3TIWAN\N=!\2:Y%J<<-JLUN+\
M+$?D 7(8@_YZ5])6X@JU<VA2HR:PNL'-1O%S<7+F4[./NM*-NKD[K1'GQP48
MX9RFOWF]KZVO:UM]=_1'4^&]>C\2:3%?1QF'<65HV.2I!QCH/\FM2N5^&L,D
M?A>.61-AN)7F"^Q.!_*NJKZS(\36QF68;$8CXYPBWI:[:WMTOO8\W%TX4L1.
M$-DV%%%%>V<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28SUI
M:* ,O5/#UGJD96:)23WQ7COC/]G'2M4N_M=M;*DV<_)E0WU X->[4E;4JU6@
M^:E)Q?D['+B,+A\7%0Q%-32UM))Z]]3Q3P;\"8=-96N6.%_A7@?E7KFE:+!I
M,(CA!4 8ZFK]+6.YTI)*R"BBB@84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E2>)]
M.AD9&EE#*<'_ $>0_P#LM-_X2O3/^>LO_@-+_P#$UKT4 9'_  E>F?\ /67_
M ,!I?_B:/^$KTS_GK+_X#2__ !-:]% &1_PE>F?\]9?_  &E_P#B:/\ A*],
M_P">LO\ X#2__$UKT4 9'_"5Z9_SUE_\!I?_ (FC_A*],_YZR_\ @-+_ /$U
MKT4 9'_"5Z9_SUE_\!I?_B:/^$KTS_GK+_X#2_\ Q-:]% &1_P )7IG_ #UE
M_P# :7_XFC_A*],_YZR_^ TO_P 36O10!D?\)7IG_/67_P !I?\ XFC_ (2O
M3/\ GK+_ . TO_Q-:]% &1_PE>F?\]9?_ :7_P")H_X2O3/^>LO_ (#2_P#Q
M-:]% &1_PE>F?\]9?_ :7_XFC_A*],_YZR_^ TO_ ,36O10!D?\ "5Z9_P ]
M9?\ P&E_^)H_X2O3/^>LO_@-+_\ $UKT4 9'_"5Z9_SUE_\  :7_ .)H_P"$
MKTS_ )ZR_P#@-+_\36O10!D?\)7IG_/67_P&E_\ B:/^$KTS_GK+_P" TO\
M\36O10!D?\)7IG_/67_P&E_^)K(\.^)-/A34=\L@W7LSC$$AX)XZ+775B^&/
MN:G_ -A"?_T*@!?^$HTO.?,DS_U[2?\ Q-*?%.EMUDD/_;M)_P#$UL44K(#'
M'BK2UZ22#_MVD_\ B:S->OM+\06Z6TE]=06^X&5(K:0&0 YVD[<@?2NKHKGQ
M&&I8NC*A6C>$M&NZ[:='U[[,TA4E3DIQ>J,6'Q+I-O"D43R)&BA55;:4  =!
M]VG_ /"5Z9_SUE_\!I?_ (FM>BNA)15EL1OJS(_X2O3/^>LO_@-+_P#$T?\
M"5Z9_P ]9?\ P&E_^)K7HIB,C_A*],_YZR_^ TO_ ,31_P )7IG_ #UE_P#
M:7_XFM>B@#(_X2O3/^>LO_@-+_\ $T?\)7IG_/67_P !I?\ XFM>B@#(_P"$
MKTS_ )ZR_P#@-+_\31_PE>F?\]9?_ :7_P")K7HH R/^$KTS_GK+_P" TO\
M\31_PE>F?\]9?_ :7_XFM>B@#(_X2O3/^>LO_@-+_P#$T?\ "5Z9_P ]9?\
MP&E_^)K7HH R/^$KTS_GK+_X#2__ !-'_"5Z9_SUE_\  :7_ .)K7HH R/\
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M\)7IG_/67_P&E_\ B:U/.C_OK^8H\Z/^^OYBBS"Z,O\ X2O3/^>LO_@-+_\
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M],_YZR_^ TO_ ,31_P )7IG_ #UE_P# :7_XFM>B@#(_X2O3/^>LO_@-+_\
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MA"?_ -"K:K%\+_<U/_L(3_\ H5 &U1110 4444 %%%% !1110 4444 %%%%
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M9L?;F_O4?;F_O5C_ &KWH^U>]'L0^O>9L?;F_O5]6?LX2&7X=EB<_P"EO_Z
ME?'?VKWKZ\_9AD\SX:$_]/LG_H"5\?Q33Y<OO_>7ZGZ+P'B?:YQR_P!R7Z'K
M=%%%?D!_1@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH *Q?"_P!S4_\ L(3_ /H5;58OA?[FI_\
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M*H V**Q_[.UC_H,1_P#@&/\ XJC^SM8_Z#$?_@&/_BJ -BBL?^SM8_Z#$?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K%\+_ '-3_P"PA/\ ^A5M5B^%_N:G_P!A"?\ ]"H VJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (B!A/\ GS+[T?<=%?#G_"QO$?\ T']4_P# V7_XJC_A8WB/_H/ZI_X&R_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 44C-M4G&<#/%>%^ _"</QQL;
MWQ/XJO+VZCFNI(;32XKAHH;2-#@?*I'S<]3U&*[\/AHU83JU9<L(VOI=W=[)
M*Z[/JCQL=CZF'JT\-AZ?/4G=I-\J2C:[;L^Z2LFW?M=GNM%>77MP/@;X=\B"
M[U/Q/<:C>+;Z5IUW,&97;H@<CA?<^PQWJ?2?B=K%IXB_L#Q1H<6EZG<6LEU8
MR6\_FPW 1263U#  G_#C.KR^I*+J47S1UL]$VENU%ZZ=?GV.=9U0ISC0Q2<*
MCM=6<E%OX4YI<J<OLIM-W6EVD>E45X+9?M#>)/\ A&](\17?@]#HM]<FS5[>
M[!E>3+!2JD<#*XY[@\]*UK[XBZUJVG^-O#7B#1XM'U.VT.:^C-K<>:IC,9&"
M?4$]1Z'@5T2R;%4W::5EO:47L[/1/I=7.&GQ3EU:*=)R;:NKPFD[Q<HZN-ES
M).SZV=CV2BO ?"'Q.\4>#_AMH&J7_A;S/"\$$44MVET&N"A^7SMG]TMC ]"#
MD9JW>>.H_"WC#XE:S96C7,UG:6,X\VY8QRK(% PN/EX/_P"K)JWDU=3E!-.V
MB::=WS1C9ZZ/WD91XIPCHTZLDXW2<DU)-)PG.ZO'WE[C2:LG9Z]'[G17E'AW
MXO:U/XKT+2_$'AZ+2+?7+5[BRECN?-9=J;SOX]/IC(Z\UG2?&OQ/J'A_4_$^
MB>$H[SPQ:^9Y4\UV$FE5,@R[?[H(Y'7 /-8?V3BN;ELNFO-&VK:23O:]T]/)
MG9_K)EW)SWEN[KDGS+E2;;CRW22E%W:MJCVBBOG+Q!XL\0^)?B!\+]5MM.M0
MM]I\UQ%#]I9%??"#*&.>-H/R^M:7P]^)3Z)\.?#%CH>CRZAK>L7-REI93719
M55)&#R/(0/E YQQWKIGDM:-*,TTV^FFGQWN[].1N^V_8X*7%6%J8B=*47&,;
MV=I7EI3M:/+JVZB22=]FD^;3WNBO*?\ A<6HZ;9^*+/6M%CT[Q'HNGMJ2VZS
M>9#<PC^)6'(Y(!'_ -?%7PW\:->O-2\)C6?#46G:9XC7;:SQ77F.&V@@E<<*
M<C ]#UKE_LK%<KE967FM=.;377370]#_ %CR[FC!R=Y?W9:>]R>]I[OO:>];
M<]@HK@OC=X?N->^'FH/9%TU'3\7]JT?W@\?)Q[E=P^I%</K/BD?%[7_AYHMH
M[);31+K>II&^"JH"HC;';>&4_4&C#9?]8IJJI67O<VGPV5[[ZWUMMJBL=G7U
M&O+#.G>34.37XW*7*UMIRNS>^CN>ZT5Y;/\ %3Q#K.NZS;^%/#,>L:=HTQMK
MF>:Z$32RK]Y(QZCWZ\=*HZ7\=KJ^\":/JBZ']HU_6+N6SLM+AEVJS(Q!+.>@
M'&?KVY(/[*Q32:2UMI=75TVKJ^FB;U%_K'ERE*+D]$W?EE9\K47RNUI>\TDH
MWN]CV"BN%TGQAXDTZWU2Z\7:#!I.GV-LUT;ZTNEE5@ 25V?>S@'GI63X?^(?
MC;Q&EAJEMX,B_L&]=3'NOU6X$+=)2#QC'./3O67]GUGS.\;+KS1MWLG?5^7W
MG0\ZPJY(M3YI=/9SYDD[7:Y;I7ZO1]+GJ%%>"7WC_P#X0'4OBKK5G8F>YL+R
MR1EN+EVCD\PD9"X^7 /\AT KJ=!^+6KKXL@TGQ-H,>B17E@^H6\D=R)2J*"S
M!\#KM4_3WKHJ93B(Q=2&JM?=)_#&3LKW=E);'%1XDP4JBHU6XR;:VDXKWYP5
MY<J2YG![]>^YZE17@:?M/EU.J#3M/&AB?R_L_P#:4?\ :!3.-_E9]?X?U[UT
MFL?&BYC^(=OX=TVUT[R'B@F6XU*Z:#[4L@!'DG:5. >YY(('-5+)<=!VE"VC
M>ZZ6OUZ71-/BK**T>:G5OJE\,M>:_+;35.SL_+O8]8K%\+_<U/\ ["$__H5;
M58OA?[FI_P#80G_]"KPSZTVJ*\*L_%=QX/\ %/QCUB.,7;V,EDZ0R,0IRI!'
MMUK4T[XR>))-8T:PU+PS;Z>VO64L^E_Z7OW2)'O D(' /'N-PZ\U[<LIK_%3
MLU9/=+[*F]&];)_@?)4^)<'=0K)QDVU9*4EI4E33;2LN:4=+]7;S/8:*^/\
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M"=K_ -_5H U:*RO^$JT?_H)VO_?U:/\ A*M'_P"@G:_]_5H U:*RO^$JT?\
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M)1A#I%+3_@GBTN"<L3]KB'.K5>\Y2;D_T7R/A_1_^"?.N:>JDZUI#-_O2_\
MQNNA3]B;Q)&H5=;TH#_>E_\ B*^QJ*N'$V8TU:,E_P" HSJ\!Y)6?-4A)_\
M;\CX[_X8I\2_]!S2O^^I?_B*/^&*?$O_ $'-*_[ZE_\ B*^Q**T_UJS/^=?^
M HQ_XA[D'_/N7_@3/CO_ (8I\2_]!S2O^^I?_B*/^&*?$O\ T'-*_P"^I?\
MXBOL2BC_ %JS/^=?^ H/^(>Y!_S[E_X$SX[_ .&*?$O_ $'-*_[ZE_\ B*/^
M&*?$O_0<TK_OJ7_XBOL2BC_6K,_YU_X"@_XA[D'_ #[E_P"!,^._^&*?$O\
MT'-*_P"^I?\ XBC_ (8I\2_]!S2O^^I?_B*^Q**/]:LS_G7_ ("@_P"(>Y!_
MS[E_X$SX[_X8I\2_]!S2O^^I?_B*/^&*?$O_ $'-*_[ZE_\ B*^Q**/]:LS_
M )U_X"@_XA[D'_/N7_@3/CO_ (8I\2_]!S2O^^I?_B*/^&*?$O\ T'-*_P"^
MI?\ XBOL2BC_ %JS/^=?^ H/^(>Y!_S[E_X$SX[_ .&*?$O_ $'-*_[ZE_\
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MK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*E"A>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBOXVGW7;$06T0R/,?')Y!X'I] =#X6:5<6/A..]ODV:IJ\KZG=@]5>4Y"?\
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MGWP#[UW0P.%QDD\-64.ZGI;T:TE^#\CR*N;9AEL&L=A74[2HKF4GYQ;YHO\
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MS_\ #)WP\_Y\+K_P*:C_ (9.^'G_ #X77_@4U'^M^7]I?<O\P_XAIG7\U/\
M\"?_ ,B?#'F^]?<G[);;OA%"?^GR7^2T_P#X9.^'G_/A=?\ @4U>B>"? ^E?
M#_0QI.C12160D:0+(Y<[CC/)^@KYW/N(,)F6#]A14KW3U2Z7\V?;<'\&YCD6
M9?6\4X<O*UHVW=M=TNQOT445^=G[8%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &5(NM^8WERZ>$S\NZ-\X]_FINW7O\ GKIW_?N3_P"*HHH
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M/_BJ** #;KW_ #UT[_OW)_\ %4;=>_YZZ=_W[D_^*HHH -NO?\]=._[]R?\
MQ5&W7O\ GKIW_?N3_P"*HHH -NO?\]=._P"_<G_Q5&W7O^>NG?\ ?N3_ .*H
MHH -NO?\]=._[]R?_%4;=>_YZZ=_W[D_^*HHH -NO?\ /73O^_<G_P 51MU[
M_GKIW_?J3_XJBB@ VZ]_SUT[_OW)_P#%4;=>_P">NG?]^Y/_ (JBB@!#'KQZ
MR::?^V4G_P 569J7AO4-47$Z:4W_ &Q?_P"*HHH --\,ZAI0Q FE+_VQ?_XJ
MM,1ZZO2331_VRD_^*HHH 7;KW_/73O\ OW)_\51MU[_GKIW_ '[D_P#BJ**
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M/_BJ** #;KW_ #UT[_OW)_\ %4;=>_YZZ=_W[D_^*HHH -NO?\]=._[]R?\
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M_P#%4;=>_P">NG?]^Y/_ (JBB@ VZ]_SUT[_ +]R?_%4;=>_YZZ=_P!^Y/\
MXJBB@ VZ]_SUT[_OW)_\51MU[_GKIW_?N3_XJBB@ VZ]_P ]=._[]R?_ !5&
MW7O^>NG?]^Y/_BJ** #;KW_/73O^_<G_ ,51MU[_ )ZZ=_W[D_\ BJ** #;K
MW_/73O\ OW)_\51MU[_GKIW_ '[D_P#BJ** #;KW_/73O^_<G_Q5&W7O^>NG
M?]^Y/_BJ** #;KW_ #UT[_OW)_\ %4;=>_YZZ=_W[D_^*HHH -NO?\]=._[]
;R?\ Q57;,7@A/VMH&ESQY*L%Q^)^M%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208395040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVAVAX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2816046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">21 Firstfield Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">268-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,215,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001000694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208608448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 185,925<span></span>
</td>
<td class="nump">$ 298,017<span></span>
</td>
<td class="nump">$ 889,896<span></span>
</td>
<td class="nump">$ 745,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">271,077<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">289,648<span></span>
</td>
<td class="nump">570,685<span></span>
</td>
<td class="nump">673,131<span></span>
</td>
<td class="nump">1,163,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">108,160<span></span>
</td>
<td class="nump">73,161<span></span>
</td>
<td class="nump">204,152<span></span>
</td>
<td class="nump">136,351<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">668,885<span></span>
</td>
<td class="nump">643,846<span></span>
</td>
<td class="nump">1,163,564<span></span>
</td>
<td class="nump">1,299,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(482,960)<span></span>
</td>
<td class="num">(345,829)<span></span>
</td>
<td class="num">(273,668)<span></span>
</td>
<td class="num">(554,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,234)<span></span>
</td>
<td class="num">(5,968)<span></span>
</td>
<td class="num">(11,110)<span></span>
</td>
<td class="num">(10,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(19,873)<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
<td class="num">(18,219)<span></span>
</td>
<td class="num">(3,203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax expense</a></td>
<td class="num">(509,067)<span></span>
</td>
<td class="num">(348,769)<span></span>
</td>
<td class="num">(302,997)<span></span>
</td>
<td class="num">(568,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">4,080<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (510,485)<span></span>
</td>
<td class="num">$ (352,317)<span></span>
</td>
<td class="num">$ (307,077)<span></span>
</td>
<td class="num">$ (575,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="num">$ (6.53)<span></span>
</td>
<td class="num">$ (4.75)<span></span>
</td>
<td class="num">$ (3.97)<span></span>
</td>
<td class="num">$ (7.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>&#8203;Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">78,143<span></span>
</td>
<td class="nump">74,118<span></span>
</td>
<td class="nump">77,305<span></span>
</td>
<td class="nump">73,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 55,455<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 641,083<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">107,774<span></span>
</td>
<td class="nump">272,489<span></span>
</td>
<td class="nump">207,075<span></span>
</td>
<td class="nump">719,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember', window );">Royalties and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 22,696<span></span>
</td>
<td class="nump">$ 25,528<span></span>
</td>
<td class="nump">$ 41,738<span></span>
</td>
<td class="nump">$ 25,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208120672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (510,485)<span></span>
</td>
<td class="num">$ (352,317)<span></span>
</td>
<td class="num">$ (307,077)<span></span>
</td>
<td class="num">$ (575,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized losses on marketable securities available-for-sale, net of reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(9,558)<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
<td class="num">(9,517)<span></span>
</td>
<td class="num">(2,845)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(9,558)<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
<td class="num">(9,517)<span></span>
</td>
<td class="num">(2,854)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (520,043)<span></span>
</td>
<td class="num">$ (347,790)<span></span>
</td>
<td class="num">$ (316,594)<span></span>
</td>
<td class="num">$ (577,890)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208921680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,375,587,000<span></span>
</td>
<td class="nump">$ 1,515,116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">10,274,000<span></span>
</td>
<td class="nump">11,490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">194,533,000<span></span>
</td>
<td class="nump">454,993,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">256,301,000<span></span>
</td>
<td class="nump">8,872,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">299,307,000<span></span>
</td>
<td class="nump">164,648,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,136,002,000<span></span>
</td>
<td class="nump">2,155,119,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">254,526,000<span></span>
</td>
<td class="nump">228,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">85,770,000<span></span>
</td>
<td class="nump">40,123,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,033,000<span></span>
</td>
<td class="nump">4,770,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">123,467,000<span></span>
</td>
<td class="nump">131,479,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">19,195,000<span></span>
</td>
<td class="nump">16,566,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,622,993,000<span></span>
</td>
<td class="nump">2,576,753,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">386,488,000<span></span>
</td>
<td class="nump">127,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">585,646,000<span></span>
</td>
<td class="nump">673,731,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">701,518,000<span></span>
</td>
<td class="nump">1,422,944,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">124,260,000<span></span>
</td>
<td class="nump">130,533,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">324,169,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">34,158,000<span></span>
</td>
<td class="nump">36,061,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,156,239,000<span></span>
</td>
<td class="nump">2,390,319,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">814,629,000<span></span>
</td>
<td class="nump">172,528,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">323,458,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">69,075,000<span></span>
</td>
<td class="nump">42,121,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,039,943,000<span></span>
</td>
<td class="nump">2,928,426,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 600,000,000 shares authorized at June 30, 2022 and December 31, 2021; and 78,776,234 shares issued and 78,166,935 shares outstanding at June 30,&#160;2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December&#160;31,&#160;2021</a></td>
<td class="nump">788,000<span></span>
</td>
<td class="nump">764,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,604,614,000<span></span>
</td>
<td class="nump">3,351,967,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,925,027,000)<span></span>
</td>
<td class="num">(3,617,950,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, cost basis, 609,299 shares at June 30,&#160;2022 and 591,980 shares at December 31, 2021</a></td>
<td class="num">(86,455,000)<span></span>
</td>
<td class="num">(85,101,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(10,870,000)<span></span>
</td>
<td class="num">(1,353,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(416,950,000)<span></span>
</td>
<td class="num">(351,673,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 2,622,993,000<span></span>
</td>
<td class="nump">$ 2,576,753,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208987024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">78,776,234<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">78,166,935<span></span>
</td>
<td class="nump">75,841,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">609,299<span></span>
</td>
<td class="nump">591,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205333488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,350,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 627,209<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 2,535,476<span></span>
</td>
<td class="num">$ (1,874,199)<span></span>
</td>
<td class="num">$ (41,806)<span></span>
</td>
<td class="nump">$ 7,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">106,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">25,201<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">30,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,578,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">564,859<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">564,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(2,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(575,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(575,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,672,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2021</a></td>
<td class="nump">745,562<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">3,237,085<span></span>
</td>
<td class="num">(2,449,235)<span></span>
</td>
<td class="num">(47,205)<span></span>
</td>
<td class="nump">4,170<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance beginning (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,470,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Mar. 31, 2021</a></td>
<td class="nump">1,039,127<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">3,180,114<span></span>
</td>
<td class="num">(2,096,918)<span></span>
</td>
<td class="num">(44,457)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">53,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">4,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(352,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,672,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2021</a></td>
<td class="nump">745,562<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">3,237,085<span></span>
</td>
<td class="num">(2,449,235)<span></span>
</td>
<td class="num">(47,205)<span></span>
</td>
<td class="nump">4,170<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2021</a></td>
<td class="num">(351,673)<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">3,351,967<span></span>
</td>
<td class="num">(3,617,950)<span></span>
</td>
<td class="num">(85,101)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,722,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Mar. 31, 2022</a></td>
<td class="nump">65,324<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">3,566,292<span></span>
</td>
<td class="num">(3,414,542)<span></span>
</td>
<td class="num">(85,901)<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2021</a></td>
<td class="num">(351,673)<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">3,351,967<span></span>
</td>
<td class="num">(3,617,950)<span></span>
</td>
<td class="num">(85,101)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">70,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,197,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">179,385<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">179,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(9,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(307,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(307,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,776,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2022</a></td>
<td class="num">(416,950)<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">3,604,614<span></span>
</td>
<td class="num">(3,925,027)<span></span>
</td>
<td class="num">(86,455)<span></span>
</td>
<td class="num">(10,870)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance beginning (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,722,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Mar. 31, 2022</a></td>
<td class="nump">65,324<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">3,566,292<span></span>
</td>
<td class="num">(3,414,542)<span></span>
</td>
<td class="num">(85,901)<span></span>
</td>
<td class="num">(1,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">38,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="num">(279)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(9,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(510,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(510,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance ending (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,776,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2022</a></td>
<td class="num">$ (416,950)<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 3,604,614<span></span>
</td>
<td class="num">$ (3,925,027)<span></span>
</td>
<td class="num">$ (86,455)<span></span>
</td>
<td class="num">$ (10,870)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued issued under incentive programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in incentive program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208118272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="nump">$ 2,311<span></span>
</td>
<td class="nump">$ 5,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208513216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (307,077)<span></span>
</td>
<td class="num">$ (575,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13,485<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">70,981<span></span>
</td>
<td class="nump">106,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">155,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_OperatingAndFinanceLeaseWriteOff', window );">Right-of-use assets expensed, net of credits received</a></td>
<td class="num">(3,291)<span></span>
</td>
<td class="nump">12,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(642)<span></span>
</td>
<td class="nump">3,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(403,725)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Accounts receivable, prepaid expenses, and other assets</a></td>
<td class="nump">112,845<span></span>
</td>
<td class="nump">193,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">179,158<span></span>
</td>
<td class="nump">115,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(76,809)<span></span>
</td>
<td class="nump">946,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(259,413)<span></span>
</td>
<td class="nump">807,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(41,402)<span></span>
</td>
<td class="num">(28,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(41,402)<span></span>
</td>
<td class="nump">128,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">179,385<span></span>
</td>
<td class="nump">564,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from the exercise of stock-based awards</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">26,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease payments</a></td>
<td class="num">(15,911)<span></span>
</td>
<td class="num">(53,618)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">164,524<span></span>
</td>
<td class="nump">538,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(4,453)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(140,744)<span></span>
</td>
<td class="nump">1,474,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">1,528,259<span></span>
</td>
<td class="nump">648,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">1,387,515<span></span>
</td>
<td class="nump">2,122,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset', window );">Right-of-use assets from new lease agreements</a></td>
<td class="nump">69,366<span></span>
</td>
<td class="nump">28,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">17,890<span></span>
</td>
<td class="nump">11,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash interest payments</a></td>
<td class="nump">8,604<span></span>
</td>
<td class="nump">10,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 17,778<span></span>
</td>
<td class="nump">$ 3,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OperatingAndFinanceLeaseWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and Finance Lease, Write-off</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_OperatingAndFinanceLeaseWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208392000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text">Organization and Business<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#8217;s coronavirus vaccine, NVX-CoV2373, and its lead influenza vaccine candidate, a quadrivalent influenza vaccine, previously known as NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. NVX-CoV2373 and the Company&#8217;s influenza vaccine include the use of the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> adjuvant. The Company is developing various variant vaccines, including for Omicron subvariants, and bivalent formulations with prototype vaccine (NVX-CoV2373). The Company has announced preclinical boosting data for NVX-CoV2373, NVX-CoV2515, and bivalent formulations which demonstrated strong antibody levels. The Company is also participating in an ongoing Phase 3 strain change trial to assess safety and antibody responses following primary vaccination with mRNA vaccines.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for NVX-CoV2373, including by the World Health Organization (&#8220;WHO&#8221;), as well as the European Medicines Agency's (&#8220;EMA&#8221;) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), both of which are considered regulatory authorities that apply stringent standards and meet the WHO standards for quality, safety, and efficacy in their regulatory review process. In July 2022, the Company received emergency use authorization for NVX-CoV2373 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company commenced commercial shipments of NVX-CoV2373 doses under the brand name Nuvaxovid&#8482; in 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210686864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Accumulated other comprehensive income included a foreign currency translation loss of $10.9 million and $1.4 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition - Product Sales</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Product sales are associated with the Company&#8217;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs which were expensed prior to regulatory authorization as described under the caption &#8220;Inventory&#8221; below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Inventory</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out (&#8220;FIFO&#8221;) methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, the services and products of third-party suppliers, and the application of manufacturing overhead. The Company utilizes third-party contract manufacturing organizations (&#8220;CMOs&#8221;), contract development and manufacturing organizations (&#8220;CDMOs&#8221;), and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020 and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; (&#8220;CECL&#8221;) model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management is currently evaluating the effect of the guidance and does not expect it to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715214323808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract', window );"><strong>U.S. Government Agreements, Grants and Licenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's accounts receivable included $165.6&#160;million and $419.7&#160;million related to amounts that were billed to customers and $29.0&#160;million and $35.3&#160;million related to amounts which had not yet been billed to customers as of June&#160;30, 2022 and December&#160;31, 2021, respectively. During the six months ended June&#160;30, 2022, changes in the Company's accounts receivables and deferred revenue balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivables:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,069,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount is comprised of $701.5&#160;million and $1.4&#160;billion of current Deferred revenue and $814.6&#160;million and $172.5&#160;million of non-current Deferred revenue as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $5&#160;billion as of June&#160;30, 2022. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 under certain of our APAs. Failure to meet regulatory milestones, product volume, or delivery timing obligations under the Company&#8217;s APA agreements may require the Company to refund portions of upfront payments or result in reduced future payments, which could result in a material and adverse effect on our unsatisfied performance obligations. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than 12 months.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government partnership (&#8220;OWS&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense (&#8220;DoD&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Government Partnership</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. government partnership consists of an agreement (&#8220;the &#8220;OWS Agreement&#8221;) with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (&#8220;OWS&#8221;). In July 2021, the U.S. government instructed the Company to prioritize alignment with the FDA on the Company's analytic methods before conducting additional U.S. manufacturing and further indicated that the U.S. government would not fund additional U.S. manufacturing until such alignment was made. In June 2022, the U.S. government agreed to the manufacture and delivery of approximately 3&#160;million doses of NVX-CoV2373 under the OWS Agreement as the Company had completed alignment with the FDA&#8217;s analytic methods. The Company updated its estimate-at-completion to reflect the impact of this authorization to the recognition of the fixed fee under the contract. In July 2022, the Company formally modified the OWS Agreement to provide for an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373, and the Company modified its existing agreement with the U.S. Department of Defense (&#8220;DoD&#8221;) to provide for an initial delivery of approximately 0.2&#160;million doses of NVX-CoV2373 (see Note 15).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, the Company recognized $1.7&#160;million and $9.2&#160;million, respectively, in revenue related to sales-based royalties. During the three months ended June 30, 2022, the Company recognized a $20.0&#160;million milestone payment upon the first sale of NVX-CoV2373 in Japan. During the three months ended June&#160;30, 2021, the Company recognized $23.5&#160;million in revenue related to sales-based royalties. During the three months ended March 31, 2021, the Company did not recognize any revenue related to sales-based royalties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Advance Purchase Agreements (APAs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Company&#8217;s contracted supply commitment with Gavi, which includes the supply obligation of its licensed partner, Serum Institute of India Private Limited (&#8220;SIIPL&#8221;), 1.1&#160;billion doses of NVX-CoV2373 are to be made available to countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. The Novavax portion is a supply agreement that contemplates that the Company will manufacture and distribute 350&#160;million doses. Under that agreement with Gavi, the Company received an upfront payment of $350&#160;million from Gavi in 2021 and an additional payment of $350&#160;million in the first quarter of 2022 related to the Company&#8217;s achieving WHO Emergency Use Listing. Although Novavax is prepared to deliver the quantities of NVX-CoV2373 doses to Gavi under the terms of the supply agreement, the Company was notified by Gavi of its intent to seek to revise the number and timing of doses of NVX-CoV2373 supplied by Novavax under such agreement. Furthermore, Gavi may seek partial or full recovery of the prior nonrefundable payments it has made to Novavax. The Company&#8217;s position is that Gavi has no contractual right to recover prior nonrefundable payments. To date, Novavax has not received an order from Gavi and the timing and quantities of future orders to deliver NVX-CoV2373 to the COVAX facility are unclear.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Company&#8217;s SARS-CoV-2 Vaccine Supply Agreement, originally entered into in October 2020 (the &#8220;Original UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373. In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with the Authority, under which the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) (see Note 15).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. The Company is in the process of finalizing a revised delivery schedule for the remaining 42&#160;million doses of the 70&#160;million previously committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. In July and August 2022, the Company was notified by the EC that it was cancelling 5&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to 65&#160;million doses (see Note 15).</span></div>Collaboration, License, and Supply Agreements<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Serum Institute</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company&#8217;s Matrix-MTM adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. The Company has expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s) so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, and supply such variant vaccine to the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases the Company&#8217;s Matrix-M&#8482; adjuvant to manufacture NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373 in the low to middle double-digit range. During the three months ended June 30, 2022, the Company recognized a milestone payment of $20.0&#160;million upon the first sale in Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">SK bioscience, Co., Ltd.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of Korea, Thailand, and Vietnam. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants (see Note 15). The companies also signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Supply Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and in doing so, recognizes that significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715303477440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Supply Agreements</a></td>
<td class="text">Revenue <div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's accounts receivable included $165.6&#160;million and $419.7&#160;million related to amounts that were billed to customers and $29.0&#160;million and $35.3&#160;million related to amounts which had not yet been billed to customers as of June&#160;30, 2022 and December&#160;31, 2021, respectively. During the six months ended June&#160;30, 2022, changes in the Company's accounts receivables and deferred revenue balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivables:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,069,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount is comprised of $701.5&#160;million and $1.4&#160;billion of current Deferred revenue and $814.6&#160;million and $172.5&#160;million of non-current Deferred revenue as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $5&#160;billion as of June&#160;30, 2022. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 under certain of our APAs. Failure to meet regulatory milestones, product volume, or delivery timing obligations under the Company&#8217;s APA agreements may require the Company to refund portions of upfront payments or result in reduced future payments, which could result in a material and adverse effect on our unsatisfied performance obligations. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than 12 months.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government partnership (&#8220;OWS&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense (&#8220;DoD&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Government Partnership</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. government partnership consists of an agreement (&#8220;the &#8220;OWS Agreement&#8221;) with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (&#8220;OWS&#8221;). In July 2021, the U.S. government instructed the Company to prioritize alignment with the FDA on the Company's analytic methods before conducting additional U.S. manufacturing and further indicated that the U.S. government would not fund additional U.S. manufacturing until such alignment was made. In June 2022, the U.S. government agreed to the manufacture and delivery of approximately 3&#160;million doses of NVX-CoV2373 under the OWS Agreement as the Company had completed alignment with the FDA&#8217;s analytic methods. The Company updated its estimate-at-completion to reflect the impact of this authorization to the recognition of the fixed fee under the contract. In July 2022, the Company formally modified the OWS Agreement to provide for an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373, and the Company modified its existing agreement with the U.S. Department of Defense (&#8220;DoD&#8221;) to provide for an initial delivery of approximately 0.2&#160;million doses of NVX-CoV2373 (see Note 15).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, the Company recognized $1.7&#160;million and $9.2&#160;million, respectively, in revenue related to sales-based royalties. During the three months ended June 30, 2022, the Company recognized a $20.0&#160;million milestone payment upon the first sale of NVX-CoV2373 in Japan. During the three months ended June&#160;30, 2021, the Company recognized $23.5&#160;million in revenue related to sales-based royalties. During the three months ended March 31, 2021, the Company did not recognize any revenue related to sales-based royalties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Advance Purchase Agreements (APAs)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Company&#8217;s contracted supply commitment with Gavi, which includes the supply obligation of its licensed partner, Serum Institute of India Private Limited (&#8220;SIIPL&#8221;), 1.1&#160;billion doses of NVX-CoV2373 are to be made available to countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. The Novavax portion is a supply agreement that contemplates that the Company will manufacture and distribute 350&#160;million doses. Under that agreement with Gavi, the Company received an upfront payment of $350&#160;million from Gavi in 2021 and an additional payment of $350&#160;million in the first quarter of 2022 related to the Company&#8217;s achieving WHO Emergency Use Listing. Although Novavax is prepared to deliver the quantities of NVX-CoV2373 doses to Gavi under the terms of the supply agreement, the Company was notified by Gavi of its intent to seek to revise the number and timing of doses of NVX-CoV2373 supplied by Novavax under such agreement. Furthermore, Gavi may seek partial or full recovery of the prior nonrefundable payments it has made to Novavax. The Company&#8217;s position is that Gavi has no contractual right to recover prior nonrefundable payments. To date, Novavax has not received an order from Gavi and the timing and quantities of future orders to deliver NVX-CoV2373 to the COVAX facility are unclear.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Company&#8217;s SARS-CoV-2 Vaccine Supply Agreement, originally entered into in October 2020 (the &#8220;Original UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373. In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with the Authority, under which the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) (see Note 15).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. The Company is in the process of finalizing a revised delivery schedule for the remaining 42&#160;million doses of the 70&#160;million previously committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. In July and August 2022, the Company was notified by the EC that it was cancelling 5&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to 65&#160;million doses (see Note 15).</span></div>Collaboration, License, and Supply Agreements<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Serum Institute</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company&#8217;s Matrix-MTM adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#8217;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. The Company has expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s) so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, and supply such variant vaccine to the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases the Company&#8217;s Matrix-M&#8482; adjuvant to manufacture NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373 in the low to middle double-digit range. During the three months ended June 30, 2022, the Company recognized a milestone payment of $20.0&#160;million upon the first sale in Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">SK bioscience, Co., Ltd.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#8220;SK bioscience&#8221;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of Korea, Thailand, and Vietnam. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants (see Note 15). The companies also signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Supply Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and in doing so, recognizes that significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715212327312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, and Restricted Cash<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as Other non-current assets as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210744448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as cash and cash equivalents as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature. Pricing of the Company's Notes&#160;(see Note&#160;10) has been estimated using other observable inputs, including the price of the Company's common stock, implied volatility, interest rates, and credit spreads among others.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six&#160;months ended June&#160;30, 2022 and 2021, the Company did not have any transfers between levels</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210754032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the three months ended June&#160;30, 2022, inventory write-downs were $155.7&#160;million. There were no inventory write-downs for the three months ended March 31, 2022. For the three months ended June&#160;30, 2022, losses on firm purchase commitments were $99.6&#160;million. There were no losses on firm purchase commitments during the three months ended March 31, 2022. There were no inventory write-downs or losses on firm purchase commitments during 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210783024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identifiable Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets consisted of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated&#160;<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible<br/>Assets,&#160;Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated&#160;<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible<br/>Assets,&#160;Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary adjuvant technology</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,469)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total identifiable intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,564&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,531)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,033&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,961&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,191)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,770&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the six months ended June&#160;30, 2022 and 2021 was $0.2 million. Estimated amortization expense for existing intangible assets for the remainder of 2022 and for each of the five succeeding&#160;years ending December&#160;31 will be as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,012)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210720016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2022, the Company concluded that changes in facts and circumstances on its CMO and CDMO agreements that had previously been determined to represent embedded lease arrangements resulted in the modification of existing leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration in the contracts and reassessed the lease classification as of the effective date of the modification. As a result, during the six months ended June&#160;30, 2022, the Company recognized a Right-Of-Use (&#8220;ROU&#8221;) asset and a corresponding long-term operating lease liability of $19.8&#160;million&#160;on the remeasurement of one of its long-term supply agreements using an average incremental borrowing rate of 3.0%. The Company expensed the ROU asset since it relates to research and development activities for the development of NVX-CoV2373 for which the Company does not have an alternative future use.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June&#160;30, 2022, the Company recognized a short-term lease expense of $5.8&#160;million and $83.9&#160;million, respectively, related to its embedded leases and expensed $9.4&#160;million and $19.8&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2021, the Company recognized a short-term lease expense of $86.6&#160;million and $214.2&#160;million, respectively, related to its embedded leases and expensed $11.4&#160;million and $12.4&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2022, the Company recognized $2.3&#160;million and $3.4&#160;million of interest expense, respectively, on its finance lease liabilities. During the three and six months ended June&#160;30, 2021, the Company recognized $1.8&#160;million and $4.0&#160;million of interest expense, respectively, on its finance lease liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland. The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the three months ended March 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the third floor of the premises and recognized a ROU asset of $47.8&#160;million and related lease obligation for the combined third floor and land lease as the lease commencement date for accounting purposes had occurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2022, the Company concluded that changes in facts and circumstances on its CMO and CDMO agreements that had previously been determined to represent embedded lease arrangements resulted in the modification of existing leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration in the contracts and reassessed the lease classification as of the effective date of the modification. As a result, during the six months ended June&#160;30, 2022, the Company recognized a Right-Of-Use (&#8220;ROU&#8221;) asset and a corresponding long-term operating lease liability of $19.8&#160;million&#160;on the remeasurement of one of its long-term supply agreements using an average incremental borrowing rate of 3.0%. The Company expensed the ROU asset since it relates to research and development activities for the development of NVX-CoV2373 for which the Company does not have an alternative future use.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June&#160;30, 2022, the Company recognized a short-term lease expense of $5.8&#160;million and $83.9&#160;million, respectively, related to its embedded leases and expensed $9.4&#160;million and $19.8&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2021, the Company recognized a short-term lease expense of $86.6&#160;million and $214.2&#160;million, respectively, related to its embedded leases and expensed $11.4&#160;million and $12.4&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2022, the Company recognized $2.3&#160;million and $3.4&#160;million of interest expense, respectively, on its finance lease liabilities. During the three and six months ended June&#160;30, 2021, the Company recognized $1.8&#160;million and $4.0&#160;million of interest expense, respectively, on its finance lease liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland. The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the three months ended March 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the third floor of the premises and recognized a ROU asset of $47.8&#160;million and related lease obligation for the combined third floor and land lease as the lease commencement date for accounting purposes had occurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210900576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $10.0 million of debt issuance costs during the first quarter of 2016 relating to the issuance of $325 million&#160;aggregate principal amount of convertible senior unsecured notes that will mature on&#160;February&#160;1, 2023&#160;(the &#8220;Notes&#8221;), which were recorded as a reduction to the Notes&#160;on the consolidated balance sheet. The $10.0 million of debt issuance costs is being amortized and recognized as additional interest expense over the seven-year contractual term of the Notes&#160;on a straight-line basis, which approximates the effective interest rate method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable consisted of the following at (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount of Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(831)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,542)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">323,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes are classified as current liabilities and as non-current liabilities in the consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense incurred in connection with the Notes&#160;consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon interest at 3.75%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on Notes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210776912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text">Stockholders' Equity (Deficit)<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022, the Company sold 2.2&#160;million of shares of its common stock resulting in net proceeds of approximately $179&#160;million, under its most recent At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;), which allows it to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock. As of June&#160;30, 2022, the remaining balance under the June 2021 Sales Agreement was approximately $318&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2021, the Company sold 2.6&#160;million shares of its common stock resulting in net proceeds of approximately $565&#160;million, under its various At Market Issuance Sales agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210737088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company's annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to 14.8&#160;million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of 2.4&#160;million shares approved for issuance under the 2015 Plan at the Company's 2022 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;4, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock units (&#8220;RSUs&#8221;). In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of ten years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company's common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQyNQ_9172cf8d-33fb-4432-8f7b-4855b5e3976b">one</span> to four years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded all stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, there was approximately $212&#160;million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the Company&#8217;s Employee Stock Purchase Plan, as amended (&#8220;ESPP&#8221;). This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately one year. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option&#160;and SAR holders exercised their stock options and SARs on June&#160;30, 2022. This amount is subject to change based on changes to the closing price of the Company's common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the six&#160;months ended June&#160;30, 2022 and 2021 was approximately $8 million and $115 million, respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2015 Plan and 2005 Plan for the six&#160;months ended June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2005&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,635,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">506,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,047,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,463,037&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.28&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,725&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.94&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for grant at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,834,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$43.21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$166.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$62.52</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$131.66</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7%-3.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%-1.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-3.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-136.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.2%-142.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-136.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.7%-142.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1-6.1</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2015 Plan and 2005 Plan as of June&#160;30, 2022 was approximately $91 million and 7.5 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2015 Plan and 2005 Plan as of June&#160;30, 2022 was approximately $30 million and 6.5 years, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">882,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(71,989)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,575,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.79&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company's annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of 1.1 million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase 5% on each anniversary of its adoption up to a maximum of 1.65 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). No ESPP option periods commenced during the three months ended June 30, 2022 and 2021. As of June&#160;30, 2022, there were 0.7&#160;million shares available for issuance under the ESPP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Range of Black-Scholes fair values of ESPP shares granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$44.67-$79.74</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$128.70-$238.85</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%-1.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2%-142.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.4%-159.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5-2.0</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210691792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective evidence evaluated was the cumulative loss incurred over the three-year period ended June&#160;30, 2022 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June&#160;30, 2022, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent Net Operating Losses (&#8220;NOLs&#8221;) have been used to reduce taxable income. The Company&#8217;s remaining U.S. Federal NOLs are subject to limitation in accordance with the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), which limits allowable NOL deductions to 80% of federal taxable income. Effective January 1, 2022, a provision of the TCJA has taken effect creating a significant change to the treatment of research and experimental expenditures under Section 174 of the IRC (&#8220;Sec. 174 expenses&#8221;). Historically, businesses have had the option of deducting Sec. 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and will require Sec. 174 expenses associated with research conducted in the U.S. to be capitalized and amortized over a five-year period. For expenses associated with research outside of the U.S., Sec. 174 expenses will be capitalized and amortized over a 15-year period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized federal and state income tax expense of $1.4&#160;million and $1.9&#160;million, in total, for the three and six months ended June&#160;30, 2022, respectively, and did not recognize federal or state income tax expense for the three and six months ended June&#160;30, 2021. The Company recognized income tax expense related to foreign withholding tax on royalties of $2.2&#160;million for the six months ended June&#160;30, 2022 and $3.5 million and $6.6 million for the three and six months ended June&#160;30, 2021, respectively. The Company did not recognize income tax expense related to foreign withholding tax on royalties for the three months ended June&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210750608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On June 9, 2022, the co-lead plaintiffs filed an opposition to the motion to dismiss and on July 11, 2022, the Company filed a reply brief. The matter is now fully briefed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Court has not indicated whether it intends to schedule any hearing on the motion before issuing a ruling.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After the Sinnathurai Action was filed, five derivative lawsuits were filed: Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), William Kirst, et al. v. Stanley C. Erck, et al., No. 8:22-cv-00024-TDC (the &#8220;Kirst Action&#8221;), Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), and Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the U.S. District Court for the District of Maryland. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the U.S. District Court for the District of Maryland by the defendants. The derivative lawsuits name members of the board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the Court issued a memorandum opinion and order remanding the Kirst Action to state court. On February 4, 2022, the Court entered an order consolidating the Meyer and Yung Actions (the &#8220;Consolidated Derivative Action&#8221;). The plaintiffs in the Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Court entered an order in the Consolidated Derivative Action granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. If a related derivative action is filed and is not stayed, the Meyer and Yung plaintiffs may seek to terminate the stay. On June 10, 2022, the Snyder and Blackburn Actions were filed. The Snyder and Blackburn plaintiffs have expressed their intent to move the court to consolidate all of the derivative actions pending in Maryland federal court and to appoint lead counsel. On July 21, 2022, the Court ordered the parties in the Consolidated Derivative Action, the Snyder Action, and the Blackburn Action to meet and confer concerning consolidation, the appointment of lead counsel, and the ongoing stay of proceedings in the Consolidated Derivative Action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Should the parties fail to reach agreement on those issues, the Snyder and Blackburn plaintiffs were granted leave to file a motion for consolidation and appointment of lead counsel by August 18, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 29, 2022, Par Sterile Products, LLC (&#8220;Par&#8221;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (&#8220;MSA&#8221;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. While the Company maintains that no breach of the MSA has occurred and intends to vigorously defend the matter, if the final resolution of the matter is adverse to the Company, it could have a material impact on the Company&#8217;s financial position, results of operations, or cash flows.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715211962400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, the Company received emergency use authorization for NVX-CoV2373 from the FDA to provide a two-dose primary series in individuals 18 years of age and over.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, the Company entered into a modification to the OWS Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373, contingent on the timing of EUA approval by the FDA, as well as the timing of label language and artwork approvals by the FDA and the recommendation of the Advisory Committee on Immunization Practices within the United States Centers for Disease Control and Prevention, and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100&#160;million doses of NVX-CoV2373 contemplated by the original OWS Agreement (inclusive of the initial batch of approximately 3&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The 3&#160;million initial doses were delivered in July 2022. Additionally, in July 2022, the Company modified its existing agreement with the DoD to provide for the initial delivery of 0.2&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, the Company entered into the Amended and Restated UK Supply Agreement with the Authority, which amended and restated in its entirety the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#8217;s timely achievement of supportive recommendations from the JCVI. In the event that the Company is unable to achieve the JCVI supportive recommendations, it may have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022 and August 2022, the Company was notified by the EC that it was cancelling its prior commitment for 5&#160;million doses originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company signed an agreement with SK bioscience for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. In addition, the companies signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715207760960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Accumulated other comprehensive income included a foreign currency translation loss of $10.9 million and $1.4 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition - Product Sales</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition - Product Sales</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Product sales are associated with the Company&#8217;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs which were expensed prior to regulatory authorization as described under the caption &#8220;Inventory&#8221; below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Inventory</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out (&#8220;FIFO&#8221;) methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, the services and products of third-party suppliers, and the application of manufacturing overhead. The Company utilizes third-party contract manufacturing organizations (&#8220;CMOs&#8221;), contract development and manufacturing organizations (&#8220;CDMOs&#8221;), and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020 and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; (&#8220;CECL&#8221;) model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management is currently evaluating the effect of the guidance and does not expect it to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715213268576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract', window );"><strong>U.S. Government Agreements, Grants and Licenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock', window );">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</a></td>
<td class="text">During the six months ended June&#160;30, 2022, changes in the Company's accounts receivables and deferred revenue balances were as follows (in thousands):<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivables:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,069,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount is comprised of $701.5&#160;million and $1.4&#160;billion of current Deferred revenue and $814.6&#160;million and $172.5&#160;million of non-current Deferred revenue as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Revenue by Major Customers by Reporting Segments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government partnership (&#8220;OWS&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense (&#8220;DoD&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715211962400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as Other non-current assets as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210832016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of fair value hierarchy</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as cash and cash equivalents as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210756464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715211023808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of identifiable intangible assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets consisted of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated&#160;<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible<br/>Assets,&#160;Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated&#160;<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible<br/>Assets,&#160;Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary adjuvant technology</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,245)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,469)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total identifiable intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,564&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,531)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,033&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,961&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,191)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,770&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text">Estimated amortization expense for existing intangible assets for the remainder of 2022 and for each of the five succeeding&#160;years ending December&#160;31 will be as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,012)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715210769792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible notes payable</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable consisted of the following at (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount of Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(831)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,542)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">323,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div>(1)&#160;&#160;&#160;&#160;Convertible notes are classified as current liabilities and as non-current liabilities in the consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense incurred in connection with the Notes&#160;consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon interest at 3.75%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on Notes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208583312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded all stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option and Appreciation Rights Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2015 Plan and 2005 Plan for the six&#160;months ended June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2005&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,635,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">506,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,047,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,463,037&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.28&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,725&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.94&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for grant at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,834,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Estimation of Fair Value of Stock</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$43.21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$166.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$62.52</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$131.66</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7%-3.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%-1.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-3.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-136.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.2%-142.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-136.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.7%-142.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1-6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1-6.1</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Range of Black-Scholes fair values of ESPP shares granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$44.67-$79.74</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$128.70-$238.85</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%-1.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2%-142.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.4%-159.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5-2.0</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock', window );">Schedule Of Share Based Compensation Restricted Stock Awards Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">882,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(71,989)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,575,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.79&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation Restricted Stock Awards Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715209023184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment | $</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715203308624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details)<br> $ in Thousands, segment in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>dose </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed contracts receivable | $</a></td>
<td class="nump">$ 165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable | $</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues | $</a></td>
<td class="nump">185,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,017<span></span>
</td>
<td class="nump">889,896<span></span>
</td>
<td class="nump">$ 745,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized | $</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Subsequent Events | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Subsequent Events | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember', window );">U.S. government partnership (&#8220;OWS&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember', window );">U.S. government partnership (&#8220;OWS&#8221;) | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember', window );">U.S. government partnership (&#8220;OWS&#8221;) | Subsequent Events | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember', window );">Gavi Advance Purchase Agreement SIIPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesRemaining', window );">Number of doses, remaining</a></td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses of vaccine to be distributed</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesCancelled', window );">Number of doses, cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember', window );">Sales-Based Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues | $</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Amount of transaction price not yet satisfied | $</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, Cancelled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Doses Of Vaccine Candidate, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, Remaining</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfVaccineDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Vaccine Doses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfVaccineDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715209382800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward', window );"><strong>Accounts Receivable, Unbilled Services and Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, beginning balance</a></td>
<td class="nump">$ 454,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ReceivablesNetCurrentAdditions', window );">Additions</a></td>
<td class="nump">808,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ReceivablesCurrentNetDeductions', window );">Deductions</a></td>
<td class="num">(1,069,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, ending balance</a></td>
<td class="nump">194,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred Revenue Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DeferredRevenueCurrentAndNonCurrent', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">1,595,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DeferredRevenueCurrentAdditions', window );">Additions</a></td>
<td class="nump">49,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DeferredRevenueCurrentDeductions', window );">Deductions</a></td>
<td class="num">(128,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DeferredRevenueCurrentAndNonCurrent', window );">Deferred revenue, ending balance</a></td>
<td class="nump">1,516,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">701,518<span></span>
</td>
<td class="nump">$ 1,422,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent deferred revenue</a></td>
<td class="nump">$ 814,629<span></span>
</td>
<td class="nump">$ 172,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Unbilled Services and Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Current, Additions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Current and Non Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueCurrentDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Current, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueCurrentDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ReceivablesCurrentNetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables, Current, Net, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ReceivablesCurrentNetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ReceivablesNetCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables, Net, Current, Additions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ReceivablesNetCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715204740704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 185,925<span></span>
</td>
<td class="nump">$ 298,017<span></span>
</td>
<td class="nump">$ 889,896<span></span>
</td>
<td class="nump">$ 745,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">107,774<span></span>
</td>
<td class="nump">272,489<span></span>
</td>
<td class="nump">207,075<span></span>
</td>
<td class="nump">719,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | U.S. government partnership (&#8220;OWS&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">107,774<span></span>
</td>
<td class="nump">239,493<span></span>
</td>
<td class="nump">207,075<span></span>
</td>
<td class="nump">603,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | U.S. Department of Defense (&#8220;DoD&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">93,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | Bill &amp; Melinda Gates Foundation (&#8220;BMGF&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USDepartmentOfDefenseDoDContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USDepartmentOfDefenseDoDContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_BillMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_BillMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715212371296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Supply Agreements (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember', window );">Takeda Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PotentialFutureMilestonePayments', window );">Potential future milestone payments</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715207873200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,375,587<span></span>
</td>
<td class="nump">$ 1,515,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">10,274<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 1,387,515<span></span>
</td>
<td class="nump">$ 1,528,259<span></span>
</td>
<td class="nump">$ 2,122,739<span></span>
</td>
<td class="nump">$ 648,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205258656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 500,885<span></span>
</td>
<td class="nump">$ 361,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">500,885<span></span>
</td>
<td class="nump">361,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">774,250<span></span>
</td>
<td class="nump">1,056,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes payable</a></td>
<td class="nump">323,112<span></span>
</td>
<td class="nump">447,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">179,500<span></span>
</td>
<td class="nump">266,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">594,750<span></span>
</td>
<td class="nump">790,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nvax_GovernmentBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nvax_GovernmentBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715207884704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 55,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Semi-finished goods</a></td>
<td class="nump">71,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">129,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">256,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">155,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 155,662<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Firm purchase commitment loss</a></td>
<td class="nump">$ 99,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4578-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208961568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Identifiable Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">10,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated&#160; Amortization</a></td>
<td class="num">(6,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,191)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets,&#160;Net</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nvax_ProprietaryAdjuvantTechnologyMember', window );">Proprietary adjuvant technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated&#160; Amortization</a></td>
<td class="num">(3,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,469)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets,&#160;Net</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nvax_CollaborationAgreementsMember', window );">Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated&#160; Amortization</a></td>
<td class="num">(3,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,722)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets,&#160;Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nvax_ProprietaryAdjuvantTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nvax_ProprietaryAdjuvantTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nvax_CollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nvax_CollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715203352992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Identifiable Intangible Assets, estimated amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Amortization expense, fiscal year maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (remainder)</a></td>
<td class="nump">$ 182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">$ 364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715213128672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 131,479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(8,012,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 123,467,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205859184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets and lease liabilities obtained, operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_LongTermSupplyAgreementIncrementalBorrowingRate', window );">Long-term supply agreement, incremental borrowing rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 86,600<span></span>
</td>
<td class="nump">$ 83,900<span></span>
</td>
<td class="nump">$ 214,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">85,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_A700Q0AgreementMember', window );">700Q0 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_FacilityNumberOfSquareFeet', window );">Facility, number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">$ 47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_FacilityNumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_FacilityNumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LongTermSupplyAgreementIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Supply Agreement, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LongTermSupplyAgreementIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_A700Q0AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_A700Q0AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205830464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred issuance costs</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715213188144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of Notes</a></td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(1,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total convertible notes payable</a></td>
<td class="nump">$ 324,169<span></span>
</td>
<td class="nump">$ 323,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208417536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Coupon interest at 3.75%</a></td>
<td class="nump">$ 3,047<span></span>
</td>
<td class="nump">$ 3,047<span></span>
</td>
<td class="nump">$ 6,094<span></span>
</td>
<td class="nump">$ 6,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense on Notes</a></td>
<td class="nump">$ 3,403<span></span>
</td>
<td class="nump">$ 3,403<span></span>
</td>
<td class="nump">$ 6,806<span></span>
</td>
<td class="nump">$ 6,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205211808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,385<span></span>
</td>
<td class="nump">$ 564,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShelfRegistrationStatementRemainingUnissuedCapital', window );">Remaining unissued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,197,398<span></span>
</td>
<td class="nump">2,578,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="nump">$ 179,363<span></span>
</td>
<td class="nump">$ 564,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShelfRegistrationStatementRemainingUnissuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement Remaining Unissued Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShelfRegistrationStatementRemainingUnissuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205809936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock options and vesting RSA's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining term, outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining term, exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease', window );">Percentage increase of shares each anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Subscription rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Maximum discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent', window );">Minimum grant price, percent of common stock fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,834,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208971808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 38,048<span></span>
</td>
<td class="nump">$ 53,123<span></span>
</td>
<td class="nump">$ 70,981<span></span>
</td>
<td class="nump">$ 106,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">19,695<span></span>
</td>
<td class="nump">24,779<span></span>
</td>
<td class="nump">36,582<span></span>
</td>
<td class="nump">48,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 18,353<span></span>
</td>
<td class="nump">$ 28,344<span></span>
</td>
<td class="nump">$ 34,399<span></span>
</td>
<td class="nump">$ 57,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205752544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options and Appreciation Rights (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,635,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">506,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(59,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(35,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">4,047,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">1,463,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">4,834,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 42.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">73.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">15.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">78.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">46.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 55.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember', window );">2005&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">68,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">63,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">63,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 109.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">31.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">121.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">112.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 112.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205213440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average Black-Scholes fair value of stop options and SARs granted (in usd per share)</a></td>
<td class="nump">$ 43.21<span></span>
</td>
<td class="nump">$ 166.66<span></span>
</td>
<td class="nump">$ 62.52<span></span>
</td>
<td class="nump">$ 131.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">120.50%<span></span>
</td>
<td class="nump">126.20%<span></span>
</td>
<td class="nump">120.50%<span></span>
</td>
<td class="nump">124.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">136.70%<span></span>
</td>
<td class="nump">142.00%<span></span>
</td>
<td class="nump">136.70%<span></span>
</td>
<td class="nump">142.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715207891760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">819,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">882,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(55,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="num">(71,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested, ending balance (in shares) | shares</a></td>
<td class="nump">1,575,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per&#160;Share Weighted- Average Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 116.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in usd per share) | $ / shares</a></td>
<td class="nump">74.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in usd per share) | $ / shares</a></td>
<td class="nump">157.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">110.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 91.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715205764496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Employee Stock Purchase Plan (Details) - ESPP - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">116.20%<span></span>
</td>
<td class="nump">120.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">142.90%<span></span>
</td>
<td class="nump">159.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of Black-Scholes fair values of ESPP shares granted (in usd per share)</a></td>
<td class="nump">$ 44.67<span></span>
</td>
<td class="nump">$ 128.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of Black-Scholes fair values of ESPP shares granted (in usd per share)</a></td>
<td class="nump">$ 79.74<span></span>
</td>
<td class="nump">$ 238.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715203369408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Federal, state and local, tax expense (benefit)</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139715208634720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> segment in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>dose </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>dose</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember', window );">U.S. government partnership (&#8220;OWS&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Amended and Restated UK Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | U.S. government partnership (&#8220;OWS&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses | segment</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Joint Committee on Vaccination and Immunization (JCVI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount | $</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses</a></td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesCancelled', window );">Number of doses, cancelled</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Minimum | Amended and Restated UK Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Maximum | Amended and Restated UK Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Maximum | U.S. government partnership (&#8220;OWS&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed', window );">Number of doses to be distributed</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, Cancelled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Doses Of Vaccine Candidate, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfVaccineDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Vaccine Doses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfVaccineDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>nvax-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nvax="http://www.novavax.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nvax-20220630.xsd" xlink:type="simple"/>
    <context id="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac274b9c236946588cbd492c3c14688d_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i7556a131e55a41578a8e85d487bf5928_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i86be659b16f6450d8c6703acf6588255_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4945289540e9464e912a257f3ab7ee3a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1dc0120310b244cb8cb07e4863cca3b8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64169e1b64be465ba651f225a820a0a7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i740226150bb146dfbab7548d73d95ec3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02740f8f66c940f49f4d45435b5f33fb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4244f94bb3dc4fe284264e5bcde0de65_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i617f9132150b4ac2b7036afe3dadd382_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id94de60b1abe4ad58c2380deef7432e1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4b847b28162428a9c29f3d458bfa24a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie1c7c77a593d4ae8b52724afa14921ab_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie0b34d6687584e9692cde7fdd2961e44_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2da027fe8b2945be929fc9906ca55864_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96110cf81ced478b94da040072a11097_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i983653fedfdd46e4964ac7eaa476f0e5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf44cd7a49ed4b979d3cd163e2c5dec2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9e37e7f85f974859b9fe1672ca2f4c4b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3693bbbf47294faf81643217cb838507_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia99b9d9cf9ba4355b1dc30fa79ba361a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic4c178e9d82a4bc383bed84c24bc1076_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff1af4fb674a440d80223f9f311ac5da_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7901003cbe7c4f97a451e89abdfb7a0f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if4a6154851b4416b8f89cad0ad7721af_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i54872cb8e40f4eb092ba0fc3d8a1095b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iefa1af89fb9648679fce07310e5756d1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic1363bb3470f4a45b7d8cc8d9e9e6aea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iab83a560ba0b4becb4f5f507cccb33e3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i69ae795236fd4899979c4bd46c38a184_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic2e3eb175a484325be7a301736e4107e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d1712c0418943ea9ef19b5b840ad622_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i263537bdec814cf6b1cc7b8e9842db81_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8ac113f7c93d433688947c243e83b2b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i747d203795fc4040966baf276eafa5a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i400373f4f92f47119a751c4590a1d32c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3df15bfb369349d6aa42604f4e939b05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaf962fca8d1f43e9a4a5c58859e8e5b3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0f0ff7a0136d4a4fb89c7bcb66b8a4d4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5f7de39972c467d8d744008d112cbdb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i595ec53f965547f3ba917a056296edf8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia5e1b68160b843778dbca3e791b341ca_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dad49772b0f48038418785e8e761874_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ice1514b2ba3b4666a00d9813765198b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec245d5ef2c943f88458628a12c5efa7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3fc8de8da83641cc91ef608da7bf7d7e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i36438295aede46c58b4392a1543df581_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6b3583256bab459492a5d569f0fabc95_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib9542317971e482c84dd6b1322d3ee2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if47b8f663b084ad7aa112c61216cecf1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77212d37c7d542c58864ca99739f51a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a6ec54d49b44673ad5cceb7f2022d14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81c45885967040cb9ddd39bab52e20d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5216318c35f44e2ca8de90f56766c348_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9cc5b57fa7f04963a7a9f040883b44c2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if166d44b16b444dda0cd485ceb01788d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibd833ef8d89041a0a5d6c047bc63754d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7880242152934fbeb18732d8cb58a141_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib399728718c84112836d2a89efc58c0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i523ac32f976545eba62aaa06ede3c7da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic95178a09622409fb2fd15e1080134c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ba72b9644274960974bf6ff07008c73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i164611e81adc4dada9d43687e47035ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55283e03483840778793f0003169278b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1298fd9885d641b1be701807b92420b3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b6e942b2faa424d97c0830be1ea20ad_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f4b6f5acde242c3ace67f89c0df4c69_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id9a7f0ae8be1457ba975ad86d4101b1b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i21d13d4609664545a43b24e97b8b072f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac2796d80cfb471e994d0da8cd0437fd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c49f33057824088903829819b53beb0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieea0fc725c2844378d5f099dfa98477e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8eaafe4f9b3348c5b10a0f78e3633e5c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i51025fa58fb149ac918fe80236b6303e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04667b8d3a384b2d9245c1a4fa29d96a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a710118bda240b8b211f8a0825036c5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i551af433d1e246e89e595442fa319aee_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6ac4f312e40a4461a57f852f3ce23cc4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie31f109abc1642b28e93db64fafa6102_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0592102fe89f4264bfef8d819f322688_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8140e44c727f43f39853c42e69847f31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifcbc5b4644bd44feaef5b01c2b51ce35_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a08399d05224436b9583db28b4671a7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i52b84098b8a748f8bfc7222df25285a4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id77272a9807949ed93e0c856eca5c6db_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i398e1d19b77d4b66b82d84fa9532c022_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64d61c79ddcb4213a12c1d9637bd0819_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3e25182664da42259f8fddcc4e30be81_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7504caa392fc4b198ba675a27efbc513_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e0b072a00284d5e86b6ae1955e77255_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i472e0a435709425884b630fb4e4abe4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic03121026d664feabb6f6d6ce32a036e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0594bb0e3d49426d8546ac3ef41f5312_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92cf89b34fba4758b7ea6b29bb2b4277_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ibe5f264f5aae46269f4b5c7f917258db_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i7ce520d7761743ec86392cca9a2d1a9d_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i603827ce2ac64ffaac1b057ac83a74b8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d0012acfa204c92bb3e3d28118477f7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife8416d2c5f7415e89f5022b56743ac4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i750e9cc522fe4374bb3945dd8f61ee58_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i3c67801e2acb4e6bb800915f121b2eaf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i99533f95b79b45b992b718e063053587_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifd7188cfe5d6445c9ccfc63027d2b369_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia17025047e164926ae984921e6dabb68_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i194bb03495444c89b63efab4dad063fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc988bf6562e4a0ab83d5998938f5d7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb8814d4d6bb460fb498f2ef6bcb3f07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1427334e93bd4a8f98fd067cf174baff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd64740178f14dfaa8b40016114d8b0b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i44d2a912e597482e88dad8af2f1eb83a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7365cb3d7724460b7e77eea77c4d02c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i961f58e0225b454ea758608f30477153_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9c82b31c56a41cabaa12f169afbc6ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id47d8623f27649b88072c3726cf612a4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05545dcab7354afb93e21cdd544ce785_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia15eacf51ca7461e831d064a18ed6ec5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i45c389f5ae034c4a9f241df636dd9408_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c9c400472e346bb83cdc03ad62f0f6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieebe69f41a92442fa317d279aecfffa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c56415ec67e4a2f92984c0168e319b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i018f2366267542d98a7442366fecb5fb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieae5da8be9b04141abe668a81dbf1b8b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i33e6ef1fb0544afd9c34afa0943a65e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee1c4e3b51c54406bfdcb545ced2f93b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb63dea6d85945d78435e4733601554d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29ef495376c841fcad701e4fb99916f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecd523551b8c4c88a444bf178a5ead31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:ProprietaryAdjuvantTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:ProprietaryAdjuvantTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3453a5c919a143e6b9635ec05f27f973_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i94545a62f6f04e5d9fe91e26c5041a86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nvax:CollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia288ba6256924eaeb4fd7095a2acd199_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib60480ff6ace4a9dada2572b7a483040_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i298d3ab6290f4c62a68f470f3b16205a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic67b8fd3c6684e26893f4f55ee228020_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700Q0AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i385f7d6a051e4dafb63d1a63b59be860_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i425b5f4d2daa419592347aa121524f6f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d5d7e6cc2a6432fad8f4e48c6a737bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6932178ef14e472084b3b902bba8f33c_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3f8b6ed41b2d43bebac3d158af889817_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i4b95e06ae99e465cbb5da325d456aede_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i101c8f6e1aa7408995876bc4fb815e07_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="iec94153dc52b4f0a884461884ed5820d_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i0c556955c19448f6919e6fc319d19b36_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i944814c48d6649559e7aaad2f652d7d9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i031d603f91304729bf3df926d55719f3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9cd34e5e916949209fde4068aa2e6022_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1437c17d92b74d498d6762b05f885fcf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6cd14661959040a9a835c1d64370e08c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i077e0d963f96436b8a57d5c0ed164f5b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac8edaad70b54946b5867782a7dc86da_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9871aabeb83498fbc621e999b2b9f8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib704932e6449470a978301c51c17020a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib8ca2be2be7e4bc99eb77502e20ad770_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i547e6d19486d49bbba36b7968e867e86_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iebc85c93fc3d4bb8b1fe33f9fc7a5679_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ba39bdd4b0c4361ab34b776c5df1842_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d1d79ddc8e64ee499a6e8568258a241_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i420df0b64ff14517bb785ae28358ddd9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i20b84332994940ec9dd4c1fa8fe32f65_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0af1ef6cf5684c3f981161750a479e9e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i307541a72a03422fb6a7905e2797b623_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if549400c21a940d9930254a6fde16714_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4319b34bddc14dc7ad516619f65f196d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i962e48035aea4045b0cfe2ace43cde76_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6e499e69dfc74d4ab90426c5104422ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ad84832faf04aac8ca995f70a7aecd3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idadbd33a708c469c910a0ca167cd16cf_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ib86f32bcfa404cf0815eaf4f567e395f_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nvax:segment</measure>
    </unit>
    <unit id="dose">
        <measure>nvax:dose</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF8zLTEtMS0xLTcwMDc3_c1eebc6c-8ab3-4d32-866c-ee790fcf3d8f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF80LTEtMS0xLTcwMDc3_41646fd1-05a7-46bc-81a1-34cd275196ef">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF81LTEtMS0xLTcwMDc3_bb955d42-4655-453b-acc8-779f7b4fe7dd">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF82LTEtMS0xLTcwMDc3_6fd0f568-f93b-4feb-bf97-dd7efa4da771">0001000694</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80L2ZyYWc6MDRmMjAwYjFiMGY4NDVkZWIzMzExMWM3NzMxYWRhODQvdGFibGU6ZmM3YTFlM2I5YjBiNDU3N2EzMzg4NWI1MGM5OTMwNDgvdGFibGVyYW5nZTpmYzdhMWUzYjliMGI0NTc3YTMzODg1YjUwYzk5MzA0OF83LTEtMS0xLTcwMDc3_0262c0a5-ca5f-4a78-9ae8-900e415bf006">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i101c8f6e1aa7408995876bc4fb815e07_D20150601-20150630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQyNQ_9172cf8d-33fb-4432-8f7b-4855b5e3976b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA5_960b61ae-16ac-47ab-8848-74294011681b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA0_03054052-79d7-46d5-b9a8-d52b9e8c3121">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA_9bf230ca-f64c-49b8-9c95-ebae334eea1f">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA1_e8e3b2b3-7826-4b5e-8de0-2b3c9395453b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA2_506d8bde-d6ba-4f6e-976e-99e7b2cda8de">000-26770</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA3_f9f4ad81-445f-4732-8b18-6f6e0d15e84c">NOVAVAX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18wLTAtMS0xLTcwMDc3_8e8a6412-232e-4b81-b0b8-1e3f20c5bb4b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18wLTMtMS0xLTcwMDc3_96b1edbb-00c5-4a31-9f12-0b2b5c3ed2d7">22-2816046</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTAtMS0xLTcwMDc3_be2e8fdf-9a45-4f94-81e4-30a2c22217ec">21 Firstfield Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTEtMS0xLTcwMDc3_b7b1292f-2070-4461-a397-4742792a223e">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTItMS0xLTcwMDc3_eca7fe6a-3117-4464-b541-ed5c152073cc">MD</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZTI3OWFlYTRiZjFlNDBkZDg1NWM4MTkyOWE0NjNmOWMvdGFibGVyYW5nZTplMjc5YWVhNGJmMWU0MGRkODU1YzgxOTI5YTQ2M2Y5Y18zLTMtMS0xLTcwMDc3_d2dad9ba-7a55-498e-b638-2f7e2ce5888c">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV80NjY_a0851b99-8bf7-4297-937f-914329a217b6">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTEy_3bd14cb3-7ec7-4565-b625-edb2dca0a2db">268-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZmM1ZmY4MWIzYWM2NDBiYzhiZmE2NDYwOTZlZDQ0ZWYvdGFibGVyYW5nZTpmYzVmZjgxYjNhYzY0MGJjOGJmYTY0NjA5NmVkNDRlZl8xLTAtMS0xLTcwMDc3_37778b15-6e19-43a5-9cc9-137fd134605c">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZmM1ZmY4MWIzYWM2NDBiYzhiZmE2NDYwOTZlZDQ0ZWYvdGFibGVyYW5nZTpmYzVmZjgxYjNhYzY0MGJjOGJmYTY0NjA5NmVkNDRlZl8xLTEtMS0xLTcwMDc3_e893880c-7b94-43a6-9b3f-8defc31488da">NVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6ZmM1ZmY4MWIzYWM2NDBiYzhiZmE2NDYwOTZlZDQ0ZWYvdGFibGVyYW5nZTpmYzVmZjgxYjNhYzY0MGJjOGJmYTY0NjA5NmVkNDRlZl8xLTItMS0xLTcwMDc3_1767fe33-e981-4dff-ad5f-8aead227677a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTEw_52540e70-680d-47c8-b039-c0a7e0f26fb2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTEx_3410d44b-aa86-4426-a5c7-d1735897f9c7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6MWQ4M2RhMmE2MjlhNDI1NjgzYmY0ZjNmNTMxNjFmNDgvdGFibGVyYW5nZToxZDgzZGEyYTYyOWE0MjU2ODNiZjRmM2Y1MzE2MWY0OF8wLTAtMS0xLTcwMDc3_c0dea015-fb2c-47c6-b899-0b0b79650828">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6MWQ4M2RhMmE2MjlhNDI1NjgzYmY0ZjNmNTMxNjFmNDgvdGFibGVyYW5nZToxZDgzZGEyYTYyOWE0MjU2ODNiZjRmM2Y1MzE2MWY0OF8yLTMtMS0xLTcwMDc3_6f00ea92-6ac3-41dd-a54a-f071bb65e709">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGFibGU6MWQ4M2RhMmE2MjlhNDI1NjgzYmY0ZjNmNTMxNjFmNDgvdGFibGVyYW5nZToxZDgzZGEyYTYyOWE0MjU2ODNiZjRmM2Y1MzE2MWY0OF80LTEtMS0xLTcwMDc3_ff821e81-8869-4341-a00a-63b92a6c52ea">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMTA4_23dd580e-6967-4d2b-8e43-3c23cbbc49d2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iac274b9c236946588cbd492c3c14688d_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xL2ZyYWc6N2I4OTE1ZjlkNjgyNDA4MTg5ZjczMjdlNzYwYWE4OGEvdGV4dHJlZ2lvbjo3Yjg5MTVmOWQ2ODI0MDgxODlmNzMyN2U3NjBhYTg4YV8yMDkx_76ba8793-dd9f-4c60-9c2c-2eba659ff9c6"
      unitRef="shares">78215105</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i7556a131e55a41578a8e85d487bf5928_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy0xLTEtMS03MDA3Nw_afe642ec-cfca-4c62-aedc-b6617d12cd2e"
      unitRef="usd">55455000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86be659b16f6450d8c6703acf6588255_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy0zLTEtMS03MDA3Nw_7c96f64c-4693-40ba-80f1-e96f26eda4c9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4945289540e9464e912a257f3ab7ee3a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy01LTEtMS03MzI3Ng_41a0b80b-dfdf-4f7a-9ad4-7d2ea92ccffb"
      unitRef="usd">641083000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1dc0120310b244cb8cb07e4863cca3b8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMy03LTEtMS03MzI3Ng_c0fd090c-b348-4a31-865b-5d4120041892"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64169e1b64be465ba651f225a820a0a7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC0xLTEtMS03MDA3Nw_f4658f0c-67ef-468c-9343-2f974a738b8b"
      unitRef="usd">107774000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i740226150bb146dfbab7548d73d95ec3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC0zLTEtMS03MDA3Nw_29a5f4a4-92f0-42f6-9415-e1703f65b471"
      unitRef="usd">272489000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02740f8f66c940f49f4d45435b5f33fb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC01LTEtMS03MDA3Nw_48e4fab0-19f4-4573-9d58-85eb2b0d8901"
      unitRef="usd">207075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4244f94bb3dc4fe284264e5bcde0de65_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNC03LTEtMS03MDA3Nw_9cf6f22a-3474-4ffc-bcfb-bef1a7893bfd"
      unitRef="usd">719382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i617f9132150b4ac2b7036afe3dadd382_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS0xLTEtMS03MDA3Nw_81fec82c-2296-466c-aede-6dfcb08b4d16"
      unitRef="usd">22696000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id94de60b1abe4ad58c2380deef7432e1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS0zLTEtMS03MDA3Nw_76f4bd7e-30a6-44e2-89e5-40c376f74e85"
      unitRef="usd">25528000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4b847b28162428a9c29f3d458bfa24a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS01LTEtMS03MDA3Nw_52b864b6-5bfa-481f-9f34-570db96acf17"
      unitRef="usd">41738000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1c7c77a593d4ae8b52724afa14921ab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNS03LTEtMS03MDA3Nw_3a571a55-c0e5-4a32-b6d3-18de42d0e740"
      unitRef="usd">25864000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi0xLTEtMS03MDA3Nw_b1cef4ec-2ed7-4349-a6f6-f9239d3b0277"
      unitRef="usd">185925000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi0zLTEtMS03MDA3Nw_c880998a-1c7c-4ec4-90b6-6ca0ab2024bc"
      unitRef="usd">298017000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi01LTEtMS03MDA3Nw_dd87340a-1b7d-4287-9c4a-f617636242d6"
      unitRef="usd">889896000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfNi03LTEtMS03MDA3Nw_abaf86db-0c55-4f25-984e-19d89f199b9c"
      unitRef="usd">745246000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS0xLTEtMS03MDA3Nw_c41cc3f6-f374-4ce0-980b-0f56092eb088"
      unitRef="usd">271077000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS0zLTEtMS03MDA3Nw_07ce742f-e3cb-43ea-91eb-1683f67581d9"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS01LTEtMS03MzI4Nw_ac2f840b-7af8-4a7b-9750-0d802417cff5"
      unitRef="usd">286281000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfOS03LTEtMS03MzI4Nw_856dc6fe-2336-44fb-8c77-bfb48ca0350b"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtMS0xLTEtNzAwNzc_d12a5e62-d254-41e7-9340-130c3afe0605"
      unitRef="usd">289648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtMy0xLTEtNzAwNzc_38c7ce33-8df6-4ba0-8ba9-69a81df38188"
      unitRef="usd">570685000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtNS0xLTEtNzAwNzc_0e5ebe8a-4f1b-4549-83d7-a29b1f2fd583"
      unitRef="usd">673131000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTAtNy0xLTEtNzAwNzc_f4c4b08b-d780-4703-b6e8-57808e16651b"
      unitRef="usd">1163356000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtMS0xLTEtNzAwNzc_bf0d4e7b-523d-4d1a-a366-097fce47f374"
      unitRef="usd">108160000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtMy0xLTEtNzAwNzc_4655f40a-4d6d-4154-b446-88606ce7f19d"
      unitRef="usd">73161000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtNS0xLTEtNzAwNzc_3f4ce3eb-145b-4210-8302-6542325ee8b9"
      unitRef="usd">204152000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTEtNy0xLTEtNzAwNzc_959c2b10-0872-4b2c-baf3-f9bba68c8dfc"
      unitRef="usd">136351000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItMS0xLTEtNzAwNzc_9112a76e-8570-48b0-a2e6-4ecd5c910326"
      unitRef="usd">668885000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItMy0xLTEtNzAwNzc_44099c0b-a342-4ca2-806c-17c201c2ad48"
      unitRef="usd">643846000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItNS0xLTEtNzAwNzc_39ec1fdd-12a2-4ee4-9d4a-b6ed05778d57"
      unitRef="usd">1163564000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTItNy0xLTEtNzAwNzc_03012985-bba0-4ef4-b42e-bd7103f9d90a"
      unitRef="usd">1299707000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtMS0xLTEtNzAwNzc_4cc07460-6692-47c3-a4b4-d90d8688ba07"
      unitRef="usd">-482960000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtMy0xLTEtNzAwNzc_d0fd5085-b623-46ac-b707-469b0a7a1f5d"
      unitRef="usd">-345829000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtNS0xLTEtNzAwNzc_eec2f9e0-5c1a-4260-a14b-f12118736539"
      unitRef="usd">-273668000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTMtNy0xLTEtNzAwNzc_60388d49-fc03-40d2-89fd-e0cd7b4c809f"
      unitRef="usd">-554461000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtMS0xLTEtNzAwNzc_b3e6d438-419c-49bc-92c2-8a825edde6f6"
      unitRef="usd">6234000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtMy0xLTEtNzAwNzc_3acbb56b-8397-474b-ba5e-427f74fb42cb"
      unitRef="usd">5968000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtNS0xLTEtNzAwNzc_f73fa66b-c752-4e7c-922e-6af24df9a453"
      unitRef="usd">11110000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTYtNy0xLTEtNzAwNzc_0a0f1e83-7ef1-4347-a4bc-4e36eeab9432"
      unitRef="usd">10807000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctMS0xLTEtNzAwNzc_8338aebb-bee4-4ff7-ae73-b4841d1336c9"
      unitRef="usd">-19873000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctMy0xLTEtNzAwNzc_dd2187ae-97b8-46ac-a78d-e976485df9b5"
      unitRef="usd">3028000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctNS0xLTEtNzAwNzc_d1bf6cd1-b981-41d2-959c-944fe9c1f12c"
      unitRef="usd">-18219000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTctNy0xLTEtNzAwNzc_5798b56f-8b49-422c-b1c2-1f8fe13395e4"
      unitRef="usd">-3203000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtMS0xLTEtNzAwNzc_d7995b38-5f5d-471e-a987-9a1e6430a7fe"
      unitRef="usd">-509067000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtMy0xLTEtNzAwNzc_da900809-e4f9-48e3-a84e-2c443f4f2951"
      unitRef="usd">-348769000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtNS0xLTEtNzAwNzc_394e07b7-2344-4dbe-a1e9-a4a37b18f866"
      unitRef="usd">-302997000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTgtNy0xLTEtNzAwNzc_f67bc456-ed6b-4094-9bf7-1d0bab5fef7b"
      unitRef="usd">-568471000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktMS0xLTEtNzAwNzc_c6e4984c-98e9-42b3-a335-0d63a1166fb1"
      unitRef="usd">1418000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktMy0xLTEtNzAwNzc_fac6e764-b997-467a-bf11-92536abb7daa"
      unitRef="usd">3548000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktNS0xLTEtNzAwNzc_52fd194f-0a21-4f14-a6ba-7572f652b329"
      unitRef="usd">4080000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMTktNy0xLTEtNzAwNzc_26ea86a4-9dfe-491a-ba9d-907d31f6920f"
      unitRef="usd">6565000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtMS0xLTEtNzAwNzc_0193cf68-54f9-40f1-8a67-e3a710993f29"
      unitRef="usd">-510485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtMy0xLTEtNzAwNzc_d12b0340-330b-4d44-b205-5d1a445e562a"
      unitRef="usd">-352317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtNS0xLTEtNzAwNzc_67a9946a-645a-45c0-8da0-3c9d288b0d95"
      unitRef="usd">-307077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjAtNy0xLTEtNzAwNzc_8a98a325-bcce-43b0-96fc-3408adf145d2"
      unitRef="usd">-575036000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtMS0xLTEtNzAwNzc_276eb772-cfca-4fb5-be27-ccad6a76f7ba"
      unitRef="usdPerShare">-6.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtMy0xLTEtNzAwNzc_b55fffe1-fe4c-4548-8300-5136ca8a4aae"
      unitRef="usdPerShare">-4.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtNS0xLTEtNzAwNzc_92b5a5af-8890-4aaf-b2ba-d55ddfe7026e"
      unitRef="usdPerShare">-3.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjMtNy0xLTEtNzAwNzc_3ffe9245-85b3-4cc0-b80a-62bbc6c8c248"
      unitRef="usdPerShare">-7.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtMS0xLTEtNzAwNzc_da56af27-e89b-4390-8990-4a3c5cd2447b"
      unitRef="shares">78143000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtMy0xLTEtNzAwNzc_86a91e34-2088-4b74-bbc9-14cca6ad18c9"
      unitRef="shares">74118000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtNS0xLTEtNzAwNzc_b3058fd8-e21c-4442-8dfe-607895a0f9e2"
      unitRef="shares">77305000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOjBjYjU4Mjk4MWYzMDRiNmZiOTFlMjAzMDI4MTA5NWMzL3RhYmxlcmFuZ2U6MGNiNTgyOTgxZjMwNGI2ZmI5MWUyMDMwMjgxMDk1YzNfMjYtNy0xLTEtNzAwNzc_a1b9c7b3-6aac-4082-a652-6f751d2c5165"
      unitRef="shares">73580000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi0xLTEtMS03MDA3Nw_9ac967a1-e7d6-4fce-9de0-4979e3e83900"
      unitRef="usd">-510485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi0zLTEtMS03MDA3Nw_a0f014ab-0173-4b63-906b-9c7a41c76fb9"
      unitRef="usd">-352317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi01LTEtMS03MDA3Nw_c4340e11-f492-4f7b-a7f3-63800a93e74a"
      unitRef="usd">-307077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfMi03LTEtMS03MDA3Nw_0f4f8599-f936-41bd-86d9-4dd9fe74561f"
      unitRef="usd">-575036000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC0xLTEtMS03MDA3Nw_fe3df98e-43ff-422c-879b-9d36ffc7eb49"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC0zLTEtMS03MDA3Nw_a4fcc064-2552-478f-a4b9-8b041cacc6ea"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC01LTEtMS03MDA3Nw_fd63d77b-c5d8-46b8-acf6-967c743dd122"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNC03LTEtMS03MDA3Nw_4b8177fa-1b17-4ca3-a134-a4623af892e4"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS0xLTEtMS03MDA3Nw_141d86ef-2ebb-4eaf-b69b-796547b6fe96"
      unitRef="usd">-9558000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS0zLTEtMS03MDA3Nw_41bf2089-0a3a-453e-9c42-e3fbe100384a"
      unitRef="usd">4527000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS01LTEtMS03MDA3Nw_cc96118d-1adc-4736-a4bc-fd095f6bbd83"
      unitRef="usd">-9517000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNS03LTEtMS03MDA3Nw_207c16d7-6149-47b5-b158-98d4aadc7db2"
      unitRef="usd">-2845000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi0xLTEtMS03MDA3Nw_9f0c5d90-edf6-4199-bace-14d68ee0dbee"
      unitRef="usd">-9558000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi0zLTEtMS03MDA3Nw_f45144d2-f6bf-4ba7-afeb-6c1911957a58"
      unitRef="usd">4527000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi01LTEtMS03MDA3Nw_ec8a9a14-998a-4795-8c2c-67bf9dba5fd3"
      unitRef="usd">-9517000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNi03LTEtMS03MDA3Nw_402ec931-5233-4edd-8795-24724108ec07"
      unitRef="usd">-2854000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy0xLTEtMS03MDA3Nw_78e46828-a331-4cbf-8f7e-663196f49669"
      unitRef="usd">-520043000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy0zLTEtMS03MDA3Nw_5159d135-1d9c-4b5d-9d6c-e78f0acaf97b"
      unitRef="usd">-347790000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy01LTEtMS03MDA3Nw_a8d28da1-dda5-4255-bdf4-29adcafdbe7c"
      unitRef="usd">-316594000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xNi9mcmFnOjhmNzA2NTA1N2Q2NjQxOGM4ZmU4NmZlYzdmOTE1ZmJhL3RhYmxlOmMyYTRhNGU5ZjhiZjRjMDI4YWI1ZWVmNzI2M2Y5NDVjL3RhYmxlcmFuZ2U6YzJhNGE0ZTlmOGJmNGMwMjhhYjVlZWY3MjYzZjk0NWNfNy03LTEtMS03MDA3Nw_bc9da64a-83d5-4c58-9b04-6f928fb812ee"
      unitRef="usd">-577890000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNC0xLTEtMS03MDA3Nw_94829871-2f04-43fa-ac7f-67c060ce2217"
      unitRef="usd">1375587000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNC0zLTEtMS03MDA3Nw_ba87fb7f-dcd4-494c-9c31-6c2d94ca3b1e"
      unitRef="usd">1515116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNi0xLTEtMS03MDA3Nw_2367c1ec-d8b8-49b0-b9b3-c1aa96de1ac9"
      unitRef="usd">10274000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNi0zLTEtMS03MDA3Nw_dd7c3c63-6acb-4018-ab2a-07eca940f46f"
      unitRef="usd">11490000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNy0xLTEtMS03MDA3Nw_a8756f77-f1b8-43c5-8001-7a442fa399d7"
      unitRef="usd">194533000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNy0zLTEtMS03MDA3Nw_9812aa77-6409-436e-a3d4-3ee3cf3405e7"
      unitRef="usd">454993000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOC0xLTEtMS03MDA3Nw_305c451a-ecd5-4a14-af63-c716ee109838"
      unitRef="usd">256301000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOC0zLTEtMS03MDA3Nw_a3835a2e-296f-42ee-a414-cc4f6c7161d5"
      unitRef="usd">8872000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOS0xLTEtMS03MDA3Nw_9d5f8203-4298-48ae-bcb4-1279c1c2cfd3"
      unitRef="usd">299307000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfOS0zLTEtMS03MDA3Nw_9d1991b7-80c5-4641-a4bb-fbd9beea2e8c"
      unitRef="usd">164648000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTAtMS0xLTEtNzAwNzc_2bcd72e2-501d-407b-b1d1-52a20a61f224"
      unitRef="usd">2136002000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTAtMy0xLTEtNzAwNzc_9fa209d0-3a79-4644-81ee-41dc8a7c8728"
      unitRef="usd">2155119000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTEtMS0xLTEtNzAwNzc_c0349c5f-f8f8-4a8d-878e-e4cb3eae0fc1"
      unitRef="usd">254526000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTEtMy0xLTEtNzAwNzc_5195ce82-5162-4912-bc8d-0385c38db4d2"
      unitRef="usd">228696000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTItMS0xLTEtNzAwNzc_881fa3ba-f5bd-47c5-93b4-69205ac5404f"
      unitRef="usd">85770000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTItMy0xLTEtNzAwNzc_d3679db3-01ce-42fd-afdc-5ea8642ae75d"
      unitRef="usd">40123000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMS0xLTEtNzM1NDM_b312d14d-bccf-4305-8223-d9e110ac0ff7"
      unitRef="usd">4033000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMy0xLTEtNzM1NDM_4b11a731-7b1e-4725-98fa-f92fd6b409ce"
      unitRef="usd">4770000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMS0xLTEtNzI3MTQ_e6b4dc5a-ee30-47d9-bfbf-a75ee03409fa"
      unitRef="usd">123467000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTMtMy0xLTEtNzI3MTQ_4578d830-3a11-4f76-8d0a-880faba608a2"
      unitRef="usd">131479000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTUtMS0xLTEtNzAwNzc_c299de3e-d94c-4107-b027-c6ed1c1719b7"
      unitRef="usd">19195000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTUtMy0xLTEtNzAwNzc_2b13f4b7-167f-443c-a876-d17039fe4d9b"
      unitRef="usd">16566000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTYtMS0xLTEtNzAwNzc_29994346-c631-4cab-b622-0df8c69d4e3a"
      unitRef="usd">2622993000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTYtMy0xLTEtNzAwNzc_a6df94b3-d625-4b88-b291-7ad702fbd778"
      unitRef="usd">2576753000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTktMS0xLTEtNzAwNzc_97c1a90b-846a-44cc-80cf-909650829b89"
      unitRef="usd">386488000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMTktMy0xLTEtNzAwNzc_9b7e0d7c-c645-4fa5-bc84-917d5e50c016"
      unitRef="usd">127050000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjAtMS0xLTEtNzAwNzc_f9417f41-cd0b-4441-87df-0b419657313b"
      unitRef="usd">585646000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjAtMy0xLTEtNzAwNzc_3151a2a5-c5aa-4065-bf99-724d46906c30"
      unitRef="usd">673731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjEtMS0xLTEtNzAwNzc_17874449-a15a-4fb0-b844-2fe4ac857ca4"
      unitRef="usd">701518000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjEtMy0xLTEtNzAwNzc_89647d2f-448b-4c6a-ac03-af5788e588d8"
      unitRef="usd">1422944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjItMS0xLTEtNzAwNzc_89543840-ca64-4615-b58a-b895a373f7c5"
      unitRef="usd">124260000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjItMy0xLTEtNzAwNzc_917ff05d-00d4-44ee-a34c-f23181b0f484"
      unitRef="usd">130533000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjMtMS0xLTEtNzAwNzc_5524f170-3e6d-4b43-910c-59f419590437"
      unitRef="usd">324169000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjMtMy0xLTEtNzAwNzc_cd3b25b7-eb39-41ed-af8d-b8fdfebf5feb"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjQtMS0xLTEtNzAwNzc_39f344c3-fdf0-479b-996c-ec734597e21e"
      unitRef="usd">34158000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjQtMy0xLTEtNzAwNzc_15035823-5d17-4a4f-aa50-9ea46745bd01"
      unitRef="usd">36061000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjUtMS0xLTEtNzAwNzc_cff91132-5107-4a8b-8f3f-c03f7b1cecef"
      unitRef="usd">2156239000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjUtMy0xLTEtNzAwNzc_1328fb64-ea37-4db3-b814-f9c354615b6f"
      unitRef="usd">2390319000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjYtMS0xLTEtNzAwNzc_a943e2db-9ee4-47a0-804c-87e88154fcf0"
      unitRef="usd">814629000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjYtMy0xLTEtNzAwNzc_a7c9692d-e6d4-4a13-b334-e8f26fc34ec5"
      unitRef="usd">172528000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjctMS0xLTEtNzAwNzc_a025a5fd-5fb1-4f68-9dd7-21d10ec3506b"
      unitRef="usd">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjctMy0xLTEtNzAwNzc_c8f19f05-01ef-45d4-8277-76fefd2edd40"
      unitRef="usd">323458000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjktMS0xLTEtNzAwNzc_e5803544-0c08-4100-a0f1-39fab99ddb12"
      unitRef="usd">69075000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMjktMy0xLTEtNzAwNzc_f8885f72-364c-4c92-8b90-b226deee7a87"
      unitRef="usd">42121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzAtMS0xLTEtNzAwNzc_4622c8eb-8cba-4ce2-8105-41c4a65220df"
      unitRef="usd">3039943000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzAtMy0xLTEtNzAwNzc_bcb898b9-4c43-4338-8d47-c32d785d0c94"
      unitRef="usd">2928426000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzItMS0xLTEtNzAwNzc_e578241d-dc17-4132-b771-80e40f34c107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzItMy0xLTEtNzAwNzc_7be1e852-8087-4766-bbe3-ba01db2da05b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xOA_3a3ad017-0d88-4a7e-baf0-31712fd7840d"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xOA_faacaa0c-480b-45f1-a9da-32e0f50fee7a"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8zMg_02a5609f-c58d-4162-bb60-092c8840572f"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8zMg_aad9caec-fd50-4ecf-8b91-383d7b179198"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV85OA_b754f6c9-dc5e-4cf2-82b1-93865b262990"
      unitRef="shares">78776234</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xMTk_a127474f-f350-4edd-921b-ddb379b04faa"
      unitRef="shares">78166935</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xNjM_85b8882a-2cb0-4d9a-aa89-bc2b793b39f7"
      unitRef="shares">76433151</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo2NTVlMjBlNzBmZmU0ZWRlOTc5ODRkYjk2OGU2MmMxMV8xODQ_caa77f7b-6c65-4e2b-9782-f70dee648cf6"
      unitRef="shares">75841171</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMS0xLTEtNzAwNzc_2ccbcc3e-3e4d-437d-b31d-d4d136c13c3a"
      unitRef="usd">788000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzctMy0xLTEtNzAwNzc_95b846d9-4607-44fe-a365-69376b776d16"
      unitRef="usd">764000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzgtMS0xLTEtNzAwNzc_5b23dff0-69e4-43d8-b09e-13b5b35c41d5"
      unitRef="usd">3604614000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzgtMy0xLTEtNzAwNzc_c4c4e1d6-92ca-4a7e-ae27-441424520b96"
      unitRef="usd">3351967000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzktMS0xLTEtNzAwNzc_982c065b-fce0-4dd7-8902-9cb753d02384"
      unitRef="usd">-3925027000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfMzktMy0xLTEtNzAwNzc_1c5dc0aa-b545-416b-b3e4-9b062b4647ab"
      unitRef="usd">-3617950000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo3MDIyOGZlNjUyOGU0OGQwYjQwZjkyNzkzNTg4ZGE0MV8zMg_2c8876d5-4d6e-40ff-a268-9a0c1d083c2d"
      unitRef="shares">609299</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjo3MDIyOGZlNjUyOGU0OGQwYjQwZjkyNzkzNTg4ZGE0MV82NA_e70be996-cd64-4e72-a137-ecdf8f4bf66c"
      unitRef="shares">591980</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMS0xLTEtNzAwNzc_09c15a31-3300-415d-8f41-bdca26ddec97"
      unitRef="usd">86455000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDAtMy0xLTEtNzAwNzc_2e1aaabd-be1e-4d79-82a5-371266883525"
      unitRef="usd">85101000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDEtMS0xLTEtNzAwNzc_88c2b89f-daf6-4d0a-b307-c1e41ebcf375"
      unitRef="usd">-10870000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDEtMy0xLTEtNzAwNzc_235cd86c-30fb-4445-830d-e4dd89b3a3b2"
      unitRef="usd">-1353000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDItMS0xLTEtNzAwNzc_7131e1b0-85c8-45b6-8b0d-f5aa6ddf8d8d"
      unitRef="usd">-416950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDItMy0xLTEtNzAwNzc_b3fe81b2-4b29-4df5-89d1-a05dd61e039b"
      unitRef="usd">-351673000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDMtMS0xLTEtNzAwNzc_98f9fe3c-1715-4a8f-9432-ed1f04a34d32"
      unitRef="usd">2622993000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8xOS9mcmFnOjAxZjdmNzYwZTEwMzQ5MDFhMjUyNWE5NDMzMjk2ZmY5L3RhYmxlOjE2ZmU4ODhlOTcxNzRkODFiN2M3MjkyMmVlYWVhYTA3L3RhYmxlcmFuZ2U6MTZmZTg4OGU5NzE3NGQ4MWI3YzcyOTIyZWVhZWFhMDdfNDMtMy0xLTEtNzAwNzc_bb74b947-8b39-465f-82f3-7f66bc034f1c"
      unitRef="usd">2576753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i96110cf81ced478b94da040072a11097_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0xLTEtMS03NzA2OA_eb57a000-269b-4e93-8877-fd1dcc5d9130"
      unitRef="shares">78722337</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i96110cf81ced478b94da040072a11097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0zLTEtMS03NzA2OA_ec860307-4f42-4e3b-bca1-e6fa11388c86"
      unitRef="usd">787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i983653fedfdd46e4964ac7eaa476f0e5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi01LTEtMS03NzA2OA_81d65d33-2aa6-41be-87ad-ac7ac7f52df0"
      unitRef="usd">3566292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf44cd7a49ed4b979d3cd163e2c5dec2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi03LTEtMS03NzA2OA_96416c52-1ffa-438a-93f6-c13b2f7f81a0"
      unitRef="usd">-3414542000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e37e7f85f974859b9fe1672ca2f4c4b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi05LTEtMS03NzA2OA_9219926e-575e-4fdd-9521-54926f81c773"
      unitRef="usd">-85901000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3693bbbf47294faf81643217cb838507_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0xMS0xLTEtNzcwNjg_c78bfb3d-d2b8-4b2f-a394-608c1cf9bd4c"
      unitRef="usd">-1312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia99b9d9cf9ba4355b1dc30fa79ba361a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMi0xMy0xLTEtNzcwNjg_43179207-d033-4e8d-bb4e-93cf622e5759"
      unitRef="usd">65324000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic4c178e9d82a4bc383bed84c24bc1076_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMy01LTEtMS03NzA2OA_3435db4d-686d-4d69-8b7a-eefd6d01e767"
      unitRef="usd">38048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMy0xMy0xLTEtNzcwNjg_b878b650-862e-46bd-b0ef-52e703e5e37d"
      unitRef="usd">38048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="iff1af4fb674a440d80223f9f311ac5da_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC0xLTEtMS03NzA2OA_ba240175-4812-4bb0-8c2b-8022bd177bbc"
      unitRef="shares">53897</nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="iff1af4fb674a440d80223f9f311ac5da_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC0zLTEtMS03NzA2OA_c5d8ddb1-2499-4fea-b83a-c3f28155b809"
      unitRef="usd">1000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ic4c178e9d82a4bc383bed84c24bc1076_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC01LTEtMS03NzA2OA_bb1b019a-edf8-4db2-9013-094503369fc5"
      unitRef="usd">274000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i7901003cbe7c4f97a451e89abdfb7a0f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC05LTEtMS03NzA2OA_d73804aa-e6b5-41d6-927f-1c309f322b79"
      unitRef="usd">-554000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNC0xMy0xLTEtNzcwNjg_dbe0b781-acc8-4e0b-80fb-334c54ddd91d"
      unitRef="usd">-279000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if4a6154851b4416b8f89cad0ad7721af_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNi0xMS0xLTEtNzcwNjg_775c8a4b-8903-4ade-9562-9f9dbc0759bb"
      unitRef="usd">-9558000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNi0xMy0xLTEtNzcwNjg_808852da-8d03-4589-8020-728edc5f1d8e"
      unitRef="usd">-9558000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i54872cb8e40f4eb092ba0fc3d8a1095b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNy03LTEtMS03NzA2OA_162d985d-1a2d-427e-9dc8-bc9b9d4123e5"
      unitRef="usd">-510485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfNy0xMy0xLTEtNzcwNjg_b2a4c1a2-d3d0-4ad8-afd3-40e1faf5bcd9"
      unitRef="usd">-510485000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0xLTEtMS03OTk2OQ_d283d895-2e80-4117-be6b-fb3faf4d0808"
      unitRef="shares">78776234</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0zLTEtMS03OTk2OQ_7d21b845-ef00-472c-a5b0-54dd3c2a6172"
      unitRef="usd">788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1363bb3470f4a45b7d8cc8d9e9e6aea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC01LTEtMS03OTk2OQ_f5d65690-b75d-441f-8ecc-249b4cf24315"
      unitRef="usd">3604614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab83a560ba0b4becb4f5f507cccb33e3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC03LTEtMS03OTk2OQ_8617db65-8f1d-4cfb-9eef-95d1559e0c23"
      unitRef="usd">-3925027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69ae795236fd4899979c4bd46c38a184_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC05LTEtMS03OTk2OQ_51964f10-fbe1-4ad7-91c7-9362b0017a81"
      unitRef="usd">-86455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2e3eb175a484325be7a301736e4107e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0xMS0xLTEtNzk5Njk_5dbd0291-fecb-4ef3-a388-ed1f815a6424"
      unitRef="usd">-10870000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfOC0xMy0xLTEtNzk5Njk_bbaac430-00df-4d18-87d7-f66ab32b8bd5"
      unitRef="usd">-416950000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i3d1712c0418943ea9ef19b5b840ad622_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMS0xLTEtNzcwNjg_d082bcdf-2253-4c06-902b-68df33ddb1a1"
      unitRef="shares">74470583</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3d1712c0418943ea9ef19b5b840ad622_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMy0xLTEtNzcwNjg_d21f5ec0-6b1d-47cc-978b-7c8ecbb248d9"
      unitRef="usd">745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i263537bdec814cf6b1cc7b8e9842db81_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtNS0xLTEtNzcwNjg_37e3b838-e71c-4f5f-90b6-dae5a2566d25"
      unitRef="usd">3180114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ac113f7c93d433688947c243e83b2b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtNy0xLTEtNzcwNjg_d4aa7dac-824c-4f50-879a-c3bd52070563"
      unitRef="usd">-2096918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i747d203795fc4040966baf276eafa5a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtOS0xLTEtNzcwNjg_98bac3fc-b463-4efc-a6d6-cf68d92b7d1d"
      unitRef="usd">-44457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i400373f4f92f47119a751c4590a1d32c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMTEtMS0xLTc3MDY4_65731675-8672-4c33-909e-4766e2aba1a4"
      unitRef="usd">-357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3df15bfb369349d6aa42604f4e939b05_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTAtMTMtMS0xLTc3MDY4_57d0edc2-704f-4def-95e7-f414d1de6cda"
      unitRef="usd">1039127000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaf962fca8d1f43e9a4a5c58859e8e5b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTEtNS0xLTEtNzcwNjg_0bf6673d-5d12-4e93-ac9a-9628fd6cb491"
      unitRef="usd">53123000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTEtMTMtMS0xLTc3MDY4_c5d83720-4eb7-452e-99cb-b1d40c7c1ec4"
      unitRef="usd">53123000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="i0f0ff7a0136d4a4fb89c7bcb66b8a4d4_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItMS0xLTEtNzcwNjg_061b5735-d32e-4d38-b253-aef2bb99a887"
      unitRef="shares">201768</nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i0f0ff7a0136d4a4fb89c7bcb66b8a4d4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItMy0xLTEtNzcwNjg_29e785ef-adcd-403d-8080-980512528110"
      unitRef="usd">2000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="iaf962fca8d1f43e9a4a5c58859e8e5b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItNS0xLTEtNzcwNjg_f866a21c-9e9c-496d-992b-fa724be2d118"
      unitRef="usd">3848000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ic5f7de39972c467d8d744008d112cbdb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItOS0xLTEtNzcwNjg_6765118c-750d-4b0d-ba06-6ac0d277802c"
      unitRef="usd">-2748000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTItMTMtMS0xLTc3MDY4_05a7b73d-d4a2-4677-85c6-9da1c4f7eb2d"
      unitRef="usd">1102000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i595ec53f965547f3ba917a056296edf8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTUtMTEtMS0xLTc3MDY4_b49e87aa-5f38-455c-9ee7-e756e608591b"
      unitRef="usd">4527000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTUtMTMtMS0xLTc3MDY4_ab20b6a2-ca01-449b-b76c-50fa22428561"
      unitRef="usd">4527000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ia5e1b68160b843778dbca3e791b341ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTYtNy0xLTEtNzcwNjg_98c66474-c35a-46fa-94f0-eedc0112974f"
      unitRef="usd">-352317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTYtMTMtMS0xLTc3MDY4_424b23d5-563f-40b9-8c7b-8881aebdb395"
      unitRef="usd">-352317000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5dad49772b0f48038418785e8e761874_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMS0xLTEtNzk5NzE_a4d77335-dac0-4aff-94d8-7c73065c765d"
      unitRef="shares">74672351</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5dad49772b0f48038418785e8e761874_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMy0xLTEtNzk5NzE_49138752-ed90-4289-b389-073fa0218d29"
      unitRef="usd">747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice1514b2ba3b4666a00d9813765198b7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctNS0xLTEtNzk5NzE_5e59dd84-b1ac-43e6-8bbd-dc0b0f2f36fc"
      unitRef="usd">3237085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec245d5ef2c943f88458628a12c5efa7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctNy0xLTEtNzk5NzE_be7fca89-e693-4c97-8118-63440de89f90"
      unitRef="usd">-2449235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fc8de8da83641cc91ef608da7bf7d7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctOS0xLTEtNzk5NzE_5eaebe9b-df09-42e0-bc00-0c8f865cc43a"
      unitRef="usd">-47205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36438295aede46c58b4392a1543df581_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMTEtMS0xLTc5OTcx_7c6b484e-14bf-4883-9ba3-de45237785e0"
      unitRef="usd">4170000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b3583256bab459492a5d569f0fabc95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOjM2Y2I3MjdlZDk2MTRjODY5YWY2MDgzYTgwMzA1YjI3L3RhYmxlcmFuZ2U6MzZjYjcyN2VkOTYxNGM4NjlhZjYwODNhODAzMDViMjdfMTctMTMtMS0xLTc5OTcx_17c5f039-0184-4c21-a111-e65cfbf14699"
      unitRef="usd">745562000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ib9542317971e482c84dd6b1322d3ee2a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0xLTEtMS03MDA3Nw_120637ea-ca57-4281-8da8-0a97328805fa"
      unitRef="shares">76433151</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib9542317971e482c84dd6b1322d3ee2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0zLTEtMS03MDA3Nw_08db1ad3-83e9-4280-a517-4c8b58bdd45f"
      unitRef="usd">764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if47b8f663b084ad7aa112c61216cecf1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy01LTEtMS03MDA3Nw_e762c2a7-d8b5-4eda-98dc-1cc96ff78c41"
      unitRef="usd">3351967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77212d37c7d542c58864ca99739f51a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy03LTEtMS03MDA3Nw_f1ceeb8b-2cb8-4be0-a940-21b7256cd932"
      unitRef="usd">-3617950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a6ec54d49b44673ad5cceb7f2022d14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy05LTEtMS03MDA3Nw_e598d411-e699-457d-8f41-dcc1cd06f0e4"
      unitRef="usd">-85101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81c45885967040cb9ddd39bab52e20d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0xMS0xLTEtNzAwNzc_e7cb9d7f-ea2e-469b-bbcb-15dcb3923aa7"
      unitRef="usd">-1353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMy0xMy0xLTEtNzAwNzc_e43926cf-1163-418b-8df8-a2887646e542"
      unitRef="usd">-351673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNC01LTEtMS03MDA3Nw_1d1ad01d-548d-4449-a3da-f5e1f93ed43a"
      unitRef="usd">70981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNC0xMy0xLTEtNzAwNzc_8b28cfaa-1320-466e-8fd2-07678f345001"
      unitRef="usd">70981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS0xLTEtMS03MDA3Nw_764f357d-b3bb-423b-bebf-111f404e2463"
      unitRef="shares">145685</nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS0zLTEtMS03MDA3Nw_cc829f79-d547-46a1-8e97-d4649b4f054e"
      unitRef="usd">2000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS01LTEtMS03MDA3Nw_a8d7b2ba-9578-4a42-8ea6-d9b60bdb2702"
      unitRef="usd">2303000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i5216318c35f44e2ca8de90f56766c348_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS05LTEtMS03MDA3Nw_7ff33c66-41e0-44af-b7b3-58e0719cee42"
      unitRef="usd">-1354000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNS0xMy0xLTEtNzAwNzc_044b8a40-0376-4045-beeb-406d97f4ba61"
      unitRef="usd">951000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0wLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjEzYjgxODY2NDhlZjQ3ZTU5OGI5YmZjNDRlMmU4MDViXzU1_ab6cd8ee-65a5-4853-9e4b-5e902b52751d"
      unitRef="usd">2311000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0xLTEtMS03MDA3Nw_a9fa2719-03b4-4ef3-a658-a7a962b52e5d"
      unitRef="shares">2197398</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic102e04d37f649fdb5187ba2e5603efe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0zLTEtMS03MDA3Nw_baf2935f-03d8-4e4c-b63a-9be943eb1bb6"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i096d1f06119f449fafe9cac1a48b8400_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi01LTEtMS03MDA3Nw_f9b5f5ad-922c-491c-9738-065532802e3a"
      unitRef="usd">179363000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfNi0xMy0xLTEtNzAwNzc_1fa05ff4-e2fb-4873-b539-6ad81f8b8c6c"
      unitRef="usd">179385000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9cc5b57fa7f04963a7a9f040883b44c2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOC0xMS0xLTEtNzAwNzc_85845994-8e20-4f9b-85c1-c0e284394450"
      unitRef="usd">-9517000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOC0xMy0xLTEtNzAwNzc_d200a6db-2462-430e-8a65-4fdfc79ffb8a"
      unitRef="usd">-9517000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="if166d44b16b444dda0cd485ceb01788d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOS03LTEtMS03MDA3Nw_c70e7e09-5b79-4da2-8b68-dcc4e3773531"
      unitRef="usd">-307077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfOS0xMy0xLTEtNzAwNzc_cfc5e28f-f08f-4ad3-b042-78eb18d7e07e"
      unitRef="usd">-307077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMS0xLTEtNzAwNzc_e2a9930b-a523-4973-a506-2574e7228a28"
      unitRef="shares">78776234</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iefa1af89fb9648679fce07310e5756d1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMy0xLTEtNzAwNzc_0605bf94-0191-4a5d-8386-1095c65a4157"
      unitRef="usd">788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1363bb3470f4a45b7d8cc8d9e9e6aea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtNS0xLTEtNzAwNzc_02cebf89-1384-46e9-b94a-0d504cddc1a9"
      unitRef="usd">3604614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab83a560ba0b4becb4f5f507cccb33e3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtNy0xLTEtNzAwNzc_8b9485c8-ac9e-40ef-a438-73b48b4ccf90"
      unitRef="usd">-3925027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69ae795236fd4899979c4bd46c38a184_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtOS0xLTEtNzAwNzc_b13df168-3df7-49ee-b245-58273ec745d0"
      unitRef="usd">-86455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2e3eb175a484325be7a301736e4107e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMTEtMS0xLTcwMDc3_f1234b90-c822-48e2-96f4-e0f5111e9480"
      unitRef="usd">-10870000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTAtMTMtMS0xLTcwMDc3_95a0f8a8-55f0-47dc-94df-6a7004d23908"
      unitRef="usd">-416950000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ibd833ef8d89041a0a5d6c047bc63754d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMS0xLTEtNzAwNzc_adaa2ae4-b64d-44ce-888f-c446569f8044"
      unitRef="shares">71350365</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ibd833ef8d89041a0a5d6c047bc63754d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMy0xLTEtNzAwNzc_f8c7aeb7-1bb0-4b58-949e-a1884bb18942"
      unitRef="usd">714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7880242152934fbeb18732d8cb58a141_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItNS0xLTEtNzAwNzc_fca54e23-99b9-492d-80c6-45a4f2aff348"
      unitRef="usd">2535476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib399728718c84112836d2a89efc58c0d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItNy0xLTEtNzAwNzc_18eeb035-084a-426c-b8f9-0e2fbd835179"
      unitRef="usd">-1874199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i523ac32f976545eba62aaa06ede3c7da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItOS0xLTEtNzAwNzc_396f2b6e-759e-4f06-9c0f-e56f8dabb05a"
      unitRef="usd">-41806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic95178a09622409fb2fd15e1080134c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMTEtMS0xLTcwMDc3_0b7cd7d9-c10e-49e5-9ee7-e2c8e82c2673"
      unitRef="usd">7024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ba72b9644274960974bf6ff07008c73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTItMTMtMS0xLTcwMDc3_b654aebb-3feb-43cc-af97-dbd54bddde5d"
      unitRef="usd">627209000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTQtNS0xLTEtNzAwNzc_5ca49b4c-21ad-4a21-b4ea-11b309880549"
      unitRef="usd">106183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTQtMTMtMS0xLTcwMDc3_99635814-0df8-44a0-aef5-7e973855bb58"
      unitRef="usd">106183000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtMS0xLTEtNzAwNzc_84b4df42-6ba9-4c8e-a6c8-33d8b7e137f6"
      unitRef="shares">743019</nvax:SharebasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtMy0xLTEtNzAwNzc_1f926456-bc53-4199-93c9-89662e0a6e26"
      unitRef="usd">7000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtNS0xLTEtNzAwNzc_0a1ddd2d-5c4d-4b03-a80f-2220ec07edc3"
      unitRef="usd">30593000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="i55283e03483840778793f0003169278b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtOS0xLTEtNzAwNzc_2e693f77-1567-4f19-8ea3-7dce1586ec3b"
      unitRef="usd">-5399000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTUtMTMtMS0xLTcwMDc3_1fa31234-1f19-40b2-af67-afc573ee83e5"
      unitRef="usd">25201000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMC0xLTEtNzAwNzcvdGV4dHJlZ2lvbjoxMmYxOWFlNzMzOGQ0YjI3OTZmODEzYThlZDdjOGFkZl81NQ_244bfb1d-5d66-459d-b5c3-37294a63df82"
      unitRef="usd">5145000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMS0xLTEtNzAwNzc_e303be49-25ab-4518-a276-735e06294239"
      unitRef="shares">2578967</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMy0xLTEtNzAwNzc_cebfca8e-17ac-4127-9be8-ad56583a2348"
      unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtNS0xLTEtNzAwNzc_f57f4eb4-fe92-4c65-a2b8-e9f667650eb8"
      unitRef="usd">564833000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTYtMTMtMS0xLTcwMDc3_5356b5ae-5d8b-47dc-8d12-0ddbca131456"
      unitRef="usd">564859000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1298fd9885d641b1be701807b92420b3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTctMTEtMS0xLTcwMDc3_762ff342-6ce2-4eca-9120-3a64e352697f"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTctMTMtMS0xLTcwMDc3_9cf61b07-c0ae-4ae9-aab4-035ca482a5cc"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1298fd9885d641b1be701807b92420b3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTgtMTEtMS0xLTcwMDc3_b65c548a-e327-47cc-a3d0-559fe77d6be6"
      unitRef="usd">-2845000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTgtMTMtMS0xLTcwMDc3_554bbb47-f638-4c68-9409-fc5383303888"
      unitRef="usd">-2845000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i4b6e942b2faa424d97c0830be1ea20ad_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTktNy0xLTEtNzAwNzc_b797b75d-ae69-45f5-ba60-295b3616f110"
      unitRef="usd">-575036000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMTktMTMtMS0xLTcwMDc3_6a8cb7b5-2140-4556-bbac-fc785d67c2a3"
      unitRef="usd">-575036000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5dad49772b0f48038418785e8e761874_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMS0xLTEtNzAwNzc_c4644608-6cf5-4017-932c-4019e1f5bbf3"
      unitRef="shares">74672351</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5dad49772b0f48038418785e8e761874_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMy0xLTEtNzAwNzc_a7d41686-0ff6-4703-9340-6723b26e7b29"
      unitRef="usd">747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice1514b2ba3b4666a00d9813765198b7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtNS0xLTEtNzAwNzc_cd2e8f11-2efe-49ba-a2b0-4d348e4c15cb"
      unitRef="usd">3237085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec245d5ef2c943f88458628a12c5efa7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtNy0xLTEtNzAwNzc_99568bc2-0bf0-4895-8192-ac9d48ddb92e"
      unitRef="usd">-2449235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fc8de8da83641cc91ef608da7bf7d7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtOS0xLTEtNzAwNzc_1431682c-a058-4b7e-91de-4837b02d26a0"
      unitRef="usd">-47205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36438295aede46c58b4392a1543df581_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMTEtMS0xLTcwMDc3_5520fef2-9bef-4398-ba44-4e490e7f698c"
      unitRef="usd">4170000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b3583256bab459492a5d569f0fabc95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yNS9mcmFnOmE1ODFhYjMzYTYxODQyMGVhMzg2ZjYxMTFlNWU3NmJmL3RhYmxlOmVkM2Q3ZTM4MDRkYjQ5MDJhOGNkNmJkMTU3NDE3MzQ3L3RhYmxlcmFuZ2U6ZWQzZDdlMzgwNGRiNDkwMmE4Y2Q2YmQxNTc0MTczNDdfMjAtMTMtMS0xLTcwMDc3_16e663af-a8a5-4c44-9263-0ea9deb87d29"
      unitRef="usd">745562000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMy0xLTEtMS03MDA3Nw_be0e94a3-b2ab-43d1-b99c-74e8f0d5cc2f"
      unitRef="usd">-307077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMy0zLTEtMS03MDA3Nw_fd04c235-d8a2-4aad-aede-e5e59826d806"
      unitRef="usd">-575036000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNS0xLTEtMS03MDA3Nw_52ebe00b-c114-4d9b-bf17-2a792a3c1ddb"
      unitRef="usd">13485000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNS0zLTEtMS03MDA3Nw_5734f9f6-0fa1-4d6b-8baa-9e65372767ce"
      unitRef="usd">4727000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNy0xLTEtMS03MDA3Nw_e111240e-f2fa-44a1-a01e-51b3ce928f6b"
      unitRef="usd">70981000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNy0zLTEtMS03MDA3Nw_c027b1c2-4453-40f0-b63c-258aa1a29e98"
      unitRef="usd">106183000</us-gaap:ShareBasedCompensation>
    <us-gaap:InventoryWriteDown
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0xLTEtMS04NDEzOA_70eae125-4a19-400f-962f-6047a9fa6899"
      unitRef="usd">155662000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0zLTEtMS04NDIwMA_62a32cf5-8faf-47dc-8f60-44805b32354b"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <nvax:OperatingAndFinanceLeaseWriteOff
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0xLTEtMS03MDA3Nw_04f65e7a-f866-4151-8c7a-bab8bf0d8316"
      unitRef="usd">-3291000</nvax:OperatingAndFinanceLeaseWriteOff>
    <nvax:OperatingAndFinanceLeaseWriteOff
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOC0zLTEtMS03MDA3Nw_39f278a0-2c78-42d0-8f80-3dffa7fa928f"
      unitRef="usd">12707000</nvax:OperatingAndFinanceLeaseWriteOff>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOS0xLTEtMS03MDA3Nw_90a8364b-bc39-4fba-ac20-39780da92493"
      unitRef="usd">642000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfOS0zLTEtMS03MDA3Nw_5274bae2-77a7-4464-a505-ea74339f7f95"
      unitRef="usd">-3855000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTEtMS0xLTEtNzAwNzc_d1b828ec-4f7e-4e0f-95b2-0e00ba8f00ec"
      unitRef="usd">403725000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTEtMy0xLTEtNzAwNzc_f407e322-95b9-468f-9a18-9881e8167226"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTItMS0xLTEtNzAwNzc_2a51bc9c-55ea-46dc-9345-b450a6dfad8a"
      unitRef="usd">-112845000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTItMy0xLTEtNzAwNzc_6864e884-cf53-4626-8141-e88466c45878"
      unitRef="usd">-193004000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTMtMS0xLTEtNzAwNzc_86546006-57a9-4084-aa1b-66372510c831"
      unitRef="usd">179158000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTMtMy0xLTEtNzAwNzc_b11fbbc5-0dda-454c-9388-5d45b6662bce"
      unitRef="usd">115212000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTQtMS0xLTEtNzAwNzc_686eb990-0b52-42d3-888b-679189c2cf6a"
      unitRef="usd">-76809000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTQtMy0xLTEtNzAwNzc_7de2a1b1-1b91-4189-a776-a02ef5c9e99d"
      unitRef="usd">946845000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTUtMS0xLTEtNzAwNzc_b9766fc2-0a77-4ef8-91b9-a659239ce4a0"
      unitRef="usd">-259413000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTUtMy0xLTEtNzAwNzc_496c0c44-2f35-4ed0-a807-a6adc389c5ac"
      unitRef="usd">807497000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTgtMS0xLTEtNzAwNzc_dbbaa9db-3a8f-4aca-88f7-51cca51c12d4"
      unitRef="usd">41402000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTgtMy0xLTEtNzAwNzc_e362652c-2ee3-4dca-bd5c-034c6daff0b4"
      unitRef="usd">28932000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTktMS0xLTEtNzAwNzc_b994aca4-0fc1-408b-9f45-7cd77e7fe2a1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMTktMy0xLTEtNzAwNzc_f22a9a91-f406-4907-8049-2f3e88657636"
      unitRef="usd">2167000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjAtMS0xLTEtNzAwNzc_6b3dee7c-e90a-4f27-a17f-7f2fbf6afdbe"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjAtMy0xLTEtNzAwNzc_d9b87fe6-e251-416f-a00a-71da85ec780e"
      unitRef="usd">159807000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjEtMS0xLTEtNzAwNzc_4abdd1bb-edc0-4063-82d8-bf103f3c83a1"
      unitRef="usd">-41402000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjEtMy0xLTEtNzAwNzc_ec04fa68-d566-4fce-9c3b-7f702262ed43"
      unitRef="usd">128708000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjQtMS0xLTEtNzAwNzc_a26653c8-a5e3-4ce2-8e8a-0e576d237b50"
      unitRef="usd">179385000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjQtMy0xLTEtNzAwNzc_90d674a5-48af-4a98-b65d-3637e2f82392"
      unitRef="usd">564859000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjUtMS0xLTEtNzAwNzc_bb02f1d5-b12a-41fd-b78f-54da6e9e5e5a"
      unitRef="usd">1050000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjUtMy0xLTEtNzAwNzc_b1ed3eb3-156b-400e-baa8-1fe446746fef"
      unitRef="usd">26903000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjYtMS0xLTEtNzAwNzc_678dbdd2-6417-41b7-a96b-81416938585b"
      unitRef="usd">15911000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjYtMy0xLTEtNzAwNzc_e963d87b-145c-42df-9021-eee461733298"
      unitRef="usd">53618000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjctMS0xLTEtNzAwNzc_875242e8-b3ff-4e92-bb02-f1d44b668fc2"
      unitRef="usd">164524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjctMy0xLTEtNzAwNzc_949835ae-48ef-4aa6-a090-b2e753fd00e7"
      unitRef="usd">538144000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjgtMS0xLTEtNzAwNzc_7e1e655a-e57c-4104-8a26-35e7a24252d6"
      unitRef="usd">-4453000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjgtMy0xLTEtNzAwNzc_aac27093-89d9-4020-a8a4-1b782a51e105"
      unitRef="usd">-348000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjktMS0xLTEtNzAwNzc_20ecc0ec-2ff6-461e-8ca9-df7f8073c0e1"
      unitRef="usd">-140744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMjktMy0xLTEtNzAwNzc_b15a68fa-541a-4f0f-a9cf-51cb216b1e0a"
      unitRef="usd">1474001000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzAtMS0xLTEtNzAwNzc_50dc1c61-9914-4042-9aec-a18389fe8d6d"
      unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4ba72b9644274960974bf6ff07008c73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzAtMy0xLTEtNzAwNzc_991105fa-640c-40af-b98f-258b14455432"
      unitRef="usd">648738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzEtMS0xLTEtNzAwNzc_5ee608fa-99a5-4852-b134-fda844d27a83"
      unitRef="usd">1387515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b3583256bab459492a5d569f0fabc95_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzEtMy0xLTEtNzAwNzc_5f1b9808-6721-48a8-8a05-49387fd14d94"
      unitRef="usd">2122739000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzYtMS0xLTEtNzAwNzc_6b14e19c-1b98-4847-aaf1-fb7eb76bc39a"
      unitRef="usd">69366000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzYtMy0xLTEtNzAwNzc_30f32306-9ad4-475d-b53d-1450e976f5e8"
      unitRef="usd">28826000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzctMS0xLTEtNzAwNzc_5ce87283-3199-4a9e-b6c0-e98c9ee9d11d"
      unitRef="usd">17890000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfMzctMy0xLTEtNzAwNzc_961d68e9-5dc5-41f9-9297-27a21b7f3402"
      unitRef="usd">11037000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDAtMS0xLTEtNzAwNzc_2546073e-b9b5-444d-97a6-cfd7315a5b72"
      unitRef="usd">8604000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDAtMy0xLTEtNzAwNzc_1d1a270b-afd8-4d8f-af87-f3bfb2228671"
      unitRef="usd">10046000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDEtMS0xLTEtNzAwNzc_61f3c126-57f8-44c3-afe3-f7b717faac0b"
      unitRef="usd">17778000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8yOC9mcmFnOjJmMDU5ZmEyZjUwNjQ3NjRhMWMxNWNiYjJlZTIwNmMxL3RhYmxlOjljNzY3Y2Y4ZDg4NzQ5ZDA5NzRiYzVkNGVhZjM2MjU5L3RhYmxlcmFuZ2U6OWM3NjdjZjhkODg3NDlkMDk3NGJjNWQ0ZWFmMzYyNTlfNDEtMy0xLTEtNzAwNzc_41226d33-4bb9-4954-b7d9-b1f2deed5ff0"
      unitRef="usd">3017000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNC9mcmFnOjYzY2EyYzY0MmYxYTRmZWY4YzUwNjJlYWZmZGE4MDNhL3RleHRyZWdpb246NjNjYTJjNjQyZjFhNGZlZjhjNTA2MmVhZmZkYTgwM2FfMTU5NQ_36643579-64b1-43fb-a4b6-d7fdcc525644">Organization and Business&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Novavax, Inc. (&#x201c;Novavax,&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#x2019;s coronavirus vaccine, NVX-CoV2373, and its lead influenza vaccine candidate, a quadrivalent influenza vaccine, previously known as NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. NVX-CoV2373 and the Company&#x2019;s influenza vaccine include the use of the Company's proprietary Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; adjuvant. The Company is developing various variant vaccines, including for Omicron subvariants, and bivalent formulations with prototype vaccine (NVX-CoV2373). The Company has announced preclinical boosting data for NVX-CoV2373, NVX-CoV2515, and bivalent formulations which demonstrated strong antibody levels. The Company is also participating in an ongoing Phase 3 strain change trial to assess safety and antibody responses following primary vaccination with mRNA vaccines.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of June 30, 2022, the Company had received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#x201c;EUA&#x201d;) from multiple regulatory authorities globally for NVX-CoV2373, including by the World Health Organization (&#x201c;WHO&#x201d;), as well as the European Medicines Agency's (&#x201c;EMA&#x201d;) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (&#x201c;MHRA&#x201d;), both of which are considered regulatory authorities that apply stringent standards and meet the WHO standards for quality, safety, and efficacy in their regulatory review process. In July 2022, the Company received emergency use authorization for NVX-CoV2373 from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company commenced commercial shipments of NVX-CoV2373 doses under the brand name Nuvaxovid&#x2122; in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMA_32122b51-0b67-4bf2-8ca8-243f67399469">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss, changes in stockholders&#x2019; equity (deficit), and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Accumulated other comprehensive income included a foreign currency translation loss of $10.9 million and $1.4 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition - Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Product sales are associated with the Company&#x2019;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#x201c;APAs&#x201d;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#x2019;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs which were expensed prior to regulatory authorization as described under the caption &#x201c;Inventory&#x201d; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Inventory is recorded at the lower of cost or net realizable value under the First In, First Out (&#x201c;FIFO&#x201d;) methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, the services and products of third-party suppliers, and the application of manufacturing overhead. The Company utilizes third-party contract manufacturing organizations (&#x201c;CMOs&#x201d;), contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;), and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020 and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; (&#x201c;CECL&#x201d;) model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management is currently evaluating the effect of the guidance and does not expect it to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxNg_76ec67b5-04b0-4ecf-a142-f7fcc01db9af">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss, changes in stockholders&#x2019; equity (deficit), and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Accumulated other comprehensive income included a foreign currency translation loss of $10.9 million and $1.4 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfMTQ1MQ_c38dcaf6-311a-4b1b-ace8-c2815ece1d1a"
      unitRef="usd">-10900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfMTQ1OA_fe6608e4-1f34-4a52-badc-35f2bdc6bd3e"
      unitRef="usd">-1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfMTg2Ng_53f4c064-8699-447d-a540-e3869ff11f0a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxNw_3faf240b-b6b6-4ed1-951c-1bc5d890c94d">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications have no material effect on previously reported financial position, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxOA_ac674b7b-a20d-41ff-9050-71ae1b3e5e35">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMQ_da58b4d1-6582-4d3f-9e70-6dce26bcc17e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition - Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Product sales are associated with the Company&#x2019;s NVX-CoV2373 supply agreements, sometimes referred to as advance purchase agreements (&#x201c;APAs&#x201d;), with various international governments. The Company recognizes revenue from product sales based on the transaction price per dose calculated in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. If an APA includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, the Company constrains the price until it is probable that a significant reversal in revenue recognized will not occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMg_9e1ad2c6-e27b-410d-9859-3fe2224e8956">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#x2019;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs which were expensed prior to regulatory authorization as described under the caption &#x201c;Inventory&#x201d; below.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYxOQ_e5aa6107-7fec-48dc-bce1-0e183efb0dc3">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Inventory is recorded at the lower of cost or net realizable value under the First In, First Out (&#x201c;FIFO&#x201d;) methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, the services and products of third-party suppliers, and the application of manufacturing overhead. The Company utilizes third-party contract manufacturing organizations (&#x201c;CMOs&#x201d;), contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;), and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF8zNy9mcmFnOjBmNDhjY2U3NDZlMDQyNDI4N2VhMGEwN2E0MDNjNGRkL3RleHRyZWdpb246MGY0OGNjZTc0NmUwNDI0Mjg3ZWEwYTA3YTQwM2M0ZGRfNzYyMw_f7926040-c9c8-4d2a-8bac-70c7ab01ab99">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020 and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; (&#x201c;CECL&#x201d;) model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The ASU is effective for the Company beginning on January 1, 2023. Management is currently evaluating the effect of the guidance and does not expect it to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplified the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the new standard removed the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removed certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and simplified the diluted earnings per share calculation for convertible instruments. The Company adopted ASU 2020-06 on January 1, 2022 using a modified retrospective approach, which did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTQ3MQ_dea22a5a-2729-4480-b159-8fb94c4b4c20">Revenue &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's accounts receivable included $165.6&#160;million and $419.7&#160;million related to amounts that were billed to customers and $29.0&#160;million and $35.3&#160;million related to amounts which had not yet been billed to customers as of June&#160;30, 2022 and December&#160;31, 2021, respectively. During the six months ended June&#160;30, 2022, changes in the Company's accounts receivables and deferred revenue balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract receivables:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,069,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount is comprised of $701.5&#160;million and $1.4&#160;billion of current Deferred revenue and $814.6&#160;million and $172.5&#160;million of non-current Deferred revenue as of June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, was approximately $5&#160;billion as of June&#160;30, 2022. The timing to fulfill performance obligations related to grant agreements will depend on the results of the Company's research and development activities, including clinical trials, and delivery of doses. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype NVX-CoV2373 under certain of our APAs. Failure to meet regulatory milestones, product volume, or delivery timing obligations under the Company&#x2019;s APA agreements may require the Company to refund portions of upfront payments or result in reduced future payments, which could result in a material and adverse effect on our unsatisfied performance obligations. The remaining unfilled performance obligations not related to grant agreements or APAs are expected to be fulfilled in less than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized grant revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government partnership (&#x201c;OWS&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Defense (&#x201c;DoD&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bill &amp;amp; Melinda Gates Foundation (&#x201c;BMGF&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;U.S. Government Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. government partnership consists of an agreement (&#x201c;the &#x201c;OWS Agreement&#x201d;) with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (&#x201c;OWS&#x201d;). In July 2021, the U.S. government instructed the Company to prioritize alignment with the FDA on the Company's analytic methods before conducting additional U.S. manufacturing and further indicated that the U.S. government would not fund additional U.S. manufacturing until such alignment was made. In June 2022, the U.S. government agreed to the manufacture and delivery of approximately 3&#160;million doses of NVX-CoV2373 under the OWS Agreement as the Company had completed alignment with the FDA&#x2019;s analytic methods. The Company updated its estimate-at-completion to reflect the impact of this authorization to the recognition of the fixed fee under the contract. In July 2022, the Company formally modified the OWS Agreement to provide for an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373, and the Company modified its existing agreement with the U.S. Department of Defense (&#x201c;DoD&#x201d;) to provide for an initial delivery of approximately 0.2&#160;million doses of NVX-CoV2373 (see Note 15).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022, the Company recognized $1.7&#160;million and $9.2&#160;million, respectively, in revenue related to sales-based royalties. During the three months ended June 30, 2022, the Company recognized a $20.0&#160;million milestone payment upon the first sale of NVX-CoV2373 in Japan. During the three months ended June&#160;30, 2021, the Company recognized $23.5&#160;million in revenue related to sales-based royalties. During the three months ended March 31, 2021, the Company did not recognize any revenue related to sales-based royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Advance Purchase Agreements (APAs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the Company&#x2019;s contracted supply commitment with Gavi, which includes the supply obligation of its licensed partner, Serum Institute of India Private Limited (&#x201c;SIIPL&#x201d;), 1.1&#160;billion doses of NVX-CoV2373 are to be made available to countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. The Novavax portion is a supply agreement that contemplates that the Company will manufacture and distribute 350&#160;million doses. Under that agreement with Gavi, the Company received an upfront payment of $350&#160;million from Gavi in 2021 and an additional payment of $350&#160;million in the first quarter of 2022 related to the Company&#x2019;s achieving WHO Emergency Use Listing. Although Novavax is prepared to deliver the quantities of NVX-CoV2373 doses to Gavi under the terms of the supply agreement, the Company was notified by Gavi of its intent to seek to revise the number and timing of doses of NVX-CoV2373 supplied by Novavax under such agreement. Furthermore, Gavi may seek partial or full recovery of the prior nonrefundable payments it has made to Novavax. The Company&#x2019;s position is that Gavi has no contractual right to recover prior nonrefundable payments. To date, Novavax has not received an order from Gavi and the timing and quantities of future orders to deliver NVX-CoV2373 to the COVAX facility are unclear.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the Company&#x2019;s SARS-CoV-2 Vaccine Supply Agreement, originally entered into in October 2020 (the &#x201c;Original UK Supply Agreement&#x201d;) with The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#x201c;Authority&#x201d;), the Authority agreed to purchase 60&#160;million doses of NVX-CoV2373. In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#x201c;Amended and Restated UK Supply Agreement&#x201d;) with the Authority, under which the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#x2019;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#x201c;JCVI&#x201d;) (see Note 15).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has an APA with the European Commission (&#x201c;EC&#x201d;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of NVX-CoV2373, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. The Company is in the process of finalizing a revised delivery schedule for the remaining 42&#160;million doses of the 70&#160;million previously committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. In July and August 2022, the Company was notified by the EC that it was cancelling 5&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to 65&#160;million doses (see Note 15).&lt;/span&gt;&lt;/div&gt;Collaboration, License, and Supply Agreements&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Serum Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of NVX-CoV2373. SIIPL agreed to purchase the Company&#x2019;s Matrix-MTM adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of NVX-CoV2373 in SIIPL&#x2019;s licensed territory solely for use in the manufacture of NVX-CoV2373. The Company and SIIPL equally split the revenue from SIIPL&#x2019;s sale of NVX-CoV2373 in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and Serum Life Sciences Limited (&#x201c;SLS&#x201d;) under which SIIPL and SLS supply the Company with NVX-CoV2373 for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#x2122; adjuvant supplied by the Company. The Company has expanded its license and supply arrangements with SIIPL to include its proprietary COVID-19 variant antigen candidate(s) so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, and supply such variant vaccine to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373 in Japan. Under the agreement, Takeda purchases the Company&#x2019;s Matrix-M&#x2122; adjuvant to manufacture NVX-CoV2373 and the Company is entitled to receive payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of NVX-CoV2373 in the low to middle double-digit range. During the three months ended June 30, 2022, the Company recognized a milestone payment of $20.0&#160;million upon the first sale in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has a collaboration and license agreement with SK bioscience, Co., Ltd. (&#x201c;SK bioscience&#x201d;) to manufacture and commercialize NVX-CoV2373 for sale to the governments of Korea, Thailand, and Vietnam. SK bioscience pays a royalty in the low to middle double-digit range. Additionally, the Company has a manufacturing supply arrangement with SK bioscience under which SK bioscience supplies the Company with the antigen component of NVX-CoV2373 for use in the final drug product globally, including product to be distributed by the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In July 2022, the Company signed an additional agreement with SK bioscience for the technology transfer of the Company&#x2019;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants (see Note 15). The companies also signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Other Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, NVX-CoV2373, and in doing so, recognizes that significant costs may be incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNjY_720575ea-5105-4e94-8c48-a8965c6b74e8"
      unitRef="usd">165600000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNzM_d0233146-8d5d-48a6-92a0-11b8f3776129"
      unitRef="usd">419700000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTI5_edc88068-49ff-4201-84de-1b1d698a45eb"
      unitRef="usd">29000000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTM2_4e43913a-0cbb-46e7-aa5e-b6640d09b857"
      unitRef="usd">35300000</us-gaap:UnbilledContractsReceivable>
    <nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTQ3Mg_73fa8616-16d1-41a6-be70-411292cbb63e">During the six months ended June&#160;30, 2022, changes in the Company's accounts receivables and deferred revenue balances were as follows (in thousands):&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract receivables:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,069,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount is comprised of $701.5&#160;million and $1.4&#160;billion of current Deferred revenue and $814.6&#160;million and $172.5&#160;million of non-current Deferred revenue as of June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi0xLTEtMS03MDA3Nw_b442634b-7cdb-4c84-bdb7-ae4b2638d70c"
      unitRef="usd">454993000</us-gaap:ReceivablesNetCurrent>
    <nvax:ReceivablesNetCurrentAdditions
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi0zLTEtMS03MDA3Nw_142e3d40-0d28-4e08-9e6b-352be8dc33a5"
      unitRef="usd">808713000</nvax:ReceivablesNetCurrentAdditions>
    <nvax:ReceivablesCurrentNetDeductions
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi01LTEtMS03MDA3Nw_82e77136-962e-4eaf-8e3b-f00bec3e140f"
      unitRef="usd">1069173000</nvax:ReceivablesCurrentNetDeductions>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfMi03LTEtMS03MDA3Nw_b55c3b48-e962-4f67-b65b-fb0150d08301"
      unitRef="usd">194533000</us-gaap:ReceivablesNetCurrent>
    <nvax:DeferredRevenueCurrentAndNonCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC0xLTEtMS03MDA3Nw_5df4dcb0-6749-494b-8460-d8813542d82a"
      unitRef="usd">1595472000</nvax:DeferredRevenueCurrentAndNonCurrent>
    <nvax:DeferredRevenueCurrentAdditions
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC0zLTEtMS03MDA3Nw_472dfdad-40b5-407a-8970-565a7fe52764"
      unitRef="usd">49107000</nvax:DeferredRevenueCurrentAdditions>
    <nvax:DeferredRevenueCurrentDeductions
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC01LTEtMS03MDA3Nw_a9f52657-c057-46bb-a199-199806d748fd"
      unitRef="usd">128432000</nvax:DeferredRevenueCurrentDeductions>
    <nvax:DeferredRevenueCurrentAndNonCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjExYjdiMGUxMzhiMTRkYjNiMmY2Mzk2MTVhYzg5YmMyL3RhYmxlcmFuZ2U6MTFiN2IwZTEzOGIxNGRiM2IyZjYzOTYxNWFjODliYzJfNC03LTEtMS03MDA3Nw_099fb986-74b2-40f9-a50a-9d37c56f924d"
      unitRef="usd">1516147000</nvax:DeferredRevenueCurrentAndNonCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDAz_f3370d7e-7d6e-4a31-8aa8-fed4e0884ae7"
      unitRef="usd">701500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDEw_9dbd40d5-9d29-4eda-b5b5-770e66dccaff"
      unitRef="usd">1400000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDQ1_b2c22db4-a110-46f2-ba0b-8ce54f1b6653"
      unitRef="usd">814600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNDUy_50aeb9d4-1f72-49d2-9a5d-b842683874eb"
      unitRef="usd">172500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4f4b6f5acde242c3ace67f89c0df4c69_I20220630"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfNzIx_f0c01316-167f-4cb0-8e78-79133af11af2"
      unitRef="usd">5000000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i4f4b6f5acde242c3ace67f89c0df4c69_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTE2Ng_a93b6a94-107e-42d0-84e9-0c79b6273cf8">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTQ3Mw_0c77827c-d081-4f7a-9556-d4c85a6503d2">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized grant revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government partnership (&#x201c;OWS&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Defense (&#x201c;DoD&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bill &amp;amp; Melinda Gates Foundation (&#x201c;BMGF&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:Revenues
      contextRef="id9a7f0ae8be1457ba975ad86d4101b1b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi0xLTEtMS03MDA3Nw_f9ce9d80-d4a1-4c6b-9cc0-d9ee1eb4ad01"
      unitRef="usd">107774000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21d13d4609664545a43b24e97b8b072f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi0zLTEtMS03MDA3Nw_f08accc6-82c3-4d2e-8d7e-992d86d6c969"
      unitRef="usd">239493000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac2796d80cfb471e994d0da8cd0437fd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi01LTEtMS03MDg0NA_cf334c6c-7bb0-4c39-af5e-c457bd8de8de"
      unitRef="usd">207075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c49f33057824088903829819b53beb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMi03LTEtMS03MDg0NA_8f18b383-17c0-45f4-afad-88826a1ef096"
      unitRef="usd">603053000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieea0fc725c2844378d5f099dfa98477e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy0xLTEtMS03MDA3Nw_3390cab5-0858-46ad-8673-1e0d369d8711"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8eaafe4f9b3348c5b10a0f78e3633e5c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy0zLTEtMS03MDA3Nw_3d8637c6-69dd-471f-b1b6-10779effad49"
      unitRef="usd">1041000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51025fa58fb149ac918fe80236b6303e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy01LTEtMS03MDg0NA_38b4de13-1efd-4567-9445-bbef97160827"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04667b8d3a384b2d9245c1a4fa29d96a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfMy03LTEtMS03MDg0NA_06405ff5-df96-4876-a80e-7ea5c2c616d8"
      unitRef="usd">20185000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a710118bda240b8b211f8a0825036c5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC0xLTEtMS03MDA3Nw_cfd2bf01-63fd-4e63-ae82-988e943a7e68"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i551af433d1e246e89e595442fa319aee_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC0zLTEtMS03MDA3Nw_066d9605-3fea-440f-846b-5eae2cfe14ed"
      unitRef="usd">31955000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ac4f312e40a4461a57f852f3ce23cc4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC01LTEtMS03MDg0NA_c6302cd2-211f-4b72-bc42-33060bdb7aba"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie31f109abc1642b28e93db64fafa6102_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNC03LTEtMS03MDg0NA_145a6fda-3269-44d4-b00b-301ce2f98e69"
      unitRef="usd">93516000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0592102fe89f4264bfef8d819f322688_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS0xLTEtMS03MDA3Nw_449cb408-955f-444a-b6f0-a3038cc9ac7c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8140e44c727f43f39853c42e69847f31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS0zLTEtMS03MDA3Nw_99cf9bfa-73b7-4bbb-82f0-aea741a31441"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifcbc5b4644bd44feaef5b01c2b51ce35_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS01LTEtMS03MDg0NA_a8d284df-39e5-41b5-a345-00d8ded9741f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a08399d05224436b9583db28b4671a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNS03LTEtMS03MDg0NA_0226ca60-4638-464f-820d-61608a18c1d4"
      unitRef="usd">2628000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64169e1b64be465ba651f225a820a0a7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi0xLTEtMS03MDA3Nw_7c8b46c9-b734-4515-95d0-1e8d2710380b"
      unitRef="usd">107774000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i740226150bb146dfbab7548d73d95ec3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi0zLTEtMS03MDA3Nw_aa8ed260-5441-44f2-b5cd-0fac40914f0b"
      unitRef="usd">272489000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02740f8f66c940f49f4d45435b5f33fb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi01LTEtMS03MzI4OQ_e6765784-3d10-4d1e-8f42-4ff2df96e85b"
      unitRef="usd">207075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4244f94bb3dc4fe284264e5bcde0de65_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RhYmxlOjdjYWY3Y2IwZjVjMjRhODVhNzhjNDlmZmMwYTY0ZDE1L3RhYmxlcmFuZ2U6N2NhZjdjYjBmNWMyNGE4NWE3OGM0OWZmYzBhNjRkMTVfNi03LTEtMS03MzI4OQ_54c9c11f-dcc4-46f0-95ce-817ce9a35a11"
      unitRef="usd">719382000</us-gaap:Revenues>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i52b84098b8a748f8bfc7222df25285a4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDcyODY2Nw_bfda9a9e-e648-4941-866d-ee34cf61f12e"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDcyODY4MA_c72967a8-eee7-44fe-803d-d85628fc8471"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1NTA2Nw_c7201d53-6c3d-4092-ad44-da59b20fafc0"
      unitRef="dose">200000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <us-gaap:Revenues
      contextRef="i398e1d19b77d4b66b82d84fa9532c022_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMTMxNw_78447692-1158-43b2-ab1a-dbd91622f610"
      unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64d61c79ddcb4213a12c1d9637bd0819_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MDk3Mg_85194190-4062-481c-86f6-42296f879ff8"
      unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTAxMw_0b2587c9-cd8b-4117-919f-37f1567ab1fe"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTAxMw_b7b60680-669b-46bf-ba7b-bda4063be69e"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:Revenues
      contextRef="i3e25182664da42259f8fddcc4e30be81_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTA3OA_890ac430-a11a-4415-9dc9-1447f1f1afd8"
      unitRef="usd">23500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7504caa392fc4b198ba675a27efbc513_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTA3MTA3OA_f9f2c548-ad08-4a66-b2f2-483ee372a04c"
      unitRef="usd">23500000</us-gaap:Revenues>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="i2e0b072a00284d5e86b6ae1955e77255_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODU3NQ_13fac051-5b9b-4937-9360-10f21311ba64"
      unitRef="dose">1100000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="i472e0a435709425884b630fb4e4abe4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODU0OA_46eb7e4b-d994-407e-ad42-b0ef680c2d03"
      unitRef="dose">350000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic03121026d664feabb6f6d6ce32a036e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODU2MQ_0b9e21f2-a1a3-44c8-a0d3-90f137e6dd14"
      unitRef="usd">350000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0594bb0e3d49426d8546ac3ef41f5312_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODUzNA_c4f2819b-e5c0-4459-96d8-6e3118932e19"
      unitRef="usd">350000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i92cf89b34fba4758b7ea6b29bb2b4277_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1NTA5MQ_d512411b-f87d-4a1b-b862-95edb57d456d"
      unitRef="dose">60000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="ibe5f264f5aae46269f4b5c7f917258db_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTEyNjQyNg_8e93467f-e4aa-4936-8655-2001ad59ecbc"
      unitRef="dose">1000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="i7ce520d7761743ec86392cca9a2d1a9d_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMjc0ODc3OTEyNjQ2MA_b4aebde9-11ff-4ec1-91e4-f65cfe44dae3"
      unitRef="dose">15000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="i603827ce2ac64ffaac1b057ac83a74b8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ0Mw_c2f12b87-4480-4320-b4f3-49135da7c8dd"
      unitRef="dose">20000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQzMA_b6c8b378-eb58-4f13-9f5b-c15088e4c3dd"
      unitRef="dose">100000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption
      contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ1NQ_d5b9fb07-7436-4ea8-925e-228c612380d4"
      unitRef="dose">100000000</nvax:PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="ife8416d2c5f7415e89f5022b56743ac4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ2OA_d5d05c8d-b02a-4d0b-900e-0967bf17e266"
      unitRef="dose">200000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesRemaining
      contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1ODQxOQ_ba004901-166d-4bde-9196-c301b6a1bb38"
      unitRef="dose">42000000</nvax:PurchaseAgreementNumberOfDosesRemaining>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i2d0012acfa204c92bb3e3d28118477f7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1ODQwNw_0c5fb594-aeed-48a1-af74-0fd3dff3432c"
      unitRef="dose">70000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfDosesCancelled
      contextRef="i750e9cc522fe4374bb3945dd8f61ee58_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc0ODQ5Mw_216f6767-c485-4dc5-afc9-f2b6c88cd903"
      unitRef="dose">5000000</nvax:PurchaseAgreementNumberOfDosesCancelled>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="i750e9cc522fe4374bb3945dd8f61ee58_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80My9mcmFnOmJlNTAxODhlYWQxMjQwMDRhMjgzZTNkOWU2MjU4M2ZlL3RleHRyZWdpb246YmU1MDE4OGVhZDEyNDAwNGEyODNlM2Q5ZTYyNTgzZmVfMzg0ODI5MDc1ODQzMQ_941fc2db-ad87-4d83-b04b-6de2cb343e14"
      unitRef="dose">65000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PotentialFutureMilestonePayments
      contextRef="i3c67801e2acb4e6bb800915f121b2eaf_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF80Ni9mcmFnOjNmN2I4NmNkZDM4ZjRkZjZhYjkxZDdkZTY0NjI5YjFhL3RleHRyZWdpb246M2Y3Yjg2Y2RkMzhmNGRmNmFiOTFkN2RlNjQ2MjliMWFfMTU2Mw_5cd50fdc-ef3f-48c1-8e9e-74c90bed97f9"
      unitRef="usd">20000000</nvax:PotentialFutureMilestonePayments>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RleHRyZWdpb246MGRkNzRkNjgxOTdkNDY0MThkZTI1MWJhNWY3ZWIxMDlfMzkz_8a00b301-09bf-4d7e-83fa-aa4a25b0e263">Cash, Cash Equivalents, and Restricted Cash&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of the same such amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Classified as Other non-current assets as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RleHRyZWdpb246MGRkNzRkNjgxOTdkNDY0MThkZTI1MWJhNWY3ZWIxMDlfMzky_240cfa87-af5a-45f2-8f25-49ad1f17ccae">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of the same such amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Classified as Other non-current assets as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMS0xLTEtMS03MDA3Nw_81b3218a-ded3-46b3-9489-8fc5e5fc3274"
      unitRef="usd">1375587000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMS0zLTEtMS03MDA3Nw_9055ac00-7881-44dd-86dd-93e39fa0ebdc"
      unitRef="usd">1515116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMi0xLTEtMS03MDA3Nw_dfd96597-b0df-49ea-8277-e42ad8ec20a6"
      unitRef="usd">10274000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMi0zLTEtMS03MDA3Nw_2882a503-ce6f-47a8-a50f-76307209937d"
      unitRef="usd">11490000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMy0xLTEtMS03MDA3Nw_1ce2ea2f-108e-4b95-923b-091484901cf6"
      unitRef="usd">1654000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfMy0zLTEtMS03MDA3Nw_3ad5dba3-ca4e-4a98-ad0a-29f23fb1c0fc"
      unitRef="usd">1653000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfNC0xLTEtMS03MDA3Nw_ff47fbf3-98db-459f-af15-d97f30d19668"
      unitRef="usd">1387515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81Mi9mcmFnOjBkZDc0ZDY4MTk3ZDQ2NDE4ZGUyNTFiYTVmN2ViMTA5L3RhYmxlOjNhYzU2N2RiZjYxNDRkMmNiODIwMWIzMTMyMzBhNzgwL3RhYmxlcmFuZ2U6M2FjNTY3ZGJmNjE0NGQyY2I4MjAxYjMxMzIzMGE3ODBfNC0zLTEtMS03MDA3Nw_350cee61-7c92-491d-b5b1-f30c341cf4c4"
      unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RleHRyZWdpb246MWI0YWFlY2I2YjgyNDM5Zjk2OGJhMjQ0OGYzMjI3ZmJfNjg1_cd919a75-7178-45db-8dba-59fbaec84fef">Fair Value Measurements&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;All investments are classified as cash and cash equivalents as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are recorded at cost, which approximate fair value due to their short-term nature. Pricing of the Company's Notes&#160;(see Note&#160;10) has been estimated using other observable inputs, including the price of the Company's common stock, implied volatility, interest rates, and credit spreads among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six&#160;months ended June&#160;30, 2022 and 2021, the Company did not have any transfers between levels&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RleHRyZWdpb246MWI0YWFlY2I2YjgyNDM5Zjk2OGJhMjQ0OGYzMjI3ZmJfNjg0_ce46b99e-f41c-4b5a-acf2-10bce174a3dc">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;All investments are classified as cash and cash equivalents as of June&#160;30, 2022 and December&#160;31, 2021, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i99533f95b79b45b992b718e063053587_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi0xLTEtMS03MDA3Nw_5bf8ff54-1f9a-4dfb-bdbb-b389b46d9b09"
      unitRef="usd">500885000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifd7188cfe5d6445c9ccfc63027d2b369_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi0zLTEtMS03MDA3Nw_192a197f-b4f6-4dfa-b1c3-701cbab46658"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia17025047e164926ae984921e6dabb68_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi01LTEtMS03MDA3Nw_da85ecaa-2209-40e9-a4bd-f1c381ad9d47"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i194bb03495444c89b63efab4dad063fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi03LTEtMS03MDA3Nw_f5ed1936-e7d7-4736-90f3-31272799d399"
      unitRef="usd">361822000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifc988bf6562e4a0ab83d5998938f5d7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi05LTEtMS03MDA3Nw_3090976b-0851-47d9-9da6-12e2d780dfb7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifb8814d4d6bb460fb498f2ef6bcb3f07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMi0xMS0xLTEtNzAwNzc_e8850438-83bb-4b72-b875-c7be476d3a2d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1427334e93bd4a8f98fd067cf174baff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy0xLTEtMS03MDA3Nw_0907b471-b1f2-4e50-866f-534fd7c486b6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icd64740178f14dfaa8b40016114d8b0b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy0zLTEtMS03MDA3Nw_ba684bcc-a9ed-4c20-b117-da6fdc1260bc"
      unitRef="usd">179500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i44d2a912e597482e88dad8af2f1eb83a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy01LTEtMS03MDA3Nw_8befbac1-0bc6-41d0-ad0f-300da02c6df5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if7365cb3d7724460b7e77eea77c4d02c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy03LTEtMS03MDA3Nw_3bdcd33d-277e-4bdb-986a-b92248974439"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i961f58e0225b454ea758608f30477153_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy05LTEtMS03MDA3Nw_68d8a6bb-693e-4492-9048-8c9ea73d7374"
      unitRef="usd">266250000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if9c82b31c56a41cabaa12f169afbc6ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfMy0xMS0xLTEtNzAwNzc_156dc1cb-bdf2-4fa9-be23-fffec7e35aeb"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id47d8623f27649b88072c3726cf612a4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS0xLTEtMS03MDA3Nw_4b7ad496-8063-4c10-b6ae-38765ed82d83"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i05545dcab7354afb93e21cdd544ce785_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS0zLTEtMS03MDA3Nw_e5148687-dc95-49e2-ae75-8504d0d7e618"
      unitRef="usd">594750000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia15eacf51ca7461e831d064a18ed6ec5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS01LTEtMS03MDA3Nw_ce1d6d86-e09c-4f92-8a99-1c631ce0a24d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i45c389f5ae034c4a9f241df636dd9408_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS03LTEtMS03MDA3Nw_e40a3082-68dd-43da-a991-636c7494e841"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8c9c400472e346bb83cdc03ad62f0f6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS05LTEtMS03MDA3Nw_1c6683ea-ebcc-4650-91d8-a7265ffc5857"
      unitRef="usd">790672000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ieebe69f41a92442fa317d279aecfffa9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNS0xMS0xLTEtNzAwNzc_6dfbe7f9-d15e-47dd-a9d8-bc16c415c22f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9c56415ec67e4a2f92984c0168e319b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy0xLTEtMS03MDA3Nw_7fa6f3b1-ca68-4864-8e9d-b698cbc5fb16"
      unitRef="usd">500885000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i018f2366267542d98a7442366fecb5fb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy0zLTEtMS03MDA3Nw_73124e02-a912-4c9f-a980-cdc40668b1b1"
      unitRef="usd">774250000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ieae5da8be9b04141abe668a81dbf1b8b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy01LTEtMS03MDA3Nw_96278320-0398-4a0c-ad66-8f33e9c78ceb"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i33e6ef1fb0544afd9c34afa0943a65e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy03LTEtMS03MDA3Nw_dd06ae4e-9f29-48ba-839c-2e6b68f553db"
      unitRef="usd">361822000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iee1c4e3b51c54406bfdcb545ced2f93b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy05LTEtMS03MDA3Nw_3020fca7-5c02-496e-93f6-deb93aabc922"
      unitRef="usd">1056922000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icb63dea6d85945d78435e4733601554d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfNy0xMS0xLTEtNzAwNzc_c9f45cae-5071-4682-984b-dbfd5f2ae735"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i9c56415ec67e4a2f92984c0168e319b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS0xLTEtMS03MDA3Nw_4123c843-a6fd-45cc-a92e-a305937ac3d0"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i018f2366267542d98a7442366fecb5fb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS0zLTEtMS03MDA3Nw_852a7717-5547-4f32-84f2-f08bb6ed75ec"
      unitRef="usd">323112000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ieae5da8be9b04141abe668a81dbf1b8b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS01LTEtMS03MDA3Nw_7213b96b-daac-4273-8eb0-9ad1ffc16307"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i33e6ef1fb0544afd9c34afa0943a65e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS03LTEtMS03MDA3Nw_b718e574-e588-46a8-b289-d2234c0b9bda"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="iee1c4e3b51c54406bfdcb545ced2f93b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS05LTEtMS03MDA3Nw_5cedec60-72db-40c3-abf8-463714470777"
      unitRef="usd">447509000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="icb63dea6d85945d78435e4733601554d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81NS9mcmFnOjFiNGFhZWNiNmI4MjQzOWY5NjhiYTI0NDhmMzIyN2ZiL3RhYmxlOjhhMTdiM2Q1N2FlODQyNTA5ZDc2OWM1ZGExZWVkMGUxL3RhYmxlcmFuZ2U6OGExN2IzZDU3YWU4NDI1MDlkNzY5YzVkYTFlZWQwZTFfOS0xMS0xLTEtNzAwNzc_4c2dc6f6-e189-4527-8283-e3b971cc619d"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNzc_f5b03686-a1c4-4bf5-89e8-1ee18d3615e1">Inventory&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our consolidated statements of operations. For the three months ended June&#160;30, 2022, inventory write-downs were $155.7&#160;million. There were no inventory write-downs for the three months ended March 31, 2022. For the three months ended June&#160;30, 2022, losses on firm purchase commitments were $99.6&#160;million. There were no losses on firm purchase commitments during the three months ended March 31, 2022. There were no inventory write-downs or losses on firm purchase commitments during 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNzg_97fed881-6748-46af-a1ea-848d0d1b965d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMS0xLTEtMS03MDA3Nw_aa235dfc-1e2d-4910-b10e-223bc99d938b"
      unitRef="usd">55154000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMS0zLTEtMS03MDA3Nw_0a69e924-a4af-44a4-800e-2ad4de9056f1"
      unitRef="usd">8872000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMi0xLTEtMS03MDA3Nw_92ddccd2-bbf0-4355-8fd5-46bcd405debf"
      unitRef="usd">71676000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMi0zLTEtMS03MDA3Nw_6d6f6f78-9116-44e4-a030-779d1b3616be"
      unitRef="usd">0</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMy0xLTEtMS03MDA3Nw_692524f2-5951-4c43-8790-0d2f0a75a9b8"
      unitRef="usd">129471000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfMy0zLTEtMS03MDA3Nw_aefe983d-05cb-4ce8-948e-2a43912f87eb"
      unitRef="usd">0</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfNC0xLTEtMS03MDA3Nw_d34209dd-2637-40f5-a05e-b12571b23a19"
      unitRef="usd">256301000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RhYmxlOmIzNDk0ZDQ1MzVmNjQzMjRiNjZhYmI1MmFiNGM4YTUwL3RhYmxlcmFuZ2U6YjM0OTRkNDUzNWY2NDMyNGI2NmFiYjUyYWI0YzhhNTBfNC0zLTEtMS03MDA3Nw_a64f1cbb-2c1f-4361-96da-23c6ae3c8557"
      unitRef="usd">8872000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfOTM0NTg0ODgzNzMzNg_48466421-ac17-4552-8baf-bdb511bfd3b8"
      unitRef="usd">155700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i29ef495376c841fcad701e4fb99916f6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4NQ_f6561524-c4a0-4083-b47a-06767297902f"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfOTg5NTYwNDY1MTQ5Mg_baa1a62f-deea-40b7-8b05-875f0d04beb6"
      unitRef="usd">99600000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="i29ef495376c841fcad701e4fb99916f6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4Nw_284df8d8-bf39-4a6c-a93f-211bc41ea593"
      unitRef="usd">0</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4Ng_91a6fd3f-adcc-4a58-b1b1-7de3b0e3c2c0"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF81OC9mcmFnOjUyNTFmYzFiMDc4MTQ1NmY5MTk5ZjcwMmRhOTUwYTNhL3RleHRyZWdpb246NTI1MWZjMWIwNzgxNDU2ZjkxOTlmNzAyZGE5NTBhM2FfNjA0NzMxMzk1ODU4Ng_ab3be8fc-b535-4fcd-b6c1-c2073e1e20e4"
      unitRef="usd">0</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfNTI1_4502db5a-1ce6-4fb1-95f1-f68483f6725d">Intangible Assets and Goodwill&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&#160;&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;Assets,&#160;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&#160;&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;Assets,&#160;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proprietary adjuvant technology&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for the six months ended June&#160;30, 2022 and 2021 was $0.2 million. Estimated amortization expense for existing intangible assets for the remainder of 2022 and for each of the five succeeding&#160;years ending December&#160;31 will be as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfNTI4_b64f8f43-7f29-4dee-870d-4247aebae5f5">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&#160;&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;Assets,&#160;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&#160;&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;Assets,&#160;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proprietary adjuvant technology&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iecd523551b8c4c88a444bf178a5ead31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy0xLTEtMS03MDA3Nw_b2c87e58-f8b7-4a98-bcd2-5d851fa50a79"
      unitRef="usd">7278000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iecd523551b8c4c88a444bf178a5ead31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy0zLTEtMS03MDA3Nw_4422f718-091a-4df7-87e3-3152e48c1d44"
      unitRef="usd">3245000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iecd523551b8c4c88a444bf178a5ead31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy01LTEtMS03MDA3Nw_16ad4d17-d060-4c04-b9e3-8f49e62a771e"
      unitRef="usd">4033000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy03LTEtMS03MDA3Nw_a8473f74-c000-47f6-a2cf-65e92769daf2"
      unitRef="usd">8239000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy05LTEtMS03MDA3Nw_1716f03a-6d43-4ff1-8ec1-c08e3d9d1596"
      unitRef="usd">3469000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idd2282ebdf5c44b7a6179354a0a6af7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfMy0xMS0xLTEtNzAwNzc_a5bf89f5-cbab-455c-9efb-3a32a8cedbb6"
      unitRef="usd">4770000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3453a5c919a143e6b9635ec05f27f973_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC0xLTEtMS03MDA3Nw_a6e35ff2-048f-439e-a6ff-6245a853dcba"
      unitRef="usd">3286000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3453a5c919a143e6b9635ec05f27f973_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC0zLTEtMS03MDA3Nw_534ba86b-206f-404c-9e16-f21e52252431"
      unitRef="usd">3286000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3453a5c919a143e6b9635ec05f27f973_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC01LTEtMS03MDA3Nw_2b9d1ae2-227f-4869-a367-cc8b3ef83e83"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i94545a62f6f04e5d9fe91e26c5041a86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC03LTEtMS03MDA3Nw_c23cac90-f0d8-4ea5-9adc-0c40a5bfcc3a"
      unitRef="usd">3722000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i94545a62f6f04e5d9fe91e26c5041a86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC05LTEtMS03MDA3Nw_aa11df11-4a1f-4c13-aeb9-a5f7c5ed5b2a"
      unitRef="usd">3722000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i94545a62f6f04e5d9fe91e26c5041a86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNC0xMS0xLTEtNzAwNzc_2855308f-e6f4-4265-96d2-2b670042a5ee"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS0xLTEtMS03MDA3Nw_2971a99e-9b54-43aa-aae5-25162d63ee54"
      unitRef="usd">10564000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS0zLTEtMS03MDA3Nw_4db40f12-aa93-46e6-bf23-89f34391d745"
      unitRef="usd">6531000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS01LTEtMS03MDA3Nw_dbbcb876-91eb-4f19-ad97-1bbd61a48879"
      unitRef="usd">4033000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS03LTEtMS03MDA3Nw_cb87db85-5f4b-49ae-b4c3-78b86fe073af"
      unitRef="usd">11961000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS05LTEtMS03MDA3Nw_568848d8-b72e-4d40-805f-e01bd9bcc9ed"
      unitRef="usd">7191000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOjM2YTIxNDAwMTYyYzQ4MGQ4NDk2ZjRkZTEwMDE4MjNkL3RhYmxlcmFuZ2U6MzZhMjE0MDAxNjJjNDgwZDg0OTZmNGRlMTAwMTgyM2RfNS0xMS0xLTEtNzAwNzc_77718245-99d9-479f-9412-f29d116bf573"
      unitRef="usd">4770000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfMzAx_09898a23-4662-4b3c-8b59-454c049f6909"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfMzAx_225e5208-2bac-42ec-be8a-892297593456"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfNTI5_65db4ef8-8734-4110-9125-99e9aea6ccb7">Estimated amortization expense for existing intangible assets for the remainder of 2022 and for each of the five succeeding&#160;years ending December&#160;31 will be as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfMS0yLTEtMS03MDA3Nw_eaebd5ee-ab04-4b5d-b8b5-766a6df41d88"
      unitRef="usd">182000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfMi0yLTEtMS03MDA3Nw_a0f172d7-688f-4a4a-ace5-b302da9db9ed"
      unitRef="usd">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfMy0yLTEtMS03MDA3Nw_a2475dfb-77a2-434e-971d-505ce3cb4b40"
      unitRef="usd">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfNC0yLTEtMS03MDA3Nw_797c5767-5989-45a5-b461-19f20f0969b4"
      unitRef="usd">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfNS0yLTEtMS03MDA3Nw_3125f1b9-4b51-401a-804e-e0c77ca7e710"
      unitRef="usd">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmQ1M2E0OWQ1ZDBhMjRhNDg4MmY4ZDk3MzRmMjFlMjZmL3RhYmxlcmFuZ2U6ZDUzYTQ5ZDVkMGEyNGE0ODgyZjhkOTczNGYyMWUyNmZfNi0yLTEtMS03MDA3Nw_d5f17be6-5a2a-4b9c-8483-d803b2d2be8e"
      unitRef="usd">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RleHRyZWdpb246MjMzNWZmMDIyYWE5NDU5ZWFkMGRiN2I1YWUyMzZkMzdfMzg0ODI5MDY5Nzk5NA_d29df0e7-ca3a-4fd1-830f-f9e6679b0ac4">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmNhNDA3MGE1MTc3ZDRmZDA5YWI4MDJlMDllZmI0OWI3L3RhYmxlcmFuZ2U6Y2E0MDcwYTUxNzdkNGZkMDlhYjgwMmUwOWVmYjQ5YjdfMS0xLTEtMS03MzU3NQ_4d3152e4-bfc4-4cca-843a-0c552e721fab"
      unitRef="usd">131479000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmNhNDA3MGE1MTc3ZDRmZDA5YWI4MDJlMDllZmI0OWI3L3RhYmxlcmFuZ2U6Y2E0MDcwYTUxNzdkNGZkMDlhYjgwMmUwOWVmYjQ5YjdfMi0xLTEtMS03MzU3NQ_b238c14e-dd25-4ea6-a64c-07028f6d2e82"
      unitRef="usd">-8012000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82MS9mcmFnOjIzMzVmZjAyMmFhOTQ1OWVhZDBkYjdiNWFlMjM2ZDM3L3RhYmxlOmNhNDA3MGE1MTc3ZDRmZDA5YWI4MDJlMDllZmI0OWI3L3RhYmxlcmFuZ2U6Y2E0MDcwYTUxNzdkNGZkMDlhYjgwMmUwOWVmYjQ5YjdfMy0xLTEtMS03MzU5MA_43430323-cfef-469f-bb94-71d8c470fd87"
      unitRef="usd">123467000</us-gaap:Goodwill>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjYzNg_0350681c-f5d1-44c1-ae37-879ced2de090">Leases&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the six months ended June&#160;30, 2022, the Company concluded that changes in facts and circumstances on its CMO and CDMO agreements that had previously been determined to represent embedded lease arrangements resulted in the modification of existing leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration in the contracts and reassessed the lease classification as of the effective date of the modification. As a result, during the six months ended June&#160;30, 2022, the Company recognized a Right-Of-Use (&#x201c;ROU&#x201d;) asset and a corresponding long-term operating lease liability of $19.8&#160;million&#160;on the remeasurement of one of its long-term supply agreements using an average incremental borrowing rate of 3.0%. The Company expensed the ROU asset since it relates to research and development activities for the development of NVX-CoV2373 for which the Company does not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June&#160;30, 2022, the Company recognized a short-term lease expense of $5.8&#160;million and $83.9&#160;million, respectively, related to its embedded leases and expensed $9.4&#160;million and $19.8&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2021, the Company recognized a short-term lease expense of $86.6&#160;million and $214.2&#160;million, respectively, related to its embedded leases and expensed $11.4&#160;million and $12.4&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2022, the Company recognized $2.3&#160;million and $3.4&#160;million of interest expense, respectively, on its finance lease liabilities. During the three and six months ended June&#160;30, 2021, the Company recognized $1.8&#160;million and $4.0&#160;million of interest expense, respectively, on its finance lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland. The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the three months ended March 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the third floor of the premises and recognized a ROU asset of $47.8&#160;million and related lease obligation for the combined third floor and land lease as the lease commencement date for accounting purposes had occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjYzNg_f531d1cb-0a01-4d61-88f3-c4afcb7fa302">Leases&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the six months ended June&#160;30, 2022, the Company concluded that changes in facts and circumstances on its CMO and CDMO agreements that had previously been determined to represent embedded lease arrangements resulted in the modification of existing leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration in the contracts and reassessed the lease classification as of the effective date of the modification. As a result, during the six months ended June&#160;30, 2022, the Company recognized a Right-Of-Use (&#x201c;ROU&#x201d;) asset and a corresponding long-term operating lease liability of $19.8&#160;million&#160;on the remeasurement of one of its long-term supply agreements using an average incremental borrowing rate of 3.0%. The Company expensed the ROU asset since it relates to research and development activities for the development of NVX-CoV2373 for which the Company does not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June&#160;30, 2022, the Company recognized a short-term lease expense of $5.8&#160;million and $83.9&#160;million, respectively, related to its embedded leases and expensed $9.4&#160;million and $19.8&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2021, the Company recognized a short-term lease expense of $86.6&#160;million and $214.2&#160;million, respectively, related to its embedded leases and expensed $11.4&#160;million and $12.4&#160;million, respectively, of ROU assets that represented assets acquired for research and development activities that did not have an alternative future use at the commencement or modification of the lease. During the three and six months ended June&#160;30, 2022, the Company recognized $2.3&#160;million and $3.4&#160;million of interest expense, respectively, on its finance lease liabilities. During the three and six months ended June&#160;30, 2021, the Company recognized $1.8&#160;million and $4.0&#160;million of interest expense, respectively, on its finance lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland. The lease is for approximately 170,000 square feet of space that the Company intends to use for manufacturing, research and development, and offices. The term of the lease is 15 years with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the three months ended March 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the third floor of the premises and recognized a ROU asset of $47.8&#160;million and related lease obligation for the combined third floor and land lease as the lease commencement date for accounting purposes had occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfNjU2_74d75fb7-7f7d-4972-a163-5f86d826e024"
      unitRef="usd">19800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nvax:LongTermSupplyAgreementIncrementalBorrowingRate
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfNzYx_842b25eb-9c3e-4127-97cf-f009e6aaba18"
      unitRef="number">0.030</nvax:LongTermSupplyAgreementIncrementalBorrowingRate>
    <us-gaap:ShortTermLeaseCost
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTM3Nw_52114bee-1fe3-44fc-b075-85606e9464ec"
      unitRef="usd">5800000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTE4Mg_0ef3a907-3adb-4868-b57b-7a7631e946e9"
      unitRef="usd">83900000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTIwOTQ2Mjc5MTE4OTA_7294d27a-67c4-4177-b2f1-19869bbf524a"
      unitRef="usd">9400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjc0ODc3OTA3OTEzMw_74d75fb7-7f7d-4972-a163-5f86d826e024"
      unitRef="usd">19800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU2OA_de33132a-e5de-4796-869d-3e78c97b1f05"
      unitRef="usd">86600000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU3Mg_1e9c1a4f-1a74-44bf-ab4b-86b8ed91977e"
      unitRef="usd">214200000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU3Ng_7020c1c4-2a7d-42ee-a8f5-018241bf430b"
      unitRef="usd">11400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTU4MA_5a813bfc-fe7e-4f7c-be9e-4345b6d6f8f0"
      unitRef="usd">12400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTcxNg_c0e0eeb1-299c-4fd3-b948-b62e6b7d7ffe"
      unitRef="usd">2300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMTk3OA_893dde33-e585-4586-9499-6e126d425caf"
      unitRef="usd">3400000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMjEzMw_cf8e1c67-5e56-46cd-abd8-5323771a450d"
      unitRef="usd">1800000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTA5OTUxMTYzMjEzNw_72c006a5-eaa0-493d-80dd-b7f46fbbfd2f"
      unitRef="usd">4000000</us-gaap:FinanceLeaseInterestExpense>
    <nvax:FacilityNumberOfSquareFeet
      contextRef="ia288ba6256924eaeb4fd7095a2acd199_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMTk2OQ_390bb36a-5e88-43fc-b0b4-718cbfc82717"
      unitRef="sqft">170000</nvax:FacilityNumberOfSquareFeet>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib60480ff6ace4a9dada2572b7a483040_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjEwOA_fb764335-5475-487a-b285-b8830e0fc452">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="i298d3ab6290f4c62a68f470f3b16205a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjE5MQ_e5eaed76-0366-4728-934d-f3bb953a4822"
      unitRef="usd">5800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic67b8fd3c6684e26893f4f55ee228020_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82NC9mcmFnOjhjNmQ3NTRhODcxMzRiM2ZiMzFiNGUzYmIyODVjNWQ4L3RleHRyZWdpb246OGM2ZDc1NGE4NzEzNGIzZmIzMWI0ZTNiYjI4NWM1ZDhfMjQ5Mw_7c4af3a3-f82d-411b-83df-749fc00345c1"
      unitRef="usd">47800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTMx_7942ef48-58e2-4ab6-8918-21ce2e92b678">Debt&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred approximately $10.0 million of debt issuance costs during the first quarter of 2016 relating to the issuance of $325 million&#160;aggregate principal amount of convertible senior unsecured notes that will mature on&#160;February&#160;1, 2023&#160;(the &#x201c;Notes&#x201d;), which were recorded as a reduction to the Notes&#160;on the consolidated balance sheet. The $10.0 million of debt issuance costs is being amortized and recognized as additional interest expense over the seven-year contractual term of the Notes&#160;on a straight-line basis, which approximates the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total convertible notes payable consisted of the following at (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amount of Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total convertible notes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;324,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;323,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible notes are classified as current liabilities and as non-current liabilities in the consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense incurred in connection with the Notes&#160;consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coupon interest at 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest expense on Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfNzM_d0ada1d3-63ff-497d-bead-d139c08f8a80"
      unitRef="usd">10000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i385f7d6a051e4dafb63d1a63b59be860_I20160331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfMTYw_58112353-5fee-4305-9dc3-6ef29215a517"
      unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i385f7d6a051e4dafb63d1a63b59be860_I20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfMzY3_310c4a53-74af-4f51-bd7b-8c85318309f2"
      unitRef="usd">10000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentTerm
      contextRef="ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTMy_7cdef1b1-72fb-4bcd-9200-3a0ff1e3fbe8">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTI5_dd1a3443-8ae8-4814-bbfc-52673d158c00">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total convertible notes payable consisted of the following at (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amount of Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total convertible notes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;324,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;323,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Convertible notes are classified as current liabilities and as non-current liabilities in the consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMS0xLTEtMS03MDA3Nw_949007cf-faf6-42c5-bfc9-8f0be318e49d"
      unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMS0zLTEtMS03MDA3Nw_999c32bd-bb96-41a9-b8da-efcd2df42f35"
      unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMi0xLTEtMS03MDA3Nw_a0f7163d-3e67-4f5d-887a-3ea0f126374b"
      unitRef="usd">831000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMi0zLTEtMS03MDA3Nw_c0aa00de-1b81-4a61-9fa9-b3f85a5f7272"
      unitRef="usd">1542000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:ConvertibleNotesPayable
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMy0xLTEtMS03MDA3Nw_26444d15-8818-451b-a534-d70eba27ed74"
      unitRef="usd">324169000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i2da027fe8b2945be929fc9906ca55864_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjQ3ZjQxMjJiNTFjOTRmZmVhZGQyY2MzNzVmYWNhMGIxL3RhYmxlcmFuZ2U6NDdmNDEyMmI1MWM5NGZmZWFkZDJjYzM3NWZhY2EwYjFfMy0zLTEtMS03MDA3Nw_3cb560c3-5a69-4ba2-8602-d571cb1f96b3"
      unitRef="usd">323458000</us-gaap:ConvertibleNotesPayable>
    <nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RleHRyZWdpb246ZWY3ZjExMzUzMzEzNDNhNGEwMjM2NTg2MWU0MmU5ZjRfOTMw_ae31818f-b862-45e3-bdbe-86f031ff3452">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense incurred in connection with the Notes&#160;consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coupon interest at 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest expense on Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0wLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmRlYjY4ZmE3ODdkNjQ5MTI5YzQ2YTA5MmExNzMxMmE5XzIz_9a2fe667-c344-46d2-bde3-9011a85dab0b"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0xLTEtMS03MDA3Nw_52d24ec4-7f95-47ed-889d-6442739e2e18"
      unitRef="usd">3047000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0xLTEtMS03MDA3Nw_ce738a56-2ab3-4023-828a-6e3ef15983b5"
      unitRef="usd">3047000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0zLTEtMS03MDA3Nw_315f6f38-9598-491d-b308-d65e62c38b7a"
      unitRef="usd">3047000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi0zLTEtMS03MDA3Nw_36906248-268b-4ab2-acad-888f7e04ba50"
      unitRef="usd">3047000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi01LTEtMS03MDA3Nw_8d8bc590-42b7-48b9-bc32-9b3b61e8e58e"
      unitRef="usd">6094000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi01LTEtMS03MDA3Nw_e4d0aa63-e1df-4416-b684-f518072ac272"
      unitRef="usd">6094000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi03LTEtMS03MDA3Nw_0e8d24a6-5852-4411-a92d-2b8b7facd30a"
      unitRef="usd">6094000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMi03LTEtMS03MDA3Nw_6f7eb5e3-35f2-425e-9b47-e9d2fdfc4477"
      unitRef="usd">6094000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0xLTEtMS03MDA3Nw_6a15b836-40e1-4fac-854f-92d1582701f3"
      unitRef="usd">356000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0xLTEtMS03MDA3Nw_9ae67e96-6594-4893-8553-d856c56188f3"
      unitRef="usd">356000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0zLTEtMS03MDA3Nw_6b03c95f-4bae-4c25-9f4b-206f2729cb42"
      unitRef="usd">356000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy0zLTEtMS03MDA3Nw_719c9878-189b-4a14-8ca0-638b67f13fd0"
      unitRef="usd">356000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy01LTEtMS03MDA3Nw_3c789a3a-acd8-4822-b353-ddc74e1deb3f"
      unitRef="usd">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy01LTEtMS03MDA3Nw_b1d9a95c-155f-4f3b-a9a6-a484ae89373e"
      unitRef="usd">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy03LTEtMS03MDA3Nw_22bf4a5a-de6f-46df-9a9e-ab7bf8cc039f"
      unitRef="usd">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfMy03LTEtMS03MDA3Nw_536b8fa5-8a16-4628-b03b-21e7a6a99f4e"
      unitRef="usd">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC0xLTEtMS03MDA3Nw_6f75f40d-b914-475d-b8d4-53726bd676b5"
      unitRef="usd">3403000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC0zLTEtMS03MDA3Nw_1b6c7a36-45df-455b-85cd-4bd268642cc5"
      unitRef="usd">3403000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC01LTEtMS03MDA3Nw_e0a21ba1-edab-465c-b7d6-e2ba3c65fa2a"
      unitRef="usd">6806000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF82Ny9mcmFnOmVmN2YxMTM1MzMxMzQzYTRhMDIzNjU4NjFlNDJlOWY0L3RhYmxlOjM0ZDIyMTNhM2JiZjRjOWVhNTE5MDYyMGY5ZWFhNDAwL3RhYmxlcmFuZ2U6MzRkMjIxM2EzYmJmNGM5ZWE1MTkwNjIwZjllYWE0MDBfNC03LTEtMS03MDA3Nw_d17ed56f-1be8-4f65-b43e-0ee4c666fbb6"
      unitRef="usd">6806000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNjU0_e7b4e050-dce2-4e11-b10d-5d58c05b2734">Stockholders' Equity (Deficit)&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2022, the Company sold 2.2&#160;million of shares of its common stock resulting in net proceeds of approximately $179&#160;million, under its most recent At Market Issuance Sales agreement entered in June 2021 (the &#x201c;June 2021 Sales Agreement&#x201d;), which allows it to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock. As of June&#160;30, 2022, the remaining balance under the June 2021 Sales Agreement was approximately $318&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the six months ended June&#160;30, 2021, the Company sold 2.6&#160;million shares of its common stock resulting in net proceeds of approximately $565&#160;million, under its various At Market Issuance Sales agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i425b5f4d2daa419592347aa121524f6f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfOTc_effed2e9-6df5-4fc7-9e44-9caf3990c55a"
      unitRef="shares">2200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2d5d7e6cc2a6432fad8f4e48c6a737bb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfMTcz_9957efbb-d6df-4d75-aabb-f5d6695df5cc"
      unitRef="usd">179000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6932178ef14e472084b3b902bba8f33c_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfMzMw_b1f46253-47c5-4b7e-9713-f99a954f6e35"
      unitRef="usd">500000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <nvax:ShelfRegistrationStatementRemainingUnissuedCapital
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNDY4_a81e1ebf-440d-4fb9-ad28-49abd1ab2467"
      unitRef="usd">318000000</nvax:ShelfRegistrationStatementRemainingUnissuedCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if4444c1c731442ff91f37b2fb4ce5a53_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNTIz_9327c6f9-283b-49d5-98f9-f5125303c418"
      unitRef="shares">2600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i164611e81adc4dada9d43687e47035ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83MC9mcmFnOjk0YmUxYTA4ZjU5MjQ3ZTRhMDcxODQ2MmI3ODI5NjQ4L3RleHRyZWdpb246OTRiZTFhMDhmNTkyNDdlNGEwNzE4NDYyYjc4Mjk2NDhfNTk2_87f788ee-b388-4c7a-8782-7b87c96f8445"
      unitRef="usd">565000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQyNw_18ba9a8b-22eb-4092-8e35-49a109e0e328">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Stock Incentive Plan, as amended (&#x201c;2015 Plan&#x201d;), was approved at the Company's annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan authorizes the issuance of up to 14.8&#160;million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of 2.4&#160;million shares approved for issuance under the 2015 Plan at the Company's 2022 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;4, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2005 Stock Incentive Plan (&#x201c;2005 Plan&#x201d;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, stock appreciation rights (&#x201c;SARs&#x201d;), and restricted stock units (&#x201c;RSUs&#x201d;). In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of ten years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company's common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQyNQ_9172cf8d-33fb-4432-8f7b-4855b5e3976b"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded all stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, there was approximately $212&#160;million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the Company&#x2019;s Employee Stock Purchase Plan, as amended (&#x201c;ESPP&#x201d;). This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately one year. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#x2019;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option&#160;and SAR holders exercised their stock options and SARs on June&#160;30, 2022. This amount is subject to change based on changes to the closing price of the Company's common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the six&#160;months ended June&#160;30, 2022 and 2021 was approximately $8 million and $115 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Stock Appreciation Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2015 Plan and 2005 Plan for the six&#160;months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2005&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,635,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;506,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,047,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,463,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for grant at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,834,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average Black-Scholes fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$43.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$166.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$62.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$131.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7%-3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-136.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.2%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-136.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124.7%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2015 Plan and 2005 Plan as of June&#160;30, 2022 was approximately $91 million and 7.5 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2015 Plan and 2005 Plan as of June&#160;30, 2022 was approximately $30 million and 6.5 years, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per&#160;Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;819,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;882,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(71,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,575,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP was approved at the Company's annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of 1.1 million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase 5% on each anniversary of its adoption up to a maximum of 1.65 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). No ESPP option periods commenced during the three months ended June 30, 2022 and 2021. As of June&#160;30, 2022, there were 0.7&#160;million shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Range of Black-Scholes fair values of ESPP shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$44.67-$79.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$128.70-$238.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2%-142.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.4%-159.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDAy_84036ca9-8f5f-4cf4-ae41-401bb05f0b40"
      unitRef="shares">14800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjc0ODc3OTA3NDQyMw_e482b19e-7160-4bfe-90cd-f02ecf84b946"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3f8b6ed41b2d43bebac3d158af889817_D20150601-20150630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTE4OA_c9a1de2f-21c9-4813-bd16-a74d0dc9020f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent
      contextRef="i4b95e06ae99e465cbb5da325d456aede_I20150630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTI2Mg_c5c45cbd-185d-4105-8440-9d891dd1e41e"
      unitRef="number">1</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iec94153dc52b4f0a884461884ed5820d_D20150601-20150630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTQzMQ_c5fb4bac-e3ee-48ad-87e1-ede6666608f2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQyOA_527c3ea4-048d-4272-8925-ea03f6ec8efe">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded all stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c556955c19448f6919e6fc319d19b36_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi0xLTEtMS03MDA3Nw_9a61af78-e42d-4487-a556-c0d618bf3417"
      unitRef="usd">19695000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i944814c48d6649559e7aaad2f652d7d9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi0zLTEtMS03MDA3Nw_f5d37f1d-5f9f-4eb7-966c-b00ed5593eff"
      unitRef="usd">24779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i031d603f91304729bf3df926d55719f3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi01LTEtMS03MTAzOQ_47c404c6-264e-4a09-9fcc-45ec3afb0c74"
      unitRef="usd">36582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9cd34e5e916949209fde4068aa2e6022_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMi03LTEtMS03MTAzOQ_9250a055-8e79-48aa-a240-278b7251bfb2"
      unitRef="usd">48569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1437c17d92b74d498d6762b05f885fcf_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy0xLTEtMS03MDA3Nw_2a1960ce-7817-4253-bbe5-8f333d590cea"
      unitRef="usd">18353000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cd14661959040a9a835c1d64370e08c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy0zLTEtMS03MDA3Nw_0c92f801-da05-4e16-8000-1cc0b7b77815"
      unitRef="usd">28344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i077e0d963f96436b8a57d5c0ed164f5b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy01LTEtMS03MTAzOQ_735ab940-eefe-4d2e-be5c-c3640ca830b8"
      unitRef="usd">34399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac8edaad70b54946b5867782a7dc86da_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfMy03LTEtMS03MTAzOQ_1a482da1-1909-48fd-978a-6bb89cf5cab0"
      unitRef="usd">57614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC0xLTEtMS03MDA3Nw_c7ea5f1c-db50-4f48-a62b-2c382caede9b"
      unitRef="usd">38048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC0zLTEtMS03MDA3Nw_b3a2d2be-56c2-4a39-895e-4270c01063b3"
      unitRef="usd">53123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC01LTEtMS03MzMwOQ_a634afd6-138a-4e5d-9da6-c377ffa90fa7"
      unitRef="usd">70981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmNlOGY5Mzc4YzA0ZDRiMGE5YTA2Zjk1NzhmYjhiNjkyL3RhYmxlcmFuZ2U6Y2U4ZjkzNzhjMDRkNGIwYTlhMDZmOTU3OGZiOGI2OTJfNC03LTEtMS03MzMwOQ_7f5fb1a2-e2f8-4126-9391-6b5fc6dc15e0"
      unitRef="usd">106183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTYwMw_ada22db7-a128-4c4d-9185-94ccbf7f4c68"
      unitRef="usd">212000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMTgzNQ_99d74da2-dbd3-41c2-90c3-50493f58aa13">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjU3OQ_898d7dcd-21a2-4d7e-8a52-1857e74e118f"
      unitRef="usd">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjU4Ng_0ad4647f-8859-4dab-8ea2-80dba52f8e86"
      unitRef="usd">115000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQzMg_79acf495-176e-479b-a268-fa9cbada3d29">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2015 Plan and 2005 Plan for the six&#160;months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2005&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,635,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;506,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,047,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,463,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for grant at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,834,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia9871aabeb83498fbc621e999b2b9f8e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi0xLTEtMS03MDA3Nw_3cd18bb7-3b49-449b-9f2b-3e003a400699"
      unitRef="shares">3635837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia9871aabeb83498fbc621e999b2b9f8e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi0zLTEtMS03MDA3Nw_e121e101-1f12-45e7-a6d7-42044eefe2f0"
      unitRef="usdPerShare">42.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib704932e6449470a978301c51c17020a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi01LTEtMS03MDA3Nw_b4f45904-518d-470f-8ef2-4bbaefc2721b"
      unitRef="shares">68225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib704932e6449470a978301c51c17020a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMi03LTEtMS03MDA3Nw_d1b16a80-591b-4a03-8038-1aa03c15691c"
      unitRef="usdPerShare">109.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy0xLTEtMS03MDA3Nw_619fccc4-3410-4a4c-823a-037022edf572"
      unitRef="shares">506821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy0zLTEtMS03MDA3Nw_03455b6a-ea93-43be-94a9-ac3a042c0a35"
      unitRef="usdPerShare">73.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy01LTEtMS03MDA3Nw_5ced7789-c82f-4aa4-b963-618038881924"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfMy03LTEtMS03MDA3Nw_e4bfc8a0-5607-41d8-baf0-54d8ef8844f4"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC0xLTEtMS03MDA3Nw_d52fc2b0-81c9-4170-842c-da9711cc4e40"
      unitRef="shares">59727</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC0zLTEtMS03MDA3Nw_c2825818-0eea-48cd-84b3-82d40f15b48b"
      unitRef="usdPerShare">15.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC01LTEtMS03MDA3Nw_72ee88c7-39e6-470a-8a20-1c731465c84f"
      unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNC03LTEtMS03MDA3Nw_97c59bd7-5f9b-486c-aaad-29a7d20e3550"
      unitRef="usdPerShare">31.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS0xLTEtMS03MDA3Nw_a9f59888-2358-48cd-bc4c-6c1b5585a1fd"
      unitRef="shares">35195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idc1a883667814891bb1aaadfb602e6fb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS0zLTEtMS03MDA3Nw_aecbab3e-ebab-45a4-ae50-1bde74e57c09"
      unitRef="usdPerShare">78.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS01LTEtMS03MDA3Nw_88feeb06-1a50-4718-bcd9-00883346e22c"
      unitRef="shares">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3a9f1730d84f4990a90f1b44633372ca_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNS03LTEtMS03MDA3Nw_6289cd6c-79fa-4ebb-b240-01eab7965714"
      unitRef="usdPerShare">121.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi0xLTEtMS03MDA3Nw_1495e523-9394-4968-b5bc-66c2a6bfff3d"
      unitRef="shares">4047736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi0zLTEtMS03MDA3Nw_784882a2-ee23-4eb4-9af9-5cd323a072eb"
      unitRef="usdPerShare">46.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi01LTEtMS03MDA3Nw_b3221a82-0b2a-492c-b479-2f1fa0970c03"
      unitRef="shares">63725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNi03LTEtMS03MDA3Nw_8f1b77a1-0509-4fce-8766-bec66d9b7df3"
      unitRef="usdPerShare">112.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy0xLTEtMS03MDA3Nw_b9605c61-4225-4e4b-a078-a4a0eebe78a4"
      unitRef="shares">1463037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy0zLTEtMS03MDA3Nw_f8f464d0-04bc-4c4c-87b3-a772c8a54882"
      unitRef="usdPerShare">55.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy01LTEtMS03MDA3Nw_2a5cfb2b-ec63-488a-a302-6b900af8adf2"
      unitRef="shares">63725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie86ae3bdf79c4f0682f4eb787d34baee_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfNy03LTEtMS03MDA3Nw_5a16253d-abfb-4b6c-9c9d-51e49946d8fd"
      unitRef="usdPerShare">112.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9e9ec9b154a341d5a0e32029a15d17b5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjliM2U2MTY2NTBhODRiMjM4NmNjODhmY2NhNDcxMGM0L3RhYmxlcmFuZ2U6OWIzZTYxNjY1MGE4NGIyMzg2Y2M4OGZjY2E0NzEwYzRfOC0xLTEtMS03MDA3Nw_14220fe7-c9c7-4112-bae1-6a70f029b2b6"
      unitRef="shares">4834171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQyOQ_69524aef-f777-48d6-b171-43cad976b057">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average Black-Scholes fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$43.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$166.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$62.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$131.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7%-3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-136.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.2%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-136.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124.7%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Range of Black-Scholes fair values of ESPP shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$44.67-$79.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$128.70-$238.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2%-142.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.4%-159.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmZiMzZjNWUwODk4MjRlODY5NmU0ZDcxNGU1MTIwYTJiXzQ_a3b976f0-f13b-4cda-b5e5-ec03150c4784"
      unitRef="usdPerShare">43.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi0zLTEtMS03MDA3Nw_9cd480b6-ad55-427c-996e-c49abf3a81ab"
      unitRef="usdPerShare">166.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi00LTEtMS03MDA3Ny90ZXh0cmVnaW9uOjdkYzJkN2YzZDg0MTRiMThhNzlkOGIxMjRlMmFjNGFjXzEwOTk1MTE2Mjc3OTA_9b0a40ab-cb3e-49ee-89de-2c91018a7ab2"
      unitRef="usdPerShare">62.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMi02LTEtMS03MDA3Nw_a58b02d7-6c91-4486-b807-bb1f3a7135f7"
      unitRef="usdPerShare">131.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjllYTE1ZGNlMjAwODRlMTZhOGM5MjQ3NDY4MzcyNWQ3XzQ_006140b0-9c48-4763-a315-9bb88b36ebe2"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjllYTE1ZGNlMjAwODRlMTZhOGM5MjQ3NDY4MzcyNWQ3Xzc_dfcab499-0462-42f2-8b93-4a5c48cb2a64"
      unitRef="number">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjhkMzA5ZjM5MGQwNjQxNjBhMzRhODM0Y2M5NjNjNGNkXzQ_90ce6687-58c4-4d1b-991e-321ef334567d"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjhkMzA5ZjM5MGQwNjQxNjBhMzRhODM0Y2M5NjNjNGNkXzc_f809c817-7ffb-454b-ace1-bf7d9c404f96"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOmIyNDI4YmI5NTg1NzQxZWNhMTY1NjY5ZWNkODU3NDIyXzEwOTk1MTE2Mjc3OTA_9a07068d-b367-4d72-bf6f-c1b3b1fda397"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOmIyNDI4YmI5NTg1NzQxZWNhMTY1NjY5ZWNkODU3NDIyXzEwOTk1MTE2Mjc3OTc_34161e85-3d43-4224-b2d1-8f8deda1ecfa"
      unitRef="number">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy03LTEtMS03MTUxMC90ZXh0cmVnaW9uOjA2NzQwNjljYWQ4MTRiM2Y5NjY3NjQ5YjlhOGNkZTViXzEwOTk1MTE2Mjc3OTM_8624253f-3e99-4045-838f-8d3322e15e31"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfMy03LTEtMS03MTUxMC90ZXh0cmVnaW9uOjA2NzQwNjljYWQ4MTRiM2Y5NjY3NjQ5YjlhOGNkZTViXzEwOTk1MTE2Mjc4MDA_087b45b0-7087-4a22-b165-b5d079a47cdc"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC0xLTEtMS03MDA3Nw_1a430459-307a-44ab-a75e-1740ae88e908"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC0zLTEtMS03MDA3Nw_112cb0ac-c29d-4f9d-a826-bb1700dab51c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC00LTEtMS03MDA3Nw_0598508c-ff16-44dc-bc56-46b7df542519"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNC02LTEtMS03MDA3Nw_9c9587ba-e38d-433e-8d94-407aca685231"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjAxZjIxZjljMTY5ZTQ4MTZiYzBiMGI2NTNkMzg0MjQ0XzQ_3a14cbd9-2603-4d88-bda0-8731e2ff7328"
      unitRef="number">1.205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i89ed3013c1b2498289b14a63301346e6_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjAxZjIxZjljMTY5ZTQ4MTZiYzBiMGI2NTNkMzg0MjQ0Xzc_c7326007-d3d1-4e96-9e1a-9ab4d516bfea"
      unitRef="number">1.367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmUyNjc0YTZjOWM0YzRiNDNiNzBmOWY3YzMzZjE5YTE1XzQ_d4a86471-1f0e-4b49-a931-e48a6624726d"
      unitRef="number">1.262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i5c4ef9385c9b433e90171bfdd09fbbe1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmUyNjc0YTZjOWM0YzRiNDNiNzBmOWY3YzMzZjE5YTE1Xzc_99d8a98c-af14-40bc-9907-38939b32d57f"
      unitRef="number">1.420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjM1YTNkZDljZjU3NTRjOTY4MWI3M2NlNmI2ZDExNDgyXzI3NDg3NzkwNjk0NTA_8c74817a-1341-4d58-bf59-8a4efa587208"
      unitRef="number">1.205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i08ae2f6bd4a44e7990538e924634539a_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjM1YTNkZDljZjU3NTRjOTY4MWI3M2NlNmI2ZDExNDgyXzI3NDg3NzkwNjk0Njc_6b456945-6b45-4a99-88e4-05bca8c842ea"
      unitRef="number">1.367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS03LTEtMS03MTUyNi90ZXh0cmVnaW9uOjdjZWEzMzc4NzY1MDQzOTA4NTI2OTcwNmE5YTY2MzdlXzEwOTk1MTE2Mjc3OTk_ea31291e-f0fa-4f16-9b4b-7209fb085e1e"
      unitRef="number">1.247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i7a34f2feab3f41b5a1054c1ff4ddcbd2_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNS03LTEtMS03MTUyNi90ZXh0cmVnaW9uOjdjZWEzMzc4NzY1MDQzOTA4NTI2OTcwNmE5YTY2MzdlXzEwOTk1MTE2Mjc4MDg_59f4e35d-90c8-433a-9e25-c0caf808e82a"
      unitRef="number">1.420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib8ca2be2be7e4bc99eb77502e20ad770_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmYyNWFiYjM5NzVkZjRiN2VhNTdmYWVhMmJiMTc1YWZmXzQ_84816be7-87b8-4f61-8215-164baa6d196b">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i547e6d19486d49bbba36b7968e867e86_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0xLTEtMS03MDA3Ny90ZXh0cmVnaW9uOmYyNWFiYjM5NzVkZjRiN2VhNTdmYWVhMmJiMTc1YWZmXzc_bcb55e98-2dfe-444d-8f44-5cd0ce3855f4">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iebc85c93fc3d4bb8b1fe33f9fc7a5679_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjNhMTY0ZGZhOTc3YzQ1OWE4NjIxN2Q5ZjE4NzlhYTNkXzQ_e209ce16-4130-410d-8bad-f271241ffcd2">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3ba39bdd4b0c4361ab34b776c5df1842_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi0zLTEtMS03MDA3Ny90ZXh0cmVnaW9uOjNhMTY0ZGZhOTc3YzQ1OWE4NjIxN2Q5ZjE4NzlhYTNkXzc_19ce18be-2586-4120-b002-f98c828c50dc">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9d1d79ddc8e64ee499a6e8568258a241_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjAyMzRjMWNmMjhkMjQ3YjFhN2ExNTY1Y2U0NjNmZjQwXzI3NDg3NzkwNjk0NTA_2e6b84ac-0766-4233-ae8b-b6dadb675a05">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i420df0b64ff14517bb785ae28358ddd9_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi01LTEtMS03Mzk2NC90ZXh0cmVnaW9uOjAyMzRjMWNmMjhkMjQ3YjFhN2ExNTY1Y2U0NjNmZjQwXzI3NDg3NzkwNjk0NTQ_b8cadc83-c21a-4dd4-92ea-0ff44e4a035e">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i20b84332994940ec9dd4c1fa8fe32f65_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi03LTEtMS03MTUzOC90ZXh0cmVnaW9uOjBmOWRiMTQxNmU4MTRmMTk4NTFjMGQ1OThiM2ZjZDE1XzEwOTk1MTE2Mjc3OTA_3b36341c-ff3a-4074-aef2-b4196f1d6939">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0af1ef6cf5684c3f981161750a479e9e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOmU3MjJhZTJhYTY4NTRhYTdiNjViNzY3MTc0MDAxOGYwL3RhYmxlcmFuZ2U6ZTcyMmFlMmFhNjg1NGFhN2I2NWI3NjcxNzQwMDE4ZjBfNi03LTEtMS03MTUzOC90ZXh0cmVnaW9uOjBmOWRiMTQxNmU4MTRmMTk4NTFjMGQ1OThiM2ZjZDE1XzEwOTk1MTE2Mjc3OTY_c19b42ac-19c7-4d31-a105-c8235937c189">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzEzNA_7e1d7bbf-aacd-4533-b210-774fbffffa11"
      unitRef="usd">91000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzE0MQ_4c30d204-fa3c-4a78-96df-f7f52e552fa2">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ie0b34d6687584e9692cde7fdd2961e44_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzM0Mg_97ec5b2c-df55-47ba-bfef-ba825f9f88d4"
      unitRef="usd">30000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzM0OQ_4f37f2ee-a1f3-460c-b00c-7ffb9107b983">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDQzMA_1cd1b29a-c97f-46f8-a46e-f2ca1bfa362f">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per&#160;Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;819,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;882,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(71,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,575,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMS0xLTEtMS03MDA3Nw_6d61bd77-13a1-475e-acf5-772b15267bc1"
      unitRef="shares">819828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMS0zLTEtMS03MDA3Nw_e267a336-90ee-4e28-9937-9f6edb9990bc"
      unitRef="usdPerShare">116.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMi0xLTEtMS03MDA3Nw_7c52155c-ab35-49de-aec8-bce265e26fc1"
      unitRef="shares">882828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMi0zLTEtMS03MDA3Nw_f7c7faae-ce7f-4565-89d8-281e20e4f316"
      unitRef="usdPerShare">74.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMy0xLTEtMS03MDA3Nw_af0fd1a5-1990-4b53-9184-c5cfb55b9137"
      unitRef="shares">55425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfMy0zLTEtMS03MDA3Nw_7039b83b-d40c-46b0-a76c-cb136957cbf4"
      unitRef="usdPerShare">157.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNC0xLTEtMS03MDA3Nw_c17dc3ed-4c4b-4e78-b2dd-a7bae74fad4d"
      unitRef="shares">71989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3586b9c6f8e443b5ae9d958c9b2de2fb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNC0zLTEtMS03MDA3Nw_01feec56-1a88-4efb-92ec-e76caa831d48"
      unitRef="usdPerShare">110.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i307541a72a03422fb6a7905e2797b623_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNS0xLTEtMS03MDA3Nw_8413ac7e-25ef-4874-8873-9038ec395c82"
      unitRef="shares">1575242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i307541a72a03422fb6a7905e2797b623_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjZlZjYyOTk1ZTM5NDRkZDI4OWNkM2IxMmYzODc1NTgwL3RhYmxlcmFuZ2U6NmVmNjI5OTVlMzk0NGRkMjg5Y2QzYjEyZjM4NzU1ODBfNS0zLTEtMS03MDA3Nw_e81f14d3-6fae-45bd-89e5-4c8795b99476"
      unitRef="usdPerShare">91.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjc0ODc3OTA3NjMyMw_2333de62-2a9e-4522-a1fc-7035a7188317"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease
      contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzg0ODI5MDcwNDc2OQ_5852f707-d0a0-4d7d-ae84-cfd13946fd28"
      unitRef="number">0.05</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMjc0ODc3OTA3NjMzNg_25b6ebf8-69eb-4587-90c3-51cdcdce8f13"
      unitRef="shares">1650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzg2NQ_1a31d31b-2247-4dcc-9654-5eebab486345"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfMzg5NA_f64fcb0d-9c5d-4854-b504-a19768d62652"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if84a8efd1a6c4a17b9b9b1dfa06e2040_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RleHRyZWdpb246NmNiMTdmMmRlZDFhNDQ4NmIzNmY1OTBmNmJjYjFiNTdfNDE1NQ_a897b57e-75aa-46d8-a5be-d65288068acb"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4319b34bddc14dc7ad516619f65f196d_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjQ1YWY0ZmViOWU4NzRkNTM4YTI4ZWE5MWVlNmFkOTgxXzI3NDg3NzkwNjk0NTQ_4483ed59-8582-48ec-bb02-e33350210982"
      unitRef="usdPerShare">44.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i962e48035aea4045b0cfe2ace43cde76_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjQ1YWY0ZmViOWU4NzRkNTM4YTI4ZWE5MWVlNmFkOTgxXzI3NDg3NzkwNjk0NTg_a759601e-a5a6-439d-8776-4e830c897c26"
      unitRef="usdPerShare">79.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6e499e69dfc74d4ab90426c5104422ea_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi03LTEtMS03MTM4NS90ZXh0cmVnaW9uOmI0NWNiZWZiMzIwODRjYjhiMzNiMjkyNGQ5OTQ0YzVjXzEwOTk1MTE2Mjc4MDQ_aeb9d6f6-1a80-418c-b010-f43fb9dfa1e8"
      unitRef="usdPerShare">128.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7ad84832faf04aac8ca995f70a7aecd3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMi03LTEtMS03MTM4NS90ZXh0cmVnaW9uOmI0NWNiZWZiMzIwODRjYjhiMzNiMjkyNGQ5OTQ0YzVjXzEwOTk1MTE2Mjc4MTQ_025a7764-e649-4437-a2d4-6067668f6214"
      unitRef="usdPerShare">238.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMy01LTEtMS03MDA3Ny90ZXh0cmVnaW9uOmJhNTUwMDIyNmViYjRjNjRiY2U0YmRhOGU2NzYzMGVhXzI3NDg3NzkwNjk0NTQ_e2a4ffba-a479-4e5c-bc60-ec3f1e4d2699"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMy01LTEtMS03MDA3Ny90ZXh0cmVnaW9uOmJhNTUwMDIyNmViYjRjNjRiY2U0YmRhOGU2NzYzMGVhXzI3NDg3NzkwNjk0NTg_b2843694-5a46-45be-9110-f50ecd022be3"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfMy03LTEtMS03MzMxMg_f4e0bd4b-c8f0-4de6-824f-e6bd77530b38"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNC01LTEtMS03MDA3Nw_ca358cd5-9c52-4691-a597-53b146f1c467"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNC03LTEtMS03MDA3Nw_aec23234-451f-4136-99dd-21501414ea05"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjhmNjg0MDUyYTdiMDQ5ODdiOTc2MDg5NWRmNGFjZDI4XzI3NDg3NzkwNjk0NTQ_a0bfccb7-cfb5-4b9c-89f3-bc5ac5eb89d4"
      unitRef="number">1.162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="if549400c21a940d9930254a6fde16714_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjhmNjg0MDUyYTdiMDQ5ODdiOTc2MDg5NWRmNGFjZDI4XzI3NDg3NzkwNjk0NTg_81b8cee7-641a-4cff-aadf-5a9a8fa73eb0"
      unitRef="number">1.429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS03LTEtMS03MTQwOS90ZXh0cmVnaW9uOjcxNTIwNmU0YzE3ZDQ4NmZiZTQ3ZGRmZTJhZTgxYTFmXzEwOTk1MTE2Mjc4MDQ_47678425-5c48-4d38-9ac4-d8fa2b6e013c"
      unitRef="number">1.204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ia909bd3527f24e238c17c38977335ce9_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNS03LTEtMS03MTQwOS90ZXh0cmVnaW9uOjcxNTIwNmU0YzE3ZDQ4NmZiZTQ3ZGRmZTJhZTgxYTFmXzEwOTk1MTE2Mjc4MDg_d9978562-6ead-4428-8a73-2f1cb6c2901a"
      unitRef="number">1.594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4319b34bddc14dc7ad516619f65f196d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjAxNThmODZhYTUyNjQzOTBhZGM3NDA2ZWQyMTU2MjRlXzI3NDg3NzkwNjk0NTQ_596f4ea0-7c70-45c4-abf5-28fec18dc42d">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i962e48035aea4045b0cfe2ace43cde76_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi01LTEtMS03ODI0MC90ZXh0cmVnaW9uOjAxNThmODZhYTUyNjQzOTBhZGM3NDA2ZWQyMTU2MjRlXzI3NDg3NzkwNjk0NTg_56e73cbf-b14d-44e8-86ce-941bf152a373">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6e499e69dfc74d4ab90426c5104422ea_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi03LTEtMS03MTQyNS90ZXh0cmVnaW9uOjAzNmFlOGU2ZTcyZDQ1ZTJiNTY2ZDI1OGQ0MGNhY2Y0XzEwOTk1MTE2Mjc3OTQ_690b4f97-968e-461f-9b57-ca7f3c292f85">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7ad84832faf04aac8ca995f70a7aecd3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83My9mcmFnOjZjYjE3ZjJkZWQxYTQ0ODZiMzZmNTkwZjZiY2IxYjU3L3RhYmxlOjczYTk0N2RmYmYxYTRkODc5YmU1Y2I0MTI1MWIxODIwL3RhYmxlcmFuZ2U6NzNhOTQ3ZGZiZjFhNGQ4NzliZTVjYjQxMjUxYjE4MjBfNi03LTEtMS03MTQyNS90ZXh0cmVnaW9uOjAzNmFlOGU2ZTcyZDQ1ZTJiNTY2ZDI1OGQ0MGNhY2Y0XzEwOTk1MTE2Mjc3OTg_f8c434b6-75a1-4e1f-a4b0-b4322db17e0c">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTM0OQ_e6c3585c-0e81-40c0-b1d6-44d51436a019">Income Taxes&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective evidence evaluated was the cumulative loss incurred over the three-year period ended June&#160;30, 2022 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June&#160;30, 2022, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent Net Operating Losses (&#x201c;NOLs&#x201d;) have been used to reduce taxable income. The Company&#x2019;s remaining U.S. Federal NOLs are subject to limitation in accordance with the 2017 Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;), which limits allowable NOL deductions to 80% of federal taxable income. Effective January 1, 2022, a provision of the TCJA has taken effect creating a significant change to the treatment of research and experimental expenditures under Section 174 of the IRC (&#x201c;Sec. 174 expenses&#x201d;). Historically, businesses have had the option of deducting Sec. 174 expenses in the year incurred or capitalizing and amortizing the costs over five years. The new TCJA provision, however, eliminates this option and will require Sec. 174 expenses associated with research conducted in the U.S. to be capitalized and amortized over a five-year period. For expenses associated with research outside of the U.S., Sec. 174 expenses will be capitalized and amortized over a 15-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognized federal and state income tax expense of $1.4&#160;million and $1.9&#160;million, in total, for the three and six months ended June&#160;30, 2022, respectively, and did not recognize federal or state income tax expense for the three and six months ended June&#160;30, 2021. The Company recognized income tax expense related to foreign withholding tax on royalties of $2.2&#160;million for the six months ended June&#160;30, 2022 and $3.5 million and $6.6 million for the three and six months ended June&#160;30, 2021, respectively. The Company did not recognize income tax expense related to foreign withholding tax on royalties for the three months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA0NA_10747308-ea86-4e7c-a6b9-4735129f973a"
      unitRef="usd">1400000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyODI2NDg_10805370-ecc3-4304-bf62-65fa3060e991"
      unitRef="usd">1900000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTM1MA_3b37c1bc-8f4e-4a42-9272-2448385bb3c5"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTM1MA_a587d0d7-fb03-464d-806b-9a90e33a091e"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyODI2NjM_a93e10f8-4c3f-465a-b531-28d3289e6d23"
      unitRef="usd">2200000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i1be1ccc0d03f484bb003e171ec30f013_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyOTI2Mw_2557dd1d-2636-42ee-85c4-0ca07b63df18"
      unitRef="usd">3500000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ifd8a159f01a5460593ee320067c679ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83Ni9mcmFnOmFhNDQyYzY5MGRkZjRhN2ViYTQyYjE1MzAzOGJiYTFmL3RleHRyZWdpb246YWE0NDJjNjkwZGRmNGE3ZWJhNDJiMTUzMDM4YmJhMWZfMTA5OTUxMTYyODI3Mjg_1ed8b242-b16c-40ec-b1fe-bc8a2de8f286"
      unitRef="usd">6600000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF83OS9mcmFnOmYxMDQzNTIzNjU3ODQyNjI5YjczY2ZiZTY0MDQ2OGQyL3RleHRyZWdpb246ZjEwNDM1MjM2NTc4NDI2MjliNzNjZmJlNjQwNDY4ZDJfNDA3NQ_fa44f2fa-6195-4e49-be1b-cd94d5ccfbd5">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#x201c;Sinnathurai Action&#x201d;). On January 26, 2022, the court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#x2019;s ability to manufacture NVX-CoV2373 on a commercial scale and to secure the vaccine&#x2019;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#x2019;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, defendants filed a motion to dismiss the consolidated amended complaint. On June 9, 2022, the co-lead plaintiffs filed an opposition to the motion to dismiss and on July 11, 2022, the Company filed a reply brief. The matter is now fully briefed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Court has not indicated whether it intends to schedule any hearing on the motion before issuing a ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;After the Sinnathurai Action was filed, five derivative lawsuits were filed: Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#x201c;Meyer Action&#x201d;), Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#x201c;Yung Action&#x201d;), William Kirst, et al. v. Stanley C. Erck, et al., No. 8:22-cv-00024-TDC (the &#x201c;Kirst Action&#x201d;), Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#x201c;Snyder Action&#x201d;), and Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#x201c;Blackburn Action&#x201d;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the U.S. District Court for the District of Maryland. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the U.S. District Court for the District of Maryland by the defendants. The derivative lawsuits name members of the board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 21, 2022, the Court issued a memorandum opinion and order remanding the Kirst Action to state court. On February 4, 2022, the Court entered an order consolidating the Meyer and Yung Actions (the &#x201c;Consolidated Derivative Action&#x201d;). The plaintiffs in the Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Court entered an order in the Consolidated Derivative Action granting the parties&#x2019; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. If a related derivative action is filed and is not stayed, the Meyer and Yung plaintiffs may seek to terminate the stay. On June 10, 2022, the Snyder and Blackburn Actions were filed. The Snyder and Blackburn plaintiffs have expressed their intent to move the court to consolidate all of the derivative actions pending in Maryland federal court and to appoint lead counsel. On July 21, 2022, the Court ordered the parties in the Consolidated Derivative Action, the Snyder Action, and the Blackburn Action to meet and confer concerning consolidation, the appointment of lead counsel, and the ongoing stay of proceedings in the Consolidated Derivative Action.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Should the parties fail to reach agreement on those issues, the Snyder and Blackburn plaintiffs were granted leave to file a motion for consolidation and appointment of lead counsel by August 18, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 29, 2022, Par Sterile Products, LLC (&#x201c;Par&#x201d;) submitted a demand for arbitration against the Company with the American Arbitration Association, alleging that the Company breached certain provisions of the Manufacturing and Services Agreement (&#x201c;MSA&#x201d;) that the Company entered into with Par in September 2020 to provide fill-finish manufacturing services for NVX-CoV2373. The matter is at a preliminary stage and therefore the potential loss is not reasonably estimable. While the Company maintains that no breach of the MSA has occurred and intends to vigorously defend the matter, if the final resolution of the matter is adverse to the Company, it could have a material impact on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMTc2MQ_c58738b7-5e8d-46d7-855f-a4d5e12629a9">Subsequent Events&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2022, the Company received emergency use authorization for NVX-CoV2373 from the FDA to provide a two-dose primary series in individuals 18 years of age and over.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2022, the Company entered into a modification to the OWS Agreement that amended the terms of such agreement to provide for (i) an initial delivery to the U.S. government of approximately 3&#160;million doses of NVX-CoV2373, contingent on the timing of EUA approval by the FDA, as well as the timing of label language and artwork approvals by the FDA and the recommendation of the Advisory Committee on Immunization Practices within the United States Centers for Disease Control and Prevention, and (ii) any additional manufacture and delivery to the U.S. government up to an aggregate of 100&#160;million doses of NVX-CoV2373 contemplated by the original OWS Agreement (inclusive of the initial batch of approximately 3&#160;million doses) dependent on U.S. government demand, FDA guidance on strain selection, agreement between the parties on the price of such doses, and available funding. The 3&#160;million initial doses were delivered in July 2022. Additionally, in July 2022, the Company modified its existing agreement with the DoD to provide for the initial delivery of 0.2&#160;million doses of NVX-CoV2373 after receipt of EUA approval from the FDA, with delivery of the remaining 9.8&#160;million doses of NVX-CoV2373 contemplated by the original agreement subject to DoD demand and available funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2022, the Company entered into the Amended and Restated UK Supply Agreement with the Authority, which amended and restated in its entirety the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses of NVX-CoV2373, with the number of additional doses contingent on the Company&#x2019;s timely achievement of supportive recommendations from the JCVI. In the event that the Company is unable to achieve the JCVI supportive recommendations, it may have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2022 and August 2022, the Company was notified by the EC that it was cancelling its prior commitment for 5&#160;million doses originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company signed an agreement with SK bioscience for the technology transfer of the Company&#x2019;s proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. In addition, the companies signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNjA0NzMxMzk5MDYwOQ_c72967a8-eee7-44fe-803d-d85628fc8471"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="idadbd33a708c469c910a0ca167cd16cf_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMzg0ODI5MDcyMTA5Mg_89da6869-1bf3-4bca-9e37-cd4afe8aab11"
      unitRef="dose">100000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2MjY4Mg_220dd5d1-e241-4896-a621-f019e78148bb"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfVaccineDoses
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNjA0NzMxMzk5MDYzNQ_c72967a8-eee7-44fe-803d-d85628fc8471"
      unitRef="dose">3000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMzg5ODA_f1168f25-ec99-40ba-a8e5-eb01009f927d"
      unitRef="dose">200000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption
      contextRef="id77272a9807949ed93e0c856eca5c6db_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMzg5ODQ_caa57b9b-9f11-4e7e-b460-64e192822be7"
      unitRef="segment">9800000</nvax:PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="ibe5f264f5aae46269f4b5c7f917258db_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2Mjc0NQ_8e93467f-e4aa-4936-8655-2001ad59ecbc"
      unitRef="dose">1000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="i7ce520d7761743ec86392cca9a2d1a9d_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2MjcyMQ_b4aebde9-11ff-4ec1-91e4-f65cfe44dae3"
      unitRef="dose">15000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount
      contextRef="ib86f32bcfa404cf0815eaf4f567e395f_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfMjc0ODc3OTEwODMwNQ_a5f35ea2-cf75-4268-9c30-59c2e9ad691a"
      unitRef="usd">225000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:PurchaseAgreementNumberOfDosesToBeDistributed
      contextRef="ib86f32bcfa404cf0815eaf4f567e395f_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNTQ5NzU1ODE2MjczMw_3d64ccfc-cdb6-4d0f-96e8-acd416c28799"
      unitRef="dose">44000000</nvax:PurchaseAgreementNumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfDosesCancelled
      contextRef="i750e9cc522fe4374bb3945dd8f61ee58_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDM4MDEzNjEzOTRmNjViMmU3YjliMDMwNTFhODRkL3NlYzo0NDQzODAxMzYxMzk0ZjY1YjJlN2I5YjAzMDUxYTg0ZF84Mi9mcmFnOjk4NWVkODY4ZWQwMTQwNDZhYzM2YTcwNDVhOTY5MWUwL3RleHRyZWdpb246OTg1ZWQ4NjhlZDAxNDA0NmFjMzZhNzA0NWE5NjkxZTBfNjA0NzMxMzk5MDczNw_216f6767-c485-4dc5-afc9-f2b6c88cd903"
      unitRef="dose">5000000</nvax:PurchaseAgreementNumberOfDosesCancelled>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MH24K697F1VT TKE4$UDMJK11:E ,0GTZ3BBK38F!#I.^^8IOL8XBCHL]HH0
M&)/ZU,-P!*)=!")C!.ZX2'/$-BL,Y&ND9\@/0S614P#FTM!55LA8AS6)]'Q7
M\1; D2@*G !V%SN]J'.,#E^6,UXP]#[G=?T!+2I>(-E:-*GF):S/'&TJ']V0
M1%JV(2!U/0E58@ !24!E6)4@0$#/<UW_0-+QGK3%QBWE2JQ8):5I%XM-^C^
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MT7Y<L73.J@8@OU]P+K87S0"[][(F_P%02P,$%     @ HIP(5:QOZ'7) P
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M31*&XX3QQYNRU@JV<W/(Q-W';"/OG@4. \;&H&4PIWP<!V1,(C+@]!'IUBG
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M41T<N Y0]Q>,R:>);A+--T'X%U!+ P04    " "BG A54=A0YD +  "09P
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MH_=@ 9UHC$;6$(XJ<:'2$E2:Q*+I*=))7/S))2YNRU(G-#0_ 8K; I>YN0
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M'9+ @A:9OA&;2ZCTG!J^6&3*?LFFBO4<$A=*B[P"8P8YX^5('ZHZ[ "09S_
MKP#^<T#K!4"S C2MT#(S*VM -0TZ4FR(--'(9B:V-A:-:A@W?S'2$D\9XG00
M3L;1Y&HTZ,V& Q+-<+@>CF<1F9R3\+(WOAA&9#3&@TGXY7)R-1C>1._(\.OM
M:/:#' Z&YZ-P-#LBAU,J@>L4-(MI=D3>D]MH0 X/CL@!89S,4E$HRA/5<36F
M;"YVXRJ]?IF>_T)Z;7(MD%B1(4\@>8IW46JMU]_J[?NO$GXN^ EI>L?$]WQ_
M3S[AO\,;KZ33K,O?M'S-%_@B335@4V@B%B32(KY+19: 5%CE^X+I1_*S-U=:
MXFO_M:]Z)7MK/[MQ@#.UHC%T'6QQ!7(-3O#V3:/M?=HG_3^1/2E$JRY$ZS7V
M8*1407D,I@ZQR'/L<&7*<4S8]B062N]]0B5SVS(;UUH'?K.!?V>]*^[OH--&
MZ[0.*I-V=QHI![FT_J+PYH+K\HW5N[6%]6SG/MOOH[653O2'IO3%:RJ7C"N2
MP0(IO9,/: RR])IRH<7*MNM<:&Q^.TW1GD&: #Q?"*&W"W-!;?C!;U!+ P04
M    " "BG A5Q7Y<*EH'   E'P  &    'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;*U9:W/;MA+]*QBUTTEGH@@//GUMS3AR,DVGB3UQ>OL9)B&+$Y)0"<A.
M^NOO I1)B03AN%=?;)):+,]B'V>7.'^4S5>U$4*C;U59JXO91NOMV6*ALHVH
MN'HCMZ*&7]:RJ;B&V^9^H;:-X+E=5)4+BG&TJ'A1SY;G]ME-LSR7.UT6M;AI
MD-I5%6^^OQ6E?+R8D=G3@\_%_4:;!XOE^9;?BUNA_]S>-'"WZ+3D125J5<@:
M-6)],;LD9RL6F056XK^%>%0'U\B8<B?E5W/S(;^888-(E"+31@6'?P]B)<K2
M: (<?^^5SKIWFH6'UT_:WUOCP9@[KL1*EG\5N=Y<S)(9RL6:[TK]63[^)O8&
MA49?)DME_Z+'O2R>H6RGM*SVBP%!5=3M?_YMOQ$'"T"/>P'=+Z##!<'$ K9?
MP*RA+3)KUA77?'G>R$?4&&G09B[LWMC58$U1&S?>Z@9^+6"=7JZN/]U>__'A
MZO++NRMT^P7^?7SWZ<LMNGZ/5I>WOZ'W?US_=8OFZ,_;*_3JYU_1SZBHT9>-
MW"E>Y^I\H0&#T;3(]N][V[Z/3KPO0A]EK3<*O:MSD1^O7P#VS@#Z9,!;ZE7X
M^ZY^@QA^C2BFU(%G]>/+B0<.Z_:367UL0M_U5C1<%_4]NC0!6NA"J#/7-K5J
M K<:D[QG:LLS<3&#[%2B>1"SY2\_D0C_QV7CB90=61QT%@<^[<M/4&M*J9RQ
MT*Z,[$I34!Z6<X9C',?GBX=#_ ZY, XQBSJY(VAA!RWT.N.SR&2=%67!;<F0
M:U3OP2(M[77&U09M&_E00#2BN^_HU4[!15'_BF3G2>[W9'A*3YY(V=%V1=UV
M15Y/7@E0FNTW"](;\4HVNOC'/G!9WJH+#]Q&6)"$ ^>.I8*8QF[/QAW4V!]T
MLIY;WT&!S+[.32'/428K8#<U"3<> 8EQFI !W+$4P1%)F!MPT@%.O(!O3(Q9
M[@/J1>);)B (S1[+.R5+H07$W(.HM6R^NZ G8U!A&$5T@'TLAMVPTPYVZH5M
M:7TNUW-("\25$EH!>+/+(G]M,PB2*FM$7L /$#P".#EW&9".D,T938=[/Y8B
M%,J%VP:">X[#7BNN]48TJ-"B4A:TD[;P&&$4##?8(<62,)P >$#"Q%NH5AM>
MWPMEN/6@[+3;;8($*M@=E+')$K17?Z(:="IMQYM!^\V@7F]]\"7"?NV1FP+,
M8CJL.@[!B5P@/;<3+Y$N+[-,[NHNTOE=*5X#>X@M+_*GM( (LVEM0ZYUH=,.
M-@YU0I-@9(9#+F48!Q.V]*Q-_+3=V;+EWUM#>)8U.^$VY"  G=8$8Y1Q2L)D
M:(U#CH24T EK>J(G7F($ZEJ+!LH0> :"9R><(,-QZ,11@M,AR+%<&D2'KCD&
MV=,K\?/KIY<W'$X[QH0ZIV$:$#8T9"R8X#A(I^II3[XD]I8KDZ'J1YI<XF7Q
M%]>E$VD[MKIG<.*G\!7?%IJ7;7X X>V:"?^,67@>D "/N,0A1Y.4325#S]G$
M3]HWNR;;0$>D##G#</Y5:)/A2(ELUTR'U9A\\1"Q@\4IB2;BB?;\3/W\#,U1
M)D2NT+J1%2#6>YBV "D.T%]B"!US]- 0AP@)TV2JTZ ]D5,O-SZ7XD67./X4
MW[_EV1!RR &)Q#B9L*/G8$J]&?Z^J#E,3L]G./5R^4LS_%3:CJWN^9WZ^=UX
M;WL4BR;X;!K!;%%!\V['#><^.'@Z3MEH&'+(A1',3.F$QWH^I\^/X<?8@;BA
M5HDF*Y1-H,-1B3_RQOWYACHH&H>C!!I+T2C%$T,2[7F<^GF\C3N!2@$P36M2
M02OHQNE@<\AA,API7'(A@X%N FK/YO1?L/FZRYMG$MPQ.D=!2(,A^K%<R!(2
M3+1_M*=PZA^@WZW7(K/3&\RB=OI T'Q G-36J->M:>+O';2YI?%!VPU"UNFF
MR+29MD' :=IX@)X'03AL3EQB+)CR2D_2U$_2QBM%#1.IB9]7N6BO3.7]O^UR
MT#64Y#@8^<PQK =Q@#&9,*XG=NHG]M6/6X"X1G?BOJAK$XS@9F@N"^D<S:EC
MZ@YI0L-A8^P0A-(5LPFGL9[_F9__7VB7,&.)SR+FH'>6Q"$95F.'( PC-&83
MY9CUC0#S3_2WN^VV%*9Z0<>8%RHKI8*&T7Z#?/IV]<QW17;2H?Y4VH[WHV\H
MF'^H=WU(LBQ5B\=]M>?WC1"3]9Z-Y_DH95$T].A8C"8)G?B0S X^Z_M; U?S
M;PI-N<MM;V>FYZ-YNOV .ABIG8:Y.H<D'3*N2XQ@-M&QLKYO8,&_#50;I.L2
M-!9U>V!8R-H=JM[>Y,6A>B)MQSO2]R#,WX.8:@06:V%*C[<'8>/>(HGPD \<
M4@3C8"HD^P:$^1L0B]-^>C*?E"$69260YM\FPBP:G;&0.(Z'7V@<8@R3890M
M#@X<*]'<VW-8A6P&M$=WW=/NK/?2GG .GK\E9ZOVQ+97TQX@?^0-L)>"VK &
ME?A-#/O7M&>R[8V66WNL>2>UEI6]W B>B\8(P.]K*?73C7E!=S*^_!]02P,$
M%     @ HIP(58+U/TD&!@  E@T  !@   !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6R=5VUOVS80_BN$"W0MX-J.D[1%DQAPT@9I!R=!LK8#AGV@*5KB0I$J
M2=EQ?_V>(R79;M*@VQ=;I.[EN;OGCM3QRKH[7T@9V'VIC3_I%2%4[X9#+PI9
M<C^PE31XL["NY %+EP]]Y23/HE*IA^/1Z/6PY,KT)L=Q[]I-CFT=M#+RVC%?
MER5WZU.I[>JDM]=K-VY47@3:&$Z.*Y[+6QD^5]<.JV%G)5.E-%Y9PYQ<G/2F
M>^].#T@^"GQ1<N6WGAE%,K?VCA8?LY/>B !)+44@"QQ_2WDFM29#@/&ML=GK
M7)+B]G-K_3S&CECFW,LSJ[^J+!0GO;<]ELD%KW6XL:L+V<1S2/:$U3[^LE4C
M.^HQ4?M@RT89"$IETC^_;_+P*PKC1F$<<2='$>5['OCDV-D5<R0-:_000XW:
M *<,%>4V.+Q5T N3*Y=SH[[SE"*3L=/:0\3[XV& >1(:BL;4:3(U_HFIUVQF
M32@\^V RF>WJ#P&KPS9NL9V.GS3XJ38#MC_JL_%H/'["WGX7ZWZTM_\+L?;9
MF37>:I5M0K]VTDL3TH9=L'-EN!&*:W:+30DJ!L_^FLY]<"#3WX]E* $X>!P
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M1$ ">+^P.#2;!3GH/L4F_P)02P,$%     @ HIP(59^:[QE_#0  620  !D
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MI(0>9X*(9L0;!\JC.G3"N<D(=@TSDDT9Q4RG%R6JM/#]E(YO*E2.#7!)%VA
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M5986X'/ZEC(]T 'YUT3G_P=02P,$%     @ HIP(50DX_4S&$   N#$  !D
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M=8L'7GP^&'===S =>B1!(37IR7XJ_ZD?48#)!5!E 2]V'DRDR%.@PC27-O%
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MI9E%NEXR^QS:^&P43L=/T:9G<3B9IOOU%V4I(SDS%>"WEE/R?'8//9Y.1Y[
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M_BL'-2@V0+5>_)K4-I T*]H!!8*DVSX,^T!+)XLHQ=-(*DK^_8Z2K3A [+F
M89%'/L\]=^0=ERV9'[9$=/!4*6U70>E<?15%-BNQ$G9$-6I>*<A4PO'4;"-;
M&Q1Y!ZI4E,;Q+*J$U,%ZV=GNS'I)C5-2XYT!VU25,,\WJ*A=!4FP-]S+;>F\
M(5HO:['%!W1_U'>&9]' DLL*M96DP6"Q"JZ3JYN)W]]M^%-B:P_&X"/9$/WP
MDZ_Y*HB](%28.<\@^/.(GU I3\0R_MUQ!H-+#SP<[]D_=[%S+!MA\1.IOV3N
MRE6P""#'0C3*W5/[!7?Q3#U?1LIV_]#V>\=I %EC'54[,"NHI.Z_XFF7AP/
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M0[JE,;",3L551A-B],I:KZNK"F*E%TJUPUTXT'8#6RX$\)X&)5RQ.9AGEKC
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M>('2<"5!XWP43.*S:=?9>X.O'%=F:PQ.R4RII9M<9Z,@<H108&H= J._1[Q
M(1P0T7A88P9-2.>X/=Z@?_#:2<N,&;Q0XAO/;#X*!@%D.&>5L'=J]1'7>GH.
M+U7"^%]8U;:=TP#2REA5K)V)0<%E_<^>UGG8<AA$>QR2M4/B>=>!/,M+9MEX
MJ-4*M+,F-#?P4KTWD>/2%>7>:MKEY&?']U:ERUR)#+5Y!U</%;?/<'R)<YYR
M>S(,+<5PEF&ZQIO6>,D>O#[<*&ES U<RP^RU?TC<&H+)AN T>1/P4R7;T(E:
MD$1)\@9>IQ'<\7B=/Q'\65F$[Y.9L9J.R8]=LFO4[FY4=W7.3,E2' 5T-PSJ
M1PS&1P=Q/SI_@W.WX=Q]"_TOBO0O>'!9:2X78'.D3R-"49<474GAANDTATY<
M5Z3ES2Y443+Y#(8P(6DG=%*%<)=.S<'DC#+B1MP:2%5!:& < [K4ABZ/B\4E
M2.I I58I8N:M64FS)TX7#\4S',:G[S>H+:B(B?9XA3*6<%*4%B;6D5L2SK4Q
M%9,IPCT3%)LM2$7A3.A#32(H'ATL=!)B.'82C@X&21*=OZS6KI.-J]^/ST]:
ML,HY)8 )ZF>&.(!5P"D> I,94+\14)5N\; 714TB*.!"*V->2=R?FC9,_+JG
MLSG]=:XUNE[KDC9CPHNLL^'V]K*'%3._9K03#S;TVMLU-_SI=<6W2<0["]YO
M=/ZG:O?ZO5W5?F2:J\K\1J5->]>]"[<:98%ZX9\#1[.2MNZ9S6KSXDSJ1OMB
M7C]7%'_!I0&!<W*-VJ>] '3]!-03JTK?=F?*4A/WPYQ>3=3.@/;GBIK.>N("
M-._P^"=02P,$%     @ HIP(5=!+M_8""P  61X  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C N>&ULO5G9<N,V%OT5E&-G["J*YJJE%U>Y.YUEJI*X[.[D
M86H>(!*2,$T2"D!:[?GZ.1<@*=*6W)Y4*B\2%^#BKN<>@&]V2G\V&R%J]J4L
M*O/V9%/7VU>7ER;;B)(;7VU%A3<KI4M>XU:O+\U6"Y[;265Q&07!]++DLCJY
M>F.?W>BK-ZJI"UF)&\U,4Y9</[P3A=J]/0E/N@>W<KVIZ<'EU9LM7XL[47_:
MWFC<7?92<EF*RDA5,2U6;T^NPU?O$AIO!_PFQ<X,KAE9LE3J,]W\E+\]"4@A
M48BL)@D<?_?BO2@*$@0U_FAEGO1+TL3A=2?]>VL[;%ER(]ZKXG>9UYNW)_,3
MEHL5;XKZ5NU^%*T]*<G+5&'L+]NYL4E\PK+&U*IL)T.#4E;NGW]I_3"8, ^.
M3(C:"9'5VRUDM?R.U_SJC58[IFDTI-&%-=7.AG*RHJ#<U1IO)>;55W>URCY/
MWL&NG+U7)6)M.+GKS64-Z33F,FLEO7.2HB.2INQG5=4;PSY4N<C'\R^A5:]:
MU*GV+GI6X#^;RF=QX+$HB*)GY,6]J;&5%Q\S=<.U:$V]X0_(K)I=:\VKM;#7
M_[I>FEHC3?Y]R'@G.SDLFTKGE=GR3+P]06T8H>_%R=6WWX33X/4SFB>]YLES
MTO^O(/TY2>S#'XVL']A-P2O#/FX$G!ZFS YG/U49_(/BL:\]Q@WC\!BBS,Z_
M_68>1<%K.YK>VOOP]87'=C1LN]7J'N-XS6H(I25Y]? /O*FJAA>L1-[*:LW4
MBAE::Z.*7&C#9,40?J>%SSYA+6T%].MX3#B-^8[KW* D'MA2L#7"66.]6D'D
M2F:0Y;%<:F" HDM1;@OU( 0N>96S3%4&Y8LYAE2@1SR_EP9C2<1 9?<._S:\
MR!:EV:JI&RV 9TLC<PE(\_>>(QT9;^J-TO*_PEA1TIB&PY>T5+.E!<+$GZ.J
MBX)"8"@_K1Z9*DMZ8+W?6./'UG9F-H<<L]O(; ,/9D63"_(T70.PC5TX\I/'
M*_91 L;OE3P@^VD8J32_$DN?71<%G 2=NO4ZM[Q@Q0U'VBV%H Y@RRI_[.0=
MC&'BRQ9!9K#I9ZZQ4F)1(W5CK]MDI1#>"E-S<AVZUN'\'N1T,,[I=I6<LO-[
ML=0-0NX4(<F58A6:T#@?2YYW=ED/;%T!%7! L]YT@ZT)R$6XKQ&4%YB)!@I-
MJYP\*JE[94KGUDT[66_(2Q*^$KHTCQVRQ4-9&ZN4<V8P>F/K8]/62A\MIK8$
M!(:=N\QQZW:.&0U!<2,8M989B;*OO'8$I9+(I,,431W1]/Z\N[XU>W@@[1Y+
M@:?D8,+MW:=^@H\HH39S29*]PXG?5,?4LG+=FO"!I3+DR8/8X;=9T?F#)I'J
M;"TJH7E1/+BDY-2&9=F4-@KDQQI9^B"X=G-:J4CPG=![9++10RS$%Z$SB9K<
M0F$$?8/:DH:RJ!"&\ )CPB XLX)AYXHCWN!-GT'4[GG1B.[%OAA'L-&6:@T&
M12/M\C[[07=8-PXZ)PU[^X!H_P%B4B;>PZ.VJ._A;_A.*CB,>B8]7&D%PP'3
M'P= B?@C4ZG<J.QMOUG:?I,-^PU*"=>"4IO4)"!6A<RY"QW^J"5;1<$_-6^U
M- ", CS29BFC(C)PM;EX!0VT$",&PN[DE_$#"U;X"0=7P -A$8-"EHM[L-2M
M90.G+%QXTT6*BRCQ9K,%+N*IE\XC7"1S+YTNV _.8VW? #N31"!LP81S+TYC
M%N$O25B<>/%BP=*9-PT3]E'5_ 6NP7IS+TCFN$AC+XQB7,P";S$/2;E@ZH7S
MF%U;']E>V5$ECSR*>/8-&%D*AR*NIU$8]>!/Z6,5H;+)U+JR@'Q0$RT*WG;5
MIJ*,Z NVS1_/5HC'J&*]'GC:C* 2#F>O$86V^;8%=M/ []25CK**#W<W-WL
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M&W#+CX\%/JO(\0*\GUL;N@$'Z#_4SOX%4$L#!!0    ( **<"%6(C_J>]@D
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MV=Z.-K^9L\$9G4M*L41L4?JX6*6E OE%PK)23":MJ[!7+<@91#QE#T2*?9)
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M$M2I/"W _<*AOIH_I*![LW3Y'U!+ P04    " "BG A5I'/G(VT&  !:$
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M!RF70*2TBSJWEH#+22PIBD&?$])TH("B$*T@T9@^"2MM2#7)W8.N76<3&.A
MEOJ"\H^!C5JME^"Y-,!%$"UZ 9=O'BN"B)NL"%?2(2C1)JXM&RVX'N]3&RLS
M%<IT7["G[]E,:IM(0>YJK78BR94N=+8*2;7S2*U=W($4(P?"T49Q\NGVZN+9
M\"5;<".YHDB<!/$8+:9X@UV,U3&;V_,BJ5N;!9HH-3XCL453T1!,D(FPY-R?
M)30"5G52W-B\I4P,K;I^5@\)N:E[*:8F"8'0:KLK.>B^^[L7&WN:;#]B^5GP
MNS:4),$./E2'V#9'_>'2K@PI3V_7F:+?.N^%?3N=:DFMO'+QZ->\;0[.XWA>
MW R/I^X/R(V$+!5B#M-![\51AYEXDHT/3E?A]#C3#F?1<)OC\"\,#<#WN=:N
M?J )FG\GG/T+4$L#!!0    ( **<"%6,5:$QZPT  %HG   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;*U:VW(;N1']%91V:V-7411)R?)=5;1L9Y6L
M+['6FTVE\@#.@"36,P,:P$C6?GU.-RXS0U.T'>?%YI! H]&7TZ=[].3:V ]N
MK907G^JJ<4\/UMYO'AT=N6*M:NG&9J,:_+(TMI8>CW9UY#96R9(WU=71;#(Y
M/:JE;@[.GO!W;^W9$]/Z2C?JK16NK6MI;YZIREP_/9@>I"_>Z=7:TQ='9T\V
M<J4NE7^_>6OQ=)2EE+I6C=.F$58MGQ[,IX^>32>T@5?\IM6UZWT6=)6%,1_H
MX:)\>C AC52E"D\B)/Z[4N>JJD@2]/@8A1[D,VEC_W.2_I(OC\LLI%/GIOJG
M+OWZZ<&# U&JI6PK_\Y<_ZSBA>Z1O,)4CO\5UV'MO9,#4;3.FSINA@:U;L+_
M\E,T1&_#@\DM&V9QPXSU#@>QEL^EEV=/K+D6EE9#&GW@J_)N**<;\LJEM_A5
M8Y\_NPS>$&8I+O6JT4M=R,:+>5&8MO&Z68FWIM*%5D[<29_N/CGR.)H$'!7Q
MF&?AF-DMQYR*5Z;Q:R=>-*4JA_N/H'+6>Y;T?C;;*_!O;3,6QY.1F$UFLSWR
MCK,=CEG>\2WR=EWXW_.%\Q9Q\Y]=%P[R3G;+HV1ZY#:R4$\/D"U.V2MU</;3
M#]/3R>,]VIYD;4_V23][)IUVY+.W)+OQDB)\EY+_@QCQZUHA60I3;V1S0P9I
M&]F6VJM2%*9QL$XIZ6&I&]D46E;"8:="JGHGUO)*B852C<"U-])BG6Y8G"VQ
M6B&\_5JL5*.LK*H;^D5M2)KL'+"Q&G(W%5R O1[JO&_X^$LZAQ6>U\HB4L6=
MGWYX,)M-'K\?7X[%7^?SM_P\?7Q7 +"PVV-9W=-4-P'(&!":DH7K!EYN&22<
M\$90MHOIY/ ?O&)NO2XJA2_HW'=JU59A^^7A[V.VU9>- C-T1AR)1>MQ:%&U
M)0Q=54*6?R#1P]([)$T[M@/.:TC;"O!7M-;2=[VU=Z&]]'R%\^ L5D67RCK1
MJ$(Y1YE-AI!B*;45F[Z;(9VV=@IOC-/TRT@ \ZUD%; !\.9&@L+!JC7!,1Q<
M&4??K66S"DX"3A4?UJ:BL\D%T_N/A?K8:G\C[@ CD4_^[HCM64BW%DL4 PB
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M??_D\X,)V&^;P5VIYR\)6^B"/9Y $%@P6Q4E^;F051'9P YJUNLOP:":4EK
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M[92*5M5/CWIA9.4^]V-IJ/Z=.*/7&BI[@/8G4IKUPE[0O/\&_P-02P,$%
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M4I;> K\LZ?%%[0Z0OE 4^';C+NB>\_E_4$L#!!0    ( **<"%7%CD ,B@(
M (H%   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;(54;4_;,!#^*Z>
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M+W-H965T,S N>&ULC57;;MI $/V5E7M1D*SX"B$4D""T:BNE0B%I'ZH^+/:
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M?KBFSPIJ%T#[*Z7L;N(.:#]4R1]02P,$%     @ HIP(55>-U)"%"P  C8P
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MJ6JL/,8J;P1=%^<T;U0(FA:7*X(CPG(#^7Q!J=C?Y 'JP\31?U!+ P04
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M)V>8CSOF8R/SDP_<^R: KU@[X>.3&$(O"(Y8&SU>REKC,8X]/>E)1WIB)/W
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MR8KZ<8-1AGDU0+U?,29?&I6#[J9W\1]02P,$%     @ HIP(5<L4\_UQ @
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M&@(.N;$,%']KN ;.+1':^+/A#'I)"]P=;]D_N]PQER75<"WY#U:8:AI<!J2
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M=]-HR<']9G#Z9+H6.[*DTXYZ] C*GVAGIGIOFTV]GT/"'$B8"PGS(&$^)"P
M@E5$V"]%V-?19]FZ K$UV@N*B!*D%$C-T2A*18FBD"S"*)2AFLW90DWF"5UU
MD5KC<"+#9)-;-0E4&[2M0"%A3@ZS,UBZ!GN:X?'(-"?&TZGR($-ZD# ?$A8
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MKO$*!F4#<'\IT8UV8IMV=ZEG?P!02P,$%     @ HIP(53M8>5H< P  \ H
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M@6L#M3]E*E7+B790-;GA7U!+ P04    " "BG A5BYD#>+D#  !&$P  &0
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MA"J4"X6 \N\)K5!5*9)\CA\=U.G;5,+#XV?Z9]UYV9D'R-&*5M]Q(<JE,W-
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M'U#W9XS)MQ-=0+D_;_0_4$L#!!0    ( **<"%4=%*<E<P,  "H0   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+68;6^;,!" _XK%JJF5UO).($N0
MFL#>I$I57[;/+C@!%7!F.TGW[V<;0@.A4;NY7X)M[A[[[LS9E\D6DT>:(<3
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MY=4 ]?R1,7FXJ #:/=_%_U!+ P04    " "BG A5)A=AKF $  #T%0  &0
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M"=#/UYRKEPLS0-UZA_\!4$L#!!0    ( **<"%6=K>Y!NP(  /((   9
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M$4<P!^ !0Z*H>@_NO8_"S7LJW/[O;OP+4$L#!!0    ( **<"%67BKL<P
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MJZ-7/2<'D/Q!'B94*IN0:*I!;(6D7%CQJX2+V&C[GT ;8!X(B#V KD4:B\X
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M"\(M!'(+TBT$=@OB+01Z*^JM!'HKZJT$>NOH89M ;T6]E4!O1;V50&]%O95
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ HIP(57)V_G[2!0  T1X  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( **<"%71'"*TM@8  *,E   8
M              " @18.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " "BG A5K&_H=<D#  ".#0  &               @($"%0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ HIP(51IO;Q7Q!@
M0QT  !@              ("! 1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( **<"%5!>5+3W0(  !\(   8              " @2@@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "BG A54=A0
MYD +  "09P  &               @($[(P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ HIP(5;DT3;>F @  _ 4  !@
M ("!L2X  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( **<
M"%7%?EPJ6@<  "4?   8              " @8TQ  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " "BG A5@O4_208&  "6#0  &
M        @($=.0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ HIP(59^:[QE_#0  620  !D              ("!63\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "BG A5"3C]3,80  "X,0
M&0              @($/30  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( **<"%47X/?RVA   /DQ   9              " @0Q>  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ HIP(50I4;:<$
M P  1@<  !D              ("!'6\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " "BG A5EVFRY30$  "'"0  &0
M@(%8<@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( **<
M"%6W9KC32P,  /8'   9              " @<-V  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ HIP(56S=_3;> P  '0D  !D
M         ("!17H  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " "BG A5G%<8V"4&  "T'   &0              @(%:?@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( **<"%4(30#V/ 0  /,)
M   9              " @;:$  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ HIP(5:QJ6&,8 P  DP<  !D              ("!*8D
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "BG A5T$NW
M]@(+  !9'@  &0              @(%XC   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( **<"%4]_T9Z@P4  +0-   9
M  " @;&7  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MHIP(58B/^I[V"0  91H  !D              ("!:YT  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " "BG A5I'/G(VT&  !:$   &0
M            @(&8IP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( **<"%6,5:$QZPT  %HG   9              " @3RN  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ HIP(52/.HG%F!
M"PH  !D              ("!7KP  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " "BG A5S, -K1@#  ! !P  &0              @('[
MP   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( **<"%55
M I, = ,  -H'   9              " @4K$  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ HIP(5<6.0 R* @  B@4  !D
M     ("!]<<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M" "BG A5H_=D1_H#  #F"0  &0              @(&VR@  >&PO=V]R:W-H
M965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( **<"%49-A@F&@,  *('   9
M              " @>?.  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L!
M A0#%     @ HIP(5<7N1ATG!@  #!   !D              ("!.-(  'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "BG A5Y%MO.*<"
M  "T!@  &0              @(&6V   >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;%!+ 0(4 Q0    ( **<"%57C=20A0L  (V,   9              "
M@73;  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ HIP(
M5?H)ZG:A P  )@X  !D              ("!,.<  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " "BG A5^\AH0*H$  !8'   &0
M        @($(ZP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( **<"%7]YL\=0@(  !0%   9              " @>GO  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ HIP(53NH/VKJ @  Q H
M !D              ("!8O(  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " "BG A5A:/L/4D%  !E)@  &0              @(&#]0
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( **<"%6]^YK<
ME0,  *P/   9              " @0/[  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ HIP(5038Z2XK!   ]14  !D
M ("!S_X  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "B
MG A5RQ3S_7$"  !]!@  &0              @($Q P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( **<"%60^3M=:P(  + %   9
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M970T-BYX;6Q02P$"% ,4    " "BG A5BYD#>+D#  !&$P  &0
M    @($'%P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M **<"%4;TNW]W04  *LG   9              " @?<: 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ HIP(51T4IR5S P  *A   !D
M             ("!"R$! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " "BG A5<'WN)) $  #_%0  &0              @(&U) $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( **<"%4F%V&N8 0
M /05   9              " @7PI 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ HIP(5> A\WY3 P  N@L  !D              ("!
M$RX! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "BG A5
M2V7;LL@#  "&#P  &0              @(&=,0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( **<"%6=K>Y!NP(  /((   9
M      " @9PU 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ HIP(58I*9I&D!0  ]B@  !D              ("!CC@! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "BG A5B ?J"S(#  #($P
M#0              @ %I/@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( **<
M"%67BKL<P    !,"   +              "  <9! 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( **<"%66"&HBJP0  %4D   /              "  :]" 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "BG A5O '6P> !  #L(   &@
M            @ &'1P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "BG A5%-1QY- !  "M(   $P              @ &?20$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     /P _ # 1  "@2P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>250</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Collaboration, License, and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements</Role>
      <ShortName>Collaboration, License, and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2121108 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2128110 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2133111 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2135112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2143113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2145114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2146115 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Revenue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails</Role>
      <ShortName>Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenue - Schedule of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Collaboration, License, and Supply Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails</Role>
      <ShortName>Collaboration, License, and Supply Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/InventoryTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - Intangible Assets and Goodwill - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Intangible Assets and Goodwill - Identifiable Intangible Assets, estimated amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Identifiable Intangible Assets, estimated amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2430413 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Debt - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/DebtNotesPayableDetails</Role>
      <ShortName>Debt - Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Stockholders' Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersEquityDeficitDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437417 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Stock-Based Compensation - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options and Appreciation Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/IncomeTaxes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nvax-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2447424 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nvax-20220630.htm">nvax-20220630.htm</File>
    <File>nvax-20220630.xsd</File>
    <File>nvax-20220630_cal.xml</File>
    <File>nvax-20220630_def.xml</File>
    <File>nvax-20220630_lab.xml</File>
    <File>nvax-20220630_pre.xml</File>
    <File>nvax-20220630xex103.htm</File>
    <File>nvax-20220630xex104.htm</File>
    <File>nvax-20220630xex105.htm</File>
    <File>nvax-20220630xex311.htm</File>
    <File>nvax-20220630xex312.htm</File>
    <File>nvax-20220630xex321.htm</File>
    <File>nvax-20220630xex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nvax-20220630_g1.jpg</File>
    <File>nvax-20220630_g2.jpg</File>
    <File>nvax-20220630_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="628">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nvax-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 188,
   "dts": {
    "calculationLink": {
     "local": [
      "nvax-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nvax-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nvax-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nvax-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvax-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nvax-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 388,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 24,
   "keyStandard": 226,
   "memberCustom": 18,
   "memberStandard": 21,
   "nsprefix": "nvax",
   "nsuri": "http://www.novavax.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.novavax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Revenue",
     "role": "http://www.novavax.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Collaboration, License, and Supply Agreements",
     "role": "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements",
     "shortName": "Collaboration, License, and Supply Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Cash, Cash Equivalents, and Restricted Cash",
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - Fair Value Measurements",
     "role": "http://www.novavax.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - Inventory",
     "role": "http://www.novavax.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121108 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.novavax.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - Leases",
     "role": "http://www.novavax.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128110 - Disclosure - Debt",
     "role": "http://www.novavax.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133111 - Disclosure - Stockholders' Equity (Deficit)",
     "role": "http://www.novavax.com/role/StockholdersEquityDeficit",
     "shortName": "Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.novavax.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143113 - Disclosure - Income Taxes",
     "role": "http://www.novavax.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.novavax.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146115 - Disclosure - Subsequent Events",
     "role": "http://www.novavax.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Revenue (Tables)",
     "role": "http://www.novavax.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.novavax.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Inventory (Tables)",
     "role": "http://www.novavax.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.novavax.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Debt (Tables)",
     "role": "http://www.novavax.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.novavax.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)",
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails",
     "shortName": "Summary of Significant Accounting Policies - Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Revenue - Additional Information (Details)",
     "role": "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2da027fe8b2945be929fc9906ca55864_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2da027fe8b2945be929fc9906ca55864_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "role": "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
     "shortName": "Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nvax:ReceivablesNetCurrentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenue - Schedule of Revenue (Details)",
     "role": "http://www.novavax.com/role/RevenueScheduleofRevenueDetails",
     "shortName": "Revenue - Schedule of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "id9a7f0ae8be1457ba975ad86d4101b1b_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i3c67801e2acb4e6bb800915f121b2eaf_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nvax:PotentialFutureMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Collaboration, License, and Supply Agreements (Details)",
     "role": "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
     "shortName": "Collaboration, License, and Supply Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i3c67801e2acb4e6bb800915f121b2eaf_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nvax:PotentialFutureMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i9c56415ec67e4a2f92984c0168e319b7_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.novavax.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i9c56415ec67e4a2f92984c0168e319b7_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Inventory (Details)",
     "role": "http://www.novavax.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2da027fe8b2945be929fc9906ca55864_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - Intangible Assets and Goodwill - Identifiable Intangible Assets (Details)",
     "role": "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Intangible Assets and Goodwill - Identifiable Intangible Assets, estimated amortization (Details)",
     "role": "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails",
     "shortName": "Intangible Assets and Goodwill - Identifiable Intangible Assets, estimated amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2da027fe8b2945be929fc9906ca55864_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)",
     "role": "http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Leases (Details)",
     "role": "http://www.novavax.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430413 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.novavax.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ibd57bef2ffc24a8b85bf44e333d1000c_D20160101-20160331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Debt - Notes Payable (Details)",
     "role": "http://www.novavax.com/role/DebtNotesPayableDetails",
     "shortName": "Debt - Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InterestExpenseDebtExcludingAmortization",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.novavax.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InterestExpenseDebtExcludingAmortization",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Stockholders' Equity (Deficit) (Details)",
     "role": "http://www.novavax.com/role/StockholdersEquityDeficitDetails",
     "shortName": "Stockholders' Equity (Deficit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "nvax:ShelfRegistrationStatementRemainingUnissuedCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437417 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "role": "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Stock-Based Compensation - Compensation Expense (Details)",
     "role": "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ie0b34d6687584e9692cde7fdd2961e44_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ia9871aabeb83498fbc621e999b2b9f8e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights (Details)",
     "role": "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails",
     "shortName": "Stock-Based Compensation - Stock Options and Appreciation Rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ia9871aabeb83498fbc621e999b2b9f8e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i89ed3013c1b2498289b14a63301346e6_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)",
     "role": "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i89ed3013c1b2498289b14a63301346e6_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i64c1865a9b2b42fb93f015bf6ac42aa6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if549400c21a940d9930254a6fde16714_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if549400c21a940d9930254a6fde16714_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Income Taxes (Details)",
     "role": "http://www.novavax.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i2dd4f1066517435185ece8ff61c6f66f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "i52b84098b8a748f8bfc7222df25285a4_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nvax:PurchaseAgreementNumberOfVaccineDoses",
      "reportCount": 1,
      "unitRef": "dose",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447424 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.novavax.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ib86f32bcfa404cf0815eaf4f567e395f_I20220731",
      "decimals": "-6",
      "lang": "en-US",
      "name": "nvax:PurchaseAgreementNumberOfDosesToBeDistributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ibd833ef8d89041a0a5d6c047bc63754d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "ibd833ef8d89041a0a5d6c047bc63754d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Business",
     "role": "http://www.novavax.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20220630.htm",
      "contextRef": "if2d6f6adc30d47bbbcc401555981c22a_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nvax_A700Q0AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "700Q0 Agreement",
        "label": "700Q0 Agreement [Member]",
        "terseLabel": "700Q0 Agreement"
       }
      }
     },
     "localname": "A700Q0AgreementMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Unbilled Services and Deferred Revenue",
        "label": "Accounts Receivable, Unbilled Services and Deferred Revenue [Roll Forward]",
        "terseLabel": "Accounts Receivable, Unbilled Services and Deferred Revenue [Roll Forward]"
       }
      }
     },
     "localname": "AccountsReceivableUnbilledServicesAndDeferredRevenueRollForward",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_AmendedAndRestatedUKSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated UK Supply Agreement",
        "label": "Amended and Restated UK Supply Agreement [Member]",
        "terseLabel": "Amended and Restated UK Supply Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedUKSupplyAgreementMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_BillMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to grant agreement with Bill &amp; Melinda Gates Foundation.",
        "label": "Bill Melinda Gates Foundation [Member]",
        "terseLabel": "Bill &amp; Melinda Gates Foundation (\u201cBMGF\u201d)"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Coalition For Epidemic Preparedness Innovations Award [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations (\u201cCEPI\u201d)"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsAwardMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CollaborationAgreementUpfrontPaymentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Upfront Payment Amount",
        "label": "Collaboration Agreement Upfront Payment Amount",
        "terseLabel": "Collaboration agreement upfront payment amount"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPaymentAmount",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_CollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements",
        "label": "Collaboration agreements [Member]",
        "terseLabel": "Collaboration agreements"
       }
      }
     },
     "localname": "CollaborationAgreementsMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_CollaborationUsGovernmentAgreementAndJointVentureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "U.S. Government Agreements, Grants and Licenses",
        "terseLabel": "U.S. Government Agreements, Grants and Licenses"
       }
      }
     },
     "localname": "CollaborationUsGovernmentAgreementAndJointVentureAbstract",
     "nsuri": "http://www.novavax.com/20220630",
     "xbrltype": "stringItemType"
    },
    "nvax_CollaborativeArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementAbstract",
     "nsuri": "http://www.novavax.com/20220630",
     "xbrltype": "stringItemType"
    },
    "nvax_CompensationStockIssuedUnderIncentiveProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued issued under incentive programs.",
        "label": "Compensation stock issued under incentive program",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "CompensationStockIssuedUnderIncentiveProgram",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DeferredRevenueCurrentAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue, Current, Additions",
        "label": "Deferred Revenue, Current, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "DeferredRevenueCurrentAdditions",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DeferredRevenueCurrentAndNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Current and Non Current",
        "label": "Deferred Revenue Current and Non Current",
        "periodEndLabel": "Deferred revenue, ending balance",
        "periodStartLabel": "Deferred revenue, beginning balance"
       }
      }
     },
     "localname": "DeferredRevenueCurrentAndNonCurrent",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DeferredRevenueCurrentDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue, Current, Deductions",
        "label": "Deferred Revenue, Current, Deductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "DeferredRevenueCurrentDeductions",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_DeferredRevenueIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Increase (Decrease)",
        "label": "Deferred Revenue Increase (Decrease) [Abstract]",
        "terseLabel": "Deferred Revenue Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "DeferredRevenueIncreaseDecreaseAbstract",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvax_EuropeanCommissionsECMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Commissions (\"EC\")",
        "label": "European Commissions (\"EC\") [Member]",
        "terseLabel": "European Commissions (\"EC\")"
       }
      }
     },
     "localname": "EuropeanCommissionsECMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_FacilityNumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Number of Square Feet",
        "label": "Facility Number of Square Feet",
        "terseLabel": "Facility, number of square feet"
       }
      }
     },
     "localname": "FacilityNumberOfSquareFeet",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gavi Advance Purchase Agreement- COVAX Facility",
        "label": "Gavi Advance Purchase Agreement- COVAX Facility [Member]",
        "terseLabel": "Gavi Advance Purchase Agreement- COVAX Facility"
       }
      }
     },
     "localname": "GaviAdvancePurchaseAgreementCOVAXFacilityMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GaviAdvancePurchaseAgreementSIIPLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gavi Advance Purchase Agreement SIIPL",
        "label": "Gavi Advance Purchase Agreement SIIPL [Member]",
        "terseLabel": "Gavi Advance Purchase Agreement SIIPL"
       }
      }
     },
     "localname": "GaviAdvancePurchaseAgreementSIIPLMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GovernmentBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to government backed securities.",
        "label": "Government Backed Securities [Member]",
        "terseLabel": "Government-backed securities"
       }
      }
     },
     "localname": "GovernmentBackedSecuritiesMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_GrantsUSGovernmentContractAndJointVentureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants, U.S. Government Contract and Joint Venture",
        "label": "Grants, U.S. Government Contract and Joint Venture [Abstract]"
       }
      }
     },
     "localname": "GrantsUSGovernmentContractAndJointVentureAbstract",
     "nsuri": "http://www.novavax.com/20220630",
     "xbrltype": "stringItemType"
    },
    "nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest expense related to convertible notes.",
        "label": "Interest Expense Related to Convertible Notes [Table Text Block]",
        "verboseLabel": "Schedule of interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedToConvertibleNotesTableTextBlock",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Committee on Vaccination and Immunization (JCVI)",
        "label": "Joint Committee on Vaccination and Immunization (JCVI) [Member]",
        "terseLabel": "Joint Committee on Vaccination and Immunization (JCVI)"
       }
      }
     },
     "localname": "JointCommitteeOnVaccinationAndImmunizationJCVIMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_LongTermSupplyAgreementIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Supply Agreement, Incremental Borrowing Rate",
        "label": "Long Term Supply Agreement, Incremental Borrowing Rate",
        "terseLabel": "Long-term supply agreement, incremental borrowing rate"
       }
      }
     },
     "localname": "LongTermSupplyAgreementIncrementalBorrowingRate",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset",
        "label": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset",
        "terseLabel": "Right-of-use assets from new lease agreements"
       }
      }
     },
     "localname": "NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_OperatingAndFinanceLeaseWriteOff": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Finance Lease, Write-off",
        "label": "Operating and Finance Lease, Write-off",
        "terseLabel": "Right-of-use assets expensed, net of credits received"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseWriteOff",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_PotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments",
        "label": "Potential Future Milestone Payments",
        "terseLabel": "Potential future milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePayments",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ProprietaryAdjuvantTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proprietary Adjuvant Technology",
        "label": "Proprietary Adjuvant Technology [Member]",
        "terseLabel": "Proprietary adjuvant technology"
       }
      }
     },
     "localname": "ProprietaryAdjuvantTechnologyMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_PurchaseAgreementNumberOfDosesCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number of Doses, Cancelled",
        "label": "Purchase Agreement, Number of Doses, Cancelled",
        "terseLabel": "Number of doses, cancelled"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfDosesCancelled",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number Of Doses Of Vaccine Candidate, Additional Purchase Option",
        "label": "Purchase Agreement, Number Of Doses Of Vaccine Candidate, Additional Purchase Option",
        "terseLabel": "Additional purchase option, number of doses"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfDosesOfVaccineCandidateAdditionalPurchaseOption",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_PurchaseAgreementNumberOfDosesRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number of Doses, Remaining",
        "label": "Purchase Agreement, Number of Doses, Remaining",
        "terseLabel": "Number of doses, remaining"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfDosesRemaining",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_PurchaseAgreementNumberOfDosesToBeDistributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number of Doses, To Be Distributed",
        "label": "Purchase Agreement, Number of Doses, To Be Distributed",
        "terseLabel": "Number of doses of vaccine to be distributed",
        "verboseLabel": "Number of doses to be distributed"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfDosesToBeDistributed",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_PurchaseAgreementNumberOfVaccineDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Number Of Vaccine Doses",
        "label": "Purchase Agreement, Number Of Vaccine Doses",
        "terseLabel": "Purchase agreement, number of vaccine doses"
       }
      }
     },
     "localname": "PurchaseAgreementNumberOfVaccineDoses",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvax_ReceivablesCurrentNetDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables, Current, Net, Deductions",
        "label": "Receivables, Current, Net, Deductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ReceivablesCurrentNetDeductions",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_ReceivablesNetCurrentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables, Net, Current, Additions",
        "label": "Receivables, Net, Current, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAdditions",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_RoyaltiesAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and Other",
        "label": "Royalties and Other [Member]",
        "terseLabel": "Royalties and other"
       }
      }
     },
     "localname": "RoyaltiesAndOtherMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_SalesBasedRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Royalties",
        "label": "Sales-Based Royalties [Member]",
        "terseLabel": "Sales-Based Royalties"
       }
      }
     },
     "localname": "SalesBasedRoyaltiesMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue",
        "label": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]",
        "terseLabel": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue"
       }
      }
     },
     "localname": "ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Compensation Restricted Stock Awards Activity",
        "label": "Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]",
        "terseLabel": "Schedule Of Share Based Compensation Restricted Stock Awards Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent",
        "terseLabel": "Minimum grant price, percent of common stock fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase",
        "terseLabel": "Percentage increase of shares each anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvax_SharebasedCompensationStockIssuedUnderIncentiveProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in incentive program.",
        "label": "Sharebased Compensation stock issued under incentive program",
        "terseLabel": "Stock issued under incentive programs (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationStockIssuedUnderIncentiveProgram",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvax_ShelfRegistrationStatementRemainingUnissuedCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement Remaining Unissued Capital",
        "label": "Shelf Registration Statement Remaining Unissued Capital",
        "terseLabel": "Remaining unissued capital"
       }
      }
     },
     "localname": "ShelfRegistrationStatementRemainingUnissuedCapital",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvax_TakedaArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Arrangement",
        "label": "Takeda Arrangement [Member]",
        "terseLabel": "Takeda Arrangement"
       }
      }
     },
     "localname": "TakedaArrangementMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_TwoThousandFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015\u00a0Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_TwoThousandFiveStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Five Stock Incentive Plan [Member]",
        "terseLabel": "2005\u00a0Plan"
       }
      }
     },
     "localname": "TwoThousandFiveStockIncentivePlanMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_USDepartmentOfDefenseDoDContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Defense (\"DoD Contract\")",
        "label": "US Department of Defense (\"DoD Contract\") [Member]",
        "terseLabel": "U.S. Department of Defense (\u201cDoD\u201d)"
       }
      }
     },
     "localname": "USDepartmentOfDefenseDoDContractMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvax_USGovernmentPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Partnership",
        "label": "US Government Partnership [Member]",
        "terseLabel": "U.S. government partnership (\u201cOWS\u201d)"
       }
      }
     },
     "localname": "USGovernmentPartnershipMember",
     "nsuri": "http://www.novavax.com/20220630",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r43",
      "r99",
      "r100",
      "r212",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r211",
      "r236",
      "r278",
      "r279",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r451",
      "r453",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r211",
      "r236",
      "r278",
      "r279",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r451",
      "r453",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r150",
      "r195",
      "r196",
      "r258",
      "r261",
      "r417",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r150",
      "r195",
      "r196",
      "r258",
      "r261",
      "r417",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r189",
      "r194",
      "r195",
      "r196",
      "r197",
      "r211",
      "r236",
      "r269",
      "r278",
      "r279",
      "r310",
      "r311",
      "r312",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r451",
      "r453",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r189",
      "r194",
      "r195",
      "r196",
      "r197",
      "r211",
      "r236",
      "r269",
      "r278",
      "r279",
      "r310",
      "r311",
      "r312",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r451",
      "r453",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r42",
      "r43",
      "r99",
      "r100",
      "r212",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r49",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r47",
      "r48",
      "r49",
      "r439",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r49",
      "r56",
      "r57",
      "r58",
      "r102",
      "r103",
      "r104",
      "r356",
      "r397",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets:"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r322",
      "r323",
      "r324",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r281",
      "r326",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "verboseLabel": "Issuance of common stock, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r82",
      "r225",
      "r381"
     ],
     "calculation": {
      "http://www.novavax.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r176",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r12",
      "r95",
      "r139",
      "r142",
      "r148",
      "r155",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r353",
      "r357",
      "r370",
      "r398",
      "r400",
      "r423",
      "r435"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r95",
      "r155",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r353",
      "r357",
      "r370",
      "r398",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed contracts receivable"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Capital expenditures included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r8",
      "r84"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r371"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r347",
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Revenue",
        "verboseLabel": "Collaboration, License, and Supply Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements",
      "http://www.novavax.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r427",
      "r444"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r198",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 600,000,000 shares authorized at June 30, 2022 and December 31, 2021; and 78,776,234 shares issued and 78,166,935 shares outstanding at June 30,\u00a02022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December\u00a031,\u00a02021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r63",
      "r430",
      "r446"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r259"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r259"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Noncurrent deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Milestone payment recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r13",
      "r424",
      "r436",
      "r461"
     ],
     "calculation": {
      "http://www.novavax.com/role/DebtNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "totalLabel": "Total convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r270",
      "r277",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r68",
      "r95",
      "r155",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r370"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Federal, state and local, tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222",
      "r226",
      "r227",
      "r228",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r210",
      "r230",
      "r231",
      "r380",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.novavax.com/role/DebtNotesPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount of Notes"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtNarrativeDetails",
      "http://www.novavax.com/role/DebtNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "verboseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r220",
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Deferred issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r82",
      "r186"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r283",
      "r284",
      "r316",
      "r317",
      "r319",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r361",
      "r362",
      "r431",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Compensation expense:"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r56",
      "r57",
      "r58",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r124",
      "r156",
      "r249",
      "r250",
      "r322",
      "r323",
      "r324",
      "r335",
      "r336",
      "r360",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r397",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value:"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r363",
      "r364",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "auth_ref": [
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value hierarchy"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r363",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r230",
      "r231",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r364",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r270",
      "r271",
      "r276",
      "r277",
      "r364",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r221",
      "r230",
      "r231",
      "r270",
      "r271",
      "r276",
      "r277",
      "r364",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r221",
      "r230",
      "r231",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r364",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r230",
      "r231",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r386",
      "r391",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r388",
      "r393"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Finance lease payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r10",
      "r181"
     ],
     "calculation": {
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated\u00a0 Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "verboseLabel": "2022 (remainder)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r181",
      "r184",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortization expense, fiscal year maturity"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsestimatedamortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r181",
      "r419"
     ],
     "calculation": {
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r177",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r181",
      "r418"
     ],
     "calculation": {
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible Assets,\u00a0Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r9",
      "r162",
      "r163",
      "r170",
      "r174",
      "r400",
      "r422"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r139",
      "r141",
      "r144",
      "r147",
      "r149",
      "r420",
      "r428",
      "r433",
      "r448"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r331",
      "r332",
      "r333",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r113",
      "r114",
      "r138",
      "r330",
      "r338",
      "r340",
      "r449"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Accounts receivable, prepaid expenses, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r175",
      "r179"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r137",
      "r379",
      "r381",
      "r432"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r70",
      "r223",
      "r229",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.novavax.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense on Notes"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r72",
      "r224",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.novavax.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "verboseLabel": "Coupon interest at 3.75%"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash interest payments"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.novavax.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory.",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "terseLabel": "Firm purchase commitment loss"
       }
      }
     },
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r29",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r27",
      "r90",
      "r123",
      "r157",
      "r159",
      "r161",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.novavax.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.novavax.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Semi-finished goods"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for excess and obsolete inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "verboseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r95",
      "r143",
      "r155",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r354",
      "r357",
      "r358",
      "r370",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r95",
      "r155",
      "r370",
      "r400",
      "r426",
      "r441"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r34",
      "r95",
      "r155",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r354",
      "r357",
      "r358",
      "r370",
      "r398",
      "r399",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Coupon interest rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r125",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r50",
      "r53",
      "r58",
      "r62",
      "r83",
      "r95",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r117",
      "r139",
      "r141",
      "r144",
      "r147",
      "r149",
      "r155",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r362",
      "r370",
      "r429",
      "r445"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r141",
      "r144",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r351",
      "r352",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r351",
      "r352",
      "r355"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r51",
      "r54",
      "r351",
      "r352",
      "r355"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r45",
      "r47"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Net unrealized losses on marketable securities available-for-sale, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r75",
      "r344",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sales of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r74",
      "r154"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities and sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r321"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Net proceeds from the exercise of stock-based awards"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r187",
      "r400",
      "r434",
      "r443"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r400",
      "r442",
      "r462"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "periodEndLabel": "Accounts receivable, ending balance",
        "periodStartLabel": "Accounts receivable, beginning balance",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r329",
      "r416",
      "r467"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r84",
      "r89",
      "r463"
     ],
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r250",
      "r400",
      "r440",
      "r457",
      "r459"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r156",
      "r322",
      "r323",
      "r324",
      "r335",
      "r336",
      "r360",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition - Product Sales"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Amount of transaction price not yet satisfied"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r95",
      "r135",
      "r136",
      "r140",
      "r145",
      "r146",
      "r150",
      "r151",
      "r152",
      "r155",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r370",
      "r433"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets and lease liabilities obtained, operating lease"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r314",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r177",
      "r180",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r177",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of identifiable intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r89",
      "r421",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Major Customers by Reporting Segments"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r280",
      "r282",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r287",
      "r302",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Option and Appreciation Rights Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Estimation of Fair Value of Stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Maximum discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedNetLabel": "Restricted stock units forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding and Unvested, ending balance (in shares)",
        "periodStartLabel": "Outstanding and Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding and Unvested, ending balance (in usd per share)",
        "periodStartLabel": "Outstanding and Unvested, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Per\u00a0Share Weighted- Average Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Subscription rate cap"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares available for grant (in shares)",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Shares exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Shares exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, stock options and vesting RSA's"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Range of Black-Scholes fair values of ESPP shares granted (in usd per share)",
        "verboseLabel": "Weighted average Black-Scholes fair value of stop options and SARs granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining term, exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance ending (in shares)",
        "periodStartLabel": "Balance beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r392",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r40",
      "r56",
      "r57",
      "r58",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r124",
      "r156",
      "r249",
      "r250",
      "r322",
      "r323",
      "r324",
      "r335",
      "r336",
      "r360",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r397",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r124",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r249",
      "r250",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r249",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from shares sold, net",
        "verboseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r95",
      "r153",
      "r155",
      "r370",
      "r400"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance ending",
        "periodStartLabel": "Balance beginning",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r253",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r378",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r378",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r378",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r378",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r14",
      "r425",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement [Domain]"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r14",
      "r425",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment [Axis]"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r39",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r39",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r39",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, cost basis, 609,299 shares at June 30,\u00a02022 and 591,980 shares at December 31, 2021"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.novavax.com/role/DebtNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleNotesPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/DebtNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled contracts receivable"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "verboseLabel": "\u200bWeighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r468": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r469": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r470": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r471": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r472": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r473": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001000694-22-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001000694-22-000016-xbrl.zip
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M*T 21(\8><[$4UXJ8^,<8&-1Y?3;./J;V"M79[_,16A^Q'?X]M1RM=$.NE^
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MCN$5LIDF11R=%^7R"H=4!(AW)H3 #6ICP2(C876(,W^;:5(D(T8&FHBDU"0
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M2NG()>=1^,K862(.FL]&:DJ82%;HY"@8ZPW5*6K"N'3(+'P9LD K#IJK^4-
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M0JW4/+UN)UL_K:M:1$OHJK:;C2+KR[6R;3NPPPUP8R#[]1[?AO[V+UJC7=1
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M042_/@95  =36"17D0SC)G!'F%*Y^ZI8-VQ2"P3WDY E6CIXJB)/'9HDWI-
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M!1;K28<-*K&>I5B/*6LCC&<.A9EHQ0IPS!?.)EXDXYR5VNN0/-K@7*ZCN[5
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M+8PIDN'HS%(7"BV#*?Y_]K[]J:U<6?=?<7%.W;-/E971H_7*[$L5&S*SF3M
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MR9>. LH0&Z,FG$5&,5M%5+7R3+B&=K2685Q?CRNSN*4R3P=XF,1LHI)0AHF
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M@D B$+*%+W0D7I2C<8A,J,!$$ V5:%-:><U=:&=D8%7.VRKG=(>/3*9 14M
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MJ\JI'$D>63G/T<2RD/\(Q3VE3#O#UM:-ZH*\S7%.!;X*?*L%?(&C0,^T=&!
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MA/)DSN<5B0ZEXU*IR)M(/&9HEZU")%Z%P@J%=WQD8%Q@3"0=K(@@A#*9^NG
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M<8R'_*+[#F;7AG(/ ]Y33-NC+B62+$%E!8%@-3&,&:($ (UH;+*E3%87P&8
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M*J4JI2JENPL?9=R:%*TQ,BI@GGG4E!FJO>7 J;_.N<L5U9KWQ@<X+'%,0SS
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M&S.E@ (HR%N.(2ID%@^4:6(%#^6119:D]TF4EA!=I7E7R-E2>\O3WGJ!ROO
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M[M]_T-=__W*4QW^RNW^8SI(@=EY2L;.U(78_O?%(T8(3Q//2J5Y$1KRU@6A
MDVB4(?"TMBZH[E(]FPNQS 4 *RJM*"K57/^E0Z4O4ZB4(H7 A219EIR <Z42
M3D2"$O/FPE4T5"TBTW^!J+0@UK\D5.\%9IT+O</>I)G#('7ZI^2O,QXTCX,;
M'70^# <?>\4,]R>=?QR/\H->_[\[@Z_6@UN,]= 6 ^'.;0#&G_"6KXPM_##,
M('C:Y*,?.^ZHU&S]TKRP*JT^KC<5]TNE+^Y5Y\6PT8\;YX10=ZY%[5QG>6KG
M=B[),5-JZDE@# A$ZXE/3!/NM.5.!!:C7UMGH@N7Y*G5XOLKH\^+;K=>]?E^
M]'F:B4HM(-E4Z@0XEO59>6*\<\2BDD)SG06*)9XT/VR1.O^ <YR=YN7!XO<1
MX+X^N4CVO 0D:7?0)PU!'I5X0^)=H<8EQ@G[HYL3I1:6\FL_46HJ8?VK"&#S
MW/Q73%T8IL[Z')$QQH$B23PY I"!U5&&1#(O EINDLH<2=-NENEM0;56Y6RO
M*B^:(U55OG-5GJ9'@7+M,_!F+9:" $V4>"4"X=(XQQRW:$TV=ZCJ,B-:I,N/
MS"GSO/CA1D4?LRYT\'/ T:AQS@Q*:"^.L=/K?\3^># \J2Z:^V(>VV=3_O>P
M-\:MP:<*50N#JKW-KZP#=O,\[&V\T10=,BY)YALV0Q5-Q"J>B**@G4U.&6LS
M5$G959=DFE37S,KH\:)IQX_T./4^8R1?<#BH*CR?"G_YIL+;GW8VWBCN!"]E
M=$URB8".(3]2-),/0Z477$CP7\OWMTB%'YEWXT5Y3 :)'(^PXT8C'(\RYRB$
M'&.W.1P<I$X88NSE-X88L/<1X^/R>#QLF%7_H_O\]&L,YT8__M+DR^'OF(VG
M!L7V4JIDY [(R)G=1$N^$6I'DE&* ).,F)"?>N>-3S0:P513T=#.>D!J>Y^V
M:O5#L)"JRP_%2LYT6=C$M7&4\* - 1YI9B6&$A%3<CJYXM#,A@7O:GKK,Z+J
M KFI;C:]B#M9'8Y&#0=Y7'Z.>^8;E[2!WAWTRXG7)(#RV80-5N29!WEF@TTL
M;0K[>>*#L 12J8L<>$8>JPV-&7C BK5U!;/NC&4.W%YM36U%I/-W-+82B86I
M\TRL"=?@'7*BM=,$0 %QDDJ"3H/(+$,G*XM18&2;0L<>5^#SYH'KO\U7Z_7/
MAS%/?!SE0.6PYWSOL(8TKQ)UW'Z<9V,/RAGSKC,L%NP63O[=[I])H8<U]V9Q
MN3=?ZV=^JSD<F3?<8,B$4B,!+ =ETG-"2URS,XE2+"4TJ>AJOH"BPY59KB2S
MO+$ZU^.RFVOR5.N%!%1GN?&BO]D^5"9KLF.&6&,8&J8TYZJ>ESVX8FZ$D&_F
MZUE8J:W4[7P8X@?7BV<'9Z/N)%ZG\6)-^.;_9^_-F]I(MKSAKZ+P,^_[=$<H
MN;E79O>$(VAC>WRG$5YP>_ _CEQ!MI 8+<;XTS\GLZJT8\" $5 W;F.0:LGE
MG)._LS\NC]E&U"58%6.ORVW:"3$,A\%7:O)VWV<5>CMO5 -7;D[(O5J!*]0(
M8IUV2(A@0,AYESHY"F2YP$;Z:. L>_*4$-I6_-IZ<^-1VURNOS5K6,/U&\#U
M2]!&*LF#4ARYF */)95($4Y0^DQ*QX4J4N"Q9FV,^09Q_2,SG4RAS8DY*W&-
M<6XX">MQS9SQ['&96C;+TE)OVNMRSU*Z:;EI?\_VIY%N-R?==E<PC9+I",,2
MB<*D6&60<\80BZ1D!14$.\4(2+="MXE0&Z2X-7:8C<,T#;-O'+,O01E+2 0Q
M+A#V'A08P9,"HQ02G@LKI:0VI9@3(MJ4;%)BPB.STM1@OS4,7T-_$AZ7^64S
MZD*NBJ]Z5]Z6F])(JIN35&]68 DH7<%JC1&V@J9(1X:44@!+"DV4=M3!KC]Y
M6LBVPKH)6[XWO+U9@*3AZ-ODZ"7L4?A 0;$@B%A-$ <N1J8H)#*8ABB<#EK[
M)T\UEQMF/'U\A;6O6$_Q.O:32]?FOQ_B;3.@"^SA,]C"U]4._G7V'K;O57^6
MN3'=ND;BW9S$>[^"8:PNI(R.(@R"#O$0%=(@_)"10E.F7>"IHS85NLW):L6*
MGVVI?:D^%_?%Y/+ Y,-=PI]&*MR15%C"05Q+AU/S41J9 *G@,3(*%R 5TED
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M2B#%PC!=!6,R&S.6UM$P'<+_Y^(M*H"#<J@=\,:S='YG5XIYNF[[[Y1,5WR
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M!W*N8 "$.>Z>])*D/DPT.H =KVY--4)FA^\*O<_XTI[E27\8#'N^]5_EH;T
MR.JW?_BOO?KM[72"G89>+_V;[GX^ 7D;8 ]W@^^6Q_-VG@V(XNGH=V>CKR7]
M^WY27%K_#0/Q@V.X>'9_NJ0<CDM')"RHAU-OU'H[FVKYBND+=O_K[?9LA'8
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M>\M!MR(8M*Q(D378(N6"X)%8*05[\E01OK&E.QH:N!8-O#_[!.@U6.TY(K$
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MX*9((C$QU=F\2IRJP-P9PS2-CENBE36R$(86(5HGR(5QJLV67G=+HX[4":Y
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M+K<.X&H&N2>][KBR#)69<-EKNCB.<W)\%W*;ID-LM_JA+.!5;H$;C,9+Q<T
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MB^B[,G:-^7_W"KN^7;0SM%O9-MT?GZO1T*O-?ZVXOM=BZZ80VT56PT: W98
MZZY@-Q^]ED(7R&(?$=?!($6+ @5.C5?!46QD*IC0!@QW7>FU7DC<*C9;>N6Y
M)HA'S]LW!4D:WKX[WEX&)U0I:@1FR 4)O)WZ-,.?$14@H0N*M69%*L5#VER?
M%XYV%[S]JPUG/TK@^[4()*6@+*&0&QV7W!*7&-B:M-*$-!';6N. 2.&Z9=+A
M;V2II="5A.R:/7QX0O97 :C.H%^142-?;TR^GJU@)^("#89&1+ *B%LMD*;,
M(JP)5ZF$BXL).[6EN#9T6B_B[M*LU7#UKX9.#5??"E<OHR9FO/#6 &HR'+C:
MZ-P;T2#85<JB)0Y'5W(UVR"N?@P6FV>7CQJY*FZM+&I5H 6#32BCU*=6M4=K
MI;_Y!7HP@O\F/9A+LG[E+%C\8.[*YBRXJ;.@\VP%X<7(BV@C0UIYB[C0$9E(
M!$IY7 Q[HF'SLV=3%<G$?T-*],WQVAV;UQJIVTC=C87;C=3=%*F[@L %!F L
M"2J<IJFBO$=66() Y#K&0:OF+L>3"*K:5.@'(W4SAO]7COQ=Y,+;*ZYVZ?RJ
M:GXHR=2<.791.#JZW?2R'\YJSA3YZU^_N%1RB_&T#L]Z9C0J*YJ:4:O,=ILS
M]^9DL/$H?3>(N6! 2<1UF&W6<>IXT^JK*NBT71=+^$%@_)J$JX6<DZ;FX"(!
M$7P310>%:(H./HJB@W>>7RA_:7[A"],=9N_M+*5P8S*].N]JR/.BVWGYXNCC
MATZW<YR@!SSCPX'H?#X"N/,*GGET###DK$,_=E<RO3Z\P@<?7O0 LM"#SX=G
M,%[Q\?,7NO?RWT?P'+SW\N#[[N=7[./QOV/G\R'YY+PFVA0"%:10H":"K@CZ
MHD&@+UH3G.(QQ.6<0LVXL@6F#%O-0Q!6!RF=5BYZ;:FGRYEA:=%;>=5;N\&D
M-9]5<+Q:_N"%;[[M_,$I_6SG0Z^:CM_K=U++VG0BPO'YEQEU'S-5X4\N<&FU
M#B@"YD7<"H.,BQ01;%T@!3?,NWN?/Y@%V;K\P6$X ;&2L_'6U8N(B1V^9G8X
MZH:A&;JCLGQB+NK4[0/X2>6@:EB5"ZR47<U3I8:+,OK6+*'(J_-K<_FTWJ)2
M_TPJ'\-;!;GY5#Z])<7/9NO].)/O<BEWS5B;L3[DL?*;2#S]^2A((J[E,-S
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MYR4O.":%BB1YRXRR\$PB"?RE++9-?,?&\?*RR],:J;AU#AD-TI$[BH&K28%
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M'C_(*7^^%:U0XG%+;!US8,0]<H()Q),/R$E/D*=8L4@BQ9%?BQ+W)3E 7!Z
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MUO_O43L'$C(GO ^]+&X4VN$>3#%OU98!AR[<Q8_]I<%,..0\[K!6>R0Q(R]
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M(H&84!&!4W&%H@DTA>0Y5VJI+>:#M_S':3G+5+_DLK;<4+GY'C5,[C45BU^
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M)8("N*1IS6)3/5_$M7J66S?&4#[(GS +_?!7\>4P0\5;P_N95/G.='&[Z??
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MD^1]*X:C3MQ.G\;Q\+_BX!>@]0TRTNGT_;C(T3?@^?N]')PH1:'8W7O/>WE
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MFQSVBJ^L,[DJ]$WE:98= 1\5':G@L8+':8+H ^-11$.DX89BDT+D6&IK:92
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M6:74KZG4^%9S?A!^[IS]\;-!=\YV-_=QO?FM76^V6HVSSL_M+ULGV;S#]QS
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MQA,=N#@&S[ 3+W:=A%NVPY":@A#^D#JAE<9IZ.\R)A%=[ PO\ZC,8&-X4HO
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MJH68^K*[A;9K4UND;+B<%0EE#64%!\%9E&OKEBC)YU^KQ%.&7\%3**)&.:8
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M8,"+L8@@P?X95.Z'TTB(]0_T%%2<\JSAH2=VHR:!>]5PV,_[=6$.6-0D2VM
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MH5*^U0@R6:5.TB<BZ6)R"!V8_$#86!>30KQ?]->CW!2*\)!-!+2:#Z9E7D3
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MWY:K.BC>].AAQ2A%\;$%92G:/EYA.O856%IT,LW#IN8:\0"8RT"VGZP32K&
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M1!$72U:5Q_R:6KQ65 [Z,8I0<L7&LK%V@5W)D_QJ)+_#*P3/(?CU55:B$22
M0HDWUO2"9AH&=B5Y)Z2P@RS#KJ(1 5L/)DKK0>6HR3*B?#*N0\+IA%+P$C"_
M9 671":M5*M2W+7UQZ";=L8KH.J8%U7%9I:B<7(%7TK 4$R>P,YK@G' BFMV
MAEM8L[T,IS0!HR9F!.JHX>?2Q2UZC^,/0 R)/TL=2N*5P^CUYC4V78$("O9"
M2IMTNT\&<,D5KWDM.!*^"0&X4=,40-GH4A*G7 ]/E<?J,.N/,P$[42#;(!!-
M5";SD4P@BW,!1E"RA@(X(RHJ1CJKWJ[-*K:&,TA@HJ;M4^3"*RO.O9^/M2]
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ML"Q@+E-WSF_AR4)V+ZF1%$X)*R>,<64BH$>1RN/7V*U!'G"U%!C5? !-J7,
M_:5R$"T>0.#>W<3)-QM%2Y\T"A;=7@)QS@I&K;HP":2C!6(-DA4&<FX!@;"#
M/$[A6^:N&@1N6-=X<"T0I#")%DDL0=WACP-!A611'!V#(H9WJ+Z$OH>ONMXX
M (G2'J?<14/*;,-XL*MV$QPP0/,X0GEZZP8A&IJPKHD G]"P.8K';"T28*:
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M>NML@-(M"?TY2+^MAEPZ;*@SHJI$8C60X52'I@1((UM&(%"R*U-#<]7<B'6
M1N.R#=PA%MJA&V#/Q#!GML<>1!+,J23?A;*?Q>CX43.'@(P\F"CV&TL2:BQ2
M2DDMFA;A70)GJ4[BF;BED^\#[NC#;2"-^"N>P(&W@:"\E80[5X2[4(1#;M]^
M17O+V[KYC$0*'PO7ET"V[.<H%$]['5L7_$DH=)*X(#!IX <N]A&2:.>EMRI"
MM9Z906IR;,(BWRV.6PTSZB-25F*Y(Y#,---M*FWK$X:9K.N,O-J1;5W?"#\
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MI#]MR6N\-]77S&/WKGXI?]*4O.*\5V.>!XD'I[PQ&C;T'<5@=,_QCU$VM_6
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MA-FX<Q7J X=%,9I-RC!=PT(&5Q 7D5S"]V$5,X9EP8)&'9)&4[)$ C:W5E,
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M]7^G1DZ4\BGM59@+L5GG=L#:^'>"C@AW0-\^%CM(<!X"5 BB61S../8W<Y,
MY,2*Z5XUI,RFDD4M U?2$HGB9"+M-8[HJ+K^AJ4A4LBHR3.LG5-:#Y]=^0&L
M 475$6$P<5F1OUF]):'D))Q#67#7? 4&JXJJDNTR-,E/%)9-D^7::Y+E9#B(
M\K!V(YFLJ']QSE9FR!$6UEN70K"WY9F92]Q=^;F,ALCZQ&T)L%="O@Q7!$:(
M0"-/?#*^E7,HR[XU]@58P^"'DED/1W5F7=H6IQJ>-92W;U).'OTJ;?\LBG*=
M!8[\^A9F!,[@\3L=5!\&F!QCS>$K,MGXC?#8%&@[*C].PG+H&P!M^5Q?G!MY
M0<K#_[*8!JQE2.4#:_@3(LB0IX_B.POD(<R)_<5]PYK%L Q3REDJZ,( YC<0
M(&6WYO+O#"]M#FM!W(4V%EA^R4A@W0(94XA=@V&*0"9( 1.@KG8ERB'MU]GG
M:[33CEM@[R1YJ;1>UON[G@?&()>.)$OQ96T-A92BL2M&E(LE,3 M5)'*>L5G
MSJ^^7KXY=OHJV4H:EQE^4EG5RO;5T\5I<>4MUGM@&<XPO[TN8V?V\M9R!"1
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MO@G=0#G72J-M(MD>7.ZCG!="#*.W84A[X])D/SNX] 1>&12P6*,CC*ZMIX0
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MN\EUKDZ3_P;>2Q,26I#H/2C)JGM/,C;%6^U#<='T4A:J)1,/"-P-T=4?X->
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MO,:*I+G3<F^*!*W,W6'J;&7J;(ZLZW-(/X0YM-Q6L_>82NWBIY(%Y4H&QT0
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M;@H7I'V8_(S/AS65+I[,,0^L1YLDDS4;-)!WYSQX,E!J^U@T)AKFKD8VKXJ
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MD6PC<UB3C%DG(Z+SD+NXOVVJJTGO@EZU2\[RX_I2ZV#]V[_\_U!+ P04
M" "BG A51^VF$4G! @"[1P, %    &YV87@M,C R,C V,S!?9S$N:G!G[+P'
M5-/KECX<0$3I2.]*$9#>02"(2A?IO8D@+88B+=0H2I$J74!!.DB)]%Y#$6E2
M(YU0I2?4""'Y<^[_WIFYY\[,N3/K^[XU\ZWS(R\+DIUWEV?OY]T[).!_X)<
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M+!BERWK/E3$YS7*U'O: 4?'+&Y$\Z*R"%>W%ZPL+Q$F&WQ<ZBQ(*C E:TDD
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MW,'01!V7^:X!W0WTA$2B9Y:XKM[WT79,O=-M&&4*LI53'YWZ:4IORU"]@,E
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MF)^H6<':=;;13:&]+!M]I VEVSP[2?NT&<Y<,:NJ(;-U4(AYPLJC\,9SUY\
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MR,U8J1A:LY ;OI(#*CTJ0^#OCF;#SNVO157N\I2#^IMNROQ[' Q<<Z!!?\\
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M O/O::#3RR<J]T7@Z1%.D@RYO"?B'J.YWWY8-IDJGCXF^YBT6 WP;0Z]\2P
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M_8$XZ%5D37^/)&N;W_7.@A-=_R<0Z:JAF</<CBTD0S ^=!<;HU[$2<)K&Q#
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MXMUI0JKRQ<NN7V3O 3U/PX;I'0(1R8&IEYWD&&=2@X]NJ#;_J$VQF0X>Y#U
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M63AWG(S%<Z@#H*D6^_8WIO^TI D*]/L3R*"0)\CXG]%\\BO-BUF[)?"X\[<
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MFUP1=I"]1 RD#<?D3[.2'K%28B-T1ER@(/? ,B=^XF!.V%PDVO'DP.944G5
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M*RBA>APE&2ZJMVV]F%Y^^%>_)P]"=49=935N8K%FU4RR;)WV,0$4&,E')9M
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M)#_7 )6\\[2G*>/;,9_$(RG_46TFQ+PW*QN;+.^.8R=MMJ\.*G,5HP>1H?1
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M!W%.LX]RJSC_U4@5V^T/^!+^6!HC/Q?Y!R^[-7*RRWJ5B?Z CMG,OU%5F.I
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M#M)$#0V.><]NQ5P/T%7G>;YI?#T^JF9+\4SX48!E!O[-$@O)*\!1NQK:OB^
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MR@"<(H"9[O00Z.Y@JW@'<&Q8?;OB*($W/K%J'[=;Y;"\KE *[/, R7B+S;)
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M+'[S88 B^!4LG6GIIM%V:52;=N2/8PN_96R9;:=&N9C/53>,8_<TKE-")V;
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M4II:6XKU4/+=.T#^NDSQSU19LE4?1 L^JLC?7V?,WD6T7W@$QUT;]^<3P^=
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MWS1W=01^_/ !HF_6U<PUWCQMZ9+U./D.($B:RD_O)=15Y7M.@?4=.!ET;@G
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M%_"QJ,W'U7VP&YOZXW*6%:EHQF5%$1OL^I2X>5F\S9P*5#E8X+3;^Z+)O:=
M(7]]&?1MA!'9>XQ>]:DM>S9*9^(NEFJU^<8K]#GY@66]7:Y]T0K?!^*".\!#
M$?@,!H().$(VIO'.DG[B'3W:_N&PZ"[QEOD)=4JP/A"3@AP+3%S'G29_V=R
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MFWP!^L=,)U2KH5ZH64W@@P4[\M1*1_V6_&9I%]/=]%IMGG9++O:P4H'AZST
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M:+ _$=5DA,LMEQ/L(Y1UW<<]^C4_5F" 43WVK27"@,J#[()0T1*EEJ>\F4
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M3PH^WY?$NV@W,6@T,;S11#H77QEP6K0N%,:[,*^_\ZD=I)%/*@$#QIK= 6A
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M#;0BD74G6&P/D7,Z=$OV^J)T,W8/6"\JL77G0*YHS_U,N<&7K^^,T%M8D4)
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ME0UB;F3\2ABL?;('>9ZF+IX"Z8Y[+[K)^\'4J*(M%Y2<!"E(4JJF=H[[,I?
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MU3PYF=8YM?FJ/C$)7^,^N9 DT-N#;Z@$AMN)KZM1KZ'4=;,*3M6[",6Y:)1
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M^FCF^W7,%<!F)'_<=X[1+FH3HM+)40C5_QU[I=6DP6T00.R]$TP*RJ1M*V:
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MO@5$'%2YP^*)M:?=W3OFQ^P<F$5$'OW^9$2[-?=7B>;G0%2KMFVU)13'8MD
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MND!I!X#V0-'K@JQ\128.#ST[0UZ+:A),9GJ[IKMX>,M;==8 T^\/VEO5TC"
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MK]Q3G:6RZ/.3TDFRM20]"*^PU%(8XU:U*BL](:W03Z:NIXP7)J)OD14)L0M
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M:FQBQM7R3ETWML1/*H,=HCR!36LL3(SF@@+>F'^I)HX5"ZIC+;IL8.HF$X&
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MNINAQE-/YK?']HJ#'J*G04=47E&3[R&/KZ0QL)X07'1,N UTUE<<S1=CS5"
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M:;L:FV+<F6^_@(H.9+.B?7YSQQ]:-&6NC%H_C!_=)WK&DTI6CIOV^%,5S$_
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MU9#^\6F.VB#+-V-]M4N8A$'9\SK)*D\;*AJCJ0 /N%6N?]+&-T/5)TK&7D0
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MOI-"K_67JT9WON7>WA2>5B. R?O_ #BEJ9EM8!;K;.!+&HR9!/^" R*!@3_
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M:0G]BARV>+#@;:TB%(QF;9ASLJ77$XM(GT?YQ=&GV(AZ\#R5[=G-"GHUH?4
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M3]"LLM!EAKUICKBS(OYS9[O=F&R']ZT'\5^J4@6_A>^0'=X@RK4UFBO%]G2
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M?+%'$7PMJ2N&RZ[?PH<:8=53@5X"J99?Q5!DZ\,>SR/%$A^XAP%N)&@6)M7
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M^@YB\5WTW2U#M%T*3^)UMN/CV2F0A::"F[91;C"!?<O>0),_ )OEEHZB[#\
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MAF?WX^=PJ=\'KLGQQ4R1/^L$<*KO3F!UB&$S>+.4-J\V]S$SZ>V=U DM_U?
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M0-K6EWF%^7LCZ((.'ZWY'EDYO0BL!FE,'YM,VU'S\2G;KSV.BR!T"E+!>@,
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M 8:0E/QBK4T7]C?J>M\]!C<^I\F<>$^AD3:FBZ_0*#"KI&S6@ZX*Z=@M\5R
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M.#S$3_794/2<U4&]P?.,9S'F%!G#"ANF?!']C@4'C+> #3;A@&\3-UO))[>
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M^V<.W+A;:]3V74\PD@-3Y X2722P'_[ZA8XLQMC\&>M+TLVPUM0HVV'0@V>
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M?8!*POSZ.1KH7\E&@)>&W;;'7;FAO-+[(2\.I1D:R&9(-_2H:$X2IZ7XZU;
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M*G5@AWH\ ;>@Q]IB['6S=1T'R:,F5(W)OW>_)UFC="3=."+?]<U?--E5&44
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MDBJ1."+&M'7NW%-_,H6G.]#0$G=L/- 2"7FJ' <,4^3PU'E=YF3]4;U'3B3
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MX)_65\!O%R@^+SW[1+OAGK(9* "3'%&DP7YR],N=*5[NKH[=[*N<J0"O$JX
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MCEJ0>0>?JR-^_]5O&NY!"=M@=DT%V4V]_WGD^ \(AA__HS5HX,-Y5Y!%1]
M\C@CZ+<EAICNSS++^?_7/3Y+\_9-^($C,8S]YZQ?('/P*5$RXUB4#R2_LC]!
MH^AS,+.%0T:34 )U> ^ZVJN@4WKO A ,T2H1JSI/2ZWYN$?U&Z2LG2:^/U4X
M[$O?LI_<F%0+<UR:SRYH)<%\[>4JWZ&X=AJ"\"JJN3(ZRG3>A=R$QM3-S?Z&
M*OU7U9&[C!EIL4X_-G*N?*?]23L&_V=E"?T/IZHH&Y*I*G*PA)>I0R*7)?*S
M/8!VN\]SCJZ9;0YW&Q,Z$.ZEW6#>\(4KUCAEW"?I0<G"<;!DZG>[#>?47-8F
M;TNEA<$@4X1,G4>#B#A"Z3<]QP"<F3)_.,XJ9>Z*E\8B&E@!-E.M5!0V!INZ
M\-IJNUW52]% +J>D?+A3'].4RU]XXFV">[?P%O&DY<[<+&SSMR>>'%DIA<Y\
M*\E^&]QK/E:>_@E<*"O=?HN$-;$ALM>4/MGMF<D(A]#3Y5IF7EXUJ4"-\*@.
MQ$3??S*Z-GO"8)L#NNH2IT'_9"#RS0_P$RQ^?^ "\)=.E][/^O-$PO_+0XSR
M_]4[FLYX<$SH[>1MQOFHG(0GOL(EL] Q2Q5URV[:\B7:UV(D="8^9X)!W8'H
MY'.OU O 0TW50)^.]P+/,8]CF+Z46*5X.8PL2_(91Z?-S%Q>?9GYK[]@EC2@
MCG&)<.8+P"_GXPN >M-+R=- 3NR] U <YC H0L283E_5DYDX@/%,(*JAE 1G
M4/:3TR%J=?C&^AFIJ59,:W5F 0A)OY_K!/7I2"E]XQ458*+:DJHS\DPV%G6U
ME>/3T<U3#J%PUG#H5YI<1H>\,\?=TJ24=":_KS&JTC4G:RY0]39%N4R$0>O"
MN;19> ?USGZT (^'"(GWD<SQ!GA2D6K*#">+I2^$J=2@BP+O8#1',A"HQNB>
M:OV"5GNK)K_C;K9QYF+\N!)MU0R'CIRE\^R0+*.-GITSUX?8RU9!5WQ+* 'K
MCLE$S%US*5E!'^4N"T_, !DU5U6Y@V %2OYSDJOCGZ,0!L[ND3YFM\^7:G0F
M3!53V#TW'F=+H*;FS(6!0W6[^+N#!S%@ ZSTXA3\>OM"@(W9J,'L!> 1]2NV
M'K+),](U-[G8:/%-$^"M^:/PHS9,^*2$*LLCJ8I'1$G974]L+:,)6'T5$_=-
MX,U"T&R4?</5TE)GB,),M6+_+=!=F7L>[_5_+A%F5/UR;JGRZ6AR:#=P3&89
M$7+EL7J8+&I.5.?520E2T-BX7\)L5UNEHR(,9F0L/#;T,1XV%Y8L^UGF*3N=
MXB=Q9#9A;C6N(+]P 8BH;"' ][$,1.2B=U)+K5I1 O&#KI^,[R_CC6VBMPF!
MA);!8P>=F(%6$.LZGGVX2%*$+B?)I S)0?WD:_H&"4: A.A(IC1^$1M7C$1O
MXVZ4NDB0U)\]U^,[;G8HP1T<(9S5,14(T0?SV"2P0@:=Q^UD?+183C0[#G<!
MR#5Z]#5G6;9X:7D4=U=*>W?D<6>GH*@_3[V7'NC[:<D94JIE$L3JM?V@W4_U
M#&NO#85\3@(8VZLL6W83+26MLKL)]1^P\UX G.%O]J94P39.B^R<IC3RY@_?
MA56F-S__OO:I6FD:9(8!PV,X^.JK,*&-\1,?<*9<O5^M?UWY(?=B=>D<7'J>
MB;_E.$=V0,4"?0TQ[\7<&0,]'SJH,OY1I OKE)F42O-2B+'=VZ@U$RO0"<3(
M[$WNVB98P<U/G,T0*E6JS#!A^8.-N1.Z"X 3)$BK%M.AR(S&W7N0!74F'EYT
MM#$2ZP'0R-\[0W(S'V7/F^6_D0ABP#VLG6SY51W6JS--,!,@,_G&_^MR8;=]
MBG:$;8J#6!\WHR_3W@]=325#R[D(G'M>'[JF;99J,+2MN+)\@Z4ROO.&CN<T
MOY7NLM%:0)^_07OM\X70V(()Z>7&U,.I%5_,UUQCHXRDJ7&[X\!PHJV!NK0=
M[VY[A>Y-T*= LD&@[!<HZT)8OF]^<SZJC[9]]?'@MO$\8H7^(26)#!^O7P@H
M,W'M!LX;$] T_L;E5D-U&(A<Y=FPF;R;*//C7-O552+^ :UVB5:C3K5K"56E
MRX.%3H-;N)A[T+?/I]-&=UU_',.#J9TX;H>CI!&<U!/FZ1 O!B/M5#(1[K)I
M NOG>A_.MVA$8_)G*_!2TNUS;\U<WZR\UGB&H5_))RZT6C^5[,PD.BHZ YT[
MM@K%S4FB\.S8[44J,FSO$XQ4G+^K3=!7V?B]62'W(],/QZ(.S$L95(;Z,!7L
M( H>)3U& RW5=]K:MJ"O+HM6*3A?,5I=17I8: N7'E:!4@:'QOR%S).FZPM/
M2K73J1BU?_G+6YZZEARWK 6HED#+.:_A; >;F4UA=X9W8!+Q]^-F-!W-3)BN
MKPHMNM =]GM4[IN.R5U//T; 8T\#FE-=)7IS"<$NU1O>F2*<-Y$D/)[%2F3X
MGXJ4@Y77@;,PLY$J5O#3=G;%52VCIG>4#UVY\LBVQS/-3BK,L>O%ZI@$4\QJ
M6![DMG]W;%<.0?N#X"M=393WB>!F>]]J@:H.,FILU3$E)\4" GQ!OE[5U753
M9DV"SF(OFQN$'(O&=<<WO$^OAI]GGMV:G9E=;YO<<;W1]DT'2&!G-QL<K-$O
M5GS"<F3IT2:G]U;)<=O?:*2RK&3@$]9J]G1 ^WF<^[VY5[&KP20-E-=A91C.
M160T7DC=CO&M)&E.=<4['?KB(B[^QM;!#[9+>(F9!XNET554G.;8WC,U>1T_
M4H8)N\HWZJQJ=2>F8@\(,SRL<O:VC*R<JK,%/+9FTZ:K30YB2W\LQ@I&"].E
M:B?G@S>QF:I0$20<8_,=1",B&12>XO+*RR:WE\TLM.GC_4#C\XE91>QFG"&V
ML*-@\0+P1HE$0D&K7:^B#&,T8EQC\#!4IURM)\A3\T0;TGJ:@F'W.*K$QJ&$
M6,^$9E006[N0E#%'AFZ5[1>OU66OAXQ+MH-!M)+;_FV!'.CED9\EJ9]H7@ _
M5&N].1;)T+&CR"M,2=622AQ-]3XVVURUMRC[N>RNTR1<;C)V 4@</!PM*; K
M@EDT8-7=T27]5*1(VOLUA2\>?GTEQK<O&I-SL"JKH*>%JA0&Z6&5SX";*;E)
M<7F;R6.*_ W#+TI<YTVE7B,>?D3R"![TBX%[2X+ 5!$U@:P0^L-?'<*,\>/:
M+L2#5IF;XN/LF!04*^IVY1Q5T,(UL?N>G-47 $>(:.!Q_^%<1L:O?&W!4CN6
M)/U&E_>I3:4^I28!H4"(? WK;']_K_9D[U( =S9._MMY-DP<O8H0H"\N7/>0
MA$<\U(J[&BG:X@N@2'B%E3TH)<!.+)J[<L T1JO8%4DAGA_FML9$E6DZL^@6
M=$D\NG'@<K1Z1['(PL#6!0!EJ:0SEJ+'"(V=5SD2+:0JOT]@<,+-+&C^>4>H
MXRBFP1VI=7"/R:FM2E-[(<I9,68&+\<WP5:;,I@HD]M0D;S4TG>::0<CPKJB
MV#F/_.M:T-O;L7&H(!I+=:")V9N\>TEEW[X;$,C>Y!#%>?7AQP*)64 =<%(H
MLC=X:F-/^?J9>3HZZNV$1\@T_>%F=2,5$D13U?)V< T#%H$<!=R>VZIV,_O.
M%2MQ ?#ARR!1',E$EWNU8$UL6BF/]M;(/8YJAS0\[A@XR*H/]"@T]7D,]Y:)
M=@0X&YHD^!BO'<P5%Q450>X8,1L<"=[M%E*27%[U#E JA8JF'DT.&0M3Z\:/
M%<B2.ROV/U91MNF<:SH=A5/B5 -(YL<[R80]T\6@G@%F*!D#C4#3)%.RD^^;
M-3Y,ZZ^L.,%G3W&/*M!#:W&;[K[D5.]J=%Y<_VGU<5]\A!+;YRZGUU'LHXJV
M;U@ ^WZ2TZU&:<])"0]54+"%#[ +I=L]C8R+!IO/+&F;?(UJ\'<9?P J&8IR
M23]<\?<Q$VD\+>WDI-_"LT!]%GC4VUF\ZWR^.*$1PIV?4J/OP8*+ J,U^_78
MGI"C,]NJ@RJ38QW@]^&/HU0'4:-;!_S?)Q1ZP_C(A[]&4WYT2=P[CE3D!^/O
M1;67;1B8BZV)WI%2?$)P[ZLR:]U)_;7!$459*/(Q]FVS-'XP=KA#B*7-OO(M
M#X0E&F+;340]+K'X?OP-2[Z05$Y&J?%2"NYNY20*NO$RN;$DP7C0NP*G!\;<
M_NR*:9]7CP$^*(7>'F\S*PU_JA!Z6'2;/CG#6OZ;)CO5B[BA>OC;C-ME0X%<
M,!$T)#.\\L/":%BZ;Q 4DMR7<#T4GB>%JU.L*TU7Y G\J2B-+<Y3S]L\?:^N
M9SP+>;%P(R=:CF%I!Z$_%B@&3;7">+]"F==!6(U^+D8*W=9^5A8:'9^:K"1M
M:$114J&=TGW7/MM[J%[3^7@4U/711F 37)-7;3;1@&?AM)C";N-N738[L61V
MV4[VPH2/]V]&S+=IKQ#+V^JWDO^ZMBB1&2[GL$V<AY/&U+<Z.8"?<4QU#'84
MTD#>N$[?9TNZZ3#15/C];K,,M&1O'/%36_(C'&%PISY#./A.#X!5]L3/?]Q\
M(2C"#-1^ 9@8-AOT++;+QYA$W#V:GNAD(I=WDTJ(%TW2#WD=>.C16%W- 1RI
M++B=.#H;*Z"%C]W=D3R=D2L9QAKXG\Z8H]6O8T(ZWV'/4+?+"B=:KY>D#9U(
MN;73=!9><4LC&#E47*F=)&&[)K19,!S#+^@^X0CU2$A+R]CBSXH<"<Z*Y ?\
M4PC7+BWA?%P^!!/'F.WK#R>8? O1C-7<XKDIW$8@P*])\EIFW4R)Y%#O&G;?
M&)L>E V50K:;>2K2!0GI&FD:\5YYU$,Y^/JE'.7H_"PU%EZ,Y=0</]@6U/:L
M&A=N[O6['>[/A&Y?ECW1^^&;_?T"0'W8$AZW*;HV9-Y9WY3Z=.8$??+Q[>HM
M7R9@!GBU<'F_0.Z0ZS!3N,I?R&K3);Q CYY)+<VJYWC0J^YP[LT=2)4(#8R@
MIK$Z;.<J>F9"5(_)2R;R#AMUY%*C/ HB?LE2JP78&)QD[F9*M.+MNK!!D4\&
M;U<>O.[P"!8/ILJ%)J6>*4-[-9O0B)G&(RY72C--F_RD2J([NE^+.#,_+*@#
MC7F/$<)!C]' 6>H4;9NL7MADE.!WH@P/&LV9C(]\T29L+[_VY4K5N9063J5
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MN?:7GC_[H?0QH"MS:UID[[^R$7X8<@]O=WP3W]=V 1!!#2 SI5%\Y]0@]@O
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M346I4<]J^V';L6@R^@2Q;2<:)NY8\=M#)C_L[A#<I$ZP J$]Y@/+P$H=ED_
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MQY_)! %@W)DHDO8^UH[)XUB@NL<BNW./@K)7,9]1TNQL]_+CM>JC+[/*,6(
M&NXDPA4^R57I#'$,'+%+ :.L!M%;KLG%?D9!U#7&JBRO=W _#AMC?1^O@10D
MRC!>:)W45;]I4F&.(Z@>>@%2_]EHAX)38G6.17#<]5X=7*2#$<)L!I40H$!W
M&Y(KE.VND#^>GB1<>.I[8?Y4<X+#?+>5Y=V> ?(;,X1M1JU$<57=&V3 >*>G
M=WWYW@)Y@^:#8JU(T: PF';I4RP(D<2XMRDUGE)T7 ZO((V4K!QN:+R+MQ^;
M=*_Y9-CWPHE++RR(0P1&G^LL5X4,]](C[2L6SLO_TN<'N9N5VBM,5R&N02C
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MOL2P\7P J[>))]VPFG8._&Q-9$/H06)2K3"#EC TK>!4\!NJ&Z*:T"+H^>1
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M.#*<4^TOOW>99I]$V>+)\\S@_;O_=;<F="NFZHN3V<]GS:F75YGIF189-F\
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MF=HX)=>W5%E,-%@7Q3XXIC5$9X[)NXAJ\/+TJCV2?=-N0]R<@<^"=,H4N0$
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MD:3Z.868YRI0%=9#=LT/;!Y<I9B2.J%S"Q?R"$U>43DQO"3 Y!H.<JYFT@0
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M!UY?<3\PB-M3AY1<?24D<"EYE-EQ9 L^(F=/#&?"/9V5LB>R?F8 <T[7T4U
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MD'QV&9H<IFK<<NEDN!S[H-KAL\P]QHVF$@0XO?9V8B=51[_.]?;U?%FSE)S
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M(MQMGXFWFK<?=/@ >DF( 0!]:VP$JD$7&QQ0L]875GT0,E\[=?7-8D&D>RI
M E;V*MW'S.PI86-U20[/9MZ#5QW#.)_N[GEH,&JM5Z!JQ;63/[&B*\ND\^N'
M >5^ZZ?UK6X<6TK]@TT$#YH:63W&KV5! M,J= =K]TYPW#7N; R03G19;-EV
M/%N)Y)+[X\2[O+:_3FP"Y3APO6A[M5NQB8E'<VOHR]JT!CO&.7>VMK=E?VEO
M*0C?G!SID9#[OAG(PQ*MX=-\_=..?@XRAF^-)FI">M-Z6)$?!L&=KYNK_J2[
M?P=GFQF9>+AL_PEBH<R_$W?W]UJ<ZKVSM21[ZFX96V#_I<F"?XT]G7)!7#+?
M%R7SUH^0-I<,,];GV\OBX_3$^%F6<.\T)2W9Z+,>O(H$"*FB1WK"0B&I]WWH
M8G?R\W<C:!@?]Y5'=2V7^H3\@;TN4+?7RB(:0OE@=2_:5S4A@&^N ;H7E*X$
MRRB(87]TE K\.\^$(T6%8ET&"]D[&V]YO^["^0M(S<BQRZO1(,%XB:<;Y(SF
M@"J3;.XZ.M)"@<MG(';4Q8!]/%SY)$[$"Z2\C<W7BCX>UUUT238F#[L''Q64
M/5&S[8NCP ^4/I>^P(6N1"S(W@ F]8,IJBY%L(Z#:PXJ? M*)DC8C-?+;S-I
MS=5_P*\RY6GG2DB2))X1"O7ENW%S\W5%:U!SU_C[F&XLO\HC O5<*B[B+",6
M)_K)RSS8B..?*:@XI%WH=&4&I),/?%VNSAGV*0JUN+?>%3$D:X\?X:**MVM^
M(-V3<';Y*8"6J<8MXHVNORA&H]URTXE"YQ6-4^D;60K(^4XTCK(,2]RGX!TK
ME2$W[7]I__4Q?Q:HT.[N5M/WG;JWJJ@B)98U,BE5/ ADR?4O8^K9*!@BL;KX
MX]V'//D%LJ]DA5J&VAS1&H(4.SG8(,1%,@[_EE;=7=X-9YD,9]N["$F"[YM'
MH/(-(BBJ\,Q%$KV%&U<4HKI>6%*U['#D36+MU^MD,3'Q@X7"Z!G;_0O?@P6X
M;4YF6[,:43HYM%SJJ?9B1$CO/<8EGA.&=8M2H,MZ86H1-G-AT"JMH@[88_\U
MM;AI%J0#;)-X(4@F%VM&=;]QO75ET/>SKY%'#[Z4I\E@[E],;BTPII\II]0,
MPH?:PK:F747V!AME+(3+K7ZQ3"O/_FCS)\MHYKB%_1_AY0N351-/<&9$^<B"
M1Z0>=9J;$T)4VY,)+]+]QZ>U;)Q^YYVKLH&D4.--EVX@E5E1J;)"3 3%/KV?
M/B;10F* MS*QD87R@TN*P\Y[C^:I_\;>>T<U'7W[@E&:]-Z;"@)*D]Z;2@<#
M*+VIU!"JM "A2.](5Y#>A8#T%GH7 >D8:D+OB5(B!'C\[IWWWGUO[IWYS9JW
M9M;,NG^</[)7LE;.Y^SOWOMSOON<SPW ;A6 #>[-Y4=OY8""P260K#/VY_HJ
M_N/'\JKWO'U&[;*>_M!\%&.STAYW?&?7+"KI))A9A_<:,57E*G[YK@XE_,1>
M+7 D\:6-!1MF3.YIZY_M[N P?][^$FR>5&P)?-9Y(K'1\># ICT#P:^T I@2
M3ONN$Y[BR[;VAB(]#VD=8\6+$0Y19,&JK5MUUK-LQYXJD:]"/FHPG,*<5]R$
M'J5R"DQ5.65COO#GEG:FHJ5"&FJBW/<PCBCWMM(*CRJ+P$)KL:N']LL\*](6
MB41./?58ZK5%Z[L66$476>TKFD U%W.[F8.I 6^!,9$,&4:R^.K^"H-[NUD"
MC&*'-P '(#$VZ&+: +UTT1S>R ^:,A46\);).]2B'*/;YQ<=3EBBHGBIZK%"
M@<[(PUP.K%)Y UD[QLO<"K"A@:2Z/QF.3 0/'H0+/7K,^AADM]SEZ;#YA$CK
M4# (L$OCQ"#%LAJ-,T0M"/":9^LJ6<Y"%QWM7J4%)A>Z\2_^$)!;EY]=I<71
M3\FKH.*2J!><$,?AC8L-)C5N<!E_P:S3UV_QOP_O;*K?:8H<8AY@P-L$LNS*
MSH>[!LE#?-4Q*S#WL[;FB ?3;J[56:C QW:YG,OO@USR3^2_=3O/%^$TT4>U
MR#Q6""-2..+0U3N'ZW5#Y[QWY SNN6#XQ<9D';_:^4,9<_RN3YA\/35 -U.-
MVM2M)U@#')LZ'X2.KQHD>%^VLUZIJ7?Y<>>BIE139+2;7F[9$8PH237ZY%%=
M,^\$TU8Y%\QQM<3N ULNK?(J0'^R T:9,4FBS.I/-*3O;YJXJY38,\K;] 01
M8:+Z;LO>%087X6<_<40%UJ,"LKD)-P#BM(L4)Y'HD54">-,>=&?X5:L)>>LP
MS&V1NL86G1?B(B"OXHWT<X."2\PD*QR$,]!%P\_9MHD2A^)1[;>/+XYE$BJ,
M4D')91^:#R@^TF"98[?IEWJVA4(PR#BB$%^3(X\,5:0WLK:50-91QL&T7M9X
MN^Z.-X!%'RI(\TOXS.'ON[ L&=%VVT3 R?943@/CJV3L+'I5 TN*OK@<NB;.
MTYN$:Q:,X/^8VJ,=;^L6_2K1V*OQ@UOTZ#[5'0H5^G2D L<FU 4S,72145"Q
M7]3K/[MTP1A%W@=KA(^\I:T_)-JVO\R7^I[_A>S+?*59T,0%R;Z9]UEE%22N
M_^S"8M2C=-?_J-C5^6##NF6?XZ=E)E8G8KA;P:^ZN?>:: K'&8R2&Y/7W09?
MQ#EE=GIE]WP:+/>)AU8V$G&:"<CEJJ,7UURC,*S(S@^H8"IP6V<7ZO!]KX(J
MW!!<,4HV]UNG8.B7(>MHHO2?<,OB-YZYX!AT33\E%=1F^I:-/C>;+XL#SMG-
M<<TVYLA<3_"TM4%S+1P3\]Q?*D$6[SW2#UF;_Z9Y*8?U%\\=?3DGKUV ]4'F
ME*%7,K\R>9VO:'J3-L"=^K]4N>8[A/#G8QA[.4FPF;W^UE&/I@DB<XK%W4HD
ML[80+A+K3.K-WIM,9(EKH2I$/'$B%AA@K#79B75D%TW0/=[(HZTI\<4)QL*Q
M DUO;O3X/LC]Q60,<VS;1N3]M4B+D^K],YNV]O8F[*?FU EW-/;/ZQB"_O@M
M\;LTY:(0"P[ >E8KT<$B\C-4/Q^;:3H+544E43L:/]L'SC3"7F@_ZJ2>&?Q:
M7DX5]>A;*[<0D+X )?S!7[$1I:!M_FT.KHK47GXM?)://LH7+)HA22@H>18O
M=?C7MW2.JV)-OWR""%T3#U=AO/5;2FP0^;MS+2 #3G/V!)P#T=$Y:^K=0X:[
MMSO8=&5P/<?)2!]:S7751X4WF$=+4%):@#EH9P^W-+-?U\WR@'AZ_J9XIW_F
M-CZZ=SS(7Y2*I PKQ0:XK?F)\_NB.]J>]+W3#CI,;Q:(_;O"3?['+^1H27,<
MG)=T%CAY) 2C:$8!&2"5P/K/KH(-,+#1'T&N9 K]V$(NS>9OR9\\AL5-8[?S
MA/N4*("7[DYM:?Y.?5]O +V<%$7L"UD&!KO56T IUZNR$$4+E_52)^%?<_U0
M1<PBY-4@PK6F#*K7VMB:<UKAMM$ZC=,E&6VMMAFEUZ03W1+]JL<ARK^4C;Q.
M6:42@MNK#ITM#Z:UB7W[%-TYS@TB9&23W%:2#.3/0UMW'S+V=/*$60=:]W-P
MS0H*6@WVNE$Y\>P?4,D03%$W>K23D$IN/5 >8V"?>%$8^V3XWST,Z)MQZ5E;
MNQ_[^P:0&"0[!Q<#(9,HL%:.+K>EQZ&^5S;K93E\N.HUEZ9"#W#=-L'D:RXI
M=5;2-?-$W_MG/"US4$./&H(;0'+(_CF_[U;PA'(LBNS2SSSPJ]N"0T6(>?[8
M(^C0I7IP[Q ZLX>2"!O4-^!2B5/NP$CDP$KKR7AFEN_].J*W?R%_I.&C*.V<
M^]3#JO@&P'KRMQ.OK#];0RHNCB"#E.BOQ4J]G[:3)\[:4='TG# N(DG[?@W^
MNW@V!S;C\.O!K,P8846Z/7^'N$;B1FO:G16NF9/]_8I/*;^)?X2Y:CX ?"1@
M#\$K<4<$#RK1=0T-8)::JQ3)G60K(10(XCOWFA^?>U/Y.P<D<[,FN318" 1:
MJA)QA?44EJO\.QU;_TN&5D)C>@<%B"^?DA+-V4/KL<89S4D!-2^S4$?R=U$M
M6RPHP+;Z FSDX]Q?I\FE^45,IJUS<174N(:*-\9*%ZC&2L\\?$A&H/<4P!Y"
MM_?8K$_^^> -@,"E@9($L6O%@B[$1JE86JV;M$S/&P0$:@WZ:09+Z7[Z9A*=
M_.FO[=>/_7=EC47R<8Q=F*A^-P+P_ 51C%<[D,RJLQ!1EG *.6[47/UNF[A"
M$*M)_6#Y@<^[[I2O(DN!@JI"^DM_NJAQ).BM#E3<*K79"CB7><Z;0'5&""KS
M5=/F;*V(Q-X0N4 A92.]+N&(HT=W='UXB\Y-IS^.$A]V547I%EJ-@+W/0A;C
M!^WD/B^DF#3Y^E;OQ?H\:Y>I >#D)CM9=LX96&0MNA#55F>_?U\@JX5JA#A9
M2[*,-A="" , @%T#[&5WFWK_Q#TG1>;YPHQ +CU#[6AD6O\&(=G3ON1A^I_Z
MRFQE Y216>H#Q_BKD%>6>091ZITDS?PE*QW%=?E*>Z-E<I3>QRO?;FF]Y%#/
M>99SDY4PINH, 3&,>MD^7YPR_:YZ5BW.D4"Y>ZC17X'.E&#!6,EFS9)+%S->
M@\(^3/<>,_J^TKMGE);F^-;!L?ME2!B7;6)K=6@LON>9(O[DR0V S2E7*)&8
MTVK&Y6UM!@JD'1XJJC7$DDNM^:Z?HBS5HGDHF&BOBPHNEX]U[9V>F#[V7GSL
M[?<CMG!EG%E^2YJ;06"R,$1L9KYX4C627W*+EXDN35_G?_9#@FS.TQG]?S2X
M]/X?-+A@+!E12?U);)")(5F'2'DEY*-I>9&J',[Q.0FYEB,A)E6VB+,AO"=)
M>4P33F=?L5%ZV2C*"*@I)GM0D0'S$N: #!0>HECA^GF2HS@54%I_R2UWY))E
M8MD\=/Y9*49E,53F,P7O;##)]:/G&.$^*?^XA<Z$<E#S/(M]Q5OQV-M:INU#
M[<,H-M$WD>3+)EY;35"E]6!R;!T(^1.G6@SV5!83]W?!&9,SC8OV,'T4V[<6
MA[Z9$L_A1%+VL<OUF&VF65/*:Z/XJKV3J)WLM1<#9K^(UX[XC HX[XI?/D_9
M4]S+E8;=<GDR;P4B$[0.XC9;$",M34^S(0T@G-S:7UC-=JJ/V;VSE:>.RWA$
M2U4?7NJR]=CLU%!!*E^@TQN,68X:RQPS?C<-;\U4KS>IN[80+-P-C)"[IG%A
M/?@#O*HM^_0@PO51YJ''02(/LRG34;>!K,C:60TKUKIHUTH:.X"Q6A]H8D"4
MQ7J-F3H["YSRS;G5[2H:B)/C.S^E>?;CQ]K[_E#(  28 .5%[IM/((ZUT*_U
ME\QOTX/$FVF37TA4\R=5+FVV-PZ .REA(9JHQ+<+ERE_]!JF#UGVCO9(S0U[
MP#&;K^-M0T3[UU.4.?4MJC/7_TH(QUD]0+^M?1&G/575^*B#AF;J\\9G+?I!
M@#4?VW;.RNS6:L/I54;SY9.7 M6PXU<FED_(I0<>MJUHS#^E,ZD]'P%\H>B^
M,*+LOWK>S\*;U"F] GFC?5L'DC>'B,\W_&;TBD5IP^LH#@A1"MT%M287>->T
MUA3!;HHQM]^A2+UJ",F8#EIE1!CC\8JX+DEOE[C? !@4%7>42%=["$X%&2!0
MS<J^MUM+3LG/:LUE-<:\RI1D'RN+G0>Y-@ZO0A6PLJMUN//W*L5)]R3#YUU0
M--^%?/^J)O2T7EX'70>='2[9-/JY)A6!LJ(.MB_YQ,\8FO/WS2Q4CF#)RT5/
M+=C+[J,AC_SMXVI_<5KOK?!,-I +2BB\,ID^61;!U)W]/I)^X_R[Q>?!2_67
M?A5<\^(C#=ZS13-5&U.F\CWE@KVL[[M6_H@U<_RMH4=71Q5AF\\RL%&,L0=K
M';,-X  ^>9E2ZT&6>PU#T0VIYOU]($$^.Q] <BT1_28GI_B8G'+V>DT4G%MQ
M!'E90_CHJ!GTSL/%YJO$]V)=)CQG3WGS7VDV5V8B[",_&!0[&S%"28%?)TH6
MG2X";XE*JD2\E <<LXY_%,_>QYI9?OU@WRCK>M8M97BI5]A*3'21F7',L:?'
M_?.('F1<).OO)8JS]Y!_[080 GVP[D8$RM4]_F#'DH!4%;78DQ3--\>(?X%7
M#T.7FMY/"H*"QET5>;%Q UW,6\9@:^JVW5S6/_ZE2:[]W+%*4>.9T-QU%[GH
MD^-8#J4ZK"GZW ICE9\@T9GI-"T(#P[RHQQET[Z>;C7D/#9T"[L!T!QT/H5*
M_(1:VI":\101[E:5W !,0;(I==W7\8G,P)::^]A#[QKH*^PDTCIJA7%:?-E^
MOK>4DP$22F[U6]O<E$W$G-4G1;I8KCDR$V25'!N&'"]8IXP(9H![('/<-*:]
MSC$E'?,Q.!EPB77'8?-9N ?J"/#[.379X>98LZM,$,A:K_;X(BE!7JYHG^%"
M]P80+9Y-;K3.H1LQ>Z)OH9V;;6-/YKF(E]7E5F&ZC!CU)-B$GTTRFO+&VCG^
M+'C0]U2:0$-F0L?3BOFV<);JOA;"4I?NFVWEE.[+)E;@+6$S#6:3'[4R%N<U
M$!=[M(G&W\/;1-#9T/\9"K/QN<J]9G;TEVQT *V1:P^UE30>5<*>/QJK&N;]
M7+7>2BQ@5YBBG)^R)D+\99O.DV)HV8H34Q,%M?A3&H%BY[4(<"<;+5T=>&]#
M5/ FW@,[60E9[,OEC 1Y ZEV96WUOM]//Q9&A:L_N!,J8L_D3.7NUS,&O5P'
M1K;E1>&LUYB]K9DAG'TLZ_M/AXJ;(W%<$K"K%5&[9E8W)B93/"*A^*]/_5'5
M4&8L& ES.PO!_D4) C4:9R6$#R_!?-?++&-L(G&D/B[1W2$FR2WKO$X7^C[\
M7#NCH")XZ./##>UH'CW,*"V1L8$HL\9:J%SLX#34%YE@8Y*J,8W3+K+>F\R@
M? LN?R[8FSS#-!M'YHOJU&Z9*44?]R4Q0][+Q7CE 1:@KV2%BN=^BY*2,VA2
MC=!\VY+6;BO@8M5?+ FD7J>,["(YA#/3[IM)19TD49I_*FZ>X:)&^.G<^YTE
M,TW>+MU#GGJLVCN4CUA%K/KUSFVQIN)',D,_T^-: ?A%;W!5=]@X_.C,K,U6
M_Z[:M49NCR079(XD6X\F!_V6I"23"QNNR0IZBD7^8Y>$<S^7K[8AY5P'<Q7;
M9^= 9O<!0Z?%U42$AS>AIJ>Y]Y;^(!@OB#4O@I.L 4@Y\;AMUM#L^#7<IK7:
MK=3F47]\0"J7U!J!7/04^CC.55A((GQN7G.J*.IUUI"NHX3XI^7^N';/1/E6
MB,OD^]="NJ =18&?\-?-Y 7[_JX-38=U]M-N7"W4(CNL-NQE^]9,^[D44W!/
ME!*98UL_X;I."W:Z2A[-3T]+T)C3)"E;:4,F%ZKN?S;!YNCO$!KL>!SFB0W6
M;9BT-F:IS@X2>&#"L+4L.*4Q.:M,WO@7/SX^S\S8IG;_^BG&)W6-DW0OZ.&\
MZ]R0QO1;L:67*N_HW 'ZHR+<@*(4#?KMLTX);#U*4,$[D*O;C".]3$-^6/R8
MQNEW7X4V,Z#"+I8WD>=-T'[3:[2'X0W "<:H/ZM(-Q!0!OJ]=P-8,!O/J[8$
M?7OL)P2#;5$^>9AH&KH9>OXK]K@*IT_9KT0HV;@6Z*G;HCT,'U70TDB8A=O^
MN1R>G6PY*DD+FZ?SQE/J5J)10@K]=*V1R"'50^M>I:\N"!U(]$;3.(=T6N0?
MI+.Z([[[C<MB+$FPJ1I@TD5DI0DK*R/DZ"AB)LBP_4%?5=*7!Z]F1/!]:Y*#
M!"%# TITG:RX9S\E<APT;IE'&5B6(L?E%M-?NF^W+!MQ/"CISV69OFDDY'MJ
M3,DSQOJ8L.[;6:S2*])@*9\K<J*'0H/&_"1R.AO+1GS?!GPM74[^$2=N9=MI
MZON*2W)KR5V7D3VI"*>$@E$.-$TM.9K-9<,6^Q>Y,W7AB9O4'<1J]SEAZC#(
M1-\**[RI84[BBE^SO?4&H.\6'$A'HSVN:.A#T+H>BZZT!JQ@W=:W/YCK89+"
MQ6NHAYLIO/)(L>_ CT_E'CW?>M1S^3JZMN+)]Z,\"*"TZGI,D0F]G0 EJG&Z
MYI_VNG(;;#8K.;#B<S&CRP"#C(SU[U#F/7D4SZ?W5'(ML;405;O3Q:PHO!M,
M?,V(+1HH/=9ISU0-?=:4R;A+,N9>V6*>,=*7C)->/K0TCH!JOUVGI#1QNG#9
M+#F%S6C?S_B.=(@6 =1%&:CT#./X4<%D.]=T-X!([:M2&$YRTFF%M6G>V[-,
M5Y%7C^'6@9K>TVWP>W?7-. 8;<"E6'75T'$$JP;!%X&'S0DVRCI.FHA\"EWQ
M([+?+NKKZDG5<&.,T&+?"@/Z\"QN#1P>NWZ(*$9;6>$Y99)O?J!.>#EWW]79
M]KVJOW5$T"-'#@&T40PJNF9M^N307-?2B+[K\P.OD')[^Y&=]DCS_.'MK+_G
MFEC. J@M-N?RA>G^15FT<\/?QFQS4.&TQ.=#P<\4><2"W%HK%I^.X53J1+%;
M\I3%B]#WF+SN 4PXU9Z/K,]GU+UWYG94O_:^(986!]S$^C\9)<S2  6@X1\&
MI2MTDY[_ZGQP/1F,AD$?E(,1559L5%+1+B<P/IX.5L'#XE155HM4G%#HLS&F
M\;NA&D02>^=!3WX>>(G/57MW2*ZJNC-+/*[ATK8G*J#)0*@<CD&#URTY@2U8
M_O5)H3P07Q0*P:W]J.UI@KE!$QD==3=7*)'^@/],FV1R3=#L?!9OK*"@[;<I
MG)R;4GA#7/F,F8R#AY^ !V?ZI@&7U6=#>>\R'P9UF!5D6C>[[YSQ@J>BV&FZ
M,>W<AT^"*5Q*T2P7VJU!?81@'GRVS5,XC7.S 2.S;RLSFCU9R3"H +*U*V3/
M0UP2=G^-V"1$[^.SUFYG#VM>G!-Z.Q2J=*F*+>2D$&PL;93J/?37-=>MZXY\
MJ'=OPW%HE"WQ#CZ E #_A/XG[CXVX#:*TM\"A,@:SZ8HD\Q$;_?M@\BGB!^H
M!<LSR]?_S@10$;,1.GL7'@@D?6T8,Q@UGU[KFG83/&5E'MRIAO&8OOOH7UEQ
M/ZF@TA"E1.CR!KT]5!-_S3JUEMCW[,,)[!F[XI)+)/-VTX\?T=*6FRKW 6*I
M5LNO8_ZC3GM*.>P\^O(UIBFA:$^1)7=N?I"#98;6>'+EA/.AJ:$6G";Y>W'Y
MCX@HKOMG5:?8V6J!AW-NX=>B0*J#H86B4-ZZ/Q[GJCO!PO;!29P1_B7TDD^V
M(_9R.3'GL7!3M-;Q@)ENX0JH#78&J\RA^RQP( +F]L'4=PFL=BRVD#$8J!%X
M(H ]7?2FN*"\YP'BUF%G%]F0E3GG;9^2^WS.M;^,+.>9=C-J2AP+>SRW8.8O
ML&%K';SK'7GA7JQ_)=QH()',XJ2;AB)EB,/\6##\Z/)CFH_";\([8TY+UP.*
M^#> B-=09I WZIY\Y0-Z^"HZ>8\0OTV_U55QW%[$88P5T\Q\:*VLKQJZS8SV
M-,7PM*(G5%HPB9D>Q9!2Z:"Q"O,E/H,_:EKBE:$JFI+'1).5]?]ZD?W_ R<6
M4/(*F-3>:SYL&2HOJBT0F=F?R]H<NG5!0[A<MWT'B*%?]RU%[EOV5HKTA@XM
M&#"E&4N58_=&=; Q11!)\X#4"J>VP/$BLN^,WS76'&=G6\=1=A9O;,(LA:98
M0?A2I3+Y^(6M8PY#1F:<B7 )I.;A$:O>?&%[ULIKTLU!P5G2J)%QX">1$'\V
M5!':+>D [E(%J7]9W] >ZD:^E_=+"NB>+U#W5U-H!_W2V#ENGDBAO(5=@:ZJ
MZHMHNB(JY3^$YY_2 Z'/+,1::Z /YV">I:"?)DM.YVIGUQJ9A%OO"W22]GS*
M.2.<])79YM+1\[W^G.%'<$$;Y++B:I^Q+O]8\;WGYC+I<2.?QM688Z39'$KY
ME7J"":#DZ'-]V:@HN 2HS/I !#:^RY,BKF#(HO8NY)PT?AZLRH#7K_@8^G@>
M:HB*.:[&/4;F19O9N%R26%MK%JZ"*I.RA!OZ6#^O"V8 0E1X8:XX)JP*;X@W
M)<T^(HW%LAI6$YC+50:B3@;9@._2QQ+8;QG]_9S[C!"U3."?3E?%**U M*;4
MMTJ*C9%8YN\U"\RH8&VHU?KP7?EPMC"^5F."-TT__HNQL1MR672^G]'_0/+I
M4-6*"CML8"]I19O.+MX16)CY7FE%HDCUJ?QIET-7)*Q:NY*38-?^M[%H6YK;
M_=:]:[5C85_HX;C?OOE/G 2ZL3,.>?50@7!,?()2EWTPU8GJH"[EZ?<DI@E\
MPC>*I6U:?-\LMN#@6_QN -0%H4HTCAF(FN0\'E,I[MKM<E.JRI" $'</G4:L
M.9)5B6@9:\1)L3"$7!S@]RZ+OM:.7^=YGC,.8:OE_3#F3:?_1CHI/I<)0Q1W
MS;1WS8:&+7?>KJ='R8>.G.]QY@YOZF7?L+7$^4P.OI2AG\;Z]IUQT*"O/Q?L
M&NV#2D%-D[\0W6%WN!*>E>-"8"1\>+SJZ-P$Y-4KTYF30\F5";TY>^T$M3T)
M1;N9V _T7W);]  'C]O.P[V"::UV&=LR\LAGSY+<74\6*QA%37_HE7V*F@=3
MA_5,/&RZC6I?CCM)L9]/MSNZT(P?<*;5S*1)])KEP#*!L=0F[1Q%Z5^/W$7:
MM^_4(CJ$D?,],*Z>/&(D6K&"O";:A>=/R4SGI',AZ4AI<DDZO.AC94>GX<'=
M<^8:E<+TVUBQ5A.F2(SUA9ZOL*,WJW.@NYM7E5ZI6N7^A0WQ W3GI"'@8$UT
M9W+^'DO'64Y9CX-?Y9+@+&[R+LN67AR3[^D#0^,= B=]'3(7J9XVAB2.>O;<
M9!"9V>R/S*RT(!/;]L_=%+\?#[_K!@08\Y=<3RB1-UB^4S"8[D'X6ZGS9C-^
MWM*F _Y*X;5A25XD$5FDW_'2MR7Z OF#G"M;/XY9(>B$I\Q?4QV3CTA6/BH2
M$5UV,O<Q3VD9'.Z3VU8*8/.M41_97XGEP\M*0N9%<,&;VG7OCKFZG,IXE]O=
M\WUT\G7D4??V<5W]W<!]=8/;252!9=5@@64]WA6[Y%R[YP9D'?4:[=Q\ :YZ
M=V!:? #\1'5"^!^SJ]P@5FR84:9!!SHB:9$G6-2X">0R9WPTGBQ;2;OTT7.E
M@R(6T-N&YHT2EI=R0^YZR7$>L/K&FG@M((GQ7=A"-7X9NM\QUEO5?P6I[V7A
M33PQ;4BB!AFUC6?S$X'!#4OM4<MO_"LI?MSCJH7Y\^%EH-5[5XFA4I>:Z+D(
MEY+1]X L;V'NJ3N3.BEB(OI72^N(<DC]6G (W!,6#-[/9:SKFOGU;,0S,Z94
M_Z=F;9H&8'U[@LVK&A4KP"AC'ARA2-&(/FK--\>"7S;_/!WRDQ"49?)1\1HO
M,*E+E %0B$RU!4"X&D/Y'JBPB=Q_H;KSE1# J0(L#)'?[E>JK^ESH\?&Z<TW
M6A,CEO<08569F1Q>(V<9AO=*58U)%@SQDG^^:\/B. OZOH+,XLUTBZ7:#!LR
MC&A5F8!UW9>^0TQL3W)B!I7"C?[1(>LII42&>^Q7L@*JWV$P6+!RXC)N;;:5
MLX/3"(3Z;!\?&SI??## +B*/(SNY=C&FD&RUIKG[$;AA*/IY[_(O=@U;WLXI
M,4MRNCN]H."[BAR.Y;VCO2RV9'.^+-"4Z%_%&2ON^)/M*:9]$8 C[C7OZC!U
M],L/R"LC7:#NE$M5([% _G0NBO[!6(,<_%/;U<S2PD768F&(Z %4N!B4=58)
M0X#0YGL77_LSYZ.5_-P?6M9&*IPEWKJRZMU_),7_-<))_U5,D/!UDD%]UMKB
MD)_+HUNVD?%8M!XSOTDD\:Y+IL%GVED1'^A;!I7NFH*K<L95;Z:BO/R]]'M*
M!MNR,]L"HC\M:<1^2"L=*Y-V2Z.UML>VHW(K>1,$H,QK+J(3EO-ETX.5WA76
MXS;3#9=&<C9^)';%(%8Y?9EN@9<$ZD__ G4*X5U]7?02.;R#-P!T%%1Y6OR*
MRR"K5U<;..?5FG.ROU/8DT/T26J ^TWDDU_?-\)ZJO(H<-K83 S7,R ]Y'EO
M%AL'<QXTRSLO6F@K3F\&:?!,J_V.!OZGO\\WUD+]IUM,SIS &K7KGE]MUUSO
MVUY0^J-=W,ZR4_70QR%VZ+D<NU*G%8&9:O'4&P"Q;0U!4[KOW53!ABU%G9*T
MKW?Z;"2B+O4TUQ<3>-<.DA%8U\$KN'59=G9 A>NC%_#^]KNR=SYYM'Q)6$KR
MEPD=FCHQCL ]NRK*[.N42NUA,!L*;<BCWCUSOW75J-A&#P<;4@V*A;=)[AE&
M]QDF[J@M;7RK$L:"6ZIP_.N8Q^BY#E02R8Y;S0NH6"7IH9S^AY?3#17"M)'=
M(EU*HA\UY-F&!2:*':NED&XQ4. M)<H!]V?1=T46=O)+YI3&F&FWP+Z'DD^@
MJ\+_-'HV4!&/^;SN_Z?EOM[GT7=R@6X14&0'7PO-C+LTM-NGO^/T!P%'Z;3D
MZEL-\5;:VK;DO=';:M@DCCB*EF9:!,@L3;;*J':T[G%I="K39X\_A4VLH/4G
ME$[/%66^U6.4>CJ(;GV)NM$Z*HA_&@<LVC-FR4R0&)WX-D(P4/*'LNFN32M(
MZ_EEJ4K]!^HUV_EV;"A3D!C4OP/M4U-NP4FPL\+9./=@ZN#(BF!VHR5Y?CSY
M9R2DZ!Y SZ.U1Z%R4<)%=-YBZMAK'VNT]?TW8W,NXRZW:XDI<(;6"G(#J%^-
M-.[K9)AVJ?%N)[T!D"&NHK0P!+#KY9>D09$\GRIH> "LEAI_U8/^T8&YI;O6
M;@VXGNUDG?)RT5K;U5V#F06X,( 0/K4V B0ZSOTM">BGQ5]$:]G!15BB8%_O
M2\8=XTPI7UJK/+)EN65=?O'VD,R4C6TN=L]<?A@ZZ> &@,PCPIX)LPYY5CFM
M")EK.MO-28#7Y>>I99XW7NNU6(8YZN7;M8SPE%L'C7$PM%__K(\RP%#D('/4
M'%HZT(V)Q>^FMGWEBG\$^'YMW4QG?_UGB"?N:9O\/!*:R>B?>=#\Z" 5Z"D<
M[DV8H1UEGSS2U#AB+Y_B.3/'V]<5.OG7NB$AKV^6@P,#!AOL(BQO (A21;-L
M<U^1E!\+2[[D6('VW[(D%Z[[R.L$7U0P.7A%YZ,5Q&<EP%*1C]-69$BTL"T-
M[R.^$Y'.N[II)$6,F\.ZAJ"0MS81QN7X+++ &^1ODRMS]I#P0_</"'4-V_EI
M49JQ],2OW,N^LS/9\Z@J>:4JB%1_EOEB#KC/O^,@\]V*>OQ!%K'I)WD#YW?L
MP$<OE>6-&XU9T;<HV6>B?V\;=X9>OIX[S;$L A_:F+<Q,KZJ<C+B%J WU+_C
M_*2<4T0^U3+=8 'H_A\)-M;_XZ600/"\O@G0$^*L^E_ODBC^;R>>S 7CK9#_
MYP=4_]\;KPK?U#U6N#,F&0OX&]8=1(VM00+#VU;[HN'$#G07"2OE,2A^F.OR
M06'DGI^)UL^"/^;WUC?P4@<]+".2>A5\U_ZQ;9P0T$.EBC*'0&4<D&- U?86
M<U"UP:R'FP=9E604X)O=^SM$]S>,FR=?O:N&; 13G-X 8G/EZS!*B>(+<)GB
MW2R[K9PR;!!K0UN+0QM0R&\[G;#G$O[U">UYC *@'$KKAI%#*H6?3! @L&:C
M@WJ['H%)NIA[L^_JH[OASUP+WL)EJ_'\5#X,JIN=9=V6O&A)+/ K5@PI'L30
MAK;/PWCM&S=G9487MK9'CI O'79!^?D6OXD@*)Z'Y)]*&"F%!HG&(1E[;@ 4
MRTM]7_<YF#'LI67E(X)(#_(J%Y'?<^I_2T2*DP>)-YOL.R,+XP@F&#%$(3CU
MM> XEAM /$X8V:$TF 6,*0R[-%9M:8E%'*WLT?-E4FGR+7R?1%HRA9(\9MXP
M"HZ#XV%(441]2C%&S1FRBG&2[26LY(Q]DI$"BU*/BEO: 82^W.Y=#R/8-7DZ
M4+$RSS8#)1D;IYV1J3$/0Z47B92>ZE'N/1F@,Z3Y9TX*/4GX0>AAH=X;'#T%
M-9CT=K$31[XMZ:M<WKV 1CX;\R6CW&0>[EYL4_T($.L-6VGKL#*]/R6\&6[_
MNBGY8W #5;(5,3H;91C56[.0U!<DT1&_I&Z3+[CZ"\D<D%W!=!BC[I/B0)ID
M5"Q6/1WL"*,UN"J44 K?=^'VS?"YBU+033IR:+MC9:YZN,4-9 MW*.+4.KG2
M-JB?K.+MG!$Z/!!X8SFU;*E5J\ITZO .P/G*FED7G8JZ9?"*%+LL$S@N19;4
M@0N&ZFN9UIE#[\6HSO;6]Q/>C"ES!9H0TX(%VVZ2(GGC,DM(W#/L *8+N;Y7
M*+>*MV?%X.*I7-_!=3#O'Z=5T%> TGP7D^G4Y-$ZS$;#LUY[9 :,.R'W9P5Y
M=?AJSQ2VVFMPC)\]#O]1)%1NF(C*#U7>S742]!SB8$%W;#!DS4<W)' <N;/P
M!SZ[9O7CQE^C-WZC,<%F'()[ABX+EY>Z?(MCS7S>7#\-U95HJIZ7]4ZITL#$
M>?_>3)'H-AI_+2FJSEZ9C258"Z;#W@"ZVZK;?2NQ=X\MVF?<B**+,(P16YT=
M#:VFEF;$Q5)QC?J&SP#E[9(?9<88;6I/,RJJ3!S]H6V19<'@,I,7>)J^?K(#
M)'@_,]\!)N:*:SN;9@60[76MD;^G["CI!^!QW.\?[QBF?51OJ<F RJ%CSX<X
M"<7OW:9T2\J!I$)(::#QBZ:.VBQRECWI7Y,'=^53Y'K+?H@,,X<B-?#Y:ARQ
M>*@KL<$\\OSV*9P<9_@ [' NS[=(>1AC;OE<C'N?M>S[+IR&Z<Y'?XJTHX><
M":NT$JL1/E8<,R=7O+JS7I5C[T:U.AE]#?H\&!$.&H8HDGA8LP>WB%5Z)0:,
MTL?>$K^[\SHN8/-Y">D&ER=#8U1#@C\^1(MJ0%Z0Q/?_AG3C9Z&"P4E_>:XY
M;@"U?2HW@"GL5TY$(AW&\ ;0=WS'B4:]%!LPP#*M&EA5ER2ZG!\_2J:G$3RK
MRY]0>7_CS>'&S^Y=J#!&JI_A-M/GHX433@*%=>:.&_YZZTKN/^](V4)L\>48
MV#Y\H:YNL.-G6<Q!H>J;^Q##\!G)3GAI-E=3,"V>S11_;IR:PA4I,OOIPCA\
M$2NYNG9^*(9D.C&_O %0 5&'LGO3KY.L.U+U.NN:FX&2C]=SG]EJQ.$BB!$_
MNA-578+F5BEQ^NL388I"3>B5CBH5N5W1WC;"3 >P](S%EP@>C2QE(# YL^31
M-V\YM[A5ZA*L WKH%28])]ZLH_/+MZ4QVA_O"&>&0TWQ 'XFO[Z0>3:S&8/I
M*N1%1EF)$E4IJF2IU%1JB+')2':;6Q)?K]3_M@9[^WO9$:1<FGF@T?@X0>-;
MYR7*ATPC,MU_8W:MZM&G#D  Y*VKFI!:IM,CSD,_[;RY<K4KNG^^J>&]N90O
M-_7,Q<6T4OW&J?5<PY8:M JF:GH]D3H;;/:OMCQ11GY^?:/@?_F0=/!7P?BT
MZ#/1?YK^T_2?IO^_FNA-Z2H3AOO E'H0B8T; &D0R5 !5.(;VC=>0'S9:>CY
MG#U\,EU;EIO?_3="[C$>C1HGTP9Y_ORW&X##R%X7C//7;_^:?:T=@>\;&=RY
MGO,*^X,X;[1%'_)*^ 4Z+Q(G40%1^_G]-_;Y*W(P<_HJ)'?E\+E">ZAU2#'5
M$%.-\[^-/G$%OW+QT(MK\A=N2>+6=$Y6G)-0+G"!RONLH(3B%<URK3_C]+:Y
M :WTIMVJ)!7-FZ.>EO.QBO@X)4QI!T]C%=;H^Y_7G_AR-Y@?2@'(*,6Y^%+Q
MDKYP2.]:Q5SE\7Z];@C^ES_,&&VFSH[JBKBFQ0Q&V12!S<AA*YEO]LY\1MH(
MFNPL\P=MGKPBT5A+) =#W/K,@&$-<@JLSZ=A)[ G8_(M H>O;#T2X90&?MR_
M-;>:;D/W?T>S<,?(GC$:+E@,:1MD50"_#'O5&+G%.HQLP?\Z1AL5JW)4=8<#
ME3K 03^)<RM< K%<?W:IW,UD$C5;YMG@9HMD[\,;?ALJQ[+R/T"2O^G O)87
M$42#=9^_+4DI5G6R-I_INC-O?IYABQ#5^+&HLNWJD3L[:YCWKRMZJ0@TO'+<
M4K'W6QT\QM\+IE%D7\%:ZZ2LT,\*":YUIB"_1]3]2:^^N\;6KE:5SZ'H"C?V
M9 .1@=B<&,3UON9[ =Z0-/];M-B&94S-8NO_K4G1ENU_SAN)_W=,_Z!9K\P0
M#:*NW/HF8\O9SU]8%,8^(?V_JL3Q_YGQ.$4K^7!E+SMQLF6=]V? ] Z@L.B6
M8$PQ9OD9,'VT*TX.+;](!8[[L<4"S!XSAU9PKU%HB@\+<;5%\$2J9O"R9F@L
MB'X[Q??.)_X?6&OY=DOB'&,6B(&IB"!7D^E).;LF;WX9OT LLX;=VX_=&]3*
M%/_$%=+_V\#4_,H[^_0S&$1)LFSYJQ]AU%7Z_:>3F?C?/P\>_#)X/<R*<B^N
M3)1-S/])5#=I%8!>1;G,)\I[8#B?Y0ZRFD#YO_:5]8F_9P!'!)B4"G0GI84]
M8&)>,YK-&Q FV%/D"J9$0+I4VN8G$9)3!3/(@/R^KY_"7(>/1)395>D-IHUK
MN^#PAJ:.YM:V>COM3P_23=?L6=-DP]*YWXO-O*KREE/0GKAD7V(,=DC/SQ[^
MMSTN^:3B1L"SWOTL\H'5R&.O*S4C31I$L-R/)M%J8[)AX)U("AFFVP#EU15K
M35=U+0OQ[&89BPH[1L&_Y1G.;$]NMM/LGI4_4^O7D$SEAC60)=(G.0'.O_-_
MQ@CW'Q-!A/5"A_HY!'Z>\/^:]S)"9)20PU/NNI-4?N-V2.0OD-*+<VM@UC,_
M^"._W&>_Y.#C;\.V%?*HL%5!&+7ZH;&ENF0:[H#<QQY:VK0$6!H1XPO\H#?\
MWHK0ILKG*/[P&OH80['=;TT']T6:"A1&KO95OIFTJ$SY$UC(D]Q,]L:%_T-B
M:S[%7NPF"ENQUMJ8#7NHQ+@CZC07>^SQINT+(<20T (>T,RG)ZK)YEN9F2N+
M7LES8SNW>C %RT^96>6NM^J/G5MG_D2S(((;_>/U-TK^)^$F?2HRCV$G2'PZ
MN &J4+5[<90''SKK$-V3BVZFJ.P@9N;X_)46IX4NMKJ?VK?>CQ"#)+S..P@^
MO-<YWSTN#UN\"- CTE:%L"DU\,;47#/C'F ,HR)@KMF#9K"2Q))[K0^\L*6K
MGZF2,^^7,PWYG[&_&N)@^WDZRLYJ,'_2H632=0-(TE7<.Y.N%I(9.EJW)\-=
MX"FS>ADQ)L*UY)G7<H*M^5)N '8+0+_-X47#>(]Z /"-1^Q6)P!GT83=1M]2
M6+'F)DDQ)\FO\SZ".7/-@'<FB7Y_S:4G],-60A1(8G\+1ZPV$#3W'\=;T\ 9
M03:;9A!5V+M87.W8?LO'EZ^I$VJ'<ZV0L^E13H>->;%69.BM5HZX2DC[LZG3
MSY('T\<2?&];7%9]J>L)90Z'Q.],3^I9K9J#FCPMEY=4P6 29NY<AWO1195B
M'(!SB2U%?NQIX>(BUF"]US\C ;7H8MZ?T4;_ Q&4GUKR+9W[W:_X;TORM;^_
M>.=3&A;6,MXB$4S;'#EO/;78KY4+!MT]$_.A95YZN]S%M"W]]?KA+3,0ON?$
M,,=R'NME27.QS:%:753^W$V@59K5<(%A.Y$/KZ@0WK?N.S1!"67'&J."&9N*
M2JVUBPE#Y22[$I4D_S";O_?L^TULW=% &SN/IDQ2*T$?RFNBV(-[IY7;5P*-
M5;K^B \H>R2+Y2Y3 ,T 1WQ5PB38/WU6LLU9P>20.$T,&573B.U4S;M6DX7?
M>$P+:U=@GW\GG%4;HYKC[;%^Z*&!(+ZFIL2S=;6I(^][AYOO*OA5::4-U._3
MB&0!]LIK\NQO:3U_#P?M)!2TSL[9>YY+ P>+>(D3'Q$L9UG4/=2.4?M%;Z9*
M5D1$Q%428( =54XU:)Z>MY@VNT:!7)"-C!Z?;3.$3\LKOV0 40"[ %2()%_U
M>[<8#NIFS!.LCS7=3BWD0[3AE+5>N&6*_QUJE]42<%/MFZRO()< U[:TC]GA
M]:(U7R;OTK7H;)1SDZTSB]]Y']N#"8X5A$N5C <MER[NU2U./(KH+(,T[7IP
M>V1R>6P[X@DHRQGSU'LE12,L.S(CJW"Z,$<6]5B).).M).VD5PGPO\QJ2+>6
MR,]B'YDH'/&^%;8J$6.+]&:R^_^ E1;.FF1=2R0:&\X841YG7H9RU:* 6#UM
M5YTO )FM:JPUBB@"YW&6A%67URR&A!ULTP;;K:IZ;G*J+0QQ)@#<)BW&6S%*
M/9U,B2"))(8=?QWWB3-3LTN#2&JVQ>=^SJ:1G" BT#8^RTJ47F-+K?9"]=N,
ML75:P5YID3KJCSU1^#9?3O))Z8QY2Z$6:,E&]J4LWP1YA6#VHB=+$M65^*$,
M]O<*_B7X%"EHWJV 6*/H)Z(5GT#6>]^;#I W1Q5,;\1N6F1F'U*W?WL;3]Y.
M*#(O?F=ITG3EX7P5E#]_SVR\3!:QBPB$9QJ+2;U(H*OG'&;Y4_.K?7V@ZY
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MY3251+]\,9XRH_A0BC56:YCRBN,37Q:=$J'O**G#3WS$3J^\PY\]JT@&8;3
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MK7<]SW6O->]]3W]$77?<._G&.[(X]',Z5(HHN"+-"S79O.#'YV56;+I=/Z_
M >Q>K;,GHRD*1P$(J]+O\*>A@UV-.:%,LDMP1VEF<)CK4!@\7/,^*&!0^;X/
M\U\_7,?'XXC)(Q[-59U>V,U3"QW\7.2GB%T;Q9G&FF9+HTI WE-/A@SA V"#
MH$YJZ+-O'#5!EX!(LRN0IW72Y.68G-.>%99S9Z5VC^ JO:7A>E_&Z$O76R3H
M)E%'B_ I6C&Y!F*>W9FIJ#1O_U H8;6P9UW'49GYV@&.R+NG<UX(I#ZO)% _
MN.)VI%-K%J23%U_8T-)1SY@O*^7,9DH6[6U:,K<7CLJ9FS(;AO-A/=]T<F*
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M2P VL?^GS/Q#MK'.*-Q#E _Y->]V-Y&<9^8GKQ#*^*B#8YO&5G2R?G[/_H9
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M@>\FM"TPNO'DW0.4=>X7FX%)!MW[(_<E[HOP#I3!=7"E$1?\=D8P;!BK6Z=
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M^/3556@^:IB1M\D5V%P4GMR5G)^T>:"N27WG0=;AO#=8F1B/72>J%1.9Z'=
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M3;IOV>J@:Z^S6X39<^:;W/S8GW8!>(01*GM-$@K/AS=9NDQ0/R7^1+4-"-]
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MM'L_X FBKA6,W#7VUI:MMK^?KF.C+]S0L 0? 3/G2S,4::<5Y3#XE6;$ZHL
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M3<\#&^WQ;^K=3 <#E&.K\_LI3@0]T_;.3=HWF7%"!MF$ML'XD4G;]Y4@^=2
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M/8^W3Y[B ?;3FGI T3O!8*H:2.4C]%3Z56.U<X=2+DS@]\,S^5!Q-K]3:]A
MS50P&&RSU&BA0IXVLB\YG_9QB(9IP_R#VP@4U?,4:_0G;#) GV+XAG0L+ZR
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M\ZD]N:(I1M1!O0G7EO#<LFKTP/AL6>_726=AEZ=\0$\3\'W\@^>]*J9D.U0
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M2^:;JRR]/Z/DW,R>6/*]\O'*)DH59XW."<<X(<#" PW>]I9-:=*_M70,6(A
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MGZ?O6\95]WZ0BU'*9C"-'&K(F1R#[]T "K?/Y)>R\Z%AJ'L:L>4NU3-]!3<
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M4L>%YJKNO9@E;&[81B,>C=,Y/[:</%246:D?7];"(IF,-4ES.3)IJ=8MF%8
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MC1>.[D,.7K8]K-BN,TL 92:O#;."TF7>$3"<&$0CK;_AQ;4A!JA[+3G1Q8*
MA>7!*GX#-[_<ESJK517JK_#/NULY<4M97M148.][^U&0"'^R*5.S$UE%S@I'
M\#*S(CDZP%=2SZ'[GEAF62/ 8M$N3S?U%XT!Z:X*>P!#-&:$#>KSTT]V$JE9
MZ7+.\6FXJF+]M*.']7' +^8<[3.X)'[V0@?J@U;/#1'+GY840.#XX1 WQ^;&
M/\"?:.3 I_Z<)TG(SXE9L2%[$^9R&/=H(!W6+=&E;+>5=UPR7NR8TZD9V6@Q
M]D)#]4G@;S:<_G@K-]3<'%M^S5^%X\CP0<\PY$",60O T(]>(G\Z5I=B0WZ-
M6EJ)QTH:T"WL2)]K5(!*1HKZN5H2QAR3YGM-'FKV:+23<IR6_=?/(YYE02M>
MIOBN67R-IDC1ZB$PH4@)#'Z^.ZCL#*? Y_?D4HU\@(G ":&A!^S*)A-C)FHO
MBQ\[;1@RKW_Z^N#6VGK[EB %SCV\C4;1FKJ;4AGCUNCAR=FY',.4LM7D^&''
MVZ6,)*BFZ,2^MG3@\RF_LM5O@WN71A.2-P!6:ZA AQ4;D!MGDQXT)_/D:&MN
MUF5JOKX\M;]T/^/%DSSANZ%00JDNZ/S98SRD!,IXH8L=B=B_5"A7!02P&M;G
MO)B2,7I9L:9B\WUNIZ7)*3M_ZP9 <ZF B7^,,<FAAQB83$N2VS[N C*''A$W
M(QJ#J[3W"T"T\BD'=YCL[GQ>HWU>8L6RVIVU/[VOAX8HH*S$SZ3+BO&Z9@W0
MO8,L3,<^1?WZZY@GI?IWJI.VRN57B4!CK>R79NX<,,KQUOOUZ?7B/H6Z)4$@
MLH'P&;:]8^FX39"-S[:-=-I7Z V@NZW6*7&5TK.3$QN/%YON1,R92-<L=HH>
MZ8HD2_A^>-,O0WS?E#SD1\I"B.42PV@@-TP&KRK>T2Q^JQ7A 08#,XKP*4I/
MEI2D=7W)]]+?#@MHF@9E,LKTL;%Q4*H]&?ZRFMG*#=.ZRH7IBPY_N6K\ZHK8
M?U7#]%2<N(98@-#[\31#S]\!<S&)$9"+I_B:+GE@-C U;W?$4U'>KE#Q*#J\
MHL%BE>Y)#'<[Q;#6_#&L@06N.]I*LV-'BW-O5_!GN/".7[FB^OVLI4VL+-+Y
MA=9PQSL?YN4BCZ6,]E8Z'%.8$W[R^P@Z?%JC$5YWG5TH-2@D)>P)H7A&]LK4
MLZZ;DZ5'EE32593J$#T2I:B'46);Q*=JC-76)SMDC4&83&3.IB7D22@JC6[S
MR"J+41MJ558C#<X\\4&E>$XS7$$5WN^PG8-\0@ 1P-J1@4A>4/H8$W\63?O*
M1\LA.>:5U#N2#NBP\+Q0>L=+=?KG-/])OT<"IYXK+WJ+?W3CCYP-[$S,?XN0
M:WM<U[46_\E*J+=F;NGX3ZZS_LN@N/VZ47F)OI^ :^VM,PL6'M)*#U-NO,H\
M'6';0;QS;N4?\_KB8/QCZKGQQVSP#)S_H;S*P2BC:/@<3]\PJ8#4+I!APFFR
MS9F:S+7MK@CZQY28(A-()G)L#U(?9AB4;:2%8",/UJ$^?#,L.^2WGM'.&6GE
MUM T61R,E *7BW2OV'<6_*R)UN;M0XKYT&F/V($+<-01)XE,+N^VFPXR0.7;
M8Y];BK[=&KH;8!K"P);?B%X2YS>8<QVVC^PCQW_"@PTY>+.F72(/J/?0[U3G
M'(];-PZSG:XG/<\@[H3SUR.,/Y;B@40/=6\ 9._E1U4E6GFOX/L=^KINBU]N
M )UQ'C%GG)1X@Z=8IRS)0^JMLWL<.:QOZ\8K4FX?[]:IL)3O@]%!83#M2K4*
MUVNZ42F]5VS,I^1#0$'0L_>=U:E=C.2YDGC"GTW%44 &/*OEK[H+ RHP!^M4
M'7B9V K_U3WBM]:KWA_]<?-GS%'"W)>]S=1J5M<BN#U..B MC!3'WII*%<)^
MF"!",+Z?:<7\A6-#YBA3A9+EM9,98=H+\%8B(Y2\$PBL#9U&+;&/(=4@A.X1
M[,;#"A_BJ^*^OU6178UI5(XXB2W3 TY!A/JM;>6UUJM#]G\5UGSMD 3'W3?4
M(G)@R6OWW!35U9X^%9_;[";_IU$G9UEKMA-,4NS$WW^DUB+<O98<E!DQ?1<T
M:+(6QJ)(8...2J2:TT2WS=W:AOF*Q]298#.KIR)R\]I?.FP^IHL[ZM!*V69Z
MJWA@ZD7Z@],:6M8.9,<MQEA",U3'8:H@UC_1)"7.&;<K=@C#PO3KL.Z1>S#I
M)7;$K]H921*UNRY&<WESU1RE#H0NI./T[Q(_E6 W._PT0R[)OVTU,<3Y>6>[
MNW#T.ASHA ZBC@91*19K*;Z5"<FT#NI/#;]_%2J- Y"J"+I&_Y=N;Y7.NM9;
M?<SPF%VR7NQS$40T6O"9/^P'\+$1'M7?EE5<B<G:V7X# 35Z?HB0_GA%?_=*
MN#?(T0)2?DVX;7<_Q]%2ZH_8I6:0E[ 7.#K'>#" 42EVCRYIQ-IZUZG57\*#
M#*F%JG!C\XWYD,0,-RP(?3P>D]-*BEWN9K]''3WGO@^XEAZS5=2NX*2VQ7LK
MV3&E4Q)\4@,)1@:BN0?SG "O18:V[<VA%SU6EZU*XS""E>4?\V"$&77ITL[Y
M1R=GR8N'UU;5*&:6USZ]Y(TJ=U YH1D/]_Q,&="/\;L84$BKU*4RUB?J+SGW
M[PR\;_M$VVM73ZF"G^2V*4J4Z=/.!SK]E9ZWJX0,G;/7D\^A%_M^K6FK\3+M
M?BHY%K6[Y(EDRSO5B]T))GHBO0S/?6W"$P/IPSZO&0TR BOS6D%3;:Z4KNX?
MYL2C>.KKL<UZ&/$]2@>4>3H3W?;Y^Q=TXBF"C#+0UW\ XK6"G@V712V_VSU=
MS3F8QM<G3Y5DK%I2E#:-QF@**_I3C[3"/!V$PX)1H&^2!\+D<.A\9PYCZWAY
M7460[NBAE*!BF;#_12\Z9;L/(.**8I+C>@%*$=:_/I_7J<DY.M]@5=!]_TC/
MPX,K07;"R\GA)Z<5+FANAWD9/1+)DF_FB(L(J\M4Y;D"BD76J5_8O7*GQ .G
MYJ2FI/(QUM;QRAW5]Z&GFXF>4LA/:".3/^$S$.,8/?X]TG*\>0\'&V[R,R+P
M'HXD \-JD?TZU<4G>2%/YML#?4K(]# 'PT2=;N)<F4$+3B9B%0_Q\D+W[9U<
MW"Y,V+P(^!!UY)M!2\"Q=6O=05F:/5%?N/BJM%7,=?G.-3TT:U=M#*;&7YEE
M@V!LZLXH+NRJ^QCV+2WS1RNR!!.[[3%OS=%<"F:\Q_Z]:0)>47OAP/V4ORGM
ME=Y!N]$[%$4-#>! B\&MU0]?AUG%&9PYXC]D<+#B.",/1&# N5";W7/7>9%4
M5,X[1?O'KR/C9-YXV"VCV2WK#LFV_+*O+N9OB['&O<.5<6[J8_X2TO]HL?X/
ML%;_"[C%.F\4Y.#IZF=PM^L&$"#(.=7J@/=:N7+ Y.Z!"F!*HZ?6 6('9/:=
M]TX'XW9YI<]^B[)/>.RST"%=;VT2TH&D3AG4W$'NH UR?R@$E>"8VA?'_UO)
M8N5=S\2Q%DB@ L:&M6M<F1\A'T /22L);735KJ[/=O-J];\A>LBR0');;D<8
MM39ZFOCA/*-SH,6^RTH4CO)7HK.ELAZR!.FQVE0GJ(SVB([:+]B(]Z_>;SW&
M_EP+4#+U4A(;L*I*&3"JKI]X4W!Q-OVVO$IYTH(F2,AL3^$WT+5N0E$5)W.6
MA??P]2ASM@I'1)9["6=?*70^;MF/3]&[I\ZJ[=W;O)YT<$NIK,[P=->VYP.2
M%">,ILKU0N>2V.#=+;$Q(R)S!F?[75TM4Q]3Y#P)+/*]&N)9$A9J06[T.8_M
M:O*W_$"1;ZY["K;K_4R+]F\ H"J$%L^"_[X*2<#.*>,!TY[O3^Q((E)FQ9I2
M?L!T#.E;H82J=AV'5N4LL7Y?$QEBLS/67A=*)S#,I\PGS7$U",ZE< /27,H@
ML*>+7>73G&^:6J'O3QQK:X\+78 C;JP;M/S[99_?RE.E;;U__J/2]W</=:3,
M#8!>4:!PV\IKLJ[@+.L@N[1YT6W.H;Y1VU;CESZF5&4_IQ9FA?<J@38;8WNB
M83(!X&(\HI/IW<*,]->X,P1M?X[-V='^GS1;CTB;-"XVCK0M2:,7BC4&6.J8
M2UL<>6>K"&[D3"PGAU4W8NPD_HZO6]*"'DOT9KJO0]QG#9U2HI4478ZT17QG
MAY5YHJ)X*=3'IEXF"UA(:&UK71[/DO)XPLWX]GF8-;TA:>KU>$9T?N!(J]!X
MQ0_$O<(L9T::'-VA]P,0.NKGQ]<J62<5U#IZI&KC[WM_DCE"&*I77KRD$3\I
MDV'\85M*MA+CP1I-HQ/2\6.KDR=4@:-.%/"?%9M@?!,T;:2>>+XC3';@3AE5
M^=_=\&S+? E>PC\W@'B!&8<3^^E+US^C;'%#>;6MG9QYUVVKFO_W6^=-U=[!
M.6'=/8ES\=UKR8 (9?6KH.Z$]_\6_;?HOT7_+?IOT?]=HA7_I,PTLI>B9@&$
M^+]JFN'SE]D"T_2""2-UU9?_ GD]_[*P:4.!V^A=KID:FK"98R2%;A3E4H4?
M.QQ,^8*/HB +%-Z5>=67IC< [NZJ&X"=9] 62;#BX5D@;CK^^CZ4L;.K5=R
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M B7Z1?K<%T?8<?[^E6X;[;9T=#W)4->>!TX.19K.N7O[?A!2@P1LH#OU1FK
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M-&6Q+RP1O9/T]=XD0^UJN%@!ZORC>ZW5@<@/BY$JJT&6[N%]&%XC+"J>4\J
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MJ4B=*MZ9D)%HT3@2968L8^_DG2CR:CI<,1,*C9^_AX@0CZ:??:#!&&6D+P+
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MQ#&';ZB)6,87DKWPIG$BKCS7B:XG=ZS/RRN_]2L+SKZ=CU)[?JC?F:Q+\/)
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M&16[%W0)Y2#"$%&.G FXY .BV$=(K=3W^,*GO"MOF^-E(D:^BYO$8=@,T;>
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M ',MS'&O-R=/^5SU2M/EQ6*2>1@)IG5AP$,JA5JGF*+LMT;QR,YIIMC-*3G
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MT4 ::&03XTP8].V%%854W;%FYW; XH87MT@S@9H$.+XUY-EXFJS<<Q@?9O]
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M[9N>6#0_E<5W)[UAHRUC:TX"W=P+QK[+GP$?QTNT L\@T_DJ'<+4PS60"21
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M#-&=HQ#M O%.O5&(;14(?.K5SPB5JTK!O^T$_ H.D1;8"E@QUOH(V<&C!D<
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MN=(C!;]L!KB)B9&X2@V<_.5U,*$:"X8"('^1I/D7)ZA3UV(;<[VFR1?%&CL
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M^N]N\_D]'<06N7\7X@M/)/'C@S3('>7?5XC7 C*CB?H4%AR4NJ<%D*#_-Q+
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M$]QALM,<Q(7>B7[A >CO2:%_5W:JG;S @>'L_EC7OZF*5E@!$51V4P]IS"B
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MU"B IDLKJ3MB5"]R*C"=S Q[3(W;$U!DDH0;!5#@!2)1(P37^O;M^J'PZQ3
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MX%]/\__@TP0YDMM[JF=D@#L4@ CY[36OU%_YW$>\HP#H%@G&T[-I$Q9M_A2
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M3'^$ZL!BCJ[%&;]9"H!PUTT$6C6<')RRT+C5P>(H;)X>U<W]0EC1[ 0IZ*Y
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M4W?&N-Z\KGHC"Q40(%^&<Y+?N=?O[_[,4\U7I0"^)"..CDP PVG%]3/\_13
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M8R74AJSBXZ,!M+D*JU>>_'#:F0HKPUQ'#O"F:I;BB(TFP[1]UVT$+E( 8&:
M#W1VQYRMN4X0B3?/@L_4WF\RQ]_H8+./^B2TGF9PDT_U52J??KCVIGTO\WE&
M-=G@4C@37F6Y'#X<LQ:S4S)F:IHXTNMB(F&IW")S2TM./SDC4EO2MT>Y WG-
ML3QFN,";EB3.^^;A0+/$O C;AX;RN$7NV3DY?T<_@?[\17H&.[(0JHYCF8,)
M%+1EJI6E?CIRG4/T_;/6I3<KIKG?I3OZX'ZG"NQ'#B_ ?'+-Z^,<[,[U"7CS
MY_(>&%U]]OZKLOYAW9:#:8(H>L1_9=5EI,/EH86P05VE%;.*,"DJ.W]AP8+H
M,5\\S.RN^%O-L/]O]B96E:%VLN89S^?+K!)6E"H?L^.NWJ9&0;[>ACHPDE^>
M7<)>\@SD_-@XA@ E2Z:ZC5\Z5:K$U>WK[$7[=GF'5FG&.N:UY8STIE.4=6Y^
MYV'RJ(+!O P5_IA6"/6O@/ZC(B/*E0)@MTN1Q@TGF<#GX?G&%G;%:EQV,]S?
M^-K>W%,XHAV WFDZ<AB,@3,,U 5W""-*(&G>](SZ;$<)^=\[MR.=BVO2:84>
M&U:URMHF3F8ZCT2]QC,IC\!1)EJ<1OW<'1752.M S4?'>#X"/5])GU#$%NW
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M,1^?K&8]_JAN2Z"#_/^; %!+ P04    " "BG A5CZWNQT"T  #6H < %0
M &YV87@M,C R,C V,S!?;&%B+GAM;-R]>7/D.)(G^O]^"KQJ>SU59D(5"0(D
MT+TS:ZH\:G,M*U.;1_?L*WL6AE/B="BH#H94J?GT"Y",0XH(!L @*=986V<I
M4R3<_0?"X7#X\=__Q[?;.7C0RS(O%O_Z7?QC]!W0"UFH?'']K]]]_?(6TN_^
MQ[_]M__VW_\?"/_]YT_OP>M"WM_JQ0J\6FJ^T@K\GJ]NP-^5+O\!S+*X!7\O
MEO_('SB$_U:]]*JX>USFUS<K@"*$GO]V^1=!3682EL(4$0(QEPIRE,:0&LDB
MAB0G*+VX_HO.1)(:&D-!(@RQ2#04F#$8<8D(XT8J50\ZSQ?_^(O[0_!2 RO<
MHJS^^J_?W:Q6=W_YZ:???__]QV]B.?^Q6%[_A*(H^6G]]'?-X]_VGO\]J9Z.
M&6,_5;_=/%KFAQZTP\8__?NO[S_+&WW+8;XH5WPA'8$R_TM9_>/[0O)5A?E)
MOL#1)]S?X/HQZ/X)Q@@F\8_?2O7=O_TW &HXEL5<?](&N/]^_?3N*$GVDWOB
MIX6^=C-[I9=YH3ZO^'+UG@L]M]Q7HZT>[_2_?E?FMW=SO?ZWFZ4VAX>=+Y=/
M1G5<,L=EG#HN_W2,V$]GL-\3OZM]7GM@KA+W0U\\MF'ZH3=VOUC]H(=G>(?,
MV2S7']2;A1KKV]V0.IOUX3GNZ[,H5GP^PF>Q);/#\MS]PWO[4T/&#=2B3"LZ
MC>K>855_6^F%TK6V?#(TR-6_?F=_FBT>^+?9+_PAOU0/3HM?W2_EC=6WE]=+
MK=U6^.KCWR[__2V7^3Q?/?ZJ;X5>SE BD$PR 65*$HB52:#(F(:4L!BE2F D
MXMEJ\[W/] )^_;QFK:+?G?AW 8BLCJSLI2X+2VJ[)][.#VUT=H]SNR+]:<%O
M=7G'FQ>L!,Y\J(7Z-\<^:/@':P' 1@((*AG 6HC__M,6A)YG9?ZB6,\G!3/X
MK9;@_Q\0;]48BY6E\V*X/^%B,O@?A;V03UB<.T.Q6#['K9!GX58K93<"='9Y
ME"91K7*[C/G3WF=SN5P+P9?RQ!PU3_PD"TOO;@6?+!-WI#A?VE5Q_I=6SX9E
M]CM0+)5>VL/2 <$WZ^6^A-><W\W>+:0]*)7ZM:[_^V[Q>57(?]P4<SM&^>:?
M]Y;0IV(^?ULL?^=+-;.''V6X/0 AA"C$L4:0QX1#F40)THA%5'"?C:,C_:GM
M'6OVP?=K 7X ^0+LRO OH)8"_.;D (T@GFJMZS2U[R0C@#_P9C( [MYZ[4ST
MMO9F:06OH#.\%)7LS= _.9WWDYZORO6_5%JPTH!=J8^B!,^$9JT'SQVFFRI\
M=;]<6AUK!]/Y]>(+__;FVYU>E/IGO= F7\T(9D9HE4$<20)QFF'(,FM"IY&0
M&.E,,ZY#5-\)>E-3=0V?=IG)XE:#%?\&=,TP^%[4+/\0IM1. >ZGQ'J$<6"E
MU7 *UDA:7L&;-80_GX(P6#]Y M.3/CI%;53]XRGZ<WWC^UJ8?JFLNC?WR^).
M\\6KXO8V+YTWNWSSJCF&)#0ETF@"D]2>P[%PAW%),10H1IE*49)%B?=AO(70
MU#3*FE6PPROX_KLWK[[S5"0GD?4X4/>$U\"JHP6J+@?E-LP"#L4]83?2 ;C+
MYQ9VV/7 H_5@V_;^>(=8#RF>'%A]G@_3F$KGLS>+E;7N+I6RGT!Y590K/O__
M\KM7A=(SG%**8X,@C84]@PK,(2620B:9E3411"CIHR_;R4Q.6U:<@H;5"U S
M"RRWP+'KM_I/(-NN+_O#:VAMV1$J[]7NA\0!RZK4\L?KXN$G.T!M5-D?MK;4
MB6%'40%^HJT5@.?3W0YD'U<W>FFURMU2WU@S+'^P!T!W]KA\X+E];JY-L2SY
M7'_6\GZ9KW)=7JK_N"]7;B_YH%<?C;7@KHJEVU4N5ZME+NY7[JTOQ15W9MZ,
M1%@R;B)(&+:GNCB+H(@B QF.B(ABJ:3 (0>Z@?F=FD+ZNK"'\GG^GUJ!>5&6
MH%B 6[[\AZZ8!N5&R+!#X="3[G>HG-!4#JPK*TG!$U%!+2OX_KV=UA\NP$9H
M:*6&GZW88"LWV I^ :SHH##N8.N4;B4^V)4?K I0(]#?,7>DJ>KIF#PTMZ,>
MLT>"_ODQ?2RR76]4'G1-JWS+\^7?^/Q>O\Y+:77D_5+/(FYXG)$4,L7=S3LB
M]IS/W54*56D6TTP(/7O02U'X7Z&T$0Q1-;MDA],X5;P$D+R\ ?J?]_F#G2G+
M>NA]2"O(OM<??0$W^&W'AM$+X%@%%:]@RVR?MQH^H/1VB=%*;.0["Q_!]Z\H
MO-[J?#EKU9K55ML1+T6Y6G+I:\>TC#"I[[NR-YP_?,LG^&W-:;]W=J?PZ.]^
M[BBEL>_B3HE\X-[MY"O=OFA[2LS=OLOG5SQ7[Q:O^%UN=X.940E+,8Y=F+6
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M[@:_IPD^.*A#V^9M':QWR@CO2G,!G"# 2=*CW7X6DGT9]-V8&-?2/PNHO2/
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M G H[6343R!%?I!Y?^GT^7Z%^F.DU@\RD>,U:^C$79AYL&VO7@6!<A=?J^W
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MG&2$QDHHB"3/(,8I@E1H^U>J#(U4&AD5M.SW*$QMQ=<,=HG W@?/;Y6?!<G
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M&:L,,8A$&D%,A3V4B91!0DRF!$TB06BG2XT-B:D9.#MUVAR/H&*RZSW&%LC
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M'-9GM)7:U%10Q9X[QMR7NB[S?@$6.M#2:<?73]OTAMK 2F8;/-I$<52LPL)
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M(E,IHZ$-0L)8"%DUX[0'^:1EY5;82 &>BA':*21P2OQ4T9 P#ZR<+.O'P;T
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MMM'N*1V]K;N^+8+BV=0RZ"O@QKBO-;"1&?E5QM2_FDT$\$/5M0FIVK 5;B*
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M,BMI* JHO?IS1]!Q;&37F&@_5M4:F2SJE>*LKA)WT]2*4QL#;FI_:+&VK[[
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ML_O/:J'GBP=F[/G$I]7]NNV$C;3[5CV82S[IK^:G2]TTKFY*DZ43G3(F(.)
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MT'ZNP]*-D:]#*#*'[K25:]6+DBNY9WKX[,A.P&OE0^X9>"8#<O_*@;</MI/
MGQZ:0L=?JN5_OE\H=3<S"W#C ']A*_5K-:L>GAXF!)>ES%,&I"HQ0 CF@-E>
MYIP3*556\IP[=5H96O&Q;3M858$VNB95JVRR,-K>) ^-O@-M1/@.?^1-BHB#
M.OX-C*WZ&UOFWR06@,0BD'00)%_J5^77"Z_*<)L</<?MM3= ?-7^,39'>@Y&
ML(V3OO)[]*LW'K*JGFU!FFX>_:A6;U5;HG YX9KE4BD,RBRS9?)Y"5B!$> Y
M)B+#I*1,3V;JWI:"^N;8N/Z"3"=.H@TG'4B.QT\;!3W:KU^"]_QL$ RM81A\
M2].U\UN?SMFBF!' \^A>'Q#$@?K77P>F7S-[1W3.MK._](SA&MH[6K/3TM[U
MGGYKBR_J6<V>U!?UP*I9LQFNYXL'F]CZB4^K^^8%SA6#%!8%P"J'9F&0$<.R
M$($"8<S2%(FB].I(XB1U;%Y]&_T\U\G*3)-+5N.?/-JV,,ELODI>U"JQ\^A2
M5\KSK-%M%-S\\^#81J?F6E_C"G<:)ULJ)QN=N_CS<"ZQ%U2!_%DWF8,ZHUXP
M['N2?C=?L0%RL*]ZZ*WR?6_UW1^/U:*^N-ETG6!,4@)S##(M"X!H@0 E$@&=
M<5A*BHE"_CL<(30;&]G9$C]U@[\7Q1;+/HW]@HR7QY;$T*,P_CV'C75Q(B9"
M(AYRMR"(7L-O!X2$\^AZ/ZB ?DS^9KYXM!66E"VATO8?KM2RZWZ3Z5)F7((\
M%PH@B5/C9M(<%#(5!4I+E"'NP\YGI8V-<=?*-I5YEFMU_;CW/,)N?!H,M\@<
MN8&LKLBST31"LHX3)H%8[+RL09G)R>Q]MG&[J1^#?)S/YH_*4M+L_FXFY@]=
M4[QUI0;-%,UPFH$LSQ% .<\ 3\L<,,6E2G$!(?>JR'%1XMB8I*EI5]6J)C^U
M6=<_>Z9=7\;9C4N"HA>93[9U3>Y:_%IU?XY2QL(9G4#,<EG>H.SB;/X^P[C?
M.-8C=_9'?>:J(!&ZH!E MBPADH4"I&0%P")5I:"TQ+E7)O)0BH^-\TX?N3?Z
MCNW(O1W^L1RY^P_J^)>__D?N%UZ5$1ZY[X[;#W/DWJK]_]F1^^Y@#'_DOB>_
MY\S7MN.QU3GJG=U?7GYE_S%?O'E:KLPTNUC^\O)%/=K*F[/[K^J^"8BUIU.;
M?CJ0IE(7)0422=Y4U^"R0,"LY\M29(PHOR:VUZLTMMEJN^=1:Y,EL]JJ9&V6
M_=':L*2SS',FNWXX'>>H00<I]NQSQ?A$;:(4#N50<\7U"@T["P0#\(#?PSW9
MOYS)N]FJ6KW<2FF^@F7[GP_53*63C.5$YCFS!8XL&:<E(%G&0:FX+H1,E:!.
MZ<)GI8R-7QM%DU;%F^XOB54V^33S*&IR&MCSM!@,KLA,UQLIK](F%Y'H5=OD
M]%,'*VYRT;#MZB:7+^X1)?EA/KNWA[5?GQX?IR^W]\8IM-12I\+5L6#37^:+
MQ?P?AG6LDSCAS'AE6DA0Y+H$B&,,C#]&0"XYHY1JI05VX8,^PL=&$U9]L+(G
MW<O:@(1U%MS8[=/.AH1W1M1["AYA@KZ#<YY38D,>F6JLYG6'IJ31/;G=H+VE
M?K+6OUZ61T3;(T@S(NH#!6T&1M\OBK,G?&>C.GV?.5R49T]K=Z(^^SZC[['\
M<K7V6R=9B:@NM00YY0J@4FK ::'MJ3Q.$<ID5GA5F-EY^MCF@#I-W"SSEFSJ
M?]2^C9KKT7I/+*(?I3<PM)J%/#<_8G"P<_+M9P]\+G[$K,-S\&,7^7VBR\5J
M\GDQM^'>GQ9M!GG=J8U 6.09)@#AM "(, 08S0H BS3+"\89*IQBLD\)&-N'
MVNI85Z5NU?3J>W<2R/,?;@AX(G^[/9!Q_HPOF7_N2S;W;GW%YE^;+_CD8P?Y
MB"\9U7W'%Z_KD]4V?V'3MCMN':C1E:3.2 J5DB#+E/FF2UO@K5 %T#E6F?D=
MA\0I:N6<D+%]TFLUZU=W;A7UR<$Z@:3#(BH /I&_Z5UHFHB>BT%M[ACYY*==
MC]50>6F'F(7*0CN/P?GLLQ/W#IAU=E[[W6RS"]?V6U_\-N/5=&I//F=U=,YR
MD]0V00SFD+ ,E I)@!B1@&B2&N)#><F584/NE5MV1M;8^*]3-1&=KLEBK:S?
M6N0<PFXKDT"X1>;%-61K-9,OER'S7K4X@!%H#7-.TJ K&@>3]]<W+K=<V;SC
M;;44T_GRR;Q#Z\!3+#,BLA(!@3,%$)(IH)!"H%/*6<$5IKA?]XXCPL9&&5M!
M35O:]NZ-=Q9G-]X(A5YDXN@/7/^^'F<0"=W8XYBHU^GL<<;HDZT]SMW3,XSI
MB2\K6;'%RU=FS^3KRI\?UDW %,1EIF0&)+-.1YE"P&0N@1:*\E++M,#8KYCJ
M>8$^'\* I5"_SZ<&TN4_)^_^ZZE:O7B&%IV'V(T]PL$6F3\VBMXD5E6[65HK
M&ZD=FALPH:)XS@L;-D+'R?"#Z!NWNWKW#ZFC+-L<@PE%@A1FU0)R!DN "I8#
M+C@%4E$A>:J*#&5=Y2$W]MB3X/3>[]89BDP7ZU#I-IW(NR?(#H!NW- 'E,$Z
M?31HO+N 1I]V'L=L#M>Y8^?I0S?I.&;:D7X<1R_KV>3;[F'8@.N%^FX>5SVK
M)EWHM]E"-6TM_Z^9 VVK#U;-/LR7RT^S3<+B[:):FE^]-?_LRL1_5*M/^AO[
M8X(P8R7,$"AP83@@A00PA*7!O)0Y+G,!2>GG0<12=7R^A^V*\[2V*C&>W]*X
MXO-9\L 6_ZE6=?CL)O\Y8<^LFMH? CU? 'M06[<ELC/P0HDI6RXK734])3U/
M<*.]'6X$-X81C\R4G][<W>QG9]\DMSLC^K4>T8W126MU8LU.?K*&_WR3<&6N
M5<FF#O=-PK2ABL08'+"O>.0A"=5J/)::PW8?CPSV04/RV/+ZS5&?%W.AE%R^
M-P#9;^%V)G]E*ROVY9->?RKOYPO[RXU"$\U3XX J C3,-$"90H"7909*1HFB
M!$.EI=\4U%.3\<TPG2&)?>G,M+):SR4S68?ZV,GCZ&SC-X'T'3JW^6& X8A,
M_[OC4*^;[0AT5MA1<)@<PM'[E8@&8N^^6@Q*SE="M<^]USZN1ZC%O\ZKV<K0
M_4.U6BGU:?8W)D0U:](N9_+NX>%I5OUW_<]_??.WN_9DW/CO#,,T YH*"I#D
M.2"<"E#BE)6T1%KETCD.HX\&8SMQJ&U(UD98-WW+C/ISWC8D^<F:XE@PKO\P
MG2?00<"/3)W]<.\3)-)K #PB2&(/Q$#A)8$_!+\(E&LP/!N>TNO!P\6N7&/W
M3F#+50_JNVW\;-[*^>)E<[RUR:I64J6"(0H@S2! J?D;PW:>22E,"2%%GCK-
M,R["QC:EK'7UW44^@Z?KEG(8E*+O+[=J;IU5)[]'R2AW0238[O,940-O15\V
M^G!?VN&>_H?5ZK^>S./?61EU5OA$%00;(E @)1D&J* ,,)T*6R.**$@+B; 7
M01P3,C9BV.B8U$JVM10\@UJ.PNE^''T-2 ,<0GOAT^O8^10  0^;#T0,?L1\
MRLAC!\LGKQVXN%P3I7$W6ZX6M<.[K#<TOWUGLT]-62#;T5C)NZYZ=D&(5*S(
M08XR:O.$;/-'0@'14#!8(,9RY'=./93JXSL _V+T6U3""$J6==B'\1=7R^2Y
M5KNNE+ZTAO<JE3[$N^#(?V,:WQ^FTEQC?+)E?9NQL3+V)Y^ZPG,-!$D5J1S[
M@,/VVH7F?-7^,0K-]1R,8(7F^LH/MCKVC#P^\X01\<OQM5R$L&,'..(MY%XG
MZ-C!9(=EW)4AQYO2/M_8'W?2/'T=CO+QJ<GM+)7(A52 ,I0"E&$-"$<"2%;(
MS/AA*'5+<;HH:6SKN;:ZE-$VV54W:?3UK<-U"N#S?!$4MLALT1NQ'O6X+J!Q
M14VN4T\>N"[7!0,/:W-=NF'@]5XC_9.N?[N\?5I]GR]LE,J$"IH75&6V'U]N
M"*4L ,/(;A!E)$]I!O.R'*1J^"D-QT9$&\U>8:EV<A@CK\E"#,[X%U^-E74Z
M1FUGLC%T! NL2V/PVBNID_K]&$NF2_ &6QM=%-0W,9X]V)*PYDDV#NINN7RR
MG1.[/ FL"#'L+D$F2F(K:>> IX4$>5D@B0I:X,PST>2\P/%MNVWIV_3%JEJ-
M$S%?^A;#OH"V&QT'0'"H5/D-='607:=J^*P5-TR"9<R?%39PTKR+X8=Y\TYW
M#>QMV@6Q[:]K(_1^K4-C/]O>QI_-^_C=7/O6ELS,!90IHBG()<, ::Z!6=+F
M@$'*,>8E+0JO#GTQE1V;#]KV9TADJ[I',=E!QC:R-QIXQ,;OF'8&-['/C<E)
M;?--TEF=O U29'7(P7EMC]5%U1_#>?4 /9@?ZR.S;S9+-5\T)P1?]K+S-KE;
M;]52+*KZ5&&"S S"D$" Y[PP<TH. <>4 ,7S0I=FOE'0JU^CKP)CFR?VE?9.
M2?'$WXWW8Z(:F<OW];VI&9TM&*^F3?.#3O_D]\_S:25>XC1OZ0MAL*P33_$#
MIYOT ^<PSZ3G<WH6JJIFU4I]J)[MN>C*O'45G]I&76JUO&U\_%ITZ]I_40^L
MFDF[D?#>$#&;_KMBBPFF6B(H&$ E,01(C6?-("< "Z00%8)RKOSR^ )HY?/]
M#I/39U_HY*=%IZSG[FV(@7)CRH'!CTR>C36@-B?9V)/4!MW46PEU4-2V:3?)
MVBJ[+]O8E5C# A;9"H=RJ%I< 30:MF17. @/*GL%?'2/S+_?OKY59H*ON?Z3
M?JNTE?)V_K8K5-CF,*5"JZS4)1"4"8"P9H#:NH((9IRA$A>9A,ZY?FXRQ^9L
M_O;GKW].-HHW";FUZLE/__0GDF7P+\:&^F_I7WRR^AR'X#RE1@(V]L;KUU.(
M_D^C]KIRZ?_LE:SGB*M'>EYX? =*R'/&.5 .GA]09[/N'!\U7)Z=GVT[F76>
MM_;L4,.6W^W_;(SB,YO:Z,1-1+;]Q>U,[OY@Z\IF.5#WSK%['*KYK_GW],E6
M^WCWA_AN]TUL(YUW6AM_9L**C.8ETJ! F .49P00P7)@0RL$4X*G"DU6\Q6;
MNCGDPZKO-<FLC8CWH=IZ3U6K?O*3; WXV49""V/J3?UGHC86W]39M(M-R+V]
MP+,YS[ OC-O28+RO0>0I\4T]S/;/Y-WV,&]E5327V''?^^'N'0T*R=WZ=>J
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M8 \36FHMJ/$.**((((DI((KFAG"$2&5:9"HE?H4-O'48'0G5B<15K7#R5!>
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MK(OR9)8_K*FE8%='4ZOU]KY4,F^MO$GFG6G-59YKSRO&T7%-.LSHQ%ZK6BO
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M?[K\Y^B*+=(;,$)K4"%E",)P<"5YYD4*6IC_Y],_HXW2%,<A:J9 18D0E??
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M&N4PY. DEY#06DR8O N'Z?[&<MLION/TY/["ZV33O_R6/H?Y)]SD57F(/J5
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M!@P93($DCA02! H7+6I3$FO=BVK/FR3^CWJ5M(L*F@*IEZ=^3=N^'++TN(\
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M12@5=?MGOS=(&+DCY1!JOO,\:'^9=P&9^A+_*'S#U04'3%K)U6;J?:K55BF
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M9>],+FC88.EQVOHU+[M@Y>&62@TUT[NI.>#%SIW/:&ILAGR9\QB"HE-""^?
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M&F-L!^=V"(5WT;=O-Z;?TDEY] ?.ON)OB_GZ\VJ2@S$\^!IIUI8O09)9"<(
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MZX94D39J9UI?QCY&S\ASI_;7_)V19JV$WL&1<,;+.[(LI(GYI]O<!%E<BJJ
MM"Z16<L,?.TYDYQ4BEFMC6S=+^QQBL9U-9J#J(G@.TW&G+%T0+[EY@>T.UF&
MS)K<0DCVRAA>*!C93(B12M!77M4VD HQ,F-4ZU3I$ ?,YC-?X"HMIU^JT,\>
MS86D2C12 =>9O-^4)015:UR]B()I'Y)HW1KB$7*Z.EYVT?O]EN%PD8]XNJR6
MZ\GSQ<F</HG$MSZMCWPW/0<2*U%[.ABUBD1_,1I"= 50%'*\&453V^T'6N :
M7.A/5U!Y:.VQ\=%(J8N&$AX9(1_PRWE[[LLWV[=9.G\9+FPTQ9%<BO98-Q&'
M4*=A<9YY*;+PF+>J5/D.;+8F:!PLM='Y8F@%C-UXX9EE[#_8)4?G70 *DR66
MHB')VCI"D-=&\;JE*#]3W.^+2%LV7+CWX\<#Q$ Z7#05:#>!SFT#_.;R96PH
MJNB$"D*H5>(R(U  1_YWRHE^QD1HWAGY.R2-'>JT/;"&T$,'L/HP_?1Y_:[\
MOCJ[]'H7*;28UWOWE]]H4\X_X:O%\F:0=S$ ^W227 A<" $V8$T5A$0[B/C-
MR@<=LBQ>M@X.#B"W1_]I3]@LQM'AV ?CF\7\TQ$NCS^>?/DR.[VTYZ_G:;GY
M(LQ^62R7BS^(RP]AC9,8.#?&!_ >+2@G+?CD,AA1O'5%6B'"5D?FC@OW:/@.
M0]K@XN_ $G[\O%BN*W\;T3U?K-83[:-A)7'(C 7:'"I#1(Y ?D.BC2%=3LW;
MF-ZA8MP+IR'MUH$2[P S-ZWJ>4':))"_&7)A8#/1KT1Q0%94@Z\W^3Q%\CU:
MP^9>0L:MW!X2.8?+O0/P7+^ >5T#'ERM+UBQ7!8C:RUCB74?)$?"T1Y\[9GN
MO7<^MBZ7>(2<<8NHAP12*QV,[1J]"FGCS[T]J;'MN_+Q[R<DVU>(9%(%<[ZR
M84SRM9.#JK/H)&!(.CK!$&/9R@MZ>(UQZY0'<W@:";4#4W/?95T]>-^5YXOY
MY<C"X*-58)5BM93$@!/&@>%T'B=96&G>G>S[5&T%+/LC 6L@C72 L9N\W(I)
M)U(GB8Q"3!UTG8B9*1C@/$/":*+#:(5N7;'U*$%;(<O]B,AJIX=.[^5?8%SO
M<QV_^7LM;N'O$M#H\KU^\'U#()ARRNCZ@D;F.BF'0ZBE>H',04 7#3>M]\[]
ME!QJ(FY^ZE6Q2.0EIL02I"CK_'5E:C<\!29B22I&X4/KUX0/D#)NDK"!_F];
M@Q8B;]CWHKTEV'^JYK6_W<HJ##@G\P%LA&R5YR61%=>JUG%1D)*+ ,GIFZ1+
M:UGK'@C#V 9R>P@NZ_K\YE*25W!-*C")7@.+GF(QE8AA)R4485@@5G/BK>/A
M1PGJTD[L@H7;=J*=^,<.A6^%\1]PT^+R:'&-P[>+-=Z9P9D]XU87T":3R\5U
M[;*5(F2?(I,"O;C=W>V!,'F_]<>],V@(J*?20=>'TMNPK#[X5SR@>O3>SVEU
M4#U.X+!'EO7.)L\,R!Q(RSDFB$%%X.CK%%PGE&Y];3R<.WL.[>>+X^/INMZ"
MO4)</9OG^K/7J]5)S2[6FXW5A((KU#DST%I84-I)B#)'$#ZY5(KVSN0!V-Z:
MP"Z/M%VP<I_K.XQZNF@$MV%A3G(ZV? 54NW'<#)?3W*=]A%3@1QK81-3]5&?
MB*"C#2+I%'@88G_=1TN7I]JAF#I8Z!TDZUZ<+WM^_['9 K4WLTE<ND*.7N"%
M54>/0DU.0:<(T7(ZFTW"UG[V Z2,>^T]"'0.%WD7R+F^ VK*>J(]SP$+!X^;
MMZ/D,,:D&7 AK5!!,9N&-3B5BG$ONP<W-3L+NN/D[<;U?Q].PR;8/,Q!ON>C
MFOG(WR-S6#=9>N9E"1:,KF_S*=B"X#@'GKV1:(W4S6<H#^<FWWMFUI(PSM&0
MMV7(Y4K*@,\)(3E5[[B48KSUZ^6#')6G=GYW0<#6CLHN0N_"S_U]?CX. &]X
M[1=5&EB*B+&^&+'UI5I!#PY%%5)D2CB>,;8^?!ZGJ$N?]Q H-51 %_-B;B>A
MSDW\A-RP$',H$(RHS5"($:\,<2.3Y<@XR[;U,, '2.G2]ST$0BU$WNDHF#-#
M>R/=>:!/\\"GM7)KMB%VX/ML6S+6[LYF4^0;,4#4I/J@@U"HA&3RQ_!L[H@R
MTI=I=I*G\T\W9FK96*11,@%+1=7N.N3"FU+G/I>$P8880^N7YMO2UJ7GLPM"
M;MN:0932A2=T<VKJ61Z!F#K/7]I(?IV1H+EUY->Y E'E @Q+($9=3/+_;^_+
M>MPXEC7?Y[\$D/OR,H!LRP>^XPV2[8MY:N02:1&G1>JPNW6M^?432;+WC4L6
M*XL2#!#=:KHJ(^*+R(C,6%KG[[VTGBZ]H$-@U8SY'9SA/*$B9]9+'0Q/4%SM
M(H::>).E!A3(;'$)N<+A3527GD]C:[03JYMY/0<D#V_JONK:?\=EJA+Y&[_#
ML"3\_SC[9]6E>47DNNR+YY)"#L"CK6V8,YG5E#)XX:7GVEH>6\^;W6V%79X4
M'H*Q 074Z2GB^\M%^O>'Q3F)ZN+M?ZYFEU]^P#)+L[WR0I]_6 N7>\NE-O*X
M'[^MQENW;7VT2A*C 2:3!A6$@("1+ ]%;XP"KHBI=8C[\HH.+MI\\NE/)3RR
MS$R6W$*V/E'XRC4X7X=SI)RMT5SYYC=;6R]N7!^\(68>57@.(IZI&:4#S@->
M?>:@)FK(LX%74%?0YH+2DF>DZAB=;" *&\%(95U G[-I[44,;*FNXL4LS\+R
MRV_+]=-_P<L/"]J:/]/&C/@^G.-O9;6&[[X\_O+UUS8-3$2F7=I*$+&6UI?:
MASY2O"&$MBYI77"[?E*[<*?A^KNV=[L@[Y&]&TO('025[TF"JSX0:UJ^7WS\
MM)C3KQ>K%E\QYAQB+<:VA=<(V=5\A]J\27IB+_%6M;[K>W%!(T-P-)P\VJ!;
M":T#!#Z@8=,VK#@TC-L"7JUJZ5RL016CCVR4-(X9U7K*R9,+&=OH-1/THC77
M.X!.31!=S%<*MVD/QW/6VIH"RO@,=?@9!"\=6*.R0A=Y:CZPXM$BQH5, \$^
MN@8\A,L=P.1-SK/*_G#^>YB1M?X^?)I=AO/KCH*>%$4&!2S6@FVC"X3:6LNP
M')1D60G5>J;GBPL:]PR^/7S:<;\#*-WNZG<V^Y]O*L"+UT[:Y"!%Y6A3%P4B
MPPBL1*ND8HJ%UM<Y+Z]H7##UXS"U$UL7=XJK]=>4'LP_7-7SXM_7,Z(^D%@N
M?L7_6?WIXBRA9ZSVY;4.:R68L.0@U+Y<UG/'BF0>6W<7W6YEO?CQAZ/AJ:.S
MMH+I&7!_A?,KO"6+2_1.*P%6A0A*UYSG4B1M$[%FQ"NAFX]CW&IAO5C!8\'M
M +&,70?\_@.>EW?X]ZR>ZU0)W81 [["Z(D3CG_/9BN*-(W&6 BO%*B0]XA0&
MU3ZHM7,<6-*QD#1*)1XD)CU3 [S[N\>]^!X 6,>00<\7 =^%BU7=8;WV7R=:
M[7O\__A)S0[]7UEDJS3 F_N>VMWJ]F4WQ9D7EQ>K?2W6Y?P>OGQ<'4Q<'\@:
MH[-2J"&$>@&5D8*'I!+(4)0RA5F+S0MG#UKQP043V[[]N[MOO[U+LS9SJ3T%
M02RM\DOJ""_R;[-,,1K&*!!J7E=QV))'3D(\'CX?E6D<4=23LI;[M_5Y\7G#
M6<XA6_\<AL_@,%DF.20F BA+GIOG*8,)T3J3N+"\=?+QN/;S??J ^:KZ,6\)
M,(LOB.]Q^7F6\%:3[B[JS?GJD:N\SG>8%G_/:ZG+VO]=K?16W;A,OK;& DRD
MY<K7N\'*2D9>2<KD%QG3/(ED*&(F;7-WP?2C4*<+>/1P!'G#B*<I7QFZWU:M
M*2_>I,O9Y]GEEP<=>S*Y_C%[#TE9<MEC]. JV3JB%ID9$U+S-(V#5SUR;GH/
MR#^*P#N%^(:E;^KP[+L4U[..-0HH(/VX_K<'U.N4B<.U9-9E7XMG/?VT.G=C
M-K,0D)?FQZ!-*1@YO[XOZ!\)"*,?A+VB]>^0^#M+)( 5$U;L>$[]E1)<%LY!
M& HU*-Y(X*)PP$TF >B"\6$L_MP)6;M%C9S/?WQ,CRK52461=[7ZT"S<K1X^
M7'SY*BE]!)M&!2.2J@?$EEQ@7L<_)4S C"[2D)/ 8NL=LI=@\YGP8;FL(]A6
M[_SNR].;S_I:.D6MA(\2I* /Q9.&(*T"3C8BBYH;HYL79[1:_*2#R5TPNZM+
M/8SX._"L?S\/\YL!OLHF;VJYAO6<UJZDA( J0\D<E2["8_.6GG??/W(2P#@0
M6#221T=8VN2(A91I?5* K7/G52+'R&ECH-A@N/.!J]AZWL']%8R+I_TE^0PD
M]F#KV#'+'_^S^./#XNHBS/./LW*)N/9_?IK7XM;99ZRD;?+^R';[I(L&HSDC
ML@S6B28&C"LI.%M8<-LU[M[^G7W@8Q^Q+H;G\8C06<T3K[9V/54^YI@L;>LF
MU:C&J=K'W%&T+FR6+JJBMFLO1T^]8T+HMUOS<>^%(^<&C;H+[<_Y'N"R03D+
M.:>L:^=>BL!58AX"BXP,+C(72BDI;C6&9AO C&E(#A#60W'OP;F1!?[+;#[[
M>/5QL_ DN$?+%3"?R+!)M.""UL"2+44H'R/;JNO)*R*_]]*1A;Z/R!8M^#>V
MX,,_=Q9N**9C+%HH'#DH;^N$-4_D,RR.V5QXVNI2_#7!WWWI.!M$,\'OS;\.
M(HSU]D9?7ID\&;PRSB'PK,CDI=K*4.L(6D070VW"(UK/&[NW@)&3/;N(5_>7
M2 =PVI]QMV3/\P-'/F>F%(H$QAI%&[$M$%.PH&4=V2B30M,Z3V<(.L8-C@Z
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M!2;K3(W4"U9:LIVV,VMJ+:9$V^K2K20YW?7KK" 0I) & 18NDEE/?_8M A$
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M,TC$9@J)?K?AK6^F>54GSXU6$EL(85=)' TLDDEHJS?8)!J/=]KWHQ@#)]1
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MX4[1*#'<"0D;'+>XT7*D/8V;R!7\-<_C!I**%V;YK?FC7F"')OB'SFX0=V
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M=DF/^S.<[8)^8I0OEL9OJPKPO+!%$_Q[ 5Y69C\$Z0?'JR+WL03Y(U?1\K+
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M?\!IMKO.:=[H#;Z%G75FI<>T&\(N;^(EE3$X*93A\Z#@Z=9O5K/!;D^S_C:
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MY;AO^EHR@J"BEGTW6L ?H;MU/6J8E 5]&39%H"&A['"L+6@']8U5&=9T>@H
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MC$TW=N'W,$B79#[7,2X14NVX?1A:/91LYR238NJ 9IT[;;(U]+4<T(>W;JY
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M-C8+C6S+"#B[54EJS&+PV;$!NKK#8P+Q1_^NB5#[7MYFM[]Y._3!S3:PB&L
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M  ;&0;YO@MS@E<%A5)KD?6E#_QAW$]PSNI/4%^XS,.??'IN7,(\!/$A0GG)
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M,H0@3O>GOY7]5\B1^+!_L!/N[ORZJ_.,[H'1)WG$ZC\0C2&061Q&FF"94X4
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MECJ-;?T'#6]UID1V=8Q]KA?MS*!?+"!7L@G(APC(E>U"LKL6H!; AG.?UV2
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M2 Z=1"4]3A00[.'!I<($[)'F4M6\S9%:7ZYV^AG2SA))*N\7CE=T(B.@,X"
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MUXK3GU2<BLF?C;5_P/;=_P%02P,$%     @ HIP(58@H;IWR&   .\$  !<
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M[7>Z0_AUT1MU3U=-(>Y8JZ0,#K]_^:G]J?V[ 8JN4WNDHOXC"D(Y6:A+TK%
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M7BAF58'F.)!%!>C-7-\ O63;RMAJ$E5$,#6W5TFFFJ;3>F#USQ^[@VY[I4C
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MP8IE;ARKFU>\N<Z]B@GJT%?6T!6"JB4OVT8.#H4O6@H>N5.P+L::1YPJ;A?
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MR%$0.!?Z<_9LCMUA+(>[A.5FL(KEK8EK!=+;4][6R(;5,!(, 4N-RB@2/#4
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M,#(R,#8S,"YH=&U02P$"% ,4    " "BG A5]D$VJX\.   2E@  $0
M        @ '>SP$ ;G9A>"TR,#(R,#8S,"YX<V102P$"% ,4    " "BG A5
M^>&-8*T5   VQP  %0              @ &<W@$ ;G9A>"TR,#(R,#8S,%]C
M86PN>&UL4$L! A0#%     @ HIP(584U9A]L0   >1T# !4
M ( !?/0! &YV87@M,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0    ( **<"%5'
M[:812<$" +M' P 4              "  1LU @!N=F%X+3(P,C(P-C,P7V<Q
M+FIP9U!+ 0(4 Q0    ( **<"%5=N+S8 KX! $@F @ 4              "
M 9;V! !N=F%X+3(P,C(P-C,P7V<R+FIP9U!+ 0(4 Q0    ( **<"%7;J3BA
M?<L  )XA 0 4              "  <JT!@!N=F%X+3(P,C(P-C,P7V<S+FIP
M9U!+ 0(4 Q0    ( **<"%6/K>['0+0  -:@!P 5              "  7F
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M,3$N:'1M4$L! A0#%     @ HIP(57><\*M%"   +"L  !<
M ( !=TT) &YV87@M,C R,C V,S!X97@S,3(N:'1M4$L! A0#%     @ HIP(
M54B&Q2SA!0  '!<  !<              ( !\54) &YV87@M,C R,C V,S!X
M97@S,C$N:'1M4$L! A0#%     @ HIP(53<C@D7W!0  ?A<  !<
M     ( !!UP) &YV87@M,C R,C V,S!X97@S,C(N:'1M4$L%!@     0 !
*,P0  #-B"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
